<SEC-DOCUMENT>0001411690-21-000014.txt : 20210513
<SEC-HEADER>0001411690-21-000014.hdr.sgml : 20210513
<ACCEPTANCE-DATETIME>20210513160748
ACCESSION NUMBER:		0001411690-21-000014
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210513
DATE AS OF CHANGE:		20210513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bionano Genomics, Inc
		CENTRAL INDEX KEY:			0001411690
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				261756290
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38613
		FILM NUMBER:		21919643

	BUSINESS ADDRESS:	
		STREET 1:		9540 TOWNE CENTRE DRIVE
		STREET 2:		SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 888-7600

	MAIL ADDRESS:	
		STREET 1:		9540 TOWNE CENTRE DRIVE
		STREET 2:		SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioNano Genomics, Inc
		DATE OF NAME CHANGE:	20120703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioNanomatrix Inc
		DATE OF NAME CHANGE:	20070906
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bngo-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:a7c25383-a88e-4d48-aec4-d74b76810e9c,g:60d85f31-0c17-478f-8e10-9a14108a4bee,d:b388395ebea54b38b0be27fba0635b12--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:bngo="http://bionanogenomics.com/20210331" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bngo-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80L2ZyYWc6YzEyNGU2OGI2ZTdlNDFiZThhZmQ0ZWJmYTJjNWY4OWIvdGFibGU6OWNjYmU0NGJjMGUwNGEwZGI0MzYwMjlmYTQ3ZWQxOGYvdGFibGVyYW5nZTo5Y2NiZTQ0YmMwZTA0YTBkYjQzNjAyOWZhNDdlZDE4Zl8xLTEtMS0xLTA_8afae427-1636-494a-9ea6-c0768cbd17aa">false</ix:nonNumeric><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80L2ZyYWc6YzEyNGU2OGI2ZTdlNDFiZThhZmQ0ZWJmYTJjNWY4OWIvdGFibGU6OWNjYmU0NGJjMGUwNGEwZGI0MzYwMjlmYTQ3ZWQxOGYvdGFibGVyYW5nZTo5Y2NiZTQ0YmMwZTA0YTBkYjQzNjAyOWZhNDdlZDE4Zl8yLTEtMS0xLTA_db0fc019-4277-42c7-8177-0afc0143fdac">2021</ix:nonNumeric><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80L2ZyYWc6YzEyNGU2OGI2ZTdlNDFiZThhZmQ0ZWJmYTJjNWY4OWIvdGFibGU6OWNjYmU0NGJjMGUwNGEwZGI0MzYwMjlmYTQ3ZWQxOGYvdGFibGVyYW5nZTo5Y2NiZTQ0YmMwZTA0YTBkYjQzNjAyOWZhNDdlZDE4Zl8zLTEtMS0xLTA_78042370-ea59-45ca-94d5-94fdb44cc647">Q1</ix:nonNumeric><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80L2ZyYWc6YzEyNGU2OGI2ZTdlNDFiZThhZmQ0ZWJmYTJjNWY4OWIvdGFibGU6OWNjYmU0NGJjMGUwNGEwZGI0MzYwMjlmYTQ3ZWQxOGYvdGFibGVyYW5nZTo5Y2NiZTQ0YmMwZTA0YTBkYjQzNjAyOWZhNDdlZDE4Zl80LTEtMS0xLTA_c4398230-9ec8-4f1d-bb80-7e1f960b1be9">0001411690</ix:nonNumeric><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80L2ZyYWc6YzEyNGU2OGI2ZTdlNDFiZThhZmQ0ZWJmYTJjNWY4OWIvdGFibGU6OWNjYmU0NGJjMGUwNGEwZGI0MzYwMjlmYTQ3ZWQxOGYvdGFibGVyYW5nZTo5Y2NiZTQ0YmMwZTA0YTBkYjQzNjAyOWZhNDdlZDE4Zl81LTEtMS0xLTA_0f30a455-653d-46fb-8688-1c04d525dbe0">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i73e99ee813de47559aff9fc89de5f48c_I20210331" format="ixt-sec:durmonth" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xMTA1L2ZyYWc6ZDc1NjRjYjcwNGM3NDkzYzhlMzRmMmNjYThlNjk2NmQvdGFibGU6NTAzMDYxMDNiZGJkNGE3NGFjYjI3N2MyYTI4ZjZhZmUvdGFibGVyYW5nZTo1MDMwNjEwM2JkYmQ0YTc0YWNiMjc3YzJhMjhmNmFmZV8wLTEtMS0xLTM4MjI_5b21cfc0-d0b9-418e-a57e-ab1c6c724c88">9</ix:nonNumeric><ix:nonNumeric contextRef="ifef7e1ffa1fc47e6b55595ac8be5b218_I20210331" format="ixt-sec:duryear" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xMTA1L2ZyYWc6ZDc1NjRjYjcwNGM3NDkzYzhlMzRmMmNjYThlNjk2NmQvdGFibGU6NTAzMDYxMDNiZGJkNGE3NGFjYjI3N2MyYTI4ZjZhZmUvdGFibGVyYW5nZTo1MDMwNjEwM2JkYmQ0YTc0YWNiMjc3YzJhMjhmNmFmZV8xLTEtMS0xLTM4MjI_fadf9178-d4e2-46ad-a555-c27a876b8504">1</ix:nonNumeric><ix:nonNumeric contextRef="i47e9e0fd70444455a6640482ac8e5229_I20210331" format="ixt-sec:duryear" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xMTA1L2ZyYWc6ZDc1NjRjYjcwNGM3NDkzYzhlMzRmMmNjYThlNjk2NmQvdGFibGU6NTAzMDYxMDNiZGJkNGE3NGFjYjI3N2MyYTI4ZjZhZmUvdGFibGVyYW5nZTo1MDMwNjEwM2JkYmQ0YTc0YWNiMjc3YzJhMjhmNmFmZV8yLTEtMS0xLTM4MjI_16de30a0-138c-4fd9-9567-212859ea8cd9">1</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bngo-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ad6314fd03947658c809e9599894823_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42cdbd7cb5924627bda45f9725b2407e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i0d4506743a254bb993d79cd1ba20bf03_I20210507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i7870f814eef549569827056ab0bbe28f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i7c91415129394ba299d78d9ff4f67598_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fd535c416994e7e9ac50885ecf579a9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6482b3482014875b2110f7ee933cadf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb9a8cd4c6ae43b780d83f3db03387c6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50064f20ffdd4afea720ea427be539bb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8da4c0227db460e9bf1844ec2b9c95d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb3bab8827334a58a6a6a830691d74a0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2cf00dd543e42b9b366c557731d37c5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib602f85292f845748876e64aa8d4d2bf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90fd0d4651674579a500a712406f6ae5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if30fe967ef764693b2f27ac326b09de3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e256cb75bb49168f54108a75282496_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd38c3fd47774b69bb42677bde40939f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaaa0a63cf624180ac4a400546f607cd_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id64fc47c76a34812be47288f3a639104_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1721a6a1dce465eaa006a924a3e1573_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia593fc3aadb14fda8e66f3cddea13f4a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dd95436f5fd45a5a4faccdc492a6ccc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fa524c836dc4ba397a51ffc0afdbbd4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c36739694c340cbb6da644df93b34b0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f252ef06c56452aa5d46538864bff17_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01c7339672134033bfa582f9fae89a1e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b58256688454d8e9bfdde4184797f9e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5b24cb157134368bae94b71658f16be_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8c88833ac5346e0b619cff8770a118d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:LoanUnderPaycheckProtectionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cec51298f734861ab7454986e9cc49e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bngo:InnovatusLSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fc5f9d8dd1f48fc82c0374b93861f35_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60f650629d034534aa18e0699f6858da_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i879adebf764c47d087517666b8c85477_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf4053f13478440e928fdfbb689fd12f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9331df46b264545b015fc8dbc0eb877_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:InstrumentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b1e545fdd7b4f708c5122ab52e04b28_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:InstrumentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb245ebe81e244599c7dfc4dd2951fb6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:ConsumableRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b4f7fff94f74c0092a3e332baf337ee_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:ConsumableRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cb3b2d35c0e49a0b13d2888567d6b29_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ic1ea4ad111304144bc23a97198dd2179_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic08fdc3d1e534710809bdee60bba27bd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e5ab6a8509443dba725afa8835b9601_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3c3a70d23fb4e3597f16a3f336f2080_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i245ac77d088a4c08ab398de10d3c4fe0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd2315279b594cd888242f46af032bc6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida0f9f015cda405dbf20c999e5715976_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd9faf0a75c448aeacba6769f5a6ed6d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic54fd087ce324e2ca363766266305d85_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib52b24a224634461aa88638273374171_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e9fe1ddcfff4117ba8ab2659f8fb841_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i457368c024694d3da4b660e9ad925a67_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ad2e939003643688e5a0c1f74143044_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e72dec2e62644f09291bd2256e18ae6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib152c322e04e4f04b400bc01f5876b20_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73e99ee813de47559aff9fc89de5f48c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifef7e1ffa1fc47e6b55595ac8be5b218_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47e9e0fd70444455a6640482ac8e5229_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia855809b84d64c008ac770b0553904dd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bngo:LineagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36ce02702176446c8658104bea1e70b3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bngo:RuhrUniversitayBochumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9b6028b6f7b4c56b41bd5ae534114cb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bngo:IlluminaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09493f03a8d24d529ba3c584f742a2e7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bngo:QuestDiagnositcsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb4b96f2629a437b92ce60228c4e9a9e_D20200417-20200417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:LoanUnderPaycheckProtectionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-17</xbrli:startDate><xbrli:endDate>2020-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dad41e3a2834af1a8bc37f1efe217ab_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:TermA1LoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id95f9fba9dd949fc975ddb0d090b6f9d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:TermA2LoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79b1a33813d74170988e5d5afca3a502_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusTerm3LoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4861f1d2c13e4caa9d9b2c243fba8ef3_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1be2f4e30d224ab9a6370097d5078fb2_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id929d97a381842f687a1e63e52a0ed66_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="payment"><xbrli:measure>bngo:payment</xbrli:measure></xbrli:unit><xbrli:context id="i471d64edc0154171beed8ed2878377a6_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bngo:DebtInstrumentPaymentTermsAxis">bngo:DebtInstrumentPaymentTermsPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02ab7766833b447ea7ab0f07e49cf492_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bngo:DebtInstrumentPaymentTermsAxis">bngo:DebtInstrumentPaymentTermsPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9d5648907484fceb630191c98780dcf_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bngo:DebtInstrumentPaymentTermsAxis">bngo:DebtInstrumentPaymentTermsPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4677e379bf9c4e6c97c7555823337d32_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bngo:DebtInstrumentPaymentTermsAxis">bngo:DebtInstrumentPaymentTermsPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic76f8d3c3fd840279c87ce3ba493143a_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:RevolverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1d4c4e068d445ac82a3fe2130562736_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:RevolverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bce457e3753459a8510d3d860bbde78_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bngo:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i749a55fa53994c25beda30839971df4c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bngo:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f0cc44ba35648fb997a749f7937547f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bngo:PPPLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57fb085856954618adbd3fae5629f1f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bngo:PPPLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1412440744f4428481b3a537ab93f461_D20210112-20210112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-12</xbrli:startDate><xbrli:endDate>2021-01-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28c5c5f8564a4e67a64f3e5b44585423_D20210112-20210112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-12</xbrli:startDate><xbrli:endDate>2021-01-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cf86dab1c3a48caa595e0ad46a9aff1_I20210112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie718fd4d2bcb4f61b4ea90e0b1f6c96b_I20210112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b5c637028ea47bd8c7f4181b517e861_D20210125-20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-25</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i588270472a6143508b7112b2fa331670_D20210125-20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-25</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00ca1925ad5b44dfa157b479aefd1f54_I20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i573ce6b1bb9b4a1fabd1ce7fd5d82397_I20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd683caf9e1c44568aeff1288d3b04e1_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3261931611534e3383079edc1d409a1a_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2decea561ca4c6794f62ce452ca3184_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i099191310b124b1e81080dfde278c6a1_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i936534e2d9074d2ca70fe416bd8db58a_D20210323-20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bngo:CowenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-23</xbrli:startDate><xbrli:endDate>2021-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75942e4e55054f78886bed570f1251f3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bngo:CowenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3978d66a078d4604a9b13bbc463817d9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i576e4374ad8d4ed4b487ff0388600fbb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14c68bbc58d744e486a0c8a007611aa9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87e1c72584cb4efa9e7e2a7589d92a4d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaefaeb1bcc134ff2b57adb93646ab3a3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac856732b955418489f120209c032ca1_D20210512-20210512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bngo:RErikHolmlinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-12</xbrli:startDate><xbrli:endDate>2021-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7ef34e0c67c4f8d810c6f8f14d356e4_D20210512-20210512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bngo:MarkOldakowskiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-12</xbrli:startDate><xbrli:endDate>2021-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i553916c7e88a4b47a7275965698ebdb5_D20210512-20210512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bngo:VestingStatusAxis">bngo:TimeBasedVestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bngo:RErikHolmlinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-12</xbrli:startDate><xbrli:endDate>2021-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0eae5cf1a454c6a93daea25421b1ac6_D20210512-20210512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bngo:RErikHolmlinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bngo:VestingStatusAxis">bngo:PerformanceSatisfactionVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-12</xbrli:startDate><xbrli:endDate>2021-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7f20b922d82432990b90d2c4766e208_D20210512-20210512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bngo:RErikHolmlinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bngo:VestingStatusAxis">bngo:PerformanceSatisfactionVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-12</xbrli:startDate><xbrli:endDate>2021-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if952551a9010425ca3350af97034ba84_D20210512-20210512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bngo:RErikHolmlinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bngo:VestingStatusAxis">bngo:PerformanceSatisfactionVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-12</xbrli:startDate><xbrli:endDate>2021-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if35c609f5b2b4a87a6bc4013c2bc1db7_D20210512-20210512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bngo:VestingStatusAxis">bngo:TimeBasedVestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bngo:MarkOldakowskiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-12</xbrli:startDate><xbrli:endDate>2021-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib33b784ee1ca47bdb4a6e098ee129696_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bngo:EscrowedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16b00547face45e1b37c18f6b4043c7b_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i056e748dff1445bf9ed9183ca6be7827_I20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc54661388eb4fe880e68defa355cc59_I20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i277d7d0d7df14699a128ed991162d604_I20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08b91758924d4450afbd57d83b618e31_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4a769484c39497e8dc3a7a689f2d800_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bngo:BusinessCombinationInfrequentAdjustmentsAxis">bngo:BusinessCombinationInfrequentAdjustmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib388395ebea54b38b0be27fba0635b12_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.431%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________________________</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yMTg3_4547da00-c3b9-48bb-b325-37935c327e88">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NTY2YmJhMDIzNjY0NDRmZGE0ZTZkNDdkZjEzYzNjZjgvdGFibGVyYW5nZTo1NjZiYmEwMjM2NjQ0NGZkYTRlNmQ0N2RmMTNjM2NmOF8wLTAtMS0xLTA_600f4e4c-6153-4368-af07-9b207b5936f9">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yNTA_f50cce26-3748-409f-bd82-188e49a8c8d6">MARCH&#160;31, 2021</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NWE4Yjk1NTU0YWVjNDhkYmI1NTdiZWYzYTdlMTk3M2IvdGFibGVyYW5nZTo1YThiOTU1NTRhZWM0OGRiYjU1N2JlZjNhN2UxOTczYl8wLTAtMS0xLTA_3683c47b-53bf-4c72-a81e-51fd0f7b1660">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TO</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yMTg4_31c98372-8991-4e78-aa7c-f84ca7c062e3">001-38613</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yMTgy_22c8666d-910e-4fc1-b32a-159c4c99d76a">Bionano Genomics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.071%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NDM0ZGM0ODA3OWZhNGQzZmFiMTIwYmEyZjdmY2M0YTEvdGFibGVyYW5nZTo0MzRkYzQ4MDc5ZmE0ZDNmYWIxMjBiYTJmN2ZjYzRhMV8wLTAtMS0xLTA_59800022-f119-45a7-a842-13cc0db037de">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NDM0ZGM0ODA3OWZhNGQzZmFiMTIwYmEyZjdmY2M0YTEvdGFibGVyYW5nZTo0MzRkYzQ4MDc5ZmE0ZDNmYWIxMjBiYTJmN2ZjYzRhMV8wLTItMS0xLTA_b69ee310-b17e-452f-a837-18320c3587a9">26-1756290</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NDM0ZGM0ODA3OWZhNGQzZmFiMTIwYmEyZjdmY2M0YTEvdGFibGVyYW5nZTo0MzRkYzQ4MDc5ZmE0ZDNmYWIxMjBiYTJmN2ZjYzRhMV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo2Nzg4MDczOGUzY2Q0NmEwYjg5NmQ5ZjdkZWI4NGI3NF80_7051dbb9-6170-4d51-b5b4-fa90d17a552d">9540 Towne Centre Drive, Suite 100</ix:nonNumeric>,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NDM0ZGM0ODA3OWZhNGQzZmFiMTIwYmEyZjdmY2M0YTEvdGFibGVyYW5nZTo0MzRkYzQ4MDc5ZmE0ZDNmYWIxMjBiYTJmN2ZjYzRhMV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo2Nzg4MDczOGUzY2Q0NmEwYjg5NmQ5ZjdkZWI4NGI3NF84_bc7e1a6e-254b-4c00-8fb1-551db83f079f">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NDM0ZGM0ODA3OWZhNGQzZmFiMTIwYmEyZjdmY2M0YTEvdGFibGVyYW5nZTo0MzRkYzQ4MDc5ZmE0ZDNmYWIxMjBiYTJmN2ZjYzRhMV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo2Nzg4MDczOGUzY2Q0NmEwYjg5NmQ5ZjdkZWI4NGI3NF8xMg_cb3b7876-57f4-4a5c-858f-d5a4520722a3">CA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NDM0ZGM0ODA3OWZhNGQzZmFiMTIwYmEyZjdmY2M0YTEvdGFibGVyYW5nZTo0MzRkYzQ4MDc5ZmE0ZDNmYWIxMjBiYTJmN2ZjYzRhMV8zLTItMS0xLTA_fa46b937-cf3e-41fb-b830-d3395797bb13">92121</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yMTkw_3c939b47-924c-489f-898a-b6004e96454b">858</ix:nonNumeric>) <ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yMTgz_dc4c47c7-999c-4e98-baff-a29888ff2769">888-7600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________________________</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:36.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.771%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ad6314fd03947658c809e9599894823_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NjI1ZTZjOTgwYzFkNDFhOTliNGZiODQ3MGRkZTA2MTEvdGFibGVyYW5nZTo2MjVlNmM5ODBjMWQ0MWE5OWI0ZmI4NDcwZGRlMDYxMV8xLTAtMS0xLTA_7bcf8976-7c15-4dc4-9bdc-ec78b764396d">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ad6314fd03947658c809e9599894823_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NjI1ZTZjOTgwYzFkNDFhOTliNGZiODQ3MGRkZTA2MTEvdGFibGVyYW5nZTo2MjVlNmM5ODBjMWQ0MWE5OWI0ZmI4NDcwZGRlMDYxMV8xLTItMS0xLTA_929257d3-9486-4db6-92cf-b02dbd63bb5b">BNGO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ad6314fd03947658c809e9599894823_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NjI1ZTZjOTgwYzFkNDFhOTliNGZiODQ3MGRkZTA2MTEvdGFibGVyYW5nZTo2MjVlNmM5ODBjMWQ0MWE5OWI0ZmI4NDcwZGRlMDYxMV8xLTQtMS0xLTA_422431cb-fe07-4296-9c30-9cd432762a57">The Nasdaq Stock Market, LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i42cdbd7cb5924627bda45f9725b2407e_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NjI1ZTZjOTgwYzFkNDFhOTliNGZiODQ3MGRkZTA2MTEvdGFibGVyYW5nZTo2MjVlNmM5ODBjMWQ0MWE5OWI0ZmI4NDcwZGRlMDYxMV8yLTAtMS0xLTA_23379e8a-4eed-4e5c-ad5d-37210d6e3baf">Warrants to purchase Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i42cdbd7cb5924627bda45f9725b2407e_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NjI1ZTZjOTgwYzFkNDFhOTliNGZiODQ3MGRkZTA2MTEvdGFibGVyYW5nZTo2MjVlNmM5ODBjMWQ0MWE5OWI0ZmI4NDcwZGRlMDYxMV8yLTItMS0xLTA_479b73bd-3f91-4ae5-a856-09a37611c907">BNGOW</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i42cdbd7cb5924627bda45f9725b2407e_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NjI1ZTZjOTgwYzFkNDFhOTliNGZiODQ3MGRkZTA2MTEvdGFibGVyYW5nZTo2MjVlNmM5ODBjMWQ0MWE5OWI0ZmI4NDcwZGRlMDYxMV8yLTQtMS0xLTA_b074da41-b7c4-4cf9-983e-9325831e7f7d">The Nasdaq Stock Market, LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yMTg0_74e44256-fee4-4d4c-891b-9e7f87431ec5">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:140%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">   No&#160;&#160;&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yMTkx_b4904312-d2d5-4dc7-9ec3-b1542721ef49">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:140%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8216;&#8216;emerging growth company&#8217;&#8217; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:20.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6MzczOTgzNjRjOTIxNDVmMjg3MzVmYzA3NTE0ZGIxNWEvdGFibGVyYW5nZTozNzM5ODM2NGM5MjE0NWYyODczNWZjMDc1MTRkYjE1YV8xLTAtMS0xLTA_00ad71f1-98e6-4c0b-bb44-6f465c6fd0be">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6MzczOTgzNjRjOTIxNDVmMjg3MzVmYzA3NTE0ZGIxNWEvdGFibGVyYW5nZTozNzM5ODM2NGM5MjE0NWYyODczNWZjMDc1MTRkYjE1YV8xLTQtMS0xLTA_cfda7d79-4508-4963-9326-a608d3fa5e8b">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6MzczOTgzNjRjOTIxNDVmMjg3MzVmYzA3NTE0ZGIxNWEvdGFibGVyYW5nZTozNzM5ODM2NGM5MjE0NWYyODczNWZjMDc1MTRkYjE1YV8yLTQtMS0xLTA_a271fbd2-e63e-4220-a5d9-f4792ee229ce">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yMTg2_612e6c53-0512-43c2-a2be-17f3bb6137d5">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;   Yes&#160;&#160;<ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yMTg1_c2449409-52ba-4dde-a90c-962e86d7be1c">&#9744;</ix:nonNumeric>  No  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:140%">x</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As of May&#160;7, 2021, the registrant had <ix:nonFraction unitRef="shares" contextRef="i0d4506743a254bb993d79cd1ba20bf03_I20210507" decimals="0" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV82MDQ3MzEzOTU0OTkw_f627eeb9-8ca9-4b8e-8517-c73213d07761">278,849,616</ix:nonFraction> shares of Common Stock ($0.0001 par value) outstanding.</span></div><div style="margin-top:5pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.431%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="15" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib388395ebea54b38b0be27fba0635b12_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:3.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_13">Item&#160;1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_16">Condensed Consolidated Balance Sheets as of March 31, 2021 (Unaudited) and December 31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_19">Condensed Consolidated Statements of Operations for the three months ended March 31, 2021 and 2020 (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_22">Condensed Consolidated Statements of Stockholders</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_22">&#8217;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_22"> Equity (Deficit) for the three months ended March 31, 2021 and 2020 (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_25">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2021 and 2020 (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_28">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_61">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_61">16</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_88">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_88">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_91">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_91">22</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_94">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_94">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_97">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_97">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_100">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_100">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_103">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_103">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_106">Item&#160;3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_106">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_109">Item&#160;4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_109">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_112">Item&#160;5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_112">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_115">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_115">65</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_118">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_118">66</a></span></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ib388395ebea54b38b0be27fba0635b12_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="ib388395ebea54b38b0be27fba0635b12_13"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1. FINANCIAL STATEMENTS</span></div><div id="ib388395ebea54b38b0be27fba0635b12_16"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNC0xLTEtMS0w_8748b6b2-04c3-4f7b-96f9-443b2c5ae8a8">362,057,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNC0zLTEtMS0w_f25abc8c-af76-4a07-a4fc-6f2d15e4fc79">38,449,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net of allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNS0wLTEtMS0wL3RleHRyZWdpb246ZDNmYzFjZDk1N2QzNGZmNjljNzY5N2M2NmY0MDI2N2FfNjA0NzMxMzk1Mjk3OA_16a66c75-0ebf-4897-83df-c54cc0158880">2,091,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNS0wLTEtMS0wL3RleHRyZWdpb246ZDNmYzFjZDk1N2QzNGZmNjljNzY5N2M2NmY0MDI2N2FfNjA0NzMxMzk1Mjk5MA_24b72b64-a04c-468f-8b77-f4bd6cdae5d0">2,119,000</ix:nonFraction> as of March&#160;31, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNS0xLTEtMS0w_80d7248e-5617-4786-83ca-50b1f78a2b33">1,992,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNS0zLTEtMS0w_d8da3dac-dd87-46ae-957d-da4146378806">2,775,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNi0xLTEtMS0w_b1c042fb-f5c9-4ee7-ad74-af63ac59c97b">3,036,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNi0zLTEtMS0w_3b98f398-d0c1-4d22-9b5b-80fc6f60f02c">3,316,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNy0xLTEtMS0w_fd7cb45a-a40d-4016-bf2f-0c51b5b3c958">3,166,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNy0zLTEtMS0w_3cd466fc-8ebb-4fe2-8689-9358b9188cee">2,250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfOC0xLTEtMS0w_f3e09802-9aeb-481e-bcb7-0810e55dce7e">370,251,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfOC0zLTEtMS0w_d045fd73-1406-4832-a76e-d00218df76cc">46,790,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfOS0xLTEtMS0w_8295b7c0-cf1b-4a9e-ae2f-c790c7603031">5,806,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfOS0zLTEtMS0w_e6ab3f33-e919-44c7-8084-61c760263504">4,910,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTAtMS0xLTEtMA_0466927f-59be-4faf-add3-103be43ca8ae">1,396,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTAtMy0xLTEtMA_244e7bf0-41f8-441c-b087-918b55fce09e">1,475,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTEtMS0xLTEtMA_b8c25d54-3506-4013-9055-4edd39a46a53">7,173,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTEtMy0xLTEtMA_0f1470d5-bfad-483e-877d-0c4eeffe3200">7,173,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTItMS0xLTEtMjA3_d8129903-36ba-41b5-8541-85d23319f9e2">235,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTItMy0xLTEtMTQw_e2dfb4f0-9489-4b0b-9b8d-56ef30c2ba97">103,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTItMS0xLTEtMA_54058fc6-8691-4d44-b1d8-89c4868eb16c">384,861,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTItMy0xLTEtMA_5680b065-0520-44fa-bfe3-26b47519c32c">60,451,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTYtMS0xLTEtMA_d3edda00-d909-472f-bf53-b4e2eba11fe0">2,209,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTYtMy0xLTEtMA_a6a998b3-4ecb-40e9-8091-900fc57fd3aa">2,930,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTctMS0xLTEtMA_d6834ba5-d508-4de1-a8b0-d063e7d98c1e">4,659,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTctMy0xLTEtMA_4f5ab9e0-357f-4ece-a030-1bf543f070f9">5,599,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTgtMS0xLTEtMA_cecd3e10-221e-4725-bcd7-e2455165c065">301,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTgtMy0xLTEtMA_ea18a16b-00f1-49fd-a8be-0d971675d602">416,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjAtMS0xLTEtMA_08a8b66d-1e57-4a42-985c-097926c6f303">7,169,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjAtMy0xLTEtMA_051689bc-227b-402e-b5ff-48cbdd2fd42d">8,945,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjEtMS0xLTEtMA_a343fa2c-8a4e-4a99-83c9-3d9bf8fc7342">14,866,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjEtMy0xLTEtMA_5cb22b5b-af58-4c00-b54a-0b4439eae97f">16,326,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjItMS0xLTEtMA_3a7bedb3-2f5a-4163-a213-fc35ab23e34c">108,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjItMy0xLTEtMA_77051f98-e9d1-4a35-82b5-0e3143c71bba">98,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjQtMS0xLTEtMA_f5eedad2-81ae-4c03-8aac-8032f2dc70ff">22,143,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjQtMy0xLTEtMA_db9a22cb-1691-4b5a-8300-7151f52e8f1c">25,369,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjUtMS0xLTEtMA_3c190fb5-a6cb-4253-bf62-b516d7438f27"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjUtMy0xLTEtMA_307b79f6-0d03-475f-8a2c-3b92bf2a9f4e"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMC0xLTEtNDAwNS90ZXh0cmVnaW9uOjkwNzk4MWIxYTE4YjQ2MzJhZjlkMjlmZmFjZjcyMmJjXzYwNDczMTM5NTI5MTE_8ce98ccc-c109-417e-b069-b27d5819b4cc"><ix:nonFraction unitRef="usdPerShare" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMC0xLTEtNDAwNS90ZXh0cmVnaW9uOjkwNzk4MWIxYTE4YjQ2MzJhZjlkMjlmZmFjZjcyMmJjXzYwNDczMTM5NTI5MTE_fb72b33d-90b1-4515-b8ef-ace916d072f6">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMC0xLTEtNDAwNS90ZXh0cmVnaW9uOjkwNzk4MWIxYTE4YjQ2MzJhZjlkMjlmZmFjZjcyMmJjXzYwNDczMTM5NTI5MjQ_89d6c04d-87df-4667-8258-0c8647d61f60"><ix:nonFraction unitRef="shares" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMC0xLTEtNDAwNS90ZXh0cmVnaW9uOjkwNzk4MWIxYTE4YjQ2MzJhZjlkMjlmZmFjZjcyMmJjXzYwNDczMTM5NTI5MjQ_fa1594b9-4260-4a5c-b2b4-b0ea473eb188">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMC0xLTEtNDAwNS90ZXh0cmVnaW9uOjkwNzk4MWIxYTE4YjQ2MzJhZjlkMjlmZmFjZjcyMmJjXzIxOTkwMjMyNTU3NDA_0fb8009c-5365-4533-ac36-24c5636782d5"><ix:nonFraction unitRef="shares" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMC0xLTEtNDAwNS90ZXh0cmVnaW9uOjkwNzk4MWIxYTE4YjQ2MzJhZjlkMjlmZmFjZjcyMmJjXzIxOTkwMjMyNTU3NDA_6c50da3b-269f-40a8-a80e-4e958bc6f52e"><ix:nonFraction unitRef="shares" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMC0xLTEtNDAwNS90ZXh0cmVnaW9uOjkwNzk4MWIxYTE4YjQ2MzJhZjlkMjlmZmFjZjcyMmJjXzIxOTkwMjMyNTU3NDA_907a8b15-9ebd-4fd3-b38e-76757c71cfe7"><ix:nonFraction unitRef="shares" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMC0xLTEtNDAwNS90ZXh0cmVnaW9uOjkwNzk4MWIxYTE4YjQ2MzJhZjlkMjlmZmFjZjcyMmJjXzIxOTkwMjMyNTU3NDA_ce093cf6-26de-4d8e-848e-e40f166676ea">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of March&#160;31, 2021 and December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMS0xLTEtNDAwNQ_e570050a-1cac-4d64-8413-85ce540304f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMy0xLTEtNDAwNQ_87ff3845-1420-4cc5-89b5-cb7e2915dd9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE3NmFjNGRmYmU4MzQ5MjZhYWJmMjVlZjg3ZTdmZWRkXzE4_c25a4a0f-3aba-4b71-8164-2f89ee815300"><ix:nonFraction unitRef="usdPerShare" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE3NmFjNGRmYmU4MzQ5MjZhYWJmMjVlZjg3ZTdmZWRkXzE4_d991ecbf-6547-4271-9a49-eefc34c6cb6e">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE3NmFjNGRmYmU4MzQ5MjZhYWJmMjVlZjg3ZTdmZWRkXzMy_009edd4c-33fd-4bac-9b93-388fb34573b2"><ix:nonFraction unitRef="shares" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE3NmFjNGRmYmU4MzQ5MjZhYWJmMjVlZjg3ZTdmZWRkXzMy_b310e8c5-fbfb-40b0-b1ba-3d1d4b1978e4">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2021 and December&#160;31, 2020; <ix:nonFraction unitRef="shares" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE3NmFjNGRmYmU4MzQ5MjZhYWJmMjVlZjg3ZTdmZWRkXzEwMw_2f17f104-47c8-45bb-8ed9-54c01a8afc7d"><ix:nonFraction unitRef="shares" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE3NmFjNGRmYmU4MzQ5MjZhYWJmMjVlZjg3ZTdmZWRkXzEwMw_6deb2a24-a92d-4b87-8071-c3b588cd6d80">278,794,000</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE3NmFjNGRmYmU4MzQ5MjZhYWJmMjVlZjg3ZTdmZWRkXzExMA_373c4d9e-ebc3-4587-9661-65b8fff2dcec"><ix:nonFraction unitRef="shares" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE3NmFjNGRmYmU4MzQ5MjZhYWJmMjVlZjg3ZTdmZWRkXzExMA_d5ee47ab-eb11-4d3e-9af2-05b6065727ae">189,953,000</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMS0xLTEtMA_7f64ebea-e552-4472-ad34-b7add776fc82">28,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMy0xLTEtMA_e6c91093-664c-4f93-8e9e-a66b43fec356">19,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzUtMS0xLTEtMA_66e3d5d5-bfe9-47c6-b520-fdcea758a582">516,321,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzUtMy0xLTEtMA_3dee2f43-e6df-4fce-b2cb-2a209ec4239d">178,747,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzYtMS0xLTEtMA_4782128a-4f7e-4bbb-9c31-904e81227f60">153,631,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzYtMy0xLTEtMA_5a3a4836-da1a-4d79-8dc3-51619be4e591">143,684,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzctMS0xLTEtMA_9b581be3-72d4-4ef7-b08b-9a3abc455a76">362,718,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzctMy0xLTEtMA_f17e3def-e7e1-4ea2-ba30-ff52c9d0a4aa">35,082,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzgtMS0xLTEtMA_4c778957-4c2a-4eb4-9aef-c8fb0bd6db9c">384,861,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzgtMy0xLTEtMA_77b357c7-ed93-4d11-9a83-2825922df776">60,451,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ib388395ebea54b38b0be27fba0635b12_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:74.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.666%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c91415129394ba299d78d9ff4f67598_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMy0xLTEtMS0w_073a8ec8-7fe5-431a-b516-766b861c3446">2,049,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fd535c416994e7e9ac50885ecf579a9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMy0zLTEtMS0w_7d73003b-5dd7-42f6-be31-3bd1861553bf">983,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service and other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6482b3482014875b2110f7ee933cadf_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfNC0xLTEtMS0w_9f6d0297-8b18-4e99-a0fa-b29d141255d4">1,119,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb9a8cd4c6ae43b780d83f3db03387c6_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfNC0zLTEtMS0w_47feb14e-3846-41fa-a6aa-384b25af2630">153,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfNS0xLTEtMS0w_421bd617-6958-4b39-85bf-de028a3570ad">3,168,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfNS0zLTEtMS0w_aaf80271-ad0e-4814-9f47-a70f7a7ceabe">1,136,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c91415129394ba299d78d9ff4f67598_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfNy0xLTEtMS0w_cd4605ca-fb91-40b4-a68d-b74d9768bb24">1,513,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fd535c416994e7e9ac50885ecf579a9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfNy0zLTEtMS0w_25109434-105d-4920-a0f1-300c3a5ef287">774,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service and other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6482b3482014875b2110f7ee933cadf_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfOC0xLTEtMS0w_bc53c92d-2ec9-440f-99a0-f33897708b71">612,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb9a8cd4c6ae43b780d83f3db03387c6_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfOC0zLTEtMS0w_5c1040a2-7309-4b2a-9a12-e7d9aa29c960">82,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfOS0xLTEtMS0w_c7cd19de-1038-456d-b9f6-2c8e88c47949">2,125,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfOS0zLTEtMS0w_462b621a-1c0f-4b99-9872-8e173ce2818f">856,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTEtMS0xLTEtMA_9c1db51e-014a-4da6-8c80-4e25c4df60d0">2,678,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTEtMy0xLTEtMA_97629cca-f1ca-4160-bcb3-06de8ae96be0">2,674,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTItMS0xLTEtMA_41c91116-dce5-4324-a63f-638975b8b94d">9,528,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTItMy0xLTEtMA_e16cdf85-c635-4b6e-9c84-839fa0a26950">7,368,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTMtMS0xLTEtMA_58a7a189-58f9-4155-9fd1-0584526cd85d">12,206,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTMtMy0xLTEtMA_3093cce0-f61d-4757-8272-8f4927e46b0a">10,042,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTQtMS0xLTEtMA_db2f11b3-cfb6-45c0-9c3e-9d5a9344d4d2">11,163,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTQtMy0xLTEtMA_bcaf0729-8d81-4ad0-ac18-ae11d2b336c1">9,762,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTYtMS0xLTEtMA_e192855e-1453-4886-83da-f08fc2c5b551">538,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTYtMy0xLTEtMA_ed7c6f81-44f4-443d-ac48-9e01a30bb7b6">761,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on forgiveness of Paycheck Protection Program loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTctMS0xLTEtMA_9a1fb2b4-7980-435d-899c-341adb0bdd43">1,775,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTctMy0xLTEtMA_731d40a4-83c3-43f1-bdd2-898971a4c356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTgtMS0xLTEtMA_22dade0b-412a-416b-b9fa-311b31414bdf">15,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTgtMy0xLTEtMA_38c9beb0-ee76-4005-8698-cf75114ad3a7">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTktMS0xLTEtMA_30babe9f-fef9-455b-944f-3a074ac34e45">1,222,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTktMy0xLTEtMA_73e58355-cf0c-4a5a-8233-a69d97a8f7d4">743,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjAtMS0xLTEtMA_a42a8928-bc87-47ae-842d-e7201172bd41">9,941,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjAtMy0xLTEtMA_56da9190-c537-46a2-875a-adbcab0587da">10,505,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjEtMS0xLTEtMA_aa29470f-945c-470e-83af-b2673322db6f">6,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjEtMy0xLTEtMA_8a36103f-057d-4ef7-97a1-8172a2720ef0">5,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjItMS0xLTEtMA_31836e57-a651-454c-9712-9b8f5e1281b9">9,947,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjItMy0xLTEtMA_9176f508-9ed2-4e9c-a83d-ec4eb25d0444">10,510,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjMtMS0xLTEtMA_4f335e45-24f0-442f-ab42-e486a2164391">0.04</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjMtMy0xLTEtMA_ccd0dc72-d916-4432-8416-ca4d00420dd6">0.30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding basic and diluted</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjQtMS0xLTEtMA_73f2af46-1baf-4cf8-a418-88d270592045">263,939,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjQtMy0xLTEtMA_51416b18-d6e5-4983-9e59-3f73a658be00">35,569,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ib388395ebea54b38b0be27fba0635b12_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) (Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.604%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity (Deficit)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50064f20ffdd4afea720ea427be539bb_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMi0yLTEtMS0zNTc_074c226d-6e96-4e56-8adc-32b477348603">34,274,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50064f20ffdd4afea720ea427be539bb_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMi00LTEtMS0zNTc_c8f6db3f-26da-4aad-a741-30f04b16cedf">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8da4c0227db460e9bf1844ec2b9c95d_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMi02LTEtMS0zNTc_caa9225a-3a16-4795-b28b-1522a96b5a0e">106,188,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb3bab8827334a58a6a6a830691d74a0_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMi04LTEtMS0zNTc_f7d83b4d-5f3d-4cf6-860f-60bdf36e84fa">102,577,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cf00dd543e42b9b366c557731d37c5_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMi0xMC0xLTEtMzU3_4385c77e-39d9-4c3a-a6a9-bf7bd9d89a3c">3,614,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib602f85292f845748876e64aa8d4d2bf_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMy02LTEtMS0zNTc_4c59d56e-111a-48ce-b2dd-9d5a19535ebf">328,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMy0xMC0xLTEtMzU3_f3d8e3d2-7eaa-49cf-b950-e0d9dc255d36">328,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issue stock for warrant exercises</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90fd0d4651674579a500a712406f6ae5_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="bngo:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfNC0yLTEtMS0zNTc_513d0004-f29d-454c-9c8a-a4ee89c5e406">3,478,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90fd0d4651674579a500a712406f6ae5_D20200101-20200331" decimals="0" format="ixt:zerodash" name="bngo:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfNC00LTEtMS0zNTc_3b78de78-f4ad-45b3-b0cd-5b9e7207b6f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib602f85292f845748876e64aa8d4d2bf_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="bngo:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfNC02LTEtMS0zNTc_05da22a5-0292-4cf2-a034-c5ea59f3441d">2,355,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="bngo:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfNC0xMC0xLTEtMzU3_f223b9c2-446f-4335-beeb-7dbc8c2a0fce">2,355,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if30fe967ef764693b2f27ac326b09de3_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfNS04LTEtMS0zNTc_807a693d-a28a-46bb-a632-10f2d9b4713e">10,510,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfNS0xMC0xLTEtMzU3_f4106568-c6a6-46d0-a5aa-c167174702f4">10,510,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48e256cb75bb49168f54108a75282496_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzAtMi0xLTEtMA_3c453a0e-e5f2-4e59-987f-4e864feed951">37,752,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e256cb75bb49168f54108a75282496_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzAtNC0xLTEtMA_8234c6f2-e8f3-4f35-b834-41ebe07c6d38">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd38c3fd47774b69bb42677bde40939f_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzAtNi0xLTEtMA_1c6420ea-79d5-4dfe-b363-5efeb500f0c1">108,871,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifaaa0a63cf624180ac4a400546f607cd_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzAtOC0xLTEtMA_41947808-42f0-4d67-848e-f8500572c774">113,087,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id64fc47c76a34812be47288f3a639104_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzAtMTAtMS0xLTA_76f3df03-f36d-4810-95d8-fb4f7a4d96d8">4,213,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1721a6a1dce465eaa006a924a3e1573_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjYtMi0xLTEtMzgz_359b97c0-c5b3-4a24-bbd8-bd28035be243">189,953,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1721a6a1dce465eaa006a924a3e1573_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjYtNC0xLTEtMzgz_582ec009-65d1-4ab3-a6cb-99e63e7a645c">19,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia593fc3aadb14fda8e66f3cddea13f4a_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjYtNi0xLTEtMzgz_117d6954-d5b7-47a6-a17b-b29a4807bcf8">178,747,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dd95436f5fd45a5a4faccdc492a6ccc_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjYtOC0xLTEtMzgz_108b1d45-1876-4907-9937-acf4fcbc8865">143,684,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjYtMTAtMS0xLTM4Mw_614e2c17-5c36-4a07-ae09-f24cad7ec8cf">35,082,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option exercises</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fa524c836dc4ba397a51ffc0afdbbd4_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjctMi0xLTEtMzg2_d3736006-06c6-4905-9412-f0704915ceee">102,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c36739694c340cbb6da644df93b34b0_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjctNi0xLTEtMzg2_b7d50dea-f6d6-4daa-ba04-e3f98cae8f1f">333,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjctMTAtMS0xLTM4Ng_f5399de5-2fbd-46f9-8c36-0948101a2c24">333,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c36739694c340cbb6da644df93b34b0_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjgtNi0xLTEtMzg2_a14e4b06-bcdb-44e7-9c3d-5d6603e03634">371,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjgtMTAtMS0xLTM4Ng_23b9b22e-d3c4-49af-b638-7fe0c45738c6">371,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issue common stock, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fa524c836dc4ba397a51ffc0afdbbd4_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjktMi0xLTEtMzg2_5ccfbe7d-9b34-4fd0-a482-2ba1b078c2af">78,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa524c836dc4ba397a51ffc0afdbbd4_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjktNC0xLTEtMzg2_e0bab42c-1016-4b63-bb1c-451ec56e56e2">8,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c36739694c340cbb6da644df93b34b0_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjktNi0xLTEtMzg2_5ecdf187-7e20-419d-8606-3a9aaf76b1a4">327,478,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjktMTAtMS0xLTM4Ng_21816a0d-1264-403e-a93a-48b4ea0e7952">327,486,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issue stock for warrant exercises</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fa524c836dc4ba397a51ffc0afdbbd4_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="bngo:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzAtMi0xLTEtMzg2_94956858-5124-4ae2-b7d2-6e2731c9a74e">10,739,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa524c836dc4ba397a51ffc0afdbbd4_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="bngo:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzAtNC0xLTEtMzg2_e37082a3-ec09-4342-9382-722b59eb6317">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c36739694c340cbb6da644df93b34b0_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="bngo:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzAtNi0xLTEtMzg2_d2bee5f7-6181-47f6-980e-4b3042599f5c">9,392,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="bngo:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzAtMTAtMS0xLTM4Ng_817bd17b-d205-41b5-9775-5717fb342aca">9,393,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f252ef06c56452aa5d46538864bff17_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzEtOC0xLTEtMzg2_9074e468-602a-4f2f-8c07-e1c05cb2b5de">9,947,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzEtMTAtMS0xLTM4Ng_c030da20-5179-473d-9f3b-463ce2c719d1">9,947,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01c7339672134033bfa582f9fae89a1e_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzItMi0xLTEtMzg2_e3c2de3b-0509-4a2b-8182-05e22163c008">278,794,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01c7339672134033bfa582f9fae89a1e_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzItNC0xLTEtMzg2_3fb18a1b-8b0f-49e2-b947-834640c9c1b2">28,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b58256688454d8e9bfdde4184797f9e_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzItNi0xLTEtMzg2_9eeee503-3442-4605-a45a-b4316d50d2bc">516,321,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5b24cb157134368bae94b71658f16be_I20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzItOC0xLTEtMzg2_a12f910c-e50e-4763-9847-af4df99b29c7">153,631,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzItMTAtMS0xLTM4Ng_60ae82d8-92e6-4edb-8160-d11b06df5876">362,718,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ib388395ebea54b38b0be27fba0635b12_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMy0xLTEtMS0w_d2165489-9995-4055-b530-9be2a3bf8b0c">9,947,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMy0zLTEtMS0w_a050db37-d494-4dd4-8216-0463233c0c6d">10,510,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used by operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNS0xLTEtMS0w_2674de53-3248-451c-a3ae-308f767c46c2">448,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNS0zLTEtMS0w_9651306b-f09e-4034-94f5-2bf0240fc050">296,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaidInKindInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNi0xLTEtMS0w_c2f5ffcd-b8ee-4b5d-bbbe-0bd5ceede61b">315,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaidInKindInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNi0zLTEtMS0w_9f0a8632-cb41-4305-94a3-e5fc84ddfb49">379,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNy0xLTEtMS0w_d32ef1e5-ae79-44e7-b02f-7e3bc3d2aeb0">371,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNy0zLTEtMS0w_1f3a7966-a9b0-4ae1-9498-218e6d6d17be">328,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for bad debt expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:zerodash" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfOC0xLTEtMS0w_3fbaa9f6-6f93-4b00-91dd-29a9fb0323a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfOC0zLTEtMS0w_1476ff16-a1c4-4258-888c-7910e574089f">958,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on forgiveness of PPP Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfOS0xLTEtMS0w_6ff95f7b-8a0b-4700-9dca-76702a551d2f">1,775,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfOS0zLTEtMS0w_16d1b3d5-9eff-4758-aacf-9aa6d5f9e4cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTItMS0xLTEtMA_041d28fd-694a-408d-96f9-02ff65af79fd">783,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTItMy0xLTEtMA_3f3f7a4b-62e5-45da-8e26-43b1c80b4eb6">1,261,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTMtMS0xLTEtMA_898a2c3c-0e84-40d0-9d68-1f1c291d69f2">961,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTMtMy0xLTEtMA_a990d555-b042-457a-bfaf-92bc569741f6">635,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTQtMS0xLTEtMA_fa15ecee-628d-4c47-9916-52d58adc7c7b">1,049,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTQtMy0xLTEtMA_cfdf3404-05a3-45de-8c57-eb9bcb5b0d1a">53,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTUtMS0xLTEtMA_84e71c15-48f6-4397-a18d-a824ab6e7e8a">1,045,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTUtMy0xLTEtMA_1cf4967b-eec6-40d0-be31-e1faa640bc9e">477,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and contract liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTYtMS0xLTEtMA_8f428360-2fcd-4f91-aad2-0da4d928e05a">1,044,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTYtMy0xLTEtMA_01ce7de5-08de-4a78-9647-58083473db9d">639,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTctMS0xLTEtMA_4e7a6914-364c-458c-be7a-a804bedda178">13,904,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTctMy0xLTEtMA_05fb5fbc-a8fc-479c-909b-2302d73e3894">8,032,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjAtMS0xLTEtMA_1c18230b-49ed-4efd-bfb2-09bbaa944ed0">24,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjAtMy0xLTEtMA_0dfe6537-df76-49ee-9e39-dfdd08f687e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjEtMS0xLTEtMA_02692fc1-7f9c-4b0a-b709-f14358c31d29">24,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjEtMy0xLTEtMA_ec5e82f6-3dee-4cd3-87d6-ab94f425af4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of term-loan debt</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:zerodash" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjQtMS0xLTEtMA_841861d4-6358-40ad-8d18-50ae2d1aae0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjQtMy0xLTEtMA_0baab011-125c-498f-bb5e-e5da8e4b278e">2,100,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from borrowing from line of credit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjYtMS0xLTEtMA_9f505410-d1c8-468e-a8ca-ec6f30d2bef9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjYtMy0xLTEtMA_04af6ceb-afc2-4f1c-a3b3-0a27361145c7">761,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of borrowing from line of credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:zerodash" name="us-gaap:RepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjctMS0xLTEtMA_a0ea70bf-7b08-478e-96cf-0d12d00c366d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjctMy0xLTEtMA_1ed2b754-50be-4870-b98a-f6b789c452bd">2,156,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjgtMS0xLTEtMA_da444bd9-9c6b-41a5-a3f1-39ddee294de7">328,635,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjgtMy0xLTEtMA_2d8e75ca-469c-4570-a58c-cc11991d2623">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offering expenses on sale of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjktMS0xLTEtMzI5Mw_a9e6feb7-cf63-4ca9-9a32-9d8852475fd3">825,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjktMy0xLTEtMzcwNQ_947361b5-036f-4700-b48c-204b2db1670b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from warrant and option exercises</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzAtMS0xLTEtMA_41a20880-4b94-452a-8543-484d84665ac3">9,726,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzAtMy0xLTEtMA_3781cbce-687b-42f9-9dc5-aa506bcea7ee">2,360,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzEtMS0xLTEtMA_d0898dee-312b-4653-abac-a7184a7fc22a">337,536,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzEtMy0xLTEtMA_af32632d-1d19-490d-ab3c-a6f2905b9734">1,135,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzItMS0xLTEtMzA_c252a71d-e70c-4025-9699-4dd41c5150ab">323,608,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzItMy0xLTEtMA_b5e30431-9747-49a7-bef8-5ac6bb8e96ae">9,167,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzMtMS0xLTEtMA_c7a7ce40-db49-4303-8df8-74af2eb728b8">38,449,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cf00dd543e42b9b366c557731d37c5_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzMtMy0xLTEtMA_68845f43-53b3-40fe-bac8-a8685c5b9cbd">17,311,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzQtMS0xLTEtMA_d4ad2492-61a3-4b44-b716-a2a858d8e011">362,057,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id64fc47c76a34812be47288f3a639104_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzQtMy0xLTEtMA_7e36b228-e9ad-438b-ae47-c0c1634376cc">8,144,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzctMS0xLTEtMA_20a4a4e4-e64a-4d64-b4ce-72d25da00a31">287,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzctMy0xLTEtMA_a30ed324-dc46-4afd-87bd-4ea2fc1535b5">382,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer of instruments and servers from property and equipment into inventory</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="bngo:TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDMtMS0xLTEtMA_ef33883c-1336-4e22-aa90-e6a2507660c2">126,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:zerodash" name="bngo:TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDMtMy0xLTEtMA_da94f7e5-e3c0-405d-b151-c07ef769c52c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer of instruments and servers from inventory to property and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="bngo:TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDQtMS0xLTEtMA_aa97fd5f-5f0b-4043-8ec5-de7b5f6270e8">1,366,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="bngo:TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDQtMy0xLTEtMA_a49b9d0a-9d57-4644-8a66-aa684462e5e0">467,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forgiveness of PPP Loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDYtMS0xLTEtNDE4NA_f9380958-2838-487a-a1fe-96a45479147c">1,775,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDYtMy0xLTEtNDc0Nw_7d5fc5cb-a0ec-484a-b810-d6d666492bfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offering costs in accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="bngo:OfferingCostsIncurredNotYetPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDctMS0xLTEtNDE3Mw_6c4c9ee0-f206-4ee7-98dd-e9b7a8126e4e">324,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:zerodash" name="bngo:OfferingCostsIncurredNotYetPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDctMy0xLTEtNDE3Mw_17cd3530-e03d-4784-ba1f-0eb9044b1518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant exercise pursuant to cashless exercise</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="bngo:WarrantExerciseNonCash" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDgtMS0xLTEtNDE5Ng_84eb215d-81c4-4072-9f67-3e1c60dcb372">129,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="bngo:WarrantExerciseNonCash" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDgtMy0xLTEtNDc0OQ_b955bc98-e220-474b-a202-459b90a11529">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ib388395ebea54b38b0be27fba0635b12_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="ib388395ebea54b38b0be27fba0635b12_31"></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zMS9mcmFnOmQxMzk5YTdiOTllYTQzM2U5ZWI0ODNlYTNhZDU4ODJjL3RleHRyZWdpb246ZDEzOTlhN2I5OWVhNDMzZTllYjQ4M2VhM2FkNTg4MmNfMTk5NDk_0667ee2d-43aa-41c2-8552-c037eca2a198" continuedAt="i9c3b9b01b393451e8a8c5aaf6c846330" escape="true">Organization and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i9c3b9b01b393451e8a8c5aaf6c846330" continuedAt="i2d2aaffebb4c4d22a38b6b1b6d70b601"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bionano Genomics, Inc. (collectively, with its consolidated subsidiaries, the &#8220;Company&#8221;) is a life sciences instrumentation company in the genome analysis space that provides tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and provides diagnostic testing for those with autism spectrum disorder (&#8220;ASD&#8221;) and other neurodevelopmental disabilities through newly acquired Lineagen, Inc., a wholly owned subsidiary of the Company (&#8220;Lineagen&#8221;). The Company currently develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that is designed to enable researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who want to evaluate Saphyr data quickly and with a low up-front investment. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zMS9mcmFnOmQxMzk5YTdiOTllYTQzM2U5ZWI0ODNlYTNhZDU4ODJjL3RleHRyZWdpb246ZDEzOTlhN2I5OWVhNDMzZTllYjQ4M2VhM2FkNTg4MmNfMTk5NTI_89ccd920-12a9-41c8-8fde-4ceedddd587e" continuedAt="ie2a6e080927a4cc6b0dad04bd8e075ce" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie2a6e080927a4cc6b0dad04bd8e075ce">The accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim reporting purposes. The condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company&#8217;s management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, changes in equity, and comprehensive loss and cash flows for each period presented in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). All intercompany transactions and balances have been eliminated. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020.</ix:continuation> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="bngo:LiquidityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zMS9mcmFnOmQxMzk5YTdiOTllYTQzM2U5ZWI0ODNlYTNhZDU4ODJjL3RleHRyZWdpb246ZDEzOTlhN2I5OWVhNDMzZTllYjQ4M2VhM2FkNTg4MmNfMjE5OTAyMzMwMjI2OQ_81d49e03-b5aa-4e16-a1c4-e13f891f8ef3" continuedAt="ib74a1664a4914220a7551d114f9afce7" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zMS9mcmFnOmQxMzk5YTdiOTllYTQzM2U5ZWI0ODNlYTNhZDU4ODJjL3RleHRyZWdpb246ZDEzOTlhN2I5OWVhNDMzZTllYjQ4M2VhM2FkNTg4MmNfMjE5OTAyMzMwNDMyNA_4b92022b-42db-42a9-b5dc-38cac759e494">362.1</ix:nonFraction>&#160;million in cash and cash equivalents, and working capital of $<ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="-5" format="ixt:numdotdecimal" name="bngo:WorkingCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zMS9mcmFnOmQxMzk5YTdiOTllYTQzM2U5ZWI0ODNlYTNhZDU4ODJjL3RleHRyZWdpb246ZDEzOTlhN2I5OWVhNDMzZTllYjQ4M2VhM2FkNTg4MmNfNjU5NzA2OTgxMDcyMg_e9ff4926-9b77-487c-ae71-f9dc4aa18e2d">363.1</ix:nonFraction> million as a result of common stock offerings executed in the quarters ended December 31, 2020 and March 31, 2021. In February 2021, we applied for forgiveness of our Paycheck Protection Program (&#8220;the PPP&#8221;) Loan, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full for $<ix:nonFraction unitRef="usd" contextRef="ib8c88833ac5346e0b619cff8770a118d_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zMS9mcmFnOmQxMzk5YTdiOTllYTQzM2U5ZWI0ODNlYTNhZDU4ODJjL3RleHRyZWdpb246ZDEzOTlhN2I5OWVhNDMzZTllYjQ4M2VhM2FkNTg4MmNfNjA0NzMxNDAxMzQ4MQ_e51669ec-cc05-4fbd-afcc-61bfd34c85b4">1.8</ix:nonFraction> million. In addition, the Company has a $<ix:nonFraction unitRef="usd" contextRef="i2cec51298f734861ab7454986e9cc49e_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zMS9mcmFnOmQxMzk5YTdiOTllYTQzM2U5ZWI0ODNlYTNhZDU4ODJjL3RleHRyZWdpb246ZDEzOTlhN2I5OWVhNDMzZTllYjQ4M2VhM2FkNTg4MmNfMjE5OTAyMzMwMjI1NQ_5e3f9b0e-2a71-47a6-8dbc-7295dd87ee8f">5.0</ix:nonFraction>&#160;million revolving line of credit with Innovatus Life Sciences Lending Fund I, LP (the &#8220;Innovatus LSA&#8221;), under which no borrowings were outstanding as of March&#160;31, 2021. This facility is scheduled to expire in March 2024. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib74a1664a4914220a7551d114f9afce7">The Company believes its available cash balance will be sufficient to fund operations, obligations as they become due and capital investments for at least the next twelve months.  However, the Company expects to continue to incur net losses for the foreseeable future. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, potentially harming the Company&#8217;s business.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to additional risks and uncertainties as a result of the continued spread of COVID-19 and uncertain market conditions, which could continue to have a material impact on the Company&#8217;s business and financial results. The Company closely monitors and complies with various applicable guidelines and legal requirements in the jurisdictions in which it operates, which may continue to result in reduced business operations in response to new or existing stay-at-home orders, travel restrictions and other social distancing measures. The Company&#8217;s manufacturing partners, suppliers, and customers, have implemented similar operational restrictions. Despite reporting an increase in revenue for the three months ended March 31, 2021 when compared to the same period in 2020, the Company believes travel restrictions and overall reduced activity has negatively impacted the Company&#8217;s first quarter 2021 financial results. The future effects of COVID-19 are unknown and the Company&#8217;s financial results may continue to be negatively affected in the future.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><ix:continuation id="i2d2aaffebb4c4d22a38b6b1b6d70b601" continuedAt="i5424d6f60fe046149b548ff81ca0e426"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be long-term negative effects of the COVID-19 pandemic, even after it has subsided. Specifically, product demand may be reduced due to an economic recession, a decrease in corporate capital expenditures, prolonged unemployment, reduction in consumer confidence, or any similar negative economic condition. These negative effects could have a material impact on the Company&#8217;s operations, business, earnings, and liquidity.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, there were no changes to the Company&#8217;s significant accounting policies as described in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zMS9mcmFnOmQxMzk5YTdiOTllYTQzM2U5ZWI0ODNlYTNhZDU4ODJjL3RleHRyZWdpb246ZDEzOTlhN2I5OWVhNDMzZTllYjQ4M2VhM2FkNTg4MmNfMTk5NTY_f9498d05-a229-4693-a7de-0b97f3077713" continuedAt="i4260d2f5317d4e9eaecc14b807d61ef1" escape="true"><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued But Not Yet Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April&#160;2012, the Jump-Start Our Business Startups Act (the &#8220;JOBS Act&#8221;) was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an emerging growth company. As an emerging growth company, the Company may elect to adopt new or revised accounting standards when they become effective for non-public companies, which typically is later than when public companies must adopt the standards. The Company has elected to take advantage of the extended transition period afforded by the JOBS Act and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for emerging growth companies, which are the dates included below. However, as of May 7, 2021, the market value of the Company&#8217;s common stock held by non-affiliates exceeded $700.0&#160;million. If the market value of the Company&#8217;s common stock held by non-affiliates exceeds $700.0 million as of June 30, 2021, the Company will be a large accelerated filer and therefore will cease to be an emerging growth company effective December 31, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2015, the FASB issued Accounting Standards Update ("ASU") 2016-2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the accounting guidance for leases and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. ASU 2016-2 initially mandated a modified retrospective transition method, however, in July 2018, the FASB issued ASU 2018-11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Targeted Improvements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which amends ASU 2016-2, permitting entities the option to adopt this standard prospectively with a cumulative-effect adjustment to opening equity in the year of adoption and include required disclosures for prior periods but will not restate prior periods. The Company anticipates implementing the accounting guidance for leases using the alternative method beginning with the annual reporting period ending December 31, 2022 and interim reporting periods in 2023. The Company is in the process of evaluating the impact of adoption of the lease accounting guidance on the consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses:  Measurement of credit Losses on Financial Instruments (ASU 2016-13)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities.  The standard is effective for the company beginning in the first quarter of 2023, with early adoption permitted. The Company is currently evaluating the expected impact of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2016-13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on its financial statements.</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i5424d6f60fe046149b548ff81ca0e426" continuedAt="ie46e70ab732d40abb8c42313c88b8524"><ix:continuation id="i4260d2f5317d4e9eaecc14b807d61ef1" continuedAt="iba9e4c9d2e4a48278dc41bec20ae651e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt - Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40):  Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity ("ASU 2020-06")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2020-06</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie46e70ab732d40abb8c42313c88b8524"><ix:continuation id="iba9e4c9d2e4a48278dc41bec20ae651e"> removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also simplifies the diluted earnings per share calculation in certain areas.  The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years beginning after December 15, 2021.  For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023.  Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and adoption must be as of the beginning of the Company&#8217;s annual fiscal year. The Company&#8217;s early adoption of this accounting standard on January 1, 2021, did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</ix:continuation></ix:continuation> </span></div><div id="ib388395ebea54b38b0be27fba0635b12_34"></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNC9mcmFnOjJkNmQ5ZWIxNzA2OTRkNjQ5MTk1ZTQwNzZmYjczZDJjL3RleHRyZWdpb246MmQ2ZDllYjE3MDY5NGQ2NDkxOTVlNDA3NmZiNzNkMmNfMTA3MQ_735a4e5d-bb00-4541-8221-2ee1da809948" continuedAt="i09215323a61b49d792f10e88bfece917" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i09215323a61b49d792f10e88bfece917" continuedAt="i15bcef1d52574e32bdbbcff639c784e9"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNC9mcmFnOjJkNmQ5ZWIxNzA2OTRkNjQ5MTk1ZTQwNzZmYjczZDJjL3RleHRyZWdpb246MmQ2ZDllYjE3MDY5NGQ2NDkxOTVlNDA3NmZiNzNkMmNfMTA3Mg_293f59d8-8823-4156-a2fc-4bc0521149ad" continuedAt="i2d38c608079948d9acd319315bf1c47f" escape="true">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company&#8217;s potentially dilutive securities which include warrants and outstanding stock options under the </ix:nonNumeric></ix:continuation></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><ix:continuation id="i15bcef1d52574e32bdbbcff639c784e9"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2d38c608079948d9acd319315bf1c47f">Company&#8217;s equity incentive plan have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.</ix:continuation></span></div><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNC9mcmFnOjJkNmQ5ZWIxNzA2OTRkNjQ5MTk1ZTQwNzZmYjczZDJjL3RleHRyZWdpb246MmQ2ZDllYjE3MDY5NGQ2NDkxOTVlNDA3NmZiNzNkMmNfMTA3Mw_cc04bce5-959c-4d21-b4c1-1f30e153a311" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9fc5f9d8dd1f48fc82c0374b93861f35_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNC9mcmFnOjJkNmQ5ZWIxNzA2OTRkNjQ5MTk1ZTQwNzZmYjczZDJjL3RhYmxlOjgxMjU4MmNiMzAwNzQ1NjFiYTUxMjcxZDFiNDdmNDY2L3RhYmxlcmFuZ2U6ODEyNTgyY2IzMDA3NDU2MWJhNTEyNzFkMWI0N2Y0NjZfMS0xLTEtMS0w_8ac53865-b2a4-435a-8ab9-ec61b6b4f6a7">5,126,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60f650629d034534aa18e0699f6858da_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNC9mcmFnOjJkNmQ5ZWIxNzA2OTRkNjQ5MTk1ZTQwNzZmYjczZDJjL3RhYmxlOjgxMjU4MmNiMzAwNzQ1NjFiYTUxMjcxZDFiNDdmNDY2L3RhYmxlcmFuZ2U6ODEyNTgyY2IzMDA3NDU2MWJhNTEyNzFkMWI0N2Y0NjZfMS0zLTEtMS0w_e2bd86c9-3050-4c28-b5f4-bf644ecddcf9">2,760,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i879adebf764c47d087517666b8c85477_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNC9mcmFnOjJkNmQ5ZWIxNzA2OTRkNjQ5MTk1ZTQwNzZmYjczZDJjL3RhYmxlOjgxMjU4MmNiMzAwNzQ1NjFiYTUxMjcxZDFiNDdmNDY2L3RhYmxlcmFuZ2U6ODEyNTgyY2IzMDA3NDU2MWJhNTEyNzFkMWI0N2Y0NjZfMi0xLTEtMS0w_69f4163c-36a5-4aeb-ba10-31aa0541c7c6">4,411,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf4053f13478440e928fdfbb689fd12f_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNC9mcmFnOjJkNmQ5ZWIxNzA2OTRkNjQ5MTk1ZTQwNzZmYjczZDJjL3RhYmxlOjgxMjU4MmNiMzAwNzQ1NjFiYTUxMjcxZDFiNDdmNDY2L3RhYmxlcmFuZ2U6ODEyNTgyY2IzMDA3NDU2MWJhNTEyNzFkMWI0N2Y0NjZfMi0zLTEtMS0w_72e5333b-3aca-4c85-863e-49a6422e3c6f">24,128,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNC9mcmFnOjJkNmQ5ZWIxNzA2OTRkNjQ5MTk1ZTQwNzZmYjczZDJjL3RhYmxlOjgxMjU4MmNiMzAwNzQ1NjFiYTUxMjcxZDFiNDdmNDY2L3RhYmxlcmFuZ2U6ODEyNTgyY2IzMDA3NDU2MWJhNTEyNzFkMWI0N2Y0NjZfMy0xLTEtMS0w_9d7c82ff-7aaf-4710-9f42-ace306543d4b">9,537,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNC9mcmFnOjJkNmQ5ZWIxNzA2OTRkNjQ5MTk1ZTQwNzZmYjczZDJjL3RhYmxlOjgxMjU4MmNiMzAwNzQ1NjFiYTUxMjcxZDFiNDdmNDY2L3RhYmxlcmFuZ2U6ODEyNTgyY2IzMDA3NDU2MWJhNTEyNzFkMWI0N2Y0NjZfMy0zLTEtMS0w_64411bcf-4a64-4499-a5d7-945ab7728818">26,888,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib388395ebea54b38b0be27fba0635b12_37"></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfMTYzMA_4cb2806f-dc65-45e1-9176-fa7b583307df" continuedAt="i9dfa45d694d742eba6705709dfabd39a" escape="true">Revenue Recognition</ix:nonNumeric></span></div><ix:continuation id="i9dfa45d694d742eba6705709dfabd39a"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfMTYyNw_ab839f8e-ee4a-4d7f-8993-26f078b5704f" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Source</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9331df46b264545b015fc8dbc0eb877_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfMi0xLTEtMS0w_b963252f-6473-4286-b63e-f44b7a830584">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b1e545fdd7b4f708c5122ab52e04b28_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfMi0zLTEtMS0w_5f027ab2-787f-4cdb-8f9b-90f7e856ed9b">534,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb245ebe81e244599c7dfc4dd2951fb6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfMy0xLTEtMS0w_142450b2-403b-4967-9d94-b688e8c2cae4">1,167,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b4f7fff94f74c0092a3e332baf337ee_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfMy0zLTEtMS0w_b31b3422-a422-4c56-8b7b-bb79748b2c80">449,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c91415129394ba299d78d9ff4f67598_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfNC0xLTEtMS0w_a5b3cbc9-ced1-43f1-b8b0-5f9379697c14">2,049,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fd535c416994e7e9ac50885ecf579a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfNC0zLTEtMS0w_0e548b94-d572-48c2-964c-d379ef93b62e">983,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6482b3482014875b2110f7ee933cadf_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfNS0xLTEtMS0w_09b6c020-828e-458e-be3c-212b51122472">1,119,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb9a8cd4c6ae43b780d83f3db03387c6_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfNS0zLTEtMS0w_ede96232-5767-447d-b76a-70ae0a3c2ae5">153,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfNi0xLTEtMS0w_6969629c-3f57-4a87-836a-ffa2e0b90310">3,168,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfNi0zLTEtMS0w_b2b2ab62-4863-416d-aed0-5e4bd92f98b9">1,136,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Geographic Location</span></div><div style="margin-top:17pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.868%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cb3b2d35c0e49a0b13d2888567d6b29_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfMy0xLTEtMS0w_3e008e81-e841-4f79-be4c-e2b69c7d23ea">1,498,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic1ea4ad111304144bc23a97198dd2179_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfMy0zLTEtMS0w_5fd68443-8d08-4ed4-bb94-b4a5f91e9cac">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic08fdc3d1e534710809bdee60bba27bd_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfMy01LTEtMS0w_c196fbc7-2ce8-4aa7-a9f1-14205240e552">726,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e5ab6a8509443dba725afa8835b9601_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfMy03LTEtMS0w_80638a3f-fd9b-4984-91f9-0b0621128410">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEIA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3c3a70d23fb4e3597f16a3f336f2080_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNC0xLTEtMS0w_8c338fb0-d687-4854-8ec6-c57c545b7226">1,587,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i245ac77d088a4c08ab398de10d3c4fe0_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNC0zLTEtMS0w_fe48e914-350d-4ceb-8f62-537f7feea7fd">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2315279b594cd888242f46af032bc6_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNC01LTEtMS0w_0a45574f-57d2-4d02-857b-c8c3e2ebd41b">390,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ida0f9f015cda405dbf20c999e5715976_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNC03LTEtMS0w_f2e3ae27-c8f5-4e6e-b548-b6d35d0513f9">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9faf0a75c448aeacba6769f5a6ed6d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNS0xLTEtMS0w_f1f42457-afca-43a1-87da-b779c7fc11de">83,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic54fd087ce324e2ca363766266305d85_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNS0zLTEtMS0w_3f2bb55f-53c9-42d4-931b-f45cdaba0ae5">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52b24a224634461aa88638273374171_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNS01LTEtMS0w_2f31a5b7-56a0-45d9-9a6b-6ce757d8bd7c">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e9fe1ddcfff4117ba8ab2659f8fb841_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNS03LTEtMS0w_3150668f-1c8c-49c6-bc26-e8f045cc56c1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNi0xLTEtMS0w_abc54f0e-e50b-40eb-bc55-4f42d267e17b">3,168,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i457368c024694d3da4b660e9ad925a67_D20210101-20210331" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNi0zLTEtMS0w_c7b962a7-d658-4a52-a2dc-9a559eaec960">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNi01LTEtMS0w_cc6bdc5f-cfea-47d3-bd75-830f0e54ec1b">1,136,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ad2e939003643688e5a0c1f74143044_D20200101-20200331" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNi03LTEtMS0w_9805c10c-218b-4a43-a80b-5e60f03d941c">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above provides revenue from contracts with customers by source and geographic region (based on the customer&#8217;s billing address) on a disaggregated basis. North America consists of the United States and Canada. EMEIA consists of Europe, the Middle East, India and Africa. Asia Pacific includes China, Japan, South Korea, Singapore and Australia. For the three months ended March&#160;31, 2021 and 2020, the United States represented <ix:nonFraction unitRef="number" contextRef="i5e72dec2e62644f09291bd2256e18ae6_D20210101-20210331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfNjA0NzMxMzk1NzgyMA_06d84eda-f1f8-4e4c-8cd7-3e174c055288">44.8</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ib152c322e04e4f04b400bc01f5876b20_D20200101-20200331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfNjQ4_e52f25d3-e399-4cf7-b96f-9d267a40d7cd">63.9</ix:nonFraction>% of total revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was $<ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfOTAx_bb758265-0ab4-4fa8-b3d6-956e57a82aea">409,000</ix:nonFraction>. These remaining performance obligations primarily relate to extended warranty and support and maintenance obligations. The Company expects to recognize approximately&#160;<ix:nonFraction unitRef="number" contextRef="i73e99ee813de47559aff9fc89de5f48c_I20210331" decimals="3" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfMTA3MQ_020164d7-d860-4228-9197-eaecf317c642">64.8</ix:nonFraction>% of this amount as revenue during the remainder of 2021,&#160;<ix:nonFraction unitRef="number" contextRef="ifef7e1ffa1fc47e6b55595ac8be5b218_I20210331" decimals="3" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfMTEzMA_f69f1db2-bb65-412f-9344-3c8fc5e39815">31.1</ix:nonFraction>%&#160;in 2022, and <ix:nonFraction unitRef="number" contextRef="i47e9e0fd70444455a6640482ac8e5229_I20210331" decimals="3" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfMTE0Mg_07355c94-1ba9-401a-a92e-4469be606e48">4.1</ix:nonFraction>%&#160;in 2023.  Warranty revenue is included in Service and other revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of&#160;$<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfMTI2NA_09313c01-ff03-439c-8dd4-f6d858db92ae">156,885</ix:nonFraction>&#160;and $<ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfMTI3MQ_4eeb164e-d1da-488b-be38-97883a1d7631">127,000</ix:nonFraction> during the three months ended March&#160;31, 2021 and 2020, respectively, which was included in the contract liability balance at the end of the previous year.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ib388395ebea54b38b0be27fba0635b12_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:16pt;text-align:justify"><span><br/></span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RleHRyZWdpb246ZWIwODBlYjE3M2RkNDdlOWI4OGEwZjkzN2NhZTI3ZDdfNjI3_9b3b67d9-0d03-42fa-bfeb-6e7a38a091ce" continuedAt="idcb228abdf6542a188a0fbe9dd6f0910" escape="true">Balance Sheet Account Details</ix:nonNumeric></span></div><ix:continuation id="idcb228abdf6542a188a0fbe9dd6f0910"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:21pt;text-align:center"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RleHRyZWdpb246ZWIwODBlYjE3M2RkNDdlOWI4OGEwZjkzN2NhZTI3ZDdfNjMw_769f9e78-e341-4381-bcbb-cceaa71a3ec9" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:74.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, trade</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjU5MjlhMDQzYmM3OTQwMWJiZjRjZmRmMjM2YzBiNmVlL3RhYmxlcmFuZ2U6NTkyOWEwNDNiYzc5NDAxYmJmNGNmZGYyMzZjMGI2ZWVfMi0xLTEtMS0w_7ccff132-6937-42a8-ba2c-96346cc71707">4,083,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjU5MjlhMDQzYmM3OTQwMWJiZjRjZmRmMjM2YzBiNmVlL3RhYmxlcmFuZ2U6NTkyOWEwNDNiYzc5NDAxYmJmNGNmZGYyMzZjMGI2ZWVfMi00LTEtMS0w_3e30c8cd-35b5-4db2-8d52-f336d1acd113">4,894,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjU5MjlhMDQzYmM3OTQwMWJiZjRjZmRmMjM2YzBiNmVlL3RhYmxlcmFuZ2U6NTkyOWEwNDNiYzc5NDAxYmJmNGNmZGYyMzZjMGI2ZWVfMy0xLTEtMS0w_99dd5368-ed7a-435e-b652-fffcc212227f">2,091,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjU5MjlhMDQzYmM3OTQwMWJiZjRjZmRmMjM2YzBiNmVlL3RhYmxlcmFuZ2U6NTkyOWEwNDNiYzc5NDAxYmJmNGNmZGYyMzZjMGI2ZWVfMy00LTEtMS0w_5da88c7c-ec32-466b-b714-84b7f201fe9c">2,119,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjU5MjlhMDQzYmM3OTQwMWJiZjRjZmRmMjM2YzBiNmVlL3RhYmxlcmFuZ2U6NTkyOWEwNDNiYzc5NDAxYmJmNGNmZGYyMzZjMGI2ZWVfNC0xLTEtMS0w_178143ae-7e6d-4d25-846d-7d8d4236d52a">1,992,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjU5MjlhMDQzYmM3OTQwMWJiZjRjZmRmMjM2YzBiNmVlL3RhYmxlcmFuZ2U6NTkyOWEwNDNiYzc5NDAxYmJmNGNmZGYyMzZjMGI2ZWVfNC00LTEtMS0w_c2758c8f-f8a8-4afc-8baa-6e6e0a3ee34c">2,775,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company extends credit to its customers in the normal course of business. For diagnostic testing services, receivables are based on either contractual rates with third-party payors, plus the amounts expected to be collected for any patient-responsibility portion, or for non-contracted arrangements, using the amounts expected to be collected from third-party payors and/or the patient-customer based on historical collection experience. The Company does not perform credit evaluations and therefore subsequent adjustments to the amount expected to be collected are recorded to revenue.  The balance of our Lineagen accounts receivable balance as of March 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ia855809b84d64c008ac770b0553904dd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RleHRyZWdpb246ZWIwODBlYjE3M2RkNDdlOWI4OGEwZjkzN2NhZTI3ZDdfMjE5OTAyMzI2MTY0MQ_aea669a4-4e9a-4ce3-9b77-ab90e5d35f05">284,000</ix:nonFraction>.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For optical genome mapping (&#8220;OGM&#8221;) products and services, credit is extended based upon an evaluation of each customer&#8217;s credit history, financial condition, and other factors. Estimates of allowances for doubtful accounts are determined by evaluating individual customer circumstances, historical payment patterns, length of time past due, and economic and other factors. Bad debt expense is recorded as necessary to maintain an appropriate level of allowance for doubtful accounts in selling, general and administrative expense. During the three months ended March&#160;31, 2021, the Company recorded a recovery of bad debt expense of $(<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RleHRyZWdpb246ZWIwODBlYjE3M2RkNDdlOWI4OGEwZjkzN2NhZTI3ZDdfNjA0NzMxMzk1ODkxNA_6b1bd642-36c7-4516-a446-2d8616364a55">28,000</ix:nonFraction>), which is included in selling, general and administrative expenses. Amounts are charged to the allowance for doubtful accounts when collection efforts have been exhausted and are deemed uncollectible.</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable is subject to concentration risk whenever a customer has a balance that meets or exceeds 10.0% of the Company&#8217;s total accounts receivable balance. As of March&#160;31, 2021, there were no customer balances that met or exceeded <ix:nonFraction unitRef="number" contextRef="i36ce02702176446c8658104bea1e70b3_D20210101-20210331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RleHRyZWdpb246ZWIwODBlYjE3M2RkNDdlOWI4OGEwZjkzN2NhZTI3ZDdfNjA0NzMxMzk1Nzk0MA_d97beb50-31ef-42a4-a878-386c56925764">10.0</ix:nonFraction>% of the Company&#8217;s total accounts receivable balance. As of December&#160;31, 2020, Illumina, and Quest Diagnostics represented <ix:nonFraction unitRef="number" contextRef="ib9b6028b6f7b4c56b41bd5ae534114cb_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RleHRyZWdpb246ZWIwODBlYjE3M2RkNDdlOWI4OGEwZjkzN2NhZTI3ZDdfNjA0NzMxMzk1ODI5Nw_9e1519c2-dffc-4ca9-87ef-93a9b83c1e0d">17.3</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="i09493f03a8d24d529ba3c584f742a2e7_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RleHRyZWdpb246ZWIwODBlYjE3M2RkNDdlOWI4OGEwZjkzN2NhZTI3ZDdfNjA0NzMxMzk1ODMwNQ_098655c2-cd5e-4440-99ee-f57d510558e5">10.1</ix:nonFraction>%, respectively, of the Company&#8217;s total accounts receivable balance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or net realizable value, on a first-in, first-out basis. Inventory includes raw materials and finished goods that may be used in the research and development process and such items are expensed as consumed or expired.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for slow-moving, excess, and obsolete inventories are estimated based on product life cycles, historical experience, and usage forecasts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories are as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RleHRyZWdpb246ZWIwODBlYjE3M2RkNDdlOWI4OGEwZjkzN2NhZTI3ZDdfNjMz_7686253e-6b70-47c2-8eca-228649dd389a" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:74.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjQ5Njg5NzUwMzMxNjQ2YTE5NGEyNzllN2JjMDI4MDNhL3RhYmxlcmFuZ2U6NDk2ODk3NTAzMzE2NDZhMTk0YTI3OWU3YmMwMjgwM2FfMi0xLTEtMS0w_7ea4273c-c494-4ec0-8a1d-9378071cb272">2,736,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjQ5Njg5NzUwMzMxNjQ2YTE5NGEyNzllN2JjMDI4MDNhL3RhYmxlcmFuZ2U6NDk2ODk3NTAzMzE2NDZhMTk0YTI3OWU3YmMwMjgwM2FfMi0zLTEtMS0w_2eaa4d15-ae5f-45a9-a0cd-073ebae0069b">2,283,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjQ5Njg5NzUwMzMxNjQ2YTE5NGEyNzllN2JjMDI4MDNhL3RhYmxlcmFuZ2U6NDk2ODk3NTAzMzE2NDZhMTk0YTI3OWU3YmMwMjgwM2FfMy0xLTEtMS0w_c0091f19-9091-44ee-bbbd-fbab0612160d">300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjQ5Njg5NzUwMzMxNjQ2YTE5NGEyNzllN2JjMDI4MDNhL3RhYmxlcmFuZ2U6NDk2ODk3NTAzMzE2NDZhMTk0YTI3OWU3YmMwMjgwM2FfMy0zLTEtMS0w_5e128c7d-aba4-44ec-8385-c853158b9b30">1,033,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjQ5Njg5NzUwMzMxNjQ2YTE5NGEyNzllN2JjMDI4MDNhL3RhYmxlcmFuZ2U6NDk2ODk3NTAzMzE2NDZhMTk0YTI3OWU3YmMwMjgwM2FfNC0xLTEtMS0w_0f1c7d2c-a6de-483f-8c7f-e91e0994cb6d">3,036,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjQ5Njg5NzUwMzMxNjQ2YTE5NGEyNzllN2JjMDI4MDNhL3RhYmxlcmFuZ2U6NDk2ODk3NTAzMzE2NDZhMTk0YTI3OWU3YmMwMjgwM2FfNC0zLTEtMS0w_cfad6958-4228-43f0-9c35-c63ef372df96">3,316,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ib388395ebea54b38b0be27fba0635b12_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfOTMwNg_8e377658-4c1c-4cb3-94d1-27585f9654fe" continuedAt="i3b29179791964327a36c8d1aa749229f" escape="true">Debt </ix:nonNumeric></span></div><ix:continuation id="i3b29179791964327a36c8d1aa749229f" continuedAt="i3b0485f58d3a471dad4a7f2228f7f374"><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2020, the Company received loan proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="icb4b96f2629a437b92ce60228c4e9a9e_D20200417-20200417" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk2MjExMA_8d475036-bc2b-4304-bcad-eb89b3c79108">1.8</ix:nonFraction> million (the &#8220;PPP Loan&#8221;) pursuant to the Paycheck Protection Program (&#8220;the PPP&#8221;) under the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) administered by the U.S. Small Business Administration (the &#8220;SBA&#8221;).  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP Loan accrued interest at a rate of 1.00% per annum, and is subject to the standard terms and conditions applicable to loans administered by the SBA under the CARES Act. In February 2021, the Company applied for forgiveness of the PPP Loan, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full. A gain on forgiveness of Paycheck Protection Program loan of $<ix:nonFraction unitRef="usd" contextRef="ib8c88833ac5346e0b619cff8770a118d_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk5MTcyOA_e51669ec-cc05-4fbd-afcc-61bfd34c85b4">1.8</ix:nonFraction> million was recognized during the three months ended March&#160;31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">nnovatus LSA</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company entered into a Loan and Security Agreement (the &#8220;LSA&#8221;) by and among Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership (&#8220;Innovatus&#8221;), as collateral agent and the lenders listed on Schedule 1.1 thereto, including East West Bank. The LSA provided a first term loan of $<ix:nonFraction unitRef="usd" contextRef="i1dad41e3a2834af1a8bc37f1efe217ab_I20190331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODU3Mg_828e26e2-4cba-4c75-a5c8-47ee92a00fe4">17.5</ix:nonFraction> million, a second term loan of $<ix:nonFraction unitRef="usd" contextRef="id95f9fba9dd949fc975ddb0d090b6f9d_I20190331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODU3Ng_a996dffc-8f9d-401c-bbc1-c399a837597d">2.5</ix:nonFraction> million and a third term loan of $<ix:nonFraction unitRef="usd" contextRef="i79b1a33813d74170988e5d5afca3a502_I20190331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODU4MA_3ff8c1ce-ce90-4edf-b146-fe98d284735b">5.0</ix:nonFraction> million (collectively, the &#8220;Term Loans&#8221;) if the Company satisfied certain funding conditions. Interest on the Term Loans is due on the first of each month at a rate of <ix:nonFraction unitRef="number" contextRef="i4861f1d2c13e4caa9d9b2c243fba8ef3_I20190331" decimals="4" name="bngo:DebtInstrumentInterestRateCashRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODU4NA_62217d9d-b132-4022-8f4c-b1f298c50757">10.25</ix:nonFraction>% per annum in cash or a discounted rate of <ix:nonFraction unitRef="number" contextRef="i4861f1d2c13e4caa9d9b2c243fba8ef3_I20190331" decimals="4" name="bngo:DebtInstrumentInterestRateDiscountedCashRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODU4OA_b4eb98ad-10ab-4e93-8a76-f8deea45b8cf">7.25</ix:nonFraction>% in cash with <ix:nonFraction unitRef="number" contextRef="i1be2f4e30d224ab9a6370097d5078fb2_I20190331" decimals="3" name="bngo:DebtInstrumentInterestRateCashRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODU5Mg_562250ea-c14e-4421-9e59-eac3f57d96a5">3.0</ix:nonFraction>% of the <ix:nonFraction unitRef="number" contextRef="i4861f1d2c13e4caa9d9b2c243fba8ef3_I20190331" decimals="4" name="bngo:DebtInstrumentInterestRateCashRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODU5Ng_62217d9d-b132-4022-8f4c-b1f298c50757">10.25</ix:nonFraction>% per annum rate added to the principal of the loan and subject to accruing interest through the end of the interest only payment period, which ends March 1, 2022. At inception, the Company elected to pay interest in cash at a rate of <ix:nonFraction unitRef="number" contextRef="i4861f1d2c13e4caa9d9b2c243fba8ef3_I20190331" decimals="4" name="bngo:DebtInstrumentInterestRateDiscountedCashRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODYwMA_b4eb98ad-10ab-4e93-8a76-f8deea45b8cf">7.25</ix:nonFraction>% per annum and have <ix:nonFraction unitRef="number" contextRef="i1be2f4e30d224ab9a6370097d5078fb2_I20190331" decimals="3" name="bngo:DebtInstrumentInterestRateCashRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODYwNA_562250ea-c14e-4421-9e59-eac3f57d96a5">3.0</ix:nonFraction>% per annum of the interest added back to the outstanding principal. As of March&#160;31, 2021, the effective interest rate, including debt issuance costs, for the Term Loans was <ix:nonFraction unitRef="number" contextRef="id929d97a381842f687a1e63e52a0ed66_I20210331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODYwOA_aa493e48-a390-4f55-a872-c13128aa7379">16.7</ix:nonFraction>%. Beginning in April 2022, the Company must make <ix:nonFraction unitRef="payment" contextRef="id929d97a381842f687a1e63e52a0ed66_I20210331" decimals="INF" name="bngo:DebtInstrumentNumberOfMonthlyPayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODYxMg_a7f40f94-4953-4454-b986-5725a3c950b9">24</ix:nonFraction> equal monthly payments of principal and interest with a final maturity date in March 2024, which may be earlier due to an event of default if not cured within time specified. </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LSA provides for prepayment fees of <ix:nonFraction unitRef="number" contextRef="i471d64edc0154171beed8ed2878377a6_D20190301-20190331" decimals="3" name="bngo:DebtInstrumentPrepaymentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3OTIzMw_cfc12cfb-e190-4734-81db-b5c643587f58">3.0</ix:nonFraction>% of the outstanding balance of the loan if the loan is repaid on or prior to March 14, 2020, <ix:nonFraction unitRef="number" contextRef="i02ab7766833b447ea7ab0f07e49cf492_D20190301-20190331" decimals="3" name="bngo:DebtInstrumentPrepaymentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3OTI0MA_e64aef37-cc8a-49bd-99c1-45e691ab5791">2.0</ix:nonFraction>% of the amount prepaid if the prepayment occurs after March 14, 2020 but prior to March 14, 2021, <ix:nonFraction unitRef="number" contextRef="id9d5648907484fceb630191c98780dcf_D20190301-20190331" decimals="3" name="bngo:DebtInstrumentPrepaymentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3OTI0Nw_44bcbb63-f88b-4299-853e-66644a6c5b51">1.0</ix:nonFraction>% of the amount prepaid after March 14, 2021 but prior to March 14, 2022 and <ix:nonFraction unitRef="number" contextRef="i4677e379bf9c4e6c97c7555823337d32_D20190301-20190331" decimals="3" name="bngo:DebtInstrumentPrepaymentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3OTI1Mg_93eed779-10c7-49cb-bcdf-44c7e9bcce8d">0</ix:nonFraction>% of the amount prepaid if the prepayment occurs thereafter. In addition, upon the final repayment of the total amounts borrowed, the Company is required to pay an end of term fee of $<ix:nonFraction unitRef="usd" contextRef="i4861f1d2c13e4caa9d9b2c243fba8ef3_I20190331" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3OTI2Nw_0324256e-f972-411d-9021-e5067ac20c90">0.8</ix:nonFraction> million. This end of term fee is being recognized as interest expense over the term of the LSA. </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LSA also provides for a revolving line of credit in an amount not to exceed $<ix:nonFraction unitRef="usd" contextRef="ic76f8d3c3fd840279c87ce3ba493143a_I20190331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3OTI3MQ_df7af782-bad0-4116-ba93-3774b33061ad">5.0</ix:nonFraction> million (the &#8220;Revolver&#8221;), under which no borrowings were outstanding as of March 31, 2021 and December 31, 2020. The Company may repay and re-borrow amounts under the Revolver at any time prior to the March 1, 2024 maturity date without penalty or premium. The outstanding balance of amounts borrowed under the Revolver bears interest at a rate equal to <ix:nonFraction unitRef="number" contextRef="if1d4c4e068d445ac82a3fe2130562736_D20190301-20190331" decimals="3" name="bngo:DebtInstrumentPrepaymentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3OTI3Ng_87626062-eac8-45fb-a23b-81fffac14004">2.0</ix:nonFraction>% above the prime rate, per annum, as specified in the terms of the Revolver. The LSA allows the Company to borrow and repay amounts at any time prior to the maturity date in 2024. </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LSA is collateralized by substantially all of the Company&#8217;s assets, including its intellectual property. The LSA&#160;requires the Company to comply with various affirmative and negative covenants, including: (1) a liquidity covenant requiring the Company to maintain a minimum cash balance at all times in a collateral account and (2) a revenue covenant requiring the Company to meet certain minimum revenue targets measured at the end of each calendar quarter. The LSA also includes certain standard events of default, and a provision that Innovatus could declare an event of default upon the occurrence of any event that it interprets as having a material adverse impact to the Company&#8217;s business, operations, or condition, a material impairment on the Company&#8217;s ability to pay the secured obligations under the LSA, or upon a material adverse effect on the collateral under the agreement, thereby requiring the Company to repay the loans immediately, together with a prepayment fee and other applicable fees. As of March&#160;31, 2021, the Company believes there have been no events or changes in conditions that could require immediate repayment of amounts due to Innovatus. As of March&#160;31, 2021, the Company was in compliance with the covenants under the Innovatus LSA and the Revolver.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i3b0485f58d3a471dad4a7f2228f7f374"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Debt Obligations</span></div><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfOTMxNQ_42164987-11e2-4573-a468-5fcc0cd23f72" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company&#8217;s debt for the periods presented was as follows:</span></div><div style="margin-top:21pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bce457e3753459a8510d3d860bbde78_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfMS0xLTEtMS0w_253b4da6-398d-455a-a382-82a876c53027">16,099,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i749a55fa53994c25beda30839971df4c_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfMS0zLTEtMS0w_7b86c67a-a0d4-499f-8195-a5dd86f51064">15,981,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PPP Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f0cc44ba35648fb997a749f7937547f_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfMy0xLTEtMS0w_4616423b-36dc-487d-9023-5aa9c7317eee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57fb085856954618adbd3fae5629f1f9_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfMy0zLTEtMS0w_7d24491f-ee59-4716-a4ca-3f7b3f3817f1">1,775,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfNC0xLTEtMS0w_59ad504c-388b-4a06-8692-7269659fd67d">16,099,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfNC0zLTEtMS0w_190eef7f-1101-4012-aba1-f81778ef4d32">17,756,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfNS0xLTEtMS0w_bee64e40-9b41-41d4-9017-71e18bab0890">1,233,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfNS0zLTEtMS0w_f196d374-e18c-4a61-9ef8-9a61443faaef">1,430,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfNi0xLTEtMS0w_846664eb-502c-4276-b7c5-3cd9890cf967">14,866,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfNi0zLTEtMS0w_7e14ddd6-a464-481b-83b0-db950c55badc">16,326,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ib388395ebea54b38b0be27fba0635b12_49"></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjkzNg_74873a40-396c-441d-8d42-81f56329d576" continuedAt="iaaccffa61e5b4bcd960407bc965c51d2" escape="true">Stockholders&#8217; Equity and Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="iaaccffa61e5b4bcd960407bc965c51d2" continuedAt="i3a7d4901ef9e4879b464299c25fb8f23"><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Follow-on Public Offerings</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">On January 12, 2021, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i1412440744f4428481b3a537ab93f461_D20210112-20210112" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDc3OA_e7e8f55d-9035-4e53-bf46-ccf1772b7ecb">33,368,851</ix:nonFraction> shares of common stock, including <ix:nonFraction unitRef="shares" contextRef="i28c5c5f8564a4e67a64f3e5b44585423_D20210112-20210112" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDc5MA_794208e6-cae7-49de-a0fd-84c2b35714e5">4,352,458</ix:nonFraction> shares of common stock sold pursuant to the underwriters&#8217; exercise in full of their option to purchase additional shares. The price to the public in the offering was $<ix:nonFraction unitRef="usdPerShare" contextRef="i3cf86dab1c3a48caa595e0ad46a9aff1_I20210112" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDgwMQ_3c31ea15-6c39-4a4b-97e7-2ec4d0ff10cd">3.05</ix:nonFraction> per share and the underwriters purchased the shares from the Company pursuant to the underwriting agreement at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie718fd4d2bcb4f61b4ea90e0b1f6c96b_I20210112" decimals="3" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDgwOA_b45b5041-4476-49ee-a4f4-d37f7931cb92">2.867</ix:nonFraction> per share. The gross proceeds were approximately $<ix:nonFraction unitRef="usd" contextRef="i1412440744f4428481b3a537ab93f461_D20210112-20210112" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDgxNg_96b3844b-8ae5-4c5f-853a-03ea4e4f53b7">101.8</ix:nonFraction>&#160;million before deducting underwriting discounts and commissions and other offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i3cf86dab1c3a48caa595e0ad46a9aff1_I20210112" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NzgzOA_9a4229fb-2f8c-47c2-925f-b8e76b4dc8aa">293,000</ix:nonFraction>.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i8b5c637028ea47bd8c7f4181b517e861_D20210125-20210125" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDgzMg_fe76d91d-d67e-4684-853b-84e9e29f1270">38,333,352</ix:nonFraction> shares of common stock, including <ix:nonFraction unitRef="shares" contextRef="i588270472a6143508b7112b2fa331670_D20210125-20210125" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDg0NA_7d96c89c-cd30-4eb2-b00e-23523428fd14">5,000,002</ix:nonFraction> shares of common stock sold pursuant to the underwriters&#8217; exercise in full of their option to purchase additional shares. The price to the public in the offering was $<ix:nonFraction unitRef="usdPerShare" contextRef="i00ca1925ad5b44dfa157b479aefd1f54_I20210125" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDg1NQ_95cc904a-dcf6-4dfe-8b5d-5aecc1aefc2f">6.00</ix:nonFraction> per share and the underwriters purchased the shares from the Company pursuant to the underwriting agreement at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i573ce6b1bb9b4a1fabd1ce7fd5d82397_I20210125" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDg2Mg_5e3acf7d-6afd-47d4-8754-812eb911e16c">5.64</ix:nonFraction> per share. The gross proceeds were approximately $<ix:nonFraction unitRef="usd" contextRef="i8b5c637028ea47bd8c7f4181b517e861_D20210125-20210125" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDg2OQ_e860faf2-a591-43d1-8ce8-b27ac037c540">230.0</ix:nonFraction>&#160;million before deducting underwriting discounts and commissions and other offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i00ca1925ad5b44dfa157b479aefd1f54_I20210125" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2Nzg0Nw_c6ce493c-6e69-4466-bd86-1b269487fb2b">435,000</ix:nonFraction>.</span></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Shelf Registration Statement and Ladenburg At-the-Market Facility</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company filed a shelf registration statement on Form S-3 with the SEC covering the offering, issuance and sale of up to $<ix:nonFraction unitRef="usd" contextRef="ifd683caf9e1c44568aeff1288d3b04e1_I20200831" decimals="INF" format="ixt:numdotdecimal" name="bngo:SaleOfStockAuthorizedAmountToBeIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NTYxMw_54451fbb-ecb1-4593-960a-31350da43c2a">125.0</ix:nonFraction> million of the Company&#8217;s securities, including up to $<ix:nonFraction unitRef="usd" contextRef="i3261931611534e3383079edc1d409a1a_I20200831" decimals="INF" format="ixt:numdotdecimal" name="bngo:SaleOfStockAuthorizedAmountToBeIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NTY2Mg_31e9fc33-7cf7-4ddf-a0fa-6185cd4f13a4">40.0</ix:nonFraction> million of common stock pursuant to the Ladenburg ATM, with Ladenburg Thalmann &amp; Co. Inc. acting as sales agent. During October through December 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NTg1Nw_e01b2efc-7410-4a73-8de2-476bd0f0e4e9">27,025,384</ix:nonFraction> shares of common stock under the Ladenburg ATM at an average share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NTkzNw_f36f2063-0a0a-4c0e-b241-9507d7474d78">0.82</ix:nonFraction>, and received gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NTk4Nw_b59e6ce1-a30f-4a92-afad-343c583726a4">22.1</ix:nonFraction> million before deducting offering costs of $<ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NjAyNg_3abe379e-61e3-4498-9d1b-206aee33ff58">573,000</ix:nonFraction>. In January 2021, the Company sold an additional <ix:nonFraction unitRef="shares" contextRef="ib2decea561ca4c6794f62ce452ca3184_D20210101-20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NjA3OQ_7b87eb57-66ae-42f8-88c2-8b7b71073849">6,298,152</ix:nonFraction> shares of common stock under the ATM at an average share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i099191310b124b1e81080dfde278c6a1_I20210131" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NjE0OQ_828fc388-51b6-43de-9605-267952c32a6f">2.68</ix:nonFraction>, and received gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ib2decea561ca4c6794f62ce452ca3184_D20210101-20210131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NjE5OQ_72cb2b18-e592-435d-9d42-92a7096287a3">16.9</ix:nonFraction> million before deducting offering costs of $<ix:nonFraction unitRef="usd" contextRef="i099191310b124b1e81080dfde278c6a1_I20210131" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NjIzOA_e7990268-52dd-4501-ae32-1b8fa2f30d21">422,000</ix:nonFraction>. The Company terminated the Ladenburg ATM in March 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2021, the Company entered into the Cowen ATM which provides for the sale, in the Company&#8217;s sole discretion, of shares of common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i936534e2d9074d2ca70fe416bd8db58a_D20210323-20210323" decimals="-5" format="ixt:numdotdecimal" name="bngo:SaleOfStockValueSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MDU1OA_5d8edbe0-65cc-4d33-922f-b398a8e33beb">350.0</ix:nonFraction>&#160;million through or to Cowen, acting as sales agent or principal. The Company will pay Cowen a commission of up to <ix:nonFraction unitRef="number" contextRef="i936534e2d9074d2ca70fe416bd8db58a_D20210323-20210323" decimals="3" name="bngo:CommissionFeeMaximumPercentageOfGrossProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MDU3NA_7f6f693d-35d1-485b-b4e4-85a6d6b76764">3.0</ix:nonFraction>% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. As of the date of this filing, <ix:nonFraction unitRef="shares" contextRef="i75942e4e55054f78886bed570f1251f3_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MDU5OQ_079bf89b-e41d-4a99-b87e-f5057068e48e">no</ix:nonFraction> shares have been issued pursuant to the Cowen ATM.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><ix:continuation id="i3a7d4901ef9e4879b464299c25fb8f23" continuedAt="i1649d7c19bf54d10bcf42da147e8ecb6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock Warrants</span></div><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjkzMw_5d4a6186-f696-46a3-a14f-6b1aced437e4" escape="true"><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s warrant activity during the three months ended March&#160;31, 2021 was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:49.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Stock under Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMS0xLTEtMS0w_cc863628-e58a-4e12-8d3e-854d168a5e9e">15,174,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMS0zLTEtMS0w_36d30d9d-00c9-4bef-b84b-fa249e5c5bba">2.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3978d66a078d4604a9b13bbc463817d9_D20200101-20201231" format="ixt-sec:duryear" name="bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMS01LTEtMS0w_2dd30b2a-d99e-4aef-8f9b-ee3596c9e222">3.76</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMS03LTEtMS0w_8ace9096-c691-482f-83e8-6b199a4dd7f6">26,841,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="bngo:ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMi0xLTEtMS0w_c59cd507-e253-4d60-91ee-a987707e524e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" xsi:nil="true" name="bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMi0zLTEtMS0w_9ac69f62-81db-40f0-9850-6b571f3e71d9"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" xsi:nil="true" name="bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMi01LTEtMS0w_4b3a0dc0-be5f-452e-bb27-d8187169eedd"></ix:nonNumeric></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="bngo:ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMy0xLTEtMS0w_c49106c8-9e73-4857-9af0-b6b0a46d4ee1">10,739,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="2" name="bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMy0zLTEtMS0w_94747c63-112e-43bc-8bc9-81dd8e814504">0.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="bngo:ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMy03LTEtMS0w_160b1906-06f3-42a1-a5e3-78e0f6b706fb">57,912,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="bngo:ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfNC0xLTEtMS0w_71a86949-c8b3-4d31-baa6-ba52e8a727a3">24,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfNS0xLTEtMS0w_1787e3ad-9ef0-4617-ac50-177da825539e">4,411,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfNS0zLTEtMS0w_7a424cbc-0bcb-47b1-bdb8-2d924876ec46">5.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" format="ixt-sec:duryear" name="bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfNS01LTEtMS0w_53c5f231-8a5a-4e42-876c-8b8d9d2de125">2.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfNS03LTEtMS0w_9395a957-a633-4f5a-aee2-303a2e076bea">2,911,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:11pt;text-align:justify"><span><br/></span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjk0Mg_35e6ff74-2f95-41b2-90f8-3f70ee09504d" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity during the three months ended March&#160;31, 2021 was as follows: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Stock under Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfMS0xLTEtMS0w_92dfbe01-33ae-4c77-ab8f-a4445e917615">5,290,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfMS0zLTEtMS0w_ec5ea361-07a7-4d03-8441-e5351187d2db">1.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3978d66a078d4604a9b13bbc463817d9_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfMS01LTEtMS0w_1d8ed6a2-7ed4-49b5-88a0-d96acef57c76">8.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfMS03LTEtMS0w_1a2150e3-b4b2-4f71-9d43-1de9b684b81d">10,178,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfMi0xLTEtMS0w_343caf3c-e275-4767-872b-c7045c828043">138,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfMi0zLTEtMS0w_f32180ad-03b9-4a9f-b4f7-f07ee1a0f463">10.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfMy0xLTEtMS0w_4c260bdd-39b8-43b7-8536-d0b0396522cd">102,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfMy0zLTEtMS0w_70b34108-a9cb-4438-bcfb-6827dc8380fe">3.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfMy03LTEtMS0w_945bd5e4-3e8e-4eea-b7bf-6b93c1624a00">1,153,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNC0xLTEtMS0w_4eb84649-654e-4e1c-acc4-571ac50524b3">200,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNC0zLTEtMS0w_5b5abddc-d4c9-4e82-bbbb-c924a60e4716">0.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNS0xLTEtMS0w_5e1601b0-bfbe-4ed8-a758-0b12cdb79f45">5,126,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNS0zLTEtMS0w_c8d34d4b-2ce5-40a3-80e9-2f1ae0294923">2.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNS01LTEtMS0w_733fdc97-aeef-487c-a14d-3f414a5b12f6">8.66</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNS03LTEtMS0w_bc8abedd-e47c-403f-86c2-8a6d72680047">31,554,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNi0xLTEtMS0w_01f2edc1-dda7-407a-ae41-556bd1a8bcb3">1,704,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNi0zLTEtMS0w_75318f76-4197-47d8-887a-7dda30f547a2">3.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNi01LTEtMS0w_358caba7-1c41-40d1-8e49-8472dbc56c71">8.02</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7870f814eef549569827056ab0bbe28f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNi03LTEtMS0w_d1526146-d10f-4c83-8c85-611457dc621f">8,403,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and 2020, the weighted-average grant date fair value of stock options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjU5NzA2OTc3NTUyMg_f9324d29-c62d-4c5c-b01f-181711d92fc6">10.83</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjU5NzA2OTc3NTUyNg_c78bc293-af5e-48a5-a61d-0fcdc402f276">1.04</ix:nonFraction> per share, respectively. </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjkzNA_c140eedb-43b1-4fee-864a-8e08c0782440" escape="true"><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense for the periods presented as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i576e4374ad8d4ed4b487ff0388600fbb_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjQ2ODU0ZDFkYWE5YjQ1ZjM4MTRiN2NjYWMwZGY0OGVkL3RhYmxlcmFuZ2U6NDY4NTRkMWRhYTliNDVmMzgxNGI3Y2NhYzBkZjQ4ZWRfMi0xLTEtMS0w_807dc5ae-b717-4a2e-9354-b32703c903cc">81,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c68bbc58d744e486a0c8a007611aa9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjQ2ODU0ZDFkYWE5YjQ1ZjM4MTRiN2NjYWMwZGY0OGVkL3RhYmxlcmFuZ2U6NDY4NTRkMWRhYTliNDVmMzgxNGI3Y2NhYzBkZjQ4ZWRfMi0zLTEtMS0w_3375eb04-9420-4c36-99a7-ce3cd7f42ed8">67,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87e1c72584cb4efa9e7e2a7589d92a4d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjQ2ODU0ZDFkYWE5YjQ1ZjM4MTRiN2NjYWMwZGY0OGVkL3RhYmxlcmFuZ2U6NDY4NTRkMWRhYTliNDVmMzgxNGI3Y2NhYzBkZjQ4ZWRfMy0xLTEtMS0w_24073068-1fd1-4d00-ac85-11bbbd41cf8f">290,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaefaeb1bcc134ff2b57adb93646ab3a3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjQ2ODU0ZDFkYWE5YjQ1ZjM4MTRiN2NjYWMwZGY0OGVkL3RhYmxlcmFuZ2U6NDY4NTRkMWRhYTliNDVmMzgxNGI3Y2NhYzBkZjQ4ZWRfMy0zLTEtMS0w_52539b4d-7c9e-4b24-9cd0-38ef93a5b527">261,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjQ2ODU0ZDFkYWE5YjQ1ZjM4MTRiN2NjYWMwZGY0OGVkL3RhYmxlcmFuZ2U6NDY4NTRkMWRhYTliNDVmMzgxNGI3Y2NhYzBkZjQ4ZWRfNC0xLTEtMS0w_4cc8d4d9-5d2c-4d4c-bce9-0bbe9f2949f6">371,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjQ2ODU0ZDFkYWE5YjQ1ZjM4MTRiN2NjYWMwZGY0OGVkL3RhYmxlcmFuZ2U6NDY4NTRkMWRhYTliNDVmMzgxNGI3Y2NhYzBkZjQ4ZWRfNC0zLTEtMS0w_13a89a76-920c-4669-aadd-8389c1e0224d">328,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><ix:continuation id="i1649d7c19bf54d10bcf42da147e8ecb6"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjk0MA_4459cbea-cdd8-44bf-ad91-8e42970a1c02" escape="true"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants during the periods presented were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:73.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.677%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjNiNjkzNTI0ZDA1YTQ0OTM4NDQ0NTYyMjc5ODdmNmNhL3RhYmxlcmFuZ2U6M2I2OTM1MjRkMDVhNDQ5Mzg0NDQ1NjIyNzk4N2Y2Y2FfMi0xLTEtMS0w_930f0d01-a4b1-4326-bc39-15584492795e">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjNiNjkzNTI0ZDA1YTQ0OTM4NDQ0NTYyMjc5ODdmNmNhL3RhYmxlcmFuZ2U6M2I2OTM1MjRkMDVhNDQ5Mzg0NDQ1NjIyNzk4N2Y2Y2FfMi0zLTEtMS0w_52919a3e-0075-4960-9282-0336ef46a8a4">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjNiNjkzNTI0ZDA1YTQ0OTM4NDQ0NTYyMjc5ODdmNmNhL3RhYmxlcmFuZ2U6M2I2OTM1MjRkMDVhNDQ5Mzg0NDQ1NjIyNzk4N2Y2Y2FfMy0xLTEtMS0w_6e90b5e8-fe30-4140-8bb9-7938fd7e591d">79.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjNiNjkzNTI0ZDA1YTQ0OTM4NDQ0NTYyMjc5ODdmNmNhL3RhYmxlcmFuZ2U6M2I2OTM1MjRkMDVhNDQ5Mzg0NDQ1NjIyNzk4N2Y2Y2FfMy0zLTEtMS0w_a523fb35-ad6d-4233-96af-2d5ed9ff660f">70.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjNiNjkzNTI0ZDA1YTQ0OTM4NDQ0NTYyMjc5ODdmNmNhL3RhYmxlcmFuZ2U6M2I2OTM1MjRkMDVhNDQ5Mzg0NDQ1NjIyNzk4N2Y2Y2FfNC0xLTEtMS0w_1bea4ba8-093d-4451-a9a2-3feb084d7c34">6.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjNiNjkzNTI0ZDA1YTQ0OTM4NDQ0NTYyMjc5ODdmNmNhL3RhYmxlcmFuZ2U6M2I2OTM1MjRkMDVhNDQ5Mzg0NDQ1NjIyNzk4N2Y2Y2FfNC0zLTEtMS0w_774177de-3f54-4690-8a21-b5159f36b220">6.0</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjNiNjkzNTI0ZDA1YTQ0OTM4NDQ0NTYyMjc5ODdmNmNhL3RhYmxlcmFuZ2U6M2I2OTM1MjRkMDVhNDQ5Mzg0NDQ1NjIyNzk4N2Y2Y2FfNS0xLTEtMS0w_e6421c9a-b280-4a1d-bfcb-0918cf08666c">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjNiNjkzNTI0ZDA1YTQ0OTM4NDQ0NTYyMjc5ODdmNmNhL3RhYmxlcmFuZ2U6M2I2OTM1MjRkMDVhNDQ5Mzg0NDQ1NjIyNzk4N2Y2Y2FfNS0zLTEtMS0w_e2a0a22b-0ff8-455e-be17-e5e32d3b9341">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2021, the compensation committee of the Company&#8217;s board of directors granted <ix:nonFraction unitRef="shares" contextRef="iac856732b955418489f120209c032ca1_D20210512-20210512" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjI1OA_91b74795-a111-4288-9a74-82be8c67e7e1">580,000</ix:nonFraction> restricted stock units (&#8220;RSUs&#8221;) to R. Erik Holmlin, Ph.D., the Company&#8217;s President and Chief Executive Officer (the &#8220;Holmlin Grant&#8221;), and <ix:nonFraction unitRef="shares" contextRef="ic7ef34e0c67c4f8d810c6f8f14d356e4_D20210512-20210512" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjI2Nw_92511363-5714-4de2-8c34-2171ed82f167">240,000</ix:nonFraction> RSUs to Mark Oldakowski, the Company&#8217;s Chief Operating Officer (the &#8220;Oldakowski Grant&#8221;), in each case with an effective grant date and vesting commencement date of May 12, 2021.</span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i553916c7e88a4b47a7275965698ebdb5_D20210512-20210512" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjI3Ng_d1639b34-6efb-4cd6-8f9f-45163e1633d4">290,000</ix:nonFraction> RSUs under the Holmlin Grant are subject to time-based vesting, with <ix:nonFraction unitRef="number" contextRef="i553916c7e88a4b47a7275965698ebdb5_D20210512-20210512" decimals="2" name="bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjM3MA_fe33c868-5aad-4143-a76a-45e007b9672c">50</ix:nonFraction>% of the shares vesting on each of the first and second anniversaries of the vesting commencement date, subject to continued service through the vesting date, and <ix:nonNumeric contextRef="i553916c7e88a4b47a7275965698ebdb5_D20210512-20210512" format="ixt-sec:durmonth" name="bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjM2Mw_dd04d2f3-b915-4c04-8f31-43cc98dba7d7">18</ix:nonNumeric> months vesting acceleration upon a termination without cause or resignation with good reason.</span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie0eae5cf1a454c6a93daea25421b1ac6_D20210512-20210512" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjI4NQ_5496a9ab-c2fc-4118-85c6-91015920999c">290,000</ix:nonFraction> RSUs under the Holmlin Grant are subject to vesting upon the satisfaction of certain specified revenue targets within <ix:nonNumeric contextRef="ia7f20b922d82432990b90d2c4766e208_D20210512-20210512" format="ixt-sec:durwordsen" name="bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjM5NQ_f71237f5-7ad3-44c0-a0af-971e6dec1b38">four years</ix:nonNumeric> following the vesting commencement date. If Dr. Holmlin&#8217;s employment with the Company is terminated without cause or he resigns with good reason, then the shares will continue to be eligible for vesting upon satisfaction of the revenue targets within a period that is the shorter of <ix:nonNumeric contextRef="if952551a9010425ca3350af97034ba84_D20210512-20210512" format="ixt-sec:durmonth" name="bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjY1OA_4dcc76f2-d6bc-4c2b-92af-9f2b5dcd4989">18</ix:nonNumeric> months following termination or <ix:nonNumeric contextRef="ia7f20b922d82432990b90d2c4766e208_D20210512-20210512" format="ixt-sec:durwordsen" name="bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjY0Mg_f71237f5-7ad3-44c0-a0af-971e6dec1b38">four years</ix:nonNumeric> following the vesting commencement date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RSUs comprising the Oldakowski Grant are subject to time-based vesting, with <ix:nonFraction unitRef="number" contextRef="if35c609f5b2b4a87a6bc4013c2bc1db7_D20210512-20210512" decimals="2" name="bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjM3NQ_71e4a2ff-e6d2-482d-a24d-0239e46dea59">50</ix:nonFraction>% of the shares vesting on each of the first and second anniversaries of the vesting commencement date, subject to continued service through the vesting date.</span></div></ix:continuation><div><span><br/></span></div><div id="ib388395ebea54b38b0be27fba0635b12_52"></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81Mi9mcmFnOjZiM2I1NTg4OGRmNjRhMjRiM2FhYjQzNjRlOTUyYWIzL3RleHRyZWdpb246NmIzYjU1ODg4ZGY2NGEyNGIzYWFiNDM2NGU5NTJhYjNfNzc1_e529f224-bebe-4f2b-8ca5-eec3105d49a8" continuedAt="if214dc61e1bd4e90a8699e6a53df1423" escape="true">Litigation </ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if214dc61e1bd4e90a8699e6a53df1423">From time to time, the Company may be subject to potential liabilities under various claims and legal actions that are pending or may be asserted. These matters arise in the ordinary course and conduct of the business. The Company regularly assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on the Company&#8217;s assessment, it currently does not have any material loss exposure as it is not a defendant in any claims or legal actions.</ix:continuation></span></div><div id="ib388395ebea54b38b0be27fba0635b12_55"></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81NS9mcmFnOjQ0ODkwMzI4ODQxYTQ3ZjM4YTc4NTA1N2E0YTA4MGJjL3RleHRyZWdpb246NDQ4OTAzMjg4NDFhNDdmMzhhNzg1MDU3YTRhMDgwYmNfMTA5Nw_7788b100-7440-4577-8ce2-9b89c1373b1f" continuedAt="i5b3bd27ff6854d479774c7047a33ab75" escape="true">Income Taxes </ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5b3bd27ff6854d479774c7047a33ab75">The Company is subject to taxation in the United States, United Kingdom and various state jurisdictions. The Company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. The primary difference between the effective tax rate and the federal statutory tax rate relates to the full valuation allowance on the Company&#8217;s U.S. net operating losses.</ix:continuation></span></div><div id="ib388395ebea54b38b0be27fba0635b12_58"></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNjg0Mg_968f9b36-d3bb-4292-9ba3-28d82adfb5a8" continuedAt="i2ad034bf3aed4c589264167d24e3aa48" escape="true">Acquisition of Lineagen</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"><ix:continuation id="i2ad034bf3aed4c589264167d24e3aa48" continuedAt="i082792ee0b754399b6edd326bfd92659">On August 21, 2020, the Company, Alta Merger Sub, Inc., a wholly owned subsidiary of the Company (&#8220;Merger Sub&#8221;), Lineagen, a Delaware corporation, and Michael S. Paul, Ph.D., solely in his capacity as exclusive agent and attorney-in-fact of the security-holders of Lineagen, entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;).  Pursuant to the terms and conditions of the Merger Agreement, Merger Sub merged with and into Lineagen whereupon the separate corporate existence of Merger Sub ceased, with Lineagen continuing as the surviving corporation of the Merger as a wholly owned subsidiary of the Company. Lineagen&#8217;s expertise in development, commercialization and reimbursement of laboratory-developed tests provides a platform for accelerating sales growth for the Company&#8217;s Saphyr system.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><ix:continuation id="i082792ee0b754399b6edd326bfd92659" continuedAt="i2c3bdf922b194942b09a3fda2a94ae7e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), the shares of capital stock of Lineagen and all options of Lineagen that were issued and outstanding immediately prior to the Effective Time were automatically cancelled and extinguished without any payment with respect thereto. Certain holders of convertible notes and other indebtedness of Lineagen at the closing of the Merger (the &#8220;Closing&#8221;) received common stock of the Company. The total number of shares of the Company&#8217;s common stock issued or reserved for issuance as consideration for the Merger was <ix:nonFraction unitRef="shares" contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfMTE0Nw_7b38dd2f-3093-4275-8208-5701c8268772">6,167,510</ix:nonFraction> shares, subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen (the &#8220;Merger Shares&#8221;). <ix:nonFraction unitRef="shares" contextRef="ib33b784ee1ca47bdb4a6e098ee129696_D20200821-20200821" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfMTMyNQ_2876d167-5d26-484e-a806-f50af090f749">925,126</ix:nonFraction> of the Merger Shares (the &#8220;Escrowed Shares&#8221;) will be held in an escrow fund for purposes of satisfying any post-closing purchase price adjustments and indemnification claims under the Merger Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Also as consideration for the Merger, pursuant to the Merger Agreement, the Company paid approximately $<ix:nonFraction unitRef="usd" contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfMTYzNA_5ee79ffb-1c7e-4b1a-a00e-39553783517b">1.9</ix:nonFraction>&#160;million in cash to certain creditors and assumed certain liabilities of Lineagen totaling approximately $<ix:nonFraction unitRef="usd" contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfMTczMw_b747259a-12e9-461f-941c-af62f17acf12">2.9</ix:nonFraction>&#160;million, reflective of the Company&#8217;s preliminary estimate of the post-closing purchase price adjustment (which adjustment is subject to finalization pursuant to the terms of the Merger Agreement).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> In addition, on August 21, 2020, concurrent with the Closing, the Company paid approximately $<ix:nonFraction unitRef="usd" contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfOtherDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfMjAxOQ_0c19b4ec-e3ba-46ad-aa8c-48d453899167">1.1</ix:nonFraction>&#160;million to satisfy all outstanding principal and accrued interest amounts due pursuant to that certain Promissory Note, dated April 22, 2020, by and between Lineagen and Silicon Valley Bank (the &#8220;Lineagen PPP Loan&#8221;), issued pursuant to the CARES Act administered by the SBA. The Lineagen PPP Loan was repaid by the Company prior to maturity without penalty.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company accounted for its acquisition of Lineagen using the acquisition method of accounting pursuant to ASC 805.  The tangible and identifiable intangible assets acquired and liabilities assumed were recorded at their estimated fair values as of the acquisition date, and the excess of the purchase price over the estimated fair value assigned to the tangible and identifiable intangible assets acquired and liabilities assumed was recorded to goodwill. Goodwill relates to the expected synergies from combining the operations of the companies. The acquisition was structured as a stock sale and therefore goodwill is non-tax deductible. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As permitted under ASC 805, the Company is allowed a measurement period, which may not exceed one year, in which to complete its accounting for the acquisition. The Company has recognized provisional amounts for tax assets and liabilities, and subsequent adjustments during the measurement period to any of these items may affect the amount of goodwill recognized. During the fourth quarter of 2020, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i16b00547face45e1b37c18f6b4043c7b_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfMjE5OTAyMzI2NzU4NQ_f5ca8bbd-d211-486d-9ad5-aa46356e6ef3">232,000</ix:nonFraction> adjustment to the original purchase price allocation to reduce the estimated fair value of accounts receivable, with the offsetting amount recorded to goodwill. There were no additional purchase price adjustments made during the first quarter of 2021. The Company is still finalizing working capital adjustments with the seller.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, the purchase price for the acquisition of Lineagen is subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen. <ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNjg0Ng_ec5b38a9-42a8-4ad0-b931-d9cedc31e04f" continuedAt="ibdaab9c4376c4864b8dfa992b2928615" escape="true">The following is the estimated purchase price for the acquisition of Lineagen:</ix:nonNumeric></span></div><ix:continuation id="ibdaab9c4376c4864b8dfa992b2928615" continuedAt="icbcda64d16b046978d192836cdabd8c4"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjZhY2NhNTBjYjQ1OTQzNDVhNjFjM2VmNWNmZjJkNjcyL3RhYmxlcmFuZ2U6NmFjY2E1MGNiNDU5NDM0NWE2MWMzZWY1Y2ZmMmQ2NzJfMC0yLTEtMS0w_8cb9ce7f-9a6e-442c-8ae4-08aa163a78b9">1,940,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash transferred for repayment of Lineage PPP Loan (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfOtherDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjZhY2NhNTBjYjQ1OTQzNDVhNjFjM2VmNWNmZjJkNjcyL3RhYmxlcmFuZ2U6NmFjY2E1MGNiNDU5NDM0NWE2MWMzZWY1Y2ZmMmQ2NzJfMS0yLTEtMS0w_db8fc476-8c9b-40e1-8b12-8d1093b38fd7">1,105,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shares common stock issued as consideration (c)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjZhY2NhNTBjYjQ1OTQzNDVhNjFjM2VmNWNmZjJkNjcyL3RhYmxlcmFuZ2U6NmFjY2E1MGNiNDU5NDM0NWE2MWMzZWY1Y2ZmMmQ2NzJfMi0yLTEtMS0w_53cb403a-7fd1-467f-8835-53b513047676">6,167,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Estimated shares of common stock to be returned to the Company (c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821" decimals="INF" format="ixt:numdotdecimal" name="bngo:BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjZhY2NhNTBjYjQ1OTQzNDVhNjFjM2VmNWNmZjJkNjcyL3RhYmxlcmFuZ2U6NmFjY2E1MGNiNDU5NDM0NWE2MWMzZWY1Y2ZmMmQ2NzJfMy0yLTEtMS0w_08133c7a-6cb4-46b8-b8f9-8ec7ab22810e">138,247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock price per share on closing date </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjZhY2NhNTBjYjQ1OTQzNDVhNjFjM2VmNWNmZjJkNjcyL3RhYmxlcmFuZ2U6NmFjY2E1MGNiNDU5NDM0NWE2MWMzZWY1Y2ZmMmQ2NzJfNC0yLTEtMS0w_72eadc8f-d8d9-4753-8b0d-45590045e6ea">0.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Value of estimated common stock consideration (c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjZhY2NhNTBjYjQ1OTQzNDVhNjFjM2VmNWNmZjJkNjcyL3RhYmxlcmFuZ2U6NmFjY2E1MGNiNDU5NDM0NWE2MWMzZWY1Y2ZmMmQ2NzJfNS0yLTEtMS0w_55800711-24aa-41e9-b041-79f4ef872dfe">4,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total estimated purchase price (c)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjZhY2NhNTBjYjQ1OTQzNDVhNjFjM2VmNWNmZjJkNjcyL3RhYmxlcmFuZ2U6NmFjY2E1MGNiNDU5NDM0NWE2MWMzZWY1Y2ZmMmQ2NzJfNi0yLTEtMS0w_94a2b83e-6457-4649-8e9d-8d6c4c0b23ad">7,144,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Company paid approximately $<ix:nonFraction unitRef="usd" contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNDAyOA_4b3d02eb-e102-4194-aba6-5dd415d3c406">1.9</ix:nonFraction>&#160;million in cash to certain creditors of Lineagen.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The Company paid approximately $<ix:nonFraction unitRef="usd" contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfOtherDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNDEwOA_8e4a834e-a749-4791-8e1f-3ec8ab6e78b0">1.1</ix:nonFraction>&#160;million to satisfy all outstanding principal and accrued interest amounts due pursuant to the Lineagen PPP Loan.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icbcda64d16b046978d192836cdabd8c4">(c) The total number of shares of the Company&#8217;s common stock issued or reserved for issuance as consideration for the Merger was <ix:nonFraction unitRef="shares" contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNDM0NQ_e105b37f-4cd1-4813-86f2-dc6e437915bc">6,167,510</ix:nonFraction> shares. <ix:nonFraction unitRef="shares" contextRef="ib33b784ee1ca47bdb4a6e098ee129696_D20200821-20200821" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNDM1Ng_49071063-22dd-4e2c-b4fc-d423aa9c7bf5">925,126</ix:nonFraction> of the Merger Shares will be held in an escrow fund for purposes of satisfying any post-closing purchase price adjustments and indemnification claims under the Merger Agreement. The total number of Merger Shares is subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen. The value of the estimated common stock consideration and the total estimated purchase price incorporate the return of an estimated <ix:nonFraction unitRef="shares" contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821" decimals="INF" format="ixt:numdotdecimal" name="bngo:BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNDg1MQ_08133c7a-6cb4-46b8-b8f9-8ec7ab22810e">138,247</ix:nonFraction> Escrowed Shares to the Company based on a preliminary estimate of this adjustment.</ix:continuation> </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><ix:continuation id="i2c3bdf922b194942b09a3fda2a94ae7e" continuedAt="i444b3f220d9d41e8a17511876de50871"><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNjg0OA_ce3a4e11-302e-4744-81e2-b7b958569d9a" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated purchase price was allocated to Lineagen&#8217;s tangible and identifiable intangible assets acquired and liabilities assumed on based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.030%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjgwYmE3NzQ2YzBiMDQ1ZDliMzYxMmNhNzVmYzFkNGNiL3RhYmxlcmFuZ2U6ODBiYTc3NDZjMGIwNDVkOWIzNjEyY2E3NWZjMWQ0Y2JfMC0yLTEtMS0w_2878c1a0-b624-4888-a5fa-a288af3921fd">596,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjgwYmE3NzQ2YzBiMDQ1ZDliMzYxMmNhNzVmYzFkNGNiL3RhYmxlcmFuZ2U6ODBiYTc3NDZjMGIwNDVkOWIzNjEyY2E3NWZjMWQ0Y2JfMS0yLTEtMS0w_25a36815-025a-4520-8b75-05fdb4127ce8">337,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjgwYmE3NzQ2YzBiMDQ1ZDliMzYxMmNhNzVmYzFkNGNiL3RhYmxlcmFuZ2U6ODBiYTc3NDZjMGIwNDVkOWIzNjEyY2E3NWZjMWQ0Y2JfMi0yLTEtMS0w_d075b5df-d171-41f8-8293-f7c7dc7d8b4a">209,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjgwYmE3NzQ2YzBiMDQ1ZDliMzYxMmNhNzVmYzFkNGNiL3RhYmxlcmFuZ2U6ODBiYTc3NDZjMGIwNDVkOWIzNjEyY2E3NWZjMWQ0Y2JfMy0yLTEtMS0w_f10c9b28-77f5-4265-986c-644cfbfd0317">111,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjgwYmE3NzQ2YzBiMDQ1ZDliMzYxMmNhNzVmYzFkNGNiL3RhYmxlcmFuZ2U6ODBiYTc3NDZjMGIwNDVkOWIzNjEyY2E3NWZjMWQ0Y2JfNC0yLTEtMS0w_b27132ce-63b4-4832-aeb1-3f18cbaac4c5">1,580,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjgwYmE3NzQ2YzBiMDQ1ZDliMzYxMmNhNzVmYzFkNGNiL3RhYmxlcmFuZ2U6ODBiYTc3NDZjMGIwNDVkOWIzNjEyY2E3NWZjMWQ0Y2JfNS0yLTEtMS0w_2fc057b7-54cd-444f-aa13-34c6f5bc00fa">7,173,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts payable and other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjgwYmE3NzQ2YzBiMDQ1ZDliMzYxMmNhNzVmYzFkNGNiL3RhYmxlcmFuZ2U6ODBiYTc3NDZjMGIwNDVkOWIzNjEyY2E3NWZjMWQ0Y2JfNi0yLTEtMS0w_aedb2669-7d28-441c-8f89-c7af9e49b179">2,862,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjgwYmE3NzQ2YzBiMDQ1ZDliMzYxMmNhNzVmYzFkNGNiL3RhYmxlcmFuZ2U6ODBiYTc3NDZjMGIwNDVkOWIzNjEyY2E3NWZjMWQ0Y2JfNy0yLTEtMS0w_403dc389-6e7b-4f71-a283-66e8ec046ca6">7,144,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNjg0NA_c7c4f922-393b-477b-b5be-54e35c5cddf2" escape="true"><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair values of identifiable intangible assets acquired are as following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.030%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="idc54661388eb4fe880e68defa355cc59_I20200821" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjhiMzRhNWUxYzkyZjQwYTQ5ZTk1Y2E4NDA3ZWY2NTQ4L3RhYmxlcmFuZ2U6OGIzNGE1ZTFjOTJmNDBhNDllOTVjYTg0MDdlZjY1NDhfMC0yLTEtMS0w_d1cce296-1099-476c-b93c-4c9d2f671b17">950,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i277d7d0d7df14699a128ed991162d604_I20200821" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjhiMzRhNWUxYzkyZjQwYTQ5ZTk1Y2E4NDA3ZWY2NTQ4L3RhYmxlcmFuZ2U6OGIzNGE1ZTFjOTJmNDBhNDllOTVjYTg0MDdlZjY1NDhfMS0yLTEtMS0w_ee5f04e9-79ef-419c-a663-e81f8992e1c6">630,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of identifiable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjhiMzRhNWUxYzkyZjQwYTQ5ZTk1Y2E4NDA3ZWY2NTQ4L3RhYmxlcmFuZ2U6OGIzNGE1ZTFjOTJmNDBhNDllOTVjYTg0MDdlZjY1NDhfMi0yLTEtMS0w_065952af-922a-42e2-9cfe-2220b4f794e4">1,580,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The customer relationships and trade name intangibles are both being amortized on a straight-line basis over their estimated useful lives of <ix:nonNumeric contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821" format="ixt-sec:durwordsen" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNTQzNw_6ade58d4-ec71-4d0d-8ab3-2580ca15e5ae">five years</ix:nonNumeric>. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma financial information in the table below summarizes the combined results of operations for the Company and Lineagen as if the companies had been combined as of January 1, 2019. <ix:nonNumeric contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfMjE5OTAyMzI3MDcwMg_b590a3ae-348f-4755-bb12-b436e4eb7b4a" continuedAt="ic1e64961b59940bab90ea5ca562dc5b6" escape="true">The unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisition had taken place as of January 1, 2019.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="ic1e64961b59940bab90ea5ca562dc5b6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.761%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08b91758924d4450afbd57d83b618e31_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOmUwYTRhNmJiMjdmMzQyOTliYTc4YmIwNjUwMzRhMDE2L3RhYmxlcmFuZ2U6ZTBhNGE2YmIyN2YzNDI5OWJhNzhiYjA2NTAzNGEwMTZfMi0yLTEtMS00MDg0_0747ab3f-d49d-45b3-bac2-df0f1471abeb">2,676,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08b91758924d4450afbd57d83b618e31_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOmUwYTRhNmJiMjdmMzQyOTliYTc4YmIwNjUwMzRhMDE2L3RhYmxlcmFuZ2U6ZTBhNGE2YmIyN2YzNDI5OWJhNzhiYjA2NTAzNGEwMTZfMy0yLTEtMS00MDg0_b9b2689c-ecd4-4791-aa76-5bdf2ec22c11">11,637,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Basic and diluted net loss per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOmUwYTRhNmJiMjdmMzQyOTliYTc4YmIwNjUwMzRhMDE2L3RhYmxlcmFuZ2U6ZTBhNGE2YmIyN2YzNDI5OWJhNzhiYjA2NTAzNGEwMTZfNC0yLTEtMS00MDg3_3c411d43-259d-4f55-a86a-4608d4c1fe0b"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOmUwYTRhNmJiMjdmMzQyOTliYTc4YmIwNjUwMzRhMDE2L3RhYmxlcmFuZ2U6ZTBhNGE2YmIyN2YzNDI5OWJhNzhiYjA2NTAzNGEwMTZfNC0yLTEtMS00MDg3_7a3e4a59-6dd1-435f-8fb1-0e977e338c9c">0.28</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i444b3f220d9d41e8a17511876de50871">These amounts have been calculated after applying the Company&#8217;s accounting policies and adjusting the results of Lineagen to reflect (i) additional amortization that would have been charged based upon the fair value of the acquired intangible assets of  $<ix:nonFraction unitRef="usd" contextRef="if4a769484c39497e8dc3a7a689f2d800_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfMjE5OTAyMzI3MzUxOA_c82b9d67-a596-4620-ad7b-04a226dfc330">77,000</ix:nonFraction> for the three months ended  March&#160;31, 2020; and (ii) the removal of interest expense related to the historical debt of Lineagen which was not acquired of $<ix:nonFraction unitRef="usd" contextRef="if4a769484c39497e8dc3a7a689f2d800_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfMjE5OTAyMzI3MzUyOA_3dbaf9cd-642c-4aef-854a-6708107205fb">312,000</ix:nonFraction> or the three months ended  March&#160;31, 2020</ix:continuation>.</span></div><div id="ib388395ebea54b38b0be27fba0635b12_61"></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto as of and for the year ended December&#160;31, 2020 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K, or our Annual Report, filed with the Securities and Exchange Commission, or the SEC, on March 23, 2021. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Bionano Genomics, Inc. and its subsidiaries or, as the context may require, Bionano Genomics, Inc. only.</span></div><div id="ib388395ebea54b38b0be27fba0635b12_64"></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the &#8220;safe harbor&#8221; created by those sections. These forward-looking statements include, but are not limited to any statements concerning the potential effects of the COVID-19 pandemic on our business, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in our filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements.</span></div><div id="ib388395ebea54b38b0be27fba0635b12_67"></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a life sciences instrumentation company in the genome analysis space that provides tools and services based on our Saphyr system to scientists and clinicians conducting genetic research and patient testing, and provides diagnostic testing for those with autism spectrum disorder (&#8220;ASD&#8221;) and other neurodevelopmental disabilities through Lineagen, Inc., our wholly owned subsidiary (&#8220;Lineagen&#8221;). We develop and market the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Our Saphyr system comprises an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who want to evaluate Saphyr data quickly and with a low up-front investment. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred losses in each year since our inception. Our net loss was $9.9 million for the three months ended March&#160;31, 2021. As of March&#160;31, 2021, we had an accumulated deficit of $153.6 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and operating losses as we:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expand our sales and marketing efforts to further commercialize our products;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue research and development efforts to improve our existing products;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">hire additional personnel;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">enter into collaboration arrangements, if any;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">add operational, financial and management information systems; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">incur increased costs as a result of operating as a public company.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Recent Highlights</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We shipped 11 Saphyr systems during the quarter ended March 31, 2021, compared to 5 systems shipped in the same quarter in 2020. The installed base of Saphyr systems was 107 at the end of the quarter.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sold 2,603 nanochannel array flow cells during the quarter ended March 31, 2021, which represents an increase of 275% over the same period in 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyzed 227 samples in our Saphyr service lab.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Overview</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic, and the measures imposed to contain this pandemic in areas where we operate our business and elsewhere have disrupted and are expected to continue to impact our business. For example, to comply with applicable regulations and to safeguard the health and safety of our employees and customers, we temporarily reduced our on-site business operations, implemented work-from-home practices, and modified other business practices, including those related to employee travel and physical participation in meetings, events, and conferences.  Limited access to our facilities or customer sites has adversely affected, and is expected to continue to adversely affect, our operations.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions resulting from the COVID-19 pandemic may continue to impact our operations and overall business. The impact of COVID-19 is evolving rapidly and its future effects remain uncertain. As a result of such uncertainties, the duration of the disruption and the related impact on our business, operating results and financial condition cannot be reasonably estimated at this time. We are continuing to closely monitor the impact of the COVID-19 pandemic on our business and are taking proactive </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efforts designed to protect the health and safety of our workforce, continue our business operations and advance our corporate objectives. </span></div><div id="ib388395ebea54b38b0be27fba0635b12_70"></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate product revenue from sales of our instruments and consumables. We currently sell our products for research use only applications and our customers are primarily laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology and contract research companies. Consumable revenue consists of sales of complete assays which are developed internally by us, plus sales of kits which contain all the elements necessary to run tests. We also generate service revenue from the sale of diagnostic testing services for those with autism spectrum disorder and other neurodevelopmental disabilities through our wholly owned subsidiary Lineagen. Other revenue consists of warranty and other service-based revenue.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our revenue for the periods indicated:</span></div><div style="margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:69.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.038%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service and other revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,168,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes $851,000 of revenue generated from Lineagen during the three months ended March&#160;31, 2021.</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects total revenue by geography and as a percentage of total revenue, based on the billing address of our customers. North America consists of the United States and Canada. EMEIA consists of Europe, Middle East, India and Africa. Asia Pacific includes China, Japan, South Korea, Singapore and Australia.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:56.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.048%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,498,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEIA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,168,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes $851,000 of revenue generated from Lineagen during the three months ended March&#160;31, 2021.</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenue for our instruments and consumables includes costs from the manufacturer, raw material parts costs and associated freight, shipping and handling costs, contract manufacturer costs, salaries and other personnel costs, overhead and other direct costs related to those sales recognized as product revenue in the period. Cost of service revenue consists of third-party laboratory costs to process the diagnostic samples, salaries of our clinical technicians who interpret and deliver the results to patients, warranty services, and other costs of servicing equipment at customer sites.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of salaries and other personnel costs, stock-based compensation, research supplies, third-party development costs for new products, materials for prototypes, and allocated overhead costs that include facility and other overhead costs. We have made substantial investments in research and development since our inception, and plan to continue to make investments in the future. Our research and development efforts have focused primarily on the tasks required to support development and commercialization of new and existing products. We believe that our continued investment in research and development is essential to our long-term competitive position.</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of salaries and other personnel costs, and stock-based compensation for our sales and marketing, finance, legal, human resources and general management, as well as professional services, such as legal and accounting services.</span></div><div id="ib388395ebea54b38b0be27fba0635b12_73"></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March 31, 2021 and 2020 </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our results of operations for the three months ended March&#160;31, 2021 and 2020:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period-to-Period Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service and other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,168,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,032,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,125,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,678,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,528,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,368,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,206,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,042,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,164,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,163,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,762,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,401,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expenses):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(538,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(761,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on forgiveness of Paycheck Protection Program loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expenses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expenses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(743,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,965,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,941,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,505,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,947,000)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,510,000)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased by $2.0 million, or 178.9%, to $3.2 million for the three months ended March&#160;31, 2021 compared to $1.1&#160;million for the same period in 2020.  The increase impacted all regions. The increase in product sales was driven by increased demand of our reagent rental program and consumables, while the increase in service and other revenue was mostly driven by sales generated by our Lineagen subsidiary. Furthermore, below is a summary of changes for the three months ended March&#160;31, 2021 as compared to the same period in 2020: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">North America revenue increased by $0.8 million, or 106%;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">EMEIA revenue increased by $1.2 million, or 307%; and</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Asia Pacific revenue increased by $0.1 million, or 315%.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the three months ended March&#160;31, 2021, includes service revenue of $0.9&#160;million generated from our Lineagen subsidiary. </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cost of revenue increased by $1.3 million, or 148.2%, to $2.1 million for the three months ended March&#160;31, 2021 compared to $0.9 million for the same period in 2020. The increase was primarily due to a shift in our product mix towards higher margin consumables and services.</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $2.2 million, or 29.3%, to $9.5 million for the three months ended March&#160;31, 2021 compared to $7.4 million for the same period in 2020. This is primarily due to additional headcount-related costs resulting from the acquisition of Lineagen, completed in August 2020. These were offset by a decrease in bad debt expense by $1.0M when compared to the same period last year.</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased by $0.2 million, or 29.3%, to $0.5 million for the three months ended March&#160;31, 2021 compared to $0.8 million for the same period in 2020, driven by changes in our term-loan debt.  In April 2020, we paid down $5 million of the $20 million outstanding under the Innovatus LSA (as defined below), resulting in a decrease to our quarterly interest expense.</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain on forgiveness of Paycheck Protection Program loan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A gain on forgiveness of Paycheck Protection Program loan of $1.8 million was recognized during the three months ended March&#160;31, 2021 in connection with the forgiveness of our PPP Loan (as defined below), including all accrued interest in full.</span></div><div id="ib388395ebea54b38b0be27fba0635b12_76"></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred net losses and negative cash flows from operations. We have primarily generated cash flows from sales of equity securities and debt financing. We anticipate that future sources of liquidity will principally come from sales of common stock and other equity instruments, borrowings from credit facilities and revenue from our commercial operations. See Note 6 to our condensed consolidated financial statements for a discussion of our recent equity activity and Note 5 to our condensed consolidated financial statements for a discussion of terms and provisions of our debt included elsewhere in this Quarterly Report on Form 10-Q for more information. We incurred net losses of $9.9 million and $10.5 million for the three months ended March&#160;31, 2021 and 2020, respectively. As of March&#160;31, 2021, we had an accumulated deficit of $153.6 million and cash and cash equivalents of $362.1 million. </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the cash flow from operating, investing and financing activities for the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:72.056%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.733%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by (used in):</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,904,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,032,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,536,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,135,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive cash flows from operations primarily from the sale of our products and services. Our cash flows from operating activities are also significantly influenced by our use of cash for operating expenses to support the growth of our business. We have historically experienced negative cash flows from operating activities as we have developed our technology, expanded our business and built our infrastructure and this may continue in the future.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $13.9 million during the three months ended March&#160;31, 2021 as compared to $8.0 million during the same period in 2020. The increase in cash used in operating activities of $5.9 million is primarily attributed to increased headcount-related costs resulting from the acquisition of Lineagen. </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our primary investing activities have consisted of capital expenditures for the purchase of capital equipment to support our expanding infrastructure. We expect to continue to incur additional costs for capital expenditures related to these efforts in future periods. During the three months ended March&#160;31, 2021, cash used in investing activities was negligible.</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $337.5 million during the three months ended March&#160;31, 2021 as compared to the same period in 2020 where we had net cash used in financing activities of $1.1 million, an increase of $338.7 million. During the three months ended March&#160;31, 2021, we raised approximately $328.6 million in net proceeds from executing two follow-on offerings and sales under our at-the-market facility with Ladenburg Thalmann.  In addition, we raised approximately $9.7 million from warrant and option exercises.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we received loan proceeds of approximately $1.8 million (the &#8220;PPP Loan&#8221;) pursuant to the Paycheck Protection Program (&#8220;the PPP&#8221;) under the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) administered by the U.S. Small Business Administration (the &#8220;SBA&#8221;).  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP Loan accrued  interest at a rate of 1.00% per annum, and is subject to the standard terms and conditions applicable to loans administered by the SBA under the CARES Act. In February 2021, we applied for forgiveness of the PPP Loan, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the CARES Act, recipients of loans under the PPP can apply for and be granted forgiveness for all or a portion of such loan granted under the PPP. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for payment of payroll costs and certain other eligible costs (the &#8220;Eligible Costs&#8221;). Pursuant to the Paycheck Protection Program Flexibility Act (the &#8220;PPPFA&#8221;), enacted on June 5, 2020, we were permitted to use loan proceeds on Eligible Costs through October 2, 2020, or the date that was 24 weeks from the PPP Loan origination date (the &#8220;Covered Period&#8221;). In order to apply for the PPP Loan, we were required to certify, among other things, that the current economic uncertainty made the PPP Loan request necessary to support our ongoing operations. This certification further required us to take into account the maintenance of our workforce, our need for additional funding to continue operations, and our ability to access alternative forms of capital in the current market environment to offset the effects of the COVID-19 pandemic.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP Loan is also described in Note 5 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Resources</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2021, we had approximately $362.1 million in cash and cash equivalents, and working capital of $363.1 million. We have a $5.0 million revolving line of credit with Innovatus Life Sciences Lending Fund I, LP (the &#8220;Innovatus LSA&#8221;), under which no borrowings were outstanding as of March&#160;31, 2021. This facility is scheduled to expire in March 2024. In addition, the carrying value of our outstanding debt as of March&#160;31, 2021 was $14.9 million.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we filed a shelf registration statement on Form S-3 with the SEC covering the offering, issuance and sale of up to $125.0 million of our securities, including up to $40.0 million of common stock pursuant to an at-the-market facility (&#8220;ATM&#8221;) with Ladenburg Thalmann &amp; Co. Inc. acting as sales agent. During October through December 2020, we sold 27,025,384 shares of common stock under the ATM at an average share price of $0.82, and received gross proceeds of approximately $22.1 million before deducting offering costs of $573,263. In January 2021, we sold an additional 6,298,152 shares of common stock under the ATM at an average share price of $2.68, and received gross proceeds of approximately $16.9 million before deducting offering costs of $422,034. The Ladenburg ATM was terminated effective March 22, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2021, we completed an underwritten public offering of 33,368,851 shares of common stock, including 4,352,458 shares of common stock sold pursuant to the underwriters&#8217; exercise in full of their option to purchase additional shares. The price to the public in the offering was $3.05 per share and the underwriters purchased the shares from us pursuant to </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the underwriting agreement at a price of $2.867 per share. The gross proceeds were approximately $101.8 million before deducting underwriting discounts and commissions and other offering expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 19, 2021, we filed an automatically effective shelf registration statement on Form S-3 (File No. 333-252216) with the SEC as a &#8220;well-known seasoned issuer.&#8221; The registration statement allows us to issue an indeterminate number or amount of common stock, preferred stock, debt securities and warrants from time to time in one or more offerings. However, there can be no assurance that we will complete any such offerings of securities. Any future offerings under this registration statement will be dependent upon, among other factors, market conditions, available pricing, our financial condition, investor perception of our prospects, our capital needs and our ability to maintain status as a well-known seasoned issuer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, we completed an underwritten public offering of 38,333,352 shares of common stock, including 5,000,002 shares of common stock sold pursuant to the underwriters&#8217; exercise in full of their option to purchase additional shares. The price to the public in the offering was $6.00 per share and the underwriters purchased the shares from us pursuant to the underwriting agreement at a price of $5.64 per share. The gross proceeds were approximately $230.0 million before deducting underwriting discounts and commissions and other offering expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2021, we entered into a Sales Agreement with Cowen and Company, LLC (&#8220;Cowen&#8221;), pursuant to which we may offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $350.0 million, through or to Cowen, acting as sales agent or principal.  As of the date of this filing, no shares have been issued pursuant to this Sales Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes the available cash balance will be sufficient to fund operations, obligations as they become due and capital investments for at least the next twelve months. See Note 1 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for more information.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib388395ebea54b38b0be27fba0635b12_79"></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules, and similarly did not and do not have any holdings in variable interest entities.</span></div><div id="ib388395ebea54b38b0be27fba0635b12_82"></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements requires us to make estimates and assumptions that materially affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and accompanying notes. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may materially differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes in our critical accounting policies and estimates during the three months ended March&#160;31, 2021. See Note 2 to the condensed consolidated financial statements in our Annual Report.&#160;&#160;&#160;&#160;</span></div><div id="ib388395ebea54b38b0be27fba0635b12_85"></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 1 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for information concerning recent accounting pronouncements.</span></div><div id="ib388395ebea54b38b0be27fba0635b12_88"></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a smaller reporting company, we are not required to provide information typically disclosed under this Item.</span></div><div id="ib388395ebea54b38b0be27fba0635b12_91"></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Disclosure controls and procedures are controls and other procedures </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">designed to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the evaluation of our disclosure controls and procedures as of March&#160;31, 2021, our principal executive and financial officer concluded that, as of such date, our disclosure controls and procedures were not effective at a reasonable assurance level as a result of the material weakness that existed in our internal control over financial reporting, as described below and previously reported in our Annual Report.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Material Weaknesses in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the preparation of our consolidated financial statements for the year ended December 31, 2020, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013 Framework). Based on this assessment, our management determined that, as of December 31, 2020 and March&#160;31, 2021, there was a material weakness in our internal control environment over financial reporting because we did not have a sufficient number of resources to support the growth and complexity of our financial reporting requirements. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that a reasonable possibility exists that a material misstatement of our annual or interim financial statements would not be prevented or detected on a timely basis. The foregoing material weakness contributed to a material weakness in our control activities based on the criteria set forth in the 2013 Framework. Specifically, the design of certain controls did not adequately provide appropriate segregation of duties and allow timely completion of financial reporting and accounting activities. The failure to maintain appropriate segregation of duties had a pervasive impact and as such, this deficiency resulted in a risk that could have impacted all financial statement account balances and disclosures. The material weaknesses did not result in any identified material misstatements to our financial statements, and there were no changes to previously released financial results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Remediation of Material Weaknesses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has been actively engaged in developing and implementing a remediation plan to address the material weaknesses described above. The remediation efforts that are in process or expected to be implemented include the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">Management has engaged external consultants to assist with our internal accounting functions and further enhance our internal controls which has increased the number of personnel involved in financial reporting.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">We recently hired a new Chief Financial Officer and are in the process of hiring additional qualified individuals that will increase the number of personnel involved in financial reporting and the control environment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional resources and procedures described above are designed to enable us to broaden the scope and quality of our internal review of underlying information related to financial reporting and to formalize and enhance our internal control procedures. While the implementation of improved controls and procedures is ongoing, we have determined that as of March&#160;31, 2021 that the material weaknesses described above have not been fully remediated.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the remediation efforts underway, as described above, there were no material changes in our internal control over financial reporting during the quarter ended March&#160;31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="ib388395ebea54b38b0be27fba0635b12_94"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="ib388395ebea54b38b0be27fba0635b12_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1. LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ib388395ebea54b38b0be27fba0635b12_100"></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A. RISK FACTORS</span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Below is a summary of the principal factors that make an investment in our securities speculative or risky. This summary does not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">address</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> all of the risks that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, and other risks and uncertainties that we face, are set forth below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q and our other filings with the SEC before making investment decisions regarding our securities.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred recurring net losses since we were formed and expect to incur losses in the future. We cannot be certain that we will achieve or sustain profitability;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our quarterly and annual operating results and cash flows have fluctuated in the past and might continue to fluctuate, which could cause the market price of our securities to decline substantially;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are an early, commercial-stage company and have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business, and that of our customers, has been adversely affected by the effects of public health crises, including the COVID-19 pandemic; in particular, the COVID-19 pandemic has materially affected our operations globally, including at our headquarters in San Diego, California, as well as the business or operations of our research partners, customers and other third parties with whom we conduct business;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future capital needs are uncertain and we will require additional funding in the future to advance the commercialization of Saphyr and our other products, as well as continue our research and development efforts; if we fail to obtain additional funding, we will be forced to delay, reduce or eliminate our commercialization and development efforts;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our products fail to achieve and sustain sufficient market acceptance, our revenue will be adversely affected;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success is dependent upon our ability to further penetrate our existing customer base and attract new customers;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently limited to &#8220;research use only&#8221; with respect to many of the materials and components used in our consumable products including our assays;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the near term, sales of our Saphyr system, consumables and genome analysis service will depend on levels of research and development spending by academic and governmental research institutions and biopharmaceutical companies, a reduction in which could limit demand for our products and adversely affect our business and operating results;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not successfully manage the development and launch of new products, our financial results could be adversely affected;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the FDA determines that our RUO products are medical devices or if we seek to market our RUO products for clinical diagnostic or health screening use, we will be required to obtain regulatory clearance(s) or approval(s), and may be required to cease or limit sales of our then marketed products, which could materially and adversely affect our business, financial condition and results of operations. Any such regulatory process would be expensive, time-consuming and uncertain both in timing and in outcome;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect our intellectual property, it may reduce our ability to maintain any technological or competitive advantage over our competitors and potential competitors, and our business may be harmed; </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The terms of our debt facility place restrictions on our operating and financial flexibility, and failure to comply with covenants or to satisfy certain conditions of the agreement governing the debt facility may result in acceleration of our repayment obligations and foreclosure on our pledged assets, which could significantly harm our liquidity, financial condition, operating results, business and prospects and cause the price of our securities to decline; and</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;The price of our securities may be volatile, and you could lose all or part of your investment.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">RISK FACTORS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the following risk factors, together with other information in this Quarterly Report on Form 10-Q and our other filings with the SEC, before making investment decisions regarding our securities. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. The risks described below are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. We have marked with an asterisk (*) those risk factors that reflect changes from the risk factors previously disclosed in Item 1A of our Annual Report. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="ib388395ebea54b38b0be27fba0635b12_1037"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our financial condition and need for additional capital</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred recurring net losses since we were formed and expect to incur losses in the future. We cannot be certain that we will achieve or sustain profitability.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred net losses of $9.9&#160;million and $10.5&#160;million, and used cash in operations of $13.9&#160;million and $8.0&#160;million for the three months ended March&#160;31, 2021 and 2020, respectively. As of March&#160;31, 2021, we had an accumulated deficit of $153.6&#160;million. We cannot predict if we will achieve sustained profitability in the near future or at all. We expect that our losses will continue for the foreseeable future as we plan to invest significant additional funds toward expansion of our commercial organization and the development of our technology. In addition, as a public company, we will incur significant legal, accounting, and other expenses that we did not incur as a private company. These increased expenses will make it harder for us to achieve and sustain future profitability. We may incur significant losses in the future for a number of reasons, many of which are beyond our control, including the other risks described in this Annual Report, the market acceptance of our products, future product development and our market penetration and margins.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly and annual operating results and cash flows have fluctuated in the past and might continue to fluctuate, which could cause the market price of our securities to decline substantially. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous factors, many of which are outside our control, may cause or contribute to significant fluctuations in our quarterly and annual operating results. These fluctuations may make financial planning and forecasting uncertain. In addition, these fluctuations may result in unanticipated decreases in our available cash, which could negatively affect our business and prospects. In addition, one or more of such factors may cause our revenue or operating expenses in one period to be disproportionately higher or lower relative to the others. As a result, comparing our operating results on a period-to-period basis might not be meaningful. You should not rely on our past results as indicative of our future performance. Moreover, our stock price might be based on expectations of future performance that are unrealistic or that we might not meet and, if our revenue or operating results fall below the expectations of investors or securities analysts, the price of our securities could decline substantially. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results have varied in the past. In addition to other risk factors listed in this section, some of the important factors that may cause fluctuations in our quarterly and annual operating results include: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adoption of our systems and related products;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of customer orders to purchase our systems;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate of utilization of consumables by our customers;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt and timing of revenue for services provided by out data solutions service;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of the introduction of new systems, products, system and product enhancements and services; </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully execute our sales and marketing strategy for our Lineagen products and diagnostic assays; and </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the receipt and timing of revenue from our distribution and marketing arrangements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a significant portion of our operating expense is relatively fixed in nature, and planned expenditures are based in part on expectations regarding future revenue. Accordingly, unexpected revenue shortfalls could decrease our gross margins and cause significant changes in our operating results from quarter to quarter. If this occurs, the trading price of our securities could fall substantially.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an early commercial-stage company and have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an early commercial-stage company and have a limited commercial history. Our limited commercial history may make it difficult to evaluate our current business and makes predictions about our future success or viability subject to significant uncertainty. We will continue to encounter risks and difficulties frequently experienced by early, commercial-stage companies, including scaling up our infrastructure and headcount. If we do not address these risks successfully, our business will suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain adequate revenue growth or do not successfully manage such growth, our business and growth prospects will be harmed. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not achieve substantial growth rates in future periods. Investors should not rely on our operating results for any prior periods as an indication of our future operating performance. To effectively manage our anticipated future growth, we must continue to maintain and enhance our financial, accounting, manufacturing, customer support and sales administration systems, processes and controls. Failure to effectively manage our anticipated growth could lead us to over-invest or under-invest in development, operational and administrative infrastructure; result in weaknesses in our infrastructure, systems, or controls; give </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rise to operational mistakes, losses, loss of customers, productivity or business opportunities; and result in loss of employees and reduced productivity of remaining employees. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our continued growth could require significant capital expenditures and might divert financial resources from other projects such as the development of new products and services. As additional products are commercialized, we may need to incorporate new equipment, implement new technology systems, or hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher product costs, declining product quality, deteriorating customer service, and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products, and could damage our reputation and the prospects for our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our management is unable to effectively manage our anticipated growth, our expenses may increase more than expected, our revenue could decline or grow more slowly than expected and we may be unable to implement our business strategy. The quality of our products and services may suffer, which could negatively affect our reputation and harm our ability to retain and attract customers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future capital needs are uncertain and we will require additional funding in the future to advance the commercialization of Saphyr and our other products and services, as well as continue our research and development efforts. If we fail to obtain additional funding, we will be forced to delay, reduce or eliminate our commercialization and development efforts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since our inception. We expect to continue to spend substantial amounts in order to continue the commercialization of our products as well as our research and development programs. During October 2020 through January 2021, as described further under the heading Liquidity and Capital Resources included in Item 2 of this Quarterly Report, we raised an aggregate of $370.8 million in gross proceeds from an at-the-market facility and other public offerings, before deducting underwriting discounts and commissions and other offering costs and expenses. However, in the future, we may need to raise additional funding. For example, we may need to raise additional capital to:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our sales and marketing efforts to further commercialize our products and services;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our research and development efforts to improve our existing products and services and develop and launch new products and services, particularly if any of our products and services are deemed by the U.S. Food and Drug Administration, or FDA, to be medical devices or otherwise subject to additional regulation by the FDA;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek FDA approval to market our existing RUO products or new products utilized for diagnostic purposes;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lease a larger facility or build out our existing facility as we continue to grow our employee headcount;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional personnel;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into collaboration arrangements, if any, or in-license other products and technologies;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational, financial and management information systems; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cover increased costs incurred as a result of continued operation as a public company.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future funding requirements will be influenced by many factors, including:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of our products and services;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of establishing additional sales, marketing and distribution capabilities;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of our research and development activities;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our existing distribution and marketing arrangements and our ability to enter into additional arrangements in the future; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that we will be able to obtain additional funds on acceptable terms, or at all. If we raise additional funds by issuing equity or equity-linked securities, our stockholders may experience dilution. Future debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. Any debt or equity financing may contain terms that are not favorable to us or our stockholders. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish some rights to our technologies or our products, or grant licenses on terms that are not favorable to us. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the COVID-19 pandemic may compromise our ability to comply with the terms of our loan agreement and could result in an event of default. If an event of default were to occur, our lender could accelerate our repayment obligations or enforce other rights under our loan agreements. Any such default may also require us to seek additional or alternative financing, which may not be available on commercially reasonable terms or at all. For example, for the three months ended September 30, 2020, we were not in compliance with the revenue covenant under the Innovatus LSA. Although we secured a waiver for such </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">noncompliance in December 2020, there can be no assurance that we will be able to maintain compliance with our covenants in the Innovatus LSA in the future and securing such waivers in the future may require us to divert further cash towards the repayment of debt and subject us to fees incurred in connection with the negotiation of such waivers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not have, or are not able to obtain, sufficient funds, we may have to delay development or commercialization of our products. We also may have to reduce marketing, customer support or other resources devoted to our products or cease operations. Any of these factors could have a material adverse effect on our financial condition, operating results and business. Any of the foregoing could significantly harm our business, prospects, financial condition and results of operation and could cause the price of our common stock to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:99%">Our business, and that of our customers, has been adversely affected by the effects of public health crises, including the COVID-19 pandemic. In particular, the COVID-19 pandemic has materially affected our operations globally, including at our headquarters in San Diego, California, as well as the business or operations of our research partners, customers and other third parties with whom we conduct business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected by health crises in regions where we have operations, concentrations of sales and marketing teams, distributors or other business operations. Such health crises could also affect the business or operations of our research partners, customers and other third parties with whom we conduct business. In particular, the COVID-19 pandemic and the measures imposed to contain this pandemic have disrupted and are expected to continue to impact our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to public health directives and orders implemented in response to the COVID-19 pandemic, we have implemented work-from-home policies for certain employees and temporarily scaled back our operations. We have also modified certain business practices, including those related to employee travel and cancellation of physical participation in meetings, events and conferences, and implemented new protocols to promote social distancing and enhance sanitary measures in our offices and facilities. The quarantine of our personnel and the inability to access our facilities or customer sites has adversely affected, and is expected to continue adversely affecting, our operations. For example, certain members of our workforce are now performing their duties remotely and these employees have not been able to maintain the same level of productivity and efficiency due a lack of resources that would otherwise be available to them in our offices and additional demands on their time, such as increased responsibilities resulting from school closures or the illness of family members.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of these public health directives and orders and our related adjustments in our business have negatively impacted productivity, disrupted our business and delayed our timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. The spread of COVID-19 has resulted in a widespread health crisis that is also adversely affecting the economies and financial markets of many countries, including in the United States, Europe and Asia, which has resulted in an economic downturn that may negatively affect demand for our products and services and materially affect us financially. For example, customers who have committed to order minimum quantities of consumables or to purchase our Saphyr instrument could delay or default on these commitments. Further, restrictions on our ability to travel, stay-at-home orders and other similar restrictions on our business have limited our ability to support our global and domestic operations, including providing installation and training and customer service, resulting in disruptions in our sales and marketing efforts and negative impacts on our commercial strategy. In addition,  disruption of global financial markets as a result of COVID-19 may limit our ability to access capital, which could negatively affect our liquidity. A recession or market correction resulting from the spread of COVID-19 could also materially affect our business and the value of our common stock even after the outbreak of COVID-19 has subsided, due to unforeseen adverse impacts on us or our third-party manufacturers, vendors and customers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in connection with our Diagnostic Services, COVID-19 poses the risk that we or our employees, contractors, suppliers, courier delivery services and other partners may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. The continued spread of COVID-19 and the measures taken by the governments of countries affected could disrupt the supply chain of materials needed for our diagnostic tests, interrupt our ability to receive specimens, impair our ability to perform or deliver the results from our tests, impede patient movement or interrupt healthcare services causing a decrease in test volumes, delay coverage decisions from Medicare and third-party payors, delay ongoing and planned clinical trials involving our tests and have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition. In addition, quarantines, stay-at-home, executive and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, could disrupt our supply chain and affect customer decision-making. For example, any actual or perceived disruption in our product distribution channel could alter customer buying decisions, prompting customers to delay or cancel their orders, which would negatively impact our sales revenue and could harm our reputation. In addition, we anticipate that ongoing disruptions in our supply chain will cause shortages in the materials required to operate our instruments, therefore limiting our ability to process customer samples and the ability of users of our system to operate our system.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are subject to various affirmative and negative covenants in our loan agreement with our lender. If the effects of COVID-19 cause us to fall out of compliance with one or more of such covenants and we are unable to secure a waiver or negotiate an amendment to our loan agreement on reasonable terms, or at all, an event of default could occur, which would allow our lender to accelerate our repayment obligations or enforce its other rights under our loan agreement. Any such default may also require us to seek additional or alternative financing, which may not be available on commercially reasonable terms or at all. If we are unable to access funds to repay our lender, our lender could take control of our pledged assets. Any of the foregoing events would negatively impact our financial condition and liquidity.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of the COVID-19 outbreak or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business or the global economy as a whole, and such impacts may not be fully recoverable. In addition, the current and potential adverse impacts of the COVID-19 pandemic on our business, financial condition, results of operations and growth prospects, may also have the effect of heightening many of the other risks and uncertainties described in this Quarterly Report.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation enacted in 2017 informally titled the Tax Cuts and Jobs Act, or the Tax Act, enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation.  For example, the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act, modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the CARES Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating losses and certain other tax attributes to offset future taxable income and taxes may be subject to limitations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we have federal and state tax net operating loss carryforwards of $266.7 million and $114.0 million, respectively. The federal tax loss carryforwards include $102.5 million that do not expire, but utilization of such tax loss carryforwards in taxable years beginning after December 31, 2020 is limited to 80% of the Company's taxable income. The remaining federal tax loss carryforwards of $164.2 million and state tax loss carryforwards begin to expire in 2027 and 2023, respectively, unless previously utilized. As of December&#160;31, 2020, we also have federal and California research credit carryforwards of $5.5 million and $5.0 million, respectively. The federal research credit carryforwards begin to expire in 2027 unless previously utilized. The California research credits carry forward indefinitely.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, utilization of net operating losses and research and development credit carryforwards may be subject to limitations due to ownership changes that have occurred or that could occur in the future in accordance with applicable provisions of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law. We may have experienced one or more ownership changes in the past and we may also experience additional ownership changes in the future as a result of subsequent changes in our stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our net operating loss or research and development credit carryforwards is materially limited, it would harm our future operating results by increasing our future tax obligations. In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. taxation of international business activities or the adoption of tax reform policies could materially impact our future financial position and results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Limitations on the ability of taxpayers to claim and utilize foreign tax credits and the deferral of certain tax deductions until earnings outside of the U.S. are repatriated to the U.S., as well as changes to U.S. tax laws that may be enacted in the future, could impact the tax treatment of future foreign earnings. Should the scale of our international business activities expand, any changes in the U.S. taxation of such activities could increase our worldwide effective tax rate and harm our future financial position and results of operations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The terms of our debt facility place restrictions on our operating and financial flexibility, and failure to comply with covenants or to satisfy certain conditions of the agreement governing the debt facility may result in acceleration of our repayment obligations and foreclosure on our pledged assets, which could significantly harm our liquidity, financial condition, operating results, business and prospects and cause the price of our securities to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2019, we entered into a Loan and Security Agreement, or the Innovatus LSA, with Innovatus Life Sciences Lending Fund I, LP, or Innovatus, and certain lenders, which provides for borrowings up to $25.0 million pursuant to certain term loans and an additional $5.0 million under a revolving credit line. The Innovatus LSA is secured by a lien covering substantially all of our assets, including our intellectual property. As of March&#160;31, 2021, we owed approximately $14.9&#160;million in principal amounts of term loans under the Innovatus LSA.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Innovatus LSA requires us to comply with a number of covenants (affirmative and negative), including restrictive covenants that limit our ability to: incur additional indebtedness; encumber the collateral securing the loan; acquire, own or make investments; repurchase or redeem any class of stock or other equity interest; declare or pay any cash dividend or make a cash distribution on any class of stock or other equity interest; transfer a material portion of our assets; acquire other businesses; and merge or consolidate with or into any other organization or otherwise suffer a change in control, in each case subject to exceptions. Our intellectual property is also subject to customary negative covenants. The Innovatus LSA also includes standard events of default, including a provision that Innovatus could declare an event of default upon the occurrence of any event that it interprets as having a material adverse effect upon our business, operations, properties, assets, or financial condition or upon our ability to perform or pay the secured obligations under the Innovatus LSA or upon the collateral or the liens on the collateral under the agreement, thereby requiring us to repay the loan immediately, together with a prepayment fee and other applicable fees.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we default under the Innovatus LSA, Innovatus may accelerate all of our repayment obligations and, if we are unable to access funds to meet those obligations or to renegotiate our agreement, Innovatus could take control of our pledged assets and we could immediately cease operations. For example, we were unable to maintain compliance with certain covenants under the Innovatus LSA as of September 30, 2019, December 31, 2019 and September 30, 2020. In order to secure waivers for the September 30, 2019, December 31, 2019, September 30, 2020 breaches, we have been required to pay consideration to Innovatus, including, with respect to our breach of our covenant as of December 31, 2019, our agreement to pay a waiver fee of $200,000 and a prepayment of $2.1 million of principal, as well as to prepay an additional $2.9 million of principal upon the earlier of April 30, 2020 or the closing of one or more equity financings during a specified period resulting in at least $15.0 million of gross proceeds to us in the aggregate, and a $100,000 prepayment fee in connection with such second repayment. In addition, to secure a waiver in December 2020 with respect to our breach of our covenant as of September 30, 2020, we agreed to close an equity financing during a specified period resulting in at least $20.0 million of gross proceeds to us in the aggregate, which we satisfied in January 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may not be able to maintain compliance with our covenants in the Innovatus LSA in the future and, although we have been able to secure waivers from Innovatus in the past, securing such waivers in the future may require us to divert further cash towards the repayment of debt and subject us to fees incurred in connection with the negotiation of such waivers. If we are unable to maintain compliance or obtain a waiver of any breach under the Innovatus LSA, Innovatus could declare an event of default or require us to renegotiate the Innovatus LSA on terms that may be significantly less favorable to us. If we were liquidated, Innovatus&#8217; right to repayment would be senior to the rights of our stockholders to receive any proceeds from the liquidation. Any declaration by Innovatus of an event of default could significantly harm our liquidity, financial condition, operating results, business, and prospects and cause the price of our securities to decline. In order to obtain waivers for any future breaches of covenants, we may be required to pay additional fees and penalties and issue shares of our common stock to Innovatus as consideration.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may incur additional indebtedness in the future. The debt instruments governing such indebtedness may contain provisions that are as, or more, restrictive than the provisions governing our existing indebtedness under the Innovatus LSA. If we are unable to repay, refinance or restructure our indebtedness when payment is due, the lenders could proceed against the collateral or force us into bankruptcy or liquidation.</span></div><div id="ib388395ebea54b38b0be27fba0635b12_1043"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our business operations </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If our products fail to achieve and sustain sufficient market acceptance, our revenue will be adversely affected. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success depends on our ability to develop and market products that are recognized and accepted as reliable, enabling and cost-effective. Most of the potential customers for our products already use expensive research systems in their laboratories that they have used for many years and may be reluctant to replace those systems with ours. Market acceptance of our systems will depend on many factors, including our ability to demonstrate to potential customers that our technology is an attractive alternative to existing technologies. Compared to some competing technologies, our technology is new and complex, and many potential customers have limited knowledge of, or experience with, our products. Prior to adopting our systems, some potential customers may need to devote time and effort to testing and validating our systems. Any failure of our systems to meet these </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">customer benchmarks could result in potential customers choosing to retain their existing systems or to purchase systems other than ours. In addition, it is important that our gene mapping systems be perceived as accurate and reliable by the scientific and medical research community as a whole. Historically, a significant part of our sales and marketing efforts has been directed at demonstrating the advantages of our technology to industry leaders and encouraging such leaders to publish or present the results of their evaluation of our system. If we are unable to continue to motivate leading researchers to use our technology, or if such researchers are unable to achieve or unwilling to publish or present significant experimental results using our systems, acceptance and adoption of our systems will be slowed and our ability to increase our revenue would be adversely affected. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Acquisitions or joint ventures could disrupt or otherwise harm our business and may cause dilution to our stockholders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our growth strategy, we have acquired and may continue to acquire other businesses, products or technologies as well as pursue strategic alliances, joint ventures, technology licenses or investments in complementary businesses. We may not be able to locate or make suitable acquisitions on acceptable terms, and future acquisitions may not be effectively and profitably integrated into our business. Our failure to successfully complete the integration of any business that we acquire could have an adverse effect on our prospects, business activities, cash flow, financial condition, results of operations and stock price. Integration challenges may include the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption in our relationships with customers, distributors or suppliers as a result of such a transaction;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated expenses and liabilities related to acquired companies;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties integrating acquired personnel, technologies and operations into our existing business;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management time and focus from operating our business to acquisition integration challenges;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in our expenses and reductions in our cash available for operations and other uses;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible write-offs or impairment charges relating to acquired businesses;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties developing and marketing new products and services;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entering markets in which we have limited or no prior experience; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coordinating our efforts throughout various localities and time zones.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign acquisitions involve unique risks in addition to those mentioned above, including those related to integration of operations across different cultures and languages, currency risks and the particular economic, political and regulatory risks associated with specific countries. In addition, in connection with any such transactions, we may also issue equity securities, incur additional debt, assume contractual obligations or liabilities or expend significant cash. Such transactions could harm our operating results and cash position, negatively affect the price of our stock and cause dilution to our current stockholders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the anticipated benefit of any acquisition may not materialize. Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on our operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, as previously disclosed, we recently completed the acquisition of Lineagen, Inc., or Lineagen, a U.S.-based provider of proprietary molecular diagnostics services for individuals presenting with certain neurodevelopmental disorders, for aggregate consideration consisting of approximately 6,167,510 shares of our common stock (subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen), $1.9 million in cash, and the assumption of approximately $2.9 million in certain liabilities of Lineagen, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of August 21, 2020, by and among us, Alta Merger Sub, Inc., Lineagen and Michael S. Paul, Ph.D., solely in his capacity as exclusive agent and attorney-in-fact of the securityholders of Lineagen, or the Lineagen Acquisition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of shares as consideration in the Lineagen Acquisition resulted in dilution to our existing stockholders. In addition, pursuant to the Lineagen Acquisition, headcount of our consolidated operations increased by 33 employees, which has resulted in and will continue to result in increased selling, general and administrative expenses. Although we conducted extensive business, financial and legal due diligence in connection with our evaluation of the Lineagen Acquisition, our due diligence investigations may not have identified every matter that could adversely affect our business, operating results and financial condition. We may be unable to adequately address the financial, legal and operational risks introduced by the Lineagen Acquisition and may have difficulty developing experience with the industry in which Lineagen operates. Accordingly, we cannot guarantee that the Lineagen Acquisition will yield the results we have anticipated and unforeseen complexities and expenses may arise. In addition, we may not achieve the revenues, growth prospects and synergies expected from this acquisition any such benefits we do achieve may not offset increased costs, resulting in a potential impairment of goodwill or other assets that were acquired. For future acquisitions, we may similarly be unable achieve revenue, growth </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prospects and synergies in a manner consistent with our expectations. Our failure to do so could adversely affect our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity issuances in connection with strategic transactions or raising additional capital may cause dilution to our stockholders or restrict our operations.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we expect to finance our strategic transactions or cash needs through a combination of equity and debt financings. To the extent that we finance our strategic transactions or raise additional capital through the sale of equity or convertible debt securities, your ownership interest could be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may be secured by all or a portion of our assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, on August 13, 2020, we entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with Ladenburg Thalmann &amp; Co. Inc., as sales agent, or Ladenburg, under which we were eligible to offer and sell up to $40.0 million of shares of our common stock from time to time through Ladenburg. During the fiscal year ended December 31, 2020, we sold 27,025,384 shares of common stock under the Sales Agreement for aggregate gross proceeds of approximately $22.1 million and from January 1, 2021 through January 11, 2021, we sold 6,298,152 shares of common stock under the Sales Agreement for aggregate gross proceeds of approximately $16.9 million. On January 12, 2021, we announced the completion of an underwritten public offering of 33,368,851 shares of our common stock for gross proceeds, before deducting underwriting discounts and commissions and offering expenses, of approximately $101.8 million. Moreover, on January 25, 2021, we announced the completion of an underwritten public offering of 38,333,352 shares of our common stock for gross proceeds, before deducting underwriting discounts and commissions and offering expenses, of approximately $230.0 million. In March 2021, we entered into a new at-the-market facility, or the Cowen ATM, with Cowen and Company, LLC, or Cowen, which provides for the sale, in our sole discretion, of shares of our common stock having an aggregate offering price of up to $350.0 million through or to Cowen, acting as sales agent or principal. To-date, no shares have been issued pursuant to the Cowen ATM. In addition, we issued shares of our common stock in connection with the Lineagen Acquisition and to Innovatus in lieu of waiver fees. Any future significant sales of our capital stock would result in dilution to our current stockholders.  As a result of these issuances, our investors experienced dilution of their ownership interests.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to execute our sales and marketing strategy for our Lineagen products and services, including diagnostic assays, and are unable to gain acceptance in the market, we may be unable to generate sufficient revenue to sustain our Lineagen business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Lineagen business provides molecular diagnostics services and has engaged in only limited sales and marketing activities for the diagnostic assays currently offered through our CLIA-certified laboratory. To date, the revenue generated by our Lineagen business has been insufficient to fund operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that our current assays and our planned future assays represent a promising commercial opportunity, our products or assays may never gain significant acceptance in the marketplace and therefore may never generate substantial revenue or profits for us. We will need to establish a market for our products and diagnostic assays and build that market through physician education, awareness programs and the publication of clinical trial results. Gaining acceptance in medical communities requires, among other things, publications in leading peer-reviewed journals of results from studies using our current products, assays and services and/or our planned future products, assays and services. The process of publication in leading medical journals is subject to a peer review process and peer reviewers may not consider the results of our studies sufficiently novel or worthy of publication. Failure to have our studies published in peer-reviewed journals would limit the adoption of our current products, assays and services and our planned future products, assays and services. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully market the products and diagnostic assays that we have developed, and may develop in the future, will depend on numerous factors, including: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conducting clinical utility studies of such assays in collaboration with key thought leaders to demonstrate their use and value in important medical decisions such as treatment selection;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether our current or future partners, vigorously support our offerings;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our sales force;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether healthcare providers believe such diagnostic assays provide clinical utility;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether the medical community accepts that such diagnostic assays are sufficiently sensitive and specific to be meaningful in patient care and treatment decisions;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to continually source raw materials, shipping kits and other products that we sell or consume in our manufacturing process that are of sufficient quality and supply;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to continue to fund planned sales and marketing activities; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether private health insurers, government health programs and other third-party payers will adopt our current and future assays in their guidelines, or cover such diagnostic assays and, if so, whether they will adequately reimburse us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic may also increase the risk and uncertainty of the events described above and delay our development timelines. Failure to achieve widespread market acceptance of our current products, assays and services, as well as our planned future products, assays and services, would materially harm our business, financial condition and results of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In the near term, sales of our Saphyr system, consumables and genome analysis services will depend on levels of research and development spending by academic and governmental research institutions and biopharmaceutical companies, a reduction in which could limit demand for our products and adversely affect our business and operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the near term, we expect that our revenue from sales of our Saphyr system, consumables and OGM services will be derived primarily from sales to academic and governmental research institutions, as well as biopharmaceutical and contract research companies worldwide for research applications. The demand for our products will depend in part upon the research and development budgets of these customers, which are impacted by factors beyond our control, such as:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in government programs that provide funding to research institutions and companies;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">macroeconomic conditions and the political climate;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the regulatory environment;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differences in budgetary cycles; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of relatively new technologies, such as ours.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in March 2017, the federal government announced the intent to cut federal biomedical research funding by as much as 18%. While there has been significant opposition to these funding cuts, the uncertainty regarding the availability of research funding for potential customers may adversely affect our operating results. Our operating results may fluctuate substantially due to reductions and delays in research and development expenditures by these customers. Any decrease in customers&#8217; budgets or expenditures, or in the size, scope or frequency of capital or operating expenditures, could materially and adversely affect our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The sales cycle for our systems can be lengthy and variable, which makes it difficult for us to forecast revenue and other operating results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The sales process for our systems generally involves numerous interactions with multiple individuals within an organization, and often includes in-depth analysis by potential customers of our technology and products and a lengthy review process. Our customers&#8217; evaluation processes often involve a number of factors, many of which are beyond our control. As a result of these factors, the capital investment required to purchase our systems and the budget cycles of our customers, the time from initial contact with a customer to our receipt of a purchase order can vary significantly. Given the length and uncertainty of our sales cycle, we have in the past experienced, and expect to in the future experience, fluctuations in our sales on a period-to-period basis. In addition, any failure to meet customer expectations could result in customers choosing to retain their existing systems, use existing assays not requiring capital equipment or purchase systems other than ours.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our long-term results depend upon our ability to improve existing products and introduce and market new products successfully. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business is dependent on the continued improvement of our existing products and our development of new products utilizing our current or other potential future technology. As we introduce new products or refine, improve or upgrade versions of existing products, we cannot predict the level of market acceptance or the amount of market share these products will achieve, if any. We cannot assure you that we will not experience material delays in the introduction of new products in the future. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consistent with our strategy of offering new products and product refinements, we expect to continue to use a substantial amount of capital for product development and refinement. We may need additional capital for product development and refinement than is available on terms favorable to us, if at all, which could adversely affect our business, financial condition or results of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We generally sell our products in industries that are characterized by rapid technological changes, frequent new product introductions and changing industry standards. If we do not develop new products and product enhancements based on technological innovation on a timely basis, our products may become obsolete over time and our revenues, cash flow, profitability and competitive position will suffer. Our success will depend on several factors, including our ability to: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">correctly identify customer needs and preferences and predict future needs and preferences;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allocate our research and development funding to products with higher growth prospects;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipate and respond to our competitors&#8217; development of new products and technological innovations;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">innovate and develop new technologies and applications, and acquire or obtain rights to third-party technologies that may have valuable applications in the markets we serve;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully commercialize new technologies in a timely manner, price them competitively and manufacture and deliver sufficient volumes of new products of appropriate quality on time; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">customers&#8217; willingness to adopt new technologies. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if we fail to accurately predict future customer needs and preferences or fail to produce viable technologies, we may invest heavily in research and development of products that do not lead to significant revenue. Even if we successfully innovate and develop new products and product enhancements, we may incur substantial costs in doing so, and our profitability may suffer. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to develop new products based on innovation can affect our competitive position and often requires the investment of significant resources. Difficulties or delays in research, development or production of new products and services or failure to gain market acceptance of new products and technologies may reduce future revenues and adversely affect our competitive position.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we do not successfully manage the development and launch of new products, our financial results could be adversely affected. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We face risks associated with launching new products. If we encounter development or manufacturing challenges or discover errors during our product development cycle, the product launch dates of new products may be delayed. The expenses or losses associated with unsuccessful product development or launch activities or lack of market acceptance of our new products could adversely affect our business or financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success is dependent upon our ability to further penetrate our existing customer base and attract new customers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current customer base for our RUO products is primarily composed of academic and governmental research institutions and biopharmaceutical and contract research companies and, for our Diagnostic Services, physicians and their patients. Our success will depend upon our ability to respond to the evolving needs of, and increase our market share among, existing customers and additional potential customers, marketing new products and services as we develop them. Identifying, engaging and marketing to customers who are unfamiliar with our current products requires substantial time, expertise and expense and involves a number of risks, including:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract, retain and manage the sales, marketing and service personnel necessary to expand market acceptance for our technology;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost of maintaining and growing a specialized sales, marketing and service force; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the fact that our sales, marketing and service force may be unable to execute successful commercial activities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have utilized third parties to assist with sales, distribution and customer support in certain regions of the world. There is no guarantee, when we enter into such arrangements, that we will be successful in attracting desirable sales and distribution partners. There is also no guarantee that we will be able to enter into such arrangements on favorable terms. Any failure of our sales and marketing efforts, or those of any third-party sales and distribution partners, would adversely affect our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently limited to &#8220;research use only&#8221; with respect to many of the materials and components used in our consumable products including our assays.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our instruments, consumable products and assays are purchased from suppliers with a restriction that they be used for research use only, or RUO. While we have focused initially on the life sciences research market and RUO products only, part of our business strategy is to expand our product line to encompass products that are intended to be used for the diagnosis of disease and precision healthcare, either alone or in collaboration with third parties. The use of our RUO products for any such diagnostic purposes would require that we obtain regulatory clearance or approval to market our products for those purposes and also that we acquire the materials and components used in such products from suppliers without an RUO restriction. There can be no assurance that we will be able to acquire these materials and components for use in diagnostic products on acceptable terms, if at all. If we are unable to do so, we would not be able to expand our non-Lineagen product offerings beyond RUO, and our business and prospects would suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA Guidance on &#8220;Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only&#8221;, or, the RUO/IUO Labeling Guidance, emphasizes that the FDA will review the totality of the circumstances when evaluating whether equipment and testing components are properly labeled as RUO. It further states that merely including a labeling statement that a product is intended for research use only will not necessarily render the device exempt from the FDA&#8217;s 510(k) clearance, PMA, or other requirements, if the circumstances surrounding the distribution of the product indicate that the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturer intends for its product to be offered for clinical diagnostic use. These circumstances may include written or verbal marketing claims or links to articles regarding a product&#8217;s performance in clinical applications, a manufacturer&#8217;s provision of technical support for clinical validation or clinical applications, or solicitation of business from clinical laboratories, all of which could be considered evidence of intended uses that conflict with RUO labeling. If the FDA were to determine that our RUO products were intended for use in clinical investigation, diagnosis or treatment decisions, or that express or implied clinical or diagnostic claims were made for our RUO products, those products could be considered misbranded or adulterated under the Federal Food, Drug, and Cosmetic Act. If the FDA determines that our RUO products are being marketed for clinical diagnostic use without the required PMA or 510(k) clearance, we may be required to cease marketing our products as planned, recall the products from customers, revise our marketing plans, and/or suspend or delay the commercialization of our products until we obtain the required authorization. We also may be subject to a range of enforcement actions by the FDA, including warning or untitled letters, injunctions, civil monetary penalties, criminal prosecution, and recall and/or seizure of products, as well as significant adverse publicity.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If, in the future, we choose to commercialize our RUO products for clinical diagnostic use, we will be required to comply with the FDA&#8217;s premarket review and post-market control requirements for IVDs, as may be applicable. Complying with the FDA&#8217;s PMA and/or 510(k) clearance requirements may be expensive, time-consuming, and subject us to significant and/or unanticipated delays. Our efforts may never result in an approved PMA or 510(k) clearance for our products. Even if we obtain a PMA or 510(k) clearance, where required, such authorization may not be for the use or uses we believe are commercially attractive and/or are critical to the commercial success of our products. As a result, being subject to the FDA&#8217;s premarket review and/or post-market control requirements for our products could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience in marketing and selling our products, and if we are unable to successfully commercialize our products, our business and operating results will be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience marketing and selling our products. We currently sell our Saphyr system for research use only, through our direct field sales and support organizations located in North America and Europe and through a combination of our own sales force and third-party distributors in additional major markets such as Australian, China, Japan and South Korea.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future sales of our products will depend in large part on our ability to effectively market and sell our products, successfully manage and expand our sales force, and increase the scope of our marketing efforts. We may also enter into additional distribution arrangements in the future. Because we have limited experience in marketing and selling our products, our ability to forecast demand, the infrastructure required to support such demand and the sales cycle to customers is unproven. If we do not build an efficient and effective sales force, our business and operating results will be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on a single contract manufacturer for our optical genome mapping systems and a single contract manufacturer for our chip consumables. If either of these manufacturers should fail or not perform satisfactorily, our ability to supply these products would be negatively and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on a single contract manufacturer to manufacture and supply all of our non-Lineagen instruments. See &#8220;Business&#8211;Key Agreements&#8221; in our Annual Report. In addition, we rely on a single contract manufacturer to manufacture and supply all of our chip consumables. Since our contracts with these manufacturers do not commit them to supply quantities beyond the amounts included in our purchase orders, and do not commit them to carry inventory or make available any particular quantities, these contract manufacturers may give other customers&#8217; needs higher priority than ours, and we may not be able to obtain adequate supplies in a timely manner or on commercially reasonable terms. If either of these manufacturers were to be unable to supply instruments, our business would be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event it becomes necessary to utilize different contract manufacturers for our non-Lineagen instruments or chip consumables, we would experience additional costs, delays and difficulties in doing so as a result of identifying and entering into an agreement with a new supplier as well as preparing such new supplier to meet the logistical requirements associated with manufacturing our units, and our business would suffer. We may also experience additional costs and delays in the event we need access to or rights under any intellectual property of these current manufacturers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may experience manufacturing problems or delays that could limit the growth of our revenue or increase our losses. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may encounter unforeseen situations that would result in delays or shortfalls in our production as well as delays or shortfalls caused by our outsourced manufacturing suppliers and by other third-party suppliers who manufacture components for our products. If we are unable to keep up with demand for our products, our revenue could be impaired, market acceptance for our products could be adversely affected and our customers might instead purchase our competitors&#8217; products. Our inability to successfully manufacture our products would have a material adverse effect on our operating results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If our laboratory facilities become damaged or inoperable or we are required to vacate our existing facilities, our ability to conduct our laboratory analysis and pursue our research and development efforts may be jeopardized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently perform all research and development activities and most of our OGM services at a single laboratory facility in San Diego, California with the remaining genome analysis services at a facility we occupy at a customer&#8217;s lab in Clermont-Ferrand, France. All of our molecular diagnostics services are processed at a single laboratory facility in Salt Lake City, Utah. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities and equipment could be harmed or rendered inoperable by natural or man-made disasters, including war, fire, earthquake, power loss, communications failure, terrorism, burglary, public health crises (including restrictions that may be imposed on businesses by state and local governments under stay-at-home or similar orders and mandates, such as those implemented in response to the COVID-19 pandemic) or other events, which may make it difficult or impossible for us to perform our testing services for some period of time or to receive and store samples. The inability to perform tests or to reduce the backlog of sample analysis that could develop if one or both of our facilities become inoperable, for even a short period of time, may result in the loss of revenue, loss of customers or harm to our reputation, and we may be unable to regain that revenue, those customers or repair our reputation in the future. Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters and man-made disasters or other sudden, unforeseen and severe adverse events.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the loss of our samples due to such events could limit or prevent our ability to conduct research and development analysis on existing tests as well as tests in development.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities and the equipment we use to perform our testing and research and development could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facilities, to locate and qualify a new facility, replace certain pieces of equipment or license or transfer our proprietary technology to a third party, particularly in light of licensure and accreditation requirements. Even in the unlikely event that we are able to find a third party with such qualifications to enable us to resume our operations, we may be unable to negotiate commercially reasonable terms. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our business, may not provide coverage in amounts sufficient to cover our potential losses and may not continue to be available to us on acceptable terms, if at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on a limited number of suppliers or, in some cases, one supplier, for some of our materials and components used in our products, and may not be able to find replacements or immediately transition to alternative suppliers, which could have a material adverse effect on our business, financial condition, results of operations and reputation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on limited or sole suppliers for certain reagents and other materials and components that are used in our products. While we periodically forecast our needs for such materials and enter into standard purchase orders with our suppliers, we do not have long-term contracts with many of these suppliers. If we were to lose such suppliers, there can be no assurance that we will be able to identify or enter into agreements with alternative suppliers on a timely basis on acceptable terms, if at all. An interruption in our operations, including our laboratory operations, could occur if we encounter delays or difficulties in securing these materials, or if the quality of the materials supplied do not meet our requirements, or if we cannot then obtain an acceptable substitute. The time and effort required to qualify a new supplier and ensure that the new materials provide the same or better quality results could result in significant additional costs. Any such interruption could significantly affect our business, financial condition, results of operations and reputation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain of the components used in our instruments are sourced from limited or sole suppliers. If we were to lose such suppliers, there can be no assurance that we will be able to identify or enter into agreements with alternative suppliers on a timely basis on acceptable terms, if at all. An interruption in our ability to sell and deliver instruments to customers could occur if we encounter delays or difficulties in securing these components, or if the quality of the components supplied do not meet specifications, or if we cannot then obtain an acceptable substitute. If any of these events occur, our business and operating results could be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in order to mitigate these risks, we maintain inventories of certain supplies at higher levels than would be the case if multiple sources of supply were available. If our sales or testing volume decreases or we switch suppliers, we may hold excess supplies with expiration dates that occur before use which would adversely affect our losses and cash flow position. As we introduce any new products, we may experience supply issues as we ramp up our sales or test volume. If we should encounter delays or difficulties in securing, reconfiguring or revalidating the equipment, reagents or other materials we require for our products, our business, financial condition, results of operations and reputation could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Undetected errors or defects in our products could harm our reputation, decrease market acceptance of our products or expose us to product liability claims. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products may contain undetected errors or defects when first introduced or as new versions or new products are released. Disruptions affecting the introduction or release of, or other performance problems with, our products may damage our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customers&#8217; businesses and could harm their and our reputations. If that occurs, we may incur significant costs, the attention of our key personnel could be diverted, or other significant customer relations problems may arise. We may also be subject to warranty and liability claims for damages related to errors or defects in our products. In addition, if we do not meet industry or quality standards, if applicable, our products may be subject to recall. A material liability claim, recall or other occurrence that harms our reputation or decreases market acceptance of our products could harm our business and operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our customers develop or use our products or assays for diagnostic purposes, someone could file a product liability claim alleging that one of our products contained a design or manufacturing defect that resulted in the failure to adequately perform, leading to death or injury. In addition, the marketing, sale and use of our current or future products and assays could lead to the filing of product liability claims against us if someone alleges that our products failed to perform as designed. We may also be subject to liability for errors in the results we provide or for a misunderstanding of, or inappropriate reliance upon, the information we provide.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product liability claim could result in substantial damages and be costly and time consuming to defend, either of which could materially harm our business or financial condition. We cannot assure investors that our product liability insurance would adequately protect our assets from the financial impact of defending a product liability claim. Any product liability claim brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could damage our reputation, or cause current partners to terminate existing agreements and potential partners to seek other partners, any of which could impact our results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also initiate a correction to our existing products or assays, which could lead to increased costs and increased scrutiny by regulatory authorities and our customers regarding the quality and safety of our products or services, as well as negative publicity. The occurrence of any of these events could have an adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our reliance on distributors for sales of our products outside of the United States could limit or prevent us from selling our products and could impact our revenue.* </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to continue to grow our business internationally, and to do so we must attract additional distributors and retain existing distributors to maximize the commercial opportunity for our products. There is no guarantee that we will be successful in attracting or retaining desirable sales and distribution partners or that we will be able to enter into such arrangements on favorable terms. Distributors may not commit the necessary resources to market and sell our products to the level of our expectations or may choose to favor marketing the products of our competitors. If current or future distributors do not perform adequately, or we are unable to enter into effective arrangements with distributors in particular geographic areas, we may not realize long-term international revenue growth. In addition, if our distributors fail to comply with applicable laws and ethical standards, including anti-bribery laws, this could damage our reputation and could have a significant adverse effect on our business and our revenues. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect to generate a substantial portion of our revenue internationally in the future and can become further subject to various risks relating to our international activities, which could adversely affect our business, operating results and financial condition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2020 approximately 58% of our product revenue was generated from customers located outside of the U.S. We believe that a substantial percentage of our future revenue will come from international sources as we expand our overseas operations and develop opportunities in additional areas. We have limited experience operating internationally and engaging in international business involves a number of difficulties and risks, including: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">required compliance with existing and changing foreign regulatory requirements and laws;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties and costs of staffing and managing foreign operations;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties protecting or procuring intellectual property rights;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">required compliance with anti-bribery laws, such as the U.S. Foreign Corrupt Practices Act, data privacy and security requirements, labor laws and anti-competition regulations;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">export or import restrictions;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws and business practices favoring local companies; </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political and economic instability; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements and other trade barriers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Historically, most of our revenue has been denominated in U.S. dollars. In the future, we may sell our products and services in local currency outside of the U.S. As our operations in countries outside of the U.S. grow, our results of operations and cash </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">flows may be subject to fluctuations due to changes in foreign currency exchange rates, which could harm our business in the future. For example, if the value of the U.S. dollar increases relative to foreign currencies, in the absence of a corresponding change in local currency prices, our revenue could be adversely affected as we convert revenue from local currencies to U.S. dollars. If we dedicate significant resources to our international operations and are unable to manage these risks effectively, our business, operating results and financial condition will suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to the U.S. Foreign Corrupt Practices Act, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, the United Kingdom Bribery Act 2010, and other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees and third-party intermediaries from authorizing, promising, offering, providing, soliciting, or accepting, directly or indirectly, improper payments or benefits to or from any person whether in the public or private sector for the purpose of obtaining or retaining business or securing any other improper advantage. We rely on third-party representatives, distributors, and other business partners to support sales of our products and services and our efforts to ensure regulatory compliance. In addition, as we increase our international sales and business, we may engage with additional business partners. We can be held liable for the corrupt or other illegal activities of our employees, representatives, contractors, business partners, and agents, even if we do not explicitly authorize or have actual knowledge of such activities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any violations of anti-corruption and anti-money laundering laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees, and could result in a material adverse effect on our business, prospects, financial condition, or results of operations. We could also incur severe penalties, including criminal and civil penalties, disgorgement, and other remedial measures. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to governmental export and import controls that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our products are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls. Exports of our products must be made in compliance with these laws and regulations. If we fail to comply with these laws and regulations, we and certain of our employees could be subject to substantial civil or criminal penalties, including the possible loss of export or import privileges; fines, which may be imposed on us and responsible employees or managers; and, in extreme cases, the incarceration of responsible employees or managers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, changes in our products or changes in applicable export or import laws and regulations may create delays in the introduction and sale of our products in international markets, prevent our customers from deploying our products or, in some cases, prevent the export or import of our products to certain countries, governments or persons altogether. Any change in export or import laws and regulations, shift in the enforcement or scope of existing laws and regulations, or change in the countries, governments, persons or technologies targeted by such laws and regulations, could also result in decreased use of our products, or in our decreased ability to export or sell our products to existing or potential customers. Any decreased use of our products or limitation on our ability to export or sell our products would likely adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to recruit, train, retain, motivate and integrate key personnel, we may not achieve our goals. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our future success depends on our ability to recruit, train, retain, motivate and integrate key personnel, including our recently expanded senior management team, as well as our research and development, manufacturing and sales and marketing personnel. Competition for qualified personnel is intense. Our growth depends, in particular, on attracting and retaining highly-trained sales personnel with the necessary scientific background and ability to understand our systems at a technical level to effectively identify and sell to potential new customers and develop new products. Because of the complex and technical nature of our products and the dynamic market in which we compete, any failure to attract, train, retain, motivate and integrate qualified personnel could materially harm our operating results and growth prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we cannot provide quality technical and applications support, we could lose customers and our business and prospects will suffer. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The placement of our products at new customer sites, the introduction of our technology into our customers&#8217; existing laboratory workflows and ongoing customer support can be complex. Accordingly, we need highly trained technical support personnel. Hiring technical support personnel is very competitive in our industry due to the limited number of people available with the necessary scientific and technical backgrounds and ability to understand our technology at a technical level. To effectively support potential new customers and the expanding needs of current customers, we will need to substantially expand our technical support staff. If we are unable to attract, train or retain the number of highly qualified technical services personnel that our business needs, our business and prospects will suffer.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security breaches or other types of security incidents of our or our third-party service providers&#8217;, consultants&#8217;, or contractors&#8217; networks or systems could result in a material disruption of our services, compromise sensitive information related to our business or other personal information, may cause us to incur significant liabilities and adversely affect our business, results of operations, financial condition, and future prospects.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of our business, we collect, store, use, transmit, and otherwise process sensitive data and confidential information, including but not limited to intellectual property, proprietary business information owned or controlled by ourselves or our customers, financial information and, where allowed, personal information (including protected health information). The secure collection, storage, use, transmission and processing of such sensitive data and confidential information is vital to our operations and business strategy. Any actual or perceived breach of our security measures or those of our third-party service providers, consultants, or contractors could adversely affect our business, operations, financial condition, and future prospects. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The procedures and controls we use to monitor cyber security threats and mitigate our exposure to such threats may not be sufficient to prevent cyber security incidents, and our internal information technology systems and those of our third-party service providers, consultants, and contractors are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war, public health crises (such as the COVID-19 global pandemic), telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, viruses, worms, denial-of-service attacks, supply chain attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our, or our third-party service providers&#8217; consultants&#8217;, or contracts&#8217; system infrastructure or lead to data leakage. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of sensitive data and confidential information, we could incur liability and reputational damage. In addition, these incidents could result in disrupted operations, lost opportunities, misstated financial data, increased costs arising from the implementation of additional security protective measures and litigation costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have security measures in place to protect sensitive data and confidential information and prevent data loss and other security breaches, we cannot guarantee that our, or our third-party service providers&#8217;, consultants&#8217;, or contractors&#8217; security measures will be sufficient to protect against unauthorized access to, or other compromise of such sensitive data and confidential information. The techniques used to sabotage or to obtain unauthorized access to our platform, systems, networks and/or physical facilities in which data is stored or through which data is transmitted change frequently, and we may be unable to anticipate such techniques or implement adequate preventative measures or stop security breaches that may arise from such techniques. As a result, our safeguards and preventive measures may not be adequate to prevent current or future cyberattacks and security incidents, including security breaches that may remain undetected for extended periods of time, which can substantially increase the potential for a material adverse impact resulting from the breach.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also required to comply with laws, rules, industry standards and regulations that require us to maintain the security of sensitive data and confidential information. We may also have contractual and other legal obligations to notify relevant stakeholders of security breaches. Failure to prevent or mitigate cyberattacks could result in unauthorized access to such sensitive data and confidential information, including personal information (and protected health information). Most jurisdictions have enacted laws requiring companies to notify individuals, regulatory authorities and others of security breaches involving certain types of data. In addition, our agreements with certain customers and partners may require us to notify them in the event of a security breach. Such disclosures are costly, could lead to negative publicity, may cause our customers to lose confidence in the effectiveness of our security measures and not use our services, and require us to expend significant capital and other resources to respond to and/or alleviate problems caused by the actual or perceived security breach. In addition, any costs or other liabilities related to responding to a cybersecurity event or to mitigate any identified security vulnerabilities could be significant, including costs for remediating the effects of such an event, paying a ransom, restoring data from backups, and conducting data analysis to determine what data may have been affected by the breach. In addition, our efforts to contain or remediate a security breach or any vulnerability exploited to cause a breach may be unsuccessful, and efforts and any related failures to contain or remediate them could result in interruptions, delays, loss in customer trust, harm to our reputation, and increases to our insurance coverage. For example, any such event that leads to unauthorized access, use, or disclosure of sensitive data and confidential information, including personal information related to our patient samples or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have adequate insurance coverage for security incidents or breaches, including fines, judgments, settlements, penalties, costs, attorney fees and other impacts that arise out of incidents or breaches. We cannot assure you that any insurance coverage will adequately cover liabilities actually incurred or that insurance will continue to be available to us on economically reasonable terms, or at all. The successful assertion of one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business. Our risks are likely to increase as we continue to expand, grow our customer base, and process, store, and transmit increasingly large amounts of confidential, proprietary and sensitive data.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and changing laws, regulations and standards, and contractual obligations related to privacy and data security. The actual or perceived failure to comply with applicable data protection, privacy, and security laws, regulations, standards, and other requirements could adversely affect our business, results of operations, and financial conditions.*</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous foreign and domestic laws, regulations and standards regarding privacy and data security that govern the personal information and other data we may collect, store, use, or process. The regulatory framework for privacy issues is rapidly evolving and is likely to remain uncertain for the foreseeable future. Many government bodies and agencies have adopted or are considering adopting laws and regulations regarding the collection, use, storage, destruction, and disclosure of personal information and breach notification procedures. We are also required to comply with laws, rules and regulations relating to data security. Interpretation of these laws, rules and regulations in applicable jurisdictions is subject to change and cannot be fully determined at this time.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Privacy has become a significant issue in the United States. For example, on June 28, 2018, California adopted the California Consumer Privacy Act of 2018, or CCPA, which took effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA also provides for civil penalties for violations and contains a private right of action for data breaches that is expected to increase litigation involving misuse of personal information of California residents. The CCPA may increase our compliance costs and potential liability. In addition, California voters recently approved the California Privacy Rights Act of 2020, or CPRA, which goes into effect on January 1, 2023. The CPRA is expected to, among other things, give California residents the ability to limit the use of their personal information, further restrict the use of cross-contextual advertising, establish restrictions on the retention of personal information, expand the types of data breaches subject to the CCPA&#8217;s private right of action, provide for increased penalties for CPRA violations concerning California residents under the age of 16, and establish a new California Privacy Protection Agency to implement and enforce the new law. Some observers have noted that the CCPA and CPRA could mark the beginning of a trend of states adopting more stringent privacy laws in the U.S., which could further increase our compliance costs, potential liability and adversely affect our business.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global data protection landscape is also rapidly evolving, and we expect there will continue to be new and proposed laws, regulations, and industry standards concerning privacy, data protection, and information security. We cannot yet determine the impact that such future laws, regulations and standards may have on our business. For example, in May 2018, the General Data Protection Regulation, or the GDPR, went into effect in the European Union. The GDPR imposes stringent data protection requirements and to date, has increased compliance burdens on us, including by mandating burdensome documentation requirements and granting certain rights to individuals to control how we collect, use, disclose, retain and process their personal data. The GDPR also provides for more robust regulatory enforcement and greater penalties for noncompliance than previous data protection laws, including fines of up to &#8364;20 million or 4% of global annual revenue of any noncompliant company for the preceding financial year, whichever is greater. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">European data protection laws including the GDPR also generally prohibit the transfer of personal information from Europe to the United States and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal information. The Court of Justice of the European Union, or &#8220;CJEU,&#8221; recently raised questions about whether the European Commission&#8217;s Standard Contractual Clauses, one of the primary mechanisms used by U.S. companies to import personal information from Europe, complies with the GDPR. While the CJEU upheld the validity of Standard Contractual Clauses, the CJEU ruled that the underlying data transfers must be assessed on a case-by-case basis by the data controller to determine whether the personal information will be adequately protected. Further, the European Commission recently proposed updates to the Standard Contractual Clauses. At present, there are few if any viable alternatives to the Standard Contractual Clauses and, therefore, there is uncertainty regarding how to ensure that transfers of personal information from Europe to the United States comply with the GDPR. As such, any transfers by us, or our third party service providers, of personal information from Europe may not comply with European data protection laws; may increase our exposure to the GDPR&#8217;s heightened sanctions for violations of its cross-border data transfer restrictions; and may reduce demand for our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services from companies subject to European data protection laws. Loss of our ability to transfer personal information from Europe may also require us to increase our data processing capabilities in those jurisdictions at significant expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the United Kingdom&#8217;s decision to leave the EU, often referred to as Brexit, has created uncertainty about the regulation of data protection in the U.K., including with respect to whether laws or regulations will apply to us consistent with the GDPR in the future and how data transfers to and from the U.K. will be regulated. Following December 31, 2020, and the expiry of transitional arrangements between the UK and EU, the data protection obligations of the GDPR continue to apply to UK-related processing of personal data in substantially unvaried form under the so-called &#8216;UK GDPR&#8217; (i.e., the GDPR as it continues to form part of UK law by virtue of section 3 of the EU (Withdrawal) Act 2018, as amended). However, going forward, there is increasing risk for divergence in application, interpretation and enforcement of the data protection laws as between the UK and European Economic Area, or EEA. Furthermore, the relationship between the UK and the EEA in relation to certain aspects of data protection law remains uncertain. For example, it is unclear whether transfers of personal data from the EEA to the UK will be permitted to take place on the basis of a future adequacy decision of the European Commission, or whether a &#8216;transfer mechanism&#8217; such as the SCCs will be required. Under the post-Brexit Trade and Cooperation Agreement between the EU and the UK, the UK and EU have agreed that transfers of personal data to the UK from EEA member states will not be treated as &#8216;restricted transfers&#8217; to a non-EEA country for a period of up to four months from January 1, 2021, plus a potential further two months extension, or the &#8220;Extended Adequacy Assessment Period.&#8221;  Although the current maximum duration of the Extended Adequacy Assessment Period is six months, it may end sooner, for example, in the event that the European Commission adopts an adequacy decision in respect of the UK, or the UK amends the UK GDPR and/or makes certain changes regarding data transfers under the UK GDPR/Data Protection Act 2018 without the consent of the EU (unless those amendments or decisions are made simply to keep relevant UK laws aligned with the EU&#8217;s data protection regime). If the European Commission does not adopt an &#8216;adequacy decision&#8217; in respect of the UK prior to the expiry of the Extended Adequacy Assessment Period, from that point onwards the UK will be an &#8216;inadequate third country&#8217; under the GDPR and transfers of personal data from the EEA to the UK will require a &#8216;transfer mechanism&#8217; such as the Standard Contractual Clauses.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. Any failure or perceived failure by us or third parties working on our behalf to comply with applicable laws and regulations, any privacy and data security obligations pursuant to contract, our stated privacy or security policies, or obligations to customers or other third parties may result in governmental enforcement actions (including fines, penalties, judgments, settlements, imprisonment of company officials and public censure), civil claims, litigation, damage to our brand and reputation and loss of goodwill (both in relation to existing customers and prospective customers), any of which could have a material adverse effect on our business, operations and financial performance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The life sciences research and diagnostic markets are highly competitive. If we fail to effectively compete, our business, financial condition and operating results will suffer. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We face significant competition in the life sciences research and diagnostic markets. We currently compete with both established and early stage companies that design, manufacture and market systems and consumable supplies. We believe our principal competitors in the life sciences research and genome mapping markets include Pacific Biosciences of California, Oxford Nanopore Technologies, 10x Genomics, Genomic Vision and Dovetail Genomics. In addition, there are a number of new market entrants in the process of developing novel technologies for the life sciences research, diagnostic and screening markets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many of our current competitors are either publicly traded, or are divisions of publicly-traded companies, and may enjoy a number of competitive advantages over us, including: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">greater name and brand recognition;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantially greater financial and human resources;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">broader product lines;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">larger sales forces and more established distributor networks;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial intellectual property portfolios;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">larger and more established customer bases and relationships; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">better established, larger scale, and lower cost manufacturing capabilities. </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We believe that the principal competitive factors in all of our target markets include: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost of instruments and consumables;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">accuracy, including sensitivity and specificity, and reproducibility of results;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reputation among customers;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">innovation in product offerings;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">flexibility and ease of use; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compatibility with existing laboratory processes, tools and methods. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot assure investors that our products will compete favorably or that we will be successful in the face of increasing competition from new products and technologies introduced by our existing competitors or new companies entering our markets. In addition, we cannot assure investors that our competitors do not have or will not develop products or technologies that currently or in the future will enable them to produce competitive products with greater capabilities or at lower costs than ours. Any failure to compete effectively could materially and adversely affect our business, financial condition and operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our application for the Paycheck Protection Program Loan, or our application for forgiveness of the Paycheck Protection Program Loan, could in the future be determined to have been impermissible or could result in damage to our reputation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2020, we received loan proceeds of approximately $1.8 million, or the PPP Loan, pursuant to the Paycheck Protection Program under the &#8220;CARES Act&#8221; administered by the U.S. Small Business Administration, or the SBA. In February 2021, we applied for forgiveness of the PPP Loan, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to apply for the PPP Loan, we were required to certify, among other things, that the current economic uncertainty made the PPP Loan request necessary to support our ongoing operations. We made this certification in good faith after analyzing, among other things, the maintenance of our workforce, our need for additional funding to continue operations, and our ability to access alternative forms of capital in the current market environment to offset the effects of the COVID-19 pandemic. Following this analysis, we believe that we satisfied all eligibility criteria for the PPP Loan, and that our receipt of the PPP Loan is consistent with the broad objectives of the CARES Act. The certification described above did not contain any objective criteria and is subject to interpretation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2020, the SBA issued guidance stating that it is unlikely that a public company with substantial market value and access to capital markets will be able to make the required certification in good faith. The lack of clarity regarding loan eligibility under the Paycheck Protection Program has resulted in significant media coverage and controversy with respect to public companies applying for and receiving loans. If, despite our good-faith belief that given our circumstances we satisfied all eligibility requirements for the PPP Loan, we are later determined to have violated any applicable laws or regulations that may apply to us in connection with the PPP Loan or it is otherwise determined that we were ineligible to receive the PPP Loan, we may be required to repay the PPP Loan in its entirety and/or be subject to additional penalties, which could also result in adverse publicity and damage to our reputation. Should we be audited or reviewed by federal or state regulatory authorities as a result of filing an application for forgiveness of the PPP Loan or otherwise, such audit or review could result in the diversion of management&#8217;s time and attention and legal and reputational costs. If we were to be audited or reviewed and receive an adverse determination or finding in such audit or review, we could be required to return the full amount of the PPP Loan. Any of these events could have a material adverse effect on our business, results of operations and financial condition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged global economic downturn could result in a variety of risks to our business, including our ability to raise additional capital when needed on acceptable terms, if at all. This is particularly true in Europe, which is undergoing a continued severe economic crisis. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The United Kingdom&#8217;s referendum to leave the European Union or &#8220;Brexit,&#8221; has and may continue to cause disruptions to capital and currency markets worldwide. The full impact of the Brexit decision, however, remains uncertain. A process of negotiation will determine the future terms of the United Kingdom&#8217;s relationship with the European Union. During this period of negotiation, our results of operations and access to capital may be negatively affected by interest rate, exchange rate and other market and economic volatility, as well as regulatory and political uncertainty. Brexit may also have a detrimental effect on our suppliers and manufacturers, which would, in turn, adversely affect our financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Legal, political and economic uncertainty surrounding the exit of the U.K., from the European Union, or EU, may be a source of instability in international markets, create significant currency fluctuations, adversely affect our operations or intended operations in the U.K. and pose additional risks to our business, revenue, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nearly 4% of our sales in fiscal year 2020 came from the United Kingdom. Following the result of a referendum in 2016, the U.K. left the EU on January 31, 2020, commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed between the U.K. and the EU, the U.K. will be subject to a transition period until December 31, 2020, or the Transition Period, during which EU rules will continue to apply. Negotiations between the U.K. and the EU are expected to continue in relation to the customs and trading relationship between the U.K. and the EU following the expiry of the Transition Period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The uncertainty concerning the U.K&#8217;s legal, political and economic relationship with the EU after the Transition Period may be a source of instability in the international markets, create significant currency fluctuations, and/or otherwise adversely affect trading agreements or similar cross-border co-operation arrangements (whether economic, tax, fiscal, legal, regulatory or otherwise).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These developments, or the perception that any of them could occur, have had, and may continue to have, a significant adverse effect on global economic conditions and the stability of global financial markets, and could significantly reduce global market liquidity and limit the ability of key market participants to operate in certain financial markets. In particular, it could also lead to a period of considerable uncertainty in relation to the U.K. financial and banking markets, as well as on the regulatory process in Europe. Asset valuations, currency exchange rates and credit ratings may also be subject to increased market volatility. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the U.K. and the EU are unable to negotiate acceptable trading and customs terms or if other EU Member States pursue withdrawal, barrier-free access between the U.K. and other EU Member States or among the European Economic Area overall could be diminished or eliminated. The long-term effects of Brexit will depend on any agreements (or lack thereof) between the U.K. and the EU and, in particular, any arrangements for the U.K. to retain access to EU markets after the Transition Period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Such a withdrawal from the EU is unprecedented, and it is unclear how the U.K&#8217;s access to the European single market for goods, capital, services and labor within the EU, or single market, and the wider commercial, legal and regulatory environment, will impact our business. Any current or planned future operations in the U.K. as well as in other countries in the EU and European Economic Area, or EEA, could be disrupted by Brexit, particularly if there is a change in the U.K&#8217;s relationship to the single market.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Brexit has caused, and may continue to create, volatility in global stock markets and regional and global economic uncertainty particularly in the United Kingdom financial and banking markets. Weakening of economic conditions or economic uncertainties tend to harm our business. There may continue to be economic uncertainty surrounding the consequences of Brexit which could adversely impact customer confidence resulting in customers reducing their spending budgets on our solutions, which could adversely affect our business, revenue, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any derivative action or proceeding brought on our behalf;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a breach of fiduciary duty;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us arising under the Delaware General Corporation Law, our amended and restated certificate of incorporation, or our amended and restated bylaws; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could adversely affect our results of operations and financial condition. </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="ib388395ebea54b38b0be27fba0635b12_1052"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to government regulation and diagnostic product reimbursement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the FDA determines that our RUO products are medical devices or if we seek to market our RUO products for clinical diagnostic or health screening use, we will be required to obtain regulatory clearance(s) or approval(s), and may be required to cease or limit sales of our then marketed products, which could materially and adversely affect our business, financial condition and results of operations. Any such regulatory process would be expensive, time-consuming and uncertain both in timing and in outcome.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our RUO products are focused on the life sciences research market. This includes laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology and contract research companies. Accordingly, our products are labeled as &#8220;Research Use Only,&#8221; or RUO, and are not intended for diagnostic use. While we have focused initially on the life sciences research market and RUO products only, our strategy is to expand our product line to encompass products that are intended to be used for the diagnosis of disease, either alone or in collaboration with third parties (such as our collaboration with Berry Genomics). Such in-vitro diagnostic, or IVD, products will be subject to regulation by the FDA as medical devices, or comparable international agencies, including requirements for regulatory clearance or approval of such products before they can be marketed. If the FDA were to determine that our products are intended for clinical use or if we decided to market our products for such use, we would be required to obtain FDA 510(k) clearance or premarket approval in order to sell our products in a manner consistent with FDA laws and regulations. Such regulatory approval processes or clearances are expensive, time-consuming and uncertain; our efforts may never result in any approved premarket approval application, or PMA, or 510(k) clearance for our products; and failure by us or a collaborator to obtain or comply with such approvals and clearances could have an adverse effect on our business, financial condition or operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">IVD products may be regulated as medical devices by the FDA and comparable international agencies and may require either clearance from the FDA following the 510(k) pre-market notification process or PMA from the FDA, in each case prior to marketing. If we or our collaborators are required to obtain a PMA or 510(k) clearance for products based on our technology, we or they would be subject to a substantial number of additional requirements for medical devices, including establishment registration, device listing, Quality Systems Regulations which cover the design, testing, production, control, quality assurance, labeling, packaging, servicing, sterilization (if required), and storage and shipping of medical devices (among other activities), product labeling, advertising, recordkeeping, post-market surveillance, post-approval studies, adverse event reporting, and correction and removal (recall) regulations. One or more of the products we or a collaborator may develop using our technology may also require clinical trials in order to generate the data required for PMA approval. Complying with these requirements may be time-consuming and expensive. We or our collaborators may be required to expend significant resources to ensure ongoing compliance with the FDA regulations and/or take satisfactory corrective action in response to enforcement action, which may have a material adverse effect on the ability to design, develop, and commercialize products using our technology as planned. Failure to comply with these requirements may subject us or a collaborator to a range of enforcement actions, such as warning letters, injunctions, civil monetary penalties, criminal prosecution, recall and/or seizure of products, and revocation of marketing authorization, as well as significant adverse publicity. If we or our collaborators fail to obtain, or experience significant delays in obtaining, regulatory approvals for IVD products, such products may not be able to be launched or successfully commercialized in a timely manner, or at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Laboratory developed tests, or LDTs, are a subset of IVD tests that are designed, manufactured and used within a single laboratory. Our Lineagen diagnostic services are provided as LDTs. The FDA maintains that LDTs are medical devices and has for the most part exercised enforcement discretion for most LDTs. A significant change in the way that the FDA regulates any LDTs that we, our collaborators or our customers market or develop using our technology could affect our business. If the FDA requires laboratories to undergo premarket review and comply with other applicable FDA requirements in the future, the cost and time required to commercialize an LDT will increase substantially, and may reduce the financial incentive for us to continue to offer our Lineagen genetic diagnostic services or for our customer laboratories to develop LDTs, which could reduce demand for our RUO instruments and our other products. In addition, if the FDA were to change the way that it regulates LDTs to require that we undergo pre-market review or comply with other applicable FDA requirements before we can sell our RUO instruments or our other products to clinical cytogenetics laboratories, our ability to sell our RUO instruments and other products to this addressable market would be delayed, thereby impeding our ability to penetrate this market and generate revenue from sales of our instruments and our other products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Failure to comply with applicable FDA requirements could subject us to misbranding or adulteration allegations under the Federal Food, Drug, and Cosmetic Act. We could be subject to a range of enforcement actions, including warning letters, injunctions, civil monetary penalties, criminal prosecution, and recall and/or seizure of products, as well as significant adverse publicity. In addition, changes to the current regulatory framework, including the imposition of additional or new regulations, could arise at any time during the development or marketing of our products, which may negatively affect our ability to obtain or maintain FDA or comparable regulatory approval of our products, if required.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign jurisdictions have laws and regulations similar to those described above, which may adversely affect our ability to market our products as planned in such countries. The number and scope of these requirements are increasing. As in the U.S., the cost and time required to comply with regulatory requirements may be substantial, and there is no guarantee that we will obtain the necessary authorization(s) required to make our products commercially viable. As a result, the imposition of foreign requirements may also have a material adverse effect on the commercial viability of our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We expect to rely on third parties in conducting any required future studies of diagnostic products that may be required by the FDA or other regulatory authorities, and those third parties may not perform satisfactorily. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not have the ability to independently conduct clinical trials or other studies that may be required to obtain FDA and other regulatory clearance or approval for future diagnostic products. Accordingly, we expect that we would rely on third parties, such as clinical investigators, consultants, and collaborators to conduct such studies if needed. Our reliance on these third parties for clinical and other development activities would reduce our control over these activities. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if the third parties need to be replaced or if the quality or accuracy of the data they obtain is compromised, we may not be able to obtain regulatory clearance or approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Billing for our Lineagen diagnostic testing procedures is complex and requires substantial time and resources to collect payment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Billing for clinical laboratory testing services in connection with our diagnostic services is complex, time-consuming and expensive. Depending on the billing arrangement and applicable law, we bill various payors, including Medicare, Medicaid, private insurance companies, private healthcare institutions, and patients, all of which have different billing requirements. We generally bill third-party payors for our diagnostic testing services and pursue reimbursement on a case-by-case basis where pricing contracts are not in place. To the extent laws or contracts require us to bill patient co-payments or co-insurance, we must also comply with these requirements. We may also face increased risk in our collection efforts, including potential write-offs of accounts receivable and long collection cycles, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Several factors make the billing process complex, including:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differences between the billing rates and reimbursement rates for our products;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with complex federal and state regulations related to billing government healthcare programs, including Medicare, Medicaid and TRICARE;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk of government audits related to billing;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes among payors as to which party is responsible for payment;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differences in coverage and information and billing requirements among payors, including the need for prior authorization and/or advanced notification;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of patient co-payments or co-insurance and our ability to collect such payments from patients;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to billing codes used for our products;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to requirements related to our current or future clinical studies, including our registry studies, which can affect eligibility for payment;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing monitoring provisions of LCDs for our products, which can affect the circumstances under which a claim would be considered medically necessary;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incorrect or missing billing information; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the resources required to manage the billing and claims appeals process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We use standard industry billing codes, known as Current Procedural Terminology, or CPT, codes, to bill for our diagnostic testing services. If these codes were to change, there is a risk of an error being made in the claim adjudication process. Such errors can occur with claims submission, third-party transmission or in the processing of the claim by the payor. Claim adjudication errors may result in a delay in payment processing or a reduction in the amount of the payment we receive.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As we introduce new products, we may need to add new codes to our billing process as well as our financial reporting systems. Failure or delays in effecting these changes in external billing and internal systems and processes could negatively affect our collection rates, revenue and cost of collecting.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, our billing activities require us to implement compliance procedures and oversight, train and monitor our employees, and undertake internal audits to evaluate compliance with applicable laws and regulations as well as internal compliance policies and procedures. When payors deny our claims, we may challenge the reason, low payment amount or payment denials. Payors also conduct external audits to evaluate payments, which add further complexity to the billing process. If the payor makes an overpayment determination, there is a risk that we may be required to return all or some portion of prior payments we have received.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the ACA, requires providers and suppliers to report and return any overpayments received from government payors under the Medicare and Medicaid programs within 60 days of identification. Failure to identify and return such overpayments exposes the provider or supplier to liability under federal false claims laws. These billing complexities, and the related uncertainty in obtaining payment for our products, could negatively affect our revenue and cash flow, our ability to achieve sustained profitability, and the consistency and comparability of our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our Lineagen diagnostic testing procedures are subject to unfavorable pricing regulations or third-party payor coverage and reimbursement policies, our business could be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Lineagen-related revenue depends on achieving and maintaining broad coverage and adequate reimbursement for our Lineagen products and diagnostic assays from third-party payors, including both government and commercial third-party payors. If third-party payors do not provide coverage of, or do not provide adequate reimbursement for, a substantial portion of the list price of our Lineagen products and diagnostic assays, we may need to seek additional payment from the patient beyond any co-payments and deductibles, which may adversely affect demand for our Lineagen products and diagnostic assays. Coverage determinations by a third-party payor may depend on a number of factors, including, but not limited to, a third-party payor&#8217;s determination of whether our products or services are appropriate, medically necessary or cost-effective. If we are unable to provide third-party payors with sufficient evidence of the clinical utility and validity of our Lineagen products and diagnostic assays, they may not provide coverage, or may provide limited coverage, which will adversely affect our revenues and our ability to succeed. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since each third-party payor makes its own decision as to whether to establish a policy to cover our Lineagen products and diagnostic assays, enter into a contract with us and set the amount it will reimburse for a product, these negotiations are a time-consuming and costly process, and they do not guarantee that the third-party payor will provide coverage or adequate reimbursement for our Lineagen products and diagnostic assays. In addition, the determinations by a third-party payor whether to cover our Lineagen products and diagnostic assays and the amount it will reimburse for them are often made on an indication-by-indication basis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In cases where there is no coverage policy or we do not have a contracted rate for reimbursement as a participating provider, the patient is typically responsible for a greater share of the cost of the product, which may result in further delay of our revenue, increase our collection costs or decrease the likelihood of collection.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our claims for reimbursement from third-party payors may be denied upon submission, and we may need to take additional steps to receive payment, such as appealing the denials. Such appeals and other processes are time-consuming and expensive, and may not result in payment. Third-party payors may perform audits of historically paid claims and attempt to recoup funds years after the funds were initially distributed if the third-party payors believe the funds were paid in error or determine that our Lineagen products and diagnostic assays were medically unnecessary. If a third-party payor audits our claims and issues a negative audit finding, and we are not able to overturn the audit findings through appeal, the recoupment may result in a material adverse effect on our revenue. Additionally, in some cases commercial third-party payors for whom we are not a participating provider may elect at any time to review claims previously paid and determine the amount they paid was too much. In these situations, the third-party payor will typically notify us of their decision and then offset whatever amount they determine they overpaid against amounts they owe us on current claims. We cannot predict when, or how often, a third-party payor might engage in these reviews and we may not be able to dispute these retroactive adjustments. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future that may adversely affect the coverage and reimbursement of our Lineagen products and diagnostic assays.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If diagnostic procedures that are enabled by our Saphyr technology are subject to unfavorable pricing regulations or third-party payor coverage and reimbursement policies, our business could be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currently, our Saphyr product is for research use only, but clinical laboratories may acquire our instrumentation through a capital purchase or capital lease and use the Saphyr and direct label stain chemistry to create their own potentially reimbursable products, such as laboratory developed tests for in vitro diagnostics. Our customers may generate revenue for these testing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">services by seeking the necessary approval of their product from the FDA or the Centers for Medicare &amp; Medicaid Services, or CMS, along with coverage and reimbursement from third-party payors, including government health programs and private health plans. The ability of our customers to commercialize diagnostic tests based on our technology will depend in part on the extent to which coverage and reimbursement for these tests will be available from such third-party payors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the U.S., molecular testing laboratories have multiple options for reimbursement coding, but we expect that the primary codes used will be the genomic sequencing procedure codes, or GSPs. The American Medical Association, or AMA, added GSPs to its clinical laboratory fee schedule in 2015. In addition, CMS recently issued a coverage determination providing for the reimbursement of next-generation sequencing for certain cancer diagnostics using an FDA-approved in vitro diagnostic test. Private health plans often follow CMS coverage and reimbursement guidelines to a substantial degree, and it is difficult to predict what CMS will decide with respect to the coverage and reimbursement of any products our customers try to commercialize.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In Europe, coverage for molecular diagnostic testing is varied. Countries with statutory health insurance (e.g., Germany, France, The Netherlands) tend to be more progressive in technology adoption with favorable reimbursement for molecular diagnostic testing. In countries such as the United Kingdom with tax-based insurance, adoption and reimbursement for molecular diagnostic testing is not uniform and is influenced by local budgets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ultimately, coverage and reimbursement of new products is uncertain, and whether laboratories that use our instruments to develop their own products will attain coverage and adequate reimbursement is unknown. In the U.S., there is no uniform policy for determining coverage and reimbursement. Coverage can differ from payor to payor, and the process for determining whether a payor will provide coverage may be separate from the process for setting the reimbursement rate. In addition, the U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls and restrictions on reimbursement. We cannot be sure that coverage will be available for any diagnostic tests based on our technology, and, if coverage is available, the level of payments. Reimbursement may impact the demand for those tests. If coverage and reimbursement is not available or is available only to limited levels, our customers may not be able to successfully commercialize any tests for which they receive marketing authorization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of operations.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2010, the ACA became law. The ACA is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. For example, the ACA contained a 2.3% excise tax on certain entities that manufacture or import medical devices offered for sale in the U.S., with limited exceptions, which has been permanently eliminated as part of the 2020 spending package.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it is unknown when a decision will be made. Additionally, on February 10, 2021, the Biden administration withdrew the federal government&#8217;s support for overturning the ACA. It is unclear how the Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the ACA and our business.  In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, on April 1, 2014, the Protecting Access to Medicare Act of 2014, or PAMA, was signed into law, which, among other things, significantly altered the payment methodology under the Medicare Clinical Laboratory Fee Schedule, or CLFS. PAMA requires certain laboratories performing clinical diagnostic laboratory tests to report to CMS the amounts paid by private payors for laboratory tests. Such reporting has been subject to numerous delays. Beginning on January 1, 2018, CMS has begun using reported private payor pricing to periodically revise payment rates under the CLFS. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we or our collaborators will receive for any cleared or approved product. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.  Any reduction in payments from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent our customers from successfully commercializing any tests for which they receive approval, which could prevent us from being able to generate revenue and attain profitability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Complying with numerous regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to the Clinical Laboratory Improvement Amendment of 1988, or CLIA, which is a federal law regulating clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. Our clinical laboratory is located in Utah and must be certified under CLIA in order for us to perform testing on human specimens. CLIA is intended to ensure the quality and reliability of clinical laboratories in the United States by mandating specific standards in the areas of personnel qualifications, administration, and participation in proficiency testing, patient test management, quality control, quality assurance and inspections. We have a current certificate of compliance under CLIA to perform cytogenetics. To renew this certificate, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make periodic inspections of our clinical laboratory outside of the renewal process. The failure to comply with CLIA requirements can result in enforcement actions, including the revocation, suspension, or limitation of our CLIA certificate of compliance, as well as a directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit and/or criminal penalties. We must maintain CLIA compliance and certification to be eligible to bill for assays provided to Medicare beneficiaries. If we were to be found out of compliance with CLIA program requirements and subjected to sanctions, our business and reputation could be harmed. Even if it were possible for us to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We hold laboratory licenses from the states of California, Pennsylvania, and Maryland, to test specimens from patients in those states or received from ordering physicians in those states. Other states may have similar requirements or may adopt similar requirements in the future. Finally, we may be subject to regulation in foreign jurisdictions if we seek to expand international distribution of our assays outside the United States. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we were to lose our CLIA certification or state laboratory licenses, whether as a result of a revocation, suspension or limitation, we would no longer be able to offer our assays, which would limit our revenues and harm our business. If we were to lose, or fail to obtain, a license in any other state where we are required to hold a license, we would not be able to test specimens from those states. If we were to lose our CAP accreditation, our reputation for quality, as well as our business, financial condition and results of operations, could be significantly and adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to federal and state healthcare fraud and abuse laws and other federal and state laws applicable to our business activities, including our marketing practices. If we are unable to comply, or have not complied, with such laws, we could face substantial penalties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations are subject to various federal and state fraud and abuse laws, including, without limitation, the federal and state anti-kickback statutes and false claims laws. These laws may impact, among other things, our sales and marketing and education programs, and our financial and business relationships with health care professionals. The laws that may affect our ability to operate include, but are not limited to:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, or the AKS, which prohibits, among other things, any person or entity from knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8216;&#8216;remuneration&#8217;&#8217; has been broadly interpreted to include anything of value. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, however these are drawn narrowly. Additionally, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.  In addition, the ACA codified case law that a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the federal False Claims Act, or the FCA;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Stark Law, which prohibits a physician from making a referral for certain designated health services covered by the Medicare or Medicaid program, including laboratory and pathology services, if the physician or an immediate family member of the physician has a financial relationship with the entity providing the designated health services and prohibits that entity from billing, presenting or causing to be presented a claim for the designated health services furnished pursuant to the prohibited referral, unless an exception applies;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, such as the FCA, which can be enforced by private citizens through civil qui tam actions, prohibits individuals or entities from, among other things, knowingly presenting, or causing to be presented false, fictitious or fraudulent claims for payment or approval by the federal government, including federal health care programs, such as Medicare and Medicaid, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim, or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Eliminating Kickbacks in Recovery Act of 2018, or EKRA, prohibits payments for referrals to recovery homes, clinical treatment facilities, and laboratories. EKRA&#8217;s reach extends beyond federal health care programs to include private insurance (i.e., it is an &#8220;all payor&#8221; statute). For purposes of EKRA, the term &#8220;laboratory&#8221; is defined broadly and without reference to any connection to substance use disorder treatment. The law includes a limited number of exceptions, some of which closely align with corresponding federal Anti-Kickback Statute exceptions and safe harbors, and others that materially differ;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, in connection with the delivery of or payment for healthcare benefits, items or services. Like the AKS, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, which imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates, individuals or entities that perform services for them that involve individually identifiable health information as well as their covered subcontractors;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws that prohibit other specified practices, such as billing physicians for tests that they order or providing tests at no or discounted cost to induce physician or patient adoption; insurance fraud laws; waiving coinsurance, copayments, deductibles, and other amounts owed by patients; billing a state Medicaid program at a price that is higher than what is charged to one or more other third-party payors employing, exercising control over or splitting professional fees with licensed professionals in violation of state laws prohibiting fee splitting or the corporate practice of medicine and other professions; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prohibition on reassignment of Medicare claims, which, subject to certain exceptions, precludes the reassignment of Medicare claims to any other party;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by any non-governmental third-party payors, including private insurers; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal, state and foreign laws that govern the privacy and security of health information or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a clinical laboratory, our business practices may face additional scrutiny from government regulatory agencies such as the Department of Justice, the U.S. Department of Health and Human Services Office of Inspector General, or OIG, and CMS. Certain arrangements between clinical laboratories and referring physicians have been identified in fraud alerts issued by the OIG as implicating the AKS. The OIG has stated that it is particularly concerned about these types of arrangements because the choice of laboratory, as well as the decision to order laboratory tests, typically are made or strongly influenced by the physician, with little or no input from patients. Moreover, the provision of payments or other items of value by a clinical laboratory to a referral source could be prohibited under the Stark Law unless the arrangement meets all criteria of an applicable exception. The government has been active in enforcement of these laws as they apply to clinical laboratories.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have entered into consulting and scientific advisory board arrangements, speaking arrangements and clinical research agreements with physicians and other healthcare providers, including some who could influence the use of our products. Although we believe that these have been structured in compliance with applicable laws, because of the complex and far-reaching nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for which we could be subject to other significant penalties. We could be adversely affected if regulatory agencies interpret our financial relationships with providers who may influence the ordering of and use of our products to be in violation of applicable laws.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations is costly. If our operations are found to be in violation of any of these laws, we may be subject to significant penalties, including, without </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">limitation, civil, criminal, and administrative penalties, damages, fines, disgorgement, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, additional integrity oversight and reporting obligations, imprisonment, contractual damages, and reputational harm, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other healthcare providers or entities with whom we do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, sales of our products outside of the U.S. will subject us to similar foreign regulatory requirements.</span></div><div id="ib388395ebea54b38b0be27fba0635b12_1059"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our intellectual property, it may reduce our ability to maintain any technological or competitive advantage over our competitors and potential competitors, and our business may be harmed. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on patent protection as well as trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. As of February 28, 2021, we (directly or through our wholly owned subsidiary Lineagen, Inc.) were the assignee or assignee-applicant of 17 granted U.S. patents and 15 pending U.S. patent applications. We also were the assignee-applicant of approximately 81 pending patent applications and granted patents in particular jurisdictions outside the U.S. If we fail to protect and/or maintain our intellectual property, third parties may be able to compete more effectively against us, we may lose our technological or competitive advantage, and/or we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot assure investors that any of our currently pending or future patent applications will result in granted patents, and we cannot predict how long it will take for such patents to issue, if at all. It is possible that, for any of our patents that have issued or that may issue in the future, our competitors may design their products or services around our patented technologies. Further, we cannot assure investors that other parties will not challenge any patents granted to us, or that courts or regulatory agencies will hold our patents to be valid, enforceable, and/or infringed. We cannot guarantee investors that we will be successful in defending challenges made against our patents and patent applications. Any successful third-party challenge or challenges to our patents could result in the unenforceability or invalidity of such patents, or such patents being interpreted narrowly and/or in a manner adverse to our interests. Our ability to establish or maintain a technological or competitive advantage over our competitors and/or market entrants may be diminished because of these uncertainties. For these and other reasons, our intellectual property may not provide us with any competitive advantage. For example: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors might not have been the first to make the inventions claimed or disclosed by our pending patent applications or issued patents;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings or derivation proceedings declared by the U.S. Patent and Trademark Office, or the USPTO, which could result in substantial cost to us, and could possibly result in a loss or narrowing of patent rights. No assurance can be given that our or our licensors&#8217; patent applications or granted patents will have priority over any other patent or patent application involved in such a proceeding, or will be held valid as an outcome of the proceeding;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other parties may independently develop similar or alternative products and technologies or duplicate any of our products and technologies, which can potentially impact our market share, revenue, and goodwill, regardless of whether intellectual property rights are successfully enforced against these other parties;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our owned or licensed pending patent applications will not result in granted patents, and even if such pending patent applications issue as patents, they may not provide intellectual property protection of commercially viable products or product features, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties, patent offices, and/or the courts;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unaware of or unfamiliar with prior art and/or interpretations of prior art that could potentially impact the validity or scope of our patents or pending patent applications, or patent applications that we intend to file; </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we take efforts and enter into agreements with employees, consultants, collaborators, and, as applicable, advisors to confirm ownership and chain of title in intellectual property rights. However, an inventorship or ownership dispute could arise that may permit one or more third parties to practice or enforce our intellectual property rights, including possible efforts to enforce rights against us; </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may elect not to maintain or pursue intellectual property rights that, at some point in time, may be considered relevant to or enforceable against a competitor; </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary products and technologies that are patentable, or we may develop additional proprietary products and technologies that are not patentable;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents or other intellectual property rights of others may have an adverse effect on our business; and </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we apply for patents relating to our products and technologies and uses thereof, as we deem appropriate. However, we or our representatives or their agents may fail to apply for patents on important products and technologies in a timely fashion or at all, or we or our representatives or their agents may fail to apply for patents in potentially relevant jurisdictions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct or indirect competition. If our intellectual property does not provide adequate coverage of our competitors&#8217; products or services, our competitive position could be adversely affected, as could our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, to the extent that computation methods implemented by software included in our products are not protected by our patents, our dependence on copyright and trade secret protection may not provide adequate protection. In addition, the Supreme Court&#8217;s ruling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alice Corporation Pty.&#160;Ltd. v. CLS Bank International</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, has narrowed the scope of patent protection available for computational methods in certain circumstances. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The measures that we use to protect the security of our intellectual property and other proprietary rights may not be adequate, which could result in the loss of legal protection for, and thereby diminish the value of, such intellectual property and other rights. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to pursuing patents on our technologies, we also rely upon trademarks, trade secrets, copyrights and unfair competition laws, as well as license agreements and other contractual provisions, to protect our intellectual property and other proprietary rights. Despite these measures, any of our intellectual property rights could be challenged, invalidated, circumvented or misappropriated. In addition, we take steps to protect our intellectual property and proprietary technologies by entering into confidentiality agreements and intellectual property assignment agreements with our employees, consultants, corporate partners and, when needed, our advisors. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets and/or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. Moreover, if a party having an agreement with us has an overlapping or conflicting obligation to a third-party, our rights in and to certain intellectual property could be undermined. Monitoring unauthorized and inadvertent disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third-party had illegally obtained and was using our trade secrets, it would be expensive and time consuming, the outcome would be unpredictable, and any remedy may be inadequate. In addition, courts outside the U.S. may be less willing to protect trade secrets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, competitors could purchase our products and attempt to replicate and/or improve some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design their products around our protected technologies or develop their own competitive technologies that fall outside of our intellectual property rights. If our intellectual property does not adequately protect our market share against competitors&#8217; products, services and methods, our competitive position could be adversely affected, as could our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have rights in some intellectual property that has been discovered through government funded programs and thus is subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements, and limit our ability to contract with non-U.S. manufacturers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the intellectual property rights assigned to us and/or in-licensed to us have been generated through the use of U.S. government funding and are therefore subject to certain federal regulations. For example, all of the intellectual property rights licensed to us under our license agreement with Princeton University have been generated using U.S. government funds. As a result, the U.S. government has certain rights to intellectual property embodied in our current or future products pursuant to the Bayh-Dole Act of 1980. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third-party if the government determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we fail, or the applicable licensor fails, to disclose the invention to the government, elect title, and file an application to register the intellectual property within specified time limits. In addition, the U.S. government may acquire title to these inventions in any country in which a patent application is not filed within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us, or the applicable licensor, to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the U.S. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential licensees that would be likely to manufacture substantially in the U.S. or that, under the circumstances, domestic manufacture is not commercially feasible. This preference for U.S. manufacturing may limit our ability to license the applicable patent rights on an exclusive basis under certain circumstances. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we enter into future arrangements involving government funding, and we make or license inventions that result from such funding, intellectual property rights to such discoveries may be subject to the applicable provisions of the Bayh-Dole Act. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. Any exercise by the government of certain of its rights could harm our competitive position, business, financial condition, results of operations and prospects. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on technology that is licensed to us by Princeton University. Any loss of our rights to this technology could prevent us from selling our products. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some technology that relates to analysis of nucleic acids is licensed exclusively to us from Princeton University, or Princeton. We do not own the patents that underlie this license. Our rights to use this technology and employ the inventions claimed in the licensed patents are subject to the continuation of and compliance with the terms of the license. Our principal obligations under our license agreement with Princeton are as follows: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">royalty payments;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">annual maintenance fees;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">using commercially reasonable efforts to develop and sell a product using the licensed technology and developing a market for such product;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">paying and/or reimbursing fees related to prosecution, maintenance and enforcement of patent rights; and </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">providing certain reports. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we breach any of these obligations, Princeton may have the right to terminate or modify the license, which could result in our being unable to develop, manufacture and sell our products or a competitor gaining access to the relevant technology. Termination or certain modifications of our license agreement with Princeton would have a material adverse effect on our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are a party to a number of other agreements that include licenses to intellectual property, including non-exclusive licenses. We may need to enter into additional license agreements in the future. Our business could suffer, for example, if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we have done previously, we may need or may choose to obtain licenses and/or acquire intellectual property rights from third parties to advance our research or begin commercialization of our current or future products or services, and we cannot provide any assurances that third-party patents do not exist that might be enforced against our current or future products or services in the absence of such a license. We may fail to obtain any of these licenses or intellectual property rights on commercially reasonable terms. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected products or services, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing of intellectual property is important to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether and the extent to which our technologies and processes infringe any intellectual property of the licensor that is not subject to the licensing agreement; </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether to take action to enforce any intellectual property rights against an allegedly infringing product or process of a third-party; </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our right to sublicense patent and other rights to third parties;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations with respect to the use of licensed technology in relation to our development and commercialization of our products and services, and what activities satisfy those diligence obligations; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how, such as intellectual property resulting from the joint creation or use of intellectual property by our licensors and us and our partners. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product or service, or the dispute may have an adverse effect on our results of operation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to agreements pursuant to which we in-license intellectual property, we may in the future grant licenses under our intellectual property, or sell certain intellectual property. Like in-licenses, out-licenses can be complex and disputes may arise between us and our licensees, such as the types of disputes described above. Moreover, licensees may breach their obligations, or we may be exposed to liability due to our failure or alleged failure to satisfy our obligations. Any such occurrence could have an adverse effect on our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or any of our partners is sued for infringing intellectual property rights of third parties, it would be costly and time consuming, and an unfavorable outcome in that litigation could have a material adverse effect on our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success also depends on our ability to develop, manufacture, market and sell our products and perform our services without infringing the proprietary rights of third parties. Numerous U.S. and foreign-issued patents and pending patent applications owned by third parties exist in the fields in which we are developing manufacturing, marketing and selling products and performing services. As part of a business strategy to impede our successful commercialization and entry into new markets, competitors may allege that our products and/or services infringe their intellectual property rights. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could incur substantial costs and divert the attention of our management and technical personnel in defending ourselves against claims of infringement made by third parties. Any adverse ruling by a court or administrative body, or perception of an adverse ruling, may have a material adverse impact on our ability to conduct our business and our finances. Moreover, third parties making claims against us may be able to obtain injunctive relief against us, which could block our ability to offer one or more products or services and could result in a substantial award of damages against us. In addition, since we sometimes indemnify customers, collaborators or licensees, we may have additional liability in connection with any infringement or alleged infringement of third-party intellectual property. Intellectual property litigation can be very expensive, and we may not have the financial means to defend ourselves or our customers, collaborators and licensees. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications can take many years to issue, there may be pending applications, some of which are unknown to us, that may result in issued patents upon which our products, services or proprietary technologies may infringe. Moreover, we may fail to identify issued patents of relevance or incorrectly conclude that an issued patent is invalid or not infringed any of our products, services or proprietary technologies. There is a substantial amount of litigation involving patents and other intellectual property rights in our industry. If a third-party claims that we or any of our licensors, customers or collaboration partners infringe upon a third-party&#8217;s intellectual property rights, we may have to: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to obtain licenses that may not be available on commercially reasonable terms, if at all;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">abandon any product or service alleged or held to infringe, or redesign our products or processes to avoid potential assertion of infringement; </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay substantial damages including, in exceptional cases, treble damages and attorneys&#8217; fees, which we may have to pay if a court decides that the product or proprietary technology at issue infringes upon or violates the third-party&#8217;s rights;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay substantial royalties or fees for, or grant cross-licenses to, our technology; or </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">defend litigation or administrative proceedings that may be costly whether we win or lose, and which could result in a substantial diversion of our financial and management resources. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or the patents we license in. In the event of infringement or unauthorized use, we may file one or more infringement lawsuits, which can be expensive and time-consuming. An adverse result in any such litigation proceedings could put one or more of our patents at risk of being invalidated, being found to be unenforceable, and/or being interpreted narrowly and could put our patent applications at risk of not issuing and/or could impact the validity or enforceability positions of our other patents or those we license. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation longer than we could. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations, continue our internal research programs, in-license needed technology, pursue, obtain or maintain intellectual property rights, or enter into development partnerships that would help us bring our products or services to market. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patent litigation can be very costly and time-consuming. An adverse outcome in such litigation or proceedings may expose us or any of our future development partners to loss of our proprietary position, expose us to significant liabilities, or require us to seek licenses that may not be available on commercially acceptable terms, if at all. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our issued patents could be found invalid or unenforceable if challenged in court or at the Patent Office or other administrative agency, which could have a material adverse impact on our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of our partners were to initiate legal proceedings against a third-party to enforce a patent related to one of our products or services, the defendant in such litigation could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace, as are validity challenges by the defendant against the subject patent or other patents before the USPTO. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement, failure to meet the written description requirement, indefiniteness, and/or failure to disclose the best mode or to claim patent eligible subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent intentionally withheld material information from the USPTO, or made a misleading statement, during prosecution. Additional grounds for an unenforceability assertion include an allegation of misuse or anticompetitive use of patent rights, and an allegation of incorrect inventorship with deceptive intent. Third parties may also raise similar claims before the USPTO even outside the context of litigation. The outcome is unpredictable following legal assertions of invalidity and unenforceability. With respect to the validity question, for example, we cannot be certain that no invalidating prior art existed of which we and the patent examiner were unaware during prosecution. These assertions may also be based on information known to us or the Patent Office. If a defendant or third-party were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the claims of the challenged patent. Such a loss of patent protection would or could have a material adverse impact on our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed alleged trade secrets of their other clients or former employers to us, and/or that their other clients or former employers allegedly have rights in our intellectual property, which could subject us to costly litigation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the life sciences industry, we engage the services of consultants and independent contractors to assist us in the development of our products and services. Many of these consultants and independent contractors were previously employed at, or may have previously or may be currently providing consulting or other services to, universities or other technology, biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may become subject to claims that our company, a consultant or an independent contractor inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. We may similarly be subject to claims stemming from similar actions of an employee, such as one who was previously employed by another company, including a competitor or potential competitor. We may become subject to claims that one or more current or former employees, consultants, advisors, or independent contractors of ours owns rights in our intellectual property and/or has assigned or is under an obligation to assign rights in our intellectual property to another party. This may include a competitor of ours. If a competitor has rights in our patents, the competitor or a licensee or related entity of the competitor may be able to make, use, sell, import, and/or export the patented technology without liability to us under our patents or the patents we license. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team. If we were not successful, we could lose valuable intellectual property rights. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, contractors, and, as applicable, advisors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively assign or may be alleged to ineffectively assign intellectual property rights to us. For example, even if we have a consulting agreement in place with an academic advisor pursuant to which such academic advisor is required to assign any inventions developed in connection with providing services to us, such academic advisor may not have the right to assign such inventions to us, as it may conflict with his or her obligations to assign all such intellectual property to his or her employing institution. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we sometimes enter into agreements where we provide services to third parties, such as customers. Under such circumstances, our agreements may provide that certain intellectual property that we conceive in the course of providing those services is assigned to the customer. In those cases, we may not be able to use that particular intellectual property in, for example, our work for other customers without a license. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world, which could materially and negatively affect our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, maintaining, and defending patents on current and future products and services in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, regardless of whether we are able to prevent third parties from practicing our inventions in the U.S., we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not pursued and obtained patent protection to develop their own products or services, and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as it is in the U.S. These products or services may compete with our products or services and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Even if we pursue and obtain issued patents in particular jurisdictions, our patent claims or other intellectual property rights may not be effective or sufficient to prevent third parties from so competing. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents or marketing of competing products or services in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license and may adversely impact our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and our partners also face the risk that our products or components thereof are imported, reimported, or exported into markets with relatively higher prices from markets with relatively lower prices, which would result in a decrease of sales and any payments we receive from the affected market. Recent developments in U.S. patent law have made it more difficult to stop these and related practices based on theories of patent infringement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other life science industry companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents involve both technological complexity and legal complexity. Therefore, obtaining and enforcing patents is costly, time-consuming and inherently uncertain. In addition, the America Invents Act, or the AIA, became effective on March&#160;16, 2013. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An important change introduced by the AIA is that the U.S. transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third-party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent claiming or disclosing an invention of ours even if we had made the invention before it was made by the third-party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions. Additionally, there can be a trade-off between obtaining an earlier filing date, and waiting to obtain additional data and/or further refine a patent application. In some circumstances, the effects of a decision to pursue an earlier filing or a later filing will not be known until prior art or third-party activities are subsequently discovered, such as by the USPTO or by a third-party seeking to challenge patent rights. These circumstances may apply, for example, to patent applications prepared and filed around the time of the implementation of the AIA, or with a priority application that preceded the implementation of the AIA. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among some of the other changes introduced by the AIA are changes that limit where a patent holder may file a patent infringement suit and providing additional opportunities for third parties to challenge an issued patent in the USPTO. This applies to all of our owned and in-licensed U.S. patents, even those issued before March&#160;16, 2013. Because of a lower standard for evidence in USPTO proceedings compared to the standard for evidence in U.S. federal courts necessary to invalidate a patent claim, a third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a court action. Accordingly, a third-party may try to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third-party in court. The AIA and its implementation could increase the uncertainties and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. In addition, the contours of the laws under the AIA are subject to further judicial interpretation and/or legislative changes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years, such as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Impression Products,&#160;Inc. v. Lexmark International,&#160;Inc., Association for Molecular Pathology v. Myriad Genetics, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Mayo Collaborative Services v. Prometheus Laboratories,&#160;Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Alice Corporation Pty.&#160;Ltd. v. CLS Bank International</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with our ability to obtain patents in the future, this combination of events has created uncertainty as to the value of patents, once obtained, including patents in the molecular biology analysis and diagnostic space in particular. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. In some cases, our licensors may be responsible for these payments, thereby decreasing our control over compliance with these requirements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may use third-party open source software components in future products, and failure to comply with the terms of the underlying open source software licenses could restrict our ability to sell such products. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our current products do not contain any software tools licensed by third-party authors under &#8220;open source&#8221; licenses, we may choose to use open source software in future products. Use and distribution of open source software may entail greater risks than use of third-party commercial software, as open source licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the code. Some open source licenses may contain requirements that we make available source code for modifications or derivative works we create based upon the type of open source software we use. If we combine our proprietary software with open source software in a certain manner, we could, under certain open source licenses, be required to release the source code of our proprietary software to the public. This would allow our competitors to create similar products with less development effort and time, and ultimately could result in a loss of product sales. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we intend to monitor any use of open source software to avoid subjecting our products to conditions, we do not intend, the terms of many open source licenses have not been interpreted by U.S. courts, and there is a risk that any such licenses could be construed in a way that could impose unanticipated conditions or restrictions on our ability to commercialize our products. Moreover, we cannot assure investors that our processes for controlling our use of open source software in our products will be effective. If we are held to have breached the terms of an open source software license, we could be required to seek licenses from third parties to continue offering our products on terms that are not economically feasible, to re-engineer our products, to discontinue the sale of our products if re-engineering could not be accomplished on a timely basis, or to make generally available, in source code form, our proprietary code, any of which could adversely affect our business, operating results, and financial condition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use third-party software that may be difficult to replace or cause errors or failures of our products that could lead to lost customers or harm to our reputation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use software licensed from third parties in our products. In the future, this software may not be available to us on commercially reasonable terms, or at all. Any loss of the right to use any of this software could result in delays in the production of our products until equivalent technology is either developed by us, or, if available, is identified, obtained and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">integrated, which could harm our business. In addition, any errors or defects in third-party software or other third-party software failures could result in errors or defects or cause our products to fail, which could harm our business and be costly to correct. Many of these providers attempt to impose limitations on their liability for such errors, defects or failures, and, if enforceable, we may have additional liability to our customers or third-party providers that could harm our reputation and increase our operating costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to maintain our relationships with third-party software providers and to seek software from such providers that does not contain any errors or defects. Any failure to do so could adversely impact our ability to deliver reliable products to our customers and could harm our results of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Numerous factors may limit any potential competitive advantage provided by our intellectual property rights. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third-party has intellectual property rights that cover or impact our use of our technologies, we may not be able to fully use or extract value from our intellectual property rights. For example: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to develop and/or use technologies that are similar to our technologies or aspects of our technologies but that does not cover the claims of any our patents or patents that may issue from our patent applications or those we license;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or the licensor of our licensed-in patents might not have been the first to make the inventions disclosed and/or claimed in a pending patent application that we own or license;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or the licensor of our licensed-in patents might not have been the first to file patent applications disclosing and/or claiming an invention;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies without infringing our or our licensors&#8217; intellectual property rights; </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pending patent applications that we own or license may not lead to issued patents or may not result in the claims that we want (for example, as to the scope of issued claims, if any);</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents, if issued, that we own or license may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors or other third parties;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection; </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to obtain and/or maintain necessary or useful licenses on reasonable terms or at all;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property; </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop or in-license additional proprietary technologies that are patentable; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents or other intellectual property of others may have an adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business and results of operations. </span></div><div id="ib388395ebea54b38b0be27fba0635b12_1066"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of our Securities </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our securities may be volatile, and you could lose all or part of your investment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our securities is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this Part I, Item 1A Risk Factors and elsewhere in our Annual Report, these factors include:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercial progress in marketing and selling our genome analysis systems, including sales and revenue trends;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to our systems;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments related to our laboratory facilities;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased competition in the diagnostics services industry;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure to obtain and/or maintain coverage and adequate reimbursement for our Lineagen products and diagnostic assays and patients&#8217; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of our customers to obtain and/or maintain coverage and adequate reimbursement for their services using our Saphyr systems;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments concerning our manufacturers and suppliers;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to establish future collaborations;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key scientific or management personnel;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new testing services offered by us or our competitors;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively manage our growth;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth, if any, of our targeted markets;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated variations in quarterly operating results;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our cash position;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall performance of the equity markets;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuances of debt or equity securities;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our securities by us or our stockholders in the future;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our securities;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting practices;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ineffectiveness of our internal controls;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including our ability to adequately protect our proprietary rights in our technologies;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general political and economic conditions; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other events or factors, many of which are beyond our control.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and diagnostic and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our securities, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to comply with the applicable continued listing requirements or standards of The Nasdaq Capital Market, Nasdaq could delist our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if we are delisted from The Nasdaq Capital Market or if we are unable to transfer our listing to another stock market. In order to maintain this listing, we must satisfy minimum financial and other continued listing requirements and standards, including a requirement to maintain a minimum bid price of our common stock of $1.00 per share.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in a letter dated April 22, 2020, or the Notice, we were notified by the Nasdaq Stock Market LLC, or Nasdaq, that for 30 consecutive trading days preceding the date of the Notice, the bid price of our common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2), or the Minimum Bid Price Requirement. Under Nasdaq Listing Rule 5810(c)(3)(A), we had 180 calendar days following the date of the Notice to regain compliance with the Minimum Bid Price Requirement, and due to extraordinary market conditions, Nasdaq determined to toll the compliance period for the Minimum Bid Price Requirement through September 30, 2020, or the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tolling Period. As a result, the compliance Period ended on December 28, 2020, or the Compliance Period, instead of October 20, 2020. Nasdaq subsequently granted us an extension until June 28, 2021 to regain compliance with the Minimum Bid Price Requirement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 13, 2021, Nasdaq notified that Company that it had regained compliance with the Minimum Bid Price Requirement because the closing bid price of our common stock had been at least $1.00 per share or greater from December 29, 2020 to January 12, 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have regained compliance with Nasdaq, if we fail to satisfy another Nasdaq requirement for continued listing, Nasdaq staff could provide notice that our common stock may become subject to delisting. In such event, Nasdaq rules permit us to appeal the decision to reject our proposed compliance plan or any delisting determination to a Nasdaq Hearings Panel. Accordingly, there can be no guarantee that we will be able to maintain our Nasdaq listing. If our common stock is delisted by Nasdaq, it could lead to a number of negative implications, including an adverse effect on the price of our common stock, increased volatility in our common stock, reduced liquidity in our common stock, the loss of federal preemption of state securities laws and greater difficulty in obtaining financing. In addition, delisting of our common stock could deter broker-dealers from making a market in or otherwise seeking or generating interest in our common stock, could result in a loss of current or future coverage by certain sell-side analysts and might deter certain institutions and persons from investing in our securities at all. Delisting could also cause a loss of confidence of our customers, collaborators, vendors, suppliers and employees, which could harm our business and future prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our common stock is delisted by Nasdaq, our common stock may be eligible to trade on the OTC Bulletin Board, OTC-QB or another over-the-counter market. Any such alternative would likely result in it being more difficult for us to raise additional capital through the public or private sale of equity securities and for investors to dispose of or obtain accurate quotations as to the market value of, our common stock. In addition, there can be no assurance that our common stock would be eligible for trading on any such alternative exchange or markets. Moreover, if our common stock is delisted, it may come within the definition of &#8220;penny stock&#8221; under the Exchange Act, which imposes additional sales practice requirements on broker-dealers who sell securities to persons other than established customers and accredited investors. For example, we and/or broker-dealers are required to make a special suitability determination for purchases of such securities and must receive a purchaser&#8217;s written consent to the transaction prior to any purchase. Additionally, unless exempt, prior to a transaction involving a penny stock, the penny stock rules require the delivery of a disclosure schedule prescribed by the SEC relating to the penny stock market. The broker-dealer must also disclose the commissions payable to the broker-dealer, current quotations for the securities and, if the broker-dealer is the sole market-maker for the security, the fact that they are the sole market-maker and their presumed control over the market. Finally, monthly statements disclosing recent price information on the limited market in penny stocks must be sent to holders of such penny stocks. These requirements may reduce trading activity in the secondary market for our common stock and may impact the ability or willingness of broker-dealers to sell our securities which could limit the ability of stockholders to sell their securities in the public market and limit our ability to attract and retain qualified employees or raise additional capital in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have never paid dividends and we do not intend to pay dividends on our capital stock. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividend on our capital stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend upon results of operations, financial condition, contractual restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant. Accordingly, realization of a gain on your investment will depend on the appreciation of the price of our securities, which may never occur. In addition, the Innovatus LSA contains a negative covenant which prohibits us from paying dividends without the prior written consent of Innovatus.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers, directors and 5% stockholders and their affiliates currently beneficially own a significant percentage of our outstanding voting stock. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our securities that you may feel are in your best interest as one of our stockholders. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an emerging growth company, and the reduced reporting requirements applicable to emerging growth companies could make our securities less attractive to investors.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oxley Act, reduced disclosure obligations regarding executive compensation in our Annual Report and our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We can remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) ending December 31, 2023, which is the end of the fiscal year following the fifth anniversary of the closing of our initial public offering, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period. Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our securities less attractive because we may rely on these exemptions, which could result in a less active trading market for our securities and increased volatility in the price of our securities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. We have elected to use this extended transition period. As a result of this election, our timeline to comply with these standards will in many cases be delayed as compared to other public companies that are not eligible to take advantage of this election or have not made this election. Therefore, our financial statements may not be comparable to those of companies that comply with the public company effective dates for these standards. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we cease to be an emerging growth company, we will no longer be able to use the extended transition period for complying with new or revised accounting standards. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May 7, 2021, the market value of our common stock held by non-affiliates exceeded $700.0 million. If the market value of our common stock held by non-affiliates exceeds $700.0 million as of June 30, 2021, we will be a large accelerated filer and thus will cease to be an emerging growth company effective December 31, 2021. Additionally, in such case, we expect to no longer qualify as a smaller reporting company beginning with our first Quarterly Report on Form 10-Q for the quarterly period ending March 31, 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have identified material weaknesses in our internal control over financial reporting. If our internal control over financial reporting is not effective, we may not be able to accurately report our financial results or file our periodic reports in a timely manner, which may cause adverse effects on our business and may cause investors to lose confidence in our reported financial information and may lead to a decline in our stock price.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal controls over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with accounting principles generally accepted in the U.S. Effective internal control over financial reporting is necessary for us to provide reliable financial reports in a timely manner.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, we concluded there was a material weakness in our internal control environment over financial reporting because we did not have a sufficient number of resources to support the growth and complexity of our financial reporting requirements. This material weakness contributed to a material weakness in our control activities based on the criteria set forth in the 2013 Framework. Specifically, the design of certain controls did not adequately provide appropriate segregation of duties. The failure to maintain appropriate segregation of duties had a pervasive impact and as such, this deficiency resulted in a risk that could have impacted all financial statement account balances and disclosures. The material weaknesses did not result in any identified material misstatements to our financial statements, and there were no changes to previously released financial results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an attempt to remediate the material weaknesses, we have (i) engaged an external consulting firm to assist with our internal accounting functions and further enhance our internal controls, which has increased the number of personnel involved in financial reporting and (ii) we are in the process of hiring additional qualified individuals that will increase the number of personnel involved in financial reporting and the control environment. However, we cannot assure you that these efforts will remediate our material weakness in a timely manner, or at all. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to remediate the material weaknesses described above, or if we or our independent registered public accounting firm are otherwise unable to conclude that our internal control over financial reporting is effective we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our securities could decline, and we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could be subject to sanctions or investigations by Nasdaq, the Securities and Exchange Commission, or the SEC, or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the evaluation of our disclosure controls and procedures as of December 31, 2020, we concluded that, as of such date, our disclosure controls and procedures were not effective at a reasonable assurance level as a result of the material weakness that existed in our internal control over financial reporting, as described above. Although we are implementing certain measures to address such material weakness, as described above, we cannot assure you that these efforts will successfully remediate our material weakness in a timely manner, or at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have begun to incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives.* </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a newly public company, we have begun to incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, which will require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive-compensation-related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas. Recent legislation permits emerging growth companies to implement many of these requirements over a longer period and up to five years from the pricing of our initial public offering. We intend to take advantage of this new legislation, but cannot assure you that we will not be required to implement these requirements sooner than planned and thereby incur unexpected expenses. For example, as of May 7, 2021, the market value of our common stock held by non-affiliates exceeded $700.0 million. If the market value of our common stock held by non-affiliates exceeds $700.0 million as of June 30, 2021, we will be a large accelerated filer and will therefore cease to be an emerging growth company effective December 31, 2021.  As a result of this transition, we will be subject to certain disclosure and compliance requirements that apply to other public companies but did not previously apply to us due to our status as an emerging growth company and expect to incur additional legal and financial compliance costs as a result. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the rules and regulations applicable to public companies will continue to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our consolidated net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we are required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time, subject to the restrictions and limitations described below. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our outstanding shares of common stock are available for sale in the public market, subject only to the restrictions of Rule 144 under the Securities Act in the case of our affiliates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of March 31, 2021, we have filed registration statements on Form S-8 under the Securities Act registering the issuance of an aggregate of 21,104,867  shares of common stock subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. Shares registered under these registration statements on Form S-8 are available for sale in the public market subject to vesting arrangements and exercise of options, the lock-up agreements described above and the restrictions of Rule 144 in the case of our affiliates. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our securities and may prevent or frustrate attempts by our securityholders to replace or remove our current management. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws, contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer, the president or by a majority of the total number of authorized directors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our securities to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our shares of common stock began trading on The Nasdaq Capital Market on September 21, 2018. Given the limited trading history of our common stock, there is a risk that an active trading market for our shares will not be sustained, which could put downward pressure on the market price of our common stock and thereby affect the ability of our stockholders to sell their shares.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="ib388395ebea54b38b0be27fba0635b12_1073"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the price of our securities and trading volume could decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our securities will depend in part on the research and reports that securities or industry analysts publish about us or our business. As a newly public company, we have only limited research coverage on our company by equity research analysts. If securities or industry analysts elect not to initiate or continue to provide coverage of our company, the trading price for our securities would likely be negatively impacted. If one or more of the analysts who covers us downgrades our securities or publishes inaccurate or unfavorable research about our business, the price of our securities may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our securities could decrease, which might cause the price of our securities and trading volume to decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Future sales of substantial amounts of our common stock, or the possibility that such sales could occur, could adversely affect the market price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future sales in the public market of shares of our common stock, including shares issued upon exercise of our outstanding stock options, or the perception by the market that these sales could occur, could lower the market price of our common stock or make it difficult for us to raise additional capital.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders may, from time to time, engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategic initiatives, or limit our ability to attract and retain qualified personnel and business partners, any of which could adversely affect our business and operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our stockholders. We may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Securities class action litigation could divert our management&#8217;s attention and harm our business and could subject us to significant liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock markets have from time to time experienced significant price and volume fluctuations that have affected the market prices for the equity securities of life sciences and biotechnology companies.  These broad market fluctuations may cause the market price of our ordinary shares to decline.  In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities.  This risk is especially relevant for us because biotechnology and biopharma companies have experienced significant stock price volatility in recent years. Even if we are successful in defending claims that may be brought in the future, such litigation could result in substantial costs and may be a distraction to our management and may lead to an unfavorable outcome that could adversely impact our financial condition and prospects.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="ib388395ebea54b38b0be27fba0635b12_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib388395ebea54b38b0be27fba0635b12_106"></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div id="ib388395ebea54b38b0be27fba0635b12_109"></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable</span></div><div id="ib388395ebea54b38b0be27fba0635b12_112"></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5. OTHER INFORMATION</span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2021, the compensation committee of our board of directors granted 580,000 restricted stock units (&#8220;RSUs&#8221;) to R. Erik Holmlin, Ph.D., our President and Chief Executive Officer (the &#8220;Holmlin Grant&#8221;), and 240,000 RSUs to Mark Oldakowski, our Chief Operating Officer (the &#8220;Oldakowski Grant&#8221;), in each case with an effective grant date and vesting commencement date of May 12, 2021.</span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">290,000 RSUs under the Holmlin Grant are subject to time-based vesting, with 50% of the shares vesting on each of the first and second anniversaries of the vesting commencement date, subject to continued service through the vesting date, and 18 months vesting acceleration upon a termination without cause or resignation with good reason.</span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">290,000 RSUs under the Holmlin Grant are subject to vesting upon the satisfaction of certain specified revenue targets within four years following the vesting commencement date. If Dr. Holmlin&#8217;s employment with the Company is terminated without cause or he resigns with good reason, then the shares will continue to be eligible for vesting upon satisfaction of the revenue targets within a period that is the shorter of 18 months following termination or four years following the vesting commencement date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RSUs comprising the Oldakowski Grant are subject to time-based vesting, with 50% of the shares vesting on each of the first and second anniversaries of the vesting commencement date, subject to continued service through the vesting date.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="ib388395ebea54b38b0be27fba0635b12_115"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6. EXHIBITS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518257763/d607608dex31.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518257763/d607608dex32.htm">Amended and Restated Bylaws.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518219135/d782664dex41.htm">Form of Common Stock Certificate</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518217313/d782664dex48.htm">Form of Warrant to Purchase Series D-1 Preferred Stock issued to Midcap Financial Trust.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518219135/d782664dex11.htm">Form of Warrant to Purchase Common Stock Issued to Underwriters.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001411690/000119312518249108/d572381dex411.htm">Form of Warrant Certificate (included in Exhibit 4.8).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001411690/000119312518249108/d572381dex411.htm">Form of Warrant Agent Agreement by and between the Registrant and American Stock Transfer &amp; Trust Company LLC, as warrant agent.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518332353/d635375dex41.htm">Form of Warrant to Purchase Common Stock for Service Providers.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312519074842/d700738dex41.htm">Registration Rights Agreement, dated March 14, 2019, between the Company and Aspire Capital Fund, LLC.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312519074842/d700738dex43.htm">Registration Rights Agreement, dated March 14, 2019, by and among the Company and the Innovatus Investors.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000114036119016923/nt10004193x3_ex4-13.htm">Form of Warrant to Purchase Common Stock issued to Investors in October 2019 Public Offering.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001411690/000141169021000004/ex1023-fourthamendmenttoir.htm">Fourth Amendment to the Lease by and between the Company and The Irvine Company LLC, dated February 15, 2021.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000114036121009777/nt10022040x3_ex1-1.htm">Sales Agreement, dated March 23, 2021, by and between the Company and Cowen and Company, LLC.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bngo-20210331xexx311.htm">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bngo-20210331xexx312.htm">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bngo-20210331xexx321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.431%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on August 24, 2018.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-225970), as amended.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on November 21, 2018.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on March 14, 2019.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-233828), as amended.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;Incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 23, 2021.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on March 24, 2021. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="ib388395ebea54b38b0be27fba0635b12_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib388395ebea54b38b0be27fba0635b12_7">Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:21pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:50.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.141%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BIONANO GENOMICS, INC.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:  May&#160;13, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By: /s/ R. Erik Holmlin, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Erik Holmlin, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:  May&#160;13, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By: /s/ Christopher Stewart</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Stewart</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>bngo-20210331xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7ec7f4dd5e4a4552a102c587008d8cb0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, R. Erik Holmlin, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Bionano Genomics, Inc., a Delaware corporation (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;   May&#160;13, 2021</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; R. Erik Holmlin, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Erik Holmlin, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)<br></font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>bngo-20210331xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6f9207ee829749e0a0ef66904058967e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher Stewart, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Bionano Genomics, Inc., a Delaware corporation (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-23.27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-26.04pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-28.81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-28.27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-23.27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:6pt;padding-left:72pt;text-indent:-26.04pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;   May&#160;13, 2021</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Christopher Stewart</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christopher Stewart</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>bngo-20210331xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i994e17086f39400980743dd052f70673_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, R. Erik Holmlin, Chief Executive Officer of Bionano Genomics, Inc., a Delaware corporation (the &#8220;Company&#8221;) and Christopher Stewart, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended March&#160;31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Periodic Report&#8221;), and to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.837%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;    May&#160;13, 2021</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;    May&#160;13, 2021</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; R. Erik Holmlin, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher Stewart</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Erik Holmlin, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Stewart</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)<br></font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Principal Financial and Accounting Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</font></div></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This certification accompanies and is being </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">furnished</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">with the Periodic Report, shall not be deemed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">filed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> by the Company for purposes of Section 18 of the Exchange Act, or otherwise subject to liability under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of the Periodic Report, irrespective of any general incorporation language contained in such filing.</font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>bngo-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a7c25383-a88e-4d48-aec4-d74b76810e9c,g:60d85f31-0c17-478f-8e10-9a14108a4bee-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bngo="http://bionanogenomics.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://bionanogenomics.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bngo-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bngo-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bngo-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bngo-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://bionanogenomics.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityDeficit" roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://bionanogenomics.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationPolicies" roleURI="http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetails" roleURI="http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails">
        <link:definition>2403401 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://bionanogenomics.com/role/NetLossPerShare">
        <link:definition>2104102 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://bionanogenomics.com/role/NetLossPerShareTables">
        <link:definition>2305301 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDetails" roleURI="http://bionanogenomics.com/role/NetLossPerShareDetails">
        <link:definition>2406402 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://bionanogenomics.com/role/RevenueRecognition">
        <link:definition>2107103 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://bionanogenomics.com/role/RevenueRecognitionTables">
        <link:definition>2308302 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionRevenuebySourceandGeographicLocationDetails" roleURI="http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails">
        <link:definition>2409403 - Disclosure - Revenue Recognition - Revenue by Source and Geographic Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionNarrativeDetails" roleURI="http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails">
        <link:definition>2410404 - Disclosure - Revenue Recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionRemainingPerformanceObligationsDetails" roleURI="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails">
        <link:definition>2411405 - Disclosure - Revenue Recognition - Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionRemainingPerformanceObligationsDetails_1" roleURI="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails_1">
        <link:definition>2411405 - Disclosure - Revenue Recognition - Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetails" roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetails">
        <link:definition>2112104 - Disclosure - Balance Sheet Account Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsTables" roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables">
        <link:definition>2313303 - Disclosure - Balance Sheet Account Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails" roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails">
        <link:definition>2414406 - Disclosure - Balance Sheet Account Details - Schedule of Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsNarrativeDetails" roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails">
        <link:definition>2415407 - Disclosure - Balance Sheet Account Details - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails" roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails">
        <link:definition>2416408 - Disclosure - Balance Sheet Account Details - Schedule of Components of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://bionanogenomics.com/role/Debt">
        <link:definition>2117105 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://bionanogenomics.com/role/DebtTables">
        <link:definition>2318304 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://bionanogenomics.com/role/DebtNarrativeDetails">
        <link:definition>2419409 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofDebtDetails" roleURI="http://bionanogenomics.com/role/DebtScheduleofDebtDetails">
        <link:definition>2420410 - Disclosure - Debt - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensation" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation">
        <link:definition>2121106 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationTables" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables">
        <link:definition>2322305 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationNarrativeDetails" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails">
        <link:definition>2423411 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationWarrantActivityDetails" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails">
        <link:definition>2424412 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation - Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails">
        <link:definition>2425413 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails">
        <link:definition>2426414 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation - Recognized Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationAssumptionsDetails" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails">
        <link:definition>2427415 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://bionanogenomics.com/role/Litigation">
        <link:definition>2128107 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://bionanogenomics.com/role/IncomeTaxes">
        <link:definition>2129108 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofLineagen" roleURI="http://bionanogenomics.com/role/AcquisitionofLineagen">
        <link:definition>2130109 - Disclosure - Acquisition of Lineagen</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofLineagenTables" roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenTables">
        <link:definition>2331306 - Disclosure - Acquisition of Lineagen (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofLineagenNarrativeDetails" roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails">
        <link:definition>2432416 - Disclosure - Acquisition of Lineagen - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofLineagenAcquisitionPurchasePriceDetails" roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails">
        <link:definition>2433417 - Disclosure - Acquisition of Lineagen - Acquisition Purchase Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2434418 - Disclosure - Acquisition of Lineagen - Fair Value of Tangible and Identifiable Intangible Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofLineagenIdentifiableIntangibleAssetsDetails" roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails">
        <link:definition>2435419 - Disclosure - Acquisition of Lineagen - Identifiable Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofLineagenProFormaInformationDetails" roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenProFormaInformationDetails">
        <link:definition>2436420 - Disclosure - Acquisition of Lineagen - Pro Forma Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" abstract="false" name="ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" abstract="false" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="bngo_PPPLoanMember" abstract="true" name="PPPLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_OfferingCostsIncurredNotYetPaid" abstract="false" name="OfferingCostsIncurredNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_TermA2LoanMember" abstract="true" name="TermA2LoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" abstract="false" name="ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bngo_DebtInstrumentPaymentTermsPeriodOneMember" abstract="true" name="DebtInstrumentPaymentTermsPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_DebtInstrumentPaymentTermsPeriodThreeMember" abstract="true" name="DebtInstrumentPaymentTermsPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_BusinessCombinationInfrequentAdjustmentsMember" abstract="true" name="BusinessCombinationInfrequentAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" abstract="true" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightOutstandingRollForward" abstract="true" name="ClassOfWarrantOrRightOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_DebtInstrumentNumberOfMonthlyPayments" abstract="false" name="DebtInstrumentNumberOfMonthlyPayments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bngo_InnovatusLSAMember" abstract="true" name="InnovatusLSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_RErikHolmlinMember" abstract="true" name="RErikHolmlinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_VestingStatusDomain" abstract="true" name="VestingStatusDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_DebtInstrumentPaymentTermsPeriodFourMember" abstract="true" name="DebtInstrumentPaymentTermsPeriodFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_DebtInstrumentInterestRateCashRate" abstract="false" name="DebtInstrumentInterestRateCashRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="bngo_WorkingCapital" abstract="false" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_TermLoansMember" abstract="true" name="TermLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" abstract="false" name="TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_EscrowedSharesMember" abstract="true" name="EscrowedSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_DebtInstrumentPaymentTermsDomain" abstract="true" name="DebtInstrumentPaymentTermsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_PerformanceSatisfactionVestingMember" abstract="true" name="PerformanceSatisfactionVestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_SaleOfStockAuthorizedAmountToBeIssued" abstract="false" name="SaleOfStockAuthorizedAmountToBeIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_DebtInstrumentInterestRateDiscountedCashRate" abstract="false" name="DebtInstrumentInterestRateDiscountedCashRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="bngo_InstrumentRevenueMember" abstract="true" name="InstrumentRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_WarrantExerciseNonCash" abstract="false" name="WarrantExerciseNonCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_DebtInstrumentPaymentTermsAxis" abstract="true" name="DebtInstrumentPaymentTermsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" abstract="false" name="BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bngo_MarkOldakowskiMember" abstract="true" name="MarkOldakowskiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_InnovatusTerm3LoanMember" abstract="true" name="InnovatusTerm3LoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_DebtInstrumentPrepaymentFeePercent" abstract="false" name="DebtInstrumentPrepaymentFeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="bngo_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" abstract="true" name="ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_RevolverMember" abstract="true" name="RevolverMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_LiquidityPolicyTextBlock" abstract="false" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" abstract="false" name="ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bngo_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_LoanUnderPaycheckProtectionProgramMember" abstract="true" name="LoanUnderPaycheckProtectionProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_SaleOfStockValueSharesIssuedInTransaction" abstract="false" name="SaleOfStockValueSharesIssuedInTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_CommissionFeeMaximumPercentageOfGrossProceeds" abstract="false" name="CommissionFeeMaximumPercentageOfGrossProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="bngo_InnovatusLoanAgreementMember" abstract="true" name="InnovatusLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" abstract="true" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" abstract="false" name="TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="bngo_VestingStatusAxis" abstract="true" name="VestingStatusAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bngo_DebtInstrumentPaymentTermsPeriodTwoMember" abstract="true" name="DebtInstrumentPaymentTermsPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_TermA1LoanMember" abstract="true" name="TermA1LoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_IlluminaMember" abstract="true" name="IlluminaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_LineagenMember" abstract="true" name="LineagenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_QuestDiagnositcsMember" abstract="true" name="QuestDiagnositcsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_RuhrUniversitayBochumMember" abstract="true" name="RuhrUniversitayBochumMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" abstract="false" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bngo_CowenMember" abstract="true" name="CowenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_BusinessCombinationInfrequentAdjustmentsAxis" abstract="true" name="BusinessCombinationInfrequentAdjustmentsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bngo_ConsumableRevenueMember" abstract="true" name="ConsumableRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_BusinessCombinationInfrequentAdjustmentsDomain" abstract="true" name="BusinessCombinationInfrequentAdjustmentsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_TimeBasedVestingMember" abstract="true" name="TimeBasedVestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bngo_CommonWarrantsMember" abstract="true" name="CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>bngo-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a7c25383-a88e-4d48-aec4-d74b76810e9c,g:60d85f31-0c17-478f-8e10-9a14108a4bee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://bionanogenomics.com/role/Cover" xlink:type="simple" xlink:href="bngo-20210331.xsd#Cover"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="bngo-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_90dcfac3-204e-4620-87e0-671ba0f181e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c4fe5d61-c1c9-4fec-af4d-b72b176f3a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_90dcfac3-204e-4620-87e0-671ba0f181e2" xlink:to="loc_us-gaap_Liabilities_c4fe5d61-c1c9-4fec-af4d-b72b176f3a39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8d45a7de-d03f-41a7-a0ab-e2ca1e8f4b84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_90dcfac3-204e-4620-87e0-671ba0f181e2" xlink:to="loc_us-gaap_StockholdersEquity_8d45a7de-d03f-41a7-a0ab-e2ca1e8f4b84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3c56731d-55b3-4122-ad4a-c06dbde4d3d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a7aac983-0d53-4151-b52f-5a53ce7b2804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3c56731d-55b3-4122-ad4a-c06dbde4d3d4" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a7aac983-0d53-4151-b52f-5a53ce7b2804" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ba72703f-a7db-4bac-a06a-3089eba5097c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3c56731d-55b3-4122-ad4a-c06dbde4d3d4" xlink:to="loc_us-gaap_LiabilitiesCurrent_ba72703f-a7db-4bac-a06a-3089eba5097c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0f7ed465-075e-4d0c-a7ea-5ccda69a5ce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3c56731d-55b3-4122-ad4a-c06dbde4d3d4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0f7ed465-075e-4d0c-a7ea-5ccda69a5ce0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5a086661-afde-45c8-b74b-f9b971cbf622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9084617b-7268-4fdc-96d5-05e7eca149af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5a086661-afde-45c8-b74b-f9b971cbf622" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9084617b-7268-4fdc-96d5-05e7eca149af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_66d88294-2e15-4cda-9696-e9b554ef043e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5a086661-afde-45c8-b74b-f9b971cbf622" xlink:to="loc_us-gaap_InventoryNet_66d88294-2e15-4cda-9696-e9b554ef043e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ae96e5a4-1662-474d-81b3-d2e39ce305be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5a086661-afde-45c8-b74b-f9b971cbf622" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ae96e5a4-1662-474d-81b3-d2e39ce305be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11dc00d0-90e7-40ff-a910-4e00340b4caa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5a086661-afde-45c8-b74b-f9b971cbf622" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11dc00d0-90e7-40ff-a910-4e00340b4caa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_93666548-284d-43a8-8632-e36e5dbb1148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_786c55ec-3b44-46d1-bedf-39dde8c21f13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_93666548-284d-43a8-8632-e36e5dbb1148" xlink:to="loc_us-gaap_AssetsCurrent_786c55ec-3b44-46d1-bedf-39dde8c21f13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ed51868f-1e7b-453d-8850-69713be78a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_93666548-284d-43a8-8632-e36e5dbb1148" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ed51868f-1e7b-453d-8850-69713be78a37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_837163d5-afe8-4b66-873a-885c00752d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_93666548-284d-43a8-8632-e36e5dbb1148" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_837163d5-afe8-4b66-873a-885c00752d66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b4a8b06b-1d3f-41f6-be40-687881d76985" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_93666548-284d-43a8-8632-e36e5dbb1148" xlink:to="loc_us-gaap_Goodwill_b4a8b06b-1d3f-41f6-be40-687881d76985" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4c8493a0-86be-4b78-ace7-a34ae95bd510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_93666548-284d-43a8-8632-e36e5dbb1148" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4c8493a0-86be-4b78-ace7-a34ae95bd510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_707006ad-0d92-4a17-b721-96fea3d99919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_819b1eb3-a8d5-4040-9313-00f930b324e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_707006ad-0d92-4a17-b721-96fea3d99919" xlink:to="loc_us-gaap_CommonStockValue_819b1eb3-a8d5-4040-9313-00f930b324e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_fddfaa79-f0c3-4f64-9264-b09c1db53965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_707006ad-0d92-4a17-b721-96fea3d99919" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_fddfaa79-f0c3-4f64-9264-b09c1db53965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c71781d0-2ab0-458b-9ab3-2fbf10033058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_707006ad-0d92-4a17-b721-96fea3d99919" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c71781d0-2ab0-458b-9ab3-2fbf10033058" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a4c74ad9-35a7-408b-b54f-daa0ae8b39d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_707006ad-0d92-4a17-b721-96fea3d99919" xlink:to="loc_us-gaap_PreferredStockValue_a4c74ad9-35a7-408b-b54f-daa0ae8b39d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2f5f03f0-b3d2-431f-b14e-be25658d2a57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ca19adfb-e5a4-4e22-8a91-189a534a7e82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2f5f03f0-b3d2-431f-b14e-be25658d2a57" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ca19adfb-e5a4-4e22-8a91-189a534a7e82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3458a295-49ba-4ab7-94cb-ab52e9a0ee43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2f5f03f0-b3d2-431f-b14e-be25658d2a57" xlink:to="loc_us-gaap_AccountsPayableCurrent_3458a295-49ba-4ab7-94cb-ab52e9a0ee43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6feebf04-b509-4f6c-8c3b-e91eab853d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2f5f03f0-b3d2-431f-b14e-be25658d2a57" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_6feebf04-b509-4f6c-8c3b-e91eab853d0d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="bngo-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="bngo-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_05181f12-2264-40fc-a1c2-5ad85049683e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b9fd2e6a-495a-4b74-a964-70549a239dbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_05181f12-2264-40fc-a1c2-5ad85049683e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b9fd2e6a-495a-4b74-a964-70549a239dbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_03582128-730d-4e7b-8da3-bc0a2010f49d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_05181f12-2264-40fc-a1c2-5ad85049683e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_03582128-730d-4e7b-8da3-bc0a2010f49d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_88c395d4-da24-44a3-8508-4ccdf6bf539c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_85293a37-908d-4d61-9134-7b0d1981ac91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_88c395d4-da24-44a3-8508-4ccdf6bf539c" xlink:to="loc_us-gaap_OperatingIncomeLoss_85293a37-908d-4d61-9134-7b0d1981ac91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4e2284d0-f4ba-4b8d-b318-a6817dad9705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_88c395d4-da24-44a3-8508-4ccdf6bf539c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4e2284d0-f4ba-4b8d-b318-a6817dad9705" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_51114e6a-d638-49af-b266-24a4e5223b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_067ec77d-aeb0-46d4-b73e-bb5b9ab237ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_51114e6a-d638-49af-b266-24a4e5223b1b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_067ec77d-aeb0-46d4-b73e-bb5b9ab237ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7d1e9faa-72de-43ab-a758-dfba619ac083" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_51114e6a-d638-49af-b266-24a4e5223b1b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7d1e9faa-72de-43ab-a758-dfba619ac083" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_15069525-985e-4b0b-9a75-0ce43432acc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_51114e6a-d638-49af-b266-24a4e5223b1b" xlink:to="loc_us-gaap_CostsAndExpenses_15069525-985e-4b0b-9a75-0ce43432acc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c696da39-b44f-4ba6-b7c2-4bb7f13eee69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0858e7d2-1fb7-46f6-8907-80647857ebf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c696da39-b44f-4ba6-b7c2-4bb7f13eee69" xlink:to="loc_us-gaap_InterestExpense_0858e7d2-1fb7-46f6-8907-80647857ebf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5d31a041-ded5-4772-b0d5-a1d71e1db6a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c696da39-b44f-4ba6-b7c2-4bb7f13eee69" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5d31a041-ded5-4772-b0d5-a1d71e1db6a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7f59bf47-aa4b-4da8-a9ef-301d40fb85c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c696da39-b44f-4ba6-b7c2-4bb7f13eee69" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7f59bf47-aa4b-4da8-a9ef-301d40fb85c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5904c775-8219-41d6-b03f-44d2e049d670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_efc07a58-4b24-47b9-b5df-53ab3b06e972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5904c775-8219-41d6-b03f-44d2e049d670" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_efc07a58-4b24-47b9-b5df-53ab3b06e972" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c12b5c97-7d5b-4a84-99a2-0af85627cb64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5904c775-8219-41d6-b03f-44d2e049d670" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c12b5c97-7d5b-4a84-99a2-0af85627cb64" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="simple" xlink:href="bngo-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquityDeficit"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="bngo-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_98c64108-3cfc-4478-9f7f-13c98b561187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bc09581f-45bb-4766-add0-d8f40ff3706a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_98c64108-3cfc-4478-9f7f-13c98b561187" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bc09581f-45bb-4766-add0-d8f40ff3706a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7785a7f2-7b65-4a59-88d7-0bca97ed670b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_98c64108-3cfc-4478-9f7f-13c98b561187" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7785a7f2-7b65-4a59-88d7-0bca97ed670b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_56b7afb7-8859-4343-b4eb-5029ccf680d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_98c64108-3cfc-4478-9f7f-13c98b561187" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_56b7afb7-8859-4343-b4eb-5029ccf680d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_45cf3677-8cab-4ab7-a70a-1f70d7c8ddff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87a6cd24-0df5-411a-bb58-25d34c184d93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_45cf3677-8cab-4ab7-a70a-1f70d7c8ddff" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87a6cd24-0df5-411a-bb58-25d34c184d93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_baa69573-6707-4e40-b914-a8dc999b9501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_56226625-4088-498e-adb3-7e9c50fa7049" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_baa69573-6707-4e40-b914-a8dc999b9501" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_56226625-4088-498e-adb3-7e9c50fa7049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_493eea57-8a2c-4611-885c-7c531506f1ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_baa69573-6707-4e40-b914-a8dc999b9501" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_493eea57-8a2c-4611-885c-7c531506f1ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3b586a7b-54ce-413a-bb56-6af601ff5a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_baa69573-6707-4e40-b914-a8dc999b9501" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3b586a7b-54ce-413a-bb56-6af601ff5a4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4147cbe1-7ef1-420d-9b4a-288d43fd5393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_baa69573-6707-4e40-b914-a8dc999b9501" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4147cbe1-7ef1-420d-9b4a-288d43fd5393" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_b29b9fed-3a12-4a6f-b93a-d735df39260b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_baa69573-6707-4e40-b914-a8dc999b9501" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_b29b9fed-3a12-4a6f-b93a-d735df39260b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_41dbb794-2834-473a-b58c-09327f2ce5ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_baa69573-6707-4e40-b914-a8dc999b9501" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_41dbb794-2834-473a-b58c-09327f2ce5ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa473e51-4fdb-49a4-8a17-c6b1e37dd5d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_abfeb7df-ccac-41ce-93cf-ac82e5d8f516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa473e51-4fdb-49a4-8a17-c6b1e37dd5d0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_abfeb7df-ccac-41ce-93cf-ac82e5d8f516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_3738bd8d-f87f-46a0-b779-8edab8a5c785" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa473e51-4fdb-49a4-8a17-c6b1e37dd5d0" xlink:to="loc_us-gaap_PaidInKindInterest_3738bd8d-f87f-46a0-b779-8edab8a5c785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7eb897fe-19b2-498b-a8e8-83667bcc7b6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa473e51-4fdb-49a4-8a17-c6b1e37dd5d0" xlink:to="loc_us-gaap_ShareBasedCompensation_7eb897fe-19b2-498b-a8e8-83667bcc7b6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a5d0c4db-1ec1-45d8-aa3f-80fa83b5a1df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa473e51-4fdb-49a4-8a17-c6b1e37dd5d0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a5d0c4db-1ec1-45d8-aa3f-80fa83b5a1df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d57069d7-d6e8-4402-9c15-b0832e7a912e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa473e51-4fdb-49a4-8a17-c6b1e37dd5d0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d57069d7-d6e8-4402-9c15-b0832e7a912e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_906c4f2a-243e-42d2-b93f-df9b7cfe2bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa473e51-4fdb-49a4-8a17-c6b1e37dd5d0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_906c4f2a-243e-42d2-b93f-df9b7cfe2bb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_69ad0489-e7d9-4282-a6dd-bea75d3b3d53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa473e51-4fdb-49a4-8a17-c6b1e37dd5d0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_69ad0489-e7d9-4282-a6dd-bea75d3b3d53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1b0bb473-90e1-48b2-bfcc-890b1d4772f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa473e51-4fdb-49a4-8a17-c6b1e37dd5d0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1b0bb473-90e1-48b2-bfcc-890b1d4772f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_ad261a76-0a2e-4f96-9c4d-d668dc8b7822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa473e51-4fdb-49a4-8a17-c6b1e37dd5d0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_ad261a76-0a2e-4f96-9c4d-d668dc8b7822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8146cf91-9aaf-4221-8d7a-7be7bf80f206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa473e51-4fdb-49a4-8a17-c6b1e37dd5d0" xlink:to="loc_us-gaap_NetIncomeLoss_8146cf91-9aaf-4221-8d7a-7be7bf80f206" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_670b30b8-d753-4d94-9dc6-4990c6f4efb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa473e51-4fdb-49a4-8a17-c6b1e37dd5d0" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_670b30b8-d753-4d94-9dc6-4990c6f4efb6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="bngo-20210331.xsd#OrganizationandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/OrganizationandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="bngo-20210331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/NetLossPerShare" xlink:type="simple" xlink:href="bngo-20210331.xsd#NetLossPerShare"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/NetLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="bngo-20210331.xsd#NetLossPerShareTables"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/NetLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#NetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/NetLossPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognition" xlink:type="simple" xlink:href="bngo-20210331.xsd#RevenueRecognition"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/RevenueRecognition" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="bngo-20210331.xsd#RevenueRecognitionTables"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#RevenueRecognitionRevenuebySourceandGeographicLocationDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#RevenueRecognitionRemainingPerformanceObligationsDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="bngo-20210331.xsd#RevenueRecognitionRemainingPerformanceObligationsDetails_1"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#BalanceSheetAccountDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables" xlink:type="simple" xlink:href="bngo-20210331.xsd#BalanceSheetAccountDetailsTables"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_58ba0ede-1e22-4171-905f-13159ca91d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_8097ee17-7883-4988-9366-4a368a70a456" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_58ba0ede-1e22-4171-905f-13159ca91d97" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_8097ee17-7883-4988-9366-4a368a70a456" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_167ddc91-c882-4c02-89dd-368dd8778034" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_58ba0ede-1e22-4171-905f-13159ca91d97" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_167ddc91-c882-4c02-89dd-368dd8778034" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#BalanceSheetAccountDetailsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_19bfe9ef-e6d3-4259-903a-63b5d1ac7f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_350f6d71-97a2-46ce-8e29-e815020e7c55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_19bfe9ef-e6d3-4259-903a-63b5d1ac7f66" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_350f6d71-97a2-46ce-8e29-e815020e7c55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_829a8529-2797-4e0c-a2f3-533b1ecf148a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_19bfe9ef-e6d3-4259-903a-63b5d1ac7f66" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_829a8529-2797-4e0c-a2f3-533b1ecf148a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/Debt" xlink:type="simple" xlink:href="bngo-20210331.xsd#Debt"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/Debt" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/DebtTables" xlink:type="simple" xlink:href="bngo-20210331.xsd#DebtTables"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/DebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#DebtNarrativeDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/DebtNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/DebtScheduleofDebtDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#DebtScheduleofDebtDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/DebtScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8cfaf071-56ed-4216-89da-a5d0f84eabb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_6d9bb7a0-0d1b-4aab-ad54-b31465b9b883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8cfaf071-56ed-4216-89da-a5d0f84eabb8" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_6d9bb7a0-0d1b-4aab-ad54-b31465b9b883" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_960db21d-5b29-487a-8332-fc602978bdfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8cfaf071-56ed-4216-89da-a5d0f84eabb8" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_960db21d-5b29-487a-8332-fc602978bdfb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensation"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensationWarrantActivityDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensationAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/Litigation" xlink:type="simple" xlink:href="bngo-20210331.xsd#Litigation"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/Litigation" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="bngo-20210331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagen" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagen"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagen" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenTables" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagenTables"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagenTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagenNarrativeDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagenAcquisitionPurchasePriceDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d72d530d-3a2a-45d8-ae6c-a4f459e8b3ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_c537e7de-99f5-4b27-8a7f-2276ae7fd882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d72d530d-3a2a-45d8-ae6c-a4f459e8b3ca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_c537e7de-99f5-4b27-8a7f-2276ae7fd882" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_7b8fb695-a8ab-451b-9e92-5cdbe1371c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d72d530d-3a2a-45d8-ae6c-a4f459e8b3ca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_7b8fb695-a8ab-451b-9e92-5cdbe1371c51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3eb283cf-3389-4d05-89ed-bb055ccb1454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d72d530d-3a2a-45d8-ae6c-a4f459e8b3ca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3eb283cf-3389-4d05-89ed-bb055ccb1454" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_4e206fe0-326b-42c6-9b1d-ce2df295fd30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d72d530d-3a2a-45d8-ae6c-a4f459e8b3ca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_4e206fe0-326b-42c6-9b1d-ce2df295fd30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1f6e56e4-c23f-41a8-9d1e-297a7e036677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d72d530d-3a2a-45d8-ae6c-a4f459e8b3ca" xlink:to="loc_us-gaap_Goodwill_1f6e56e4-c23f-41a8-9d1e-297a7e036677" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_af0a3fba-9acc-40f2-a2fc-34dcb7bf949a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d72d530d-3a2a-45d8-ae6c-a4f459e8b3ca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_af0a3fba-9acc-40f2-a2fc-34dcb7bf949a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e241d0a8-cd76-44a5-8031-da9888ab5205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d72d530d-3a2a-45d8-ae6c-a4f459e8b3ca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e241d0a8-cd76-44a5-8031-da9888ab5205" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagenIdentifiableIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenProFormaInformationDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagenProFormaInformationDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagenProFormaInformationDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>bngo-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a7c25383-a88e-4d48-aec4-d74b76810e9c,g:60d85f31-0c17-478f-8e10-9a14108a4bee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/Cover" xlink:type="simple" xlink:href="bngo-20210331.xsd#Cover"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/Cover" xlink:type="extended" id="idd1aa1a2fbb1477c98032b88b5ad6636_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0897be5d-4230-4b10-b328-66f56811816c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_DocumentType_0897be5d-4230-4b10-b328-66f56811816c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_99b17140-b316-4694-947c-a8b23307c02b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_DocumentQuarterlyReport_99b17140-b316-4694-947c-a8b23307c02b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a7709f52-4e68-4e49-aad0-47b09a326c77" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_DocumentPeriodEndDate_a7709f52-4e68-4e49-aad0-47b09a326c77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_8a9b0e07-128f-40c3-817c-3a5fdd626a35" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_DocumentTransitionReport_8a9b0e07-128f-40c3-817c-3a5fdd626a35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_263b79cb-d805-4736-abe2-494c517b2a96" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityFileNumber_263b79cb-d805-4736-abe2-494c517b2a96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0eac242c-219d-49b7-a83a-b1fdca9e85f7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityRegistrantName_0eac242c-219d-49b7-a83a-b1fdca9e85f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_66cfb957-388d-437d-8dfc-ef684f329f70" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityIncorporationStateCountryCode_66cfb957-388d-437d-8dfc-ef684f329f70" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ad21dcec-8de6-4d3b-814a-4c4c788811ee" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityTaxIdentificationNumber_ad21dcec-8de6-4d3b-814a-4c4c788811ee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4bf37cf8-b23b-45d5-9826-15b0a73df560" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityAddressAddressLine1_4bf37cf8-b23b-45d5-9826-15b0a73df560" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f1db83b7-399f-4d6f-92c9-a207e8057de2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityAddressCityOrTown_f1db83b7-399f-4d6f-92c9-a207e8057de2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_603fe52c-ea29-46f5-98d3-a48f99308bf1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityAddressStateOrProvince_603fe52c-ea29-46f5-98d3-a48f99308bf1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_55af2fc2-67d7-423b-8e34-3a296d28379d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityAddressPostalZipCode_55af2fc2-67d7-423b-8e34-3a296d28379d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_11eb1aa0-28e3-4bc4-8e0b-78359a2f1430" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_CityAreaCode_11eb1aa0-28e3-4bc4-8e0b-78359a2f1430" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d3a7a011-282f-4883-9616-531c03ecb9d8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_LocalPhoneNumber_d3a7a011-282f-4883-9616-531c03ecb9d8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_123baaca-d586-4dff-b0da-215bd35434c2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_Security12bTitle_123baaca-d586-4dff-b0da-215bd35434c2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7b456a87-dc4a-4b8e-884a-41286b290c20" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_TradingSymbol_7b456a87-dc4a-4b8e-884a-41286b290c20" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d7348a83-3e8e-438f-9cc1-ef0ff2694e83" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_SecurityExchangeName_d7348a83-3e8e-438f-9cc1-ef0ff2694e83" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_bbb669dc-2a75-479f-9ffc-6829b5d18f7a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityCurrentReportingStatus_bbb669dc-2a75-479f-9ffc-6829b5d18f7a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f74b2683-c400-4126-9bab-1453db173dd1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityInteractiveDataCurrent_f74b2683-c400-4126-9bab-1453db173dd1" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_34605658-da79-4624-b8a3-b608d968cc23" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityFilerCategory_34605658-da79-4624-b8a3-b608d968cc23" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1e293bb8-19da-4e5f-ac2e-e6898a5ed18f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntitySmallBusiness_1e293bb8-19da-4e5f-ac2e-e6898a5ed18f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_740a60a4-3124-4582-9eb7-dac1537cf0fd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityEmergingGrowthCompany_740a60a4-3124-4582-9eb7-dac1537cf0fd" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_f3b11af3-8ff9-433a-944e-9c6878f4af19" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityExTransitionPeriod_f3b11af3-8ff9-433a-944e-9c6878f4af19" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d621c8fc-d570-4734-8425-a602e3072b9c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityShellCompany_d621c8fc-d570-4734-8425-a602e3072b9c" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_950959f1-22cd-4105-aeef-62209c151d4c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_950959f1-22cd-4105-aeef-62209c151d4c" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_489f4bff-3e51-4555-8ed1-4b0fce033cf9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_AmendmentFlag_489f4bff-3e51-4555-8ed1-4b0fce033cf9" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_bcd44efa-1c32-4df0-957d-b62cd1b798db" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_DocumentFiscalYearFocus_bcd44efa-1c32-4df0-957d-b62cd1b798db" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9e007ea6-bc92-4e17-a544-e620783c5907" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9e007ea6-bc92-4e17-a544-e620783c5907" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e510934f-b3b3-4894-9a39-85628d55e9aa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityCentralIndexKey_e510934f-b3b3-4894-9a39-85628d55e9aa" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d026c8a7-1bd3-4a30-a41f-33efe58c193d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_CurrentFiscalYearEndDate_d026c8a7-1bd3-4a30-a41f-33efe58c193d" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_1b5d661f-dd0f-4280-8e10-a7b002dd3c91" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_DocumentInformationTable_1b5d661f-dd0f-4280-8e10-a7b002dd3c91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8ace505d-440d-4fad-a080-65e38cd7e40a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_1b5d661f-dd0f-4280-8e10-a7b002dd3c91" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8ace505d-440d-4fad-a080-65e38cd7e40a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8ace505d-440d-4fad-a080-65e38cd7e40a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8ace505d-440d-4fad-a080-65e38cd7e40a" xlink:to="loc_us-gaap_ClassOfStockDomain_8ace505d-440d-4fad-a080-65e38cd7e40a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f3dad4ae-fe8f-4462-9078-1ae54dc5c284" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8ace505d-440d-4fad-a080-65e38cd7e40a" xlink:to="loc_us-gaap_ClassOfStockDomain_f3dad4ae-fe8f-4462-9078-1ae54dc5c284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f7bbf1aa-bac1-4f0f-ba20-150b69f2350f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f3dad4ae-fe8f-4462-9078-1ae54dc5c284" xlink:to="loc_us-gaap_CommonStockMember_f7bbf1aa-bac1-4f0f-ba20-150b69f2350f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_dd8a16b8-1129-4937-8528-fc3d6b423947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f3dad4ae-fe8f-4462-9078-1ae54dc5c284" xlink:to="loc_us-gaap_WarrantMember_dd8a16b8-1129-4937-8528-fc3d6b423947" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="bngo-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i35d4696065454deb8bdc14a67cfee2ce_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="bngo-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i5a410a50b52a454ea455f34e81432dc7_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="bngo-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="i23911bcfe4fa455e98744583924fe703_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_536cd330-0f2a-4a19-9460-f6ea17d32443" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_RevenuesAbstract_536cd330-0f2a-4a19-9460-f6ea17d32443" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_58271d2d-084b-4da1-96ca-159ce596f90d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_536cd330-0f2a-4a19-9460-f6ea17d32443" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_58271d2d-084b-4da1-96ca-159ce596f90d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_5b0bd550-e2df-466b-91eb-c20dffbae341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_CostOfRevenueAbstract_5b0bd550-e2df-466b-91eb-c20dffbae341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_45be8216-9b8c-4e63-a0a1-fe421b3dc9d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_5b0bd550-e2df-466b-91eb-c20dffbae341" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_45be8216-9b8c-4e63-a0a1-fe421b3dc9d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_d4976f9e-31b3-495c-b074-eb19794bf0c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_d4976f9e-31b3-495c-b074-eb19794bf0c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_33e472d0-015a-47c8-a89d-eac1931d4c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d4976f9e-31b3-495c-b074-eb19794bf0c3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_33e472d0-015a-47c8-a89d-eac1931d4c29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_41ea3d4d-2307-49cd-8c49-efe44132259f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d4976f9e-31b3-495c-b074-eb19794bf0c3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_41ea3d4d-2307-49cd-8c49-efe44132259f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7ff48df1-8315-4c11-a8c5-94e496b0bc07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d4976f9e-31b3-495c-b074-eb19794bf0c3" xlink:to="loc_us-gaap_CostsAndExpenses_7ff48df1-8315-4c11-a8c5-94e496b0bc07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6a179b68-3883-4e6d-a7ed-8c91b2e4953e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_OperatingIncomeLoss_6a179b68-3883-4e6d-a7ed-8c91b2e4953e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_921f9aef-fcbf-4f06-86a1-6dd80adfb395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_921f9aef-fcbf-4f06-86a1-6dd80adfb395" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_cac25de5-77bd-4e6e-a82b-8e99495e76f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_921f9aef-fcbf-4f06-86a1-6dd80adfb395" xlink:to="loc_us-gaap_InterestExpense_cac25de5-77bd-4e6e-a82b-8e99495e76f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8a15b9c2-669c-433f-b323-f41ec8a87cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_921f9aef-fcbf-4f06-86a1-6dd80adfb395" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8a15b9c2-669c-433f-b323-f41ec8a87cb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_871e5162-4d68-48c3-aa6c-3988e603fb07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_921f9aef-fcbf-4f06-86a1-6dd80adfb395" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_871e5162-4d68-48c3-aa6c-3988e603fb07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e93a320d-486c-4eee-9b27-a1a6cf57cd4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_921f9aef-fcbf-4f06-86a1-6dd80adfb395" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e93a320d-486c-4eee-9b27-a1a6cf57cd4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2a181cfc-7c36-49cf-99b5-049f3bd34fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2a181cfc-7c36-49cf-99b5-049f3bd34fee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9eed50bf-b664-4a78-a04d-79a70bda13c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9eed50bf-b664-4a78-a04d-79a70bda13c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_be60448a-081f-421c-a803-b6d4e991c4d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_NetIncomeLoss_be60448a-081f-421c-a803-b6d4e991c4d0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_9c10dd22-5658-4d7f-a453-ee8d4fb2ffda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_9c10dd22-5658-4d7f-a453-ee8d4fb2ffda" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e279c636-ab68-4f65-81ac-73a1dcc6b384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e279c636-ab68-4f65-81ac-73a1dcc6b384" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5fc385b2-fcd3-4bb0-9437-a0bf45636d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_StatementTable_5fc385b2-fcd3-4bb0-9437-a0bf45636d0f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2e284fdb-320d-4067-8852-0ef120be5662" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5fc385b2-fcd3-4bb0-9437-a0bf45636d0f" xlink:to="loc_srt_ProductOrServiceAxis_2e284fdb-320d-4067-8852-0ef120be5662" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2e284fdb-320d-4067-8852-0ef120be5662_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2e284fdb-320d-4067-8852-0ef120be5662" xlink:to="loc_srt_ProductsAndServicesDomain_2e284fdb-320d-4067-8852-0ef120be5662_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1557232b-6ba8-4781-9c35-e50d452cac6a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2e284fdb-320d-4067-8852-0ef120be5662" xlink:to="loc_srt_ProductsAndServicesDomain_1557232b-6ba8-4781-9c35-e50d452cac6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_25df503e-c6fc-4b4d-96f3-5ceb2d00cad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1557232b-6ba8-4781-9c35-e50d452cac6a" xlink:to="loc_us-gaap_ProductMember_25df503e-c6fc-4b4d-96f3-5ceb2d00cad3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_9e9fdb4a-cb2e-4a6b-8529-79e0953cae4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1557232b-6ba8-4781-9c35-e50d452cac6a" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_9e9fdb4a-cb2e-4a6b-8529-79e0953cae4f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="simple" xlink:href="bngo-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="extended" id="ibdbf5d1cc2d348cb86d77a84f85ce119_CondensedConsolidatedStatementsofStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1e4c092f-e9f8-4ab8-a0bf-9da8541e8146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e4c092f-e9f8-4ab8-a0bf-9da8541e8146" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_95474f8a-a497-4989-986d-eaf59ded9a55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_us-gaap_SharesOutstanding_95474f8a-a497-4989-986d-eaf59ded9a55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_850ee7bf-054e-4c1b-90de-9e2b564bc96f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_us-gaap_StockholdersEquity_850ee7bf-054e-4c1b-90de-9e2b564bc96f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6edd93b7-3880-4791-9919-1f26ec157953" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6edd93b7-3880-4791-9919-1f26ec157953" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_71852362-62f7-4bfb-9147-2f4b1f130986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_71852362-62f7-4bfb-9147-2f4b1f130986" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3a1e4d00-8b2f-429b-8f3b-aa3dc424c25d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3a1e4d00-8b2f-429b-8f3b-aa3dc424c25d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a5281668-dcee-4310-b37a-020afd3b92a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a5281668-dcee-4310-b37a-020afd3b92a1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2da85979-7ae8-4fd6-88ce-cdb4b4b6c10d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2da85979-7ae8-4fd6-88ce-cdb4b4b6c10d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedDuringPeriodSharesWarrantsExercised_160c060d-884b-4915-88d8-84998309aece" xlink:href="bngo-20210331.xsd#bngo_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_bngo_StockIssuedDuringPeriodSharesWarrantsExercised_160c060d-884b-4915-88d8-84998309aece" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedDuringPeriodValueWarrantsExercised_c68a6076-9f07-4e59-b14b-a941235fc932" xlink:href="bngo-20210331.xsd#bngo_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_bngo_StockIssuedDuringPeriodValueWarrantsExercised_c68a6076-9f07-4e59-b14b-a941235fc932" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_67b80008-916b-4a2f-96e9-6d98198e0b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_us-gaap_NetIncomeLoss_67b80008-916b-4a2f-96e9-6d98198e0b4c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_db55b1f8-c373-4591-9e78-b150730663bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a70a9739-7613-466a-8081-d91c9da319b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ac1ec1a0-e60c-4fb4-a07e-26a7b167ee9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1e4c092f-e9f8-4ab8-a0bf-9da8541e8146" xlink:to="loc_us-gaap_StatementTable_ac1ec1a0-e60c-4fb4-a07e-26a7b167ee9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fd4da404-82d8-4889-b697-ed20a47cfe46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ac1ec1a0-e60c-4fb4-a07e-26a7b167ee9d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fd4da404-82d8-4889-b697-ed20a47cfe46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fd4da404-82d8-4889-b697-ed20a47cfe46_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fd4da404-82d8-4889-b697-ed20a47cfe46" xlink:to="loc_us-gaap_EquityComponentDomain_fd4da404-82d8-4889-b697-ed20a47cfe46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_79369c6e-5e63-4651-8c4f-c33a58551ed7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fd4da404-82d8-4889-b697-ed20a47cfe46" xlink:to="loc_us-gaap_EquityComponentDomain_79369c6e-5e63-4651-8c4f-c33a58551ed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_031ccbec-ad1d-4438-9af0-fa29f83fd1bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_79369c6e-5e63-4651-8c4f-c33a58551ed7" xlink:to="loc_us-gaap_CommonStockMember_031ccbec-ad1d-4438-9af0-fa29f83fd1bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8d6f49a6-099d-4a33-963b-d3e31bbbd97f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_79369c6e-5e63-4651-8c4f-c33a58551ed7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8d6f49a6-099d-4a33-963b-d3e31bbbd97f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a434f1f3-daea-42f5-9ef4-a4e338187218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_79369c6e-5e63-4651-8c4f-c33a58551ed7" xlink:to="loc_us-gaap_RetainedEarningsMember_a434f1f3-daea-42f5-9ef4-a4e338187218" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="bngo-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="i48b20d528b6d4b30a29d622ba8e4ed35_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="bngo-20210331.xsd#OrganizationandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/OrganizationandBasisofPresentation" xlink:type="extended" id="i280d88890c2b4881866951a26a2ba124_OrganizationandBasisofPresentation"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="bngo-20210331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended" id="i4192bf437883479693e3b17fddff3e40_OrganizationandBasisofPresentationPolicies"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended" id="ide38e5a3cc6949f7bcd4d5d97b62cace_OrganizationandBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2bfcb296-bbcd-4001-8638-f1373d4ceb29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8dc8d681-19d4-4d9d-8f9f-469a7e391de3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2bfcb296-bbcd-4001-8638-f1373d4ceb29" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8dc8d681-19d4-4d9d-8f9f-469a7e391de3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f4ccb0f1-1034-43b8-b897-ea5cd1ad703b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2bfcb296-bbcd-4001-8638-f1373d4ceb29" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f4ccb0f1-1034-43b8-b897-ea5cd1ad703b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d78a669c-75d6-44c6-aada-168540759b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_2bfcb296-bbcd-4001-8638-f1373d4ceb29" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d78a669c-75d6-44c6-aada-168540759b6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ddfb29fa-8212-4159-bc17-a8dde93cf827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d78a669c-75d6-44c6-aada-168540759b6e" xlink:to="loc_us-gaap_CreditFacilityAxis_ddfb29fa-8212-4159-bc17-a8dde93cf827" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ddfb29fa-8212-4159-bc17-a8dde93cf827_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_ddfb29fa-8212-4159-bc17-a8dde93cf827" xlink:to="loc_us-gaap_CreditFacilityDomain_ddfb29fa-8212-4159-bc17-a8dde93cf827_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4afb237c-6baa-4931-a31d-6da862dd4d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_ddfb29fa-8212-4159-bc17-a8dde93cf827" xlink:to="loc_us-gaap_CreditFacilityDomain_4afb237c-6baa-4931-a31d-6da862dd4d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_3aeac0e6-e794-4a5e-b573-dc633f8c9ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_4afb237c-6baa-4931-a31d-6da862dd4d5a" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_3aeac0e6-e794-4a5e-b573-dc633f8c9ccd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_f5903846-24dc-43d5-acb7-8d8ba48169a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d78a669c-75d6-44c6-aada-168540759b6e" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_f5903846-24dc-43d5-acb7-8d8ba48169a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_f5903846-24dc-43d5-acb7-8d8ba48169a8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_f5903846-24dc-43d5-acb7-8d8ba48169a8" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_f5903846-24dc-43d5-acb7-8d8ba48169a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_eefa9a1b-c2d2-44bc-bef8-94e2b2f1f867" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_f5903846-24dc-43d5-acb7-8d8ba48169a8" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_eefa9a1b-c2d2-44bc-bef8-94e2b2f1f867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InnovatusLSAMember_df735419-ae7b-4dd2-bfb4-475ec2321e04" xlink:href="bngo-20210331.xsd#bngo_InnovatusLSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_eefa9a1b-c2d2-44bc-bef8-94e2b2f1f867" xlink:to="loc_bngo_InnovatusLSAMember_df735419-ae7b-4dd2-bfb4-475ec2321e04" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/NetLossPerShare" xlink:type="simple" xlink:href="bngo-20210331.xsd#NetLossPerShare"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/NetLossPerShare" xlink:type="extended" id="ic7c71e3f45a545c899f4f2b91cf15a63_NetLossPerShare"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="bngo-20210331.xsd#NetLossPerShareTables"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/NetLossPerShareTables" xlink:type="extended" id="i9c210340878d4d938fae30c9550242be_NetLossPerShareTables"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#NetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/NetLossPerShareDetails" xlink:type="extended" id="i3951d0a0ee474d98b2176f09984262fe_NetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e568daf2-0983-4454-a972-0fb429872010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3bb0e225-a039-4965-9bdf-e4ddd5af5374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e568daf2-0983-4454-a972-0fb429872010" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3bb0e225-a039-4965-9bdf-e4ddd5af5374" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_99384fa9-0abe-4abc-9aaa-dea7e85b33cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e568daf2-0983-4454-a972-0fb429872010" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_99384fa9-0abe-4abc-9aaa-dea7e85b33cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a81df0a-a451-4aba-993b-243b2ddb1024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_99384fa9-0abe-4abc-9aaa-dea7e85b33cd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a81df0a-a451-4aba-993b-243b2ddb1024" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a81df0a-a451-4aba-993b-243b2ddb1024_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a81df0a-a451-4aba-993b-243b2ddb1024" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a81df0a-a451-4aba-993b-243b2ddb1024_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_606647b1-d340-401d-ae61-da6d487f90e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a81df0a-a451-4aba-993b-243b2ddb1024" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_606647b1-d340-401d-ae61-da6d487f90e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_44c05be0-9dfb-40ac-a801-aa69167b5346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_606647b1-d340-401d-ae61-da6d487f90e1" xlink:to="loc_us-gaap_StockOptionMember_44c05be0-9dfb-40ac-a801-aa69167b5346" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonWarrantsMember_ea3794a7-bf2b-44fd-8dd6-d94e339dbde8" xlink:href="bngo-20210331.xsd#bngo_CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_606647b1-d340-401d-ae61-da6d487f90e1" xlink:to="loc_bngo_CommonWarrantsMember_ea3794a7-bf2b-44fd-8dd6-d94e339dbde8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognition" xlink:type="simple" xlink:href="bngo-20210331.xsd#RevenueRecognition"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/RevenueRecognition" xlink:type="extended" id="i0fcba3847726436ab01f4ae115da61e4_RevenueRecognition"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="bngo-20210331.xsd#RevenueRecognitionTables"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionTables" xlink:type="extended" id="i57a96fa2a7dd45ae893dbc38a906acf3_RevenueRecognitionTables"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#RevenueRecognitionRevenuebySourceandGeographicLocationDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails" xlink:type="extended" id="iffdd2ee7a35c411294df3d5de5358315_RevenueRecognitionRevenuebySourceandGeographicLocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c30a6f97-559b-41e1-8cce-a82d66008d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_407beb03-e904-4a19-95cf-64a49e49f962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c30a6f97-559b-41e1-8cce-a82d66008d66" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_407beb03-e904-4a19-95cf-64a49e49f962" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_546c6319-a8a4-4e51-a0ef-8a8bc5bf1ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c30a6f97-559b-41e1-8cce-a82d66008d66" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_546c6319-a8a4-4e51-a0ef-8a8bc5bf1ad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e33c4a18-3927-45ce-83b5-53eb419e7df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c30a6f97-559b-41e1-8cce-a82d66008d66" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e33c4a18-3927-45ce-83b5-53eb419e7df6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d72c1f5a-d288-4ac9-92be-c4ad7b4b9cf8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e33c4a18-3927-45ce-83b5-53eb419e7df6" xlink:to="loc_srt_ProductOrServiceAxis_d72c1f5a-d288-4ac9-92be-c4ad7b4b9cf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d72c1f5a-d288-4ac9-92be-c4ad7b4b9cf8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d72c1f5a-d288-4ac9-92be-c4ad7b4b9cf8" xlink:to="loc_srt_ProductsAndServicesDomain_d72c1f5a-d288-4ac9-92be-c4ad7b4b9cf8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_afb5071a-a4a3-483e-a1c8-1c721b830d06" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d72c1f5a-d288-4ac9-92be-c4ad7b4b9cf8" xlink:to="loc_srt_ProductsAndServicesDomain_afb5071a-a4a3-483e-a1c8-1c721b830d06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InstrumentRevenueMember_c6a625fc-0792-49ba-b1c9-2a71ff46d6a8" xlink:href="bngo-20210331.xsd#bngo_InstrumentRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_afb5071a-a4a3-483e-a1c8-1c721b830d06" xlink:to="loc_bngo_InstrumentRevenueMember_c6a625fc-0792-49ba-b1c9-2a71ff46d6a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ConsumableRevenueMember_9422302d-1966-49c4-8f8e-eceedc8a844f" xlink:href="bngo-20210331.xsd#bngo_ConsumableRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_afb5071a-a4a3-483e-a1c8-1c721b830d06" xlink:to="loc_bngo_ConsumableRevenueMember_9422302d-1966-49c4-8f8e-eceedc8a844f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_aa74ed97-59f8-4117-b2d7-262797f904af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_afb5071a-a4a3-483e-a1c8-1c721b830d06" xlink:to="loc_us-gaap_ProductMember_aa74ed97-59f8-4117-b2d7-262797f904af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_10961cda-5017-4e9f-85f5-3a1bd572a700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_afb5071a-a4a3-483e-a1c8-1c721b830d06" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_10961cda-5017-4e9f-85f5-3a1bd572a700" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0c6c56a0-77af-4ffc-aea0-882ca0d5fb97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e33c4a18-3927-45ce-83b5-53eb419e7df6" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0c6c56a0-77af-4ffc-aea0-882ca0d5fb97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0c6c56a0-77af-4ffc-aea0-882ca0d5fb97_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0c6c56a0-77af-4ffc-aea0-882ca0d5fb97" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0c6c56a0-77af-4ffc-aea0-882ca0d5fb97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dafac91f-15d2-47aa-a695-8b26fd061a78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0c6c56a0-77af-4ffc-aea0-882ca0d5fb97" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dafac91f-15d2-47aa-a695-8b26fd061a78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_cc716b82-3939-488b-be00-589b45691062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dafac91f-15d2-47aa-a695-8b26fd061a78" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_cc716b82-3939-488b-be00-589b45691062" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e4809c28-3403-47bf-b737-5bb4e1ea3abf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e33c4a18-3927-45ce-83b5-53eb419e7df6" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e4809c28-3403-47bf-b737-5bb4e1ea3abf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e4809c28-3403-47bf-b737-5bb4e1ea3abf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e4809c28-3403-47bf-b737-5bb4e1ea3abf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e4809c28-3403-47bf-b737-5bb4e1ea3abf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c14d0796-a14a-4678-8a5f-b5cd6ed17487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e4809c28-3403-47bf-b737-5bb4e1ea3abf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c14d0796-a14a-4678-8a5f-b5cd6ed17487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_ec541026-1ac4-4ccf-892a-3b2ee26ba4d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c14d0796-a14a-4678-8a5f-b5cd6ed17487" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_ec541026-1ac4-4ccf-892a-3b2ee26ba4d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a96f0820-b55d-4270-b45f-8faaa8b9222d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e33c4a18-3927-45ce-83b5-53eb419e7df6" xlink:to="loc_srt_StatementGeographicalAxis_a96f0820-b55d-4270-b45f-8faaa8b9222d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a96f0820-b55d-4270-b45f-8faaa8b9222d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a96f0820-b55d-4270-b45f-8faaa8b9222d" xlink:to="loc_srt_SegmentGeographicalDomain_a96f0820-b55d-4270-b45f-8faaa8b9222d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c74d885e-5fee-418e-8719-6045a0a5ab59" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a96f0820-b55d-4270-b45f-8faaa8b9222d" xlink:to="loc_srt_SegmentGeographicalDomain_c74d885e-5fee-418e-8719-6045a0a5ab59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_ddbe603d-3ad5-4da6-af21-0aa5894d0796" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NorthAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c74d885e-5fee-418e-8719-6045a0a5ab59" xlink:to="loc_srt_NorthAmericaMember_ddbe603d-3ad5-4da6-af21-0aa5894d0796" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_3fb27696-ccef-4509-96b3-f394dfabfdbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c74d885e-5fee-418e-8719-6045a0a5ab59" xlink:to="loc_us-gaap_EMEAMember_3fb27696-ccef-4509-96b3-f394dfabfdbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_974a7d50-a3fb-4c7e-bec4-f94902ccc82f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c74d885e-5fee-418e-8719-6045a0a5ab59" xlink:to="loc_srt_AsiaPacificMember_974a7d50-a3fb-4c7e-bec4-f94902ccc82f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended" id="i4d32247cf57045c6a921bb8d42109c68_RevenueRecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3741643a-21d0-4049-a7b4-1a8908c02e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b8134c26-493f-425e-afb6-789e92302d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3741643a-21d0-4049-a7b4-1a8908c02e7b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b8134c26-493f-425e-afb6-789e92302d72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_85ad0b9c-42dd-45f7-980a-6689dc6a8aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3741643a-21d0-4049-a7b4-1a8908c02e7b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_85ad0b9c-42dd-45f7-980a-6689dc6a8aca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5f06300e-c468-4108-93e9-621983eed5ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_85ad0b9c-42dd-45f7-980a-6689dc6a8aca" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5f06300e-c468-4108-93e9-621983eed5ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5f06300e-c468-4108-93e9-621983eed5ca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5f06300e-c468-4108-93e9-621983eed5ca" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5f06300e-c468-4108-93e9-621983eed5ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_104d4368-0178-4750-b5df-e770cbe63ace" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5f06300e-c468-4108-93e9-621983eed5ca" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_104d4368-0178-4750-b5df-e770cbe63ace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_1fc5d1b5-3e37-41f0-9cda-f164e7321204" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_104d4368-0178-4750-b5df-e770cbe63ace" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_1fc5d1b5-3e37-41f0-9cda-f164e7321204" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_575cb190-e330-47f1-9eb7-ca3f65c37a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_85ad0b9c-42dd-45f7-980a-6689dc6a8aca" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_575cb190-e330-47f1-9eb7-ca3f65c37a3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_575cb190-e330-47f1-9eb7-ca3f65c37a3e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_575cb190-e330-47f1-9eb7-ca3f65c37a3e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_575cb190-e330-47f1-9eb7-ca3f65c37a3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6494a06f-a550-4747-a197-a11b4ef9131b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_575cb190-e330-47f1-9eb7-ca3f65c37a3e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6494a06f-a550-4747-a197-a11b4ef9131b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_b513134d-1cf2-481a-b47c-e28fc3a733ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6494a06f-a550-4747-a197-a11b4ef9131b" xlink:to="loc_us-gaap_SalesRevenueNetMember_b513134d-1cf2-481a-b47c-e28fc3a733ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_224f8e10-979f-4eff-a907-3ae1ec4b94f3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_85ad0b9c-42dd-45f7-980a-6689dc6a8aca" xlink:to="loc_srt_StatementGeographicalAxis_224f8e10-979f-4eff-a907-3ae1ec4b94f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_224f8e10-979f-4eff-a907-3ae1ec4b94f3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_224f8e10-979f-4eff-a907-3ae1ec4b94f3" xlink:to="loc_srt_SegmentGeographicalDomain_224f8e10-979f-4eff-a907-3ae1ec4b94f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8c71724e-c577-4175-b488-d9d79f8a63d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_224f8e10-979f-4eff-a907-3ae1ec4b94f3" xlink:to="loc_srt_SegmentGeographicalDomain_8c71724e-c577-4175-b488-d9d79f8a63d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9941d9f5-9869-468d-b83f-a25150d7fa72" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c71724e-c577-4175-b488-d9d79f8a63d3" xlink:to="loc_country_US_9941d9f5-9869-468d-b83f-a25150d7fa72" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#RevenueRecognitionRemainingPerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails" xlink:type="extended" id="i76fd0e661f024b6c9d9e7a3ed26aad08_RevenueRecognitionRemainingPerformanceObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_c7bff6a2-ab8f-41db-8b07-49bfa6043f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6fe41029-446b-425f-b428-89c5c24627bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_c7bff6a2-ab8f-41db-8b07-49bfa6043f01" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6fe41029-446b-425f-b428-89c5c24627bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_615b79af-1500-4b2c-9cfd-bf0cbc2a7f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_c7bff6a2-ab8f-41db-8b07-49bfa6043f01" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_615b79af-1500-4b2c-9cfd-bf0cbc2a7f1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_11836223-2bc8-4fde-bc0c-e675db17cd3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_c7bff6a2-ab8f-41db-8b07-49bfa6043f01" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_11836223-2bc8-4fde-bc0c-e675db17cd3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_82a935e9-d3a7-4a5d-91f7-4e9f46b95155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_c7bff6a2-ab8f-41db-8b07-49bfa6043f01" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_82a935e9-d3a7-4a5d-91f7-4e9f46b95155" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d6125dd5-379c-47d4-a985-e9b886ea0417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_c7bff6a2-ab8f-41db-8b07-49bfa6043f01" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d6125dd5-379c-47d4-a985-e9b886ea0417" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_213cde56-dbbc-46ae-ab6e-b0abd44445bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d6125dd5-379c-47d4-a985-e9b886ea0417" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_213cde56-dbbc-46ae-ab6e-b0abd44445bc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="bngo-20210331.xsd#RevenueRecognitionRemainingPerformanceObligationsDetails_1"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails_1" xlink:type="extended" id="ieecb711b1a6e48b6b520a9373aa954d8_RevenueRecognitionRemainingPerformanceObligationsDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_c7bff6a2-ab8f-41db-8b07-49bfa6043f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6fe41029-446b-425f-b428-89c5c24627bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_c7bff6a2-ab8f-41db-8b07-49bfa6043f01" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6fe41029-446b-425f-b428-89c5c24627bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_615b79af-1500-4b2c-9cfd-bf0cbc2a7f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_c7bff6a2-ab8f-41db-8b07-49bfa6043f01" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_615b79af-1500-4b2c-9cfd-bf0cbc2a7f1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_11836223-2bc8-4fde-bc0c-e675db17cd3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_c7bff6a2-ab8f-41db-8b07-49bfa6043f01" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_11836223-2bc8-4fde-bc0c-e675db17cd3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_82a935e9-d3a7-4a5d-91f7-4e9f46b95155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_c7bff6a2-ab8f-41db-8b07-49bfa6043f01" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_82a935e9-d3a7-4a5d-91f7-4e9f46b95155" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d6125dd5-379c-47d4-a985-e9b886ea0417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_c7bff6a2-ab8f-41db-8b07-49bfa6043f01" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d6125dd5-379c-47d4-a985-e9b886ea0417" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#BalanceSheetAccountDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetails" xlink:type="extended" id="ic7d3671105404d69bc14b3c523ed4cb5_BalanceSheetAccountDetails"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables" xlink:type="simple" xlink:href="bngo-20210331.xsd#BalanceSheetAccountDetailsTables"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables" xlink:type="extended" id="i4d7984ab04b044669c162f97e11a6389_BalanceSheetAccountDetailsTables"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails" xlink:type="extended" id="ia37bf2c56f3845029e423ba857a140fb_BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#BalanceSheetAccountDetailsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="extended" id="i56d2accba88c46a8b93f3c92f5ce2f79_BalanceSheetAccountDetailsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_dcdb7d6b-3335-4d3c-a3e8-b29c5ff2c5da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0d065459-ed88-45e6-a51d-9b71b797fa25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_dcdb7d6b-3335-4d3c-a3e8-b29c5ff2c5da" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0d065459-ed88-45e6-a51d-9b71b797fa25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_65542dc9-975a-4279-a568-071d0b7901cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_dcdb7d6b-3335-4d3c-a3e8-b29c5ff2c5da" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_65542dc9-975a-4279-a568-071d0b7901cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_43b45c22-e8e6-46e8-b802-cf36a994a6c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_dcdb7d6b-3335-4d3c-a3e8-b29c5ff2c5da" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_43b45c22-e8e6-46e8-b802-cf36a994a6c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fa46678b-f51b-4ba5-83cf-a502671dccc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_dcdb7d6b-3335-4d3c-a3e8-b29c5ff2c5da" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fa46678b-f51b-4ba5-83cf-a502671dccc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_964a3750-d608-4ba0-8d6b-501d4e215057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductInformationLineItems_dcdb7d6b-3335-4d3c-a3e8-b29c5ff2c5da" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_964a3750-d608-4ba0-8d6b-501d4e215057" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_92c30c0f-f7eb-4dd2-a97d-168879306898" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_964a3750-d608-4ba0-8d6b-501d4e215057" xlink:to="loc_srt_MajorCustomersAxis_92c30c0f-f7eb-4dd2-a97d-168879306898" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_92c30c0f-f7eb-4dd2-a97d-168879306898_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_92c30c0f-f7eb-4dd2-a97d-168879306898" xlink:to="loc_srt_NameOfMajorCustomerDomain_92c30c0f-f7eb-4dd2-a97d-168879306898_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3977623f-d201-4178-994c-7a7d7445b6c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_92c30c0f-f7eb-4dd2-a97d-168879306898" xlink:to="loc_srt_NameOfMajorCustomerDomain_3977623f-d201-4178-994c-7a7d7445b6c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_RuhrUniversitayBochumMember_01f34b16-7b50-4410-ac56-8ce7183f531f" xlink:href="bngo-20210331.xsd#bngo_RuhrUniversitayBochumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3977623f-d201-4178-994c-7a7d7445b6c1" xlink:to="loc_bngo_RuhrUniversitayBochumMember_01f34b16-7b50-4410-ac56-8ce7183f531f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_IlluminaMember_e93e6312-1550-4ff6-96b5-741e9bba0572" xlink:href="bngo-20210331.xsd#bngo_IlluminaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3977623f-d201-4178-994c-7a7d7445b6c1" xlink:to="loc_bngo_IlluminaMember_e93e6312-1550-4ff6-96b5-741e9bba0572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_QuestDiagnositcsMember_18efd066-afeb-4ea9-8e9b-2db66c73cfcd" xlink:href="bngo-20210331.xsd#bngo_QuestDiagnositcsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3977623f-d201-4178-994c-7a7d7445b6c1" xlink:to="loc_bngo_QuestDiagnositcsMember_18efd066-afeb-4ea9-8e9b-2db66c73cfcd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_bb206135-bb60-4345-ae5e-010f287ac395" xlink:href="bngo-20210331.xsd#bngo_LineagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3977623f-d201-4178-994c-7a7d7445b6c1" xlink:to="loc_bngo_LineagenMember_bb206135-bb60-4345-ae5e-010f287ac395" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bd084fca-981e-4619-989d-e9cfdaa107d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_964a3750-d608-4ba0-8d6b-501d4e215057" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bd084fca-981e-4619-989d-e9cfdaa107d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bd084fca-981e-4619-989d-e9cfdaa107d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bd084fca-981e-4619-989d-e9cfdaa107d7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bd084fca-981e-4619-989d-e9cfdaa107d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_875a88a7-0c73-4c27-8d33-9f32fba0596d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bd084fca-981e-4619-989d-e9cfdaa107d7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_875a88a7-0c73-4c27-8d33-9f32fba0596d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_53d1f6ef-2b55-44e6-9000-fe905741645e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_875a88a7-0c73-4c27-8d33-9f32fba0596d" xlink:to="loc_us-gaap_AccountsReceivableMember_53d1f6ef-2b55-44e6-9000-fe905741645e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_74df31a5-9612-46a7-ad6e-edf018e8e00c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_964a3750-d608-4ba0-8d6b-501d4e215057" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_74df31a5-9612-46a7-ad6e-edf018e8e00c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_74df31a5-9612-46a7-ad6e-edf018e8e00c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_74df31a5-9612-46a7-ad6e-edf018e8e00c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_74df31a5-9612-46a7-ad6e-edf018e8e00c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_58f26c51-7a70-4663-987b-0a7e2090c21c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_74df31a5-9612-46a7-ad6e-edf018e8e00c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_58f26c51-7a70-4663-987b-0a7e2090c21c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_011d8125-2b6c-45e3-9d2c-00bed446bcf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_58f26c51-7a70-4663-987b-0a7e2090c21c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_011d8125-2b6c-45e3-9d2c-00bed446bcf3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails" xlink:type="extended" id="i8bd8320f633642dc895abb416e9ac1dd_BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/Debt" xlink:type="simple" xlink:href="bngo-20210331.xsd#Debt"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/Debt" xlink:type="extended" id="i5c176b243af0405a94001b82feba79fb_Debt"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/DebtTables" xlink:type="simple" xlink:href="bngo-20210331.xsd#DebtTables"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/DebtTables" xlink:type="extended" id="i0863fa15b5bf40f89e281c9d2e767619_DebtTables"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/DebtNarrativeDetails" xlink:type="extended" id="i559c6a45e1a44f53ab782323af4ae9a0_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_b3958625-d586-42a6-a429-10a720470c5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_b3958625-d586-42a6-a429-10a720470c5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f39b5f60-4550-4afc-96c2-766e47e11043" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f39b5f60-4550-4afc-96c2-766e47e11043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8404596d-369c-42cb-8ba0-d90de1b9abfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8404596d-369c-42cb-8ba0-d90de1b9abfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentInterestRateCashRate_4ce0501e-e81c-4b5a-be86-7dd280cd9329" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentInterestRateCashRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_bngo_DebtInstrumentInterestRateCashRate_4ce0501e-e81c-4b5a-be86-7dd280cd9329" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentInterestRateDiscountedCashRate_96062259-e1b7-45e5-af1f-2d2d3350483c" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentInterestRateDiscountedCashRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_bngo_DebtInstrumentInterestRateDiscountedCashRate_96062259-e1b7-45e5-af1f-2d2d3350483c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7c27e431-63a2-4eff-8ad4-275174d9847f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7c27e431-63a2-4eff-8ad4-275174d9847f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentNumberOfMonthlyPayments_613d839d-55ee-487f-9dbf-d90b9b7f5a32" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentNumberOfMonthlyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_bngo_DebtInstrumentNumberOfMonthlyPayments_613d839d-55ee-487f-9dbf-d90b9b7f5a32" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPrepaymentFeePercent_f6e78039-32ce-4940-86f6-30a6bd92c165" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPrepaymentFeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_bngo_DebtInstrumentPrepaymentFeePercent_f6e78039-32ce-4940-86f6-30a6bd92c165" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_9514ace7-223e-4a87-8430-d20e34c15552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_9514ace7-223e-4a87-8430-d20e34c15552" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0246998b-97c5-4c59-b838-9225729f2d2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0246998b-97c5-4c59-b838-9225729f2d2e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d153de1d-7fe0-46d9-80ac-04f14d0da39f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_us-gaap_DebtInstrumentTable_d153de1d-7fe0-46d9-80ac-04f14d0da39f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_93698d39-6fcc-457e-b983-f2515f51c1bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d153de1d-7fe0-46d9-80ac-04f14d0da39f" xlink:to="loc_us-gaap_DebtInstrumentAxis_93698d39-6fcc-457e-b983-f2515f51c1bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_93698d39-6fcc-457e-b983-f2515f51c1bf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_93698d39-6fcc-457e-b983-f2515f51c1bf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_93698d39-6fcc-457e-b983-f2515f51c1bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fd6a30a4-73b9-43cc-b0ac-f4ace6b3a155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_93698d39-6fcc-457e-b983-f2515f51c1bf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fd6a30a4-73b9-43cc-b0ac-f4ace6b3a155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LoanUnderPaycheckProtectionProgramMember_0aaa0bb2-ac6a-455d-ba18-22d7f57d4514" xlink:href="bngo-20210331.xsd#bngo_LoanUnderPaycheckProtectionProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fd6a30a4-73b9-43cc-b0ac-f4ace6b3a155" xlink:to="loc_bngo_LoanUnderPaycheckProtectionProgramMember_0aaa0bb2-ac6a-455d-ba18-22d7f57d4514" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TermA1LoanMember_6eca3205-cf9f-40d6-9630-8002b014b263" xlink:href="bngo-20210331.xsd#bngo_TermA1LoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fd6a30a4-73b9-43cc-b0ac-f4ace6b3a155" xlink:to="loc_bngo_TermA1LoanMember_6eca3205-cf9f-40d6-9630-8002b014b263" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TermA2LoanMember_b60e6077-3ad1-4376-9be6-17ce811e7d4a" xlink:href="bngo-20210331.xsd#bngo_TermA2LoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fd6a30a4-73b9-43cc-b0ac-f4ace6b3a155" xlink:to="loc_bngo_TermA2LoanMember_b60e6077-3ad1-4376-9be6-17ce811e7d4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InnovatusTerm3LoanMember_e736aa97-3c4a-4da0-a03c-455d2f3ccba5" xlink:href="bngo-20210331.xsd#bngo_InnovatusTerm3LoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fd6a30a4-73b9-43cc-b0ac-f4ace6b3a155" xlink:to="loc_bngo_InnovatusTerm3LoanMember_e736aa97-3c4a-4da0-a03c-455d2f3ccba5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InnovatusLoanAgreementMember_fa84a2a3-52df-4e8b-b992-22dc1263c329" xlink:href="bngo-20210331.xsd#bngo_InnovatusLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fd6a30a4-73b9-43cc-b0ac-f4ace6b3a155" xlink:to="loc_bngo_InnovatusLoanAgreementMember_fa84a2a3-52df-4e8b-b992-22dc1263c329" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_RevolverMember_19c22c3a-8769-4e52-b7d3-0e5a9fb6e29f" xlink:href="bngo-20210331.xsd#bngo_RevolverMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fd6a30a4-73b9-43cc-b0ac-f4ace6b3a155" xlink:to="loc_bngo_RevolverMember_19c22c3a-8769-4e52-b7d3-0e5a9fb6e29f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_af21ef99-8661-4b5b-9705-f734bb62c228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d153de1d-7fe0-46d9-80ac-04f14d0da39f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_af21ef99-8661-4b5b-9705-f734bb62c228" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_af21ef99-8661-4b5b-9705-f734bb62c228_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_af21ef99-8661-4b5b-9705-f734bb62c228" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_af21ef99-8661-4b5b-9705-f734bb62c228_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2e823775-ee49-4dde-b9b2-fa0c4d33cb12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_af21ef99-8661-4b5b-9705-f734bb62c228" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2e823775-ee49-4dde-b9b2-fa0c4d33cb12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_7eef4ae6-ab86-4148-981c-eb40da6237d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2e823775-ee49-4dde-b9b2-fa0c4d33cb12" xlink:to="loc_us-gaap_UnsecuredDebtMember_7eef4ae6-ab86-4148-981c-eb40da6237d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_031195ff-e9bc-4dca-b3a0-7d55cbb27189" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2e823775-ee49-4dde-b9b2-fa0c4d33cb12" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_031195ff-e9bc-4dca-b3a0-7d55cbb27189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsAxis_8cb26137-7e95-44d1-bc56-2a340c259c3a" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d153de1d-7fe0-46d9-80ac-04f14d0da39f" xlink:to="loc_bngo_DebtInstrumentPaymentTermsAxis_8cb26137-7e95-44d1-bc56-2a340c259c3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsDomain_8cb26137-7e95-44d1-bc56-2a340c259c3a_default" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bngo_DebtInstrumentPaymentTermsAxis_8cb26137-7e95-44d1-bc56-2a340c259c3a" xlink:to="loc_bngo_DebtInstrumentPaymentTermsDomain_8cb26137-7e95-44d1-bc56-2a340c259c3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsDomain_e1b2ed39-74b2-4011-82e7-dc3c03092c03" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bngo_DebtInstrumentPaymentTermsAxis_8cb26137-7e95-44d1-bc56-2a340c259c3a" xlink:to="loc_bngo_DebtInstrumentPaymentTermsDomain_e1b2ed39-74b2-4011-82e7-dc3c03092c03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodOneMember_b0751b09-b3f2-4fe9-be4f-97281f13d8c1" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_DebtInstrumentPaymentTermsDomain_e1b2ed39-74b2-4011-82e7-dc3c03092c03" xlink:to="loc_bngo_DebtInstrumentPaymentTermsPeriodOneMember_b0751b09-b3f2-4fe9-be4f-97281f13d8c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodTwoMember_fdf47b60-a6ff-49cd-b864-8151891c49d5" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_DebtInstrumentPaymentTermsDomain_e1b2ed39-74b2-4011-82e7-dc3c03092c03" xlink:to="loc_bngo_DebtInstrumentPaymentTermsPeriodTwoMember_fdf47b60-a6ff-49cd-b864-8151891c49d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodThreeMember_5be10f33-4e9d-4e76-b8f3-2de616e07676" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_DebtInstrumentPaymentTermsDomain_e1b2ed39-74b2-4011-82e7-dc3c03092c03" xlink:to="loc_bngo_DebtInstrumentPaymentTermsPeriodThreeMember_5be10f33-4e9d-4e76-b8f3-2de616e07676" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodFourMember_3ca5f1b2-1255-455b-8745-504a4074e004" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsPeriodFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_DebtInstrumentPaymentTermsDomain_e1b2ed39-74b2-4011-82e7-dc3c03092c03" xlink:to="loc_bngo_DebtInstrumentPaymentTermsPeriodFourMember_3ca5f1b2-1255-455b-8745-504a4074e004" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/DebtScheduleofDebtDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#DebtScheduleofDebtDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/DebtScheduleofDebtDetails" xlink:type="extended" id="i33bb7a1e73294391a4c9f962cd79d646_DebtScheduleofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c713e24e-ade1-431a-8c95-a01675f19aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d9416fa0-7ac4-4343-8fc3-cf7e85cdaeb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c713e24e-ade1-431a-8c95-a01675f19aa3" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d9416fa0-7ac4-4343-8fc3-cf7e85cdaeb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_14d084c4-d88d-421a-a23f-d40d8158de04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c713e24e-ade1-431a-8c95-a01675f19aa3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_14d084c4-d88d-421a-a23f-d40d8158de04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_36a8849f-933e-49c4-a606-e323fdf78289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c713e24e-ade1-431a-8c95-a01675f19aa3" xlink:to="loc_us-gaap_LongTermDebt_36a8849f-933e-49c4-a606-e323fdf78289" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cafdd18a-ca2f-4a01-a643-bf2376bb3910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c713e24e-ade1-431a-8c95-a01675f19aa3" xlink:to="loc_us-gaap_DebtInstrumentTable_cafdd18a-ca2f-4a01-a643-bf2376bb3910" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e109f10d-26aa-46c8-a5ae-17564239acb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cafdd18a-ca2f-4a01-a643-bf2376bb3910" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e109f10d-26aa-46c8-a5ae-17564239acb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e109f10d-26aa-46c8-a5ae-17564239acb5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e109f10d-26aa-46c8-a5ae-17564239acb5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e109f10d-26aa-46c8-a5ae-17564239acb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b9e12365-6909-40e2-864d-af53fbc4387e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e109f10d-26aa-46c8-a5ae-17564239acb5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b9e12365-6909-40e2-864d-af53fbc4387e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TermLoansMember_86d0dcc6-93b6-4d73-9137-b5ed023bcdd8" xlink:href="bngo-20210331.xsd#bngo_TermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b9e12365-6909-40e2-864d-af53fbc4387e" xlink:to="loc_bngo_TermLoansMember_86d0dcc6-93b6-4d73-9137-b5ed023bcdd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PPPLoanMember_1c02685e-2c07-456b-b660-1f1b66783b5c" xlink:href="bngo-20210331.xsd#bngo_PPPLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b9e12365-6909-40e2-864d-af53fbc4387e" xlink:to="loc_bngo_PPPLoanMember_1c02685e-2c07-456b-b660-1f1b66783b5c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensation"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation" xlink:type="extended" id="i8ef42d0ec92d42e8bfe172e4a4a3e10a_StockholdersEquityandStockBasedCompensation"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables" xlink:type="extended" id="ic280c6d8a7fd4e04937bc617e42a696e_StockholdersEquityandStockBasedCompensationTables"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails" xlink:type="extended" id="i71022f89a8f54929bde3c0308c016690_StockholdersEquityandStockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f0c0a991-48c3-4436-8ca6-ae4cfab86f24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f0c0a991-48c3-4436-8ca6-ae4cfab86f24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_a593faf9-e660-4233-8843-e65e74fb3fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_a593faf9-e660-4233-8843-e65e74fb3fb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_a6d582fa-1455-44ff-8140-b321545ad21a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_a6d582fa-1455-44ff-8140-b321545ad21a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_825269fe-4c32-4a57-8063-dc2259e05882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_825269fe-4c32-4a57-8063-dc2259e05882" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SaleOfStockAuthorizedAmountToBeIssued_dc06a10c-9875-4066-980b-36a911f3bcf1" xlink:href="bngo-20210331.xsd#bngo_SaleOfStockAuthorizedAmountToBeIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_bngo_SaleOfStockAuthorizedAmountToBeIssued_dc06a10c-9875-4066-980b-36a911f3bcf1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SaleOfStockValueSharesIssuedInTransaction_c37f9591-1353-4fb1-bc75-55b2f940e615" xlink:href="bngo-20210331.xsd#bngo_SaleOfStockValueSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_bngo_SaleOfStockValueSharesIssuedInTransaction_c37f9591-1353-4fb1-bc75-55b2f940e615" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_df3b53c9-5655-4877-85da-caa2dfbe3121" xlink:href="bngo-20210331.xsd#bngo_CommissionFeeMaximumPercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_df3b53c9-5655-4877-85da-caa2dfbe3121" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_685db8b6-3742-4f6e-abba-1277bc63ef77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_685db8b6-3742-4f6e-abba-1277bc63ef77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary_2d08833c-5e35-4bf6-b0dc-2f71fe101bfe" xlink:href="bngo-20210331.xsd#bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary_2d08833c-5e35-4bf6-b0dc-2f71fe101bfe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment_f2f559ac-41ea-42b5-b3e7-5ecc344e8d4f" xlink:href="bngo-20210331.xsd#bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment_f2f559ac-41ea-42b5-b3e7-5ecc344e8d4f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_87359226-68a8-4e4b-a4a3-737d5964dabb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:to="loc_us-gaap_StatementClassOfStockAxis_87359226-68a8-4e4b-a4a3-737d5964dabb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_87359226-68a8-4e4b-a4a3-737d5964dabb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_87359226-68a8-4e4b-a4a3-737d5964dabb" xlink:to="loc_us-gaap_ClassOfStockDomain_87359226-68a8-4e4b-a4a3-737d5964dabb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_620513e6-455f-448a-933d-79376fac6afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_87359226-68a8-4e4b-a4a3-737d5964dabb" xlink:to="loc_us-gaap_ClassOfStockDomain_620513e6-455f-448a-933d-79376fac6afb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_df26f78d-df7b-4003-b126-6ea5f2bacfe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_620513e6-455f-448a-933d-79376fac6afb" xlink:to="loc_us-gaap_CommonStockMember_df26f78d-df7b-4003-b126-6ea5f2bacfe2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_06fdb9f8-8158-4b48-8128-8fb38fb38c0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_06fdb9f8-8158-4b48-8128-8fb38fb38c0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06fdb9f8-8158-4b48-8128-8fb38fb38c0a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_06fdb9f8-8158-4b48-8128-8fb38fb38c0a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06fdb9f8-8158-4b48-8128-8fb38fb38c0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9489bdd8-60be-4481-93e4-5807dd7080d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_06fdb9f8-8158-4b48-8128-8fb38fb38c0a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9489bdd8-60be-4481-93e4-5807dd7080d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_143c83a1-63d5-4e77-83d3-6bec84a39a58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9489bdd8-60be-4481-93e4-5807dd7080d0" xlink:to="loc_us-gaap_OverAllotmentOptionMember_143c83a1-63d5-4e77-83d3-6bec84a39a58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_851d5d7c-25a4-47aa-9004-893cb47c9816" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:to="loc_srt_CounterpartyNameAxis_851d5d7c-25a4-47aa-9004-893cb47c9816" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_851d5d7c-25a4-47aa-9004-893cb47c9816_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_851d5d7c-25a4-47aa-9004-893cb47c9816" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_851d5d7c-25a4-47aa-9004-893cb47c9816_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91dcece9-7dba-49b9-b725-312596ec958e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_851d5d7c-25a4-47aa-9004-893cb47c9816" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91dcece9-7dba-49b9-b725-312596ec958e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CowenMember_cd1bd01f-368e-498d-aa1b-a2aed7e85e25" xlink:href="bngo-20210331.xsd#bngo_CowenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91dcece9-7dba-49b9-b725-312596ec958e" xlink:to="loc_bngo_CowenMember_cd1bd01f-368e-498d-aa1b-a2aed7e85e25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9d38e0e4-eb99-41fe-8a0c-b5c3d398109b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:to="loc_us-gaap_AwardTypeAxis_9d38e0e4-eb99-41fe-8a0c-b5c3d398109b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d38e0e4-eb99-41fe-8a0c-b5c3d398109b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9d38e0e4-eb99-41fe-8a0c-b5c3d398109b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d38e0e4-eb99-41fe-8a0c-b5c3d398109b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45fec91d-3eb4-419d-a6b8-e0c307e4c8b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9d38e0e4-eb99-41fe-8a0c-b5c3d398109b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45fec91d-3eb4-419d-a6b8-e0c307e4c8b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ebfba1f7-7841-493e-b9e2-1447fb286a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45fec91d-3eb4-419d-a6b8-e0c307e4c8b1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ebfba1f7-7841-493e-b9e2-1447fb286a30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_76a2b5e2-2fd9-48de-b106-f49a5c7d76e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:to="loc_srt_TitleOfIndividualAxis_76a2b5e2-2fd9-48de-b106-f49a5c7d76e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_76a2b5e2-2fd9-48de-b106-f49a5c7d76e1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_76a2b5e2-2fd9-48de-b106-f49a5c7d76e1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_76a2b5e2-2fd9-48de-b106-f49a5c7d76e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e8663eeb-4925-496f-9348-3cd96bb7ba31" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_76a2b5e2-2fd9-48de-b106-f49a5c7d76e1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e8663eeb-4925-496f-9348-3cd96bb7ba31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_RErikHolmlinMember_35afa4f9-c11a-4638-b258-0dd934752b39" xlink:href="bngo-20210331.xsd#bngo_RErikHolmlinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e8663eeb-4925-496f-9348-3cd96bb7ba31" xlink:to="loc_bngo_RErikHolmlinMember_35afa4f9-c11a-4638-b258-0dd934752b39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_MarkOldakowskiMember_a474467f-11a6-494c-a7e6-cae403555776" xlink:href="bngo-20210331.xsd#bngo_MarkOldakowskiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e8663eeb-4925-496f-9348-3cd96bb7ba31" xlink:to="loc_bngo_MarkOldakowskiMember_a474467f-11a6-494c-a7e6-cae403555776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_VestingStatusAxis_b7767a82-0218-43f3-a7cb-f4c2eb121629" xlink:href="bngo-20210331.xsd#bngo_VestingStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:to="loc_bngo_VestingStatusAxis_b7767a82-0218-43f3-a7cb-f4c2eb121629" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_VestingStatusDomain_b7767a82-0218-43f3-a7cb-f4c2eb121629_default" xlink:href="bngo-20210331.xsd#bngo_VestingStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bngo_VestingStatusAxis_b7767a82-0218-43f3-a7cb-f4c2eb121629" xlink:to="loc_bngo_VestingStatusDomain_b7767a82-0218-43f3-a7cb-f4c2eb121629_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_VestingStatusDomain_9b3f9537-772f-4c5b-9cbd-53f70a05f5f9" xlink:href="bngo-20210331.xsd#bngo_VestingStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bngo_VestingStatusAxis_b7767a82-0218-43f3-a7cb-f4c2eb121629" xlink:to="loc_bngo_VestingStatusDomain_9b3f9537-772f-4c5b-9cbd-53f70a05f5f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TimeBasedVestingMember_befb578d-3a7e-48d1-a5c6-f520f8f15397" xlink:href="bngo-20210331.xsd#bngo_TimeBasedVestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_VestingStatusDomain_9b3f9537-772f-4c5b-9cbd-53f70a05f5f9" xlink:to="loc_bngo_TimeBasedVestingMember_befb578d-3a7e-48d1-a5c6-f520f8f15397" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PerformanceSatisfactionVestingMember_6bc864d6-6d1b-480d-b9a9-85654f0658d0" xlink:href="bngo-20210331.xsd#bngo_PerformanceSatisfactionVestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_VestingStatusDomain_9b3f9537-772f-4c5b-9cbd-53f70a05f5f9" xlink:to="loc_bngo_PerformanceSatisfactionVestingMember_6bc864d6-6d1b-480d-b9a9-85654f0658d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5d234bec-252f-4373-861d-dec664020fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5d234bec-252f-4373-861d-dec664020fed" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5d234bec-252f-4373-861d-dec664020fed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5d234bec-252f-4373-861d-dec664020fed" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5d234bec-252f-4373-861d-dec664020fed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_efc5f457-bd11-47f3-af81-9a473993c4d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5d234bec-252f-4373-861d-dec664020fed" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_efc5f457-bd11-47f3-af81-9a473993c4d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_87e94ead-75d4-4567-819c-f5af3691dbcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_efc5f457-bd11-47f3-af81-9a473993c4d8" xlink:to="loc_us-gaap_SubsequentEventMember_87e94ead-75d4-4567-819c-f5af3691dbcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c0f7339c-8c50-46af-ae5d-23ce38ab1650" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:to="loc_srt_RangeAxis_c0f7339c-8c50-46af-ae5d-23ce38ab1650" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c0f7339c-8c50-46af-ae5d-23ce38ab1650_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c0f7339c-8c50-46af-ae5d-23ce38ab1650" xlink:to="loc_srt_RangeMember_c0f7339c-8c50-46af-ae5d-23ce38ab1650_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_53829a75-ee6d-4b9a-a6fa-c4211d8490e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c0f7339c-8c50-46af-ae5d-23ce38ab1650" xlink:to="loc_srt_RangeMember_53829a75-ee6d-4b9a-a6fa-c4211d8490e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_41fea43f-6eb8-42b0-bd63-ed2e1bead47b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_53829a75-ee6d-4b9a-a6fa-c4211d8490e0" xlink:to="loc_srt_MinimumMember_41fea43f-6eb8-42b0-bd63-ed2e1bead47b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4652c0b6-499f-44ff-9f7d-861ace1b2fbf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_53829a75-ee6d-4b9a-a6fa-c4211d8490e0" xlink:to="loc_srt_MaximumMember_4652c0b6-499f-44ff-9f7d-861ace1b2fbf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensationWarrantActivityDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails" xlink:type="extended" id="i6433820535154b6380070d7469e7862f_StockholdersEquityandStockBasedCompensationWarrantActivityDetails"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended" id="i8a8f610f4ba44f2e83821aa2d1cd5344_StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xlink:type="extended" id="i56ddcf86e528454688331c50c099a885_StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacb6656-fdf3-493b-b274-6c4404e2b86d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_60b4cea6-51d9-4ccd-aca8-2ddafdb06642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacb6656-fdf3-493b-b274-6c4404e2b86d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_60b4cea6-51d9-4ccd-aca8-2ddafdb06642" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc33b75e-4423-45f1-b633-d02008729e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacb6656-fdf3-493b-b274-6c4404e2b86d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc33b75e-4423-45f1-b633-d02008729e9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_89ef8fb0-a63d-4e22-995e-afeb24a60ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc33b75e-4423-45f1-b633-d02008729e9e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_89ef8fb0-a63d-4e22-995e-afeb24a60ae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_89ef8fb0-a63d-4e22-995e-afeb24a60ae5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_89ef8fb0-a63d-4e22-995e-afeb24a60ae5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_89ef8fb0-a63d-4e22-995e-afeb24a60ae5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42d858fc-5338-4a19-9df6-4bd0ea29ce81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_89ef8fb0-a63d-4e22-995e-afeb24a60ae5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42d858fc-5338-4a19-9df6-4bd0ea29ce81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9218d04b-815a-40db-b52c-c686bc43ea20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42d858fc-5338-4a19-9df6-4bd0ea29ce81" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9218d04b-815a-40db-b52c-c686bc43ea20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cfc87d54-d6cf-4f16-9252-f34623744513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42d858fc-5338-4a19-9df6-4bd0ea29ce81" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cfc87d54-d6cf-4f16-9252-f34623744513" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails" xlink:type="extended" id="i395ceecf9a424dbeb58c56c26800fcf3_StockholdersEquityandStockBasedCompensationAssumptionsDetails"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/Litigation" xlink:type="simple" xlink:href="bngo-20210331.xsd#Litigation"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/Litigation" xlink:type="extended" id="i1e578c9fda94449a9ef53bdc711c9881_Litigation"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="bngo-20210331.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/IncomeTaxes" xlink:type="extended" id="i803097b1bb444f1f9fd4dbca2c95e616_IncomeTaxes"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagen" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagen"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagen" xlink:type="extended" id="i1f1994634ba444ad9ff1c1e173152838_AcquisitionofLineagen"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenTables" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagenTables"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagenTables" xlink:type="extended" id="i6c16844454d64c5cb0c7594347cf0b80_AcquisitionofLineagenTables"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagenNarrativeDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails" xlink:type="extended" id="ie8711e3cc020418aa51796e1d908273f_AcquisitionofLineagenNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_d1bc84ae-7c16-459b-b782-a69f4cae54fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_d1bc84ae-7c16-459b-b782-a69f4cae54fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_7de68353-1b6e-40ec-9e86-39ac4261ba6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_7de68353-1b6e-40ec-9e86-39ac4261ba6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_40772e98-f97d-4d67-8ab7-901b29a3b29d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_40772e98-f97d-4d67-8ab7-901b29a3b29d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt_1ba106b6-8480-4095-a9e7-3fce2bb460aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:to="loc_us-gaap_RepaymentsOfOtherDebt_1ba106b6-8480-4095-a9e7-3fce2bb460aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_a9ff593a-f40c-4e93-bca3-36c4c684d23a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_a9ff593a-f40c-4e93-bca3-36c4c684d23a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_6ee030c8-6dcd-462a-809b-c44306eb63e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_6ee030c8-6dcd-462a-809b-c44306eb63e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9a8f1393-2310-4e10-b6b1-f5ab0f308209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9a8f1393-2310-4e10-b6b1-f5ab0f308209" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_5987639c-16ac-4afb-8092-3bbb3e9bb091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:to="loc_us-gaap_InterestExpenseDebt_5987639c-16ac-4afb-8092-3bbb3e9bb091" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b169602-6745-4302-8fa6-5dd2c1e30940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b169602-6745-4302-8fa6-5dd2c1e30940" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_01b0abdf-28f9-4bfc-a6c6-d9463ae7962c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b169602-6745-4302-8fa6-5dd2c1e30940" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_01b0abdf-28f9-4bfc-a6c6-d9463ae7962c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01b0abdf-28f9-4bfc-a6c6-d9463ae7962c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_01b0abdf-28f9-4bfc-a6c6-d9463ae7962c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01b0abdf-28f9-4bfc-a6c6-d9463ae7962c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37b61c3c-510a-4f45-a519-6be4f5dcb8b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_01b0abdf-28f9-4bfc-a6c6-d9463ae7962c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37b61c3c-510a-4f45-a519-6be4f5dcb8b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_ed84180e-56cd-4acb-858c-757ec1c59782" xlink:href="bngo-20210331.xsd#bngo_LineagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37b61c3c-510a-4f45-a519-6be4f5dcb8b8" xlink:to="loc_bngo_LineagenMember_ed84180e-56cd-4acb-858c-757ec1c59782" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_50c0fea8-b9e8-4b4c-8c73-a1c364fe2709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b169602-6745-4302-8fa6-5dd2c1e30940" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_50c0fea8-b9e8-4b4c-8c73-a1c364fe2709" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_50c0fea8-b9e8-4b4c-8c73-a1c364fe2709_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_50c0fea8-b9e8-4b4c-8c73-a1c364fe2709" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_50c0fea8-b9e8-4b4c-8c73-a1c364fe2709_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_49beee07-7feb-4894-9850-b3dc3f091cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_50c0fea8-b9e8-4b4c-8c73-a1c364fe2709" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_49beee07-7feb-4894-9850-b3dc3f091cf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_EscrowedSharesMember_35112b79-1983-45e5-8a45-1cafe5489dbb" xlink:href="bngo-20210331.xsd#bngo_EscrowedSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_49beee07-7feb-4894-9850-b3dc3f091cf4" xlink:to="loc_bngo_EscrowedSharesMember_35112b79-1983-45e5-8a45-1cafe5489dbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationInfrequentAdjustmentsAxis_86674c49-7716-4293-97d7-cb8582b525cd" xlink:href="bngo-20210331.xsd#bngo_BusinessCombinationInfrequentAdjustmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b169602-6745-4302-8fa6-5dd2c1e30940" xlink:to="loc_bngo_BusinessCombinationInfrequentAdjustmentsAxis_86674c49-7716-4293-97d7-cb8582b525cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationInfrequentAdjustmentsDomain_86674c49-7716-4293-97d7-cb8582b525cd_default" xlink:href="bngo-20210331.xsd#bngo_BusinessCombinationInfrequentAdjustmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bngo_BusinessCombinationInfrequentAdjustmentsAxis_86674c49-7716-4293-97d7-cb8582b525cd" xlink:to="loc_bngo_BusinessCombinationInfrequentAdjustmentsDomain_86674c49-7716-4293-97d7-cb8582b525cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationInfrequentAdjustmentsDomain_ec12e2b3-5537-46d4-8142-4a2b5f052360" xlink:href="bngo-20210331.xsd#bngo_BusinessCombinationInfrequentAdjustmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bngo_BusinessCombinationInfrequentAdjustmentsAxis_86674c49-7716-4293-97d7-cb8582b525cd" xlink:to="loc_bngo_BusinessCombinationInfrequentAdjustmentsDomain_ec12e2b3-5537-46d4-8142-4a2b5f052360" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationInfrequentAdjustmentsMember_24a02e7a-d405-4e87-801d-c26230cfd3b8" xlink:href="bngo-20210331.xsd#bngo_BusinessCombinationInfrequentAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_BusinessCombinationInfrequentAdjustmentsDomain_ec12e2b3-5537-46d4-8142-4a2b5f052360" xlink:to="loc_bngo_BusinessCombinationInfrequentAdjustmentsMember_24a02e7a-d405-4e87-801d-c26230cfd3b8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagenAcquisitionPurchasePriceDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails" xlink:type="extended" id="i573b702e32e64bc09b132a8527afef49_AcquisitionofLineagenAcquisitionPurchasePriceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_403559d4-8415-43e0-8942-eabc1edb8ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a5597dcd-f738-4e23-a534-6eb695337f17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403559d4-8415-43e0-8942-eabc1edb8ff4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a5597dcd-f738-4e23-a534-6eb695337f17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt_fe02694c-6f5f-4fe8-9ce7-0514448a4dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403559d4-8415-43e0-8942-eabc1edb8ff4" xlink:to="loc_us-gaap_RepaymentsOfOtherDebt_fe02694c-6f5f-4fe8-9ce7-0514448a4dd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_d060ecc7-885a-49dc-a06d-65f5a2986310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403559d4-8415-43e0-8942-eabc1edb8ff4" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_d060ecc7-885a-49dc-a06d-65f5a2986310" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment_989b38a4-6385-41f4-9ad4-38a17df47084" xlink:href="bngo-20210331.xsd#bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403559d4-8415-43e0-8942-eabc1edb8ff4" xlink:to="loc_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment_989b38a4-6385-41f4-9ad4-38a17df47084" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_fdd708ed-080e-4e3f-83bc-733f946a50c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403559d4-8415-43e0-8942-eabc1edb8ff4" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_fdd708ed-080e-4e3f-83bc-733f946a50c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c1402d35-df4e-47e5-8cd2-88adab911e88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403559d4-8415-43e0-8942-eabc1edb8ff4" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c1402d35-df4e-47e5-8cd2-88adab911e88" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_069d0fa5-aae5-43f9-aff5-be71cdf61eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403559d4-8415-43e0-8942-eabc1edb8ff4" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_069d0fa5-aae5-43f9-aff5-be71cdf61eaa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b6b5b84-7e6b-416a-92f2-7c91327475a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403559d4-8415-43e0-8942-eabc1edb8ff4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b6b5b84-7e6b-416a-92f2-7c91327475a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ad945e54-a85b-4578-8962-f38c183f9459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b6b5b84-7e6b-416a-92f2-7c91327475a8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ad945e54-a85b-4578-8962-f38c183f9459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad945e54-a85b-4578-8962-f38c183f9459_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ad945e54-a85b-4578-8962-f38c183f9459" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad945e54-a85b-4578-8962-f38c183f9459_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b669e74d-239c-4fb4-a3ce-35955e742de9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ad945e54-a85b-4578-8962-f38c183f9459" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b669e74d-239c-4fb4-a3ce-35955e742de9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_30f64c6f-f199-4efa-bb78-358d96c7cbca" xlink:href="bngo-20210331.xsd#bngo_LineagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b669e74d-239c-4fb4-a3ce-35955e742de9" xlink:to="loc_bngo_LineagenMember_30f64c6f-f199-4efa-bb78-358d96c7cbca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_62802f54-68d2-42aa-ab39-fd699d7d122b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b6b5b84-7e6b-416a-92f2-7c91327475a8" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_62802f54-68d2-42aa-ab39-fd699d7d122b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_62802f54-68d2-42aa-ab39-fd699d7d122b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_62802f54-68d2-42aa-ab39-fd699d7d122b" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_62802f54-68d2-42aa-ab39-fd699d7d122b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_491d587d-422f-4229-bdbe-febc44c4a7bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_62802f54-68d2-42aa-ab39-fd699d7d122b" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_491d587d-422f-4229-bdbe-febc44c4a7bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_EscrowedSharesMember_ebe060aa-2fa4-47f1-8b29-f638bf8a82e2" xlink:href="bngo-20210331.xsd#bngo_EscrowedSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_491d587d-422f-4229-bdbe-febc44c4a7bd" xlink:to="loc_bngo_EscrowedSharesMember_ebe060aa-2fa4-47f1-8b29-f638bf8a82e2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="ia97b4229ae3f488a8052b8f832eff914_AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2fe26298-8c7e-48bc-8174-f79f98aaad73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2fe26298-8c7e-48bc-8174-f79f98aaad73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_6e39296c-5e62-4d00-a187-b035c8b7b47b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_6e39296c-5e62-4d00-a187-b035c8b7b47b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_72e47064-7553-4931-92a5-9cd4f29d9bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_72e47064-7553-4931-92a5-9cd4f29d9bd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_61dfea64-5fa7-43ca-9470-f0b5918c58ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_61dfea64-5fa7-43ca-9470-f0b5918c58ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2663fc5b-4a0a-415a-8525-4dee8265caec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2663fc5b-4a0a-415a-8525-4dee8265caec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1aae99cb-0947-4f13-a465-446744f3bb9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:to="loc_us-gaap_Goodwill_1aae99cb-0947-4f13-a465-446744f3bb9d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1c26da8c-7d2d-4636-945d-21a5b1490c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1c26da8c-7d2d-4636-945d-21a5b1490c3c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0a36c353-b031-46bc-8a07-ac2782d17247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0a36c353-b031-46bc-8a07-ac2782d17247" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f54add65-5ef3-4541-900f-f7e7350ebb62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f54add65-5ef3-4541-900f-f7e7350ebb62" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0b78a581-34fe-4b91-b6bb-336af990e1cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f54add65-5ef3-4541-900f-f7e7350ebb62" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0b78a581-34fe-4b91-b6bb-336af990e1cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b78a581-34fe-4b91-b6bb-336af990e1cd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0b78a581-34fe-4b91-b6bb-336af990e1cd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b78a581-34fe-4b91-b6bb-336af990e1cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e830c11-ee53-49e4-b391-645131459bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0b78a581-34fe-4b91-b6bb-336af990e1cd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e830c11-ee53-49e4-b391-645131459bfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_5f8c1e45-8602-4faf-91ae-93e6b8e25b02" xlink:href="bngo-20210331.xsd#bngo_LineagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e830c11-ee53-49e4-b391-645131459bfa" xlink:to="loc_bngo_LineagenMember_5f8c1e45-8602-4faf-91ae-93e6b8e25b02" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagenIdentifiableIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails" xlink:type="extended" id="ie9be2373303942829ad2ca78620d858c_AcquisitionofLineagenIdentifiableIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0f780156-94f9-47a0-8a98-f486b1419fad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d01055a4-ffd6-4766-b10c-54372c5443ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0f780156-94f9-47a0-8a98-f486b1419fad" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d01055a4-ffd6-4766-b10c-54372c5443ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d036b605-0190-47ed-93c0-a634832fbee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0f780156-94f9-47a0-8a98-f486b1419fad" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d036b605-0190-47ed-93c0-a634832fbee3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_364fa6bb-08ca-4392-a0d6-7a801b0e9075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d036b605-0190-47ed-93c0-a634832fbee3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_364fa6bb-08ca-4392-a0d6-7a801b0e9075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_364fa6bb-08ca-4392-a0d6-7a801b0e9075_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_364fa6bb-08ca-4392-a0d6-7a801b0e9075" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_364fa6bb-08ca-4392-a0d6-7a801b0e9075_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bee02c5b-3cf5-4846-a5d2-397f7646b7d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_364fa6bb-08ca-4392-a0d6-7a801b0e9075" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bee02c5b-3cf5-4846-a5d2-397f7646b7d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_30774755-4919-49f1-b2ac-26fe2c448f60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bee02c5b-3cf5-4846-a5d2-397f7646b7d9" xlink:to="loc_us-gaap_CustomerRelationshipsMember_30774755-4919-49f1-b2ac-26fe2c448f60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_57b576eb-ebbc-43e3-bb1e-af2bf1c8cd16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bee02c5b-3cf5-4846-a5d2-397f7646b7d9" xlink:to="loc_us-gaap_TradeNamesMember_57b576eb-ebbc-43e3-bb1e-af2bf1c8cd16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ddcfed0f-7e7a-4867-954a-7c1c9af22b36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d036b605-0190-47ed-93c0-a634832fbee3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ddcfed0f-7e7a-4867-954a-7c1c9af22b36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ddcfed0f-7e7a-4867-954a-7c1c9af22b36_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ddcfed0f-7e7a-4867-954a-7c1c9af22b36" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ddcfed0f-7e7a-4867-954a-7c1c9af22b36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6350ccd0-4419-4a79-9082-7995061af6e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ddcfed0f-7e7a-4867-954a-7c1c9af22b36" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6350ccd0-4419-4a79-9082-7995061af6e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_29703b06-ec42-4897-8801-f0203cf4d675" xlink:href="bngo-20210331.xsd#bngo_LineagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6350ccd0-4419-4a79-9082-7995061af6e9" xlink:to="loc_bngo_LineagenMember_29703b06-ec42-4897-8801-f0203cf4d675" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenProFormaInformationDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagenProFormaInformationDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagenProFormaInformationDetails" xlink:type="extended" id="i77176b9e2d1c4dd69eb9066d1e7aa338_AcquisitionofLineagenProFormaInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_99374ea4-1e99-4a02-a872-fd370d408bb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_13ccecde-7292-4adb-ac35-c615431782ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99374ea4-1e99-4a02-a872-fd370d408bb2" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_13ccecde-7292-4adb-ac35-c615431782ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_dc5e2f1f-804d-4332-b9ce-c26ca1841f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99374ea4-1e99-4a02-a872-fd370d408bb2" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_dc5e2f1f-804d-4332-b9ce-c26ca1841f58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_137e66bb-69d9-4e9d-9b50-d19aea5376be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99374ea4-1e99-4a02-a872-fd370d408bb2" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_137e66bb-69d9-4e9d-9b50-d19aea5376be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_583f9989-6faa-4360-8482-b8c58b5f63ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99374ea4-1e99-4a02-a872-fd370d408bb2" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_583f9989-6faa-4360-8482-b8c58b5f63ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d117e-f3a9-411c-afb6-164cd4632e0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99374ea4-1e99-4a02-a872-fd370d408bb2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d117e-f3a9-411c-afb6-164cd4632e0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e6592e60-960b-4887-9012-4dbbf2ada612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d117e-f3a9-411c-afb6-164cd4632e0d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e6592e60-960b-4887-9012-4dbbf2ada612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e6592e60-960b-4887-9012-4dbbf2ada612_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e6592e60-960b-4887-9012-4dbbf2ada612" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e6592e60-960b-4887-9012-4dbbf2ada612_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a78af877-f672-4935-8392-4091e166f6e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e6592e60-960b-4887-9012-4dbbf2ada612" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a78af877-f672-4935-8392-4091e166f6e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_92c87f06-04b1-47e4-bfe1-08f7c214459f" xlink:href="bngo-20210331.xsd#bngo_LineagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a78af877-f672-4935-8392-4091e166f6e5" xlink:to="loc_bngo_LineagenMember_92c87f06-04b1-47e4-bfe1-08f7c214459f" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>bngo-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a7c25383-a88e-4d48-aec4-d74b76810e9c,g:60d85f31-0c17-478f-8e10-9a14108a4bee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6b8bd204-0c66-4d1f-b8b2-0ebe5a0f230b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_96861cac-255b-44ab-a0fa-910126e8bd2c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e21f3982-8af2-4698-a1f4-304acf00b97f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8fd0b7d8-3237-44ae-ac86-cbc32f0eae1a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_78ea0d69-450c-4ca5-8fd5-10ce8b0b27a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f350d7fe-2487-4d44-a43d-dd3b22d29b1c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a386ab58-6bd4-4f0c-9fa4-ece16b751d79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductInformationLineItems_53ddd0e3-51e2-48ef-9f21-2099db5e6700_terseLabel_en-US" xlink:label="lab_us-gaap_ProductInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_ProductInformationLineItems_label_en-US" xlink:label="lab_us-gaap_ProductInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductInformationLineItems" xlink:to="lab_us-gaap_ProductInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_f3c6696b-b497-4a59-bf46-cf495536ae99_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights [Abstract]</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" xlink:to="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_IlluminaMember_8e31ef65-c546-444d-aad6-d9f82841a3ff_terseLabel_en-US" xlink:label="lab_bngo_IlluminaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Illumina</link:label>
    <link:label id="lab_bngo_IlluminaMember_label_en-US" xlink:label="lab_bngo_IlluminaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Illumina [Member]</link:label>
    <link:label id="lab_bngo_IlluminaMember_documentation_en-US" xlink:label="lab_bngo_IlluminaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Illumina</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_IlluminaMember" xlink:href="bngo-20210331.xsd#bngo_IlluminaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_IlluminaMember" xlink:to="lab_bngo_IlluminaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessCombinationInfrequentAdjustmentsAxis_980455e3-158a-40a5-84a5-41b5c9ae9e74_terseLabel_en-US" xlink:label="lab_bngo_BusinessCombinationInfrequentAdjustmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Infrequent Adjustments [Axis]</link:label>
    <link:label id="lab_bngo_BusinessCombinationInfrequentAdjustmentsAxis_label_en-US" xlink:label="lab_bngo_BusinessCombinationInfrequentAdjustmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Infrequent Adjustments [Axis]</link:label>
    <link:label id="lab_bngo_BusinessCombinationInfrequentAdjustmentsAxis_documentation_en-US" xlink:label="lab_bngo_BusinessCombinationInfrequentAdjustmentsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Infrequent Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationInfrequentAdjustmentsAxis" xlink:href="bngo-20210331.xsd#bngo_BusinessCombinationInfrequentAdjustmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessCombinationInfrequentAdjustmentsAxis" xlink:to="lab_bngo_BusinessCombinationInfrequentAdjustmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod_3c1e2c23-c03a-42c2-9516-c3cb68a5c178_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercised In Period</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercised In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" xlink:to="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_a3c9098b-0ecf-414d-b70f-c3ee8e30ce9c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrant Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_667d7564-ba17-4599-b368-ed0dd33a1535_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb1ddc35-ad94-42ed-9090-85a6fd6ed56e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_feee89c6-7556-4df7-84cd-77ce5e638487_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_122f036c-6fc9-4514-ad3f-c10c753ee5dd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ba4cf7c5-b16d-4aee-8e07-9a371c0d445e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_483cd0dc-cb1b-404c-8f6a-84b712884a9f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b4e5a404-509b-49c4-aff9-c7ebc894ffa3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_0079ffbb-56fa-4797-9d3a-7376a215a11f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_3946b0e9-4aa5-4cd9-9542-72a9812f33e0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod_bf9cb1ec-79b8-4d28-b0ac-3c11cf4dd8fc_negatedTerseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Canceled In Period</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Canceled In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" xlink:to="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a43c078c-b76a-45d5-8204-c4db092e9353_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d61f5299-d818-46ed-8aa3-3a5e06881481_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d15fa09f-eb42-4fea-be3e-ad08582b6c9c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_48aa6fbd-e4a9-4880-8030-d11ba8d1b7bd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_25738c6c-9033-48f2-8db4-ab6c2b0badb6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_641be062-9e53-42de-8e84-5769cd97b53d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2ee1b26f-4ba4-4f8e-bb3f-d416d74b9045_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_e3a322a4-0eb5-4484-9785-8188e798bc83_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowing from line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_62c8dcd9-6cb2-409b-b193-144627e3f58b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_a698b261-2c00-40f4-8285-6feb181af10c_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on forgiveness of Paycheck Protection Program loan</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_20eef0dc-38fe-47eb-ab24-54b2d1f7b2d3_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on forgiveness of PPP Loan</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_3f194dfb-7ff2-4a46-bbe4-d2f096215dac_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_6bfe73a8-99ee-4f6a-aeb1-339a051b615f_negatedTerseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Exercised In Period</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Exercised In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:to="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_c62deefd-b1f4-457b-9c16-315dd55e7869_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8637a5c9-999c-4081-aec4-8c8b127236a6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b21e78bd-5ce5-4e8d-92fc-7d626abca63e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_3d294f41-3507-40b0-ba96-5a28f12b5524_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_e4ac88d4-6785-47b4-8585-405ac14cc955_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_2e561f2a-87f3-4080-b389-ccbc1e392d08_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_ee0f647d-4596-497a-a61e-51dbf7991af9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March&#160;31, 2021 and December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessCombinationInfrequentAdjustmentsDomain_64fcf6d4-d798-49e6-bb62-71bbe44e9133_terseLabel_en-US" xlink:label="lab_bngo_BusinessCombinationInfrequentAdjustmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Infrequent Adjustments [Domain]</link:label>
    <link:label id="lab_bngo_BusinessCombinationInfrequentAdjustmentsDomain_label_en-US" xlink:label="lab_bngo_BusinessCombinationInfrequentAdjustmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Infrequent Adjustments [Domain]</link:label>
    <link:label id="lab_bngo_BusinessCombinationInfrequentAdjustmentsDomain_documentation_en-US" xlink:label="lab_bngo_BusinessCombinationInfrequentAdjustmentsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Infrequent Adjustments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationInfrequentAdjustmentsDomain" xlink:href="bngo-20210331.xsd#bngo_BusinessCombinationInfrequentAdjustmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessCombinationInfrequentAdjustmentsDomain" xlink:to="lab_bngo_BusinessCombinationInfrequentAdjustmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_afd1b528-1e31-423d-99b2-5a81bda4c0cd_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d67582ce-737b-46c6-b07f-24b7304119dd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_ff88cf5f-218d-4fee-8fb0-d0e9b94006e5_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue:</link:label>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenueAbstract" xlink:to="lab_us-gaap_CostOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_VestingStatusDomain_24357216-a1c9-4dfa-b30a-c3e1d4ce5036_terseLabel_en-US" xlink:label="lab_bngo_VestingStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Status [Domain]</link:label>
    <link:label id="lab_bngo_VestingStatusDomain_label_en-US" xlink:label="lab_bngo_VestingStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Status [Domain]</link:label>
    <link:label id="lab_bngo_VestingStatusDomain_documentation_en-US" xlink:label="lab_bngo_VestingStatusDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_VestingStatusDomain" xlink:href="bngo-20210331.xsd#bngo_VestingStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_VestingStatusDomain" xlink:to="lab_bngo_VestingStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_339a4f42-8a75-4b69-8b4b-9c9c0a7bce88_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_8e052f9c-c605-435b-b5c4-b1c5247e15ef_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NorthAmericaMember_2f9761fe-fe85-4f0d-9030-0d1a446a457d_terseLabel_en-US" xlink:label="lab_srt_NorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">North America</link:label>
    <link:label id="lab_srt_NorthAmericaMember_label_en-US" xlink:label="lab_srt_NorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">North America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NorthAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NorthAmericaMember" xlink:to="lab_srt_NorthAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_1aaebd49-a919-49c8-9606-664aecd9df7d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_78499815-8371-4cf9-a268-25c646287582_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8df37706-7e7f-410d-9f33-1c7c43c793a3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8d2ede61-34c2-430f-b905-3b43254cb1d1_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CowenMember_2b8f1575-c7c4-4faa-b7b5-382dde67c2c3_terseLabel_en-US" xlink:label="lab_bngo_CowenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen</link:label>
    <link:label id="lab_bngo_CowenMember_label_en-US" xlink:label="lab_bngo_CowenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen [Member]</link:label>
    <link:label id="lab_bngo_CowenMember_documentation_en-US" xlink:label="lab_bngo_CowenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CowenMember" xlink:href="bngo-20210331.xsd#bngo_CowenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CowenMember" xlink:to="lab_bngo_CowenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_ed10ae44-26c1-47d9-b719-484e5b917723_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_bc909e5e-32d3-41ed-ae6d-3dfb9d47fe5c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_a51c7ca4-649d-41ac-b730-2f86b3512082_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_41c5dcfe-ca54-43cd-8e9f-7541b4cf8d8a_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_80d2b726-0850-4e86-984a-4534c271b789_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f50ac50f-883f-4c52-a621-f6fe7b0a7ed2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_e992ae94-a6fa-4f8d-980f-3d08a12efbf2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_38500633-38f3-4988-9d5b-4d9c2603d652_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_InnovatusTerm3LoanMember_520fec0c-3a37-4807-826a-583ee79e47b0_terseLabel_en-US" xlink:label="lab_bngo_InnovatusTerm3LoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Term 3 Loan</link:label>
    <link:label id="lab_bngo_InnovatusTerm3LoanMember_label_en-US" xlink:label="lab_bngo_InnovatusTerm3LoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Term 3 Loan [Member]</link:label>
    <link:label id="lab_bngo_InnovatusTerm3LoanMember_documentation_en-US" xlink:label="lab_bngo_InnovatusTerm3LoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Term 3 Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InnovatusTerm3LoanMember" xlink:href="bngo-20210331.xsd#bngo_InnovatusTerm3LoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_InnovatusTerm3LoanMember" xlink:to="lab_bngo_InnovatusTerm3LoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_6f849373-84ff-4b90-a6df-955a9d303efe_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_d7812ded-c0b9-4376-88bc-176aa185dd0f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b72e1187-5492-4ae2-a53b-3a2a01c9c1d8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f7cb3c8e-5184-4275-a537-389d5604b311_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c5fc9b1b-cc1a-482a-b2d8-95c520127931_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentInterestRateCashRate_3c69ee70-ead8-4d31-a644-6a46852d5213_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentInterestRateCashRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash rate</link:label>
    <link:label id="lab_bngo_DebtInstrumentInterestRateCashRate_label_en-US" xlink:label="lab_bngo_DebtInstrumentInterestRateCashRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Cash Rate</link:label>
    <link:label id="lab_bngo_DebtInstrumentInterestRateCashRate_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentInterestRateCashRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Cash Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentInterestRateCashRate" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentInterestRateCashRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentInterestRateCashRate" xlink:to="lab_bngo_DebtInstrumentInterestRateCashRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_b61a0f39-037d-452a-a67b-f9c93e25a723_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_682e303d-5ff7-4297-8963-6c2c8437399c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodOneMember_a5319cc3-bd70-4563-b7f3-4acf64b1afb1_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period One</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodOneMember_label_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms, Period One [Member]</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodOneMember_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodOneMember" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentPaymentTermsPeriodOneMember" xlink:to="lab_bngo_DebtInstrumentPaymentTermsPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26700403-4d4c-4c8f-ba8d-ffd6cf27bfc5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_61577434-0808-4d78-8e18-bc7023f58bf4_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5c43ab0d-f6a1-459d-ac89-212e2d2e8d16_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_328d811d-51ac-4e4b-a1a6-df4eebddc30f_terseLabel_en-US" xlink:label="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission fee</link:label>
    <link:label id="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_label_en-US" xlink:label="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission Fee, Maximum Percentage Of Gross Proceeds</link:label>
    <link:label id="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_documentation_en-US" xlink:label="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission Fee, Maximum Percentage Of Gross Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommissionFeeMaximumPercentageOfGrossProceeds" xlink:href="bngo-20210331.xsd#bngo_CommissionFeeMaximumPercentageOfGrossProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CommissionFeeMaximumPercentageOfGrossProceeds" xlink:to="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_bbdf1571-d944-4a41-a733-eef97606a0a5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsDomain_b23f4ff1-8602-4960-8b58-6107b6add44a_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms [Domain]</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsDomain_label_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms [Domain]</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsDomain_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsDomain" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentPaymentTermsDomain" xlink:to="lab_bngo_DebtInstrumentPaymentTermsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_00cef1eb-4339-44e2-9d2b-5cee2f7ee79e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_b1fb2ccc-dd1b-4a04-a8bc-bc19960f299d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CommonWarrantsMember_003a6fd1-e3bb-43e6-b33a-069b73be68e4_terseLabel_en-US" xlink:label="lab_bngo_CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_bngo_CommonWarrantsMember_label_en-US" xlink:label="lab_bngo_CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Warrants [Member]</link:label>
    <link:label id="lab_bngo_CommonWarrantsMember_documentation_en-US" xlink:label="lab_bngo_CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonWarrantsMember" xlink:href="bngo-20210331.xsd#bngo_CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CommonWarrantsMember" xlink:to="lab_bngo_CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment_c8864c80-4804-4dd4-b498-9b5ab7aac518_terseLabel_en-US" xlink:label="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period, termination of employment</link:label>
    <link:label id="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment_label_en-US" xlink:label="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Termination of Employment</link:label>
    <link:label id="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment_documentation_en-US" xlink:label="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Termination of Employment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment" xlink:href="bngo-20210331.xsd#bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment" xlink:to="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_9bea6f81-1dfd-4a44-b254-10abd734e7cc_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Account Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d4692430-282a-4bba-9488-125f677d0bce_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_fa41a3ba-f1c6-4b7c-99cf-e6fa58a26f7f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cbc7e587-6646-4544-b3c7-9bd92887e93a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_RErikHolmlinMember_e67b5426-91d2-463f-903b-ed4b66ffcf27_terseLabel_en-US" xlink:label="lab_bngo_RErikHolmlinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R. Erik Holmlin</link:label>
    <link:label id="lab_bngo_RErikHolmlinMember_label_en-US" xlink:label="lab_bngo_RErikHolmlinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R. Erik Holmlin [Member]</link:label>
    <link:label id="lab_bngo_RErikHolmlinMember_documentation_en-US" xlink:label="lab_bngo_RErikHolmlinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R. Erik Holmlin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_RErikHolmlinMember" xlink:href="bngo-20210331.xsd#bngo_RErikHolmlinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_RErikHolmlinMember" xlink:to="lab_bngo_RErikHolmlinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_TermA1LoanMember_b2469475-6778-438a-9a96-7cc7dba3b40a_terseLabel_en-US" xlink:label="lab_bngo_TermA1LoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A-1 Loan</link:label>
    <link:label id="lab_bngo_TermA1LoanMember_label_en-US" xlink:label="lab_bngo_TermA1LoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A-1 Loan [Member]</link:label>
    <link:label id="lab_bngo_TermA1LoanMember_documentation_en-US" xlink:label="lab_bngo_TermA1LoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A-1 Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TermA1LoanMember" xlink:href="bngo-20210331.xsd#bngo_TermA1LoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_TermA1LoanMember" xlink:to="lab_bngo_TermA1LoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_b161f065-8c4c-46bc-9e18-bf05bb7e5081_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_96538af9-85a5-49ae-bc7a-983af250587d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_92b20eb5-908b-4da0-8235-7dc634c3d2e9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_a283674d-3d4a-4408-a595-bbdb06f1169b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_17e9aab6-9633-4878-8a4d-ee3ccb14382d_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_9d544731-840f-4673-8353-43cd405ed31f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_09ff7a84-d752-4690-b54f-9b26048d7840_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_671fe51c-8e3d-451f-9426-90705e524c2d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c9930a-0478-449a-a12a-f735d2febfc4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_f9011be7-de0f-468a-b1ad-ffd92ef56b9d_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_InstrumentRevenueMember_7bcca34f-be5d-4bb9-bdee-1c012bb0885f_terseLabel_en-US" xlink:label="lab_bngo_InstrumentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments</link:label>
    <link:label id="lab_bngo_InstrumentRevenueMember_label_en-US" xlink:label="lab_bngo_InstrumentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instrument Revenue [Member]</link:label>
    <link:label id="lab_bngo_InstrumentRevenueMember_documentation_en-US" xlink:label="lab_bngo_InstrumentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instrument Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InstrumentRevenueMember" xlink:href="bngo-20210331.xsd#bngo_InstrumentRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_InstrumentRevenueMember" xlink:to="lab_bngo_InstrumentRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_2ce277b0-0366-456d-9986-58025be72774_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1ebf0420-4f99-4ce3-9f35-ae8631d679e9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1d8c7e30-4fcd-4406-a768-beede5294881_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment_cae569c8-766c-465b-a6fa-f9c8c91fa8b3_negatedTerseLabel_en-US" xlink:label="lab_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated shares of common stock to be returned to the Company</link:label>
    <link:label id="lab_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment_label_en-US" xlink:label="lab_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued Or Issuable, Number Of Shares, Incomplete Accounting, Adjustment</link:label>
    <link:label id="lab_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment_documentation_en-US" xlink:label="lab_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued Or Issuable, Number Of Shares, Incomplete Accounting, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" xlink:href="bngo-20210331.xsd#bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" xlink:to="lab_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_42749ca9-8e2b-468d-b321-7063a6e45f87_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_5ad5c860-78f1-4c11-9a95-58663aa7943e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_b60976f8-76b9-4869-a5ad-f7331c5451ee_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_MarkOldakowskiMember_eccf670f-3483-458d-8fb8-449ea753468b_terseLabel_en-US" xlink:label="lab_bngo_MarkOldakowskiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mark Oldakowski</link:label>
    <link:label id="lab_bngo_MarkOldakowskiMember_label_en-US" xlink:label="lab_bngo_MarkOldakowskiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mark Oldakowski [Member]</link:label>
    <link:label id="lab_bngo_MarkOldakowskiMember_documentation_en-US" xlink:label="lab_bngo_MarkOldakowskiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mark Oldakowski</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_MarkOldakowskiMember" xlink:href="bngo-20210331.xsd#bngo_MarkOldakowskiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_MarkOldakowskiMember" xlink:to="lab_bngo_MarkOldakowskiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_48b9ff86-909c-4428-87d4-a6f15a74eeb3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_16a17974-b198-4582-a191-710544d019aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_02628ea3-37c0-4bd4-8540-a7725bea7183_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_20100e33-5f85-48ee-82db-fb0c1aca9f81_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_de7e27ba-f61c-4d14-af01-fd19e1d75966_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_TermLoansMember_22f413dc-14ff-4468-914c-cfa02957ab86_terseLabel_en-US" xlink:label="lab_bngo_TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loans</link:label>
    <link:label id="lab_bngo_TermLoansMember_label_en-US" xlink:label="lab_bngo_TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loans [Member]</link:label>
    <link:label id="lab_bngo_TermLoansMember_documentation_en-US" xlink:label="lab_bngo_TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TermLoansMember" xlink:href="bngo-20210331.xsd#bngo_TermLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_TermLoansMember" xlink:to="lab_bngo_TermLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_38ede46a-fb56-4ad9-bf8a-722956b30d6d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_SaleOfStockAuthorizedAmountToBeIssued_622e3ae7-24c6-4d8d-a10b-049d1dea806a_terseLabel_en-US" xlink:label="lab_bngo_SaleOfStockAuthorizedAmountToBeIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized amount of stock to be issued</link:label>
    <link:label id="lab_bngo_SaleOfStockAuthorizedAmountToBeIssued_label_en-US" xlink:label="lab_bngo_SaleOfStockAuthorizedAmountToBeIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Authorized Amount To Be Issued</link:label>
    <link:label id="lab_bngo_SaleOfStockAuthorizedAmountToBeIssued_documentation_en-US" xlink:label="lab_bngo_SaleOfStockAuthorizedAmountToBeIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Authorized Amount To Be Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SaleOfStockAuthorizedAmountToBeIssued" xlink:href="bngo-20210331.xsd#bngo_SaleOfStockAuthorizedAmountToBeIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_SaleOfStockAuthorizedAmountToBeIssued" xlink:to="lab_bngo_SaleOfStockAuthorizedAmountToBeIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2ce6ebfb-fb03-4527-8056-4a06dc830168_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_QuestDiagnositcsMember_d50652b8-1331-44e5-bdbc-24ac84168d89_terseLabel_en-US" xlink:label="lab_bngo_QuestDiagnositcsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quest Diagnositcs</link:label>
    <link:label id="lab_bngo_QuestDiagnositcsMember_label_en-US" xlink:label="lab_bngo_QuestDiagnositcsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quest Diagnositcs [Member]</link:label>
    <link:label id="lab_bngo_QuestDiagnositcsMember_documentation_en-US" xlink:label="lab_bngo_QuestDiagnositcsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quest Diagnositcs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_QuestDiagnositcsMember" xlink:href="bngo-20210331.xsd#bngo_QuestDiagnositcsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_QuestDiagnositcsMember" xlink:to="lab_bngo_QuestDiagnositcsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_464a33a4-9296-4035-8f1c-25d9fdfa7f99_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_82189d92-4d1c-4456-a932-bf7da27f1300_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_16eda121-84e3-4c31-8048-2015b3a13484_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_05b2b051-77a1-4d28-9966-208612738e83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d961b174-7792-44c1-8dfb-7bb87654e90c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_428e5cff-90ae-4c8e-960b-b53d1da12c1a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_e7d8013c-d746-4103-933d-db9fc3bda01a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4f5fde68-1709-4160-875c-58e5f57a5282_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_d6c10980-c527-44fc-a6b0-34eb928845a2_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights [Roll Forward]</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" xlink:to="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_d1591b71-a598-4e1e-a7c1-bb2df2d36c71_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_LineagenMember_2bbde53d-cc03-408c-bda4-a2376552d320_terseLabel_en-US" xlink:label="lab_bngo_LineagenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lineagen</link:label>
    <link:label id="lab_bngo_LineagenMember_label_en-US" xlink:label="lab_bngo_LineagenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lineagen [Member]</link:label>
    <link:label id="lab_bngo_LineagenMember_documentation_en-US" xlink:label="lab_bngo_LineagenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lineagen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember" xlink:href="bngo-20210331.xsd#bngo_LineagenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_LineagenMember" xlink:to="lab_bngo_LineagenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2137a503-001d-4dd2-8415-159ee7bd18bf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_StockIssuedDuringPeriodValueWarrantsExercised_15414ea5-e061-4b1a-8927-bbc7330754d8_terseLabel_en-US" xlink:label="lab_bngo_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue stock for warrant exercises</link:label>
    <link:label id="lab_bngo_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_bngo_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_bngo_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_bngo_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="bngo-20210331.xsd#bngo_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_bngo_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_b9f9e059-e30a-4929-86d7-08b0f1bce426_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8747ba5d-1ad1-4d93-b856-3908128e62a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights_5f3d9f71-f3ba-4706-ad1a-3650ccb7a1dd_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Granted In Period Of Warrants Or Rights</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Granted In Period Of Warrants Or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights" xlink:to="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_acc7836e-6fdc-4456-98d3-2d294c4e319a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_6bed0ad5-2320-4519-828f-d9e716440fa6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_e6ee61d1-b943-4196-b8c1-2778f94ae943_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09bb6ed8-a5e5-4c53-84ab-0b38d1a0e832_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_9acbb461-f3c3-45bc-b67e-83901799aec0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, trade</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_1818e292-e9c5-42d7-aa68-65a7dc81e2c2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_d742e598-5026-4dc0-a827-0aacf7fd97bf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_PerformanceSatisfactionVestingMember_46ecb83f-b0bc-46c8-8515-684c4663d00d_terseLabel_en-US" xlink:label="lab_bngo_PerformanceSatisfactionVestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Satisfaction Vesting</link:label>
    <link:label id="lab_bngo_PerformanceSatisfactionVestingMember_label_en-US" xlink:label="lab_bngo_PerformanceSatisfactionVestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Satisfaction Vesting [Member]</link:label>
    <link:label id="lab_bngo_PerformanceSatisfactionVestingMember_documentation_en-US" xlink:label="lab_bngo_PerformanceSatisfactionVestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Satisfaction Vesting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PerformanceSatisfactionVestingMember" xlink:href="bngo-20210331.xsd#bngo_PerformanceSatisfactionVestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_PerformanceSatisfactionVestingMember" xlink:to="lab_bngo_PerformanceSatisfactionVestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_InnovatusLoanAgreementMember_fa2412b9-ffbd-47c0-91df-3c153971d89d_terseLabel_en-US" xlink:label="lab_bngo_InnovatusLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus LSA</link:label>
    <link:label id="lab_bngo_InnovatusLoanAgreementMember_label_en-US" xlink:label="lab_bngo_InnovatusLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Loan Agreement [Member]</link:label>
    <link:label id="lab_bngo_InnovatusLoanAgreementMember_documentation_en-US" xlink:label="lab_bngo_InnovatusLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InnovatusLoanAgreementMember" xlink:href="bngo-20210331.xsd#bngo_InnovatusLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_InnovatusLoanAgreementMember" xlink:to="lab_bngo_InnovatusLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f2610a42-78ad-4603-83c2-8880a0a8771f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_0e6533cc-2637-45d6-8122-3df05f4614cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_a90bc680-ddf4-49cc-9e16-3960a5b7dca2_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f45d1704-80e0-4616-94b4-0f5245b9a918_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_f551fd36-5c28-41a4-a810-8249436c29f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_45e3bcd3-57d9-47dd-8602-cd1809ec4838_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_feb21482-4eeb-4194-926a-295638f81c77_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_257a65c5-5ac2-42ce-8e0e-b5390afc48e4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d1059641-ed32-4d23-ba83-53fe2b864f27_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e38bc212-b005-4473-bd85-aeada62283ef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_e7cefe46-79e7-4a4d-aebb-2facba6a1c47_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_419c776d-d851-4e6a-af98-3a9b2e94681c_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrant and option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_e59d27fe-5a4d-448f-9745-fc78433945b8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed of acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessCombinationInfrequentAdjustmentsMember_a92dd0e9-d1a9-42a1-bf61-12cda9deebaa_terseLabel_en-US" xlink:label="lab_bngo_BusinessCombinationInfrequentAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Infrequent Adjustments</link:label>
    <link:label id="lab_bngo_BusinessCombinationInfrequentAdjustmentsMember_label_en-US" xlink:label="lab_bngo_BusinessCombinationInfrequentAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Infrequent Adjustments [Member]</link:label>
    <link:label id="lab_bngo_BusinessCombinationInfrequentAdjustmentsMember_documentation_en-US" xlink:label="lab_bngo_BusinessCombinationInfrequentAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Infrequent Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationInfrequentAdjustmentsMember" xlink:href="bngo-20210331.xsd#bngo_BusinessCombinationInfrequentAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessCombinationInfrequentAdjustmentsMember" xlink:to="lab_bngo_BusinessCombinationInfrequentAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_21a14bd3-8087-4917-8343-6a54fe51af8a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_782ca810-5e2f-4aed-baac-e509ad326353_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_24ad2b37-2338-47ee-9c93-c7a101f0d168_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_65b46af7-f2f5-47b8-982e-e77a65cca878_periodStartLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_f622ff7c-deee-4a37-8c77-7dd27ef24ad3_periodEndLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:to="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_LiquidityPolicyTextBlock_e91c24a4-7799-4916-aeec-1a035eb111fb_terseLabel_en-US" xlink:label="lab_bngo_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_bngo_LiquidityPolicyTextBlock_label_en-US" xlink:label="lab_bngo_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity [Policy Text Block]</link:label>
    <link:label id="lab_bngo_LiquidityPolicyTextBlock_documentation_en-US" xlink:label="lab_bngo_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LiquidityPolicyTextBlock" xlink:href="bngo-20210331.xsd#bngo_LiquidityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_LiquidityPolicyTextBlock" xlink:to="lab_bngo_LiquidityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_bc8c4567-5694-43b8-88dd-f4a792940617_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_9708d8f7-fad1-447b-9b06-5e93d8834354_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets Acquired as Part of Business Combination</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f36a06ea-f004-43a2-9de1-17a3bca969fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsAxis_6269474e-cf9a-4846-9877-8ee3db9ae1b2_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms [Axis]</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsAxis_label_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms [Axis]</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsAxis_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsAxis" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentPaymentTermsAxis" xlink:to="lab_bngo_DebtInstrumentPaymentTermsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_400661c4-7260-4ae2-a114-54ba395b210e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_f7cd9a95-1f5d-43e4-bc27-cbf4c9b5127c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_68f3527b-bf5d-4b6b-967a-8ffa1b8c8bcd_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8a452749-599c-45c8-8212-2a0704cb9865_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_06d14825-888c-415b-b398-b85036f8c7e1_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodTwoMember_7ce7a301-21ab-40b7-a574-148fce91a006_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Two</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodTwoMember_label_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms, Period Two [Member]</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodTwoMember_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodTwoMember" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentPaymentTermsPeriodTwoMember" xlink:to="lab_bngo_DebtInstrumentPaymentTermsPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_147a7840-9986-4697-8b76-e2e0e5f1fe70_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_4e6fd527-de17-47cd-9748-db48bb48e567_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_d619198f-39bd-4c98-b86e-580a12fdcf36_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_VestingStatusAxis_97aacda4-704f-49ef-9dcb-d971d507fa88_terseLabel_en-US" xlink:label="lab_bngo_VestingStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Status [Axis]</link:label>
    <link:label id="lab_bngo_VestingStatusAxis_label_en-US" xlink:label="lab_bngo_VestingStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Status [Axis]</link:label>
    <link:label id="lab_bngo_VestingStatusAxis_documentation_en-US" xlink:label="lab_bngo_VestingStatusAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_VestingStatusAxis" xlink:href="bngo-20210331.xsd#bngo_VestingStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_VestingStatusAxis" xlink:to="lab_bngo_VestingStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_23bf8e3e-65cc-48de-a838-bfea4defc02d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation, percentage</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_755198aa-651e-47c1-9504-a803da20cc25_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_6b06a32f-1f9f-41b7-8564-9e8d7a75b3ed_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_OfferingCostsIncurredNotYetPaid_910f12b7-49ba-4ccb-9192-a11eaafcf7a8_terseLabel_en-US" xlink:label="lab_bngo_OfferingCostsIncurredNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs in accounts payable</link:label>
    <link:label id="lab_bngo_OfferingCostsIncurredNotYetPaid_label_en-US" xlink:label="lab_bngo_OfferingCostsIncurredNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Costs Incurred, Not Yet Paid</link:label>
    <link:label id="lab_bngo_OfferingCostsIncurredNotYetPaid_documentation_en-US" xlink:label="lab_bngo_OfferingCostsIncurredNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Costs Incurred, Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_OfferingCostsIncurredNotYetPaid" xlink:href="bngo-20210331.xsd#bngo_OfferingCostsIncurredNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_OfferingCostsIncurredNotYetPaid" xlink:to="lab_bngo_OfferingCostsIncurredNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_bc0e1fd1-8242-4e22-ab59-6a4dde92d22a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0f634c3b-1df6-4552-94ca-413909839260_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary_bba3ac9e-159e-45d7-87e4-18ccf4ba5eee_terseLabel_en-US" xlink:label="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of shares vesting on the first and second anniversary</link:label>
    <link:label id="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary_label_en-US" xlink:label="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Percentage of Shares Vesting on First and Second Anniversary</link:label>
    <link:label id="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary_documentation_en-US" xlink:label="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Percentage of Shares Vesting on First and Second Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary" xlink:href="bngo-20210331.xsd#bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary" xlink:to="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_05084607-0352-4c7b-86ee-2620fa8a302f_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total carrying value of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_8f97ab4c-8e1e-492e-9f79-40323545de7d_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_01bdaa0a-4900-4789-83f3-40c525ba09d0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_838027c0-3725-4283-bfd9-3f1180c42db6_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_WarrantExerciseNonCash_6505a418-bc07-4000-8542-ed440692a75f_terseLabel_en-US" xlink:label="lab_bngo_WarrantExerciseNonCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise pursuant to cashless exercise</link:label>
    <link:label id="lab_bngo_WarrantExerciseNonCash_label_en-US" xlink:label="lab_bngo_WarrantExerciseNonCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise, Non-cash</link:label>
    <link:label id="lab_bngo_WarrantExerciseNonCash_documentation_en-US" xlink:label="lab_bngo_WarrantExerciseNonCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise, Non-cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_WarrantExerciseNonCash" xlink:href="bngo-20210331.xsd#bngo_WarrantExerciseNonCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_WarrantExerciseNonCash" xlink:to="lab_bngo_WarrantExerciseNonCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_efdc4bca-bd08-49a3-8fe4-484ab4b82591_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3f5b48cc-2cec-4199-932c-2c7324d07920_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_147bc759-7355-4552-a749-4fe7f2b5eebd_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9866f44a-dad1-4fa4-b8a1-1ee01eecafd2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_ca989ee1-a994-401f-b8da-460cc9b28fb2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1360eb0d-7fdc-4c56-8065-984d5bb7ae9a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_3f2acb4f-6de1-4304-a5d2-c0eebc39e0f8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d196ae0d-2d61-4d0e-85af-ccb385fcd746_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_1e571b6b-255c-403a-8089-352ce3faf5ed_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of term-loan debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_PPPLoanMember_2e78dc10-9bd0-4ef3-8747-792359d51a82_terseLabel_en-US" xlink:label="lab_bngo_PPPLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP Loan</link:label>
    <link:label id="lab_bngo_PPPLoanMember_label_en-US" xlink:label="lab_bngo_PPPLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP Loan [Member]</link:label>
    <link:label id="lab_bngo_PPPLoanMember_documentation_en-US" xlink:label="lab_bngo_PPPLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PPPLoanMember" xlink:href="bngo-20210331.xsd#bngo_PPPLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_PPPLoanMember" xlink:to="lab_bngo_PPPLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_04c4c7d9-2417-4deb-b623-d9ca98da69ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Assumptions in Black -Scholes Option Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_152de13e-ab73-40b1-a027-275c34b0e78a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_a1e4f0a5-57fb-4e87-bca0-00f9d5cb5d9b_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f6efbef1-ec6a-4e64-8fcc-e2de47588822_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_e43ac10c-9c98-4bfb-83aa-b7bccfab2fc4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_070bfd37-99b8-40d5-9963-0a302a2df6ae_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_EscrowedSharesMember_e8c13332-3533-4ca4-8388-3976b8dc9eb4_terseLabel_en-US" xlink:label="lab_bngo_EscrowedSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrowed Shares</link:label>
    <link:label id="lab_bngo_EscrowedSharesMember_label_en-US" xlink:label="lab_bngo_EscrowedSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrowed Shares [Member]</link:label>
    <link:label id="lab_bngo_EscrowedSharesMember_documentation_en-US" xlink:label="lab_bngo_EscrowedSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrowed Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_EscrowedSharesMember" xlink:href="bngo-20210331.xsd#bngo_EscrowedSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_EscrowedSharesMember" xlink:to="lab_bngo_EscrowedSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_eb5d737f-6311-449c-a221-b756ec8e685f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_1777845f-1b16-49c1-92e0-a2b9010d0570_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_2ed2d72b-4987-4ee1-bcba-d4d5155ad865_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_35f42c57-244a-44a0-8b54-9d2b5b644c75_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_17d9167a-bac4-423d-9051-5e698d7bf56b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_a70f33e7-2cce-4417-842e-1527ef9404c7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_399e4cd8-0c67-43d4-b7c6-ce84981057ed_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_327b8f5e-8294-41c2-bb2c-29c828938243_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1127ed6f-40d8-4be5-93e1-7e4722508fa9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_159fa635-c064-42d6-9521-bfa38d5b2d16_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_acf566e1-2154-4e9c-8627-e2123c7e44ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_4de2f388-e2eb-425c-a3c2-884183d289f7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PIK</link:label>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_label_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment in Kind (PIK) Note [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:to="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_TermA2LoanMember_fb0a27c4-50b2-4e41-b787-ea0dca2e66cf_terseLabel_en-US" xlink:label="lab_bngo_TermA2LoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A-2 Loan</link:label>
    <link:label id="lab_bngo_TermA2LoanMember_label_en-US" xlink:label="lab_bngo_TermA2LoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A-2 Loan [Member]</link:label>
    <link:label id="lab_bngo_TermA2LoanMember_documentation_en-US" xlink:label="lab_bngo_TermA2LoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A-2 Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TermA2LoanMember" xlink:href="bngo-20210331.xsd#bngo_TermA2LoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_TermA2LoanMember" xlink:to="lab_bngo_TermA2LoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_056423ac-a994-4bef-b9a2-54979853ff57_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_c6810a38-84cf-4b89-b62e-1edb3fc0f567_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_28c743af-55e2-413f-bc64-955b628a923e_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d05efbac-f744-49ce-94e4-ece81bf566df_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e73d83b6-d6d2-4bce-8908-a8c81a16a66c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $2,091,000 and $2,119,000 as of March&#160;31, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_06bd432d-c74d-4608-b3fb-332e59e1298a_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5f8aa474-caf1-4c80-af11-2365ec300209_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_bf6f27d8-7521-4d1f-aef4-4315912a2dd6_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_3c3bf633-f36a-4548-be63-c1553a966b53_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_628b4ebf-0ac3-40dd-953c-a521c956b5a1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_aeefb07c-e2fa-4810-9d5c-5347a18b025f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding basic and diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_1e2f32f0-1048-4085-8c95-5bc00a895e47_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_81ea8f0f-2c56-4c09-94f6-a5b8db601cc6_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights_d5f400f7-d161-40e6-9634-0db973a3bcab_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Of Warrants Or Rights</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Of Warrants Or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" xlink:to="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_f47d2215-b8b2-4963-b7c8-98669398f64a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_37e322cb-08b6-4f6d-9806-40780c3a1ee6_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_39b07bda-ee60-4b6e-95f3-9102998128d5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_47e8304e-3e41-4a39-aa37-270d6b0c5e6a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_5b6dce86-066e-45c3-a81a-7d925b7fc502_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1df9c8e2-0060-46a1-b449-ab32d4ebeaf0_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_da6bc1da-6042-483f-9237-0359ffedbb6f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan face value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_fd7aeaf2-39ce-4f06-ae43-bbf87a2d2051_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_58714a51-2ec4-4db0-8af9-0ebd07f7fb88_terseLabel_en-US" xlink:label="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term</link:label>
    <link:label id="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_label_en-US" xlink:label="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Roll Forward]</link:label>
    <link:label id="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_documentation_en-US" xlink:label="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" xlink:href="bngo-20210331.xsd#bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" xlink:to="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_afb37c59-5dda-4b74-aa56-db6bf7e14499_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_b302e584-01aa-4e2f-a65b-783a1f6ed5fc_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EMEAMember_f5427762-f9fb-4cbc-ac32-ba0aea88d40c_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEIA</link:label>
    <link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EMEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2452353c-8b1c-4d00-a5da-4657e95cc0cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2c507a63-1697-4055-b7de-92ee7363f9a7_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_d51bced0-8090-4bde-b3f5-0e5ae86ce9b2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3e6612c2-dcdc-4b4c-a742-637ddb49965f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_128ed3fc-483c-46ea-9bbf-4eaf095487dd_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_115c7b7b-4642-416d-aaef-233799d843e2_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_InnovatusLSAMember_6f49eed0-8fd8-45ad-a0af-996498a3e965_terseLabel_en-US" xlink:label="lab_bngo_InnovatusLSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus LSA</link:label>
    <link:label id="lab_bngo_InnovatusLSAMember_label_en-US" xlink:label="lab_bngo_InnovatusLSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus LSA [Member]</link:label>
    <link:label id="lab_bngo_InnovatusLSAMember_documentation_en-US" xlink:label="lab_bngo_InnovatusLSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus LSA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InnovatusLSAMember" xlink:href="bngo-20210331.xsd#bngo_InnovatusLSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_InnovatusLSAMember" xlink:to="lab_bngo_InnovatusLSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_cd296575-54c1-46ab-a986-7e4952bb7e58_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Noncurrent [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2cc663ff-05c4-4bdc-bccb-5cae5125aeea_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0429f5d1-e884-4af2-9f1a-ee031217849a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_60e8f24a-6f1d-48cf-b87d-631d2dcafedb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_71fa346d-7cd0-44a6-a565-9a455a718754_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of bad debt expense</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_dfe4cbb2-a5a4-4afd-a4d3-115e83159403_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Loan</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_f06342f3-8222-4cfa-aff2-dbea55117d22_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_a75876ca-e469-4c1a-902d-55003fae4886_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_925b8e8e-69d5-41f1-9880-e8cc68224bed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodFourMember_cd052cc4-02fe-4b2f-a061-b861f74fb894_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Four</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodFourMember_label_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms, Period Four [Member]</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodFourMember_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms, Period Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodFourMember" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsPeriodFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentPaymentTermsPeriodFourMember" xlink:to="lab_bngo_DebtInstrumentPaymentTermsPeriodFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_da40b13f-4c2a-4923-b443-57fe558ca368_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_a0e4abd3-1cfe-4b55-a0be-c3a0d867ed21_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_c5cb07f3-b225-4bcd-bbad-97a2da040c03_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value, 400,000,000 shares authorized at March&#160;31, 2021 and December&#160;31, 2020; 278,794,000 and 189,953,000 shares issued and outstanding at March&#160;31, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_362b7114-b958-4c27-a617-3e5bfe7c1951_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f123d688-0ed1-4e05-a6cd-097efd67f328_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_9ca50225-94bb-4ec6-8f44-879e295254ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_4a4116c2-d343-44da-9725-06dfe09ede63_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_ba9f2939-a73f-4bbc-982f-716e971a882f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_2aeef9bd-d750-421e-9bfa-a13a8c5cea32_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_1495d52d-9f24-486e-8112-1ffb48b9d84b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_ced60ecf-4592-406a-86cc-354c876927ec_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price per share on closing date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_789b3c17-7cd9-4929-9696-064064bfe91a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_dcedc98d-c0f3-4c6e-b862-94b5c4c7504c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_722311d6-0220-431d-8f05-613e19869e56_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7ed85121-f94a-426b-9eca-a198e42641ba_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfProductInformationTable_2005a74d-9a26-43f4-aa99-d422114cb8de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfProductInformationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable" xlink:to="lab_us-gaap_ScheduleOfProductInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_ae98f703-225c-4dfd-82d2-b0733dd955ec_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_e89da704-95be-494e-8693-edcb74ae6ec0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_8f98ae56-24eb-415e-bed2-7e236d04750e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c15319fe-dcb6-444d-97a0-14d194662f48_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_25c1b136-3701-4e4f-ad54-b40ec3fcbae5_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d9b14646-3174-4437-9667-ec7576fcce34_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_91c58975-7355-4423-9a4d-0aad6a8cadb2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses on sale of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_9d57cb33-554f-4c3c-920d-5dfdb02373bf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_a3719774-3567-4492-9bea-1ac960a37599_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a1e73c62-43d0-4b5b-8331-f30a5d87ac75_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_8fad4f50-6405-4656-9e41-c4c65fa73619_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued or reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_8f22b471-7451-4e2f-96f1-e2c39dfbe34f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock issued as consideration (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7ecaf085-5311-434b-9322-e40db6e22346_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c1320032-2175-497d-b1bd-1f4be39d7339_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_4d4e0a84-7e9e-4f3f-8f63-2d886420561f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to original purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_b97ade5f-1594-4dd0-8e00-635c1cb1958d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_791295dd-b037-460a-825b-089f96bac445_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e1dd457e-193a-4353-ba9b-950f492d64ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod_bf986c97-c1fb-4f15-8bf4-5c245a54c7ce_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Granted In Period</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Granted In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" xlink:to="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_83b76961-8318-4874-a175-d3e6cc409f6d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share amount (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_551af2b0-e822-4db2-892e-46253cfdcf41_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_b9680148-aff2-4d7f-b3f4-807d54bf3e57_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3ba4c286-ed0b-4f7d-8d2e-b7314df08258_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_50ab551f-61e0-42be-89bd-ae5483908a00_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights_9289e10f-62ed-4087-bfe3-487786218e66_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value Exercised In Period Of Warrants Or Rights</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value Exercised In Period Of Warrants Or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" xlink:to="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_75971cfa-5dda-46ae-80e2-25bc94735044_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1143e5a9-cdcc-4e1f-9010-98beefdcec58_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity and Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1c86d763-5c24-4815-ac06-5ec7f8c2c093_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_57c573b2-6eb4-46e0-9c92-6e2ffd122c9a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_de48f5a2-bf65-434e-a319-f4c13e9b7417_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_037fb542-d033-4d06-9e28-4c0561802e9a_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_8aa6bac9-3099-4049-bdc4-dade387b8ec0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_1012859d-a049-4fca-88c7-77e71dfdfc89_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9c69d413-7bea-45d2-a763-a3ad693b1b68_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a919675e-56e4-47db-8687-cc48e335ad4c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa60eebc-45b9-4944-95ff-8b28956c5803_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_TimeBasedVestingMember_7f15b3a3-1e19-4fc5-a67e-0b256b8ef33f_terseLabel_en-US" xlink:label="lab_bngo_TimeBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-Based Vesting</link:label>
    <link:label id="lab_bngo_TimeBasedVestingMember_label_en-US" xlink:label="lab_bngo_TimeBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-Based Vesting [Member]</link:label>
    <link:label id="lab_bngo_TimeBasedVestingMember_documentation_en-US" xlink:label="lab_bngo_TimeBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-Based Vesting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TimeBasedVestingMember" xlink:href="bngo-20210331.xsd#bngo_TimeBasedVestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_TimeBasedVestingMember" xlink:to="lab_bngo_TimeBasedVestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_c6552dfd-2e54-45b6-b38e-3ccca4300a26_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_fdac082c-3a76-499f-ad96-1ed57265e724_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b9ae73c7-8db5-4e83-92d7-d6b2365eeb43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of Stock under Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_8258aa3a-4ae3-4edd-ac3d-7bd69da5e932_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory_9e63565c-a1e4-43cc-9b2b-e0a0cebb4314_terseLabel_en-US" xlink:label="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of instruments and servers from inventory to property and equipment</link:label>
    <link:label id="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory_label_en-US" xlink:label="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Instruments And Servers To Property And Equipment From Inventory</link:label>
    <link:label id="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory_documentation_en-US" xlink:label="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of instruments and servers to property and equipment from inventory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" xlink:href="bngo-20210331.xsd#bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" xlink:to="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_d4d4b069-20d2-4258-95dc-20fccdf2d15c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodThreeMember_d113014f-2ebd-4263-94a3-e68a125b7e79_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Three</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodThreeMember_label_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms, Period Three [Member]</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodThreeMember_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodThreeMember" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentPaymentTermsPeriodThreeMember" xlink:to="lab_bngo_DebtInstrumentPaymentTermsPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ConsumableRevenueMember_ce945573-81e4-4e39-b9a4-24872c511b5a_terseLabel_en-US" xlink:label="lab_bngo_ConsumableRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumables</link:label>
    <link:label id="lab_bngo_ConsumableRevenueMember_label_en-US" xlink:label="lab_bngo_ConsumableRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumable Revenue [Member]</link:label>
    <link:label id="lab_bngo_ConsumableRevenueMember_documentation_en-US" xlink:label="lab_bngo_ConsumableRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumable Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ConsumableRevenueMember" xlink:href="bngo-20210331.xsd#bngo_ConsumableRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ConsumableRevenueMember" xlink:to="lab_bngo_ConsumableRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_fd162f53-89d1-49d6-8acd-30be930b6e7c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_c12f8c97-12ab-473d-a158-3292990cb8cc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_1a13c077-d024-4619-8a17-769a59ea2ef7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8db10bae-531f-4439-8d0e-a1e0a8b694cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Recognized Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_626a85fb-ba7f-4e3e-8f30-a873c704181f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_558e9520-a588-4646-8bf0-d0ada8eafba6_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_b6f01638-fcbb-4ca3-8cc5-c4db337c7b4e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_2608b2b2-f721-4d9c-982d-79f5c676fe0c_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted-Average Remaining Contractual Term Of Warrants Or Rights [Roll Forward]</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted-Average Remaining Contractual Term Of Warrants Or Rights [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" xlink:to="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_242b6cf9-16cf-4f18-afcf-5ad2c64c5155_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_StockIssuedDuringPeriodSharesWarrantsExercised_02e818ea-fcbb-4c80-ad78-55055ec1af5a_terseLabel_en-US" xlink:label="lab_bngo_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue stock for warrant exercises (in shares)</link:label>
    <link:label id="lab_bngo_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_bngo_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_bngo_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_bngo_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="bngo-20210331.xsd#bngo_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_bngo_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_70d07f5c-52d7-44bb-b476-28498a559d69_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_557d4151-74ce-4e52-84da-8eefc7664308_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_RevolverMember_f3a3670b-1d44-404c-9079-cf227b51d716_terseLabel_en-US" xlink:label="lab_bngo_RevolverMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver</link:label>
    <link:label id="lab_bngo_RevolverMember_label_en-US" xlink:label="lab_bngo_RevolverMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver [Member]</link:label>
    <link:label id="lab_bngo_RevolverMember_documentation_en-US" xlink:label="lab_bngo_RevolverMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_RevolverMember" xlink:href="bngo-20210331.xsd#bngo_RevolverMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_RevolverMember" xlink:to="lab_bngo_RevolverMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_e6e27af1-3f72-451d-9ce2-10ad7962bf01_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of satisfaction of remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_78254384-3bb7-4386-b8bd-d8436361da28_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for bad debt expense</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentNumberOfMonthlyPayments_92e3d4a9-9916-4423-bdde-11369ef5c5f1_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentNumberOfMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of monthly payments</link:label>
    <link:label id="lab_bngo_DebtInstrumentNumberOfMonthlyPayments_label_en-US" xlink:label="lab_bngo_DebtInstrumentNumberOfMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Monthly Payments</link:label>
    <link:label id="lab_bngo_DebtInstrumentNumberOfMonthlyPayments_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentNumberOfMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Monthly Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentNumberOfMonthlyPayments" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentNumberOfMonthlyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentNumberOfMonthlyPayments" xlink:to="lab_bngo_DebtInstrumentNumberOfMonthlyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_d491290e-5b65-4c40-b5d5-39c266355727_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service and other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d2de3f23-11e3-4367-931a-f6c640a9621d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a664cf49-3598-445b-ae97-bdc2a7849262_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_17d7dc3e-bba5-45ea-bb99-3e000579ad0f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_abc7ca51-1ecb-4912-8008-b7eb19e81420_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Lineagen</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_87f09ff1-0d3d-4896-b62e-0b6b5205be23_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_WorkingCapital_547aec1a-db09-4410-96d1-39b7a22896e7_terseLabel_en-US" xlink:label="lab_bngo_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_bngo_WorkingCapital_label_en-US" xlink:label="lab_bngo_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_bngo_WorkingCapital_documentation_en-US" xlink:label="lab_bngo_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_WorkingCapital" xlink:href="bngo-20210331.xsd#bngo_WorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_WorkingCapital" xlink:to="lab_bngo_WorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_LoanUnderPaycheckProtectionProgramMember_68063a8b-1d57-40cc-ba50-560753526e4d_terseLabel_en-US" xlink:label="lab_bngo_LoanUnderPaycheckProtectionProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Under Paycheck Protection Program</link:label>
    <link:label id="lab_bngo_LoanUnderPaycheckProtectionProgramMember_label_en-US" xlink:label="lab_bngo_LoanUnderPaycheckProtectionProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Under Paycheck Protection Program [Member]</link:label>
    <link:label id="lab_bngo_LoanUnderPaycheckProtectionProgramMember_documentation_en-US" xlink:label="lab_bngo_LoanUnderPaycheckProtectionProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Under Paycheck Protection Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LoanUnderPaycheckProtectionProgramMember" xlink:href="bngo-20210331.xsd#bngo_LoanUnderPaycheckProtectionProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_LoanUnderPaycheckProtectionProgramMember" xlink:to="lab_bngo_LoanUnderPaycheckProtectionProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f9cd1196-9ee4-4722-8ae4-ab8cf3122728_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_e8afd1cc-7211-492d-a08a-120d07887431_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_557a05f2-f064-49cb-ad2c-bf6148280841_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d4d8a308-0d23-40e2-91f5-27785e9ea074_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_add4963a-b4ea-46b2-bffe-1d4ed9a33e5d_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Granted In Period</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Granted In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" xlink:to="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_444f52c5-6480-407b-842c-09a76e6aa03b_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_0d4f8ceb-82e7-4848-8ddb-009c0d11c18c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0ed9499d-ec29-43c5-bc4e-6afcbfcfec57_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_55aafeb2-84f2-4029-b599-422d6eafa199_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_181d0830-f4eb-437b-9e49-83b661954bda_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_933fa1d8-4209-4467-9f21-e42a6faf0b65_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_14e81dde-92be-48d8-b4bb-cb3b7523c4a0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward_f187c087-6cb2-413c-94cb-f4712d0503ae_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of Stock under Warrants</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory_3185a344-bdaa-459e-81f7-94316aed4b95_terseLabel_en-US" xlink:label="lab_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of instruments and servers from property and equipment into inventory</link:label>
    <link:label id="lab_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory_label_en-US" xlink:label="lab_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Instruments And Servers From Property And Equipment Into Inventory</link:label>
    <link:label id="lab_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory_documentation_en-US" xlink:label="lab_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Instruments And Servers From Property And Equipment Into Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" xlink:href="bngo-20210331.xsd#bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" xlink:to="lab_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_e59b1584-7295-40ab-8c9b-b3c73e7a2208_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f98314f4-d892-4872-a008-00de11f77b2f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_82ff2f68-78a9-4423-a4e0-013a208f0f79_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dd88c53a-9db8-4829-9574-5759dc3b29a9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_1c4ca6ce-0015-4ad3-a452-02bd92b9f334_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_982e31b6-b29d-4379-819a-c625a8b20c04_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d66e7640-1a26-4bb5-8344-e0a0652fbeeb_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_74ec1469-c2b0-4a94-beea-9ea449cd9cc6_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration transferred in acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_79ed55da-7e2d-4b0d-bfae-6a2d6dfd3500_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_f2012f5c-73ea-4000-9cf1-4afa51b34d7b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_82f0c63c-a6db-4642-ad5f-9c4ce780e9e6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_54e4062e-07c7-430b-a378-13cdc715f2ae_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of estimated common stock consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_b46639ab-5c55-49d7-9792-b5f432a81816_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_22411184-334f-41df-a3c6-eccc4dab6a0e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_6df96b6e-6404-4223-8ee8-81d185ffa030_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_3bd7d2aa-dbfa-4b65-9837-08e321eec929_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_RuhrUniversitayBochumMember_c69c2d1f-c83c-4a63-8fec-183d1db7f848_terseLabel_en-US" xlink:label="lab_bngo_RuhrUniversitayBochumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ruhr-Universitay Bochum</link:label>
    <link:label id="lab_bngo_RuhrUniversitayBochumMember_label_en-US" xlink:label="lab_bngo_RuhrUniversitayBochumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ruhr-Universitay Bochum [Member]</link:label>
    <link:label id="lab_bngo_RuhrUniversitayBochumMember_documentation_en-US" xlink:label="lab_bngo_RuhrUniversitayBochumMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ruhr-Universitay Bochum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_RuhrUniversitayBochumMember" xlink:href="bngo-20210331.xsd#bngo_RuhrUniversitayBochumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_RuhrUniversitayBochumMember" xlink:to="lab_bngo_RuhrUniversitayBochumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_83d5543b-99ab-4e98-b9d2-2a91ef12e044_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4bf4fce3-b4ee-4370-90bb-5e9468ea7d13_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e88a5fcd-4fee-4b12-b3cf-41b61ccde420_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e0e45946-286d-4c56-8901-237803b6fe7f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_234abbd2-ad2c-45cb-8b92-6afbe78e0eba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of term fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dd976fd0-a899-4a9f-af79-a68b50c7bd57_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_c54f1529-d280-47bf-af3c-c71607e2e2e4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentPrepaymentFeePercent_384daca3-e86b-4c4c-8c5e-f142ce06a996_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentPrepaymentFeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee percentage</link:label>
    <link:label id="lab_bngo_DebtInstrumentPrepaymentFeePercent_label_en-US" xlink:label="lab_bngo_DebtInstrumentPrepaymentFeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Fee Percent</link:label>
    <link:label id="lab_bngo_DebtInstrumentPrepaymentFeePercent_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentPrepaymentFeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument prepayment fee percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPrepaymentFeePercent" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPrepaymentFeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentPrepaymentFeePercent" xlink:to="lab_bngo_DebtInstrumentPrepaymentFeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ba0d33a9-5707-49b3-9388-68f564e1d761_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facility available</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_08c159fd-8774-42d2-ad43-9c895e145977_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_SaleOfStockValueSharesIssuedInTransaction_7d2fb89d-5fcf-4833-9bbe-7a846016b156_terseLabel_en-US" xlink:label="lab_bngo_SaleOfStockValueSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering price</link:label>
    <link:label id="lab_bngo_SaleOfStockValueSharesIssuedInTransaction_label_en-US" xlink:label="lab_bngo_SaleOfStockValueSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Value, Shares Issued in Transaction</link:label>
    <link:label id="lab_bngo_SaleOfStockValueSharesIssuedInTransaction_documentation_en-US" xlink:label="lab_bngo_SaleOfStockValueSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Value, Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SaleOfStockValueSharesIssuedInTransaction" xlink:href="bngo-20210331.xsd#bngo_SaleOfStockValueSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_SaleOfStockValueSharesIssuedInTransaction" xlink:to="lab_bngo_SaleOfStockValueSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_af905bb9-359c-47d2-9ecc-a2ad7e1016ab_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_72ba9c6f-d3c7-4a11-9164-62ac18b20bae_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_b14b7f35-3dd6-4959-a2ce-055fa24c8dfa_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfOtherDebt_648c21d9-2032-4ccc-bf93-531d46a1482d_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to satisfy outstanding principal and accrued interest amounts</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfOtherDebt_81aec017-d3cb-4653-874f-54c3b85208ca_verboseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash transferred for repayment of Lineage PPP Loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfOtherDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Other Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfOtherDebt" xlink:to="lab_us-gaap_RepaymentsOfOtherDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2957a803-0dd8-4f95-bb22-31d43290bf9c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_3cf56e1b-2041-4cd5-835e-f11f054d2a3e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_f0ae453f-952e-4728-91b6-8e1b8d177f22_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_eb90259e-d934-4f93-86a8-821a28f99bf2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_704dfe38-56b5-4968-9e01-395ab9ad521b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_acacb383-0cce-49e5-b837-0c430bb9b888_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84f5fc65-7205-4b6c-952e-834a2137ea59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentInterestRateDiscountedCashRate_188ce5d9-7aca-4f05-a8e6-d0946cc25e33_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentInterestRateDiscountedCashRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted cash rate</link:label>
    <link:label id="lab_bngo_DebtInstrumentInterestRateDiscountedCashRate_label_en-US" xlink:label="lab_bngo_DebtInstrumentInterestRateDiscountedCashRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Discounted Cash Rate</link:label>
    <link:label id="lab_bngo_DebtInstrumentInterestRateDiscountedCashRate_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentInterestRateDiscountedCashRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Discounted Cash Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentInterestRateDiscountedCashRate" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentInterestRateDiscountedCashRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentInterestRateDiscountedCashRate" xlink:to="lab_bngo_DebtInstrumentInterestRateDiscountedCashRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_04d45bc4-d6ae-476b-85b8-112cc934e8c3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_550ca8ce-88fb-4c4f-80ce-e3aa0faa05ab_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_25d31058-a3f6-4f49-8cba-891c2d4cb983_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_2a5cacfe-65cd-480b-b005-1bf69f5206b9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_7e275026-edec-41c7-862f-96d66e50cf66_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d3989746-7372-4179-b892-4c0590c4a482_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued But Not Yet Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_d3f2ec5e-91ac-4629-9967-ef8df3161a3d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowing from line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_265dd293-6300-4a7d-acf8-6b99a7de781a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>bngo-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a7c25383-a88e-4d48-aec4-d74b76810e9c,g:60d85f31-0c17-478f-8e10-9a14108a4bee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://bionanogenomics.com/role/Cover" xlink:type="simple" xlink:href="bngo-20210331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c57673a9-39d6-475d-b48d-538ff85505a6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_1b5d661f-dd0f-4280-8e10-a7b002dd3c91" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c57673a9-39d6-475d-b48d-538ff85505a6" xlink:to="loc_dei_DocumentInformationTable_1b5d661f-dd0f-4280-8e10-a7b002dd3c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8ace505d-440d-4fad-a080-65e38cd7e40a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1b5d661f-dd0f-4280-8e10-a7b002dd3c91" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8ace505d-440d-4fad-a080-65e38cd7e40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f3dad4ae-fe8f-4462-9078-1ae54dc5c284" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8ace505d-440d-4fad-a080-65e38cd7e40a" xlink:to="loc_us-gaap_ClassOfStockDomain_f3dad4ae-fe8f-4462-9078-1ae54dc5c284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f7bbf1aa-bac1-4f0f-ba20-150b69f2350f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f3dad4ae-fe8f-4462-9078-1ae54dc5c284" xlink:to="loc_us-gaap_CommonStockMember_f7bbf1aa-bac1-4f0f-ba20-150b69f2350f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_dd8a16b8-1129-4937-8528-fc3d6b423947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f3dad4ae-fe8f-4462-9078-1ae54dc5c284" xlink:to="loc_us-gaap_WarrantMember_dd8a16b8-1129-4937-8528-fc3d6b423947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1b5d661f-dd0f-4280-8e10-a7b002dd3c91" xlink:to="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0897be5d-4230-4b10-b328-66f56811816c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_DocumentType_0897be5d-4230-4b10-b328-66f56811816c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_99b17140-b316-4694-947c-a8b23307c02b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_DocumentQuarterlyReport_99b17140-b316-4694-947c-a8b23307c02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a7709f52-4e68-4e49-aad0-47b09a326c77" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_DocumentPeriodEndDate_a7709f52-4e68-4e49-aad0-47b09a326c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_8a9b0e07-128f-40c3-817c-3a5fdd626a35" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_DocumentTransitionReport_8a9b0e07-128f-40c3-817c-3a5fdd626a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_263b79cb-d805-4736-abe2-494c517b2a96" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityFileNumber_263b79cb-d805-4736-abe2-494c517b2a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0eac242c-219d-49b7-a83a-b1fdca9e85f7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityRegistrantName_0eac242c-219d-49b7-a83a-b1fdca9e85f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_66cfb957-388d-437d-8dfc-ef684f329f70" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityIncorporationStateCountryCode_66cfb957-388d-437d-8dfc-ef684f329f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ad21dcec-8de6-4d3b-814a-4c4c788811ee" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityTaxIdentificationNumber_ad21dcec-8de6-4d3b-814a-4c4c788811ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4bf37cf8-b23b-45d5-9826-15b0a73df560" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityAddressAddressLine1_4bf37cf8-b23b-45d5-9826-15b0a73df560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f1db83b7-399f-4d6f-92c9-a207e8057de2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityAddressCityOrTown_f1db83b7-399f-4d6f-92c9-a207e8057de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_603fe52c-ea29-46f5-98d3-a48f99308bf1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityAddressStateOrProvince_603fe52c-ea29-46f5-98d3-a48f99308bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_55af2fc2-67d7-423b-8e34-3a296d28379d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityAddressPostalZipCode_55af2fc2-67d7-423b-8e34-3a296d28379d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_11eb1aa0-28e3-4bc4-8e0b-78359a2f1430" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_CityAreaCode_11eb1aa0-28e3-4bc4-8e0b-78359a2f1430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d3a7a011-282f-4883-9616-531c03ecb9d8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_LocalPhoneNumber_d3a7a011-282f-4883-9616-531c03ecb9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_123baaca-d586-4dff-b0da-215bd35434c2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_Security12bTitle_123baaca-d586-4dff-b0da-215bd35434c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7b456a87-dc4a-4b8e-884a-41286b290c20" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_TradingSymbol_7b456a87-dc4a-4b8e-884a-41286b290c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d7348a83-3e8e-438f-9cc1-ef0ff2694e83" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_SecurityExchangeName_d7348a83-3e8e-438f-9cc1-ef0ff2694e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_bbb669dc-2a75-479f-9ffc-6829b5d18f7a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityCurrentReportingStatus_bbb669dc-2a75-479f-9ffc-6829b5d18f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f74b2683-c400-4126-9bab-1453db173dd1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityInteractiveDataCurrent_f74b2683-c400-4126-9bab-1453db173dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_34605658-da79-4624-b8a3-b608d968cc23" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityFilerCategory_34605658-da79-4624-b8a3-b608d968cc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1e293bb8-19da-4e5f-ac2e-e6898a5ed18f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntitySmallBusiness_1e293bb8-19da-4e5f-ac2e-e6898a5ed18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_740a60a4-3124-4582-9eb7-dac1537cf0fd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityEmergingGrowthCompany_740a60a4-3124-4582-9eb7-dac1537cf0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_f3b11af3-8ff9-433a-944e-9c6878f4af19" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityExTransitionPeriod_f3b11af3-8ff9-433a-944e-9c6878f4af19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d621c8fc-d570-4734-8425-a602e3072b9c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityShellCompany_d621c8fc-d570-4734-8425-a602e3072b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_950959f1-22cd-4105-aeef-62209c151d4c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_950959f1-22cd-4105-aeef-62209c151d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_489f4bff-3e51-4555-8ed1-4b0fce033cf9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_AmendmentFlag_489f4bff-3e51-4555-8ed1-4b0fce033cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_bcd44efa-1c32-4df0-957d-b62cd1b798db" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_DocumentFiscalYearFocus_bcd44efa-1c32-4df0-957d-b62cd1b798db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9e007ea6-bc92-4e17-a544-e620783c5907" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9e007ea6-bc92-4e17-a544-e620783c5907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e510934f-b3b3-4894-9a39-85628d55e9aa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_EntityCentralIndexKey_e510934f-b3b3-4894-9a39-85628d55e9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d026c8a7-1bd3-4a30-a41f-33efe58c193d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f039c796-5128-4092-a4c1-ad518bf63603" xlink:to="loc_dei_CurrentFiscalYearEndDate_d026c8a7-1bd3-4a30-a41f-33efe58c193d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="bngo-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d340e185-7983-4a4b-8fa2-d9f25408c0c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_fb8f6781-ce7c-40e1-8baa-4dc2053d35f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d340e185-7983-4a4b-8fa2-d9f25408c0c2" xlink:to="loc_us-gaap_AssetsAbstract_fb8f6781-ce7c-40e1-8baa-4dc2053d35f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2a5dc059-4036-44eb-a34c-aa3d8a22ce30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb8f6781-ce7c-40e1-8baa-4dc2053d35f2" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2a5dc059-4036-44eb-a34c-aa3d8a22ce30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b5c6d395-5cbb-4bb9-b378-cc219fd59a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2a5dc059-4036-44eb-a34c-aa3d8a22ce30" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b5c6d395-5cbb-4bb9-b378-cc219fd59a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b0259747-d9e1-470b-826e-af90cd06aaa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2a5dc059-4036-44eb-a34c-aa3d8a22ce30" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b0259747-d9e1-470b-826e-af90cd06aaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f59f8374-9970-44df-9b1e-54726b00ffd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2a5dc059-4036-44eb-a34c-aa3d8a22ce30" xlink:to="loc_us-gaap_InventoryNet_f59f8374-9970-44df-9b1e-54726b00ffd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_14cfc726-d90f-428c-bc37-6d3585cbc2f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2a5dc059-4036-44eb-a34c-aa3d8a22ce30" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_14cfc726-d90f-428c-bc37-6d3585cbc2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f76379bd-c0f1-4975-8b99-ba296d31cf5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2a5dc059-4036-44eb-a34c-aa3d8a22ce30" xlink:to="loc_us-gaap_AssetsCurrent_f76379bd-c0f1-4975-8b99-ba296d31cf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_08cadf39-a4bc-4e9c-b0b8-37e7d26c8bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb8f6781-ce7c-40e1-8baa-4dc2053d35f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_08cadf39-a4bc-4e9c-b0b8-37e7d26c8bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_30e7bf64-b656-4d46-a090-80fb592d4c2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb8f6781-ce7c-40e1-8baa-4dc2053d35f2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_30e7bf64-b656-4d46-a090-80fb592d4c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7a4cb1e7-aa77-46f4-9c9e-80f40c0b4dfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb8f6781-ce7c-40e1-8baa-4dc2053d35f2" xlink:to="loc_us-gaap_Goodwill_7a4cb1e7-aa77-46f4-9c9e-80f40c0b4dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6353bd65-f0db-4892-b9c5-dd5dbf55a64d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb8f6781-ce7c-40e1-8baa-4dc2053d35f2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6353bd65-f0db-4892-b9c5-dd5dbf55a64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_501b457b-475e-4c6d-85f4-983b6cde47f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb8f6781-ce7c-40e1-8baa-4dc2053d35f2" xlink:to="loc_us-gaap_Assets_501b457b-475e-4c6d-85f4-983b6cde47f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5102d3da-06da-4fce-86ca-341e68b527af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d340e185-7983-4a4b-8fa2-d9f25408c0c2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5102d3da-06da-4fce-86ca-341e68b527af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_605fde1f-12fa-4f7b-acb6-a1e62e755b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5102d3da-06da-4fce-86ca-341e68b527af" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_605fde1f-12fa-4f7b-acb6-a1e62e755b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f461a457-d8d7-49fa-b787-c4e3835f73fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_605fde1f-12fa-4f7b-acb6-a1e62e755b9b" xlink:to="loc_us-gaap_AccountsPayableCurrent_f461a457-d8d7-49fa-b787-c4e3835f73fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_caca38df-15a8-4a5a-9c61-6766416a9576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_605fde1f-12fa-4f7b-acb6-a1e62e755b9b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_caca38df-15a8-4a5a-9c61-6766416a9576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b5622f59-2437-473d-94cf-7a30d2ed19ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_605fde1f-12fa-4f7b-acb6-a1e62e755b9b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b5622f59-2437-473d-94cf-7a30d2ed19ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_62c907d9-c177-46bd-9fb6-965efabd8b89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_605fde1f-12fa-4f7b-acb6-a1e62e755b9b" xlink:to="loc_us-gaap_LiabilitiesCurrent_62c907d9-c177-46bd-9fb6-965efabd8b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3877984a-ac76-4e33-9561-3a2d2bb6a3ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5102d3da-06da-4fce-86ca-341e68b527af" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3877984a-ac76-4e33-9561-3a2d2bb6a3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d70fc56a-1ee1-4e50-9c57-c60bccdb3e82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5102d3da-06da-4fce-86ca-341e68b527af" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d70fc56a-1ee1-4e50-9c57-c60bccdb3e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ce61554e-29b9-42dd-9250-478b77093abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5102d3da-06da-4fce-86ca-341e68b527af" xlink:to="loc_us-gaap_Liabilities_ce61554e-29b9-42dd-9250-478b77093abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7836cfb9-9777-4a96-97e6-a3f26a227f2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5102d3da-06da-4fce-86ca-341e68b527af" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7836cfb9-9777-4a96-97e6-a3f26a227f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_b61b123d-ab9c-4372-bf88-1d243fd2ba26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5102d3da-06da-4fce-86ca-341e68b527af" xlink:to="loc_us-gaap_StockholdersEquityAbstract_b61b123d-ab9c-4372-bf88-1d243fd2ba26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d226371e-8573-4773-86f9-221cf7e946eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b61b123d-ab9c-4372-bf88-1d243fd2ba26" xlink:to="loc_us-gaap_CommonStockValue_d226371e-8573-4773-86f9-221cf7e946eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_fd76b67c-75e1-4a9c-b203-e2f72dc5ce09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b61b123d-ab9c-4372-bf88-1d243fd2ba26" xlink:to="loc_us-gaap_PreferredStockValue_fd76b67c-75e1-4a9c-b203-e2f72dc5ce09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_985b6128-8702-4eb5-a7ed-77904a1beb2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b61b123d-ab9c-4372-bf88-1d243fd2ba26" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_985b6128-8702-4eb5-a7ed-77904a1beb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28a22603-e45b-410d-9516-a279d265ecad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b61b123d-ab9c-4372-bf88-1d243fd2ba26" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28a22603-e45b-410d-9516-a279d265ecad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_367411db-82a7-460d-a075-18dba2e7f130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b61b123d-ab9c-4372-bf88-1d243fd2ba26" xlink:to="loc_us-gaap_StockholdersEquity_367411db-82a7-460d-a075-18dba2e7f130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_318f38c2-fe52-400b-b184-ecef849319d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5102d3da-06da-4fce-86ca-341e68b527af" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_318f38c2-fe52-400b-b184-ecef849319d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="bngo-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_eb06a4d0-b7d8-433b-aeb7-0d767c7681a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4064400e-aefe-4108-9cb0-27b38765c352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb06a4d0-b7d8-433b-aeb7-0d767c7681a1" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4064400e-aefe-4108-9cb0-27b38765c352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e960d27d-67a1-4e0e-80bb-1db9f305e121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb06a4d0-b7d8-433b-aeb7-0d767c7681a1" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e960d27d-67a1-4e0e-80bb-1db9f305e121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_91969f52-678f-43c0-b8b9-918837d6da98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb06a4d0-b7d8-433b-aeb7-0d767c7681a1" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_91969f52-678f-43c0-b8b9-918837d6da98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_098fbae8-e90e-4869-ae58-d044aa96a77b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb06a4d0-b7d8-433b-aeb7-0d767c7681a1" xlink:to="loc_us-gaap_PreferredStockSharesIssued_098fbae8-e90e-4869-ae58-d044aa96a77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ffb23cb6-828f-423a-aa54-aadd4b9be7da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb06a4d0-b7d8-433b-aeb7-0d767c7681a1" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ffb23cb6-828f-423a-aa54-aadd4b9be7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b4d16847-f958-415b-b211-b5d90a815554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb06a4d0-b7d8-433b-aeb7-0d767c7681a1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b4d16847-f958-415b-b211-b5d90a815554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_89823671-7fe4-499e-b9e4-5f0331d82938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb06a4d0-b7d8-433b-aeb7-0d767c7681a1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_89823671-7fe4-499e-b9e4-5f0331d82938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b87c51c2-db49-46f2-b801-603b6a38e0de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb06a4d0-b7d8-433b-aeb7-0d767c7681a1" xlink:to="loc_us-gaap_CommonStockSharesIssued_b87c51c2-db49-46f2-b801-603b6a38e0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5ba11278-89e7-496e-988c-5c352442295e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb06a4d0-b7d8-433b-aeb7-0d767c7681a1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5ba11278-89e7-496e-988c-5c352442295e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="bngo-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b01d0e63-60e7-466c-bc74-6897e58e1c5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5fc385b2-fcd3-4bb0-9437-a0bf45636d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b01d0e63-60e7-466c-bc74-6897e58e1c5d" xlink:to="loc_us-gaap_StatementTable_5fc385b2-fcd3-4bb0-9437-a0bf45636d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2e284fdb-320d-4067-8852-0ef120be5662" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5fc385b2-fcd3-4bb0-9437-a0bf45636d0f" xlink:to="loc_srt_ProductOrServiceAxis_2e284fdb-320d-4067-8852-0ef120be5662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1557232b-6ba8-4781-9c35-e50d452cac6a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2e284fdb-320d-4067-8852-0ef120be5662" xlink:to="loc_srt_ProductsAndServicesDomain_1557232b-6ba8-4781-9c35-e50d452cac6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_25df503e-c6fc-4b4d-96f3-5ceb2d00cad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1557232b-6ba8-4781-9c35-e50d452cac6a" xlink:to="loc_us-gaap_ProductMember_25df503e-c6fc-4b4d-96f3-5ceb2d00cad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_9e9fdb4a-cb2e-4a6b-8529-79e0953cae4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1557232b-6ba8-4781-9c35-e50d452cac6a" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_9e9fdb4a-cb2e-4a6b-8529-79e0953cae4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5fc385b2-fcd3-4bb0-9437-a0bf45636d0f" xlink:to="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_536cd330-0f2a-4a19-9460-f6ea17d32443" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_RevenuesAbstract_536cd330-0f2a-4a19-9460-f6ea17d32443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_58271d2d-084b-4da1-96ca-159ce596f90d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_536cd330-0f2a-4a19-9460-f6ea17d32443" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_58271d2d-084b-4da1-96ca-159ce596f90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_5b0bd550-e2df-466b-91eb-c20dffbae341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_CostOfRevenueAbstract_5b0bd550-e2df-466b-91eb-c20dffbae341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_45be8216-9b8c-4e63-a0a1-fe421b3dc9d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_5b0bd550-e2df-466b-91eb-c20dffbae341" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_45be8216-9b8c-4e63-a0a1-fe421b3dc9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_d4976f9e-31b3-495c-b074-eb19794bf0c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_d4976f9e-31b3-495c-b074-eb19794bf0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_33e472d0-015a-47c8-a89d-eac1931d4c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d4976f9e-31b3-495c-b074-eb19794bf0c3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_33e472d0-015a-47c8-a89d-eac1931d4c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_41ea3d4d-2307-49cd-8c49-efe44132259f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d4976f9e-31b3-495c-b074-eb19794bf0c3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_41ea3d4d-2307-49cd-8c49-efe44132259f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7ff48df1-8315-4c11-a8c5-94e496b0bc07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d4976f9e-31b3-495c-b074-eb19794bf0c3" xlink:to="loc_us-gaap_CostsAndExpenses_7ff48df1-8315-4c11-a8c5-94e496b0bc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6a179b68-3883-4e6d-a7ed-8c91b2e4953e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_OperatingIncomeLoss_6a179b68-3883-4e6d-a7ed-8c91b2e4953e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_921f9aef-fcbf-4f06-86a1-6dd80adfb395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_921f9aef-fcbf-4f06-86a1-6dd80adfb395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_cac25de5-77bd-4e6e-a82b-8e99495e76f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_921f9aef-fcbf-4f06-86a1-6dd80adfb395" xlink:to="loc_us-gaap_InterestExpense_cac25de5-77bd-4e6e-a82b-8e99495e76f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8a15b9c2-669c-433f-b323-f41ec8a87cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_921f9aef-fcbf-4f06-86a1-6dd80adfb395" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8a15b9c2-669c-433f-b323-f41ec8a87cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_871e5162-4d68-48c3-aa6c-3988e603fb07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_921f9aef-fcbf-4f06-86a1-6dd80adfb395" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_871e5162-4d68-48c3-aa6c-3988e603fb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e93a320d-486c-4eee-9b27-a1a6cf57cd4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_921f9aef-fcbf-4f06-86a1-6dd80adfb395" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e93a320d-486c-4eee-9b27-a1a6cf57cd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2a181cfc-7c36-49cf-99b5-049f3bd34fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2a181cfc-7c36-49cf-99b5-049f3bd34fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9eed50bf-b664-4a78-a04d-79a70bda13c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9eed50bf-b664-4a78-a04d-79a70bda13c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_be60448a-081f-421c-a803-b6d4e991c4d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_NetIncomeLoss_be60448a-081f-421c-a803-b6d4e991c4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_9c10dd22-5658-4d7f-a453-ee8d4fb2ffda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_9c10dd22-5658-4d7f-a453-ee8d4fb2ffda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e279c636-ab68-4f65-81ac-73a1dcc6b384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a9b2b29-b3cb-426a-b6c6-6b6f9eeac7cb" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e279c636-ab68-4f65-81ac-73a1dcc6b384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="simple" xlink:href="bngo-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_248223b5-62d1-4320-bf6f-94c1d009cf4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ac1ec1a0-e60c-4fb4-a07e-26a7b167ee9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_248223b5-62d1-4320-bf6f-94c1d009cf4b" xlink:to="loc_us-gaap_StatementTable_ac1ec1a0-e60c-4fb4-a07e-26a7b167ee9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fd4da404-82d8-4889-b697-ed20a47cfe46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ac1ec1a0-e60c-4fb4-a07e-26a7b167ee9d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fd4da404-82d8-4889-b697-ed20a47cfe46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_79369c6e-5e63-4651-8c4f-c33a58551ed7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fd4da404-82d8-4889-b697-ed20a47cfe46" xlink:to="loc_us-gaap_EquityComponentDomain_79369c6e-5e63-4651-8c4f-c33a58551ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_031ccbec-ad1d-4438-9af0-fa29f83fd1bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_79369c6e-5e63-4651-8c4f-c33a58551ed7" xlink:to="loc_us-gaap_CommonStockMember_031ccbec-ad1d-4438-9af0-fa29f83fd1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8d6f49a6-099d-4a33-963b-d3e31bbbd97f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_79369c6e-5e63-4651-8c4f-c33a58551ed7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8d6f49a6-099d-4a33-963b-d3e31bbbd97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a434f1f3-daea-42f5-9ef4-a4e338187218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_79369c6e-5e63-4651-8c4f-c33a58551ed7" xlink:to="loc_us-gaap_RetainedEarningsMember_a434f1f3-daea-42f5-9ef4-a4e338187218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1e4c092f-e9f8-4ab8-a0bf-9da8541e8146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ac1ec1a0-e60c-4fb4-a07e-26a7b167ee9d" xlink:to="loc_us-gaap_StatementLineItems_1e4c092f-e9f8-4ab8-a0bf-9da8541e8146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e4c092f-e9f8-4ab8-a0bf-9da8541e8146" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_95474f8a-a497-4989-986d-eaf59ded9a55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_us-gaap_SharesOutstanding_95474f8a-a497-4989-986d-eaf59ded9a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_850ee7bf-054e-4c1b-90de-9e2b564bc96f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_us-gaap_StockholdersEquity_850ee7bf-054e-4c1b-90de-9e2b564bc96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6edd93b7-3880-4791-9919-1f26ec157953" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6edd93b7-3880-4791-9919-1f26ec157953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_71852362-62f7-4bfb-9147-2f4b1f130986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_71852362-62f7-4bfb-9147-2f4b1f130986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3a1e4d00-8b2f-429b-8f3b-aa3dc424c25d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3a1e4d00-8b2f-429b-8f3b-aa3dc424c25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a5281668-dcee-4310-b37a-020afd3b92a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a5281668-dcee-4310-b37a-020afd3b92a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2da85979-7ae8-4fd6-88ce-cdb4b4b6c10d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2da85979-7ae8-4fd6-88ce-cdb4b4b6c10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedDuringPeriodSharesWarrantsExercised_160c060d-884b-4915-88d8-84998309aece" xlink:href="bngo-20210331.xsd#bngo_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_bngo_StockIssuedDuringPeriodSharesWarrantsExercised_160c060d-884b-4915-88d8-84998309aece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedDuringPeriodValueWarrantsExercised_c68a6076-9f07-4e59-b14b-a941235fc932" xlink:href="bngo-20210331.xsd#bngo_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_bngo_StockIssuedDuringPeriodValueWarrantsExercised_c68a6076-9f07-4e59-b14b-a941235fc932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_67b80008-916b-4a2f-96e9-6d98198e0b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_us-gaap_NetIncomeLoss_67b80008-916b-4a2f-96e9-6d98198e0b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_db55b1f8-c373-4591-9e78-b150730663bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_us-gaap_SharesOutstanding_db55b1f8-c373-4591-9e78-b150730663bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a70a9739-7613-466a-8081-d91c9da319b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_850a9026-13fb-4f5e-8c43-25aa456c1f75" xlink:to="loc_us-gaap_StockholdersEquity_a70a9739-7613-466a-8081-d91c9da319b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="bngo-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_346a5c7b-2b02-4dca-bb5b-c16c6707d377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_16ad16c9-3999-4814-a922-4ad7e8df4d93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_346a5c7b-2b02-4dca-bb5b-c16c6707d377" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_16ad16c9-3999-4814-a922-4ad7e8df4d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c98c9a1c-9d1e-4abd-ad92-dffb0caea94e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_16ad16c9-3999-4814-a922-4ad7e8df4d93" xlink:to="loc_us-gaap_NetIncomeLoss_c98c9a1c-9d1e-4abd-ad92-dffb0caea94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9edeb00e-416d-4b79-ae29-036744360038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_16ad16c9-3999-4814-a922-4ad7e8df4d93" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9edeb00e-416d-4b79-ae29-036744360038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_327d3f29-20c6-47d4-8d48-3f9f68c22b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9edeb00e-416d-4b79-ae29-036744360038" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_327d3f29-20c6-47d4-8d48-3f9f68c22b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_77cda002-95f2-4999-9257-006a63d25f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9edeb00e-416d-4b79-ae29-036744360038" xlink:to="loc_us-gaap_PaidInKindInterest_77cda002-95f2-4999-9257-006a63d25f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_75a2f404-f09e-42e1-ae91-511a28d10592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9edeb00e-416d-4b79-ae29-036744360038" xlink:to="loc_us-gaap_ShareBasedCompensation_75a2f404-f09e-42e1-ae91-511a28d10592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_840543fd-6fba-4819-b37c-fc7115998445" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9edeb00e-416d-4b79-ae29-036744360038" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_840543fd-6fba-4819-b37c-fc7115998445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fdd63e0b-e3cf-4800-84a2-5049bb1ebd15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9edeb00e-416d-4b79-ae29-036744360038" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fdd63e0b-e3cf-4800-84a2-5049bb1ebd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_631f735e-3c8a-4c52-9a0f-9596485cd77c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9edeb00e-416d-4b79-ae29-036744360038" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_631f735e-3c8a-4c52-9a0f-9596485cd77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e5be076b-eae4-486c-95d8-e8db5f7c0819" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_631f735e-3c8a-4c52-9a0f-9596485cd77c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e5be076b-eae4-486c-95d8-e8db5f7c0819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_71abfde4-793b-40dd-83f6-60a42a898a69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_631f735e-3c8a-4c52-9a0f-9596485cd77c" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_71abfde4-793b-40dd-83f6-60a42a898a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e0dcbbc2-3d4b-4f02-ac6f-b3c0a6cc4110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_631f735e-3c8a-4c52-9a0f-9596485cd77c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e0dcbbc2-3d4b-4f02-ac6f-b3c0a6cc4110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_45542844-e669-4549-837d-79564d3e75e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_631f735e-3c8a-4c52-9a0f-9596485cd77c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_45542844-e669-4549-837d-79564d3e75e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_7f5aa74e-0564-4978-a5ba-902a880735e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_631f735e-3c8a-4c52-9a0f-9596485cd77c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_7f5aa74e-0564-4978-a5ba-902a880735e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aac4a013-fcca-4720-a265-c388cacdec01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_16ad16c9-3999-4814-a922-4ad7e8df4d93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aac4a013-fcca-4720-a265-c388cacdec01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e0ec82d7-4755-429c-9605-5d1c740cd28f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_346a5c7b-2b02-4dca-bb5b-c16c6707d377" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e0ec82d7-4755-429c-9605-5d1c740cd28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4f70e67a-9720-4295-b105-8e8d22c183d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e0ec82d7-4755-429c-9605-5d1c740cd28f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4f70e67a-9720-4295-b105-8e8d22c183d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d8e9d59d-3bf3-4537-99a4-281b074a8ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e0ec82d7-4755-429c-9605-5d1c740cd28f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d8e9d59d-3bf3-4537-99a4-281b074a8ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2f81ffe6-ef21-4759-8af7-2d547c2c1e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_346a5c7b-2b02-4dca-bb5b-c16c6707d377" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2f81ffe6-ef21-4759-8af7-2d547c2c1e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_9089ab07-824f-480f-8d07-165c6d0a6c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2f81ffe6-ef21-4759-8af7-2d547c2c1e65" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_9089ab07-824f-480f-8d07-165c6d0a6c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_e29b63ab-6742-41ce-869f-5db97f2dea31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2f81ffe6-ef21-4759-8af7-2d547c2c1e65" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_e29b63ab-6742-41ce-869f-5db97f2dea31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_173ce804-dda2-4563-bd80-d615eed76826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2f81ffe6-ef21-4759-8af7-2d547c2c1e65" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_173ce804-dda2-4563-bd80-d615eed76826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1dcb96ff-77df-4a7f-9b96-51766b7dcd86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2f81ffe6-ef21-4759-8af7-2d547c2c1e65" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1dcb96ff-77df-4a7f-9b96-51766b7dcd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_00881290-1ea3-4bae-b31a-3d74ea178511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2f81ffe6-ef21-4759-8af7-2d547c2c1e65" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_00881290-1ea3-4bae-b31a-3d74ea178511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f37db24a-9407-41d4-84b6-4e07959d6536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2f81ffe6-ef21-4759-8af7-2d547c2c1e65" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f37db24a-9407-41d4-84b6-4e07959d6536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b6081aee-e164-4adc-beff-22631d819817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2f81ffe6-ef21-4759-8af7-2d547c2c1e65" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b6081aee-e164-4adc-beff-22631d819817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_48ac40e8-3205-49a9-a806-541f3925091e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_346a5c7b-2b02-4dca-bb5b-c16c6707d377" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_48ac40e8-3205-49a9-a806-541f3925091e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c286848c-d69c-4f92-b62a-348b228661a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_346a5c7b-2b02-4dca-bb5b-c16c6707d377" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c286848c-d69c-4f92-b62a-348b228661a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e0f54f05-1e56-4cb3-84f3-22084b78701a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_346a5c7b-2b02-4dca-bb5b-c16c6707d377" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e0f54f05-1e56-4cb3-84f3-22084b78701a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_a00e1269-9f21-438f-a00d-fe04178a780c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_346a5c7b-2b02-4dca-bb5b-c16c6707d377" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_a00e1269-9f21-438f-a00d-fe04178a780c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_47bb3c18-5404-4387-afe1-c72371a8b429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a00e1269-9f21-438f-a00d-fe04178a780c" xlink:to="loc_us-gaap_InterestPaidNet_47bb3c18-5404-4387-afe1-c72371a8b429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8e7ef4b8-2ef6-4774-9812-f7dd07d08ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_346a5c7b-2b02-4dca-bb5b-c16c6707d377" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8e7ef4b8-2ef6-4774-9812-f7dd07d08ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory_868d3091-efee-4644-8f4c-66553559b53b" xlink:href="bngo-20210331.xsd#bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8e7ef4b8-2ef6-4774-9812-f7dd07d08ed2" xlink:to="loc_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory_868d3091-efee-4644-8f4c-66553559b53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory_d37c4660-5e7e-4427-bec7-45c6981dbedd" xlink:href="bngo-20210331.xsd#bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8e7ef4b8-2ef6-4774-9812-f7dd07d08ed2" xlink:to="loc_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory_d37c4660-5e7e-4427-bec7-45c6981dbedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_OfferingCostsIncurredNotYetPaid_2182a834-a7f9-4a04-8293-007c315ab9ac" xlink:href="bngo-20210331.xsd#bngo_OfferingCostsIncurredNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8e7ef4b8-2ef6-4774-9812-f7dd07d08ed2" xlink:to="loc_bngo_OfferingCostsIncurredNotYetPaid_2182a834-a7f9-4a04-8293-007c315ab9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_WarrantExerciseNonCash_ae90f0bf-cecf-4253-a9b5-ea24dfa624f6" xlink:href="bngo-20210331.xsd#bngo_WarrantExerciseNonCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8e7ef4b8-2ef6-4774-9812-f7dd07d08ed2" xlink:to="loc_bngo_WarrantExerciseNonCash_ae90f0bf-cecf-4253-a9b5-ea24dfa624f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="bngo-20210331.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f550288f-c68a-49ae-8479-b2172653b1b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b5028c49-3021-45ba-ba4b-0df1b3807921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f550288f-c68a-49ae-8479-b2172653b1b2" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b5028c49-3021-45ba-ba4b-0df1b3807921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="bngo-20210331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2b689f0c-32c1-4691-b699-e125a358501e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6147ef64-dc30-4cb5-90dd-d37db96f48ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2b689f0c-32c1-4691-b699-e125a358501e" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6147ef64-dc30-4cb5-90dd-d37db96f48ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LiquidityPolicyTextBlock_bba023d3-e63c-4cc5-b204-188689a3d62a" xlink:href="bngo-20210331.xsd#bngo_LiquidityPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2b689f0c-32c1-4691-b699-e125a358501e" xlink:to="loc_bngo_LiquidityPolicyTextBlock_bba023d3-e63c-4cc5-b204-188689a3d62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c136b623-0647-48f9-8ccf-288709f68265" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2b689f0c-32c1-4691-b699-e125a358501e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c136b623-0647-48f9-8ccf-288709f68265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_d987f1a3-a03c-49de-a4db-7cd23f034b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2b689f0c-32c1-4691-b699-e125a358501e" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_d987f1a3-a03c-49de-a4db-7cd23f034b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f12d283-6c8a-4578-9796-0c47243f4a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_751944d7-1902-439c-8a1a-37de2bceb920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f12d283-6c8a-4578-9796-0c47243f4a39" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_751944d7-1902-439c-8a1a-37de2bceb920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_WorkingCapital_c3762921-ecdc-4abc-a88a-ce39c6630999" xlink:href="bngo-20210331.xsd#bngo_WorkingCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f12d283-6c8a-4578-9796-0c47243f4a39" xlink:to="loc_bngo_WorkingCapital_c3762921-ecdc-4abc-a88a-ce39c6630999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d78a669c-75d6-44c6-aada-168540759b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f12d283-6c8a-4578-9796-0c47243f4a39" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d78a669c-75d6-44c6-aada-168540759b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ddfb29fa-8212-4159-bc17-a8dde93cf827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d78a669c-75d6-44c6-aada-168540759b6e" xlink:to="loc_us-gaap_CreditFacilityAxis_ddfb29fa-8212-4159-bc17-a8dde93cf827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4afb237c-6baa-4931-a31d-6da862dd4d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_ddfb29fa-8212-4159-bc17-a8dde93cf827" xlink:to="loc_us-gaap_CreditFacilityDomain_4afb237c-6baa-4931-a31d-6da862dd4d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_3aeac0e6-e794-4a5e-b573-dc633f8c9ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_4afb237c-6baa-4931-a31d-6da862dd4d5a" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_3aeac0e6-e794-4a5e-b573-dc633f8c9ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_f5903846-24dc-43d5-acb7-8d8ba48169a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d78a669c-75d6-44c6-aada-168540759b6e" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_f5903846-24dc-43d5-acb7-8d8ba48169a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_eefa9a1b-c2d2-44bc-bef8-94e2b2f1f867" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_f5903846-24dc-43d5-acb7-8d8ba48169a8" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_eefa9a1b-c2d2-44bc-bef8-94e2b2f1f867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InnovatusLSAMember_df735419-ae7b-4dd2-bfb4-475ec2321e04" xlink:href="bngo-20210331.xsd#bngo_InnovatusLSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_eefa9a1b-c2d2-44bc-bef8-94e2b2f1f867" xlink:to="loc_bngo_InnovatusLSAMember_df735419-ae7b-4dd2-bfb4-475ec2321e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2bfcb296-bbcd-4001-8638-f1373d4ceb29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d78a669c-75d6-44c6-aada-168540759b6e" xlink:to="loc_us-gaap_ClassOfStockLineItems_2bfcb296-bbcd-4001-8638-f1373d4ceb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8dc8d681-19d4-4d9d-8f9f-469a7e391de3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2bfcb296-bbcd-4001-8638-f1373d4ceb29" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8dc8d681-19d4-4d9d-8f9f-469a7e391de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f4ccb0f1-1034-43b8-b897-ea5cd1ad703b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2bfcb296-bbcd-4001-8638-f1373d4ceb29" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f4ccb0f1-1034-43b8-b897-ea5cd1ad703b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/NetLossPerShare" xlink:type="simple" xlink:href="bngo-20210331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5e760a16-bc26-4b91-96a5-41bf0d8386a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_47d53e80-c092-4d74-bbb5-233ced034d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5e760a16-bc26-4b91-96a5-41bf0d8386a5" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_47d53e80-c092-4d74-bbb5-233ced034d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="bngo-20210331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a100e5c4-3f67-44e2-a195-c70abfb243d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_066f5972-728a-46e6-bc95-76e2cc029e78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a100e5c4-3f67-44e2-a195-c70abfb243d6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_066f5972-728a-46e6-bc95-76e2cc029e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#NetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/NetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5ddb05a4-eceb-42f5-b369-50e0302a8f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_99384fa9-0abe-4abc-9aaa-dea7e85b33cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5ddb05a4-eceb-42f5-b369-50e0302a8f6f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_99384fa9-0abe-4abc-9aaa-dea7e85b33cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a81df0a-a451-4aba-993b-243b2ddb1024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_99384fa9-0abe-4abc-9aaa-dea7e85b33cd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a81df0a-a451-4aba-993b-243b2ddb1024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_606647b1-d340-401d-ae61-da6d487f90e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a81df0a-a451-4aba-993b-243b2ddb1024" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_606647b1-d340-401d-ae61-da6d487f90e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_44c05be0-9dfb-40ac-a801-aa69167b5346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_606647b1-d340-401d-ae61-da6d487f90e1" xlink:to="loc_us-gaap_StockOptionMember_44c05be0-9dfb-40ac-a801-aa69167b5346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonWarrantsMember_ea3794a7-bf2b-44fd-8dd6-d94e339dbde8" xlink:href="bngo-20210331.xsd#bngo_CommonWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_606647b1-d340-401d-ae61-da6d487f90e1" xlink:to="loc_bngo_CommonWarrantsMember_ea3794a7-bf2b-44fd-8dd6-d94e339dbde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e568daf2-0983-4454-a972-0fb429872010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_99384fa9-0abe-4abc-9aaa-dea7e85b33cd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e568daf2-0983-4454-a972-0fb429872010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3bb0e225-a039-4965-9bdf-e4ddd5af5374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e568daf2-0983-4454-a972-0fb429872010" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3bb0e225-a039-4965-9bdf-e4ddd5af5374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognition" xlink:type="simple" xlink:href="bngo-20210331.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4c40275a-e565-421f-88f4-382aa9b846ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_906a5a05-1128-4043-aa2c-5aa0263d4e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4c40275a-e565-421f-88f4-382aa9b846ef" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_906a5a05-1128-4043-aa2c-5aa0263d4e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="bngo-20210331.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7b765cca-1447-4bd0-9c52-de9a29b58f3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_54472ede-da3e-4e6b-8e4b-51736b921b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7b765cca-1447-4bd0-9c52-de9a29b58f3b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_54472ede-da3e-4e6b-8e4b-51736b921b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#RevenueRecognitionRevenuebySourceandGeographicLocationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a671e414-50fc-4ceb-b15e-553f28ed8c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e33c4a18-3927-45ce-83b5-53eb419e7df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a671e414-50fc-4ceb-b15e-553f28ed8c7d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e33c4a18-3927-45ce-83b5-53eb419e7df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d72c1f5a-d288-4ac9-92be-c4ad7b4b9cf8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e33c4a18-3927-45ce-83b5-53eb419e7df6" xlink:to="loc_srt_ProductOrServiceAxis_d72c1f5a-d288-4ac9-92be-c4ad7b4b9cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_afb5071a-a4a3-483e-a1c8-1c721b830d06" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d72c1f5a-d288-4ac9-92be-c4ad7b4b9cf8" xlink:to="loc_srt_ProductsAndServicesDomain_afb5071a-a4a3-483e-a1c8-1c721b830d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InstrumentRevenueMember_c6a625fc-0792-49ba-b1c9-2a71ff46d6a8" xlink:href="bngo-20210331.xsd#bngo_InstrumentRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_afb5071a-a4a3-483e-a1c8-1c721b830d06" xlink:to="loc_bngo_InstrumentRevenueMember_c6a625fc-0792-49ba-b1c9-2a71ff46d6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ConsumableRevenueMember_9422302d-1966-49c4-8f8e-eceedc8a844f" xlink:href="bngo-20210331.xsd#bngo_ConsumableRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_afb5071a-a4a3-483e-a1c8-1c721b830d06" xlink:to="loc_bngo_ConsumableRevenueMember_9422302d-1966-49c4-8f8e-eceedc8a844f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_aa74ed97-59f8-4117-b2d7-262797f904af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_afb5071a-a4a3-483e-a1c8-1c721b830d06" xlink:to="loc_us-gaap_ProductMember_aa74ed97-59f8-4117-b2d7-262797f904af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_10961cda-5017-4e9f-85f5-3a1bd572a700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_afb5071a-a4a3-483e-a1c8-1c721b830d06" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_10961cda-5017-4e9f-85f5-3a1bd572a700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0c6c56a0-77af-4ffc-aea0-882ca0d5fb97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e33c4a18-3927-45ce-83b5-53eb419e7df6" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0c6c56a0-77af-4ffc-aea0-882ca0d5fb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dafac91f-15d2-47aa-a695-8b26fd061a78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0c6c56a0-77af-4ffc-aea0-882ca0d5fb97" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dafac91f-15d2-47aa-a695-8b26fd061a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_cc716b82-3939-488b-be00-589b45691062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dafac91f-15d2-47aa-a695-8b26fd061a78" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_cc716b82-3939-488b-be00-589b45691062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e4809c28-3403-47bf-b737-5bb4e1ea3abf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e33c4a18-3927-45ce-83b5-53eb419e7df6" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e4809c28-3403-47bf-b737-5bb4e1ea3abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c14d0796-a14a-4678-8a5f-b5cd6ed17487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e4809c28-3403-47bf-b737-5bb4e1ea3abf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c14d0796-a14a-4678-8a5f-b5cd6ed17487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_ec541026-1ac4-4ccf-892a-3b2ee26ba4d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c14d0796-a14a-4678-8a5f-b5cd6ed17487" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_ec541026-1ac4-4ccf-892a-3b2ee26ba4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a96f0820-b55d-4270-b45f-8faaa8b9222d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e33c4a18-3927-45ce-83b5-53eb419e7df6" xlink:to="loc_srt_StatementGeographicalAxis_a96f0820-b55d-4270-b45f-8faaa8b9222d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c74d885e-5fee-418e-8719-6045a0a5ab59" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a96f0820-b55d-4270-b45f-8faaa8b9222d" xlink:to="loc_srt_SegmentGeographicalDomain_c74d885e-5fee-418e-8719-6045a0a5ab59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_ddbe603d-3ad5-4da6-af21-0aa5894d0796" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NorthAmericaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c74d885e-5fee-418e-8719-6045a0a5ab59" xlink:to="loc_srt_NorthAmericaMember_ddbe603d-3ad5-4da6-af21-0aa5894d0796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_3fb27696-ccef-4509-96b3-f394dfabfdbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c74d885e-5fee-418e-8719-6045a0a5ab59" xlink:to="loc_us-gaap_EMEAMember_3fb27696-ccef-4509-96b3-f394dfabfdbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_974a7d50-a3fb-4c7e-bec4-f94902ccc82f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c74d885e-5fee-418e-8719-6045a0a5ab59" xlink:to="loc_srt_AsiaPacificMember_974a7d50-a3fb-4c7e-bec4-f94902ccc82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c30a6f97-559b-41e1-8cce-a82d66008d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e33c4a18-3927-45ce-83b5-53eb419e7df6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_c30a6f97-559b-41e1-8cce-a82d66008d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_407beb03-e904-4a19-95cf-64a49e49f962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c30a6f97-559b-41e1-8cce-a82d66008d66" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_407beb03-e904-4a19-95cf-64a49e49f962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_546c6319-a8a4-4e51-a0ef-8a8bc5bf1ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c30a6f97-559b-41e1-8cce-a82d66008d66" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_546c6319-a8a4-4e51-a0ef-8a8bc5bf1ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b2c60bae-fb67-4d70-bb93-e794aadf0e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_85ad0b9c-42dd-45f7-980a-6689dc6a8aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b2c60bae-fb67-4d70-bb93-e794aadf0e1d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_85ad0b9c-42dd-45f7-980a-6689dc6a8aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5f06300e-c468-4108-93e9-621983eed5ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_85ad0b9c-42dd-45f7-980a-6689dc6a8aca" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5f06300e-c468-4108-93e9-621983eed5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_104d4368-0178-4750-b5df-e770cbe63ace" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5f06300e-c468-4108-93e9-621983eed5ca" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_104d4368-0178-4750-b5df-e770cbe63ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_1fc5d1b5-3e37-41f0-9cda-f164e7321204" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_104d4368-0178-4750-b5df-e770cbe63ace" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_1fc5d1b5-3e37-41f0-9cda-f164e7321204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_575cb190-e330-47f1-9eb7-ca3f65c37a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_85ad0b9c-42dd-45f7-980a-6689dc6a8aca" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_575cb190-e330-47f1-9eb7-ca3f65c37a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6494a06f-a550-4747-a197-a11b4ef9131b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_575cb190-e330-47f1-9eb7-ca3f65c37a3e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6494a06f-a550-4747-a197-a11b4ef9131b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_b513134d-1cf2-481a-b47c-e28fc3a733ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6494a06f-a550-4747-a197-a11b4ef9131b" xlink:to="loc_us-gaap_SalesRevenueNetMember_b513134d-1cf2-481a-b47c-e28fc3a733ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_224f8e10-979f-4eff-a907-3ae1ec4b94f3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_85ad0b9c-42dd-45f7-980a-6689dc6a8aca" xlink:to="loc_srt_StatementGeographicalAxis_224f8e10-979f-4eff-a907-3ae1ec4b94f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8c71724e-c577-4175-b488-d9d79f8a63d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_224f8e10-979f-4eff-a907-3ae1ec4b94f3" xlink:to="loc_srt_SegmentGeographicalDomain_8c71724e-c577-4175-b488-d9d79f8a63d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9941d9f5-9869-468d-b83f-a25150d7fa72" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c71724e-c577-4175-b488-d9d79f8a63d3" xlink:to="loc_country_US_9941d9f5-9869-468d-b83f-a25150d7fa72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3741643a-21d0-4049-a7b4-1a8908c02e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_85ad0b9c-42dd-45f7-980a-6689dc6a8aca" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3741643a-21d0-4049-a7b4-1a8908c02e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b8134c26-493f-425e-afb6-789e92302d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3741643a-21d0-4049-a7b4-1a8908c02e7b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b8134c26-493f-425e-afb6-789e92302d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#RevenueRecognitionRemainingPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cb9af9de-706e-4de6-be1a-4a1374e5d736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d6125dd5-379c-47d4-a985-e9b886ea0417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cb9af9de-706e-4de6-be1a-4a1374e5d736" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d6125dd5-379c-47d4-a985-e9b886ea0417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_213cde56-dbbc-46ae-ab6e-b0abd44445bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d6125dd5-379c-47d4-a985-e9b886ea0417" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_213cde56-dbbc-46ae-ab6e-b0abd44445bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_c7bff6a2-ab8f-41db-8b07-49bfa6043f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d6125dd5-379c-47d4-a985-e9b886ea0417" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_c7bff6a2-ab8f-41db-8b07-49bfa6043f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6fe41029-446b-425f-b428-89c5c24627bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_c7bff6a2-ab8f-41db-8b07-49bfa6043f01" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6fe41029-446b-425f-b428-89c5c24627bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_615b79af-1500-4b2c-9cfd-bf0cbc2a7f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_c7bff6a2-ab8f-41db-8b07-49bfa6043f01" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_615b79af-1500-4b2c-9cfd-bf0cbc2a7f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_11836223-2bc8-4fde-bc0c-e675db17cd3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_c7bff6a2-ab8f-41db-8b07-49bfa6043f01" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_11836223-2bc8-4fde-bc0c-e675db17cd3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_82a935e9-d3a7-4a5d-91f7-4e9f46b95155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_c7bff6a2-ab8f-41db-8b07-49bfa6043f01" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_82a935e9-d3a7-4a5d-91f7-4e9f46b95155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="bngo-20210331.xsd#RevenueRecognitionRemainingPerformanceObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#BalanceSheetAccountDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_10026bca-59a4-41ad-908d-e255bd033650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_6eaf777e-38a1-4c3f-8b2a-e8890140c01e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_10026bca-59a4-41ad-908d-e255bd033650" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_6eaf777e-38a1-4c3f-8b2a-e8890140c01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables" xlink:type="simple" xlink:href="bngo-20210331.xsd#BalanceSheetAccountDetailsTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad81243d-6c86-44b2-b906-a70358f402cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_06fa25e0-117d-4aee-b4c6-e981b002c24f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad81243d-6c86-44b2-b906-a70358f402cd" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_06fa25e0-117d-4aee-b4c6-e981b002c24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_2e741fbb-2378-43ef-b906-ec873d1c410c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad81243d-6c86-44b2-b906-a70358f402cd" xlink:to="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_2e741fbb-2378-43ef-b906-ec873d1c410c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_541a8cab-d5b8-42b5-a0fd-f920e240f558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_fd09c9e3-00db-4c8b-a9a6-0e66bacf273d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_541a8cab-d5b8-42b5-a0fd-f920e240f558" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_fd09c9e3-00db-4c8b-a9a6-0e66bacf273d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7955fde4-2cea-431a-aafe-9cefd6e4919e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_541a8cab-d5b8-42b5-a0fd-f920e240f558" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7955fde4-2cea-431a-aafe-9cefd6e4919e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_88fc6ca6-faa4-42e1-8a72-ec58d18a8da6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_541a8cab-d5b8-42b5-a0fd-f920e240f558" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_88fc6ca6-faa4-42e1-8a72-ec58d18a8da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#BalanceSheetAccountDetailsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7dce033c-a9db-49aa-9245-b6fc4fa71ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_964a3750-d608-4ba0-8d6b-501d4e215057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7dce033c-a9db-49aa-9245-b6fc4fa71ee6" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_964a3750-d608-4ba0-8d6b-501d4e215057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_92c30c0f-f7eb-4dd2-a97d-168879306898" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_964a3750-d608-4ba0-8d6b-501d4e215057" xlink:to="loc_srt_MajorCustomersAxis_92c30c0f-f7eb-4dd2-a97d-168879306898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3977623f-d201-4178-994c-7a7d7445b6c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_92c30c0f-f7eb-4dd2-a97d-168879306898" xlink:to="loc_srt_NameOfMajorCustomerDomain_3977623f-d201-4178-994c-7a7d7445b6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_RuhrUniversitayBochumMember_01f34b16-7b50-4410-ac56-8ce7183f531f" xlink:href="bngo-20210331.xsd#bngo_RuhrUniversitayBochumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3977623f-d201-4178-994c-7a7d7445b6c1" xlink:to="loc_bngo_RuhrUniversitayBochumMember_01f34b16-7b50-4410-ac56-8ce7183f531f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_IlluminaMember_e93e6312-1550-4ff6-96b5-741e9bba0572" xlink:href="bngo-20210331.xsd#bngo_IlluminaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3977623f-d201-4178-994c-7a7d7445b6c1" xlink:to="loc_bngo_IlluminaMember_e93e6312-1550-4ff6-96b5-741e9bba0572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_QuestDiagnositcsMember_18efd066-afeb-4ea9-8e9b-2db66c73cfcd" xlink:href="bngo-20210331.xsd#bngo_QuestDiagnositcsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3977623f-d201-4178-994c-7a7d7445b6c1" xlink:to="loc_bngo_QuestDiagnositcsMember_18efd066-afeb-4ea9-8e9b-2db66c73cfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_bb206135-bb60-4345-ae5e-010f287ac395" xlink:href="bngo-20210331.xsd#bngo_LineagenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3977623f-d201-4178-994c-7a7d7445b6c1" xlink:to="loc_bngo_LineagenMember_bb206135-bb60-4345-ae5e-010f287ac395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bd084fca-981e-4619-989d-e9cfdaa107d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_964a3750-d608-4ba0-8d6b-501d4e215057" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bd084fca-981e-4619-989d-e9cfdaa107d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_875a88a7-0c73-4c27-8d33-9f32fba0596d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bd084fca-981e-4619-989d-e9cfdaa107d7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_875a88a7-0c73-4c27-8d33-9f32fba0596d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_53d1f6ef-2b55-44e6-9000-fe905741645e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_875a88a7-0c73-4c27-8d33-9f32fba0596d" xlink:to="loc_us-gaap_AccountsReceivableMember_53d1f6ef-2b55-44e6-9000-fe905741645e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_74df31a5-9612-46a7-ad6e-edf018e8e00c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_964a3750-d608-4ba0-8d6b-501d4e215057" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_74df31a5-9612-46a7-ad6e-edf018e8e00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_58f26c51-7a70-4663-987b-0a7e2090c21c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_74df31a5-9612-46a7-ad6e-edf018e8e00c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_58f26c51-7a70-4663-987b-0a7e2090c21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_011d8125-2b6c-45e3-9d2c-00bed446bcf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_58f26c51-7a70-4663-987b-0a7e2090c21c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_011d8125-2b6c-45e3-9d2c-00bed446bcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_dcdb7d6b-3335-4d3c-a3e8-b29c5ff2c5da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_964a3750-d608-4ba0-8d6b-501d4e215057" xlink:to="loc_us-gaap_ProductInformationLineItems_dcdb7d6b-3335-4d3c-a3e8-b29c5ff2c5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0d065459-ed88-45e6-a51d-9b71b797fa25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_dcdb7d6b-3335-4d3c-a3e8-b29c5ff2c5da" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0d065459-ed88-45e6-a51d-9b71b797fa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_65542dc9-975a-4279-a568-071d0b7901cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_dcdb7d6b-3335-4d3c-a3e8-b29c5ff2c5da" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_65542dc9-975a-4279-a568-071d0b7901cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_43b45c22-e8e6-46e8-b802-cf36a994a6c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_dcdb7d6b-3335-4d3c-a3e8-b29c5ff2c5da" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_43b45c22-e8e6-46e8-b802-cf36a994a6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fa46678b-f51b-4ba5-83cf-a502671dccc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_dcdb7d6b-3335-4d3c-a3e8-b29c5ff2c5da" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fa46678b-f51b-4ba5-83cf-a502671dccc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b922585c-addc-4a1f-b69b-82b567cae9eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_bade0432-7d19-42f7-9712-4456dcbaf525" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b922585c-addc-4a1f-b69b-82b567cae9eb" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_bade0432-7d19-42f7-9712-4456dcbaf525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_6a7d35fb-66c6-400b-94b6-bb9ed86386cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b922585c-addc-4a1f-b69b-82b567cae9eb" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_6a7d35fb-66c6-400b-94b6-bb9ed86386cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7026c015-f3cb-4441-a615-9cccc468e4f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b922585c-addc-4a1f-b69b-82b567cae9eb" xlink:to="loc_us-gaap_InventoryNet_7026c015-f3cb-4441-a615-9cccc468e4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/Debt" xlink:type="simple" xlink:href="bngo-20210331.xsd#Debt"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2f7989fc-d4a6-4f2d-a953-a28705d8ca2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_2ec9e10a-087d-4276-907d-db73ed373641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2f7989fc-d4a6-4f2d-a953-a28705d8ca2d" xlink:to="loc_us-gaap_LongTermDebtTextBlock_2ec9e10a-087d-4276-907d-db73ed373641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/DebtTables" xlink:type="simple" xlink:href="bngo-20210331.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6872ac80-e5d3-4ea7-8513-14d9b0581432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_f334d735-4ca3-42f2-a0f5-eb734604da8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6872ac80-e5d3-4ea7-8513-14d9b0581432" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_f334d735-4ca3-42f2-a0f5-eb734604da8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_05915306-1d6e-400b-8d74-2bccc79082b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d153de1d-7fe0-46d9-80ac-04f14d0da39f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_05915306-1d6e-400b-8d74-2bccc79082b3" xlink:to="loc_us-gaap_DebtInstrumentTable_d153de1d-7fe0-46d9-80ac-04f14d0da39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_93698d39-6fcc-457e-b983-f2515f51c1bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d153de1d-7fe0-46d9-80ac-04f14d0da39f" xlink:to="loc_us-gaap_DebtInstrumentAxis_93698d39-6fcc-457e-b983-f2515f51c1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fd6a30a4-73b9-43cc-b0ac-f4ace6b3a155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_93698d39-6fcc-457e-b983-f2515f51c1bf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fd6a30a4-73b9-43cc-b0ac-f4ace6b3a155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LoanUnderPaycheckProtectionProgramMember_0aaa0bb2-ac6a-455d-ba18-22d7f57d4514" xlink:href="bngo-20210331.xsd#bngo_LoanUnderPaycheckProtectionProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fd6a30a4-73b9-43cc-b0ac-f4ace6b3a155" xlink:to="loc_bngo_LoanUnderPaycheckProtectionProgramMember_0aaa0bb2-ac6a-455d-ba18-22d7f57d4514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TermA1LoanMember_6eca3205-cf9f-40d6-9630-8002b014b263" xlink:href="bngo-20210331.xsd#bngo_TermA1LoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fd6a30a4-73b9-43cc-b0ac-f4ace6b3a155" xlink:to="loc_bngo_TermA1LoanMember_6eca3205-cf9f-40d6-9630-8002b014b263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TermA2LoanMember_b60e6077-3ad1-4376-9be6-17ce811e7d4a" xlink:href="bngo-20210331.xsd#bngo_TermA2LoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fd6a30a4-73b9-43cc-b0ac-f4ace6b3a155" xlink:to="loc_bngo_TermA2LoanMember_b60e6077-3ad1-4376-9be6-17ce811e7d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InnovatusTerm3LoanMember_e736aa97-3c4a-4da0-a03c-455d2f3ccba5" xlink:href="bngo-20210331.xsd#bngo_InnovatusTerm3LoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fd6a30a4-73b9-43cc-b0ac-f4ace6b3a155" xlink:to="loc_bngo_InnovatusTerm3LoanMember_e736aa97-3c4a-4da0-a03c-455d2f3ccba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InnovatusLoanAgreementMember_fa84a2a3-52df-4e8b-b992-22dc1263c329" xlink:href="bngo-20210331.xsd#bngo_InnovatusLoanAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fd6a30a4-73b9-43cc-b0ac-f4ace6b3a155" xlink:to="loc_bngo_InnovatusLoanAgreementMember_fa84a2a3-52df-4e8b-b992-22dc1263c329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_RevolverMember_19c22c3a-8769-4e52-b7d3-0e5a9fb6e29f" xlink:href="bngo-20210331.xsd#bngo_RevolverMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fd6a30a4-73b9-43cc-b0ac-f4ace6b3a155" xlink:to="loc_bngo_RevolverMember_19c22c3a-8769-4e52-b7d3-0e5a9fb6e29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_af21ef99-8661-4b5b-9705-f734bb62c228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d153de1d-7fe0-46d9-80ac-04f14d0da39f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_af21ef99-8661-4b5b-9705-f734bb62c228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2e823775-ee49-4dde-b9b2-fa0c4d33cb12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_af21ef99-8661-4b5b-9705-f734bb62c228" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2e823775-ee49-4dde-b9b2-fa0c4d33cb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_7eef4ae6-ab86-4148-981c-eb40da6237d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2e823775-ee49-4dde-b9b2-fa0c4d33cb12" xlink:to="loc_us-gaap_UnsecuredDebtMember_7eef4ae6-ab86-4148-981c-eb40da6237d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_031195ff-e9bc-4dca-b3a0-7d55cbb27189" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2e823775-ee49-4dde-b9b2-fa0c4d33cb12" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_031195ff-e9bc-4dca-b3a0-7d55cbb27189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsAxis_8cb26137-7e95-44d1-bc56-2a340c259c3a" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d153de1d-7fe0-46d9-80ac-04f14d0da39f" xlink:to="loc_bngo_DebtInstrumentPaymentTermsAxis_8cb26137-7e95-44d1-bc56-2a340c259c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsDomain_e1b2ed39-74b2-4011-82e7-dc3c03092c03" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_DebtInstrumentPaymentTermsAxis_8cb26137-7e95-44d1-bc56-2a340c259c3a" xlink:to="loc_bngo_DebtInstrumentPaymentTermsDomain_e1b2ed39-74b2-4011-82e7-dc3c03092c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodOneMember_b0751b09-b3f2-4fe9-be4f-97281f13d8c1" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_DebtInstrumentPaymentTermsDomain_e1b2ed39-74b2-4011-82e7-dc3c03092c03" xlink:to="loc_bngo_DebtInstrumentPaymentTermsPeriodOneMember_b0751b09-b3f2-4fe9-be4f-97281f13d8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodTwoMember_fdf47b60-a6ff-49cd-b864-8151891c49d5" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_DebtInstrumentPaymentTermsDomain_e1b2ed39-74b2-4011-82e7-dc3c03092c03" xlink:to="loc_bngo_DebtInstrumentPaymentTermsPeriodTwoMember_fdf47b60-a6ff-49cd-b864-8151891c49d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodThreeMember_5be10f33-4e9d-4e76-b8f3-2de616e07676" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_DebtInstrumentPaymentTermsDomain_e1b2ed39-74b2-4011-82e7-dc3c03092c03" xlink:to="loc_bngo_DebtInstrumentPaymentTermsPeriodThreeMember_5be10f33-4e9d-4e76-b8f3-2de616e07676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodFourMember_3ca5f1b2-1255-455b-8745-504a4074e004" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPaymentTermsPeriodFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_DebtInstrumentPaymentTermsDomain_e1b2ed39-74b2-4011-82e7-dc3c03092c03" xlink:to="loc_bngo_DebtInstrumentPaymentTermsPeriodFourMember_3ca5f1b2-1255-455b-8745-504a4074e004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d153de1d-7fe0-46d9-80ac-04f14d0da39f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_b3958625-d586-42a6-a429-10a720470c5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_b3958625-d586-42a6-a429-10a720470c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f39b5f60-4550-4afc-96c2-766e47e11043" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f39b5f60-4550-4afc-96c2-766e47e11043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8404596d-369c-42cb-8ba0-d90de1b9abfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8404596d-369c-42cb-8ba0-d90de1b9abfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentInterestRateCashRate_4ce0501e-e81c-4b5a-be86-7dd280cd9329" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentInterestRateCashRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_bngo_DebtInstrumentInterestRateCashRate_4ce0501e-e81c-4b5a-be86-7dd280cd9329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentInterestRateDiscountedCashRate_96062259-e1b7-45e5-af1f-2d2d3350483c" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentInterestRateDiscountedCashRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_bngo_DebtInstrumentInterestRateDiscountedCashRate_96062259-e1b7-45e5-af1f-2d2d3350483c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7c27e431-63a2-4eff-8ad4-275174d9847f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7c27e431-63a2-4eff-8ad4-275174d9847f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentNumberOfMonthlyPayments_613d839d-55ee-487f-9dbf-d90b9b7f5a32" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentNumberOfMonthlyPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_bngo_DebtInstrumentNumberOfMonthlyPayments_613d839d-55ee-487f-9dbf-d90b9b7f5a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPrepaymentFeePercent_f6e78039-32ce-4940-86f6-30a6bd92c165" xlink:href="bngo-20210331.xsd#bngo_DebtInstrumentPrepaymentFeePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_bngo_DebtInstrumentPrepaymentFeePercent_f6e78039-32ce-4940-86f6-30a6bd92c165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_9514ace7-223e-4a87-8430-d20e34c15552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_9514ace7-223e-4a87-8430-d20e34c15552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0246998b-97c5-4c59-b838-9225729f2d2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c62b3c13-d23f-41e1-bc1d-62a833e28c49" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0246998b-97c5-4c59-b838-9225729f2d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/DebtScheduleofDebtDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#DebtScheduleofDebtDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/DebtScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_09b7627e-07c6-41b2-80e2-de6376c4697e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cafdd18a-ca2f-4a01-a643-bf2376bb3910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_09b7627e-07c6-41b2-80e2-de6376c4697e" xlink:to="loc_us-gaap_DebtInstrumentTable_cafdd18a-ca2f-4a01-a643-bf2376bb3910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e109f10d-26aa-46c8-a5ae-17564239acb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cafdd18a-ca2f-4a01-a643-bf2376bb3910" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e109f10d-26aa-46c8-a5ae-17564239acb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b9e12365-6909-40e2-864d-af53fbc4387e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e109f10d-26aa-46c8-a5ae-17564239acb5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b9e12365-6909-40e2-864d-af53fbc4387e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TermLoansMember_86d0dcc6-93b6-4d73-9137-b5ed023bcdd8" xlink:href="bngo-20210331.xsd#bngo_TermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b9e12365-6909-40e2-864d-af53fbc4387e" xlink:to="loc_bngo_TermLoansMember_86d0dcc6-93b6-4d73-9137-b5ed023bcdd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PPPLoanMember_1c02685e-2c07-456b-b660-1f1b66783b5c" xlink:href="bngo-20210331.xsd#bngo_PPPLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b9e12365-6909-40e2-864d-af53fbc4387e" xlink:to="loc_bngo_PPPLoanMember_1c02685e-2c07-456b-b660-1f1b66783b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c713e24e-ade1-431a-8c95-a01675f19aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cafdd18a-ca2f-4a01-a643-bf2376bb3910" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c713e24e-ade1-431a-8c95-a01675f19aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d9416fa0-7ac4-4343-8fc3-cf7e85cdaeb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c713e24e-ade1-431a-8c95-a01675f19aa3" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d9416fa0-7ac4-4343-8fc3-cf7e85cdaeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_14d084c4-d88d-421a-a23f-d40d8158de04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c713e24e-ade1-431a-8c95-a01675f19aa3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_14d084c4-d88d-421a-a23f-d40d8158de04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_36a8849f-933e-49c4-a606-e323fdf78289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c713e24e-ade1-431a-8c95-a01675f19aa3" xlink:to="loc_us-gaap_LongTermDebt_36a8849f-933e-49c4-a606-e323fdf78289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensation"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_90cb9e61-8061-45cc-881e-863f436a4b6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6f1a99c3-0c16-4981-870a-97536809376c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_90cb9e61-8061-45cc-881e-863f436a4b6d" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6f1a99c3-0c16-4981-870a-97536809376c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40259bd7-aea8-444e-8b65-8129e6ea58ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_49956a29-6d20-4902-80f5-7f8438297599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40259bd7-aea8-444e-8b65-8129e6ea58ad" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_49956a29-6d20-4902-80f5-7f8438297599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_80976bbf-e67d-4ec0-aae9-93fda69c6c61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40259bd7-aea8-444e-8b65-8129e6ea58ad" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_80976bbf-e67d-4ec0-aae9-93fda69c6c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f4ecfbbb-d322-4558-a49c-527249962335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40259bd7-aea8-444e-8b65-8129e6ea58ad" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f4ecfbbb-d322-4558-a49c-527249962335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a426adfe-f6b4-42f8-ba35-a9e5624b4d09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40259bd7-aea8-444e-8b65-8129e6ea58ad" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a426adfe-f6b4-42f8-ba35-a9e5624b4d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a0042a7-9340-407b-9960-cf06b378e30f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a0042a7-9340-407b-9960-cf06b378e30f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_87359226-68a8-4e4b-a4a3-737d5964dabb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:to="loc_us-gaap_StatementClassOfStockAxis_87359226-68a8-4e4b-a4a3-737d5964dabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_620513e6-455f-448a-933d-79376fac6afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_87359226-68a8-4e4b-a4a3-737d5964dabb" xlink:to="loc_us-gaap_ClassOfStockDomain_620513e6-455f-448a-933d-79376fac6afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_df26f78d-df7b-4003-b126-6ea5f2bacfe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_620513e6-455f-448a-933d-79376fac6afb" xlink:to="loc_us-gaap_CommonStockMember_df26f78d-df7b-4003-b126-6ea5f2bacfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_06fdb9f8-8158-4b48-8128-8fb38fb38c0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_06fdb9f8-8158-4b48-8128-8fb38fb38c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9489bdd8-60be-4481-93e4-5807dd7080d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_06fdb9f8-8158-4b48-8128-8fb38fb38c0a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9489bdd8-60be-4481-93e4-5807dd7080d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_143c83a1-63d5-4e77-83d3-6bec84a39a58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9489bdd8-60be-4481-93e4-5807dd7080d0" xlink:to="loc_us-gaap_OverAllotmentOptionMember_143c83a1-63d5-4e77-83d3-6bec84a39a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_851d5d7c-25a4-47aa-9004-893cb47c9816" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:to="loc_srt_CounterpartyNameAxis_851d5d7c-25a4-47aa-9004-893cb47c9816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91dcece9-7dba-49b9-b725-312596ec958e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_851d5d7c-25a4-47aa-9004-893cb47c9816" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91dcece9-7dba-49b9-b725-312596ec958e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CowenMember_cd1bd01f-368e-498d-aa1b-a2aed7e85e25" xlink:href="bngo-20210331.xsd#bngo_CowenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91dcece9-7dba-49b9-b725-312596ec958e" xlink:to="loc_bngo_CowenMember_cd1bd01f-368e-498d-aa1b-a2aed7e85e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9d38e0e4-eb99-41fe-8a0c-b5c3d398109b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:to="loc_us-gaap_AwardTypeAxis_9d38e0e4-eb99-41fe-8a0c-b5c3d398109b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45fec91d-3eb4-419d-a6b8-e0c307e4c8b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9d38e0e4-eb99-41fe-8a0c-b5c3d398109b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45fec91d-3eb4-419d-a6b8-e0c307e4c8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ebfba1f7-7841-493e-b9e2-1447fb286a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45fec91d-3eb4-419d-a6b8-e0c307e4c8b1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ebfba1f7-7841-493e-b9e2-1447fb286a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_76a2b5e2-2fd9-48de-b106-f49a5c7d76e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:to="loc_srt_TitleOfIndividualAxis_76a2b5e2-2fd9-48de-b106-f49a5c7d76e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e8663eeb-4925-496f-9348-3cd96bb7ba31" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_76a2b5e2-2fd9-48de-b106-f49a5c7d76e1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e8663eeb-4925-496f-9348-3cd96bb7ba31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_RErikHolmlinMember_35afa4f9-c11a-4638-b258-0dd934752b39" xlink:href="bngo-20210331.xsd#bngo_RErikHolmlinMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e8663eeb-4925-496f-9348-3cd96bb7ba31" xlink:to="loc_bngo_RErikHolmlinMember_35afa4f9-c11a-4638-b258-0dd934752b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_MarkOldakowskiMember_a474467f-11a6-494c-a7e6-cae403555776" xlink:href="bngo-20210331.xsd#bngo_MarkOldakowskiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e8663eeb-4925-496f-9348-3cd96bb7ba31" xlink:to="loc_bngo_MarkOldakowskiMember_a474467f-11a6-494c-a7e6-cae403555776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_VestingStatusAxis_b7767a82-0218-43f3-a7cb-f4c2eb121629" xlink:href="bngo-20210331.xsd#bngo_VestingStatusAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:to="loc_bngo_VestingStatusAxis_b7767a82-0218-43f3-a7cb-f4c2eb121629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_VestingStatusDomain_9b3f9537-772f-4c5b-9cbd-53f70a05f5f9" xlink:href="bngo-20210331.xsd#bngo_VestingStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_VestingStatusAxis_b7767a82-0218-43f3-a7cb-f4c2eb121629" xlink:to="loc_bngo_VestingStatusDomain_9b3f9537-772f-4c5b-9cbd-53f70a05f5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TimeBasedVestingMember_befb578d-3a7e-48d1-a5c6-f520f8f15397" xlink:href="bngo-20210331.xsd#bngo_TimeBasedVestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_VestingStatusDomain_9b3f9537-772f-4c5b-9cbd-53f70a05f5f9" xlink:to="loc_bngo_TimeBasedVestingMember_befb578d-3a7e-48d1-a5c6-f520f8f15397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PerformanceSatisfactionVestingMember_6bc864d6-6d1b-480d-b9a9-85654f0658d0" xlink:href="bngo-20210331.xsd#bngo_PerformanceSatisfactionVestingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_VestingStatusDomain_9b3f9537-772f-4c5b-9cbd-53f70a05f5f9" xlink:to="loc_bngo_PerformanceSatisfactionVestingMember_6bc864d6-6d1b-480d-b9a9-85654f0658d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5d234bec-252f-4373-861d-dec664020fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5d234bec-252f-4373-861d-dec664020fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_efc5f457-bd11-47f3-af81-9a473993c4d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5d234bec-252f-4373-861d-dec664020fed" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_efc5f457-bd11-47f3-af81-9a473993c4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_87e94ead-75d4-4567-819c-f5af3691dbcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_efc5f457-bd11-47f3-af81-9a473993c4d8" xlink:to="loc_us-gaap_SubsequentEventMember_87e94ead-75d4-4567-819c-f5af3691dbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c0f7339c-8c50-46af-ae5d-23ce38ab1650" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:to="loc_srt_RangeAxis_c0f7339c-8c50-46af-ae5d-23ce38ab1650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_53829a75-ee6d-4b9a-a6fa-c4211d8490e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c0f7339c-8c50-46af-ae5d-23ce38ab1650" xlink:to="loc_srt_RangeMember_53829a75-ee6d-4b9a-a6fa-c4211d8490e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_41fea43f-6eb8-42b0-bd63-ed2e1bead47b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_53829a75-ee6d-4b9a-a6fa-c4211d8490e0" xlink:to="loc_srt_MinimumMember_41fea43f-6eb8-42b0-bd63-ed2e1bead47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4652c0b6-499f-44ff-9f7d-861ace1b2fbf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_53829a75-ee6d-4b9a-a6fa-c4211d8490e0" xlink:to="loc_srt_MaximumMember_4652c0b6-499f-44ff-9f7d-861ace1b2fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d64d5e2c-98ff-4779-9f08-4da42036f7fa" xlink:to="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f0c0a991-48c3-4436-8ca6-ae4cfab86f24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f0c0a991-48c3-4436-8ca6-ae4cfab86f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_a593faf9-e660-4233-8843-e65e74fb3fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_a593faf9-e660-4233-8843-e65e74fb3fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_a6d582fa-1455-44ff-8140-b321545ad21a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_a6d582fa-1455-44ff-8140-b321545ad21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_825269fe-4c32-4a57-8063-dc2259e05882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_825269fe-4c32-4a57-8063-dc2259e05882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SaleOfStockAuthorizedAmountToBeIssued_dc06a10c-9875-4066-980b-36a911f3bcf1" xlink:href="bngo-20210331.xsd#bngo_SaleOfStockAuthorizedAmountToBeIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_bngo_SaleOfStockAuthorizedAmountToBeIssued_dc06a10c-9875-4066-980b-36a911f3bcf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SaleOfStockValueSharesIssuedInTransaction_c37f9591-1353-4fb1-bc75-55b2f940e615" xlink:href="bngo-20210331.xsd#bngo_SaleOfStockValueSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_bngo_SaleOfStockValueSharesIssuedInTransaction_c37f9591-1353-4fb1-bc75-55b2f940e615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_df3b53c9-5655-4877-85da-caa2dfbe3121" xlink:href="bngo-20210331.xsd#bngo_CommissionFeeMaximumPercentageOfGrossProceeds"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_df3b53c9-5655-4877-85da-caa2dfbe3121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_685db8b6-3742-4f6e-abba-1277bc63ef77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_685db8b6-3742-4f6e-abba-1277bc63ef77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary_2d08833c-5e35-4bf6-b0dc-2f71fe101bfe" xlink:href="bngo-20210331.xsd#bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary_2d08833c-5e35-4bf6-b0dc-2f71fe101bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment_f2f559ac-41ea-42b5-b3e7-5ecc344e8d4f" xlink:href="bngo-20210331.xsd#bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5f11e2d6-eb0f-4157-981c-0e16296a965b" xlink:to="loc_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment_f2f559ac-41ea-42b5-b3e7-5ecc344e8d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensationWarrantActivityDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af13518e-02cf-494e-8ee7-184330371ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_cc569ed9-e3ca-401c-b3c9-ede0752eb1a9" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af13518e-02cf-494e-8ee7-184330371ba2" xlink:to="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_cc569ed9-e3ca-401c-b3c9-ede0752eb1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5cf0feee-2613-4f93-9a4d-027cb35fe045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_cc569ed9-e3ca-401c-b3c9-ede0752eb1a9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5cf0feee-2613-4f93-9a4d-027cb35fe045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_04152f2e-d862-45c4-9db5-2c9cee4602b2" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_cc569ed9-e3ca-401c-b3c9-ede0752eb1a9" xlink:to="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_04152f2e-d862-45c4-9db5-2c9cee4602b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_70e1fbfd-0f68-4b7e-9c4a-65708f6e679d" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_cc569ed9-e3ca-401c-b3c9-ede0752eb1a9" xlink:to="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_70e1fbfd-0f68-4b7e-9c4a-65708f6e679d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod_143a6a3f-30c1-4e98-a61d-d2c11da1efa4" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_cc569ed9-e3ca-401c-b3c9-ede0752eb1a9" xlink:to="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod_143a6a3f-30c1-4e98-a61d-d2c11da1efa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b983b23d-2a8b-4851-89ca-a8cae5e77d4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_cc569ed9-e3ca-401c-b3c9-ede0752eb1a9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b983b23d-2a8b-4851-89ca-a8cae5e77d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_ced9b311-d8c6-40af-bda1-9428bb94ef15" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af13518e-02cf-494e-8ee7-184330371ba2" xlink:to="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_ced9b311-d8c6-40af-bda1-9428bb94ef15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7cee556b-e214-4aa0-9676-bf4fae70cb5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_ced9b311-d8c6-40af-bda1-9428bb94ef15" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7cee556b-e214-4aa0-9676-bf4fae70cb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod_b3cca9a4-52aa-4ee1-bf82-111c882f9f6b" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_ced9b311-d8c6-40af-bda1-9428bb94ef15" xlink:to="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod_b3cca9a4-52aa-4ee1-bf82-111c882f9f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod_7cafb92e-ea30-4b7c-8fac-13ec07c7b6a7" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_ced9b311-d8c6-40af-bda1-9428bb94ef15" xlink:to="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod_7cafb92e-ea30-4b7c-8fac-13ec07c7b6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_31fca8ca-6825-46da-8085-d8b7879c749c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_ced9b311-d8c6-40af-bda1-9428bb94ef15" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_31fca8ca-6825-46da-8085-d8b7879c749c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_98e8f3ac-ee25-4054-af16-8f0cec30f3cc" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af13518e-02cf-494e-8ee7-184330371ba2" xlink:to="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_98e8f3ac-ee25-4054-af16-8f0cec30f3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights_4f034cfc-e09e-4d19-abd2-cbac78941ec9" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_98e8f3ac-ee25-4054-af16-8f0cec30f3cc" xlink:to="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights_4f034cfc-e09e-4d19-abd2-cbac78941ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights_e425dc28-5d1b-4112-8428-c4357fdd04cf" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_98e8f3ac-ee25-4054-af16-8f0cec30f3cc" xlink:to="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights_e425dc28-5d1b-4112-8428-c4357fdd04cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_bc59c264-045f-4715-a2ff-8daaa23575fb" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af13518e-02cf-494e-8ee7-184330371ba2" xlink:to="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_bc59c264-045f-4715-a2ff-8daaa23575fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_fb89ef8a-ec64-48ba-b809-06d6d603121e" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_bc59c264-045f-4715-a2ff-8daaa23575fb" xlink:to="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_fb89ef8a-ec64-48ba-b809-06d6d603121e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights_046be434-eba1-4247-97dd-b59a2a10d425" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_bc59c264-045f-4715-a2ff-8daaa23575fb" xlink:to="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights_046be434-eba1-4247-97dd-b59a2a10d425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_6a70b875-6a05-4557-8b92-88a1b0ea087b" xlink:href="bngo-20210331.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_bc59c264-045f-4715-a2ff-8daaa23575fb" xlink:to="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_6a70b875-6a05-4557-8b92-88a1b0ea087b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a2ffb60-0396-4160-af06-6a24a2d162d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d108e00-bd48-4d31-ad48-e56074a3bf85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a2ffb60-0396-4160-af06-6a24a2d162d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d108e00-bd48-4d31-ad48-e56074a3bf85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8230da70-c2f0-4f49-bcc7-e8eecb9593c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d108e00-bd48-4d31-ad48-e56074a3bf85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8230da70-c2f0-4f49-bcc7-e8eecb9593c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a4ce621b-5075-412d-830b-c09bce709168" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d108e00-bd48-4d31-ad48-e56074a3bf85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a4ce621b-5075-412d-830b-c09bce709168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9ba05d93-0eb2-4801-a371-6eace10bd0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d108e00-bd48-4d31-ad48-e56074a3bf85" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9ba05d93-0eb2-4801-a371-6eace10bd0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_db5a8ecf-8dc3-49a7-b3b8-3fd08b9eb2e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d108e00-bd48-4d31-ad48-e56074a3bf85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_db5a8ecf-8dc3-49a7-b3b8-3fd08b9eb2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0de3ddd6-8571-4206-8dc9-71adba03fcca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d108e00-bd48-4d31-ad48-e56074a3bf85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0de3ddd6-8571-4206-8dc9-71adba03fcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_6f79c3dc-03e0-44cf-9c64-3d221d7de272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a2ffb60-0396-4160-af06-6a24a2d162d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_6f79c3dc-03e0-44cf-9c64-3d221d7de272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d5829cb-fbe5-4c07-a204-c89e49095280" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a2ffb60-0396-4160-af06-6a24a2d162d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d5829cb-fbe5-4c07-a204-c89e49095280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06377cd6-2eb4-4ec3-8574-431bbf8923c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d5829cb-fbe5-4c07-a204-c89e49095280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06377cd6-2eb4-4ec3-8574-431bbf8923c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2c59300d-d37f-4a14-9997-def27ded4501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d5829cb-fbe5-4c07-a204-c89e49095280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2c59300d-d37f-4a14-9997-def27ded4501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d4c189d2-a322-4788-a6c4-9ddf2b1640bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d5829cb-fbe5-4c07-a204-c89e49095280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d4c189d2-a322-4788-a6c4-9ddf2b1640bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_aafa536b-7f6a-4c6d-9180-963742919e45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d5829cb-fbe5-4c07-a204-c89e49095280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_aafa536b-7f6a-4c6d-9180-963742919e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_850a4c99-9d4b-4f27-ac44-0a64ae873b27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d5829cb-fbe5-4c07-a204-c89e49095280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_850a4c99-9d4b-4f27-ac44-0a64ae873b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_ec64a834-c2d5-485f-9718-0eaf92611ee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a2ffb60-0396-4160-af06-6a24a2d162d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_ec64a834-c2d5-485f-9718-0eaf92611ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_b309967c-6945-45e9-af88-51c1d069ca1c" xlink:href="bngo-20210331.xsd#bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a2ffb60-0396-4160-af06-6a24a2d162d5" xlink:to="loc_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_b309967c-6945-45e9-af88-51c1d069ca1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1d528cf7-aa65-4668-888e-2a5df6be9637" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_b309967c-6945-45e9-af88-51c1d069ca1c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1d528cf7-aa65-4668-888e-2a5df6be9637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1dabd1b7-4e60-4995-a71e-d3b9cbba0b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_b309967c-6945-45e9-af88-51c1d069ca1c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1dabd1b7-4e60-4995-a71e-d3b9cbba0b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1b5b804-172d-4c7e-be30-7374370b4164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a2ffb60-0396-4160-af06-6a24a2d162d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1b5b804-172d-4c7e-be30-7374370b4164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_be1ff0b2-1278-461f-b667-e74006b85413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1b5b804-172d-4c7e-be30-7374370b4164" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_be1ff0b2-1278-461f-b667-e74006b85413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b54d0099-39b9-4769-9d15-68daf0d34563" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1b5b804-172d-4c7e-be30-7374370b4164" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b54d0099-39b9-4769-9d15-68daf0d34563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_580e19dc-f4a9-4ef1-a021-d3930616da68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1b5b804-172d-4c7e-be30-7374370b4164" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_580e19dc-f4a9-4ef1-a021-d3930616da68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_31dae7ad-edcb-4d43-addf-ebf2466a0d65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1b5b804-172d-4c7e-be30-7374370b4164" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_31dae7ad-edcb-4d43-addf-ebf2466a0d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9da0f744-9dbf-4715-bba7-6d758c494624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a2ffb60-0396-4160-af06-6a24a2d162d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9da0f744-9dbf-4715-bba7-6d758c494624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88f19c1b-f2f7-40ac-8d9b-caecd185dc2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc33b75e-4423-45f1-b633-d02008729e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88f19c1b-f2f7-40ac-8d9b-caecd185dc2d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc33b75e-4423-45f1-b633-d02008729e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_89ef8fb0-a63d-4e22-995e-afeb24a60ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc33b75e-4423-45f1-b633-d02008729e9e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_89ef8fb0-a63d-4e22-995e-afeb24a60ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42d858fc-5338-4a19-9df6-4bd0ea29ce81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_89ef8fb0-a63d-4e22-995e-afeb24a60ae5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42d858fc-5338-4a19-9df6-4bd0ea29ce81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9218d04b-815a-40db-b52c-c686bc43ea20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42d858fc-5338-4a19-9df6-4bd0ea29ce81" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9218d04b-815a-40db-b52c-c686bc43ea20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cfc87d54-d6cf-4f16-9252-f34623744513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42d858fc-5338-4a19-9df6-4bd0ea29ce81" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cfc87d54-d6cf-4f16-9252-f34623744513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacb6656-fdf3-493b-b274-6c4404e2b86d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc33b75e-4423-45f1-b633-d02008729e9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacb6656-fdf3-493b-b274-6c4404e2b86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_60b4cea6-51d9-4ccd-aca8-2ddafdb06642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacb6656-fdf3-493b-b274-6c4404e2b86d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_60b4cea6-51d9-4ccd-aca8-2ddafdb06642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#StockholdersEquityandStockBasedCompensationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d636882-4e3a-4e54-a3eb-7f339e90e831" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e1a600dc-a076-454d-bacc-75ea331a5d85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d636882-4e3a-4e54-a3eb-7f339e90e831" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e1a600dc-a076-454d-bacc-75ea331a5d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_771106d8-5132-4434-a07f-db3ab9c97b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d636882-4e3a-4e54-a3eb-7f339e90e831" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_771106d8-5132-4434-a07f-db3ab9c97b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6a644e85-2c98-4e47-b611-5b919649b3a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d636882-4e3a-4e54-a3eb-7f339e90e831" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6a644e85-2c98-4e47-b611-5b919649b3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3622f9de-4557-4a17-972b-6d7ee1356500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d636882-4e3a-4e54-a3eb-7f339e90e831" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3622f9de-4557-4a17-972b-6d7ee1356500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/Litigation" xlink:type="simple" xlink:href="bngo-20210331.xsd#Litigation"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_617fac75-050f-42a3-a176-130509ee16c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2b9313cf-fec7-4dab-a97b-89d9e64663c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_617fac75-050f-42a3-a176-130509ee16c5" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2b9313cf-fec7-4dab-a97b-89d9e64663c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="bngo-20210331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ce9a527b-cddb-458a-a879-fdbef8931eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_7c33d388-ece2-4412-9e45-dae4c0f3fa9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce9a527b-cddb-458a-a879-fdbef8931eb0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_7c33d388-ece2-4412-9e45-dae4c0f3fa9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagen" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagen"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagen" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_19b1da73-b701-4f79-913b-b8defe01cd84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_54307fde-40db-4586-9075-3bd2511af7a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_19b1da73-b701-4f79-913b-b8defe01cd84" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_54307fde-40db-4586-9075-3bd2511af7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenTables" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagenTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagenTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_602e39a2-8800-46dc-9bab-9dac1fbd461f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_87c5fb3c-2f1b-4377-abc7-ea495505bca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_602e39a2-8800-46dc-9bab-9dac1fbd461f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_87c5fb3c-2f1b-4377-abc7-ea495505bca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_247b1499-44e0-48f1-b144-ade3c7674b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_602e39a2-8800-46dc-9bab-9dac1fbd461f" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_247b1499-44e0-48f1-b144-ade3c7674b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_8d237c6c-55c3-4809-8f3a-3729927ceee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_602e39a2-8800-46dc-9bab-9dac1fbd461f" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_8d237c6c-55c3-4809-8f3a-3729927ceee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_9566f325-7cb3-4615-9970-adc33e1e142c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_602e39a2-8800-46dc-9bab-9dac1fbd461f" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_9566f325-7cb3-4615-9970-adc33e1e142c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagenNarrativeDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_9ea4d9c1-c33f-4387-96d2-e8215ed46b84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b169602-6745-4302-8fa6-5dd2c1e30940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_9ea4d9c1-c33f-4387-96d2-e8215ed46b84" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b169602-6745-4302-8fa6-5dd2c1e30940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_01b0abdf-28f9-4bfc-a6c6-d9463ae7962c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b169602-6745-4302-8fa6-5dd2c1e30940" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_01b0abdf-28f9-4bfc-a6c6-d9463ae7962c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37b61c3c-510a-4f45-a519-6be4f5dcb8b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_01b0abdf-28f9-4bfc-a6c6-d9463ae7962c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37b61c3c-510a-4f45-a519-6be4f5dcb8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_ed84180e-56cd-4acb-858c-757ec1c59782" xlink:href="bngo-20210331.xsd#bngo_LineagenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37b61c3c-510a-4f45-a519-6be4f5dcb8b8" xlink:to="loc_bngo_LineagenMember_ed84180e-56cd-4acb-858c-757ec1c59782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_50c0fea8-b9e8-4b4c-8c73-a1c364fe2709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b169602-6745-4302-8fa6-5dd2c1e30940" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_50c0fea8-b9e8-4b4c-8c73-a1c364fe2709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_49beee07-7feb-4894-9850-b3dc3f091cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_50c0fea8-b9e8-4b4c-8c73-a1c364fe2709" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_49beee07-7feb-4894-9850-b3dc3f091cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_EscrowedSharesMember_35112b79-1983-45e5-8a45-1cafe5489dbb" xlink:href="bngo-20210331.xsd#bngo_EscrowedSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_49beee07-7feb-4894-9850-b3dc3f091cf4" xlink:to="loc_bngo_EscrowedSharesMember_35112b79-1983-45e5-8a45-1cafe5489dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationInfrequentAdjustmentsAxis_86674c49-7716-4293-97d7-cb8582b525cd" xlink:href="bngo-20210331.xsd#bngo_BusinessCombinationInfrequentAdjustmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b169602-6745-4302-8fa6-5dd2c1e30940" xlink:to="loc_bngo_BusinessCombinationInfrequentAdjustmentsAxis_86674c49-7716-4293-97d7-cb8582b525cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationInfrequentAdjustmentsDomain_ec12e2b3-5537-46d4-8142-4a2b5f052360" xlink:href="bngo-20210331.xsd#bngo_BusinessCombinationInfrequentAdjustmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_BusinessCombinationInfrequentAdjustmentsAxis_86674c49-7716-4293-97d7-cb8582b525cd" xlink:to="loc_bngo_BusinessCombinationInfrequentAdjustmentsDomain_ec12e2b3-5537-46d4-8142-4a2b5f052360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationInfrequentAdjustmentsMember_24a02e7a-d405-4e87-801d-c26230cfd3b8" xlink:href="bngo-20210331.xsd#bngo_BusinessCombinationInfrequentAdjustmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_BusinessCombinationInfrequentAdjustmentsDomain_ec12e2b3-5537-46d4-8142-4a2b5f052360" xlink:to="loc_bngo_BusinessCombinationInfrequentAdjustmentsMember_24a02e7a-d405-4e87-801d-c26230cfd3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b169602-6745-4302-8fa6-5dd2c1e30940" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_d1bc84ae-7c16-459b-b782-a69f4cae54fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_d1bc84ae-7c16-459b-b782-a69f4cae54fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_7de68353-1b6e-40ec-9e86-39ac4261ba6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_7de68353-1b6e-40ec-9e86-39ac4261ba6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_40772e98-f97d-4d67-8ab7-901b29a3b29d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_40772e98-f97d-4d67-8ab7-901b29a3b29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt_1ba106b6-8480-4095-a9e7-3fce2bb460aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:to="loc_us-gaap_RepaymentsOfOtherDebt_1ba106b6-8480-4095-a9e7-3fce2bb460aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_a9ff593a-f40c-4e93-bca3-36c4c684d23a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_a9ff593a-f40c-4e93-bca3-36c4c684d23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_6ee030c8-6dcd-462a-809b-c44306eb63e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_6ee030c8-6dcd-462a-809b-c44306eb63e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9a8f1393-2310-4e10-b6b1-f5ab0f308209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9a8f1393-2310-4e10-b6b1-f5ab0f308209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_5987639c-16ac-4afb-8092-3bbb3e9bb091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ad404a9-3820-42a9-97af-653db1cb1ee3" xlink:to="loc_us-gaap_InterestExpenseDebt_5987639c-16ac-4afb-8092-3bbb3e9bb091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagenAcquisitionPurchasePriceDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_5d8d1da4-b43c-4d0f-a4bd-6ca8ce08b431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b6b5b84-7e6b-416a-92f2-7c91327475a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5d8d1da4-b43c-4d0f-a4bd-6ca8ce08b431" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b6b5b84-7e6b-416a-92f2-7c91327475a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ad945e54-a85b-4578-8962-f38c183f9459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b6b5b84-7e6b-416a-92f2-7c91327475a8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ad945e54-a85b-4578-8962-f38c183f9459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b669e74d-239c-4fb4-a3ce-35955e742de9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ad945e54-a85b-4578-8962-f38c183f9459" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b669e74d-239c-4fb4-a3ce-35955e742de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_30f64c6f-f199-4efa-bb78-358d96c7cbca" xlink:href="bngo-20210331.xsd#bngo_LineagenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b669e74d-239c-4fb4-a3ce-35955e742de9" xlink:to="loc_bngo_LineagenMember_30f64c6f-f199-4efa-bb78-358d96c7cbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_62802f54-68d2-42aa-ab39-fd699d7d122b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b6b5b84-7e6b-416a-92f2-7c91327475a8" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_62802f54-68d2-42aa-ab39-fd699d7d122b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_491d587d-422f-4229-bdbe-febc44c4a7bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_62802f54-68d2-42aa-ab39-fd699d7d122b" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_491d587d-422f-4229-bdbe-febc44c4a7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_EscrowedSharesMember_ebe060aa-2fa4-47f1-8b29-f638bf8a82e2" xlink:href="bngo-20210331.xsd#bngo_EscrowedSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_491d587d-422f-4229-bdbe-febc44c4a7bd" xlink:to="loc_bngo_EscrowedSharesMember_ebe060aa-2fa4-47f1-8b29-f638bf8a82e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_403559d4-8415-43e0-8942-eabc1edb8ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b6b5b84-7e6b-416a-92f2-7c91327475a8" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_403559d4-8415-43e0-8942-eabc1edb8ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a5597dcd-f738-4e23-a534-6eb695337f17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403559d4-8415-43e0-8942-eabc1edb8ff4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a5597dcd-f738-4e23-a534-6eb695337f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt_fe02694c-6f5f-4fe8-9ce7-0514448a4dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403559d4-8415-43e0-8942-eabc1edb8ff4" xlink:to="loc_us-gaap_RepaymentsOfOtherDebt_fe02694c-6f5f-4fe8-9ce7-0514448a4dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_d060ecc7-885a-49dc-a06d-65f5a2986310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403559d4-8415-43e0-8942-eabc1edb8ff4" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_d060ecc7-885a-49dc-a06d-65f5a2986310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment_989b38a4-6385-41f4-9ad4-38a17df47084" xlink:href="bngo-20210331.xsd#bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403559d4-8415-43e0-8942-eabc1edb8ff4" xlink:to="loc_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment_989b38a4-6385-41f4-9ad4-38a17df47084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_fdd708ed-080e-4e3f-83bc-733f946a50c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403559d4-8415-43e0-8942-eabc1edb8ff4" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_fdd708ed-080e-4e3f-83bc-733f946a50c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c1402d35-df4e-47e5-8cd2-88adab911e88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403559d4-8415-43e0-8942-eabc1edb8ff4" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c1402d35-df4e-47e5-8cd2-88adab911e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_069d0fa5-aae5-43f9-aff5-be71cdf61eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403559d4-8415-43e0-8942-eabc1edb8ff4" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_069d0fa5-aae5-43f9-aff5-be71cdf61eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_6a9c9a69-a358-41e4-94fb-5c20cc0170a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f54add65-5ef3-4541-900f-f7e7350ebb62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_6a9c9a69-a358-41e4-94fb-5c20cc0170a2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f54add65-5ef3-4541-900f-f7e7350ebb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0b78a581-34fe-4b91-b6bb-336af990e1cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f54add65-5ef3-4541-900f-f7e7350ebb62" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0b78a581-34fe-4b91-b6bb-336af990e1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e830c11-ee53-49e4-b391-645131459bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0b78a581-34fe-4b91-b6bb-336af990e1cd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e830c11-ee53-49e4-b391-645131459bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_5f8c1e45-8602-4faf-91ae-93e6b8e25b02" xlink:href="bngo-20210331.xsd#bngo_LineagenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e830c11-ee53-49e4-b391-645131459bfa" xlink:to="loc_bngo_LineagenMember_5f8c1e45-8602-4faf-91ae-93e6b8e25b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f54add65-5ef3-4541-900f-f7e7350ebb62" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2fe26298-8c7e-48bc-8174-f79f98aaad73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2fe26298-8c7e-48bc-8174-f79f98aaad73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_6e39296c-5e62-4d00-a187-b035c8b7b47b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_6e39296c-5e62-4d00-a187-b035c8b7b47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_72e47064-7553-4931-92a5-9cd4f29d9bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_72e47064-7553-4931-92a5-9cd4f29d9bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_61dfea64-5fa7-43ca-9470-f0b5918c58ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_61dfea64-5fa7-43ca-9470-f0b5918c58ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2663fc5b-4a0a-415a-8525-4dee8265caec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2663fc5b-4a0a-415a-8525-4dee8265caec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1aae99cb-0947-4f13-a465-446744f3bb9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:to="loc_us-gaap_Goodwill_1aae99cb-0947-4f13-a465-446744f3bb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1c26da8c-7d2d-4636-945d-21a5b1490c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1c26da8c-7d2d-4636-945d-21a5b1490c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0a36c353-b031-46bc-8a07-ac2782d17247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13063009-7c25-4af3-afd7-efada81881e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0a36c353-b031-46bc-8a07-ac2782d17247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagenIdentifiableIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_4a4f9743-0e87-4512-a92d-141166709696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d036b605-0190-47ed-93c0-a634832fbee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4a4f9743-0e87-4512-a92d-141166709696" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d036b605-0190-47ed-93c0-a634832fbee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_364fa6bb-08ca-4392-a0d6-7a801b0e9075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d036b605-0190-47ed-93c0-a634832fbee3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_364fa6bb-08ca-4392-a0d6-7a801b0e9075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bee02c5b-3cf5-4846-a5d2-397f7646b7d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_364fa6bb-08ca-4392-a0d6-7a801b0e9075" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bee02c5b-3cf5-4846-a5d2-397f7646b7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_30774755-4919-49f1-b2ac-26fe2c448f60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bee02c5b-3cf5-4846-a5d2-397f7646b7d9" xlink:to="loc_us-gaap_CustomerRelationshipsMember_30774755-4919-49f1-b2ac-26fe2c448f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_57b576eb-ebbc-43e3-bb1e-af2bf1c8cd16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bee02c5b-3cf5-4846-a5d2-397f7646b7d9" xlink:to="loc_us-gaap_TradeNamesMember_57b576eb-ebbc-43e3-bb1e-af2bf1c8cd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ddcfed0f-7e7a-4867-954a-7c1c9af22b36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d036b605-0190-47ed-93c0-a634832fbee3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ddcfed0f-7e7a-4867-954a-7c1c9af22b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6350ccd0-4419-4a79-9082-7995061af6e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ddcfed0f-7e7a-4867-954a-7c1c9af22b36" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6350ccd0-4419-4a79-9082-7995061af6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_29703b06-ec42-4897-8801-f0203cf4d675" xlink:href="bngo-20210331.xsd#bngo_LineagenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6350ccd0-4419-4a79-9082-7995061af6e9" xlink:to="loc_bngo_LineagenMember_29703b06-ec42-4897-8801-f0203cf4d675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0f780156-94f9-47a0-8a98-f486b1419fad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d036b605-0190-47ed-93c0-a634832fbee3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0f780156-94f9-47a0-8a98-f486b1419fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d01055a4-ffd6-4766-b10c-54372c5443ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0f780156-94f9-47a0-8a98-f486b1419fad" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d01055a4-ffd6-4766-b10c-54372c5443ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionofLineagenProFormaInformationDetails" xlink:type="simple" xlink:href="bngo-20210331.xsd#AcquisitionofLineagenProFormaInformationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionofLineagenProFormaInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_5b923d08-849b-427d-8fe6-33a260b59d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d117e-f3a9-411c-afb6-164cd4632e0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5b923d08-849b-427d-8fe6-33a260b59d8e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d117e-f3a9-411c-afb6-164cd4632e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e6592e60-960b-4887-9012-4dbbf2ada612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d117e-f3a9-411c-afb6-164cd4632e0d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e6592e60-960b-4887-9012-4dbbf2ada612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a78af877-f672-4935-8392-4091e166f6e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e6592e60-960b-4887-9012-4dbbf2ada612" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a78af877-f672-4935-8392-4091e166f6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_92c87f06-04b1-47e4-bfe1-08f7c214459f" xlink:href="bngo-20210331.xsd#bngo_LineagenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a78af877-f672-4935-8392-4091e166f6e5" xlink:to="loc_bngo_LineagenMember_92c87f06-04b1-47e4-bfe1-08f7c214459f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_99374ea4-1e99-4a02-a872-fd370d408bb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d117e-f3a9-411c-afb6-164cd4632e0d" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_99374ea4-1e99-4a02-a872-fd370d408bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_13ccecde-7292-4adb-ac35-c615431782ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99374ea4-1e99-4a02-a872-fd370d408bb2" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_13ccecde-7292-4adb-ac35-c615431782ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_dc5e2f1f-804d-4332-b9ce-c26ca1841f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99374ea4-1e99-4a02-a872-fd370d408bb2" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_dc5e2f1f-804d-4332-b9ce-c26ca1841f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_137e66bb-69d9-4e9d-9b50-d19aea5376be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99374ea4-1e99-4a02-a872-fd370d408bb2" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_137e66bb-69d9-4e9d-9b50-d19aea5376be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_583f9989-6faa-4360-8482-b8c58b5f63ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99374ea4-1e99-4a02-a872-fd370d408bb2" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_583f9989-6faa-4360-8482-b8c58b5f63ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>bngo-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bngo="http://bionanogenomics.com/20210331"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bngo-20210331.xsd" xlink:type="simple"/>
    <context id="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6ad6314fd03947658c809e9599894823_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i42cdbd7cb5924627bda45f9725b2407e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0d4506743a254bb993d79cd1ba20bf03_I20210507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2021-05-07</instant>
        </period>
    </context>
    <context id="i7870f814eef549569827056ab0bbe28f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c91415129394ba299d78d9ff4f67598_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6fd535c416994e7e9ac50885ecf579a9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic6482b3482014875b2110f7ee933cadf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icb9a8cd4c6ae43b780d83f3db03387c6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i50064f20ffdd4afea720ea427be539bb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib8da4c0227db460e9bf1844ec2b9c95d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifb3bab8827334a58a6a6a830691d74a0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if2cf00dd543e42b9b366c557731d37c5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib602f85292f845748876e64aa8d4d2bf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i90fd0d4651674579a500a712406f6ae5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if30fe967ef764693b2f27ac326b09de3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i48e256cb75bb49168f54108a75282496_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="idd38c3fd47774b69bb42677bde40939f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ifaaa0a63cf624180ac4a400546f607cd_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id64fc47c76a34812be47288f3a639104_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id1721a6a1dce465eaa006a924a3e1573_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia593fc3aadb14fda8e66f3cddea13f4a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9dd95436f5fd45a5a4faccdc492a6ccc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7fa524c836dc4ba397a51ffc0afdbbd4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7c36739694c340cbb6da644df93b34b0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2f252ef06c56452aa5d46538864bff17_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i01c7339672134033bfa582f9fae89a1e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5b58256688454d8e9bfdde4184797f9e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie5b24cb157134368bae94b71658f16be_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib8c88833ac5346e0b619cff8770a118d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:LoanUnderPaycheckProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2cec51298f734861ab7454986e9cc49e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bngo:InnovatusLSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9fc5f9d8dd1f48fc82c0374b93861f35_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i60f650629d034534aa18e0699f6858da_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i879adebf764c47d087517666b8c85477_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaf4053f13478440e928fdfbb689fd12f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie9331df46b264545b015fc8dbc0eb877_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:InstrumentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2b1e545fdd7b4f708c5122ab52e04b28_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:InstrumentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibb245ebe81e244599c7dfc4dd2951fb6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:ConsumableRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6b4f7fff94f74c0092a3e332baf337ee_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:ConsumableRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7cb3b2d35c0e49a0b13d2888567d6b29_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic1ea4ad111304144bc23a97198dd2179_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic08fdc3d1e534710809bdee60bba27bd_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4e5ab6a8509443dba725afa8835b9601_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id3c3a70d23fb4e3597f16a3f336f2080_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i245ac77d088a4c08ab398de10d3c4fe0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icd2315279b594cd888242f46af032bc6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ida0f9f015cda405dbf20c999e5715976_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibd9faf0a75c448aeacba6769f5a6ed6d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic54fd087ce324e2ca363766266305d85_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib52b24a224634461aa88638273374171_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6e9fe1ddcfff4117ba8ab2659f8fb841_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i457368c024694d3da4b660e9ad925a67_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3ad2e939003643688e5a0c1f74143044_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5e72dec2e62644f09291bd2256e18ae6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib152c322e04e4f04b400bc01f5876b20_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i73e99ee813de47559aff9fc89de5f48c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifef7e1ffa1fc47e6b55595ac8be5b218_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i47e9e0fd70444455a6640482ac8e5229_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia855809b84d64c008ac770b0553904dd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bngo:LineagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i36ce02702176446c8658104bea1e70b3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bngo:RuhrUniversitayBochumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib9b6028b6f7b4c56b41bd5ae534114cb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bngo:IlluminaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i09493f03a8d24d529ba3c584f742a2e7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bngo:QuestDiagnositcsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icb4b96f2629a437b92ce60228c4e9a9e_D20200417-20200417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:LoanUnderPaycheckProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-17</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="i1dad41e3a2834af1a8bc37f1efe217ab_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:TermA1LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="id95f9fba9dd949fc975ddb0d090b6f9d_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:TermA2LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i79b1a33813d74170988e5d5afca3a502_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusTerm3LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i4861f1d2c13e4caa9d9b2c243fba8ef3_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i1be2f4e30d224ab9a6370097d5078fb2_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="id929d97a381842f687a1e63e52a0ed66_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i471d64edc0154171beed8ed2878377a6_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bngo:DebtInstrumentPaymentTermsAxis">bngo:DebtInstrumentPaymentTermsPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i02ab7766833b447ea7ab0f07e49cf492_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bngo:DebtInstrumentPaymentTermsAxis">bngo:DebtInstrumentPaymentTermsPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="id9d5648907484fceb630191c98780dcf_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bngo:DebtInstrumentPaymentTermsAxis">bngo:DebtInstrumentPaymentTermsPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i4677e379bf9c4e6c97c7555823337d32_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bngo:DebtInstrumentPaymentTermsAxis">bngo:DebtInstrumentPaymentTermsPeriodFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic76f8d3c3fd840279c87ce3ba493143a_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:RevolverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="if1d4c4e068d445ac82a3fe2130562736_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:RevolverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i3bce457e3753459a8510d3d860bbde78_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bngo:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i749a55fa53994c25beda30839971df4c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bngo:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f0cc44ba35648fb997a749f7937547f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bngo:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i57fb085856954618adbd3fae5629f1f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bngo:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1412440744f4428481b3a537ab93f461_D20210112-20210112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2021-01-12</startDate>
            <endDate>2021-01-12</endDate>
        </period>
    </context>
    <context id="i28c5c5f8564a4e67a64f3e5b44585423_D20210112-20210112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-12</startDate>
            <endDate>2021-01-12</endDate>
        </period>
    </context>
    <context id="i3cf86dab1c3a48caa595e0ad46a9aff1_I20210112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2021-01-12</instant>
        </period>
    </context>
    <context id="ie718fd4d2bcb4f61b4ea90e0b1f6c96b_I20210112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-12</instant>
        </period>
    </context>
    <context id="i8b5c637028ea47bd8c7f4181b517e861_D20210125-20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="i588270472a6143508b7112b2fa331670_D20210125-20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="i00ca1925ad5b44dfa157b479aefd1f54_I20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2021-01-25</instant>
        </period>
    </context>
    <context id="i573ce6b1bb9b4a1fabd1ce7fd5d82397_I20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-25</instant>
        </period>
    </context>
    <context id="ifd683caf9e1c44568aeff1288d3b04e1_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i3261931611534e3383079edc1d409a1a_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ib2decea561ca4c6794f62ce452ca3184_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i099191310b124b1e81080dfde278c6a1_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i936534e2d9074d2ca70fe416bd8db58a_D20210323-20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bngo:CowenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-23</startDate>
            <endDate>2021-03-23</endDate>
        </period>
    </context>
    <context id="i75942e4e55054f78886bed570f1251f3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bngo:CowenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3978d66a078d4604a9b13bbc463817d9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i576e4374ad8d4ed4b487ff0388600fbb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i14c68bbc58d744e486a0c8a007611aa9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i87e1c72584cb4efa9e7e2a7589d92a4d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaefaeb1bcc134ff2b57adb93646ab3a3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iac856732b955418489f120209c032ca1_D20210512-20210512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bngo:RErikHolmlinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-12</startDate>
            <endDate>2021-05-12</endDate>
        </period>
    </context>
    <context id="ic7ef34e0c67c4f8d810c6f8f14d356e4_D20210512-20210512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bngo:MarkOldakowskiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-12</startDate>
            <endDate>2021-05-12</endDate>
        </period>
    </context>
    <context id="i553916c7e88a4b47a7275965698ebdb5_D20210512-20210512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bngo:VestingStatusAxis">bngo:TimeBasedVestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bngo:RErikHolmlinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-12</startDate>
            <endDate>2021-05-12</endDate>
        </period>
    </context>
    <context id="ie0eae5cf1a454c6a93daea25421b1ac6_D20210512-20210512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bngo:VestingStatusAxis">bngo:PerformanceSatisfactionVestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bngo:RErikHolmlinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-12</startDate>
            <endDate>2021-05-12</endDate>
        </period>
    </context>
    <context id="ia7f20b922d82432990b90d2c4766e208_D20210512-20210512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bngo:VestingStatusAxis">bngo:PerformanceSatisfactionVestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bngo:RErikHolmlinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-12</startDate>
            <endDate>2021-05-12</endDate>
        </period>
    </context>
    <context id="if952551a9010425ca3350af97034ba84_D20210512-20210512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bngo:VestingStatusAxis">bngo:PerformanceSatisfactionVestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bngo:RErikHolmlinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-12</startDate>
            <endDate>2021-05-12</endDate>
        </period>
    </context>
    <context id="if35c609f5b2b4a87a6bc4013c2bc1db7_D20210512-20210512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bngo:VestingStatusAxis">bngo:TimeBasedVestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bngo:MarkOldakowskiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-12</startDate>
            <endDate>2021-05-12</endDate>
        </period>
    </context>
    <context id="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="ib33b784ee1ca47bdb4a6e098ee129696_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bngo:EscrowedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="i16b00547face45e1b37c18f6b4043c7b_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i056e748dff1445bf9ed9183ca6be7827_I20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-21</instant>
        </period>
    </context>
    <context id="idc54661388eb4fe880e68defa355cc59_I20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-21</instant>
        </period>
    </context>
    <context id="i277d7d0d7df14699a128ed991162d604_I20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-21</instant>
        </period>
    </context>
    <context id="i08b91758924d4450afbd57d83b618e31_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if4a769484c39497e8dc3a7a689f2d800_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bngo:BusinessCombinationInfrequentAdjustmentsAxis">bngo:BusinessCombinationInfrequentAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="payment">
        <measure>bngo:payment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80L2ZyYWc6YzEyNGU2OGI2ZTdlNDFiZThhZmQ0ZWJmYTJjNWY4OWIvdGFibGU6OWNjYmU0NGJjMGUwNGEwZGI0MzYwMjlmYTQ3ZWQxOGYvdGFibGVyYW5nZTo5Y2NiZTQ0YmMwZTA0YTBkYjQzNjAyOWZhNDdlZDE4Zl8xLTEtMS0xLTA_8afae427-1636-494a-9ea6-c0768cbd17aa">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80L2ZyYWc6YzEyNGU2OGI2ZTdlNDFiZThhZmQ0ZWJmYTJjNWY4OWIvdGFibGU6OWNjYmU0NGJjMGUwNGEwZGI0MzYwMjlmYTQ3ZWQxOGYvdGFibGVyYW5nZTo5Y2NiZTQ0YmMwZTA0YTBkYjQzNjAyOWZhNDdlZDE4Zl8yLTEtMS0xLTA_db0fc019-4277-42c7-8177-0afc0143fdac">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80L2ZyYWc6YzEyNGU2OGI2ZTdlNDFiZThhZmQ0ZWJmYTJjNWY4OWIvdGFibGU6OWNjYmU0NGJjMGUwNGEwZGI0MzYwMjlmYTQ3ZWQxOGYvdGFibGVyYW5nZTo5Y2NiZTQ0YmMwZTA0YTBkYjQzNjAyOWZhNDdlZDE4Zl8zLTEtMS0xLTA_78042370-ea59-45ca-94d5-94fdb44cc647">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80L2ZyYWc6YzEyNGU2OGI2ZTdlNDFiZThhZmQ0ZWJmYTJjNWY4OWIvdGFibGU6OWNjYmU0NGJjMGUwNGEwZGI0MzYwMjlmYTQ3ZWQxOGYvdGFibGVyYW5nZTo5Y2NiZTQ0YmMwZTA0YTBkYjQzNjAyOWZhNDdlZDE4Zl80LTEtMS0xLTA_c4398230-9ec8-4f1d-bb80-7e1f960b1be9">0001411690</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80L2ZyYWc6YzEyNGU2OGI2ZTdlNDFiZThhZmQ0ZWJmYTJjNWY4OWIvdGFibGU6OWNjYmU0NGJjMGUwNGEwZGI0MzYwMjlmYTQ3ZWQxOGYvdGFibGVyYW5nZTo5Y2NiZTQ0YmMwZTA0YTBkYjQzNjAyOWZhNDdlZDE4Zl81LTEtMS0xLTA_0f30a455-653d-46fb-8688-1c04d525dbe0">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i73e99ee813de47559aff9fc89de5f48c_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xMTA1L2ZyYWc6ZDc1NjRjYjcwNGM3NDkzYzhlMzRmMmNjYThlNjk2NmQvdGFibGU6NTAzMDYxMDNiZGJkNGE3NGFjYjI3N2MyYTI4ZjZhZmUvdGFibGVyYW5nZTo1MDMwNjEwM2JkYmQ0YTc0YWNiMjc3YzJhMjhmNmFmZV8wLTEtMS0xLTM4MjI_5b21cfc0-d0b9-418e-a57e-ab1c6c724c88">P9M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ifef7e1ffa1fc47e6b55595ac8be5b218_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xMTA1L2ZyYWc6ZDc1NjRjYjcwNGM3NDkzYzhlMzRmMmNjYThlNjk2NmQvdGFibGU6NTAzMDYxMDNiZGJkNGE3NGFjYjI3N2MyYTI4ZjZhZmUvdGFibGVyYW5nZTo1MDMwNjEwM2JkYmQ0YTc0YWNiMjc3YzJhMjhmNmFmZV8xLTEtMS0xLTM4MjI_fadf9178-d4e2-46ad-a555-c27a876b8504">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i47e9e0fd70444455a6640482ac8e5229_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xMTA1L2ZyYWc6ZDc1NjRjYjcwNGM3NDkzYzhlMzRmMmNjYThlNjk2NmQvdGFibGU6NTAzMDYxMDNiZGJkNGE3NGFjYjI3N2MyYTI4ZjZhZmUvdGFibGVyYW5nZTo1MDMwNjEwM2JkYmQ0YTc0YWNiMjc3YzJhMjhmNmFmZV8yLTEtMS0xLTM4MjI_16de30a0-138c-4fd9-9567-212859ea8cd9">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <dei:DocumentType
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yMTg3_4547da00-c3b9-48bb-b325-37935c327e88">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NTY2YmJhMDIzNjY0NDRmZGE0ZTZkNDdkZjEzYzNjZjgvdGFibGVyYW5nZTo1NjZiYmEwMjM2NjQ0NGZkYTRlNmQ0N2RmMTNjM2NmOF8wLTAtMS0xLTA_600f4e4c-6153-4368-af07-9b207b5936f9">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yNTA_f50cce26-3748-409f-bd82-188e49a8c8d6">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NWE4Yjk1NTU0YWVjNDhkYmI1NTdiZWYzYTdlMTk3M2IvdGFibGVyYW5nZTo1YThiOTU1NTRhZWM0OGRiYjU1N2JlZjNhN2UxOTczYl8wLTAtMS0xLTA_3683c47b-53bf-4c72-a81e-51fd0f7b1660">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yMTg4_31c98372-8991-4e78-aa7c-f84ca7c062e3">001-38613</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yMTgy_22c8666d-910e-4fc1-b32a-159c4c99d76a">Bionano Genomics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NDM0ZGM0ODA3OWZhNGQzZmFiMTIwYmEyZjdmY2M0YTEvdGFibGVyYW5nZTo0MzRkYzQ4MDc5ZmE0ZDNmYWIxMjBiYTJmN2ZjYzRhMV8wLTAtMS0xLTA_59800022-f119-45a7-a842-13cc0db037de">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NDM0ZGM0ODA3OWZhNGQzZmFiMTIwYmEyZjdmY2M0YTEvdGFibGVyYW5nZTo0MzRkYzQ4MDc5ZmE0ZDNmYWIxMjBiYTJmN2ZjYzRhMV8wLTItMS0xLTA_b69ee310-b17e-452f-a837-18320c3587a9">26-1756290</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NDM0ZGM0ODA3OWZhNGQzZmFiMTIwYmEyZjdmY2M0YTEvdGFibGVyYW5nZTo0MzRkYzQ4MDc5ZmE0ZDNmYWIxMjBiYTJmN2ZjYzRhMV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo2Nzg4MDczOGUzY2Q0NmEwYjg5NmQ5ZjdkZWI4NGI3NF80_7051dbb9-6170-4d51-b5b4-fa90d17a552d">9540 Towne Centre Drive, Suite 100</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NDM0ZGM0ODA3OWZhNGQzZmFiMTIwYmEyZjdmY2M0YTEvdGFibGVyYW5nZTo0MzRkYzQ4MDc5ZmE0ZDNmYWIxMjBiYTJmN2ZjYzRhMV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo2Nzg4MDczOGUzY2Q0NmEwYjg5NmQ5ZjdkZWI4NGI3NF84_bc7e1a6e-254b-4c00-8fb1-551db83f079f">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NDM0ZGM0ODA3OWZhNGQzZmFiMTIwYmEyZjdmY2M0YTEvdGFibGVyYW5nZTo0MzRkYzQ4MDc5ZmE0ZDNmYWIxMjBiYTJmN2ZjYzRhMV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo2Nzg4MDczOGUzY2Q0NmEwYjg5NmQ5ZjdkZWI4NGI3NF8xMg_cb3b7876-57f4-4a5c-858f-d5a4520722a3">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NDM0ZGM0ODA3OWZhNGQzZmFiMTIwYmEyZjdmY2M0YTEvdGFibGVyYW5nZTo0MzRkYzQ4MDc5ZmE0ZDNmYWIxMjBiYTJmN2ZjYzRhMV8zLTItMS0xLTA_fa46b937-cf3e-41fb-b830-d3395797bb13">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yMTkw_3c939b47-924c-489f-898a-b6004e96454b">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yMTgz_dc4c47c7-999c-4e98-baff-a29888ff2769">888-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i6ad6314fd03947658c809e9599894823_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NjI1ZTZjOTgwYzFkNDFhOTliNGZiODQ3MGRkZTA2MTEvdGFibGVyYW5nZTo2MjVlNmM5ODBjMWQ0MWE5OWI0ZmI4NDcwZGRlMDYxMV8xLTAtMS0xLTA_7bcf8976-7c15-4dc4-9bdc-ec78b764396d">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6ad6314fd03947658c809e9599894823_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NjI1ZTZjOTgwYzFkNDFhOTliNGZiODQ3MGRkZTA2MTEvdGFibGVyYW5nZTo2MjVlNmM5ODBjMWQ0MWE5OWI0ZmI4NDcwZGRlMDYxMV8xLTItMS0xLTA_929257d3-9486-4db6-92cf-b02dbd63bb5b">BNGO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6ad6314fd03947658c809e9599894823_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NjI1ZTZjOTgwYzFkNDFhOTliNGZiODQ3MGRkZTA2MTEvdGFibGVyYW5nZTo2MjVlNmM5ODBjMWQ0MWE5OWI0ZmI4NDcwZGRlMDYxMV8xLTQtMS0xLTA_422431cb-fe07-4296-9c30-9cd432762a57">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i42cdbd7cb5924627bda45f9725b2407e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NjI1ZTZjOTgwYzFkNDFhOTliNGZiODQ3MGRkZTA2MTEvdGFibGVyYW5nZTo2MjVlNmM5ODBjMWQ0MWE5OWI0ZmI4NDcwZGRlMDYxMV8yLTAtMS0xLTA_23379e8a-4eed-4e5c-ad5d-37210d6e3baf">Warrants to purchase Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i42cdbd7cb5924627bda45f9725b2407e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NjI1ZTZjOTgwYzFkNDFhOTliNGZiODQ3MGRkZTA2MTEvdGFibGVyYW5nZTo2MjVlNmM5ODBjMWQ0MWE5OWI0ZmI4NDcwZGRlMDYxMV8yLTItMS0xLTA_479b73bd-3f91-4ae5-a856-09a37611c907">BNGOW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i42cdbd7cb5924627bda45f9725b2407e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6NjI1ZTZjOTgwYzFkNDFhOTliNGZiODQ3MGRkZTA2MTEvdGFibGVyYW5nZTo2MjVlNmM5ODBjMWQ0MWE5OWI0ZmI4NDcwZGRlMDYxMV8yLTQtMS0xLTA_b074da41-b7c4-4cf9-983e-9325831e7f7d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yMTg0_74e44256-fee4-4d4c-891b-9e7f87431ec5">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yMTkx_b4904312-d2d5-4dc7-9ec3-b1542721ef49">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6MzczOTgzNjRjOTIxNDVmMjg3MzVmYzA3NTE0ZGIxNWEvdGFibGVyYW5nZTozNzM5ODM2NGM5MjE0NWYyODczNWZjMDc1MTRkYjE1YV8xLTAtMS0xLTA_00ad71f1-98e6-4c0b-bb44-6f465c6fd0be">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6MzczOTgzNjRjOTIxNDVmMjg3MzVmYzA3NTE0ZGIxNWEvdGFibGVyYW5nZTozNzM5ODM2NGM5MjE0NWYyODczNWZjMDc1MTRkYjE1YV8xLTQtMS0xLTA_cfda7d79-4508-4963-9326-a608d3fa5e8b">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGFibGU6MzczOTgzNjRjOTIxNDVmMjg3MzVmYzA3NTE0ZGIxNWEvdGFibGVyYW5nZTozNzM5ODM2NGM5MjE0NWYyODczNWZjMDc1MTRkYjE1YV8yLTQtMS0xLTA_a271fbd2-e63e-4220-a5d9-f4792ee229ce">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yMTg2_612e6c53-0512-43c2-a2be-17f3bb6137d5">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV8yMTg1_c2449409-52ba-4dde-a90c-962e86d7be1c">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i0d4506743a254bb993d79cd1ba20bf03_I20210507"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xL2ZyYWc6YmRmMDU4Y2JlNzRjNDJkZTkyZTU5NDgyYzE4MDBiYjUvdGV4dHJlZ2lvbjpiZGYwNThjYmU3NGM0MmRlOTJlNTk0ODJjMTgwMGJiNV82MDQ3MzEzOTU0OTkw_f627eeb9-8ca9-4b8e-8517-c73213d07761"
      unitRef="shares">278849616</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNC0xLTEtMS0w_8748b6b2-04c3-4f7b-96f9-443b2c5ae8a8"
      unitRef="usd">362057000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNC0zLTEtMS0w_f25abc8c-af76-4a07-a4fc-6f2d15e4fc79"
      unitRef="usd">38449000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNS0wLTEtMS0wL3RleHRyZWdpb246ZDNmYzFjZDk1N2QzNGZmNjljNzY5N2M2NmY0MDI2N2FfNjA0NzMxMzk1Mjk3OA_16a66c75-0ebf-4897-83df-c54cc0158880"
      unitRef="usd">2091000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNS0wLTEtMS0wL3RleHRyZWdpb246ZDNmYzFjZDk1N2QzNGZmNjljNzY5N2M2NmY0MDI2N2FfNjA0NzMxMzk1Mjk5MA_24b72b64-a04c-468f-8b77-f4bd6cdae5d0"
      unitRef="usd">2119000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNS0xLTEtMS0w_80d7248e-5617-4786-83ca-50b1f78a2b33"
      unitRef="usd">1992000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNS0zLTEtMS0w_d8da3dac-dd87-46ae-957d-da4146378806"
      unitRef="usd">2775000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNi0xLTEtMS0w_b1c042fb-f5c9-4ee7-ad74-af63ac59c97b"
      unitRef="usd">3036000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNi0zLTEtMS0w_3b98f398-d0c1-4d22-9b5b-80fc6f60f02c"
      unitRef="usd">3316000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNy0xLTEtMS0w_fd7cb45a-a40d-4016-bf2f-0c51b5b3c958"
      unitRef="usd">3166000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfNy0zLTEtMS0w_3cd466fc-8ebb-4fe2-8689-9358b9188cee"
      unitRef="usd">2250000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfOC0xLTEtMS0w_f3e09802-9aeb-481e-bcb7-0810e55dce7e"
      unitRef="usd">370251000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfOC0zLTEtMS0w_d045fd73-1406-4832-a76e-d00218df76cc"
      unitRef="usd">46790000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfOS0xLTEtMS0w_8295b7c0-cf1b-4a9e-ae2f-c790c7603031"
      unitRef="usd">5806000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfOS0zLTEtMS0w_e6ab3f33-e919-44c7-8084-61c760263504"
      unitRef="usd">4910000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTAtMS0xLTEtMA_0466927f-59be-4faf-add3-103be43ca8ae"
      unitRef="usd">1396000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTAtMy0xLTEtMA_244e7bf0-41f8-441c-b087-918b55fce09e"
      unitRef="usd">1475000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTEtMS0xLTEtMA_b8c25d54-3506-4013-9055-4edd39a46a53"
      unitRef="usd">7173000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTEtMy0xLTEtMA_0f1470d5-bfad-483e-877d-0c4eeffe3200"
      unitRef="usd">7173000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTItMS0xLTEtMjA3_d8129903-36ba-41b5-8541-85d23319f9e2"
      unitRef="usd">235000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTItMy0xLTEtMTQw_e2dfb4f0-9489-4b0b-9b8d-56ef30c2ba97"
      unitRef="usd">103000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTItMS0xLTEtMA_54058fc6-8691-4d44-b1d8-89c4868eb16c"
      unitRef="usd">384861000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTItMy0xLTEtMA_5680b065-0520-44fa-bfe3-26b47519c32c"
      unitRef="usd">60451000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTYtMS0xLTEtMA_d3edda00-d909-472f-bf53-b4e2eba11fe0"
      unitRef="usd">2209000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTYtMy0xLTEtMA_a6a998b3-4ecb-40e9-8091-900fc57fd3aa"
      unitRef="usd">2930000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTctMS0xLTEtMA_d6834ba5-d508-4de1-a8b0-d063e7d98c1e"
      unitRef="usd">4659000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTctMy0xLTEtMA_4f5ab9e0-357f-4ece-a030-1bf543f070f9"
      unitRef="usd">5599000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTgtMS0xLTEtMA_cecd3e10-221e-4725-bcd7-e2455165c065"
      unitRef="usd">301000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMTgtMy0xLTEtMA_ea18a16b-00f1-49fd-a8be-0d971675d602"
      unitRef="usd">416000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjAtMS0xLTEtMA_08a8b66d-1e57-4a42-985c-097926c6f303"
      unitRef="usd">7169000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjAtMy0xLTEtMA_051689bc-227b-402e-b5ff-48cbdd2fd42d"
      unitRef="usd">8945000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjEtMS0xLTEtMA_a343fa2c-8a4e-4a99-83c9-3d9bf8fc7342"
      unitRef="usd">14866000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjEtMy0xLTEtMA_5cb22b5b-af58-4c00-b54a-0b4439eae97f"
      unitRef="usd">16326000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjItMS0xLTEtMA_3a7bedb3-2f5a-4163-a213-fc35ab23e34c"
      unitRef="usd">108000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjItMy0xLTEtMA_77051f98-e9d1-4a35-82b5-0e3143c71bba"
      unitRef="usd">98000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjQtMS0xLTEtMA_f5eedad2-81ae-4c03-8aac-8032f2dc70ff"
      unitRef="usd">22143000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjQtMy0xLTEtMA_db9a22cb-1691-4b5a-8300-7151f52e8f1c"
      unitRef="usd">25369000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjUtMS0xLTEtMA_3c190fb5-a6cb-4253-bf62-b516d7438f27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMjUtMy0xLTEtMA_307b79f6-0d03-475f-8a2c-3b92bf2a9f4e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMC0xLTEtNDAwNS90ZXh0cmVnaW9uOjkwNzk4MWIxYTE4YjQ2MzJhZjlkMjlmZmFjZjcyMmJjXzYwNDczMTM5NTI5MTE_8ce98ccc-c109-417e-b069-b27d5819b4cc"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMC0xLTEtNDAwNS90ZXh0cmVnaW9uOjkwNzk4MWIxYTE4YjQ2MzJhZjlkMjlmZmFjZjcyMmJjXzYwNDczMTM5NTI5MTE_fb72b33d-90b1-4515-b8ef-ace916d072f6"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMC0xLTEtNDAwNS90ZXh0cmVnaW9uOjkwNzk4MWIxYTE4YjQ2MzJhZjlkMjlmZmFjZjcyMmJjXzYwNDczMTM5NTI5MjQ_89d6c04d-87df-4667-8258-0c8647d61f60"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMC0xLTEtNDAwNS90ZXh0cmVnaW9uOjkwNzk4MWIxYTE4YjQ2MzJhZjlkMjlmZmFjZjcyMmJjXzYwNDczMTM5NTI5MjQ_fa1594b9-4260-4a5c-b2b4-b0ea473eb188"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMC0xLTEtNDAwNS90ZXh0cmVnaW9uOjkwNzk4MWIxYTE4YjQ2MzJhZjlkMjlmZmFjZjcyMmJjXzIxOTkwMjMyNTU3NDA_0fb8009c-5365-4533-ac36-24c5636782d5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMC0xLTEtNDAwNS90ZXh0cmVnaW9uOjkwNzk4MWIxYTE4YjQ2MzJhZjlkMjlmZmFjZjcyMmJjXzIxOTkwMjMyNTU3NDA_6c50da3b-269f-40a8-a80e-4e958bc6f52e"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMC0xLTEtNDAwNS90ZXh0cmVnaW9uOjkwNzk4MWIxYTE4YjQ2MzJhZjlkMjlmZmFjZjcyMmJjXzIxOTkwMjMyNTU3NDA_907a8b15-9ebd-4fd3-b38e-76757c71cfe7"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMC0xLTEtNDAwNS90ZXh0cmVnaW9uOjkwNzk4MWIxYTE4YjQ2MzJhZjlkMjlmZmFjZjcyMmJjXzIxOTkwMjMyNTU3NDA_ce093cf6-26de-4d8e-848e-e40f166676ea"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMS0xLTEtNDAwNQ_e570050a-1cac-4d64-8413-85ce540304f1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzQtMy0xLTEtNDAwNQ_87ff3845-1420-4cc5-89b5-cb7e2915dd9f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE3NmFjNGRmYmU4MzQ5MjZhYWJmMjVlZjg3ZTdmZWRkXzE4_c25a4a0f-3aba-4b71-8164-2f89ee815300"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE3NmFjNGRmYmU4MzQ5MjZhYWJmMjVlZjg3ZTdmZWRkXzE4_d991ecbf-6547-4271-9a49-eefc34c6cb6e"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE3NmFjNGRmYmU4MzQ5MjZhYWJmMjVlZjg3ZTdmZWRkXzMy_009edd4c-33fd-4bac-9b93-388fb34573b2"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE3NmFjNGRmYmU4MzQ5MjZhYWJmMjVlZjg3ZTdmZWRkXzMy_b310e8c5-fbfb-40b0-b1ba-3d1d4b1978e4"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE3NmFjNGRmYmU4MzQ5MjZhYWJmMjVlZjg3ZTdmZWRkXzEwMw_2f17f104-47c8-45bb-8ed9-54c01a8afc7d"
      unitRef="shares">278794000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE3NmFjNGRmYmU4MzQ5MjZhYWJmMjVlZjg3ZTdmZWRkXzEwMw_6deb2a24-a92d-4b87-8071-c3b588cd6d80"
      unitRef="shares">278794000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE3NmFjNGRmYmU4MzQ5MjZhYWJmMjVlZjg3ZTdmZWRkXzExMA_373c4d9e-ebc3-4587-9661-65b8fff2dcec"
      unitRef="shares">189953000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE3NmFjNGRmYmU4MzQ5MjZhYWJmMjVlZjg3ZTdmZWRkXzExMA_d5ee47ab-eb11-4d3e-9af2-05b6065727ae"
      unitRef="shares">189953000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMS0xLTEtMA_7f64ebea-e552-4472-ad34-b7add776fc82"
      unitRef="usd">28000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzMtMy0xLTEtMA_e6c91093-664c-4f93-8e9e-a66b43fec356"
      unitRef="usd">19000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzUtMS0xLTEtMA_66e3d5d5-bfe9-47c6-b520-fdcea758a582"
      unitRef="usd">516321000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzUtMy0xLTEtMA_3dee2f43-e6df-4fce-b2cb-2a209ec4239d"
      unitRef="usd">178747000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzYtMS0xLTEtMA_4782128a-4f7e-4bbb-9c31-904e81227f60"
      unitRef="usd">-153631000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzYtMy0xLTEtMA_5a3a4836-da1a-4d79-8dc3-51619be4e591"
      unitRef="usd">-143684000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzctMS0xLTEtMA_9b581be3-72d4-4ef7-b08b-9a3abc455a76"
      unitRef="usd">362718000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzctMy0xLTEtMA_f17e3def-e7e1-4ea2-ba30-ff52c9d0a4aa"
      unitRef="usd">35082000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzgtMS0xLTEtMA_4c778957-4c2a-4eb4-9aef-c8fb0bd6db9c"
      unitRef="usd">384861000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xNi9mcmFnOjE3MTIyYjZkNWM0NDRkNjBiODM3Mjg1Njk2MjlkZGQ4L3RhYmxlOjUwNGE1MGRjMmU5MzQzNGY4MmYwNzA0YTI0OWE2MmI4L3RhYmxlcmFuZ2U6NTA0YTUwZGMyZTkzNDM0ZjgyZjA3MDRhMjQ5YTYyYjhfMzgtMy0xLTEtMA_77b357c7-ed93-4d11-9a83-2825922df776"
      unitRef="usd">60451000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c91415129394ba299d78d9ff4f67598_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMy0xLTEtMS0w_073a8ec8-7fe5-431a-b516-766b861c3446"
      unitRef="usd">2049000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fd535c416994e7e9ac50885ecf579a9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMy0zLTEtMS0w_7d73003b-5dd7-42f6-be31-3bd1861553bf"
      unitRef="usd">983000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6482b3482014875b2110f7ee933cadf_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfNC0xLTEtMS0w_9f6d0297-8b18-4e99-a0fa-b29d141255d4"
      unitRef="usd">1119000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb9a8cd4c6ae43b780d83f3db03387c6_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfNC0zLTEtMS0w_47feb14e-3846-41fa-a6aa-384b25af2630"
      unitRef="usd">153000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfNS0xLTEtMS0w_421bd617-6958-4b39-85bf-de028a3570ad"
      unitRef="usd">3168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfNS0zLTEtMS0w_aaf80271-ad0e-4814-9f47-a70f7a7ceabe"
      unitRef="usd">1136000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7c91415129394ba299d78d9ff4f67598_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfNy0xLTEtMS0w_cd4605ca-fb91-40b4-a68d-b74d9768bb24"
      unitRef="usd">1513000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6fd535c416994e7e9ac50885ecf579a9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfNy0zLTEtMS0w_25109434-105d-4920-a0f1-300c3a5ef287"
      unitRef="usd">774000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic6482b3482014875b2110f7ee933cadf_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfOC0xLTEtMS0w_bc53c92d-2ec9-440f-99a0-f33897708b71"
      unitRef="usd">612000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icb9a8cd4c6ae43b780d83f3db03387c6_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfOC0zLTEtMS0w_5c1040a2-7309-4b2a-9a12-e7d9aa29c960"
      unitRef="usd">82000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfOS0xLTEtMS0w_c7cd19de-1038-456d-b9f6-2c8e88c47949"
      unitRef="usd">2125000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfOS0zLTEtMS0w_462b621a-1c0f-4b99-9872-8e173ce2818f"
      unitRef="usd">856000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTEtMS0xLTEtMA_9c1db51e-014a-4da6-8c80-4e25c4df60d0"
      unitRef="usd">2678000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTEtMy0xLTEtMA_97629cca-f1ca-4160-bcb3-06de8ae96be0"
      unitRef="usd">2674000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTItMS0xLTEtMA_41c91116-dce5-4324-a63f-638975b8b94d"
      unitRef="usd">9528000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTItMy0xLTEtMA_e16cdf85-c635-4b6e-9c84-839fa0a26950"
      unitRef="usd">7368000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTMtMS0xLTEtMA_58a7a189-58f9-4155-9fd1-0584526cd85d"
      unitRef="usd">12206000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTMtMy0xLTEtMA_3093cce0-f61d-4757-8272-8f4927e46b0a"
      unitRef="usd">10042000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTQtMS0xLTEtMA_db2f11b3-cfb6-45c0-9c3e-9d5a9344d4d2"
      unitRef="usd">-11163000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTQtMy0xLTEtMA_bcaf0729-8d81-4ad0-ac18-ae11d2b336c1"
      unitRef="usd">-9762000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTYtMS0xLTEtMA_e192855e-1453-4886-83da-f08fc2c5b551"
      unitRef="usd">538000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTYtMy0xLTEtMA_ed7c6f81-44f4-443d-ac48-9e01a30bb7b6"
      unitRef="usd">761000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTctMS0xLTEtMA_9a1fb2b4-7980-435d-899c-341adb0bdd43"
      unitRef="usd">1775000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTctMy0xLTEtMA_731d40a4-83c3-43f1-bdd2-898971a4c356"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTgtMS0xLTEtMA_22dade0b-412a-416b-b9fa-311b31414bdf"
      unitRef="usd">-15000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTgtMy0xLTEtMA_38c9beb0-ee76-4005-8698-cf75114ad3a7"
      unitRef="usd">18000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTktMS0xLTEtMA_30babe9f-fef9-455b-944f-3a074ac34e45"
      unitRef="usd">1222000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMTktMy0xLTEtMA_73e58355-cf0c-4a5a-8233-a69d97a8f7d4"
      unitRef="usd">-743000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjAtMS0xLTEtMA_a42a8928-bc87-47ae-842d-e7201172bd41"
      unitRef="usd">-9941000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjAtMy0xLTEtMA_56da9190-c537-46a2-875a-adbcab0587da"
      unitRef="usd">-10505000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjEtMS0xLTEtMA_aa29470f-945c-470e-83af-b2673322db6f"
      unitRef="usd">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjEtMy0xLTEtMA_8a36103f-057d-4ef7-97a1-8172a2720ef0"
      unitRef="usd">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjItMS0xLTEtMA_31836e57-a651-454c-9712-9b8f5e1281b9"
      unitRef="usd">-9947000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjItMy0xLTEtMA_9176f508-9ed2-4e9c-a83d-ec4eb25d0444"
      unitRef="usd">-10510000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjMtMS0xLTEtMA_4f335e45-24f0-442f-ab42-e486a2164391"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjMtMy0xLTEtMA_ccd0dc72-d916-4432-8416-ca4d00420dd6"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjQtMS0xLTEtMA_73f2af46-1baf-4cf8-a418-88d270592045"
      unitRef="shares">263939000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8xOS9mcmFnOmY5MWU2N2JjMTQzODQ2ZWI5OGUyZDgxY2ZiZTllYjFhL3RhYmxlOjZlMzAxZjIzNjU4ZTQ4NDc4YjczNWE5MWEwOTI5NTg3L3RhYmxlcmFuZ2U6NmUzMDFmMjM2NThlNDg0NzhiNzM1YTkxYTA5Mjk1ODdfMjQtMy0xLTEtMA_51416b18-d6e5-4983-9e59-3f73a658be00"
      unitRef="shares">35569000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="i50064f20ffdd4afea720ea427be539bb_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMi0yLTEtMS0zNTc_074c226d-6e96-4e56-8adc-32b477348603"
      unitRef="shares">34274000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i50064f20ffdd4afea720ea427be539bb_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMi00LTEtMS0zNTc_c8f6db3f-26da-4aad-a741-30f04b16cedf"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib8da4c0227db460e9bf1844ec2b9c95d_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMi02LTEtMS0zNTc_caa9225a-3a16-4795-b28b-1522a96b5a0e"
      unitRef="usd">106188000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifb3bab8827334a58a6a6a830691d74a0_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMi04LTEtMS0zNTc_f7d83b4d-5f3d-4cf6-860f-60bdf36e84fa"
      unitRef="usd">-102577000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if2cf00dd543e42b9b366c557731d37c5_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMi0xMC0xLTEtMzU3_4385c77e-39d9-4c3a-a6a9-bf7bd9d89a3c"
      unitRef="usd">3614000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib602f85292f845748876e64aa8d4d2bf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMy02LTEtMS0zNTc_4c59d56e-111a-48ce-b2dd-9d5a19535ebf"
      unitRef="usd">328000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMy0xMC0xLTEtMzU3_f3d8e3d2-7eaa-49cf-b950-e0d9dc255d36"
      unitRef="usd">328000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <bngo:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i90fd0d4651674579a500a712406f6ae5_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfNC0yLTEtMS0zNTc_513d0004-f29d-454c-9c8a-a4ee89c5e406"
      unitRef="shares">3478000</bngo:StockIssuedDuringPeriodSharesWarrantsExercised>
    <bngo:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i90fd0d4651674579a500a712406f6ae5_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfNC00LTEtMS0zNTc_3b78de78-f4ad-45b3-b0cd-5b9e7207b6f2"
      unitRef="usd">0</bngo:StockIssuedDuringPeriodValueWarrantsExercised>
    <bngo:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ib602f85292f845748876e64aa8d4d2bf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfNC02LTEtMS0zNTc_05da22a5-0292-4cf2-a034-c5ea59f3441d"
      unitRef="usd">2355000</bngo:StockIssuedDuringPeriodValueWarrantsExercised>
    <bngo:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfNC0xMC0xLTEtMzU3_f223b9c2-446f-4335-beeb-7dbc8c2a0fce"
      unitRef="usd">2355000</bngo:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="if30fe967ef764693b2f27ac326b09de3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfNS04LTEtMS0zNTc_807a693d-a28a-46bb-a632-10f2d9b4713e"
      unitRef="usd">-10510000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfNS0xMC0xLTEtMzU3_f4106568-c6a6-46d0-a5aa-c167174702f4"
      unitRef="usd">-10510000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i48e256cb75bb49168f54108a75282496_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzAtMi0xLTEtMA_3c453a0e-e5f2-4e59-987f-4e864feed951"
      unitRef="shares">37752000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i48e256cb75bb49168f54108a75282496_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzAtNC0xLTEtMA_8234c6f2-e8f3-4f35-b834-41ebe07c6d38"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idd38c3fd47774b69bb42677bde40939f_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzAtNi0xLTEtMA_1c6420ea-79d5-4dfe-b363-5efeb500f0c1"
      unitRef="usd">108871000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifaaa0a63cf624180ac4a400546f607cd_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzAtOC0xLTEtMA_41947808-42f0-4d67-848e-f8500572c774"
      unitRef="usd">-113087000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id64fc47c76a34812be47288f3a639104_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzAtMTAtMS0xLTA_76f3df03-f36d-4810-95d8-fb4f7a4d96d8"
      unitRef="usd">-4213000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="id1721a6a1dce465eaa006a924a3e1573_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjYtMi0xLTEtMzgz_359b97c0-c5b3-4a24-bbd8-bd28035be243"
      unitRef="shares">189953000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id1721a6a1dce465eaa006a924a3e1573_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjYtNC0xLTEtMzgz_582ec009-65d1-4ab3-a6cb-99e63e7a645c"
      unitRef="usd">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia593fc3aadb14fda8e66f3cddea13f4a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjYtNi0xLTEtMzgz_117d6954-d5b7-47a6-a17b-b29a4807bcf8"
      unitRef="usd">178747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9dd95436f5fd45a5a4faccdc492a6ccc_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjYtOC0xLTEtMzgz_108b1d45-1876-4907-9937-acf4fcbc8865"
      unitRef="usd">-143684000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjYtMTAtMS0xLTM4Mw_614e2c17-5c36-4a07-ae09-f24cad7ec8cf"
      unitRef="usd">35082000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7fa524c836dc4ba397a51ffc0afdbbd4_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjctMi0xLTEtMzg2_d3736006-06c6-4905-9412-f0704915ceee"
      unitRef="shares">102000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7c36739694c340cbb6da644df93b34b0_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjctNi0xLTEtMzg2_b7d50dea-f6d6-4daa-ba04-e3f98cae8f1f"
      unitRef="usd">333000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjctMTAtMS0xLTM4Ng_f5399de5-2fbd-46f9-8c36-0948101a2c24"
      unitRef="usd">333000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7c36739694c340cbb6da644df93b34b0_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjgtNi0xLTEtMzg2_a14e4b06-bcdb-44e7-9c3d-5d6603e03634"
      unitRef="usd">371000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjgtMTAtMS0xLTM4Ng_23b9b22e-d3c4-49af-b638-7fe0c45738c6"
      unitRef="usd">371000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7fa524c836dc4ba397a51ffc0afdbbd4_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjktMi0xLTEtMzg2_5ccfbe7d-9b34-4fd0-a482-2ba1b078c2af"
      unitRef="shares">78000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7fa524c836dc4ba397a51ffc0afdbbd4_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjktNC0xLTEtMzg2_e0bab42c-1016-4b63-bb1c-451ec56e56e2"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7c36739694c340cbb6da644df93b34b0_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjktNi0xLTEtMzg2_5ecdf187-7e20-419d-8606-3a9aaf76b1a4"
      unitRef="usd">327478000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMjktMTAtMS0xLTM4Ng_21816a0d-1264-403e-a93a-48b4ea0e7952"
      unitRef="usd">327486000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <bngo:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i7fa524c836dc4ba397a51ffc0afdbbd4_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzAtMi0xLTEtMzg2_94956858-5124-4ae2-b7d2-6e2731c9a74e"
      unitRef="shares">10739000</bngo:StockIssuedDuringPeriodSharesWarrantsExercised>
    <bngo:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i7fa524c836dc4ba397a51ffc0afdbbd4_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzAtNC0xLTEtMzg2_e37082a3-ec09-4342-9382-722b59eb6317"
      unitRef="usd">1000</bngo:StockIssuedDuringPeriodValueWarrantsExercised>
    <bngo:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i7c36739694c340cbb6da644df93b34b0_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzAtNi0xLTEtMzg2_d2bee5f7-6181-47f6-980e-4b3042599f5c"
      unitRef="usd">9392000</bngo:StockIssuedDuringPeriodValueWarrantsExercised>
    <bngo:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzAtMTAtMS0xLTM4Ng_817bd17b-d205-41b5-9775-5717fb342aca"
      unitRef="usd">9393000</bngo:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="i2f252ef06c56452aa5d46538864bff17_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzEtOC0xLTEtMzg2_9074e468-602a-4f2f-8c07-e1c05cb2b5de"
      unitRef="usd">-9947000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzEtMTAtMS0xLTM4Ng_c030da20-5179-473d-9f3b-463ce2c719d1"
      unitRef="usd">-9947000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i01c7339672134033bfa582f9fae89a1e_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzItMi0xLTEtMzg2_e3c2de3b-0509-4a2b-8182-05e22163c008"
      unitRef="shares">278794000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i01c7339672134033bfa582f9fae89a1e_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzItNC0xLTEtMzg2_3fb18a1b-8b0f-49e2-b947-834640c9c1b2"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5b58256688454d8e9bfdde4184797f9e_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzItNi0xLTEtMzg2_9eeee503-3442-4605-a45a-b4316d50d2bc"
      unitRef="usd">516321000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie5b24cb157134368bae94b71658f16be_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzItOC0xLTEtMzg2_a12f910c-e50e-4763-9847-af4df99b29c7"
      unitRef="usd">-153631000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yMi9mcmFnOjc3NTg0MTZhZmFlNjQxZTlhZDQ2NDM0YWRjZTg3YWI4L3RhYmxlOjAwYzIwMWZkNjQyYzQwMWViNjhmMDZmZWEyOTZkNTBhL3RhYmxlcmFuZ2U6MDBjMjAxZmQ2NDJjNDAxZWI2OGYwNmZlYTI5NmQ1MGFfMzItMTAtMS0xLTM4Ng_60ae82d8-92e6-4edb-8160-d11b06df5876"
      unitRef="usd">362718000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMy0xLTEtMS0w_d2165489-9995-4055-b530-9be2a3bf8b0c"
      unitRef="usd">-9947000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMy0zLTEtMS0w_a050db37-d494-4dd4-8216-0463233c0c6d"
      unitRef="usd">-10510000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNS0xLTEtMS0w_2674de53-3248-451c-a3ae-308f767c46c2"
      unitRef="usd">448000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNS0zLTEtMS0w_9651306b-f09e-4034-94f5-2bf0240fc050"
      unitRef="usd">296000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PaidInKindInterest
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNi0xLTEtMS0w_c2f5ffcd-b8ee-4b5d-bbbe-0bd5ceede61b"
      unitRef="usd">315000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNi0zLTEtMS0w_9f0a8632-cb41-4305-94a3-e5fc84ddfb49"
      unitRef="usd">379000</us-gaap:PaidInKindInterest>
    <us-gaap:ShareBasedCompensation
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNy0xLTEtMS0w_d32ef1e5-ae79-44e7-b02f-7e3bc3d2aeb0"
      unitRef="usd">371000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNy0zLTEtMS0w_1f3a7966-a9b0-4ae1-9498-218e6d6d17be"
      unitRef="usd">328000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfOC0xLTEtMS0w_3fbaa9f6-6f93-4b00-91dd-29a9fb0323a0"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfOC0zLTEtMS0w_1476ff16-a1c4-4258-888c-7910e574089f"
      unitRef="usd">958000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfOS0xLTEtMS0w_6ff95f7b-8a0b-4700-9dca-76702a551d2f"
      unitRef="usd">1775000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfOS0zLTEtMS0w_16d1b3d5-9eff-4758-aacf-9aa6d5f9e4cc"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTItMS0xLTEtMA_041d28fd-694a-408d-96f9-02ff65af79fd"
      unitRef="usd">-783000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTItMy0xLTEtMA_3f3f7a4b-62e5-45da-8e26-43b1c80b4eb6"
      unitRef="usd">-1261000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTMtMS0xLTEtMA_898a2c3c-0e84-40d0-9d68-1f1c291d69f2"
      unitRef="usd">961000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTMtMy0xLTEtMA_a990d555-b042-457a-bfaf-92bc569741f6"
      unitRef="usd">635000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTQtMS0xLTEtMA_fa15ecee-628d-4c47-9916-52d58adc7c7b"
      unitRef="usd">1049000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTQtMy0xLTEtMA_cfdf3404-05a3-45de-8c57-eb9bcb5b0d1a"
      unitRef="usd">-53000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTUtMS0xLTEtMA_84e71c15-48f6-4397-a18d-a824ab6e7e8a"
      unitRef="usd">-1045000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTUtMy0xLTEtMA_1cf4967b-eec6-40d0-be31-e1faa640bc9e"
      unitRef="usd">477000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTYtMS0xLTEtMA_8f428360-2fcd-4f91-aad2-0da4d928e05a"
      unitRef="usd">-1044000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTYtMy0xLTEtMA_01ce7de5-08de-4a78-9647-58083473db9d"
      unitRef="usd">-639000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTctMS0xLTEtMA_4e7a6914-364c-458c-be7a-a804bedda178"
      unitRef="usd">-13904000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMTctMy0xLTEtMA_05fb5fbc-a8fc-479c-909b-2302d73e3894"
      unitRef="usd">-8032000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjAtMS0xLTEtMA_1c18230b-49ed-4efd-bfb2-09bbaa944ed0"
      unitRef="usd">24000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjAtMy0xLTEtMA_0dfe6537-df76-49ee-9e39-dfdd08f687e3"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjEtMS0xLTEtMA_02692fc1-7f9c-4b0a-b709-f14358c31d29"
      unitRef="usd">-24000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjEtMy0xLTEtMA_ec5e82f6-3dee-4cd3-87d6-ab94f425af4c"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjQtMS0xLTEtMA_841861d4-6358-40ad-8d18-50ae2d1aae0d"
      unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjQtMy0xLTEtMA_0baab011-125c-498f-bb5e-e5da8e4b278e"
      unitRef="usd">2100000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjYtMS0xLTEtMA_9f505410-d1c8-468e-a8ca-ec6f30d2bef9"
      unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjYtMy0xLTEtMA_04af6ceb-afc2-4f1c-a3b3-0a27361145c7"
      unitRef="usd">761000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjctMS0xLTEtMA_a0ea70bf-7b08-478e-96cf-0d12d00c366d"
      unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjctMy0xLTEtMA_1ed2b754-50be-4870-b98a-f6b789c452bd"
      unitRef="usd">2156000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjgtMS0xLTEtMA_da444bd9-9c6b-41a5-a3f1-39ddee294de7"
      unitRef="usd">328635000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjgtMy0xLTEtMA_2d8e75ca-469c-4570-a58c-cc11991d2623"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjktMS0xLTEtMzI5Mw_a9e6feb7-cf63-4ca9-9a32-9d8852475fd3"
      unitRef="usd">825000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMjktMy0xLTEtMzcwNQ_947361b5-036f-4700-b48c-204b2db1670b"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzAtMS0xLTEtMA_41a20880-4b94-452a-8543-484d84665ac3"
      unitRef="usd">9726000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzAtMy0xLTEtMA_3781cbce-687b-42f9-9dc5-aa506bcea7ee"
      unitRef="usd">2360000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzEtMS0xLTEtMA_d0898dee-312b-4653-abac-a7184a7fc22a"
      unitRef="usd">337536000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzEtMy0xLTEtMA_af32632d-1d19-490d-ab3c-a6f2905b9734"
      unitRef="usd">-1135000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzItMS0xLTEtMzA_c252a71d-e70c-4025-9699-4dd41c5150ab"
      unitRef="usd">323608000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzItMy0xLTEtMA_b5e30431-9747-49a7-bef8-5ac6bb8e96ae"
      unitRef="usd">-9167000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzMtMS0xLTEtMA_c7a7ce40-db49-4303-8df8-74af2eb728b8"
      unitRef="usd">38449000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if2cf00dd543e42b9b366c557731d37c5_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzMtMy0xLTEtMA_68845f43-53b3-40fe-bac8-a8685c5b9cbd"
      unitRef="usd">17311000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzQtMS0xLTEtMA_d4ad2492-61a3-4b44-b716-a2a858d8e011"
      unitRef="usd">362057000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id64fc47c76a34812be47288f3a639104_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzQtMy0xLTEtMA_7e36b228-e9ad-438b-ae47-c0c1634376cc"
      unitRef="usd">8144000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzctMS0xLTEtMA_20a4a4e4-e64a-4d64-b4ce-72d25da00a31"
      unitRef="usd">287000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfMzctMy0xLTEtMA_a30ed324-dc46-4afd-87bd-4ea2fc1535b5"
      unitRef="usd">382000</us-gaap:InterestPaidNet>
    <bngo:TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDMtMS0xLTEtMA_ef33883c-1336-4e22-aa90-e6a2507660c2"
      unitRef="usd">126000</bngo:TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory>
    <bngo:TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDMtMy0xLTEtMA_da94f7e5-e3c0-405d-b151-c07ef769c52c"
      unitRef="usd">0</bngo:TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory>
    <bngo:TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDQtMS0xLTEtMA_aa97fd5f-5f0b-4043-8ec5-de7b5f6270e8"
      unitRef="usd">1366000</bngo:TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory>
    <bngo:TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDQtMy0xLTEtMA_a49b9d0a-9d57-4644-8a66-aa684462e5e0"
      unitRef="usd">467000</bngo:TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDYtMS0xLTEtNDE4NA_f9380958-2838-487a-a1fe-96a45479147c"
      unitRef="usd">1775000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDYtMy0xLTEtNDc0Nw_7d5fc5cb-a0ec-484a-b810-d6d666492bfb"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <bngo:OfferingCostsIncurredNotYetPaid
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDctMS0xLTEtNDE3Mw_6c4c9ee0-f206-4ee7-98dd-e9b7a8126e4e"
      unitRef="usd">324000</bngo:OfferingCostsIncurredNotYetPaid>
    <bngo:OfferingCostsIncurredNotYetPaid
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDctMy0xLTEtNDE3Mw_17cd3530-e03d-4784-ba1f-0eb9044b1518"
      unitRef="usd">0</bngo:OfferingCostsIncurredNotYetPaid>
    <bngo:WarrantExerciseNonCash
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDgtMS0xLTEtNDE5Ng_84eb215d-81c4-4072-9f67-3e1c60dcb372"
      unitRef="usd">129000</bngo:WarrantExerciseNonCash>
    <bngo:WarrantExerciseNonCash
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8yNS9mcmFnOjU3MWQ4YjUyYzE5ODQyYjU4N2M1NTRkY2ZiYzg3NDNhL3RhYmxlOjA3MWNmYjU3MTkxZDQzYWZhYTE3ZDUxOTFkYmYyYTAxL3RhYmxlcmFuZ2U6MDcxY2ZiNTcxOTFkNDNhZmFhMTdkNTE5MWRiZjJhMDFfNDgtMy0xLTEtNDc0OQ_b955bc98-e220-474b-a202-459b90a11529"
      unitRef="usd">0</bngo:WarrantExerciseNonCash>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zMS9mcmFnOmQxMzk5YTdiOTllYTQzM2U5ZWI0ODNlYTNhZDU4ODJjL3RleHRyZWdpb246ZDEzOTlhN2I5OWVhNDMzZTllYjQ4M2VhM2FkNTg4MmNfMTk5NDk_0667ee2d-43aa-41c2-8552-c037eca2a198">Organization and Basis of Presentation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Bionano Genomics, Inc. (collectively, with its consolidated subsidiaries, the &#x201c;Company&#x201d;) is a life sciences instrumentation company in the genome analysis space that provides tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and provides diagnostic testing for those with autism spectrum disorder (&#x201c;ASD&#x201d;) and other neurodevelopmental disabilities through newly acquired Lineagen, Inc., a wholly owned subsidiary of the Company (&#x201c;Lineagen&#x201d;). The Company currently develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that is designed to enable researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who want to evaluate Saphyr data quickly and with a low up-front investment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim reporting purposes. The condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company&#x2019;s management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, changes in equity, and comprehensive loss and cash flows for each period presented in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). All intercompany transactions and balances have been eliminated. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, the Company had approximately $362.1&#160;million in cash and cash equivalents, and working capital of $363.1 million as a result of common stock offerings executed in the quarters ended December 31, 2020 and March 31, 2021. In February 2021, we applied for forgiveness of our Paycheck Protection Program (&#x201c;the PPP&#x201d;) Loan, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full for $1.8 million. In addition, the Company has a $5.0&#160;million revolving line of credit with Innovatus Life Sciences Lending Fund I, LP (the &#x201c;Innovatus LSA&#x201d;), under which no borrowings were outstanding as of March&#160;31, 2021. This facility is scheduled to expire in March 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes its available cash balance will be sufficient to fund operations, obligations as they become due and capital investments for at least the next twelve months.  However, the Company expects to continue to incur net losses for the foreseeable future. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, potentially harming the Company&#x2019;s business. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COVID-19&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to additional risks and uncertainties as a result of the continued spread of COVID-19 and uncertain market conditions, which could continue to have a material impact on the Company&#x2019;s business and financial results. The Company closely monitors and complies with various applicable guidelines and legal requirements in the jurisdictions in which it operates, which may continue to result in reduced business operations in response to new or existing stay-at-home orders, travel restrictions and other social distancing measures. The Company&#x2019;s manufacturing partners, suppliers, and customers, have implemented similar operational restrictions. Despite reporting an increase in revenue for the three months ended March 31, 2021 when compared to the same period in 2020, the Company believes travel restrictions and overall reduced activity has negatively impacted the Company&#x2019;s first quarter 2021 financial results. The future effects of COVID-19 are unknown and the Company&#x2019;s financial results may continue to be negatively affected in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There may be long-term negative effects of the COVID-19 pandemic, even after it has subsided. Specifically, product demand may be reduced due to an economic recession, a decrease in corporate capital expenditures, prolonged unemployment, reduction in consumer confidence, or any similar negative economic condition. These negative effects could have a material impact on the Company&#x2019;s operations, business, earnings, and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021, there were no changes to the Company&#x2019;s significant accounting policies as described in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued But Not Yet Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April&#160;2012, the Jump-Start Our Business Startups Act (the &#x201c;JOBS Act&#x201d;) was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an emerging growth company. As an emerging growth company, the Company may elect to adopt new or revised accounting standards when they become effective for non-public companies, which typically is later than when public companies must adopt the standards. The Company has elected to take advantage of the extended transition period afforded by the JOBS Act and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for emerging growth companies, which are the dates included below. However, as of May 7, 2021, the market value of the Company&#x2019;s common stock held by non-affiliates exceeded $700.0&#160;million. If the market value of the Company&#x2019;s common stock held by non-affiliates exceeds $700.0 million as of June 30, 2021, the Company will be a large accelerated filer and therefore will cease to be an emerging growth company effective December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2015, the FASB issued Accounting Standards Update ("ASU") 2016-2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends the accounting guidance for leases and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. ASU 2016-2 initially mandated a modified retrospective transition method, however, in July 2018, the FASB issued ASU 2018-11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842): Targeted Improvements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which amends ASU 2016-2, permitting entities the option to adopt this standard prospectively with a cumulative-effect adjustment to opening equity in the year of adoption and include required disclosures for prior periods but will not restate prior periods. The Company anticipates implementing the accounting guidance for leases using the alternative method beginning with the annual reporting period ending December 31, 2022 and interim reporting periods in 2023. The Company is in the process of evaluating the impact of adoption of the lease accounting guidance on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses:  Measurement of credit Losses on Financial Instruments (ASU 2016-13)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities.  The standard is effective for the company beginning in the first quarter of 2023, with early adoption permitted. The Company is currently evaluating the expected impact of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2016-13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt - Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40):  Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity ("ASU 2020-06")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2020-06&lt;/span&gt; removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also simplifies the diluted earnings per share calculation in certain areas.  The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years beginning after December 15, 2021.  For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023.  Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and adoption must be as of the beginning of the Company&#x2019;s annual fiscal year. The Company&#x2019;s early adoption of this accounting standard on January 1, 2021, did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zMS9mcmFnOmQxMzk5YTdiOTllYTQzM2U5ZWI0ODNlYTNhZDU4ODJjL3RleHRyZWdpb246ZDEzOTlhN2I5OWVhNDMzZTllYjQ4M2VhM2FkNTg4MmNfMTk5NTI_89ccd920-12a9-41c8-8fde-4ceedddd587e">Basis of PresentationThe accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim reporting purposes. The condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company&#x2019;s management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, changes in equity, and comprehensive loss and cash flows for each period presented in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). All intercompany transactions and balances have been eliminated. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <bngo:LiquidityPolicyTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zMS9mcmFnOmQxMzk5YTdiOTllYTQzM2U5ZWI0ODNlYTNhZDU4ODJjL3RleHRyZWdpb246ZDEzOTlhN2I5OWVhNDMzZTllYjQ4M2VhM2FkNTg4MmNfMjE5OTAyMzMwMjI2OQ_81d49e03-b5aa-4e16-a1c4-e13f891f8ef3">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, the Company had approximately $362.1&#160;million in cash and cash equivalents, and working capital of $363.1 million as a result of common stock offerings executed in the quarters ended December 31, 2020 and March 31, 2021. In February 2021, we applied for forgiveness of our Paycheck Protection Program (&#x201c;the PPP&#x201d;) Loan, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full for $1.8 million. In addition, the Company has a $5.0&#160;million revolving line of credit with Innovatus Life Sciences Lending Fund I, LP (the &#x201c;Innovatus LSA&#x201d;), under which no borrowings were outstanding as of March&#160;31, 2021. This facility is scheduled to expire in March 2024. &lt;/span&gt;&lt;/div&gt;The Company believes its available cash balance will be sufficient to fund operations, obligations as they become due and capital investments for at least the next twelve months.  However, the Company expects to continue to incur net losses for the foreseeable future. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, potentially harming the Company&#x2019;s business.</bngo:LiquidityPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zMS9mcmFnOmQxMzk5YTdiOTllYTQzM2U5ZWI0ODNlYTNhZDU4ODJjL3RleHRyZWdpb246ZDEzOTlhN2I5OWVhNDMzZTllYjQ4M2VhM2FkNTg4MmNfMjE5OTAyMzMwNDMyNA_4b92022b-42db-42a9-b5dc-38cac759e494"
      unitRef="usd">362100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <bngo:WorkingCapital
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zMS9mcmFnOmQxMzk5YTdiOTllYTQzM2U5ZWI0ODNlYTNhZDU4ODJjL3RleHRyZWdpb246ZDEzOTlhN2I5OWVhNDMzZTllYjQ4M2VhM2FkNTg4MmNfNjU5NzA2OTgxMDcyMg_e9ff4926-9b77-487c-ae71-f9dc4aa18e2d"
      unitRef="usd">363100000</bngo:WorkingCapital>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib8c88833ac5346e0b619cff8770a118d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zMS9mcmFnOmQxMzk5YTdiOTllYTQzM2U5ZWI0ODNlYTNhZDU4ODJjL3RleHRyZWdpb246ZDEzOTlhN2I5OWVhNDMzZTllYjQ4M2VhM2FkNTg4MmNfNjA0NzMxNDAxMzQ4MQ_e51669ec-cc05-4fbd-afcc-61bfd34c85b4"
      unitRef="usd">1800000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2cec51298f734861ab7454986e9cc49e_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zMS9mcmFnOmQxMzk5YTdiOTllYTQzM2U5ZWI0ODNlYTNhZDU4ODJjL3RleHRyZWdpb246ZDEzOTlhN2I5OWVhNDMzZTllYjQ4M2VhM2FkNTg4MmNfMjE5OTAyMzMwMjI1NQ_5e3f9b0e-2a71-47a6-8dbc-7295dd87ee8f"
      unitRef="usd">5000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zMS9mcmFnOmQxMzk5YTdiOTllYTQzM2U5ZWI0ODNlYTNhZDU4ODJjL3RleHRyZWdpb246ZDEzOTlhN2I5OWVhNDMzZTllYjQ4M2VhM2FkNTg4MmNfMTk5NTY_f9498d05-a229-4693-a7de-0b97f3077713">&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued But Not Yet Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April&#160;2012, the Jump-Start Our Business Startups Act (the &#x201c;JOBS Act&#x201d;) was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an emerging growth company. As an emerging growth company, the Company may elect to adopt new or revised accounting standards when they become effective for non-public companies, which typically is later than when public companies must adopt the standards. The Company has elected to take advantage of the extended transition period afforded by the JOBS Act and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for emerging growth companies, which are the dates included below. However, as of May 7, 2021, the market value of the Company&#x2019;s common stock held by non-affiliates exceeded $700.0&#160;million. If the market value of the Company&#x2019;s common stock held by non-affiliates exceeds $700.0 million as of June 30, 2021, the Company will be a large accelerated filer and therefore will cease to be an emerging growth company effective December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2015, the FASB issued Accounting Standards Update ("ASU") 2016-2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends the accounting guidance for leases and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. ASU 2016-2 initially mandated a modified retrospective transition method, however, in July 2018, the FASB issued ASU 2018-11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842): Targeted Improvements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which amends ASU 2016-2, permitting entities the option to adopt this standard prospectively with a cumulative-effect adjustment to opening equity in the year of adoption and include required disclosures for prior periods but will not restate prior periods. The Company anticipates implementing the accounting guidance for leases using the alternative method beginning with the annual reporting period ending December 31, 2022 and interim reporting periods in 2023. The Company is in the process of evaluating the impact of adoption of the lease accounting guidance on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses:  Measurement of credit Losses on Financial Instruments (ASU 2016-13)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities.  The standard is effective for the company beginning in the first quarter of 2023, with early adoption permitted. The Company is currently evaluating the expected impact of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2016-13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt - Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40):  Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity ("ASU 2020-06")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2020-06&lt;/span&gt; removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also simplifies the diluted earnings per share calculation in certain areas.  The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years beginning after December 15, 2021.  For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023.  Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and adoption must be as of the beginning of the Company&#x2019;s annual fiscal year. The Company&#x2019;s early adoption of this accounting standard on January 1, 2021, did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNC9mcmFnOjJkNmQ5ZWIxNzA2OTRkNjQ5MTk1ZTQwNzZmYjczZDJjL3RleHRyZWdpb246MmQ2ZDllYjE3MDY5NGQ2NDkxOTVlNDA3NmZiNzNkMmNfMTA3MQ_735a4e5d-bb00-4541-8221-2ee1da809948">Net Loss Per ShareBasic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company&#x2019;s potentially dilutive securities which include warrants and outstanding stock options under the &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s equity incentive plan have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.653%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,126,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,760,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,411,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,128,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,537,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,888,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNC9mcmFnOjJkNmQ5ZWIxNzA2OTRkNjQ5MTk1ZTQwNzZmYjczZDJjL3RleHRyZWdpb246MmQ2ZDllYjE3MDY5NGQ2NDkxOTVlNDA3NmZiNzNkMmNfMTA3Mg_293f59d8-8823-4156-a2fc-4bc0521149ad">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company&#x2019;s potentially dilutive securities which include warrants and outstanding stock options under the Company&#x2019;s equity incentive plan have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNC9mcmFnOjJkNmQ5ZWIxNzA2OTRkNjQ5MTk1ZTQwNzZmYjczZDJjL3RleHRyZWdpb246MmQ2ZDllYjE3MDY5NGQ2NDkxOTVlNDA3NmZiNzNkMmNfMTA3Mw_cc04bce5-959c-4d21-b4c1-1f30e153a311">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.653%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,126,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,760,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,411,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,128,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,537,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,888,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9fc5f9d8dd1f48fc82c0374b93861f35_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNC9mcmFnOjJkNmQ5ZWIxNzA2OTRkNjQ5MTk1ZTQwNzZmYjczZDJjL3RhYmxlOjgxMjU4MmNiMzAwNzQ1NjFiYTUxMjcxZDFiNDdmNDY2L3RhYmxlcmFuZ2U6ODEyNTgyY2IzMDA3NDU2MWJhNTEyNzFkMWI0N2Y0NjZfMS0xLTEtMS0w_8ac53865-b2a4-435a-8ab9-ec61b6b4f6a7"
      unitRef="shares">5126000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i60f650629d034534aa18e0699f6858da_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNC9mcmFnOjJkNmQ5ZWIxNzA2OTRkNjQ5MTk1ZTQwNzZmYjczZDJjL3RhYmxlOjgxMjU4MmNiMzAwNzQ1NjFiYTUxMjcxZDFiNDdmNDY2L3RhYmxlcmFuZ2U6ODEyNTgyY2IzMDA3NDU2MWJhNTEyNzFkMWI0N2Y0NjZfMS0zLTEtMS0w_e2bd86c9-3050-4c28-b5f4-bf644ecddcf9"
      unitRef="shares">2760000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i879adebf764c47d087517666b8c85477_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNC9mcmFnOjJkNmQ5ZWIxNzA2OTRkNjQ5MTk1ZTQwNzZmYjczZDJjL3RhYmxlOjgxMjU4MmNiMzAwNzQ1NjFiYTUxMjcxZDFiNDdmNDY2L3RhYmxlcmFuZ2U6ODEyNTgyY2IzMDA3NDU2MWJhNTEyNzFkMWI0N2Y0NjZfMi0xLTEtMS0w_69f4163c-36a5-4aeb-ba10-31aa0541c7c6"
      unitRef="shares">4411000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaf4053f13478440e928fdfbb689fd12f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNC9mcmFnOjJkNmQ5ZWIxNzA2OTRkNjQ5MTk1ZTQwNzZmYjczZDJjL3RhYmxlOjgxMjU4MmNiMzAwNzQ1NjFiYTUxMjcxZDFiNDdmNDY2L3RhYmxlcmFuZ2U6ODEyNTgyY2IzMDA3NDU2MWJhNTEyNzFkMWI0N2Y0NjZfMi0zLTEtMS0w_72e5333b-3aca-4c85-863e-49a6422e3c6f"
      unitRef="shares">24128000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNC9mcmFnOjJkNmQ5ZWIxNzA2OTRkNjQ5MTk1ZTQwNzZmYjczZDJjL3RhYmxlOjgxMjU4MmNiMzAwNzQ1NjFiYTUxMjcxZDFiNDdmNDY2L3RhYmxlcmFuZ2U6ODEyNTgyY2IzMDA3NDU2MWJhNTEyNzFkMWI0N2Y0NjZfMy0xLTEtMS0w_9d7c82ff-7aaf-4710-9f42-ace306543d4b"
      unitRef="shares">9537000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNC9mcmFnOjJkNmQ5ZWIxNzA2OTRkNjQ5MTk1ZTQwNzZmYjczZDJjL3RhYmxlOjgxMjU4MmNiMzAwNzQ1NjFiYTUxMjcxZDFiNDdmNDY2L3RhYmxlcmFuZ2U6ODEyNTgyY2IzMDA3NDU2MWJhNTEyNzFkMWI0N2Y0NjZfMy0zLTEtMS0w_64411bcf-4a64-4499-a5d7-945ab7728818"
      unitRef="shares">26888000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfMTYzMA_4cb2806f-dc65-45e1-9176-fa7b583307df">Revenue Recognition&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue by Source&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,167,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,049,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,168,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue by Geographic Location&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.868%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;North America&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,498,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EMEIA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,168,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table above provides revenue from contracts with customers by source and geographic region (based on the customer&#x2019;s billing address) on a disaggregated basis. North America consists of the United States and Canada. EMEIA consists of Europe, the Middle East, India and Africa. Asia Pacific includes China, Japan, South Korea, Singapore and Australia. For the three months ended March&#160;31, 2021 and 2020, the United States represented 44.8% and 63.9% of total revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Remaining Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was $409,000. These remaining performance obligations primarily relate to extended warranty and support and maintenance obligations. The Company expects to recognize approximately&#160;64.8% of this amount as revenue during the remainder of 2021,&#160;31.1%&#160;in 2022, and 4.1%&#160;in 2023.  Warranty revenue is included in Service and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized revenue of&#160;$156,885&#160;and $127,000 during the three months ended March&#160;31, 2021 and 2020, respectively, which was included in the contract liability balance at the end of the previous year.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfMTYyNw_ab839f8e-ee4a-4d7f-8993-26f078b5704f">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue by Source&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,167,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,049,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,168,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue by Geographic Location&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.868%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;North America&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,498,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EMEIA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,168,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9331df46b264545b015fc8dbc0eb877_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfMi0xLTEtMS0w_b963252f-6473-4286-b63e-f44b7a830584"
      unitRef="usd">882000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b1e545fdd7b4f708c5122ab52e04b28_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfMi0zLTEtMS0w_5f027ab2-787f-4cdb-8f9b-90f7e856ed9b"
      unitRef="usd">534000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb245ebe81e244599c7dfc4dd2951fb6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfMy0xLTEtMS0w_142450b2-403b-4967-9d94-b688e8c2cae4"
      unitRef="usd">1167000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b4f7fff94f74c0092a3e332baf337ee_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfMy0zLTEtMS0w_b31b3422-a422-4c56-8b7b-bb79748b2c80"
      unitRef="usd">449000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c91415129394ba299d78d9ff4f67598_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfNC0xLTEtMS0w_a5b3cbc9-ced1-43f1-b8b0-5f9379697c14"
      unitRef="usd">2049000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fd535c416994e7e9ac50885ecf579a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfNC0zLTEtMS0w_0e548b94-d572-48c2-964c-d379ef93b62e"
      unitRef="usd">983000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6482b3482014875b2110f7ee933cadf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfNS0xLTEtMS0w_09b6c020-828e-458e-be3c-212b51122472"
      unitRef="usd">1119000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb9a8cd4c6ae43b780d83f3db03387c6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfNS0zLTEtMS0w_ede96232-5767-447d-b76a-70ae0a3c2ae5"
      unitRef="usd">153000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfNi0xLTEtMS0w_6969629c-3f57-4a87-836a-ffa2e0b90310"
      unitRef="usd">3168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjQ1YTg2NzM3Y2FkZjQ2MTk4MWIxNDE0YmE0YjY3MTNmL3RhYmxlcmFuZ2U6NDVhODY3MzdjYWRmNDYxOTgxYjE0MTRiYTRiNjcxM2ZfNi0zLTEtMS0w_b2b2ab62-4863-416d-aed0-5e4bd92f98b9"
      unitRef="usd">1136000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cb3b2d35c0e49a0b13d2888567d6b29_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfMy0xLTEtMS0w_3e008e81-e841-4f79-be4c-e2b69c7d23ea"
      unitRef="usd">1498000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic1ea4ad111304144bc23a97198dd2179_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfMy0zLTEtMS0w_5fd68443-8d08-4ed4-bb94-b4a5f91e9cac"
      unitRef="number">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic08fdc3d1e534710809bdee60bba27bd_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfMy01LTEtMS0w_c196fbc7-2ce8-4aa7-a9f1-14205240e552"
      unitRef="usd">726000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4e5ab6a8509443dba725afa8835b9601_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfMy03LTEtMS0w_80638a3f-fd9b-4984-91f9-0b0621128410"
      unitRef="number">0.64</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3c3a70d23fb4e3597f16a3f336f2080_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNC0xLTEtMS0w_8c338fb0-d687-4854-8ec6-c57c545b7226"
      unitRef="usd">1587000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i245ac77d088a4c08ab398de10d3c4fe0_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNC0zLTEtMS0w_fe48e914-350d-4ceb-8f62-537f7feea7fd"
      unitRef="number">0.50</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd2315279b594cd888242f46af032bc6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNC01LTEtMS0w_0a45574f-57d2-4d02-857b-c8c3e2ebd41b"
      unitRef="usd">390000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ida0f9f015cda405dbf20c999e5715976_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNC03LTEtMS0w_f2e3ae27-c8f5-4e6e-b548-b6d35d0513f9"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd9faf0a75c448aeacba6769f5a6ed6d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNS0xLTEtMS0w_f1f42457-afca-43a1-87da-b779c7fc11de"
      unitRef="usd">83000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic54fd087ce324e2ca363766266305d85_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNS0zLTEtMS0w_3f2bb55f-53c9-42d4-931b-f45cdaba0ae5"
      unitRef="number">0.03</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib52b24a224634461aa88638273374171_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNS01LTEtMS0w_2f31a5b7-56a0-45d9-9a6b-6ce757d8bd7c"
      unitRef="usd">20000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6e9fe1ddcfff4117ba8ab2659f8fb841_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNS03LTEtMS0w_3150668f-1c8c-49c6-bc26-e8f045cc56c1"
      unitRef="number">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNi0xLTEtMS0w_abc54f0e-e50b-40eb-bc55-4f42d267e17b"
      unitRef="usd">3168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i457368c024694d3da4b660e9ad925a67_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNi0zLTEtMS0w_c7b962a7-d658-4a52-a2dc-9a559eaec960"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNi01LTEtMS0w_cc6bdc5f-cfea-47d3-bd75-830f0e54ec1b"
      unitRef="usd">1136000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3ad2e939003643688e5a0c1f74143044_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RhYmxlOjE3ODFiMmI0MTU4MjRhNWU4YjhjYzI1ZDQ5NWJlNDZhL3RhYmxlcmFuZ2U6MTc4MWIyYjQxNTgyNGE1ZThiOGNjMjVkNDk1YmU0NmFfNi03LTEtMS0w_9805c10c-218b-4a43-a80b-5e60f03d941c"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5e72dec2e62644f09291bd2256e18ae6_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfNjA0NzMxMzk1NzgyMA_06d84eda-f1f8-4e4c-8cd7-3e174c055288"
      unitRef="number">0.448</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib152c322e04e4f04b400bc01f5876b20_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfNjQ4_e52f25d3-e399-4cf7-b96f-9d267a40d7cd"
      unitRef="number">0.639</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfOTAx_bb758265-0ab4-4fa8-b3d6-956e57a82aea"
      unitRef="usd">409000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i73e99ee813de47559aff9fc89de5f48c_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfMTA3MQ_020164d7-d860-4228-9197-eaecf317c642"
      unitRef="number">0.648</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="ifef7e1ffa1fc47e6b55595ac8be5b218_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfMTEzMA_f69f1db2-bb65-412f-9344-3c8fc5e39815"
      unitRef="number">0.311</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i47e9e0fd70444455a6640482ac8e5229_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfMTE0Mg_07355c94-1ba9-401a-a92e-4469be606e48"
      unitRef="number">0.041</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfMTI2NA_09313c01-ff03-439c-8dd4-f6d858db92ae"
      unitRef="usd">156885</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl8zNy9mcmFnOjA2NTY4MDY3MDNlODQxYWVhNzdiNjUwMzE1MzUxMmE0L3RleHRyZWdpb246MDY1NjgwNjcwM2U4NDFhZWE3N2I2NTAzMTUzNTEyYTRfMTI3MQ_4eeb164e-d1da-488b-be38-97883a1d7631"
      unitRef="usd">127000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RleHRyZWdpb246ZWIwODBlYjE3M2RkNDdlOWI4OGEwZjkzN2NhZTI3ZDdfNjI3_9b3b67d9-0d03-42fa-bfeb-6e7a38a091ce">Balance Sheet Account Details&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:21pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, trade&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,083,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,894,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,091,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,119,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,775,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company extends credit to its customers in the normal course of business. For diagnostic testing services, receivables are based on either contractual rates with third-party payors, plus the amounts expected to be collected for any patient-responsibility portion, or for non-contracted arrangements, using the amounts expected to be collected from third-party payors and/or the patient-customer based on historical collection experience. The Company does not perform credit evaluations and therefore subsequent adjustments to the amount expected to be collected are recorded to revenue.  The balance of our Lineagen accounts receivable balance as of March 31, 2021 was $284,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For optical genome mapping (&#x201c;OGM&#x201d;) products and services, credit is extended based upon an evaluation of each customer&#x2019;s credit history, financial condition, and other factors. Estimates of allowances for doubtful accounts are determined by evaluating individual customer circumstances, historical payment patterns, length of time past due, and economic and other factors. Bad debt expense is recorded as necessary to maintain an appropriate level of allowance for doubtful accounts in selling, general and administrative expense. During the three months ended March&#160;31, 2021, the Company recorded a recovery of bad debt expense of $(28,000), which is included in selling, general and administrative expenses. Amounts are charged to the allowance for doubtful accounts when collection efforts have been exhausted and are deemed uncollectible.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable is subject to concentration risk whenever a customer has a balance that meets or exceeds 10.0% of the Company&#x2019;s total accounts receivable balance. As of March&#160;31, 2021, there were no customer balances that met or exceeded 10.0% of the Company&#x2019;s total accounts receivable balance. As of December&#160;31, 2020, Illumina, and Quest Diagnostics represented 17.3%, and 10.1%, respectively, of the Company&#x2019;s total accounts receivable balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is stated at the lower of cost or net realizable value, on a first-in, first-out basis. Inventory includes raw materials and finished goods that may be used in the research and development process and such items are expensed as consumed or expired.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for slow-moving, excess, and obsolete inventories are estimated based on product life cycles, historical experience, and usage forecasts.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventories are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,736,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,283,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,036,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,316,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RleHRyZWdpb246ZWIwODBlYjE3M2RkNDdlOWI4OGEwZjkzN2NhZTI3ZDdfNjMw_769f9e78-e341-4381-bcbb-cceaa71a3ec9">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, trade&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,083,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,894,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,091,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,119,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,775,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjU5MjlhMDQzYmM3OTQwMWJiZjRjZmRmMjM2YzBiNmVlL3RhYmxlcmFuZ2U6NTkyOWEwNDNiYzc5NDAxYmJmNGNmZGYyMzZjMGI2ZWVfMi0xLTEtMS0w_7ccff132-6937-42a8-ba2c-96346cc71707"
      unitRef="usd">4083000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjU5MjlhMDQzYmM3OTQwMWJiZjRjZmRmMjM2YzBiNmVlL3RhYmxlcmFuZ2U6NTkyOWEwNDNiYzc5NDAxYmJmNGNmZGYyMzZjMGI2ZWVfMi00LTEtMS0w_3e30c8cd-35b5-4db2-8d52-f336d1acd113"
      unitRef="usd">4894000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjU5MjlhMDQzYmM3OTQwMWJiZjRjZmRmMjM2YzBiNmVlL3RhYmxlcmFuZ2U6NTkyOWEwNDNiYzc5NDAxYmJmNGNmZGYyMzZjMGI2ZWVfMy0xLTEtMS0w_99dd5368-ed7a-435e-b652-fffcc212227f"
      unitRef="usd">2091000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjU5MjlhMDQzYmM3OTQwMWJiZjRjZmRmMjM2YzBiNmVlL3RhYmxlcmFuZ2U6NTkyOWEwNDNiYzc5NDAxYmJmNGNmZGYyMzZjMGI2ZWVfMy00LTEtMS0w_5da88c7c-ec32-466b-b714-84b7f201fe9c"
      unitRef="usd">2119000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjU5MjlhMDQzYmM3OTQwMWJiZjRjZmRmMjM2YzBiNmVlL3RhYmxlcmFuZ2U6NTkyOWEwNDNiYzc5NDAxYmJmNGNmZGYyMzZjMGI2ZWVfNC0xLTEtMS0w_178143ae-7e6d-4d25-846d-7d8d4236d52a"
      unitRef="usd">1992000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjU5MjlhMDQzYmM3OTQwMWJiZjRjZmRmMjM2YzBiNmVlL3RhYmxlcmFuZ2U6NTkyOWEwNDNiYzc5NDAxYmJmNGNmZGYyMzZjMGI2ZWVfNC00LTEtMS0w_c2758c8f-f8a8-4afc-8baa-6e6e0a3ee34c"
      unitRef="usd">2775000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia855809b84d64c008ac770b0553904dd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RleHRyZWdpb246ZWIwODBlYjE3M2RkNDdlOWI4OGEwZjkzN2NhZTI3ZDdfMjE5OTAyMzI2MTY0MQ_aea669a4-4e9a-4ce3-9b77-ab90e5d35f05"
      unitRef="usd">284000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RleHRyZWdpb246ZWIwODBlYjE3M2RkNDdlOWI4OGEwZjkzN2NhZTI3ZDdfNjA0NzMxMzk1ODkxNA_6b1bd642-36c7-4516-a446-2d8616364a55"
      unitRef="usd">28000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i36ce02702176446c8658104bea1e70b3_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RleHRyZWdpb246ZWIwODBlYjE3M2RkNDdlOWI4OGEwZjkzN2NhZTI3ZDdfNjA0NzMxMzk1Nzk0MA_d97beb50-31ef-42a4-a878-386c56925764"
      unitRef="number">0.100</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib9b6028b6f7b4c56b41bd5ae534114cb_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RleHRyZWdpb246ZWIwODBlYjE3M2RkNDdlOWI4OGEwZjkzN2NhZTI3ZDdfNjA0NzMxMzk1ODI5Nw_9e1519c2-dffc-4ca9-87ef-93a9b83c1e0d"
      unitRef="number">0.173</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i09493f03a8d24d529ba3c584f742a2e7_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RleHRyZWdpb246ZWIwODBlYjE3M2RkNDdlOWI4OGEwZjkzN2NhZTI3ZDdfNjA0NzMxMzk1ODMwNQ_098655c2-cd5e-4440-99ee-f57d510558e5"
      unitRef="number">0.101</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RleHRyZWdpb246ZWIwODBlYjE3M2RkNDdlOWI4OGEwZjkzN2NhZTI3ZDdfNjMz_7686253e-6b70-47c2-8eca-228649dd389a">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,736,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,283,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,036,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,316,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjQ5Njg5NzUwMzMxNjQ2YTE5NGEyNzllN2JjMDI4MDNhL3RhYmxlcmFuZ2U6NDk2ODk3NTAzMzE2NDZhMTk0YTI3OWU3YmMwMjgwM2FfMi0xLTEtMS0w_7ea4273c-c494-4ec0-8a1d-9378071cb272"
      unitRef="usd">2736000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjQ5Njg5NzUwMzMxNjQ2YTE5NGEyNzllN2JjMDI4MDNhL3RhYmxlcmFuZ2U6NDk2ODk3NTAzMzE2NDZhMTk0YTI3OWU3YmMwMjgwM2FfMi0zLTEtMS0w_2eaa4d15-ae5f-45a9-a0cd-073ebae0069b"
      unitRef="usd">2283000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjQ5Njg5NzUwMzMxNjQ2YTE5NGEyNzllN2JjMDI4MDNhL3RhYmxlcmFuZ2U6NDk2ODk3NTAzMzE2NDZhMTk0YTI3OWU3YmMwMjgwM2FfMy0xLTEtMS0w_c0091f19-9091-44ee-bbbd-fbab0612160d"
      unitRef="usd">300000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjQ5Njg5NzUwMzMxNjQ2YTE5NGEyNzllN2JjMDI4MDNhL3RhYmxlcmFuZ2U6NDk2ODk3NTAzMzE2NDZhMTk0YTI3OWU3YmMwMjgwM2FfMy0zLTEtMS0w_5e128c7d-aba4-44ec-8385-c853158b9b30"
      unitRef="usd">1033000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjQ5Njg5NzUwMzMxNjQ2YTE5NGEyNzllN2JjMDI4MDNhL3RhYmxlcmFuZ2U6NDk2ODk3NTAzMzE2NDZhMTk0YTI3OWU3YmMwMjgwM2FfNC0xLTEtMS0w_0f1c7d2c-a6de-483f-8c7f-e91e0994cb6d"
      unitRef="usd">3036000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80My9mcmFnOmViMDgwZWIxNzNkZDQ3ZTliODhhMGY5MzdjYWUyN2Q3L3RhYmxlOjQ5Njg5NzUwMzMxNjQ2YTE5NGEyNzllN2JjMDI4MDNhL3RhYmxlcmFuZ2U6NDk2ODk3NTAzMzE2NDZhMTk0YTI3OWU3YmMwMjgwM2FfNC0zLTEtMS0w_cfad6958-4228-43f0-9c35-c63ef372df96"
      unitRef="usd">3316000</us-gaap:InventoryNet>
    <us-gaap:LongTermDebtTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfOTMwNg_8e377658-4c1c-4cb3-94d1-27585f9654fe">Debt &lt;div style="margin-top:16pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Paycheck Protection Program&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 17, 2020, the Company received loan proceeds of approximately $1.8 million (the &#x201c;PPP Loan&#x201d;) pursuant to the Paycheck Protection Program (&#x201c;the PPP&#x201d;) under the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) administered by the U.S. Small Business Administration (the &#x201c;SBA&#x201d;).  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The PPP Loan accrued interest at a rate of 1.00% per annum, and is subject to the standard terms and conditions applicable to loans administered by the SBA under the CARES Act. In February 2021, the Company applied for forgiveness of the PPP Loan, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full. A gain on forgiveness of Paycheck Protection Program loan of $1.8 million was recognized during the three months ended March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;I&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;nnovatus LSA&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, the Company entered into a Loan and Security Agreement (the &#x201c;LSA&#x201d;) by and among Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership (&#x201c;Innovatus&#x201d;), as collateral agent and the lenders listed on Schedule 1.1 thereto, including East West Bank. The LSA provided a first term loan of $17.5 million, a second term loan of $2.5 million and a third term loan of $5.0 million (collectively, the &#x201c;Term Loans&#x201d;) if the Company satisfied certain funding conditions. Interest on the Term Loans is due on the first of each month at a rate of 10.25% per annum in cash or a discounted rate of 7.25% in cash with 3.0% of the 10.25% per annum rate added to the principal of the loan and subject to accruing interest through the end of the interest only payment period, which ends March 1, 2022. At inception, the Company elected to pay interest in cash at a rate of 7.25% per annum and have 3.0% per annum of the interest added back to the outstanding principal. As of March&#160;31, 2021, the effective interest rate, including debt issuance costs, for the Term Loans was 16.7%. Beginning in April 2022, the Company must make 24 equal monthly payments of principal and interest with a final maturity date in March 2024, which may be earlier due to an event of default if not cured within time specified. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The LSA provides for prepayment fees of 3.0% of the outstanding balance of the loan if the loan is repaid on or prior to March 14, 2020, 2.0% of the amount prepaid if the prepayment occurs after March 14, 2020 but prior to March 14, 2021, 1.0% of the amount prepaid after March 14, 2021 but prior to March 14, 2022 and 0% of the amount prepaid if the prepayment occurs thereafter. In addition, upon the final repayment of the total amounts borrowed, the Company is required to pay an end of term fee of $0.8 million. This end of term fee is being recognized as interest expense over the term of the LSA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The LSA also provides for a revolving line of credit in an amount not to exceed $5.0 million (the &#x201c;Revolver&#x201d;), under which no borrowings were outstanding as of March 31, 2021 and December 31, 2020. The Company may repay and re-borrow amounts under the Revolver at any time prior to the March 1, 2024 maturity date without penalty or premium. The outstanding balance of amounts borrowed under the Revolver bears interest at a rate equal to 2.0% above the prime rate, per annum, as specified in the terms of the Revolver. The LSA allows the Company to borrow and repay amounts at any time prior to the maturity date in 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The LSA is collateralized by substantially all of the Company&#x2019;s assets, including its intellectual property. The LSA&#160;requires the Company to comply with various affirmative and negative covenants, including: (1) a liquidity covenant requiring the Company to maintain a minimum cash balance at all times in a collateral account and (2) a revenue covenant requiring the Company to meet certain minimum revenue targets measured at the end of each calendar quarter. The LSA also includes certain standard events of default, and a provision that Innovatus could declare an event of default upon the occurrence of any event that it interprets as having a material adverse impact to the Company&#x2019;s business, operations, or condition, a material impairment on the Company&#x2019;s ability to pay the secured obligations under the LSA, or upon a material adverse effect on the collateral under the agreement, thereby requiring the Company to repay the loans immediately, together with a prepayment fee and other applicable fees. As of March&#160;31, 2021, the Company believes there have been no events or changes in conditions that could require immediate repayment of amounts due to Innovatus. As of March&#160;31, 2021, the Company was in compliance with the covenants under the Innovatus LSA and the Revolver.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Debt Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Company&#x2019;s debt for the periods presented was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:21pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,099,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,981,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PPP Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,775,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,099,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,756,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,233,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,430,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying value of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,866,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,326,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="icb4b96f2629a437b92ce60228c4e9a9e_D20200417-20200417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk2MjExMA_8d475036-bc2b-4304-bcad-eb89b3c79108"
      unitRef="usd">1800000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib8c88833ac5346e0b619cff8770a118d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk5MTcyOA_e51669ec-cc05-4fbd-afcc-61bfd34c85b4"
      unitRef="usd">1800000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1dad41e3a2834af1a8bc37f1efe217ab_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODU3Mg_828e26e2-4cba-4c75-a5c8-47ee92a00fe4"
      unitRef="usd">17500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id95f9fba9dd949fc975ddb0d090b6f9d_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODU3Ng_a996dffc-8f9d-401c-bbc1-c399a837597d"
      unitRef="usd">2500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i79b1a33813d74170988e5d5afca3a502_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODU4MA_3ff8c1ce-ce90-4edf-b146-fe98d284735b"
      unitRef="usd">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <bngo:DebtInstrumentInterestRateCashRate
      contextRef="i4861f1d2c13e4caa9d9b2c243fba8ef3_I20190331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODU4NA_62217d9d-b132-4022-8f4c-b1f298c50757"
      unitRef="number">0.1025</bngo:DebtInstrumentInterestRateCashRate>
    <bngo:DebtInstrumentInterestRateDiscountedCashRate
      contextRef="i4861f1d2c13e4caa9d9b2c243fba8ef3_I20190331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODU4OA_b4eb98ad-10ab-4e93-8a76-f8deea45b8cf"
      unitRef="number">0.0725</bngo:DebtInstrumentInterestRateDiscountedCashRate>
    <bngo:DebtInstrumentInterestRateCashRate
      contextRef="i1be2f4e30d224ab9a6370097d5078fb2_I20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODU5Mg_562250ea-c14e-4421-9e59-eac3f57d96a5"
      unitRef="number">0.030</bngo:DebtInstrumentInterestRateCashRate>
    <bngo:DebtInstrumentInterestRateCashRate
      contextRef="i4861f1d2c13e4caa9d9b2c243fba8ef3_I20190331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODU5Ng_62217d9d-b132-4022-8f4c-b1f298c50757"
      unitRef="number">0.1025</bngo:DebtInstrumentInterestRateCashRate>
    <bngo:DebtInstrumentInterestRateDiscountedCashRate
      contextRef="i4861f1d2c13e4caa9d9b2c243fba8ef3_I20190331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODYwMA_b4eb98ad-10ab-4e93-8a76-f8deea45b8cf"
      unitRef="number">0.0725</bngo:DebtInstrumentInterestRateDiscountedCashRate>
    <bngo:DebtInstrumentInterestRateCashRate
      contextRef="i1be2f4e30d224ab9a6370097d5078fb2_I20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODYwNA_562250ea-c14e-4421-9e59-eac3f57d96a5"
      unitRef="number">0.030</bngo:DebtInstrumentInterestRateCashRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id929d97a381842f687a1e63e52a0ed66_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODYwOA_aa493e48-a390-4f55-a872-c13128aa7379"
      unitRef="number">0.167</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <bngo:DebtInstrumentNumberOfMonthlyPayments
      contextRef="id929d97a381842f687a1e63e52a0ed66_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3ODYxMg_a7f40f94-4953-4454-b986-5725a3c950b9"
      unitRef="payment">24</bngo:DebtInstrumentNumberOfMonthlyPayments>
    <bngo:DebtInstrumentPrepaymentFeePercent
      contextRef="i471d64edc0154171beed8ed2878377a6_D20190301-20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3OTIzMw_cfc12cfb-e190-4734-81db-b5c643587f58"
      unitRef="number">0.030</bngo:DebtInstrumentPrepaymentFeePercent>
    <bngo:DebtInstrumentPrepaymentFeePercent
      contextRef="i02ab7766833b447ea7ab0f07e49cf492_D20190301-20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3OTI0MA_e64aef37-cc8a-49bd-99c1-45e691ab5791"
      unitRef="number">0.020</bngo:DebtInstrumentPrepaymentFeePercent>
    <bngo:DebtInstrumentPrepaymentFeePercent
      contextRef="id9d5648907484fceb630191c98780dcf_D20190301-20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3OTI0Nw_44bcbb63-f88b-4299-853e-66644a6c5b51"
      unitRef="number">0.010</bngo:DebtInstrumentPrepaymentFeePercent>
    <bngo:DebtInstrumentPrepaymentFeePercent
      contextRef="i4677e379bf9c4e6c97c7555823337d32_D20190301-20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3OTI1Mg_93eed779-10c7-49cb-bcdf-44c7e9bcce8d"
      unitRef="number">0</bngo:DebtInstrumentPrepaymentFeePercent>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent
      contextRef="i4861f1d2c13e4caa9d9b2c243fba8ef3_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3OTI2Nw_0324256e-f972-411d-9021-e5067ac20c90"
      unitRef="usd">800000</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic76f8d3c3fd840279c87ce3ba493143a_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3OTI3MQ_df7af782-bad0-4116-ba93-3774b33061ad"
      unitRef="usd">5000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <bngo:DebtInstrumentPrepaymentFeePercent
      contextRef="if1d4c4e068d445ac82a3fe2130562736_D20190301-20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfNjA0NzMxMzk3OTI3Ng_87626062-eac8-45fb-a23b-81fffac14004"
      unitRef="number">0.020</bngo:DebtInstrumentPrepaymentFeePercent>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RleHRyZWdpb246MmQzOTNiZDI4YWIxNGJmNGE4N2E2YThhYjc5NTIzMWZfOTMxNQ_42164987-11e2-4573-a468-5fcc0cd23f72">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Company&#x2019;s debt for the periods presented was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:21pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,099,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,981,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PPP Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,775,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,099,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,756,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,233,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,430,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying value of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,866,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,326,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3bce457e3753459a8510d3d860bbde78_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfMS0xLTEtMS0w_253b4da6-398d-455a-a382-82a876c53027"
      unitRef="usd">16099000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i749a55fa53994c25beda30839971df4c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfMS0zLTEtMS0w_7b86c67a-a0d4-499f-8195-a5dd86f51064"
      unitRef="usd">15981000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5f0cc44ba35648fb997a749f7937547f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfMy0xLTEtMS0w_4616423b-36dc-487d-9023-5aa9c7317eee"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i57fb085856954618adbd3fae5629f1f9_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfMy0zLTEtMS0w_7d24491f-ee59-4716-a4ca-3f7b3f3817f1"
      unitRef="usd">1775000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfNC0xLTEtMS0w_59ad504c-388b-4a06-8692-7269659fd67d"
      unitRef="usd">16099000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfNC0zLTEtMS0w_190eef7f-1101-4012-aba1-f81778ef4d32"
      unitRef="usd">17756000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfNS0xLTEtMS0w_bee64e40-9b41-41d4-9017-71e18bab0890"
      unitRef="usd">1233000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfNS0zLTEtMS0w_f196d374-e18c-4a61-9ef8-9a61443faaef"
      unitRef="usd">1430000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfNi0xLTEtMS0w_846664eb-502c-4276-b7c5-3cd9890cf967"
      unitRef="usd">14866000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80Ni9mcmFnOjJkMzkzYmQyOGFiMTRiZjRhODdhNmE4YWI3OTUyMzFmL3RhYmxlOjRlMGI3MDlkM2Y3ZjRiMmU5NjE2NTg2M2YyMGZjYjE2L3RhYmxlcmFuZ2U6NGUwYjcwOWQzZjdmNGIyZTk2MTY1ODYzZjIwZmNiMTZfNi0zLTEtMS0w_7e14ddd6-a464-481b-83b0-db950c55badc"
      unitRef="usd">16326000</us-gaap:LongTermDebt>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjkzNg_74873a40-396c-441d-8d42-81f56329d576">Stockholders&#x2019; Equity and Stock-Based Compensation&lt;div style="margin-top:16pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Follow-on Public Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;On January 12, 2021, the Company completed an underwritten public offering of 33,368,851 shares of common stock, including 4,352,458 shares of common stock sold pursuant to the underwriters&#x2019; exercise in full of their option to purchase additional shares. The price to the public in the offering was $3.05 per share and the underwriters purchased the shares from the Company pursuant to the underwriting agreement at a price of $2.867 per share. The gross proceeds were approximately $101.8&#160;million before deducting underwriting discounts and commissions and other offering expenses of $293,000.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 25, 2021, the Company completed an underwritten public offering of 38,333,352 shares of common stock, including 5,000,002 shares of common stock sold pursuant to the underwriters&#x2019; exercise in full of their option to purchase additional shares. The price to the public in the offering was $6.00 per share and the underwriters purchased the shares from the Company pursuant to the underwriting agreement at a price of $5.64 per share. The gross proceeds were approximately $230.0&#160;million before deducting underwriting discounts and commissions and other offering expenses of $435,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Shelf Registration Statement and Ladenburg At-the-Market Facility&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company filed a shelf registration statement on Form S-3 with the SEC covering the offering, issuance and sale of up to $125.0 million of the Company&#x2019;s securities, including up to $40.0 million of common stock pursuant to the Ladenburg ATM, with Ladenburg Thalmann &amp;amp; Co. Inc. acting as sales agent. During October through December 2020, the Company sold 27,025,384 shares of common stock under the Ladenburg ATM at an average share price of $0.82, and received gross proceeds of approximately $22.1 million before deducting offering costs of $573,000. In January 2021, the Company sold an additional 6,298,152 shares of common stock under the ATM at an average share price of $2.68, and received gross proceeds of approximately $16.9 million before deducting offering costs of $422,000. The Company terminated the Ladenburg ATM in March 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 23, 2021, the Company entered into the Cowen ATM which provides for the sale, in the Company&#x2019;s sole discretion, of shares of common stock having an aggregate offering price of up to $350.0&#160;million through or to Cowen, acting as sales agent or principal. The Company will pay Cowen a commission of up to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. As of the date of this filing, no shares have been issued pursuant to the Cowen ATM.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s warrant activity during the three months ended March&#160;31, 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares of Stock under Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,174,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,841,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,739,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,912,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,411,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,911,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity during the three months ended March&#160;31, 2021 was as follows: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares of Stock under Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,178,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,126,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,554,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,704,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,403,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2021 and 2020, the weighted-average grant date fair value of stock options granted was $10.83 and $1.04 per share, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized stock-based compensation expense for the periods presented as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants during the periods presented were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 12, 2021, the compensation committee of the Company&#x2019;s board of directors granted 580,000 restricted stock units (&#x201c;RSUs&#x201d;) to R. Erik Holmlin, Ph.D., the Company&#x2019;s President and Chief Executive Officer (the &#x201c;Holmlin Grant&#x201d;), and 240,000 RSUs to Mark Oldakowski, the Company&#x2019;s Chief Operating Officer (the &#x201c;Oldakowski Grant&#x201d;), in each case with an effective grant date and vesting commencement date of May 12, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;290,000 RSUs under the Holmlin Grant are subject to time-based vesting, with 50% of the shares vesting on each of the first and second anniversaries of the vesting commencement date, subject to continued service through the vesting date, and 18 months vesting acceleration upon a termination without cause or resignation with good reason.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;290,000 RSUs under the Holmlin Grant are subject to vesting upon the satisfaction of certain specified revenue targets within four years following the vesting commencement date. If Dr. Holmlin&#x2019;s employment with the Company is terminated without cause or he resigns with good reason, then the shares will continue to be eligible for vesting upon satisfaction of the revenue targets within a period that is the shorter of 18 months following termination or four years following the vesting commencement date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The RSUs comprising the Oldakowski Grant are subject to time-based vesting, with 50% of the shares vesting on each of the first and second anniversaries of the vesting commencement date, subject to continued service through the vesting date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i1412440744f4428481b3a537ab93f461_D20210112-20210112"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDc3OA_e7e8f55d-9035-4e53-bf46-ccf1772b7ecb"
      unitRef="shares">33368851</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i28c5c5f8564a4e67a64f3e5b44585423_D20210112-20210112"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDc5MA_794208e6-cae7-49de-a0fd-84c2b35714e5"
      unitRef="shares">4352458</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i3cf86dab1c3a48caa595e0ad46a9aff1_I20210112"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDgwMQ_3c31ea15-6c39-4a4b-97e7-2ec4d0ff10cd"
      unitRef="usdPerShare">3.05</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ie718fd4d2bcb4f61b4ea90e0b1f6c96b_I20210112"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDgwOA_b45b5041-4476-49ee-a4f4-d37f7931cb92"
      unitRef="usdPerShare">2.867</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i1412440744f4428481b3a537ab93f461_D20210112-20210112"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDgxNg_96b3844b-8ae5-4c5f-853a-03ea4e4f53b7"
      unitRef="usd">101800000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i3cf86dab1c3a48caa595e0ad46a9aff1_I20210112"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NzgzOA_9a4229fb-2f8c-47c2-925f-b8e76b4dc8aa"
      unitRef="usd">293000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8b5c637028ea47bd8c7f4181b517e861_D20210125-20210125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDgzMg_fe76d91d-d67e-4684-853b-84e9e29f1270"
      unitRef="shares">38333352</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i588270472a6143508b7112b2fa331670_D20210125-20210125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDg0NA_7d96c89c-cd30-4eb2-b00e-23523428fd14"
      unitRef="shares">5000002</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i00ca1925ad5b44dfa157b479aefd1f54_I20210125"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDg1NQ_95cc904a-dcf6-4dfe-8b5d-5aecc1aefc2f"
      unitRef="usdPerShare">6.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i573ce6b1bb9b4a1fabd1ce7fd5d82397_I20210125"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDg2Mg_5e3acf7d-6afd-47d4-8754-812eb911e16c"
      unitRef="usdPerShare">5.64</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i8b5c637028ea47bd8c7f4181b517e861_D20210125-20210125"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI2NDg2OQ_e860faf2-a591-43d1-8ce8-b27ac037c540"
      unitRef="usd">230000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i00ca1925ad5b44dfa157b479aefd1f54_I20210125"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2Nzg0Nw_c6ce493c-6e69-4466-bd86-1b269487fb2b"
      unitRef="usd">435000</us-gaap:DeferredFinanceCostsNet>
    <bngo:SaleOfStockAuthorizedAmountToBeIssued
      contextRef="ifd683caf9e1c44568aeff1288d3b04e1_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NTYxMw_54451fbb-ecb1-4593-960a-31350da43c2a"
      unitRef="usd">125000000.0</bngo:SaleOfStockAuthorizedAmountToBeIssued>
    <bngo:SaleOfStockAuthorizedAmountToBeIssued
      contextRef="i3261931611534e3383079edc1d409a1a_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NTY2Mg_31e9fc33-7cf7-4ddf-a0fa-6185cd4f13a4"
      unitRef="usd">40000000.0</bngo:SaleOfStockAuthorizedAmountToBeIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NTg1Nw_e01b2efc-7410-4a73-8de2-476bd0f0e4e9"
      unitRef="shares">27025384</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NTkzNw_f36f2063-0a0a-4c0e-b241-9507d7474d78"
      unitRef="usdPerShare">0.82</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NTk4Nw_b59e6ce1-a30f-4a92-afad-343c583726a4"
      unitRef="usd">22100000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NjAyNg_3abe379e-61e3-4498-9d1b-206aee33ff58"
      unitRef="usd">573000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ib2decea561ca4c6794f62ce452ca3184_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NjA3OQ_7b87eb57-66ae-42f8-88c2-8b7b71073849"
      unitRef="shares">6298152</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i099191310b124b1e81080dfde278c6a1_I20210131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NjE0OQ_828fc388-51b6-43de-9605-267952c32a6f"
      unitRef="usdPerShare">2.68</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="ib2decea561ca4c6794f62ce452ca3184_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NjE5OQ_72cb2b18-e592-435d-9d42-92a7096287a3"
      unitRef="usd">16900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i099191310b124b1e81080dfde278c6a1_I20210131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjA0NzMxMzk2NjIzOA_e7990268-52dd-4501-ae32-1b8fa2f30d21"
      unitRef="usd">422000</us-gaap:DeferredFinanceCostsNet>
    <bngo:SaleOfStockValueSharesIssuedInTransaction
      contextRef="i936534e2d9074d2ca70fe416bd8db58a_D20210323-20210323"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MDU1OA_5d8edbe0-65cc-4d33-922f-b398a8e33beb"
      unitRef="usd">350000000.0</bngo:SaleOfStockValueSharesIssuedInTransaction>
    <bngo:CommissionFeeMaximumPercentageOfGrossProceeds
      contextRef="i936534e2d9074d2ca70fe416bd8db58a_D20210323-20210323"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MDU3NA_7f6f693d-35d1-485b-b4e4-85a6d6b76764"
      unitRef="number">0.030</bngo:CommissionFeeMaximumPercentageOfGrossProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i75942e4e55054f78886bed570f1251f3_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MDU5OQ_079bf89b-e41d-4a99-b87e-f5057068e48e"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjkzMw_5d4a6186-f696-46a3-a14f-6b1aced437e4">&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s warrant activity during the three months ended March&#160;31, 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares of Stock under Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,174,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,841,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,739,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,912,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,411,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,911,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMS0xLTEtMS0w_cc863628-e58a-4e12-8d3e-854d168a5e9e"
      unitRef="shares">15174000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMS0zLTEtMS0w_36d30d9d-00c9-4bef-b84b-fa249e5c5bba"
      unitRef="usdPerShare">2.34</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights
      contextRef="i3978d66a078d4604a9b13bbc463817d9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMS01LTEtMS0w_2dd30b2a-d99e-4aef-8f9b-ee3596c9e222">P3Y9M3D</bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights>
    <bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMS03LTEtMS0w_8ace9096-c691-482f-83e8-6b199a4dd7f6"
      unitRef="usd">26841000</bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights>
    <bngo:ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMi0xLTEtMS0w_c59cd507-e253-4d60-91ee-a987707e524e"
      unitRef="shares">0</bngo:ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod>
    <bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMi0zLTEtMS0w_9ac69f62-81db-40f0-9850-6b571f3e71d9"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMi01LTEtMS0w_4b3a0dc0-be5f-452e-bb27-d8187169eedd"
      xsi:nil="true"/>
    <bngo:ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMy0xLTEtMS0w_c49106c8-9e73-4857-9af0-b6b0a46d4ee1"
      unitRef="shares">10739000</bngo:ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod>
    <bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMy0zLTEtMS0w_94747c63-112e-43bc-8bc9-81dd8e814504"
      unitRef="usdPerShare">0.89</bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod>
    <bngo:ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfMy03LTEtMS0w_160b1906-06f3-42a1-a5e3-78e0f6b706fb"
      unitRef="usd">57912000</bngo:ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights>
    <bngo:ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfNC0xLTEtMS0w_71a86949-c8b3-4d31-baa6-ba52e8a727a3"
      unitRef="shares">24000</bngo:ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfNS0xLTEtMS0w_1787e3ad-9ef0-4617-ac50-177da825539e"
      unitRef="shares">4411000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfNS0zLTEtMS0w_7a424cbc-0bcb-47b1-bdb8-2d924876ec46"
      unitRef="usdPerShare">5.89</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfNS01LTEtMS0w_53c5f231-8a5a-4e42-876c-8b8d9d2de125">P2Y6M</bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights>
    <bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjFkNmVmYWYyNjA3MjRmMDNhMjc1OWQ4ODg2NjM2ZDVlL3RhYmxlcmFuZ2U6MWQ2ZWZhZjI2MDcyNGYwM2EyNzU5ZDg4ODY2MzZkNWVfNS03LTEtMS0w_9395a957-a633-4f5a-aee2-303a2e076bea"
      unitRef="usd">2911000</bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjk0Mg_35e6ff74-2f95-41b2-90f8-3f70ee09504d">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity during the three months ended March&#160;31, 2021 was as follows: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares of Stock under Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,178,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,126,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,554,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,704,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,403,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfMS0xLTEtMS0w_92dfbe01-33ae-4c77-ab8f-a4445e917615"
      unitRef="shares">5290000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfMS0zLTEtMS0w_ec5ea361-07a7-4d03-8441-e5351187d2db"
      unitRef="usdPerShare">1.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3978d66a078d4604a9b13bbc463817d9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfMS01LTEtMS0w_1d8ed6a2-7ed4-49b5-88a0-d96acef57c76">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfMS03LTEtMS0w_1a2150e3-b4b2-4f71-9d43-1de9b684b81d"
      unitRef="usd">10178000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfMi0xLTEtMS0w_343caf3c-e275-4767-872b-c7045c828043"
      unitRef="shares">138000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfMi0zLTEtMS0w_f32180ad-03b9-4a9f-b4f7-f07ee1a0f463"
      unitRef="usdPerShare">10.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfMy0xLTEtMS0w_4c260bdd-39b8-43b7-8536-d0b0396522cd"
      unitRef="shares">102000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfMy0zLTEtMS0w_70b34108-a9cb-4438-bcfb-6827dc8380fe"
      unitRef="usdPerShare">3.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfMy03LTEtMS0w_945bd5e4-3e8e-4eea-b7bf-6b93c1624a00"
      unitRef="usd">1153000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNC0xLTEtMS0w_4eb84649-654e-4e1c-acc4-571ac50524b3"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNC0zLTEtMS0w_5b5abddc-d4c9-4e82-bbbb-c924a60e4716"
      unitRef="usdPerShare">0.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNS0xLTEtMS0w_5e1601b0-bfbe-4ed8-a758-0b12cdb79f45"
      unitRef="shares">5126000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNS0zLTEtMS0w_c8d34d4b-2ce5-40a3-80e9-2f1ae0294923"
      unitRef="usdPerShare">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNS01LTEtMS0w_733fdc97-aeef-487c-a14d-3f414a5b12f6">P8Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNS03LTEtMS0w_bc8abedd-e47c-403f-86c2-8a6d72680047"
      unitRef="usd">31554000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNi0xLTEtMS0w_01f2edc1-dda7-407a-ae41-556bd1a8bcb3"
      unitRef="shares">1704000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNi0zLTEtMS0w_75318f76-4197-47d8-887a-7dda30f547a2"
      unitRef="usdPerShare">3.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNi01LTEtMS0w_358caba7-1c41-40d1-8e49-8472dbc56c71">P8Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i7870f814eef549569827056ab0bbe28f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjgyOGJiZTQ2ZjgyZTQ3MWM4NGExMTc2ZmE1YmM1ZjJkL3RhYmxlcmFuZ2U6ODI4YmJlNDZmODJlNDcxYzg0YTExNzZmYTViYzVmMmRfNi03LTEtMS0w_d1526146-d10f-4c83-8c85-611457dc621f"
      unitRef="usd">8403000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjU5NzA2OTc3NTUyMg_f9324d29-c62d-4c5c-b01f-181711d92fc6"
      unitRef="usdPerShare">10.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfNjU5NzA2OTc3NTUyNg_c78bc293-af5e-48a5-a61d-0fcdc402f276"
      unitRef="usdPerShare">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjkzNA_c140eedb-43b1-4fee-864a-8e08c0782440">&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized stock-based compensation expense for the periods presented as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i576e4374ad8d4ed4b487ff0388600fbb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjQ2ODU0ZDFkYWE5YjQ1ZjM4MTRiN2NjYWMwZGY0OGVkL3RhYmxlcmFuZ2U6NDY4NTRkMWRhYTliNDVmMzgxNGI3Y2NhYzBkZjQ4ZWRfMi0xLTEtMS0w_807dc5ae-b717-4a2e-9354-b32703c903cc"
      unitRef="usd">81000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i14c68bbc58d744e486a0c8a007611aa9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjQ2ODU0ZDFkYWE5YjQ1ZjM4MTRiN2NjYWMwZGY0OGVkL3RhYmxlcmFuZ2U6NDY4NTRkMWRhYTliNDVmMzgxNGI3Y2NhYzBkZjQ4ZWRfMi0zLTEtMS0w_3375eb04-9420-4c36-99a7-ce3cd7f42ed8"
      unitRef="usd">67000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i87e1c72584cb4efa9e7e2a7589d92a4d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjQ2ODU0ZDFkYWE5YjQ1ZjM4MTRiN2NjYWMwZGY0OGVkL3RhYmxlcmFuZ2U6NDY4NTRkMWRhYTliNDVmMzgxNGI3Y2NhYzBkZjQ4ZWRfMy0xLTEtMS0w_24073068-1fd1-4d00-ac85-11bbbd41cf8f"
      unitRef="usd">290000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaefaeb1bcc134ff2b57adb93646ab3a3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjQ2ODU0ZDFkYWE5YjQ1ZjM4MTRiN2NjYWMwZGY0OGVkL3RhYmxlcmFuZ2U6NDY4NTRkMWRhYTliNDVmMzgxNGI3Y2NhYzBkZjQ4ZWRfMy0zLTEtMS0w_52539b4d-7c9e-4b24-9cd0-38ef93a5b527"
      unitRef="usd">261000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjQ2ODU0ZDFkYWE5YjQ1ZjM4MTRiN2NjYWMwZGY0OGVkL3RhYmxlcmFuZ2U6NDY4NTRkMWRhYTliNDVmMzgxNGI3Y2NhYzBkZjQ4ZWRfNC0xLTEtMS0w_4cc8d4d9-5d2c-4d4c-bce9-0bbe9f2949f6"
      unitRef="usd">371000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjQ2ODU0ZDFkYWE5YjQ1ZjM4MTRiN2NjYWMwZGY0OGVkL3RhYmxlcmFuZ2U6NDY4NTRkMWRhYTliNDVmMzgxNGI3Y2NhYzBkZjQ4ZWRfNC0zLTEtMS0w_13a89a76-920c-4669-aadd-8389c1e0224d"
      unitRef="usd">328000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjk0MA_4459cbea-cdd8-44bf-ad91-8e42970a1c02">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants during the periods presented were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjNiNjkzNTI0ZDA1YTQ0OTM4NDQ0NTYyMjc5ODdmNmNhL3RhYmxlcmFuZ2U6M2I2OTM1MjRkMDVhNDQ5Mzg0NDQ1NjIyNzk4N2Y2Y2FfMi0xLTEtMS0w_930f0d01-a4b1-4326-bc39-15584492795e"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjNiNjkzNTI0ZDA1YTQ0OTM4NDQ0NTYyMjc5ODdmNmNhL3RhYmxlcmFuZ2U6M2I2OTM1MjRkMDVhNDQ5Mzg0NDQ1NjIyNzk4N2Y2Y2FfMi0zLTEtMS0w_52919a3e-0075-4960-9282-0336ef46a8a4"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjNiNjkzNTI0ZDA1YTQ0OTM4NDQ0NTYyMjc5ODdmNmNhL3RhYmxlcmFuZ2U6M2I2OTM1MjRkMDVhNDQ5Mzg0NDQ1NjIyNzk4N2Y2Y2FfMy0xLTEtMS0w_6e90b5e8-fe30-4140-8bb9-7938fd7e591d"
      unitRef="number">0.793</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjNiNjkzNTI0ZDA1YTQ0OTM4NDQ0NTYyMjc5ODdmNmNhL3RhYmxlcmFuZ2U6M2I2OTM1MjRkMDVhNDQ5Mzg0NDQ1NjIyNzk4N2Y2Y2FfMy0zLTEtMS0w_a523fb35-ad6d-4233-96af-2d5ed9ff660f"
      unitRef="number">0.700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjNiNjkzNTI0ZDA1YTQ0OTM4NDQ0NTYyMjc5ODdmNmNhL3RhYmxlcmFuZ2U6M2I2OTM1MjRkMDVhNDQ5Mzg0NDQ1NjIyNzk4N2Y2Y2FfNC0xLTEtMS0w_1bea4ba8-093d-4451-a9a2-3feb084d7c34">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjNiNjkzNTI0ZDA1YTQ0OTM4NDQ0NTYyMjc5ODdmNmNhL3RhYmxlcmFuZ2U6M2I2OTM1MjRkMDVhNDQ5Mzg0NDQ1NjIyNzk4N2Y2Y2FfNC0zLTEtMS0w_774177de-3f54-4690-8a21-b5159f36b220">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjNiNjkzNTI0ZDA1YTQ0OTM4NDQ0NTYyMjc5ODdmNmNhL3RhYmxlcmFuZ2U6M2I2OTM1MjRkMDVhNDQ5Mzg0NDQ1NjIyNzk4N2Y2Y2FfNS0xLTEtMS0w_e6421c9a-b280-4a1d-bfcb-0918cf08666c"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7b49b6fbb9db41a39e6d5e9e881b38e3_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RhYmxlOjNiNjkzNTI0ZDA1YTQ0OTM4NDQ0NTYyMjc5ODdmNmNhL3RhYmxlcmFuZ2U6M2I2OTM1MjRkMDVhNDQ5Mzg0NDQ1NjIyNzk4N2Y2Y2FfNS0zLTEtMS0w_e2a0a22b-0ff8-455e-be17-e5e32d3b9341"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iac856732b955418489f120209c032ca1_D20210512-20210512"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjI1OA_91b74795-a111-4288-9a74-82be8c67e7e1"
      unitRef="shares">580000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic7ef34e0c67c4f8d810c6f8f14d356e4_D20210512-20210512"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjI2Nw_92511363-5714-4de2-8c34-2171ed82f167"
      unitRef="shares">240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i553916c7e88a4b47a7275965698ebdb5_D20210512-20210512"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjI3Ng_d1639b34-6efb-4cd6-8f9f-45163e1633d4"
      unitRef="shares">290000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary
      contextRef="i553916c7e88a4b47a7275965698ebdb5_D20210512-20210512"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjM3MA_fe33c868-5aad-4143-a76a-45e007b9672c"
      unitRef="number">0.50</bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary>
    <bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment
      contextRef="i553916c7e88a4b47a7275965698ebdb5_D20210512-20210512"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjM2Mw_dd04d2f3-b915-4c04-8f31-43cc98dba7d7">P18M</bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie0eae5cf1a454c6a93daea25421b1ac6_D20210512-20210512"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjI4NQ_5496a9ab-c2fc-4118-85c6-91015920999c"
      unitRef="shares">290000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment
      contextRef="ia7f20b922d82432990b90d2c4766e208_D20210512-20210512"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjM5NQ_f71237f5-7ad3-44c0-a0af-971e6dec1b38">P4Y</bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment>
    <bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment
      contextRef="if952551a9010425ca3350af97034ba84_D20210512-20210512"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjY1OA_4dcc76f2-d6bc-4c2b-92af-9f2b5dcd4989">P18M</bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment>
    <bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment
      contextRef="ia7f20b922d82432990b90d2c4766e208_D20210512-20210512"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjY0Mg_f71237f5-7ad3-44c0-a0af-971e6dec1b38">P4Y</bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment>
    <bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary
      contextRef="if35c609f5b2b4a87a6bc4013c2bc1db7_D20210512-20210512"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl80OS9mcmFnOjUzMzAyZjIyM2RjZTRkN2Q4NWNkNWFiYjYxY2ZhZTA1L3RleHRyZWdpb246NTMzMDJmMjIzZGNlNGQ3ZDg1Y2Q1YWJiNjFjZmFlMDVfMjE5OTAyMzI3MjM3NQ_71e4a2ff-e6d2-482d-a24d-0239e46dea59"
      unitRef="number">0.50</bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81Mi9mcmFnOjZiM2I1NTg4OGRmNjRhMjRiM2FhYjQzNjRlOTUyYWIzL3RleHRyZWdpb246NmIzYjU1ODg4ZGY2NGEyNGIzYWFiNDM2NGU5NTJhYjNfNzc1_e529f224-bebe-4f2b-8ca5-eec3105d49a8">Litigation From time to time, the Company may be subject to potential liabilities under various claims and legal actions that are pending or may be asserted. These matters arise in the ordinary course and conduct of the business. The Company regularly assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on the Company&#x2019;s assessment, it currently does not have any material loss exposure as it is not a defendant in any claims or legal actions.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81NS9mcmFnOjQ0ODkwMzI4ODQxYTQ3ZjM4YTc4NTA1N2E0YTA4MGJjL3RleHRyZWdpb246NDQ4OTAzMjg4NDFhNDdmMzhhNzg1MDU3YTRhMDgwYmNfMTA5Nw_7788b100-7440-4577-8ce2-9b89c1373b1f">Income Taxes The Company is subject to taxation in the United States, United Kingdom and various state jurisdictions. The Company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. The primary difference between the effective tax rate and the federal statutory tax rate relates to the full valuation allowance on the Company&#x2019;s U.S. net operating losses.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNjg0Mg_968f9b36-d3bb-4292-9ba3-28d82adfb5a8">Acquisition of LineagenOn August 21, 2020, the Company, Alta Merger Sub, Inc., a wholly owned subsidiary of the Company (&#x201c;Merger Sub&#x201d;), Lineagen, a Delaware corporation, and Michael S. Paul, Ph.D., solely in his capacity as exclusive agent and attorney-in-fact of the security-holders of Lineagen, entered into an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;).  Pursuant to the terms and conditions of the Merger Agreement, Merger Sub merged with and into Lineagen whereupon the separate corporate existence of Merger Sub ceased, with Lineagen continuing as the surviving corporation of the Merger as a wholly owned subsidiary of the Company. Lineagen&#x2019;s expertise in development, commercialization and reimbursement of laboratory-developed tests provides a platform for accelerating sales growth for the Company&#x2019;s Saphyr system.&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the &#x201c;Effective Time&#x201d;), the shares of capital stock of Lineagen and all options of Lineagen that were issued and outstanding immediately prior to the Effective Time were automatically cancelled and extinguished without any payment with respect thereto. Certain holders of convertible notes and other indebtedness of Lineagen at the closing of the Merger (the &#x201c;Closing&#x201d;) received common stock of the Company. The total number of shares of the Company&#x2019;s common stock issued or reserved for issuance as consideration for the Merger was 6,167,510 shares, subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen (the &#x201c;Merger Shares&#x201d;). 925,126 of the Merger Shares (the &#x201c;Escrowed Shares&#x201d;) will be held in an escrow fund for purposes of satisfying any post-closing purchase price adjustments and indemnification claims under the Merger Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Also as consideration for the Merger, pursuant to the Merger Agreement, the Company paid approximately $1.9&#160;million in cash to certain creditors and assumed certain liabilities of Lineagen totaling approximately $2.9&#160;million, reflective of the Company&#x2019;s preliminary estimate of the post-closing purchase price adjustment (which adjustment is subject to finalization pursuant to the terms of the Merger Agreement).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; In addition, on August 21, 2020, concurrent with the Closing, the Company paid approximately $1.1&#160;million to satisfy all outstanding principal and accrued interest amounts due pursuant to that certain Promissory Note, dated April 22, 2020, by and between Lineagen and Silicon Valley Bank (the &#x201c;Lineagen PPP Loan&#x201d;), issued pursuant to the CARES Act administered by the SBA. The Lineagen PPP Loan was repaid by the Company prior to maturity without penalty.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company accounted for its acquisition of Lineagen using the acquisition method of accounting pursuant to ASC 805.  The tangible and identifiable intangible assets acquired and liabilities assumed were recorded at their estimated fair values as of the acquisition date, and the excess of the purchase price over the estimated fair value assigned to the tangible and identifiable intangible assets acquired and liabilities assumed was recorded to goodwill. Goodwill relates to the expected synergies from combining the operations of the companies. The acquisition was structured as a stock sale and therefore goodwill is non-tax deductible. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As permitted under ASC 805, the Company is allowed a measurement period, which may not exceed one year, in which to complete its accounting for the acquisition. The Company has recognized provisional amounts for tax assets and liabilities, and subsequent adjustments during the measurement period to any of these items may affect the amount of goodwill recognized. During the fourth quarter of 2020, the Company recorded a $232,000 adjustment to the original purchase price allocation to reduce the estimated fair value of accounts receivable, with the offsetting amount recorded to goodwill. There were no additional purchase price adjustments made during the first quarter of 2021. The Company is still finalizing working capital adjustments with the seller.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed above, the purchase price for the acquisition of Lineagen is subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen. The following is the estimated purchase price for the acquisition of Lineagen:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,940,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash transferred for repayment of Lineage PPP Loan (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,105,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Shares common stock issued as consideration (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6,167,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Estimated shares of common stock to be returned to the Company (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(138,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock price per share on closing date &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Value of estimated common stock consideration (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total estimated purchase price (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,144,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) The Company paid approximately $1.9&#160;million in cash to certain creditors of Lineagen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) The Company paid approximately $1.1&#160;million to satisfy all outstanding principal and accrued interest amounts due pursuant to the Lineagen PPP Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c) The total number of shares of the Company&#x2019;s common stock issued or reserved for issuance as consideration for the Merger was 6,167,510 shares. 925,126 of the Merger Shares will be held in an escrow fund for purposes of satisfying any post-closing purchase price adjustments and indemnification claims under the Merger Agreement. The total number of Merger Shares is subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen. The value of the estimated common stock consideration and the total estimated purchase price incorporate the return of an estimated 138,247 Escrowed Shares to the Company based on a preliminary estimate of this adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total estimated purchase price was allocated to Lineagen&#x2019;s tangible and identifiable intangible assets acquired and liabilities assumed on based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.030%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;596,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;337,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;209,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;111,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,580,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,173,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2,862,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,144,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition date fair values of identifiable intangible assets acquired are as following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.030%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;950,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;630,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of identifiable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,580,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The customer relationships and trade name intangibles are both being amortized on a straight-line basis over their estimated useful lives of five years. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited pro forma financial information in the table below summarizes the combined results of operations for the Company and Lineagen as if the companies had been combined as of January 1, 2019. The unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisition had taken place as of January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,676,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,637,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;These amounts have been calculated after applying the Company&#x2019;s accounting policies and adjusting the results of Lineagen to reflect (i) additional amortization that would have been charged based upon the fair value of the acquired intangible assets of  $77,000 for the three months ended  March&#160;31, 2020; and (ii) the removal of interest expense related to the historical debt of Lineagen which was not acquired of $312,000 or the three months ended  March&#160;31, 2020</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfMTE0Nw_7b38dd2f-3093-4275-8208-5701c8268772"
      unitRef="shares">6167510</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="ib33b784ee1ca47bdb4a6e098ee129696_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfMTMyNQ_2876d167-5d26-484e-a806-f50af090f749"
      unitRef="shares">925126</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfMTYzNA_5ee79ffb-1c7e-4b1a-a00e-39553783517b"
      unitRef="usd">1900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfMTczMw_b747259a-12e9-461f-941c-af62f17acf12"
      unitRef="usd">2900000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:RepaymentsOfOtherDebt
      contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfMjAxOQ_0c19b4ec-e3ba-46ad-aa8c-48d453899167"
      unitRef="usd">1100000</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
      contextRef="i16b00547face45e1b37c18f6b4043c7b_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfMjE5OTAyMzI2NzU4NQ_f5ca8bbd-d211-486d-9ad5-aa46356e6ef3"
      unitRef="usd">232000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNjg0Ng_ec5b38a9-42a8-4ad0-b931-d9cedc31e04f">The following is the estimated purchase price for the acquisition of Lineagen:&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,940,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash transferred for repayment of Lineage PPP Loan (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,105,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Shares common stock issued as consideration (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6,167,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Estimated shares of common stock to be returned to the Company (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(138,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock price per share on closing date &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Value of estimated common stock consideration (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total estimated purchase price (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,144,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) The Company paid approximately $1.9&#160;million in cash to certain creditors of Lineagen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) The Company paid approximately $1.1&#160;million to satisfy all outstanding principal and accrued interest amounts due pursuant to the Lineagen PPP Loan.&lt;/span&gt;&lt;/div&gt;(c) The total number of shares of the Company&#x2019;s common stock issued or reserved for issuance as consideration for the Merger was 6,167,510 shares. 925,126 of the Merger Shares will be held in an escrow fund for purposes of satisfying any post-closing purchase price adjustments and indemnification claims under the Merger Agreement. The total number of Merger Shares is subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen. The value of the estimated common stock consideration and the total estimated purchase price incorporate the return of an estimated 138,247 Escrowed Shares to the Company based on a preliminary estimate of this adjustment.</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjZhY2NhNTBjYjQ1OTQzNDVhNjFjM2VmNWNmZjJkNjcyL3RhYmxlcmFuZ2U6NmFjY2E1MGNiNDU5NDM0NWE2MWMzZWY1Y2ZmMmQ2NzJfMC0yLTEtMS0w_8cb9ce7f-9a6e-442c-8ae4-08aa163a78b9"
      unitRef="usd">1940000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RepaymentsOfOtherDebt
      contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjZhY2NhNTBjYjQ1OTQzNDVhNjFjM2VmNWNmZjJkNjcyL3RhYmxlcmFuZ2U6NmFjY2E1MGNiNDU5NDM0NWE2MWMzZWY1Y2ZmMmQ2NzJfMS0yLTEtMS0w_db8fc476-8c9b-40e1-8b12-8d1093b38fd7"
      unitRef="usd">1105000</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjZhY2NhNTBjYjQ1OTQzNDVhNjFjM2VmNWNmZjJkNjcyL3RhYmxlcmFuZ2U6NmFjY2E1MGNiNDU5NDM0NWE2MWMzZWY1Y2ZmMmQ2NzJfMi0yLTEtMS0w_53cb403a-7fd1-467f-8835-53b513047676"
      unitRef="shares">6167510</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <bngo:BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment
      contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjZhY2NhNTBjYjQ1OTQzNDVhNjFjM2VmNWNmZjJkNjcyL3RhYmxlcmFuZ2U6NmFjY2E1MGNiNDU5NDM0NWE2MWMzZWY1Y2ZmMmQ2NzJfMy0yLTEtMS0w_08133c7a-6cb4-46b8-b8f9-8ec7ab22810e"
      unitRef="shares">138247</bngo:BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjZhY2NhNTBjYjQ1OTQzNDVhNjFjM2VmNWNmZjJkNjcyL3RhYmxlcmFuZ2U6NmFjY2E1MGNiNDU5NDM0NWE2MWMzZWY1Y2ZmMmQ2NzJfNC0yLTEtMS0w_72eadc8f-d8d9-4753-8b0d-45590045e6ea"
      unitRef="usdPerShare">0.68</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjZhY2NhNTBjYjQ1OTQzNDVhNjFjM2VmNWNmZjJkNjcyL3RhYmxlcmFuZ2U6NmFjY2E1MGNiNDU5NDM0NWE2MWMzZWY1Y2ZmMmQ2NzJfNS0yLTEtMS0w_55800711-24aa-41e9-b041-79f4ef872dfe"
      unitRef="usd">4100000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjZhY2NhNTBjYjQ1OTQzNDVhNjFjM2VmNWNmZjJkNjcyL3RhYmxlcmFuZ2U6NmFjY2E1MGNiNDU5NDM0NWE2MWMzZWY1Y2ZmMmQ2NzJfNi0yLTEtMS0w_94a2b83e-6457-4649-8e9d-8d6c4c0b23ad"
      unitRef="usd">7144000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNDAyOA_4b3d02eb-e102-4194-aba6-5dd415d3c406"
      unitRef="usd">1900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RepaymentsOfOtherDebt
      contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNDEwOA_8e4a834e-a749-4791-8e1f-3ec8ab6e78b0"
      unitRef="usd">1100000</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNDM0NQ_e105b37f-4cd1-4813-86f2-dc6e437915bc"
      unitRef="shares">6167510</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="ib33b784ee1ca47bdb4a6e098ee129696_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNDM1Ng_49071063-22dd-4e2c-b4fc-d423aa9c7bf5"
      unitRef="shares">925126</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <bngo:BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment
      contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNDg1MQ_08133c7a-6cb4-46b8-b8f9-8ec7ab22810e"
      unitRef="shares">138247</bngo:BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNjg0OA_ce3a4e11-302e-4744-81e2-b7b958569d9a">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total estimated purchase price was allocated to Lineagen&#x2019;s tangible and identifiable intangible assets acquired and liabilities assumed on based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.030%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;596,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;337,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;209,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;111,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,580,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,173,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2,862,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,144,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjgwYmE3NzQ2YzBiMDQ1ZDliMzYxMmNhNzVmYzFkNGNiL3RhYmxlcmFuZ2U6ODBiYTc3NDZjMGIwNDVkOWIzNjEyY2E3NWZjMWQ0Y2JfMC0yLTEtMS0w_2878c1a0-b624-4888-a5fa-a288af3921fd"
      unitRef="usd">596000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjgwYmE3NzQ2YzBiMDQ1ZDliMzYxMmNhNzVmYzFkNGNiL3RhYmxlcmFuZ2U6ODBiYTc3NDZjMGIwNDVkOWIzNjEyY2E3NWZjMWQ0Y2JfMS0yLTEtMS0w_25a36815-025a-4520-8b75-05fdb4127ce8"
      unitRef="usd">337000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjgwYmE3NzQ2YzBiMDQ1ZDliMzYxMmNhNzVmYzFkNGNiL3RhYmxlcmFuZ2U6ODBiYTc3NDZjMGIwNDVkOWIzNjEyY2E3NWZjMWQ0Y2JfMi0yLTEtMS0w_d075b5df-d171-41f8-8293-f7c7dc7d8b4a"
      unitRef="usd">209000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjgwYmE3NzQ2YzBiMDQ1ZDliMzYxMmNhNzVmYzFkNGNiL3RhYmxlcmFuZ2U6ODBiYTc3NDZjMGIwNDVkOWIzNjEyY2E3NWZjMWQ0Y2JfMy0yLTEtMS0w_f10c9b28-77f5-4265-986c-644cfbfd0317"
      unitRef="usd">111000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjgwYmE3NzQ2YzBiMDQ1ZDliMzYxMmNhNzVmYzFkNGNiL3RhYmxlcmFuZ2U6ODBiYTc3NDZjMGIwNDVkOWIzNjEyY2E3NWZjMWQ0Y2JfNC0yLTEtMS0w_b27132ce-63b4-4832-aeb1-3f18cbaac4c5"
      unitRef="usd">1580000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjgwYmE3NzQ2YzBiMDQ1ZDliMzYxMmNhNzVmYzFkNGNiL3RhYmxlcmFuZ2U6ODBiYTc3NDZjMGIwNDVkOWIzNjEyY2E3NWZjMWQ0Y2JfNS0yLTEtMS0w_2fc057b7-54cd-444f-aa13-34c6f5bc00fa"
      unitRef="usd">7173000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjgwYmE3NzQ2YzBiMDQ1ZDliMzYxMmNhNzVmYzFkNGNiL3RhYmxlcmFuZ2U6ODBiYTc3NDZjMGIwNDVkOWIzNjEyY2E3NWZjMWQ0Y2JfNi0yLTEtMS0w_aedb2669-7d28-441c-8f89-c7af9e49b179"
      unitRef="usd">2862000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjgwYmE3NzQ2YzBiMDQ1ZDliMzYxMmNhNzVmYzFkNGNiL3RhYmxlcmFuZ2U6ODBiYTc3NDZjMGIwNDVkOWIzNjEyY2E3NWZjMWQ0Y2JfNy0yLTEtMS0w_403dc389-6e7b-4f71-a283-66e8ec046ca6"
      unitRef="usd">7144000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNjg0NA_c7c4f922-393b-477b-b5be-54e35c5cddf2">&lt;div style="margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition date fair values of identifiable intangible assets acquired are as following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.030%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;950,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;630,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of identifiable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,580,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="idc54661388eb4fe880e68defa355cc59_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjhiMzRhNWUxYzkyZjQwYTQ5ZTk1Y2E4NDA3ZWY2NTQ4L3RhYmxlcmFuZ2U6OGIzNGE1ZTFjOTJmNDBhNDllOTVjYTg0MDdlZjY1NDhfMC0yLTEtMS0w_d1cce296-1099-476c-b93c-4c9d2f671b17"
      unitRef="usd">950000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i277d7d0d7df14699a128ed991162d604_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjhiMzRhNWUxYzkyZjQwYTQ5ZTk1Y2E4NDA3ZWY2NTQ4L3RhYmxlcmFuZ2U6OGIzNGE1ZTFjOTJmNDBhNDllOTVjYTg0MDdlZjY1NDhfMS0yLTEtMS0w_ee5f04e9-79ef-419c-a663-e81f8992e1c6"
      unitRef="usd">630000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i056e748dff1445bf9ed9183ca6be7827_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOjhiMzRhNWUxYzkyZjQwYTQ5ZTk1Y2E4NDA3ZWY2NTQ4L3RhYmxlcmFuZ2U6OGIzNGE1ZTFjOTJmNDBhNDllOTVjYTg0MDdlZjY1NDhfMi0yLTEtMS0w_065952af-922a-42e2-9cfe-2220b4f794e4"
      unitRef="usd">1580000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfNTQzNw_6ade58d4-ec71-4d0d-8ab3-2580ca15e5ae">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfMjE5OTAyMzI3MDcwMg_b590a3ae-348f-4755-bb12-b436e4eb7b4a">The unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisition had taken place as of January 1, 2019.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,676,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,637,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i08b91758924d4450afbd57d83b618e31_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOmUwYTRhNmJiMjdmMzQyOTliYTc4YmIwNjUwMzRhMDE2L3RhYmxlcmFuZ2U6ZTBhNGE2YmIyN2YzNDI5OWJhNzhiYjA2NTAzNGEwMTZfMi0yLTEtMS00MDg0_0747ab3f-d49d-45b3-bac2-df0f1471abeb"
      unitRef="usd">2676000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i08b91758924d4450afbd57d83b618e31_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOmUwYTRhNmJiMjdmMzQyOTliYTc4YmIwNjUwMzRhMDE2L3RhYmxlcmFuZ2U6ZTBhNGE2YmIyN2YzNDI5OWJhNzhiYjA2NTAzNGEwMTZfMy0yLTEtMS00MDg0_b9b2689c-ecd4-4791-aa76-5bdf2ec22c11"
      unitRef="usd">-11637000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOmUwYTRhNmJiMjdmMzQyOTliYTc4YmIwNjUwMzRhMDE2L3RhYmxlcmFuZ2U6ZTBhNGE2YmIyN2YzNDI5OWJhNzhiYjA2NTAzNGEwMTZfNC0yLTEtMS00MDg3_3c411d43-259d-4f55-a86a-4608d4c1fe0b"
      unitRef="usdPerShare">-0.28</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RhYmxlOmUwYTRhNmJiMjdmMzQyOTliYTc4YmIwNjUwMzRhMDE2L3RhYmxlcmFuZ2U6ZTBhNGE2YmIyN2YzNDI5OWJhNzhiYjA2NTAzNGEwMTZfNC0yLTEtMS00MDg3_7a3e4a59-6dd1-435f-8fb1-0e977e338c9c"
      unitRef="usdPerShare">-0.28</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if4a769484c39497e8dc3a7a689f2d800_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfMjE5OTAyMzI3MzUxOA_c82b9d67-a596-4620-ad7b-04a226dfc330"
      unitRef="usd">77000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:InterestExpenseDebt
      contextRef="if4a769484c39497e8dc3a7a689f2d800_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzODgzOTVlYmVhNTRiMzhiMGJlMjdmYmEwNjM1YjEyL3NlYzpiMzg4Mzk1ZWJlYTU0YjM4YjBiZTI3ZmJhMDYzNWIxMl81OC9mcmFnOjRjOGI5MWYxYjJmODQ4YzNiZWZjZWExNzBjMWRiMzI4L3RleHRyZWdpb246NGM4YjkxZjFiMmY4NDhjM2JlZmNlYTE3MGMxZGIzMjhfMjE5OTAyMzI3MzUyOA_3dbaf9cd-642c-4aef-854a-6708107205fb"
      unitRef="usd">-312000</us-gaap:InterestExpenseDebt>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175452822264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 07, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Bionano Genomics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1756290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9540 Towne Centre Drive, Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">888-7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,849,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001411690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BNGO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BNGOW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175456604232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 362,057,000<span></span>
</td>
<td class="nump">$ 38,449,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $2,091,000 and $2,119,000 as of March&#160;31, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">1,992,000<span></span>
</td>
<td class="nump">2,775,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">3,036,000<span></span>
</td>
<td class="nump">3,316,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,166,000<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">370,251,000<span></span>
</td>
<td class="nump">46,790,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,806,000<span></span>
</td>
<td class="nump">4,910,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">1,396,000<span></span>
</td>
<td class="nump">1,475,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">7,173,000<span></span>
</td>
<td class="nump">7,173,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">235,000<span></span>
</td>
<td class="nump">103,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">384,861,000<span></span>
</td>
<td class="nump">60,451,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,209,000<span></span>
</td>
<td class="nump">2,930,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">4,659,000<span></span>
</td>
<td class="nump">5,599,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">301,000<span></span>
</td>
<td class="nump">416,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,169,000<span></span>
</td>
<td class="nump">8,945,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
<td class="nump">14,866,000<span></span>
</td>
<td class="nump">16,326,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term contract liabilities</a></td>
<td class="nump">108,000<span></span>
</td>
<td class="nump">98,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">22,143,000<span></span>
</td>
<td class="nump">25,369,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 400,000,000 shares authorized at March&#160;31, 2021 and December&#160;31, 2020; 278,794,000 and 189,953,000 shares issued and outstanding at March&#160;31, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March&#160;31, 2021 and December&#160;31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">516,321,000<span></span>
</td>
<td class="nump">178,747,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(153,631,000)<span></span>
</td>
<td class="num">(143,684,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">362,718,000<span></span>
</td>
<td class="nump">35,082,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 384,861,000<span></span>
</td>
<td class="nump">$ 60,451,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175456721720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 2,091,000<span></span>
</td>
<td class="nump">$ 2,119,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">278,794,000<span></span>
</td>
<td class="nump">189,953,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">278,794,000<span></span>
</td>
<td class="nump">189,953,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175452832904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 3,168,000<span></span>
</td>
<td class="nump">$ 1,136,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="nump">2,125,000<span></span>
</td>
<td class="nump">856,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,678,000<span></span>
</td>
<td class="nump">2,674,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">9,528,000<span></span>
</td>
<td class="nump">7,368,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">12,206,000<span></span>
</td>
<td class="nump">10,042,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(11,163,000)<span></span>
</td>
<td class="num">(9,762,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="num">(538,000)<span></span>
</td>
<td class="num">(761,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on forgiveness of Paycheck Protection Program loan</a></td>
<td class="nump">1,775,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">1,222,000<span></span>
</td>
<td class="num">(743,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(9,941,000)<span></span>
</td>
<td class="num">(10,505,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,947,000)<span></span>
</td>
<td class="num">$ (10,510,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (USD per share)</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding basic and diluted (shares)</a></td>
<td class="nump">263,939,000<span></span>
</td>
<td class="nump">35,569,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 2,049,000<span></span>
</td>
<td class="nump">$ 983,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="nump">1,513,000<span></span>
</td>
<td class="nump">774,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Service and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,119,000<span></span>
</td>
<td class="nump">153,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="nump">$ 612,000<span></span>
</td>
<td class="nump">$ 82,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175452526472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,274,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 3,614,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 106,188,000<span></span>
</td>
<td class="num">$ (102,577,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">328,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issue stock for warrant exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,478,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issue stock for warrant exercises</a></td>
<td class="nump">2,355,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,510,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,510,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,752,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2020</a></td>
<td class="num">(4,213,000)<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">108,871,000<span></span>
</td>
<td class="num">(113,087,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,953,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 35,082,000<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="nump">178,747,000<span></span>
</td>
<td class="num">(143,684,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises (in shares)</a></td>
<td class="nump">102,000<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises</a></td>
<td class="nump">$ 333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">371,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issue common stock, net of issuance costs</a></td>
<td class="nump">327,486,000<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">327,478,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issue stock for warrant exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,739,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issue stock for warrant exercises</a></td>
<td class="nump">9,393,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">9,392,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,947,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,947,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,794,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 362,718,000<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="nump">$ 516,321,000<span></span>
</td>
<td class="num">$ (153,631,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175453042424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,947,000)<span></span>
</td>
<td class="num">$ (10,510,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">448,000<span></span>
</td>
<td class="nump">296,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest</a></td>
<td class="nump">315,000<span></span>
</td>
<td class="nump">379,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">371,000<span></span>
</td>
<td class="nump">328,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debt expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">958,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on forgiveness of PPP Loan</a></td>
<td class="num">(1,775,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">783,000<span></span>
</td>
<td class="nump">1,261,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(961,000)<span></span>
</td>
<td class="num">(635,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,049,000)<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,045,000)<span></span>
</td>
<td class="nump">477,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and contract liabilities</a></td>
<td class="num">(1,044,000)<span></span>
</td>
<td class="num">(639,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,904,000)<span></span>
</td>
<td class="num">(8,032,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(24,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(24,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of term-loan debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,100,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from borrowing from line of credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">761,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of borrowing from line of credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,156,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="nump">328,635,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses on sale of common stock</a></td>
<td class="num">(825,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from warrant and option exercises</a></td>
<td class="nump">9,726,000<span></span>
</td>
<td class="nump">2,360,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">337,536,000<span></span>
</td>
<td class="num">(1,135,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">323,608,000<span></span>
</td>
<td class="num">(9,167,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">38,449,000<span></span>
</td>
<td class="nump">17,311,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">362,057,000<span></span>
</td>
<td class="nump">8,144,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">287,000<span></span>
</td>
<td class="nump">382,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory', window );">Transfer of instruments and servers from property and equipment into inventory</a></td>
<td class="nump">126,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory', window );">Transfer of instruments and servers from inventory to property and equipment</a></td>
<td class="nump">1,366,000<span></span>
</td>
<td class="nump">467,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_OfferingCostsIncurredNotYetPaid', window );">Offering costs in accounts payable</a></td>
<td class="nump">324,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_WarrantExerciseNonCash', window );">Warrant exercise pursuant to cashless exercise</a></td>
<td class="nump">$ 129,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_OfferingCostsIncurredNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering Costs Incurred, Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_OfferingCostsIncurredNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer Of Instruments And Servers From Property And Equipment Into Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer of instruments and servers to property and equipment from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_WarrantExerciseNonCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Exercise, Non-cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_WarrantExerciseNonCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175450311672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bionano Genomics, Inc. (collectively, with its consolidated subsidiaries, the &#8220;Company&#8221;) is a life sciences instrumentation company in the genome analysis space that provides tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and provides diagnostic testing for those with autism spectrum disorder (&#8220;ASD&#8221;) and other neurodevelopmental disabilities through newly acquired Lineagen, Inc., a wholly owned subsidiary of the Company (&#8220;Lineagen&#8221;). The Company currently develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that is designed to enable researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who want to evaluate Saphyr data quickly and with a low up-front investment. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim reporting purposes. The condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company&#8217;s management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, changes in equity, and comprehensive loss and cash flows for each period presented in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). All intercompany transactions and balances have been eliminated. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the Company had approximately $362.1&#160;million in cash and cash equivalents, and working capital of $363.1 million as a result of common stock offerings executed in the quarters ended December 31, 2020 and March 31, 2021. In February 2021, we applied for forgiveness of our Paycheck Protection Program (&#8220;the PPP&#8221;) Loan, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full for $1.8 million. In addition, the Company has a $5.0&#160;million revolving line of credit with Innovatus Life Sciences Lending Fund I, LP (the &#8220;Innovatus LSA&#8221;), under which no borrowings were outstanding as of March&#160;31, 2021. This facility is scheduled to expire in March 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes its available cash balance will be sufficient to fund operations, obligations as they become due and capital investments for at least the next twelve months.  However, the Company expects to continue to incur net losses for the foreseeable future. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, potentially harming the Company&#8217;s business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to additional risks and uncertainties as a result of the continued spread of COVID-19 and uncertain market conditions, which could continue to have a material impact on the Company&#8217;s business and financial results. The Company closely monitors and complies with various applicable guidelines and legal requirements in the jurisdictions in which it operates, which may continue to result in reduced business operations in response to new or existing stay-at-home orders, travel restrictions and other social distancing measures. The Company&#8217;s manufacturing partners, suppliers, and customers, have implemented similar operational restrictions. Despite reporting an increase in revenue for the three months ended March 31, 2021 when compared to the same period in 2020, the Company believes travel restrictions and overall reduced activity has negatively impacted the Company&#8217;s first quarter 2021 financial results. The future effects of COVID-19 are unknown and the Company&#8217;s financial results may continue to be negatively affected in the future.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be long-term negative effects of the COVID-19 pandemic, even after it has subsided. Specifically, product demand may be reduced due to an economic recession, a decrease in corporate capital expenditures, prolonged unemployment, reduction in consumer confidence, or any similar negative economic condition. These negative effects could have a material impact on the Company&#8217;s operations, business, earnings, and liquidity.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, there were no changes to the Company&#8217;s significant accounting policies as described in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued But Not Yet Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April&#160;2012, the Jump-Start Our Business Startups Act (the &#8220;JOBS Act&#8221;) was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an emerging growth company. As an emerging growth company, the Company may elect to adopt new or revised accounting standards when they become effective for non-public companies, which typically is later than when public companies must adopt the standards. The Company has elected to take advantage of the extended transition period afforded by the JOBS Act and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for emerging growth companies, which are the dates included below. However, as of May 7, 2021, the market value of the Company&#8217;s common stock held by non-affiliates exceeded $700.0&#160;million. If the market value of the Company&#8217;s common stock held by non-affiliates exceeds $700.0 million as of June 30, 2021, the Company will be a large accelerated filer and therefore will cease to be an emerging growth company effective December 31, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2015, the FASB issued Accounting Standards Update ("ASU") 2016-2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the accounting guidance for leases and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. ASU 2016-2 initially mandated a modified retrospective transition method, however, in July 2018, the FASB issued ASU 2018-11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Targeted Improvements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which amends ASU 2016-2, permitting entities the option to adopt this standard prospectively with a cumulative-effect adjustment to opening equity in the year of adoption and include required disclosures for prior periods but will not restate prior periods. The Company anticipates implementing the accounting guidance for leases using the alternative method beginning with the annual reporting period ending December 31, 2022 and interim reporting periods in 2023. The Company is in the process of evaluating the impact of adoption of the lease accounting guidance on the consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses:  Measurement of credit Losses on Financial Instruments (ASU 2016-13)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities.  The standard is effective for the company beginning in the first quarter of 2023, with early adoption permitted. The Company is currently evaluating the expected impact of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2016-13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on its financial statements.</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt - Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40):  Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity ("ASU 2020-06")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2020-06</span> removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also simplifies the diluted earnings per share calculation in certain areas.  The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years beginning after December 15, 2021.  For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023.  Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and adoption must be as of the beginning of the Company&#8217;s annual fiscal year. The Company&#8217;s early adoption of this accounting standard on January 1, 2021, did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175450305544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per ShareBasic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company&#8217;s potentially dilutive securities which include warrants and outstanding stock options under the <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s equity incentive plan have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.653%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,126,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,760,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,411,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,128,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,537,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,888,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175450099960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Source</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,168,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Geographic Location</span></div><div style="margin-top:17pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.868%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,498,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEIA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,168,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above provides revenue from contracts with customers by source and geographic region (based on the customer&#8217;s billing address) on a disaggregated basis. North America consists of the United States and Canada. EMEIA consists of Europe, the Middle East, India and Africa. Asia Pacific includes China, Japan, South Korea, Singapore and Australia. For the three months ended March&#160;31, 2021 and 2020, the United States represented 44.8% and 63.9% of total revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was $409,000. These remaining performance obligations primarily relate to extended warranty and support and maintenance obligations. The Company expects to recognize approximately&#160;64.8% of this amount as revenue during the remainder of 2021,&#160;31.1%&#160;in 2022, and 4.1%&#160;in 2023.  Warranty revenue is included in Service and other revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of&#160;$156,885&#160;and $127,000 during the three months ended March&#160;31, 2021 and 2020, respectively, which was included in the contract liability balance at the end of the previous year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175450311672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Account Details</a></td>
<td class="text">Balance Sheet Account Details<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:21pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:74.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, trade</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,083,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,894,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,091,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,119,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,775,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company extends credit to its customers in the normal course of business. For diagnostic testing services, receivables are based on either contractual rates with third-party payors, plus the amounts expected to be collected for any patient-responsibility portion, or for non-contracted arrangements, using the amounts expected to be collected from third-party payors and/or the patient-customer based on historical collection experience. The Company does not perform credit evaluations and therefore subsequent adjustments to the amount expected to be collected are recorded to revenue.  The balance of our Lineagen accounts receivable balance as of March 31, 2021 was $284,000.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For optical genome mapping (&#8220;OGM&#8221;) products and services, credit is extended based upon an evaluation of each customer&#8217;s credit history, financial condition, and other factors. Estimates of allowances for doubtful accounts are determined by evaluating individual customer circumstances, historical payment patterns, length of time past due, and economic and other factors. Bad debt expense is recorded as necessary to maintain an appropriate level of allowance for doubtful accounts in selling, general and administrative expense. During the three months ended March&#160;31, 2021, the Company recorded a recovery of bad debt expense of $(28,000), which is included in selling, general and administrative expenses. Amounts are charged to the allowance for doubtful accounts when collection efforts have been exhausted and are deemed uncollectible.</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable is subject to concentration risk whenever a customer has a balance that meets or exceeds 10.0% of the Company&#8217;s total accounts receivable balance. As of March&#160;31, 2021, there were no customer balances that met or exceeded 10.0% of the Company&#8217;s total accounts receivable balance. As of December&#160;31, 2020, Illumina, and Quest Diagnostics represented 17.3%, and 10.1%, respectively, of the Company&#8217;s total accounts receivable balance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or net realizable value, on a first-in, first-out basis. Inventory includes raw materials and finished goods that may be used in the research and development process and such items are expensed as consumed or expired.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for slow-moving, excess, and obsolete inventories are estimated based on product life cycles, historical experience, and usage forecasts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories are as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:74.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,736,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,283,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,036,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,316,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175451816264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Debt</a></td>
<td class="text">Debt <div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2020, the Company received loan proceeds of approximately $1.8 million (the &#8220;PPP Loan&#8221;) pursuant to the Paycheck Protection Program (&#8220;the PPP&#8221;) under the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) administered by the U.S. Small Business Administration (the &#8220;SBA&#8221;).  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP Loan accrued interest at a rate of 1.00% per annum, and is subject to the standard terms and conditions applicable to loans administered by the SBA under the CARES Act. In February 2021, the Company applied for forgiveness of the PPP Loan, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full. A gain on forgiveness of Paycheck Protection Program loan of $1.8 million was recognized during the three months ended March&#160;31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">nnovatus LSA</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company entered into a Loan and Security Agreement (the &#8220;LSA&#8221;) by and among Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership (&#8220;Innovatus&#8221;), as collateral agent and the lenders listed on Schedule 1.1 thereto, including East West Bank. The LSA provided a first term loan of $17.5 million, a second term loan of $2.5 million and a third term loan of $5.0 million (collectively, the &#8220;Term Loans&#8221;) if the Company satisfied certain funding conditions. Interest on the Term Loans is due on the first of each month at a rate of 10.25% per annum in cash or a discounted rate of 7.25% in cash with 3.0% of the 10.25% per annum rate added to the principal of the loan and subject to accruing interest through the end of the interest only payment period, which ends March 1, 2022. At inception, the Company elected to pay interest in cash at a rate of 7.25% per annum and have 3.0% per annum of the interest added back to the outstanding principal. As of March&#160;31, 2021, the effective interest rate, including debt issuance costs, for the Term Loans was 16.7%. Beginning in April 2022, the Company must make 24 equal monthly payments of principal and interest with a final maturity date in March 2024, which may be earlier due to an event of default if not cured within time specified. </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LSA provides for prepayment fees of 3.0% of the outstanding balance of the loan if the loan is repaid on or prior to March 14, 2020, 2.0% of the amount prepaid if the prepayment occurs after March 14, 2020 but prior to March 14, 2021, 1.0% of the amount prepaid after March 14, 2021 but prior to March 14, 2022 and 0% of the amount prepaid if the prepayment occurs thereafter. In addition, upon the final repayment of the total amounts borrowed, the Company is required to pay an end of term fee of $0.8 million. This end of term fee is being recognized as interest expense over the term of the LSA. </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LSA also provides for a revolving line of credit in an amount not to exceed $5.0 million (the &#8220;Revolver&#8221;), under which no borrowings were outstanding as of March 31, 2021 and December 31, 2020. The Company may repay and re-borrow amounts under the Revolver at any time prior to the March 1, 2024 maturity date without penalty or premium. The outstanding balance of amounts borrowed under the Revolver bears interest at a rate equal to 2.0% above the prime rate, per annum, as specified in the terms of the Revolver. The LSA allows the Company to borrow and repay amounts at any time prior to the maturity date in 2024. </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LSA is collateralized by substantially all of the Company&#8217;s assets, including its intellectual property. The LSA&#160;requires the Company to comply with various affirmative and negative covenants, including: (1) a liquidity covenant requiring the Company to maintain a minimum cash balance at all times in a collateral account and (2) a revenue covenant requiring the Company to meet certain minimum revenue targets measured at the end of each calendar quarter. The LSA also includes certain standard events of default, and a provision that Innovatus could declare an event of default upon the occurrence of any event that it interprets as having a material adverse impact to the Company&#8217;s business, operations, or condition, a material impairment on the Company&#8217;s ability to pay the secured obligations under the LSA, or upon a material adverse effect on the collateral under the agreement, thereby requiring the Company to repay the loans immediately, together with a prepayment fee and other applicable fees. As of March&#160;31, 2021, the Company believes there have been no events or changes in conditions that could require immediate repayment of amounts due to Innovatus. As of March&#160;31, 2021, the Company was in compliance with the covenants under the Innovatus LSA and the Revolver.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Debt Obligations</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company&#8217;s debt for the periods presented was as follows:</span></div><div style="margin-top:21pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,099,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,981,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PPP Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,099,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,756,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,233,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,430,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,866,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,326,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175451793304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stockholders&#8217; Equity and Stock-Based Compensation</a></td>
<td class="text">Stockholders&#8217; Equity and Stock-Based Compensation<div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Follow-on Public Offerings</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">On January 12, 2021, the Company completed an underwritten public offering of 33,368,851 shares of common stock, including 4,352,458 shares of common stock sold pursuant to the underwriters&#8217; exercise in full of their option to purchase additional shares. The price to the public in the offering was $3.05 per share and the underwriters purchased the shares from the Company pursuant to the underwriting agreement at a price of $2.867 per share. The gross proceeds were approximately $101.8&#160;million before deducting underwriting discounts and commissions and other offering expenses of $293,000.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company completed an underwritten public offering of 38,333,352 shares of common stock, including 5,000,002 shares of common stock sold pursuant to the underwriters&#8217; exercise in full of their option to purchase additional shares. The price to the public in the offering was $6.00 per share and the underwriters purchased the shares from the Company pursuant to the underwriting agreement at a price of $5.64 per share. The gross proceeds were approximately $230.0&#160;million before deducting underwriting discounts and commissions and other offering expenses of $435,000.</span></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Shelf Registration Statement and Ladenburg At-the-Market Facility</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company filed a shelf registration statement on Form S-3 with the SEC covering the offering, issuance and sale of up to $125.0 million of the Company&#8217;s securities, including up to $40.0 million of common stock pursuant to the Ladenburg ATM, with Ladenburg Thalmann &amp; Co. Inc. acting as sales agent. During October through December 2020, the Company sold 27,025,384 shares of common stock under the Ladenburg ATM at an average share price of $0.82, and received gross proceeds of approximately $22.1 million before deducting offering costs of $573,000. In January 2021, the Company sold an additional 6,298,152 shares of common stock under the ATM at an average share price of $2.68, and received gross proceeds of approximately $16.9 million before deducting offering costs of $422,000. The Company terminated the Ladenburg ATM in March 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2021, the Company entered into the Cowen ATM which provides for the sale, in the Company&#8217;s sole discretion, of shares of common stock having an aggregate offering price of up to $350.0&#160;million through or to Cowen, acting as sales agent or principal. The Company will pay Cowen a commission of up to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. As of the date of this filing, no shares have been issued pursuant to the Cowen ATM.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock Warrants</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s warrant activity during the three months ended March&#160;31, 2021 was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:49.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Stock under Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,174,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,841,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,739,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,912,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,411,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,911,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:11pt;text-align:justify"><span><br/></span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity during the three months ended March&#160;31, 2021 was as follows: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Stock under Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,290,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,178,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,126,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,554,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.62&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.02</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,403,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and 2020, the weighted-average grant date fair value of stock options granted was $10.83 and $1.04 per share, respectively. </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense for the periods presented as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants during the periods presented were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:73.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.677%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2021, the compensation committee of the Company&#8217;s board of directors granted 580,000 restricted stock units (&#8220;RSUs&#8221;) to R. Erik Holmlin, Ph.D., the Company&#8217;s President and Chief Executive Officer (the &#8220;Holmlin Grant&#8221;), and 240,000 RSUs to Mark Oldakowski, the Company&#8217;s Chief Operating Officer (the &#8220;Oldakowski Grant&#8221;), in each case with an effective grant date and vesting commencement date of May 12, 2021.</span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">290,000 RSUs under the Holmlin Grant are subject to time-based vesting, with 50% of the shares vesting on each of the first and second anniversaries of the vesting commencement date, subject to continued service through the vesting date, and 18 months vesting acceleration upon a termination without cause or resignation with good reason.</span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">290,000 RSUs under the Holmlin Grant are subject to vesting upon the satisfaction of certain specified revenue targets within four years following the vesting commencement date. If Dr. Holmlin&#8217;s employment with the Company is terminated without cause or he resigns with good reason, then the shares will continue to be eligible for vesting upon satisfaction of the revenue targets within a period that is the shorter of 18 months following termination or four years following the vesting commencement date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RSUs comprising the Oldakowski Grant are subject to time-based vesting, with 50% of the shares vesting on each of the first and second anniversaries of the vesting commencement date, subject to continued service through the vesting date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175450280600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Litigation</a></td>
<td class="text">Litigation From time to time, the Company may be subject to potential liabilities under various claims and legal actions that are pending or may be asserted. These matters arise in the ordinary course and conduct of the business. The Company regularly assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on the Company&#8217;s assessment, it currently does not have any material loss exposure as it is not a defendant in any claims or legal actions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175450262744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes The Company is subject to taxation in the United States, United Kingdom and various state jurisdictions. The Company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. The primary difference between the effective tax rate and the federal statutory tax rate relates to the full valuation allowance on the Company&#8217;s U.S. net operating losses.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175452754888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Lineagen<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisition of Lineagen</a></td>
<td class="text">Acquisition of LineagenOn August 21, 2020, the Company, Alta Merger Sub, Inc., a wholly owned subsidiary of the Company (&#8220;Merger Sub&#8221;), Lineagen, a Delaware corporation, and Michael S. Paul, Ph.D., solely in his capacity as exclusive agent and attorney-in-fact of the security-holders of Lineagen, entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;).  Pursuant to the terms and conditions of the Merger Agreement, Merger Sub merged with and into Lineagen whereupon the separate corporate existence of Merger Sub ceased, with Lineagen continuing as the surviving corporation of the Merger as a wholly owned subsidiary of the Company. Lineagen&#8217;s expertise in development, commercialization and reimbursement of laboratory-developed tests provides a platform for accelerating sales growth for the Company&#8217;s Saphyr system.<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), the shares of capital stock of Lineagen and all options of Lineagen that were issued and outstanding immediately prior to the Effective Time were automatically cancelled and extinguished without any payment with respect thereto. Certain holders of convertible notes and other indebtedness of Lineagen at the closing of the Merger (the &#8220;Closing&#8221;) received common stock of the Company. The total number of shares of the Company&#8217;s common stock issued or reserved for issuance as consideration for the Merger was 6,167,510 shares, subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen (the &#8220;Merger Shares&#8221;). 925,126 of the Merger Shares (the &#8220;Escrowed Shares&#8221;) will be held in an escrow fund for purposes of satisfying any post-closing purchase price adjustments and indemnification claims under the Merger Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Also as consideration for the Merger, pursuant to the Merger Agreement, the Company paid approximately $1.9&#160;million in cash to certain creditors and assumed certain liabilities of Lineagen totaling approximately $2.9&#160;million, reflective of the Company&#8217;s preliminary estimate of the post-closing purchase price adjustment (which adjustment is subject to finalization pursuant to the terms of the Merger Agreement).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> In addition, on August 21, 2020, concurrent with the Closing, the Company paid approximately $1.1&#160;million to satisfy all outstanding principal and accrued interest amounts due pursuant to that certain Promissory Note, dated April 22, 2020, by and between Lineagen and Silicon Valley Bank (the &#8220;Lineagen PPP Loan&#8221;), issued pursuant to the CARES Act administered by the SBA. The Lineagen PPP Loan was repaid by the Company prior to maturity without penalty.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company accounted for its acquisition of Lineagen using the acquisition method of accounting pursuant to ASC 805.  The tangible and identifiable intangible assets acquired and liabilities assumed were recorded at their estimated fair values as of the acquisition date, and the excess of the purchase price over the estimated fair value assigned to the tangible and identifiable intangible assets acquired and liabilities assumed was recorded to goodwill. Goodwill relates to the expected synergies from combining the operations of the companies. The acquisition was structured as a stock sale and therefore goodwill is non-tax deductible. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As permitted under ASC 805, the Company is allowed a measurement period, which may not exceed one year, in which to complete its accounting for the acquisition. The Company has recognized provisional amounts for tax assets and liabilities, and subsequent adjustments during the measurement period to any of these items may affect the amount of goodwill recognized. During the fourth quarter of 2020, the Company recorded a $232,000 adjustment to the original purchase price allocation to reduce the estimated fair value of accounts receivable, with the offsetting amount recorded to goodwill. There were no additional purchase price adjustments made during the first quarter of 2021. The Company is still finalizing working capital adjustments with the seller.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, the purchase price for the acquisition of Lineagen is subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen. The following is the estimated purchase price for the acquisition of Lineagen:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,940,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash transferred for repayment of Lineage PPP Loan (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,105,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shares common stock issued as consideration (c)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,167,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Estimated shares of common stock to be returned to the Company (c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(138,247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock price per share on closing date </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Value of estimated common stock consideration (c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,100,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total estimated purchase price (c)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,144,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Company paid approximately $1.9&#160;million in cash to certain creditors of Lineagen.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The Company paid approximately $1.1&#160;million to satisfy all outstanding principal and accrued interest amounts due pursuant to the Lineagen PPP Loan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) The total number of shares of the Company&#8217;s common stock issued or reserved for issuance as consideration for the Merger was 6,167,510 shares. 925,126 of the Merger Shares will be held in an escrow fund for purposes of satisfying any post-closing purchase price adjustments and indemnification claims under the Merger Agreement. The total number of Merger Shares is subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen. The value of the estimated common stock consideration and the total estimated purchase price incorporate the return of an estimated 138,247 Escrowed Shares to the Company based on a preliminary estimate of this adjustment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated purchase price was allocated to Lineagen&#8217;s tangible and identifiable intangible assets acquired and liabilities assumed on based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.030%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">596,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">337,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">209,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">111,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,580,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,173,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts payable and other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2,862,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,144,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair values of identifiable intangible assets acquired are as following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.030%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">950,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">630,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of identifiable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,580,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The customer relationships and trade name intangibles are both being amortized on a straight-line basis over their estimated useful lives of five years. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma financial information in the table below summarizes the combined results of operations for the Company and Lineagen as if the companies had been combined as of January 1, 2019. The unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisition had taken place as of January 1, 2019.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.761%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,676,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,637,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Basic and diluted net loss per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>These amounts have been calculated after applying the Company&#8217;s accounting policies and adjusting the results of Lineagen to reflect (i) additional amortization that would have been charged based upon the fair value of the acquired intangible assets of  $77,000 for the three months ended  March&#160;31, 2020; and (ii) the removal of interest expense related to the historical debt of Lineagen which was not acquired of $312,000 or the three months ended  March&#160;31, 2020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175452639864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim reporting purposes. The condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company&#8217;s management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, changes in equity, and comprehensive loss and cash flows for each period presented in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). All intercompany transactions and balances have been eliminated. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the Company had approximately $362.1&#160;million in cash and cash equivalents, and working capital of $363.1 million as a result of common stock offerings executed in the quarters ended December 31, 2020 and March 31, 2021. In February 2021, we applied for forgiveness of our Paycheck Protection Program (&#8220;the PPP&#8221;) Loan, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full for $1.8 million. In addition, the Company has a $5.0&#160;million revolving line of credit with Innovatus Life Sciences Lending Fund I, LP (the &#8220;Innovatus LSA&#8221;), under which no borrowings were outstanding as of March&#160;31, 2021. This facility is scheduled to expire in March 2024. </span></div>The Company believes its available cash balance will be sufficient to fund operations, obligations as they become due and capital investments for at least the next twelve months.  However, the Company expects to continue to incur net losses for the foreseeable future. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, potentially harming the Company&#8217;s business.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued But Not Yet Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued But Not Yet Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April&#160;2012, the Jump-Start Our Business Startups Act (the &#8220;JOBS Act&#8221;) was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an emerging growth company. As an emerging growth company, the Company may elect to adopt new or revised accounting standards when they become effective for non-public companies, which typically is later than when public companies must adopt the standards. The Company has elected to take advantage of the extended transition period afforded by the JOBS Act and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for emerging growth companies, which are the dates included below. However, as of May 7, 2021, the market value of the Company&#8217;s common stock held by non-affiliates exceeded $700.0&#160;million. If the market value of the Company&#8217;s common stock held by non-affiliates exceeds $700.0 million as of June 30, 2021, the Company will be a large accelerated filer and therefore will cease to be an emerging growth company effective December 31, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2015, the FASB issued Accounting Standards Update ("ASU") 2016-2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the accounting guidance for leases and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. ASU 2016-2 initially mandated a modified retrospective transition method, however, in July 2018, the FASB issued ASU 2018-11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Targeted Improvements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which amends ASU 2016-2, permitting entities the option to adopt this standard prospectively with a cumulative-effect adjustment to opening equity in the year of adoption and include required disclosures for prior periods but will not restate prior periods. The Company anticipates implementing the accounting guidance for leases using the alternative method beginning with the annual reporting period ending December 31, 2022 and interim reporting periods in 2023. The Company is in the process of evaluating the impact of adoption of the lease accounting guidance on the consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses:  Measurement of credit Losses on Financial Instruments (ASU 2016-13)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities.  The standard is effective for the company beginning in the first quarter of 2023, with early adoption permitted. The Company is currently evaluating the expected impact of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2016-13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on its financial statements.</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt - Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40):  Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity ("ASU 2020-06")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2020-06</span> removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also simplifies the diluted earnings per share calculation in certain areas.  The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years beginning after December 15, 2021.  For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023.  Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and adoption must be as of the beginning of the Company&#8217;s annual fiscal year. The Company&#8217;s early adoption of this accounting standard on January 1, 2021, did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company&#8217;s potentially dilutive securities which include warrants and outstanding stock options under the Company&#8217;s equity incentive plan have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175452789208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.653%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,126,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,760,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,411,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,128,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,537,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,888,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175481739688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Source</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,168,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Geographic Location</span></div><div style="margin-top:17pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.868%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,498,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEIA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,168,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175450338872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:74.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, trade</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,083,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,894,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,091,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,119,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,775,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock', window );">Schedule of Components of Inventories</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:74.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,736,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,283,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,036,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,316,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175481739688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company&#8217;s debt for the periods presented was as follows:</span></div><div style="margin-top:21pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,099,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,981,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PPP Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,099,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,756,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,233,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,430,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,866,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,326,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175450293128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s warrant activity during the three months ended March&#160;31, 2021 was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:49.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Stock under Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,174,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,841,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,739,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,912,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,411,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,911,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity during the three months ended March&#160;31, 2021 was as follows: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Stock under Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,290,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,178,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,126,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,554,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.62&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.02</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,403,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Recognized Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense for the periods presented as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions in Black -Scholes Option Pricing Model</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants during the periods presented were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:73.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.677%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175450343144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Lineagen (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisition</a></td>
<td class="text">The following is the estimated purchase price for the acquisition of Lineagen:<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,940,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash transferred for repayment of Lineage PPP Loan (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,105,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shares common stock issued as consideration (c)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,167,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Estimated shares of common stock to be returned to the Company (c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(138,247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock price per share on closing date </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Value of estimated common stock consideration (c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,100,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total estimated purchase price (c)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,144,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Company paid approximately $1.9&#160;million in cash to certain creditors of Lineagen.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The Company paid approximately $1.1&#160;million to satisfy all outstanding principal and accrued interest amounts due pursuant to the Lineagen PPP Loan.</span></div>(c) The total number of shares of the Company&#8217;s common stock issued or reserved for issuance as consideration for the Merger was 6,167,510 shares. 925,126 of the Merger Shares will be held in an escrow fund for purposes of satisfying any post-closing purchase price adjustments and indemnification claims under the Merger Agreement. The total number of Merger Shares is subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen. The value of the estimated common stock consideration and the total estimated purchase price incorporate the return of an estimated 138,247 Escrowed Shares to the Company based on a preliminary estimate of this adjustment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated purchase price was allocated to Lineagen&#8217;s tangible and identifiable intangible assets acquired and liabilities assumed on based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.030%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">596,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">337,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">209,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">111,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,580,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,173,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts payable and other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2,862,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,144,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock', window );">Schedule of Intangible Assets Acquired as Part of Business Combination</a></td>
<td class="text"><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair values of identifiable intangible assets acquired are as following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.030%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">950,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">630,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of identifiable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,580,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Business Acquisition, Pro Forma Information</a></td>
<td class="text">The unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisition had taken place as of January 1, 2019.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.761%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,676,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,637,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Basic and diluted net loss per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175457065480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 362,057,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,449,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_WorkingCapital', window );">Working capital</a></td>
<td class="nump">363,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on forgiveness of Paycheck Protection Program loan</a></td>
<td class="nump">1,775,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Innovatus LSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility available</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bngo_InnovatusLSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bngo_InnovatusLSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175452615752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount (in shares)</a></td>
<td class="nump">9,537<span></span>
</td>
<td class="nump">26,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount (in shares)</a></td>
<td class="nump">5,126<span></span>
</td>
<td class="nump">2,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_CommonWarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount (in shares)</a></td>
<td class="nump">4,411<span></span>
</td>
<td class="nump">24,128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175453540536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Revenue by Source and Geographic Location (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 3,168,000<span></span>
</td>
<td class="nump">$ 1,136,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,498,000<span></span>
</td>
<td class="nump">726,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">EMEIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,587,000<span></span>
</td>
<td class="nump">390,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer | Geographic Concentration Risk | North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer | Geographic Concentration Risk | EMEIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer | Geographic Concentration Risk | Asia Pacific</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bngo_InstrumentRevenueMember', window );">Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 882,000<span></span>
</td>
<td class="nump">$ 534,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bngo_ConsumableRevenueMember', window );">Consumables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,167,000<span></span>
</td>
<td class="nump">449,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">2,049,000<span></span>
</td>
<td class="nump">983,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Service and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,119,000<span></span>
</td>
<td class="nump">$ 153,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bngo_InstrumentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bngo_InstrumentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bngo_ConsumableRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bngo_ConsumableRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175450286184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk | Revenue Benchmark | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">44.80%<span></span>
</td>
<td class="nump">63.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175452607672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Remaining Performance Obligations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligation</a></td>
<td class="nump">$ 409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 156,885<span></span>
</td>
<td class="nump">$ 127,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-04-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Performance obligation, percentage</a></td>
<td class="nump">64.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Timing of satisfaction of remaining performance obligation</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Performance obligation, percentage</a></td>
<td class="nump">31.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Timing of satisfaction of remaining performance obligation</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Performance obligation, percentage</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Timing of satisfaction of remaining performance obligation</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175452318392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Schedule of Accounts Receivable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable, trade</a></td>
<td class="nump">$ 4,083,000<span></span>
</td>
<td class="nump">$ 4,894,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less allowance for doubtful accounts</a></td>
<td class="num">(2,091,000)<span></span>
</td>
<td class="num">(2,119,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 1,992,000<span></span>
</td>
<td class="nump">$ 2,775,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175452067208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 1,992,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,775,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Recovery of bad debt expense</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debt expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 958,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=bngo_RuhrUniversitayBochumMember', window );">Ruhr-Universitay Bochum | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=bngo_IlluminaMember', window );">Illumina | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=bngo_QuestDiagnositcsMember', window );">Quest Diagnositcs | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=bngo_LineagenMember', window );">Lineagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 284,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bngo_RuhrUniversitayBochumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bngo_RuhrUniversitayBochumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bngo_IlluminaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bngo_IlluminaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bngo_QuestDiagnositcsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bngo_QuestDiagnositcsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bngo_LineagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bngo_LineagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175453156968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Schedule of Components of Inventories (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 2,736,000<span></span>
</td>
<td class="nump">$ 2,283,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">1,033,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">$ 3,036,000<span></span>
</td>
<td class="nump">$ 3,316,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175447788520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 17, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>payment</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on forgiveness of Paycheck Protection Program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,775,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_LoanUnderPaycheckProtectionProgramMember', window );">Loan Under Paycheck Protection Program | Unsecured Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on forgiveness of Paycheck Protection Program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_TermA1LoanMember', window );">Term A-1 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_TermA2LoanMember', window );">Term A-2 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_InnovatusTerm3LoanMember', window );">Innovatus Term 3 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_InnovatusLoanAgreementMember', window );">Innovatus LSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentInterestRateCashRate', window );">Cash rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentInterestRateDiscountedCashRate', window );">Discounted cash rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentNumberOfMonthlyPayments', window );">Number of monthly payments | payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">End of term fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_InnovatusLoanAgreementMember', window );">Innovatus LSA | Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_InnovatusLoanAgreementMember', window );">Innovatus LSA | Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_InnovatusLoanAgreementMember', window );">Innovatus LSA | Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_InnovatusLoanAgreementMember', window );">Innovatus LSA | Period Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_InnovatusLoanAgreementMember', window );">Innovatus LSA | PIK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentInterestRateCashRate', window );">Cash rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_RevolverMember', window );">Revolver</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentInterestRateCashRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Cash Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentInterestRateCashRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentInterestRateDiscountedCashRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Discounted Cash Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentInterestRateDiscountedCashRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentNumberOfMonthlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Monthly Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentNumberOfMonthlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentPrepaymentFeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument prepayment fee percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentPrepaymentFeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bngo_LoanUnderPaycheckProtectionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bngo_LoanUnderPaycheckProtectionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bngo_TermA1LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bngo_TermA1LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bngo_TermA2LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bngo_TermA2LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bngo_InnovatusTerm3LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bngo_InnovatusTerm3LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bngo_InnovatusLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bngo_InnovatusLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bngo_RevolverMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bngo_RevolverMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175452464472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Debt (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal</a></td>
<td class="nump">$ 16,099,000<span></span>
</td>
<td class="nump">$ 17,756,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less unamortized debt issuance costs</a></td>
<td class="num">(1,233,000)<span></span>
</td>
<td class="num">(1,430,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total carrying value of debt</a></td>
<td class="nump">14,866,000<span></span>
</td>
<td class="nump">16,326,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bngo_TermLoansMember', window );">Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal</a></td>
<td class="nump">16,099,000<span></span>
</td>
<td class="nump">15,981,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bngo_PPPLoanMember', window );">PPP Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,775,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bngo_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bngo_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bngo_PPPLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bngo_PPPLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175377074472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 12, 2021</div></th>
<th class="th"><div>Mar. 23, 2021</div></th>
<th class="th"><div>Jan. 25, 2021</div></th>
<th class="th"><div>Jan. 12, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,333,352<span></span>
</td>
<td class="nump">33,368,851<span></span>
</td>
<td class="nump">6,298,152<span></span>
</td>
<td class="nump">27,025,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Average share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000,000.0<span></span>
</td>
<td class="nump">$ 101,800,000<span></span>
</td>
<td class="nump">$ 16,900,000<span></span>
</td>
<td class="nump">$ 22,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435,000<span></span>
</td>
<td class="nump">$ 293,000<span></span>
</td>
<td class="nump">$ 422,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 573,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SaleOfStockAuthorizedAmountToBeIssued', window );">Authorized amount of stock to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | R. Erik Holmlin | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Units granted (in shares)</a></td>
<td class="nump">580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | R. Erik Holmlin | Time-Based Vesting | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Units granted (in shares)</a></td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary', window );">Percentage of shares vesting on the first and second anniversary</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment', window );">Vesting period, termination of employment</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | R. Erik Holmlin | Performance Satisfaction Vesting | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Units granted (in shares)</a></td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | R. Erik Holmlin | Performance Satisfaction Vesting | Subsequent Event | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment', window );">Vesting period, termination of employment</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | R. Erik Holmlin | Performance Satisfaction Vesting | Subsequent Event | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment', window );">Vesting period, termination of employment</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Mark Oldakowski | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Units granted (in shares)</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Mark Oldakowski | Time-Based Vesting | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary', window );">Percentage of shares vesting on the first and second anniversary</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bngo_CowenMember', window );">Cowen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SaleOfStockValueSharesIssuedInTransaction', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_CommissionFeeMaximumPercentageOfGrossProceeds', window );">Commission fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,002<span></span>
</td>
<td class="nump">4,352,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Average share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.64<span></span>
</td>
<td class="nump">$ 2.867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SaleOfStockAuthorizedAmountToBeIssued', window );">Authorized amount of stock to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_CommissionFeeMaximumPercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission Fee, Maximum Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_CommissionFeeMaximumPercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_SaleOfStockAuthorizedAmountToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Authorized Amount To Be Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_SaleOfStockAuthorizedAmountToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_SaleOfStockValueSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Value, Shares Issued in Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_SaleOfStockValueSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Termination of Employment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Percentage of Shares Vesting on First and Second Anniversary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bngo_RErikHolmlinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bngo_RErikHolmlinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_VestingStatusAxis=bngo_TimeBasedVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_VestingStatusAxis=bngo_TimeBasedVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_VestingStatusAxis=bngo_PerformanceSatisfactionVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_VestingStatusAxis=bngo_PerformanceSatisfactionVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bngo_MarkOldakowskiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bngo_MarkOldakowskiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bngo_CowenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bngo_CowenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175452832008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation - Warrant Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightOutstandingRollForward', window );"><strong>Shares of Stock under Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="nump">15,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod', window );">Exercised (in shares)</a></td>
<td class="num">(10,739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending balance (in shares)</a></td>
<td class="nump">4,411<span></span>
</td>
<td class="nump">15,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Beginning balance (in USD per share)</a></td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod', window );">Granted (in USD per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod', window );">Exercised (in USD per share)</a></td>
<td class="nump">0.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Ending balance (in USD per share)</a></td>
<td class="nump">$ 5.89<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward', window );"><strong>Weighted- Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights', window );">Balance</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">3 years 9 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights', window );">Beginning balance</a></td>
<td class="nump">$ 26,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights', window );">Exercised</a></td>
<td class="nump">57,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights', window );">Ending balance</a></td>
<td class="nump">$ 2,911<span></span>
</td>
<td class="nump">$ 26,841<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Aggregate Intrinsic Value Exercised In Period Of Warrants Or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercised In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Granted In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Securities Canceled In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Securities Exercised In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Securities Granted In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Granted In Period Of Warrants Or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Of Warrants Or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Weighted-Average Remaining Contractual Term Of Warrants Or Rights [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175447732744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares of Stock under Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">5,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">5,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="nump">1,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in USD per share)</a></td>
<td class="nump">$ 1.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">10.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">3.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in USD per share)</a></td>
<td class="nump">0.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in USD per share)</a></td>
<td class="nump">2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in USD per share)</a></td>
<td class="nump">$ 3.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward', window );"><strong>Weighted- Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (in years)</a></td>
<td class="text">8 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable (in years)</a></td>
<td class="text">8 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Beginning balance</a></td>
<td class="nump">$ 10,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">1,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Ending balance</a></td>
<td class="nump">31,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and exercisable</a></td>
<td class="nump">$ 8,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in USD per share)</a></td>
<td class="nump">$ 10.83<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175549860568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation - Recognized Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">General and administrative</a></td>
<td class="nump">$ 371<span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">General and administrative</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">General and administrative</a></td>
<td class="nump">$ 290<span></span>
</td>
<td class="nump">$ 261<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175452217832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">79.30%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175452515976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Lineagen - Narrative (Details) - Lineagen - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 21, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued or reserved for issuance (in shares)</a></td>
<td class="nump">6,167,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration transferred in acquisition</a></td>
<td class="nump">$ 1,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liabilities assumed of acquiree</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherDebt', window );">Payment to satisfy outstanding principal and accrued interest amounts</a></td>
<td class="nump">$ 1,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred', window );">Adjustment to original purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember', window );">Business Combination, Infrequent Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (312)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember', window );">Escrowed Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued or reserved for issuance (in shares)</a></td>
<td class="nump">925,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_BusinessCombinationInfrequentAdjustmentsAxis=bngo_BusinessCombinationInfrequentAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_BusinessCombinationInfrequentAdjustmentsAxis=bngo_BusinessCombinationInfrequentAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bngo_EscrowedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bngo_EscrowedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175457065480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition of Lineagen - Acquisition Purchase Price (Details) - Lineagen<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Aug. 21, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="nump">$ 1,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherDebt', window );">Cash transferred for repayment of Lineage PPP Loan</a></td>
<td class="nump">$ 1,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares of common stock issued as consideration (in shares) | shares</a></td>
<td class="nump">6,167,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment', window );">Estimated shares of common stock to be returned to the Company | shares</a></td>
<td class="num">(138,247)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Stock price per share on closing date (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Value of estimated common stock consideration</a></td>
<td class="nump">$ 4,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total estimated purchase price</a></td>
<td class="nump">$ 7,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember', window );">Escrowed Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares of common stock issued as consideration (in shares) | shares</a></td>
<td class="nump">925,126<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Equity Interest Issued Or Issuable, Number Of Shares, Incomplete Accounting, Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bngo_EscrowedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bngo_EscrowedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175452548392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition of Lineagen - Fair Value of Tangible and Identifiable Intangible Assets Acquired and Liabilities Assumed (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 21, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 7,173,000<span></span>
</td>
<td class="nump">$ 7,173,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember', window );">Lineagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 596,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,580,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,173,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,862,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,144,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175453078872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition of Lineagen - Identifiable Intangible Assets (Details) - Lineagen<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Aug. 21, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 1,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade name</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 630<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140175452591752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Lineagen - Pro Forma Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Basic net loss per share (in dollars per share) | $ / shares</a></td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share) | $ / shares</a></td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember', window );">Lineagen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenue | $</a></td>
<td class="nump">$ 2,676,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss | $</a></td>
<td class="num">$ (11,637,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M$-T9@L?P#LB1>.']WB92*>O5A>&J\IS1O:&C' DB!]:A',$>J#VO$7I&,GD
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MXQ^T<<C7]A*>B>H7'&O94 DG!R%YWB@K!#DKZG_RW 3B1 %Z PJH44"O%?"
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M\NRWRH]+#PD22 =P1/!\N TG/6=(G#/G>=>L:-3*LK1MFG8],*@YY(EM95^
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M26PV5?-5J3DQLO8?9C;2&%GZPSUG.5?.P/Z^E=(\G[@;=-_V;O\#4$L#!!0
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M>ZIH;'%DPY2K(VH L(KM0GR4:BS\54).(EDY<08%IVZH-?F9K%M(U-7ZBJH
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MW61B.:@>>(,WD4WLUT92+T$D%'XL7J$=ZLAJF!XZV=_3RISDD@(YG&,,\V;
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MKHW,9, *"\ZRR=EY=CH9IX,S2KQ?&4SP6/$K")]QIJVY],N, M\V!ID1;90
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M%\$7SMR]&KH[P*9X!9T*>1Q=2<2,;I;3K3)@\>UX.&-]P4=-&=C@WA"Y=3_
MZ&]>H(#QMX9,3%;TIH7O5I+@F.?_DJ8A,N.73)/+WVU(5*7W* X"J12:,JK&
MLVE ?A)KP$J^22NXQFW>U^VV--X3V :%=RGO531"YDNM[J,1^C%9D;%!?L3"
MNI2Q(]AM*FKHX-I7O).@:+ZUW?^Y!>& )S?Q'@>:AAK%:79V'IF+4A]U'7P
MUCF+E'4@KA'#.=M=Z+(A&$V[;M-_/A/[X]'TXF#7M>U1[SZ<+][HUI^Z&C!4
MO!KOGG9_6' 5[],WR^-?)< @#(]>E&J.K>/1^>F></&F/WX)MN;;=20HTIH_
M+A72V-$"_#ZW-K1?Z(#NSRU>_0]02P,$%     @ ]8"M4A]<0BQ["P  _1T
M !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&ULM5EM;]LX$OXKA+=8M(#M
MV$[2!'T#G+2]32_=!G5[A\/A/M 2;7,KD2I)V?']^GMF2,ERZ[C= _9#&XOB
MR[P\\\P,]6)CW1>_4BJ(^[(P_F5O%4+U[.3$9RM52C^TE3)XL["NE &/;GGB
M*Z=DSHO*XF0R&CT]*:4VO5<O>.S.O7IAZU!HH^Z<\'592K>]4H7=O.R->\W
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MNECS1VUBBF%]"0<=:/T(F1PO!4\PEBR$]4XAIF")HLZC30]A:VI,C;T^<G@
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MC-?!_M&1UCI,1P=L,665\>Y,@5'4Y)7(:!L8$?O4DO)X!G9*T)@Q<$9DNG"
MCQ5_8H+4U,7-^03H=:6Y?UZOEC]$4*6C;V#8BY-1+XHB2'J7H\A;]TQKJFU@
MT!O$<>T<4-S8FW?*,@&?>\/^9>T:]<;CVO7>^PH[G5N@WOOY9(AZ)6W=Q.UN
M.P(7=>>_AM?SDS3L.7$6N*/4Z.)R&("N9U*]L*KT<V"K+$T5;^8TQE&[ /+O
M%-UVLW %VC^&^5]02P,$%     @ ]8"M4MG,!N;1 @  /08  !D   !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&ULC57;;MLP#/T5PNB #2CJ:VY%$B#)NJW
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ME_0_JSZ#=^[W32HZXP6=+T^9RY-,VIS)R+F,HC;M,"'UZN;J>D$^@W';A4%
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MH0C\8X[/*&%( ._76KO=@A2T'V87_P%02P,$%     @ ]8"M4HZY4Z,D P
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M ^H4@8#,.@J&?SM(00C'A#I^UJ1!$],!#\</[-<^>4QFR0RD2GSCN5V/@_.
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M3XA7QH(<V+=QQS<^IG1..EF3(TKGY%VF1GXPWDOG^Z!@,O8.9W/:V9P.VGS
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M1TE 16:@GV\Y5V\WV0NJ,>[L/U!+ P04    " #U@*U2[.%*[ED"  "W!0
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MXC84_BL:>IGLS"Y8DFW,EC"3D&NGNYL)S?:ATP<%!'BP+5:2PV:G/[Z2[5B
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M%/LH2@=!OR;H6X+^$8(%K%/&4K;6>951%@$ZUR$M@WW1%= 2;F#A3+G9SO$
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MV&%!V0VXOI+2' SKH.G9DS]02P,$%     @ ]8"M4N\-_U*8 P  +@L  !D
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M>NCT'!+#DF9<WXOM%R@<:AM[D>#*_I)ML==S2)0I+9("C H2EN;_]*T(Q '
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MH,%H8KX/V0[4=J-%[8;8H]!F)+IE:?Y!**V#.5\+H0\;2]#]U;)?4$L#!!0
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M046-85K>V(E;[(POH*@9WZ\JJW"FZ:K;NR0;!W>S029*YTRW8;ID;1H-!"M
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M',$4@ 8,21)W#NZ<1_'ZG(HWOQ.-?@-02P,$%     @ ]8"M4I>*NQS
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MJT0AJT0A:X)"U@2%K,E_DO5=Z]5?_TMHU[A697/T9]T/F_DG4$L! A0#%
M  @ ]8"M4@=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " #U@*U2_:<K9N\    K @  $0
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M=#(N>&UL4$L! A0#%     @ ]8"M4AMBM',0 P  ?@H  !@
M ("!X!,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( /6
MK5*3WP#^]P0  &H4   8              " @287  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " #U@*U2(]WJ>Z($   5%   &
M        @(%3'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ ]8"M4A9Y!)NM!@  YQL  !@              ("!*R$  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( /6 K5*/!=5I@ \  +DG   8
M              " @0XH  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " #U@*U2]@]^.*@#  #0"   &               @('$-P  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ ]8"M4BC<N4O(!
MYPH  !@              ("!HCL  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( /6 K5*NR$NGI@8  ,@/   9              " @:!
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ ]8"M4MOH
M>R=Y"0  /Q@  !D              ("!?4<  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " #U@*U2E]UNQ\P)  !='   &0
M    @($M40  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M /6 K5+!D*=]1P,  !D'   9              " @3!;  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ ]8"M4@:W?CG% @  " 8  !D
M             ("!KEX  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " #U@*U2.*2WKEP+  !Z(0  &0              @(&J80  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( /6 K5(?7$(L>PL
M /T=   9              " @3UM  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ ]8"M4H81&,S2 @  ) 8  !D              ("!
M[W@  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #U@*U2
MV<P&YM$"   ]!@  &0              @('X>P  >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( /6 K5+189SOV0(  )0&   9
M      " @0!_  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ ]8"M4G]J:[2O @  EP4  !D              ("!$((  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #U@*U2$>OG5L$$  ")#
M&0              @('VA   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( /6 K5*E5F0:CP4  *0-   9              " @>Z)  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ ]8"M4HZY4Z,D
M P  KP@  !D              ("!M(\  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " #U@*U2++AR#,@"   F"0  &0
M@($/DP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( /6
MK5*;K%DD400  -(5   9              " @0Z6  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ ]8"M4NSA2NY9 @  MP4  !D
M         ("!EIH  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " #U@*U2JKO5'S8#  "W#0  &0              @($FG0  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( /6 K5*WJ;N ?P(  ",&
M   9              " @9.@  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ ]8"M4CE&2]IN P  O@P  !D              ("!2:,
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #U@*U28B97
MRG,"  #Y!0  &0              @('NI@  >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( /6 K5(ESRF F@0  .<6   9
M  " @9BI  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
M]8"M4IRMR0^O @  8@@  !D              ("!::X  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " #U@*U2NZK#4^H%  !$'0  &0
M            @(%/L0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( /6 K5+H&;].]0,  #8.   9              " @7"W  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ ]8"M4M>.'7Z)!
MSQ$  !D              ("!G+L  'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " #U@*U2&F1\W-@"  "V"   &0              @(%<
MP   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( /6 K5+2
M\F(HMP(  +\'   9              " @6O#  !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ ]8"M4N\-_U*8 P  +@L  !D
M     ("!6<8  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /6 K5*W(GQ6' ,  #02   -              "
M 4'6  !X;"]S='EL97,N>&UL4$L! A0#%     @ ]8"M4I>*NQS     $P(
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9>&UL4$L%!@     R #( E0T  -CA      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>115</ContextCount>
  <ElementCount>291</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>58</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Balance Sheet Account Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/BalanceSheetAccountDetails</Role>
      <ShortName>Balance Sheet Account Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Stockholders??? Equity and Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2128107 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130109 - Disclosure - Acquisition of Lineagen</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionofLineagen</Role>
      <ShortName>Acquisition of Lineagen</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/NetLossPerShare</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/RevenueRecognition</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Balance Sheet Account Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables</Role>
      <ShortName>Balance Sheet Account Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/BalanceSheetAccountDetails</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/Debt</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Stockholders??? Equity and Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Acquisition of Lineagen (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionofLineagenTables</Role>
      <ShortName>Acquisition of Lineagen (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/AcquisitionofLineagen</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/NetLossPerShareTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Revenue Recognition - Revenue by Source and Geographic Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails</Role>
      <ShortName>Revenue Recognition - Revenue by Source and Geographic Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Revenue Recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails</Role>
      <ShortName>Revenue Recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Revenue Recognition - Remaining Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails</Role>
      <ShortName>Revenue Recognition - Remaining Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Balance Sheet Account Details - Schedule of Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails</Role>
      <ShortName>Balance Sheet Account Details - Schedule of Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Balance Sheet Account Details - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails</Role>
      <ShortName>Balance Sheet Account Details - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Balance Sheet Account Details - Schedule of Components of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails</Role>
      <ShortName>Balance Sheet Account Details - Schedule of Components of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Debt - Schedule of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/DebtScheduleofDebtDetails</Role>
      <ShortName>Debt - Schedule of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Stockholders??? Equity and Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Stockholders??? Equity and Stock-Based Compensation - Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation - Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Stockholders??? Equity and Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Stockholders??? Equity and Stock-Based Compensation - Recognized Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation - Recognized Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - Stockholders??? Equity and Stock-Based Compensation - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Acquisition of Lineagen - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails</Role>
      <ShortName>Acquisition of Lineagen - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Acquisition of Lineagen - Acquisition Purchase Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails</Role>
      <ShortName>Acquisition of Lineagen - Acquisition Purchase Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Acquisition of Lineagen - Fair Value of Tangible and Identifiable Intangible Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisition of Lineagen - Fair Value of Tangible and Identifiable Intangible Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Acquisition of Lineagen - Identifiable Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails</Role>
      <ShortName>Acquisition of Lineagen - Identifiable Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bngo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - Acquisition of Lineagen - Pro Forma Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionofLineagenProFormaInformationDetails</Role>
      <ShortName>Acquisition of Lineagen - Pro Forma Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="bngo-20210331.htm">bngo-20210331.htm</File>
    <File>bngo-20210331.xsd</File>
    <File>bngo-20210331_cal.xml</File>
    <File>bngo-20210331_def.xml</File>
    <File>bngo-20210331_lab.xml</File>
    <File>bngo-20210331_pre.xml</File>
    <File>bngo-20210331xexx311.htm</File>
    <File>bngo-20210331xexx312.htm</File>
    <File>bngo-20210331xexx321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bngo-20210331.htm": {
   "axisCustom": 3,
   "axisStandard": 23,
   "contextCount": 115,
   "dts": {
    "calculationLink": {
     "local": [
      "bngo-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bngo-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "bngo-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bngo-20210331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bngo-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "bngo-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 391,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 3,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 8
   },
   "keyCustom": 27,
   "keyStandard": 264,
   "memberCustom": 27,
   "memberStandard": 29,
   "nsprefix": "bngo",
   "nsuri": "http://bionanogenomics.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://bionanogenomics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Balance Sheet Account Details",
     "role": "http://bionanogenomics.com/role/BalanceSheetAccountDetails",
     "shortName": "Balance Sheet Account Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Debt",
     "role": "http://bionanogenomics.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128107 - Disclosure - Litigation",
     "role": "http://bionanogenomics.com/role/Litigation",
     "shortName": "Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Income Taxes",
     "role": "http://bionanogenomics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130109 - Disclosure - Acquisition of Lineagen",
     "role": "http://bionanogenomics.com/role/AcquisitionofLineagen",
     "shortName": "Acquisition of Lineagen",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Basis of Presentation (Policies)",
     "role": "http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://bionanogenomics.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Revenue Recognition (Tables)",
     "role": "http://bionanogenomics.com/role/RevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Balance Sheet Account Details (Tables)",
     "role": "http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables",
     "shortName": "Balance Sheet Account Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i7870f814eef549569827056ab0bbe28f_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i7870f814eef549569827056ab0bbe28f_I20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Debt (Tables)",
     "role": "http://bionanogenomics.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation (Tables)",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Acquisition of Lineagen (Tables)",
     "role": "http://bionanogenomics.com/role/AcquisitionofLineagenTables",
     "shortName": "Acquisition of Lineagen (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i7870f814eef549569827056ab0bbe28f_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Basis of Presentation (Details)",
     "role": "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails",
     "shortName": "Organization and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "bngo:LiquidityPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i7870f814eef549569827056ab0bbe28f_I20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "bngo:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Net Loss Per Share (Details)",
     "role": "http://bionanogenomics.com/role/NetLossPerShareDetails",
     "shortName": "Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Revenue Recognition - Revenue by Source and Geographic Location (Details)",
     "role": "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails",
     "shortName": "Revenue Recognition - Revenue by Source and Geographic Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i7cb3b2d35c0e49a0b13d2888567d6b29_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i5e72dec2e62644f09291bd2256e18ae6_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Revenue Recognition - Narrative (Details)",
     "role": "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
     "shortName": "Revenue Recognition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i5e72dec2e62644f09291bd2256e18ae6_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i7870f814eef549569827056ab0bbe28f_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Revenue Recognition - Remaining Performance Obligations (Details)",
     "role": "http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails",
     "shortName": "Revenue Recognition - Remaining Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i7870f814eef549569827056ab0bbe28f_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i7870f814eef549569827056ab0bbe28f_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Balance Sheet Account Details - Schedule of Accounts Receivable (Details)",
     "role": "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails",
     "shortName": "Balance Sheet Account Details - Schedule of Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i7870f814eef549569827056ab0bbe28f_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i7870f814eef549569827056ab0bbe28f_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Balance Sheet Account Details - Narrative (Details)",
     "role": "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails",
     "shortName": "Balance Sheet Account Details - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i7870f814eef549569827056ab0bbe28f_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i7870f814eef549569827056ab0bbe28f_I20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i7870f814eef549569827056ab0bbe28f_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Balance Sheet Account Details - Schedule of Components of Inventories (Details)",
     "role": "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails",
     "shortName": "Balance Sheet Account Details - Schedule of Components of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i7870f814eef549569827056ab0bbe28f_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Debt - Narrative (Details)",
     "role": "http://bionanogenomics.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "icb4b96f2629a437b92ce60228c4e9a9e_D20200417-20200417",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i7870f814eef549569827056ab0bbe28f_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Debt - Schedule of Debt (Details)",
     "role": "http://bionanogenomics.com/role/DebtScheduleofDebtDetails",
     "shortName": "Debt - Schedule of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i7870f814eef549569827056ab0bbe28f_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i8b5c637028ea47bd8c7f4181b517e861_D20210125-20210125",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation - Narrative (Details)",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i8b5c637028ea47bd8c7f4181b517e861_D20210125-20210125",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation - Warrant Activity (Details)",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation - Warrant Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "bngo:ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i2cbadbaa2d7a47048345a3ceb06bb6ea_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation - Recognized Stock-Based Compensation Expense (Details)",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation - Recognized Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation - Assumptions (Details)",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation - Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Acquisition of Lineagen - Narrative (Details)",
     "role": "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails",
     "shortName": "Acquisition of Lineagen - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Acquisition of Lineagen - Acquisition Purchase Price (Details)",
     "role": "http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails",
     "shortName": "Acquisition of Lineagen - Acquisition Purchase Price (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "if9feeaef3e4340f6b6496076ccb10c9a_D20200821-20200821",
      "decimals": "INF",
      "lang": "en-US",
      "name": "bngo:BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i7870f814eef549569827056ab0bbe28f_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Acquisition of Lineagen - Fair Value of Tangible and Identifiable Intangible Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisition of Lineagen - Fair Value of Tangible and Identifiable Intangible Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i056e748dff1445bf9ed9183ca6be7827_I20200821",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i056e748dff1445bf9ed9183ca6be7827_I20200821",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Acquisition of Lineagen - Identifiable Intangible Assets (Details)",
     "role": "http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails",
     "shortName": "Acquisition of Lineagen - Identifiable Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "idc54661388eb4fe880e68defa355cc59_I20200821",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - Acquisition of Lineagen - Pro Forma Information (Details)",
     "role": "http://bionanogenomics.com/role/AcquisitionofLineagenProFormaInformationDetails",
     "shortName": "Acquisition of Lineagen - Pro Forma Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i50064f20ffdd4afea720ea427be539bb_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Deficit)",
     "role": "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "i50064f20ffdd4afea720ea427be539bb_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://bionanogenomics.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Net Loss Per Share",
     "role": "http://bionanogenomics.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Revenue Recognition",
     "role": "http://bionanogenomics.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20210331.htm",
      "contextRef": "iaf1c292fc2554ed48bf973cf29150b8e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 58,
   "tag": {
    "bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Equity Interest Issued Or Issuable, Number Of Shares, Incomplete Accounting, Adjustment",
        "label": "Business Acquisition, Equity Interest Issued Or Issuable, Number Of Shares, Incomplete Accounting, Adjustment",
        "negatedTerseLabel": "Estimated shares of common stock to be returned to the Company"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bngo_BusinessCombinationInfrequentAdjustmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Infrequent Adjustments",
        "label": "Business Combination, Infrequent Adjustments [Axis]",
        "terseLabel": "Business Combination, Infrequent Adjustments [Axis]"
       }
      }
     },
     "localname": "BusinessCombinationInfrequentAdjustmentsAxis",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_BusinessCombinationInfrequentAdjustmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Infrequent Adjustments [Domain]",
        "label": "Business Combination, Infrequent Adjustments [Domain]",
        "terseLabel": "Business Combination, Infrequent Adjustments [Domain]"
       }
      }
     },
     "localname": "BusinessCombinationInfrequentAdjustmentsDomain",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_BusinessCombinationInfrequentAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Infrequent Adjustments",
        "label": "Business Combination, Infrequent Adjustments [Member]",
        "terseLabel": "Business Combination, Infrequent Adjustments"
       }
      }
     },
     "localname": "BusinessCombinationInfrequentAdjustmentsMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Aggregate Intrinsic Value Exercised In Period Of Warrants Or Rights",
        "label": "Class Of Warrant Or Right, Aggregate Intrinsic Value Exercised In Period Of Warrants Or Rights",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights",
        "label": "Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights [Abstract]",
        "label": "Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercised In Period",
        "label": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercised In Period",
        "terseLabel": "Exercised (in USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Granted In Period",
        "label": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Granted In Period",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights [Roll Forward]",
        "label": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights [Roll Forward]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Securities Canceled In Period",
        "label": "Class Of Warrant Or Right, Number Of Securities Canceled In Period",
        "negatedTerseLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Securities Exercised In Period",
        "label": "Class Of Warrant Or Right, Number Of Securities Exercised In Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Securities Granted In Period",
        "label": "Class Of Warrant Or Right, Number Of Securities Granted In Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bngo_ClassOfWarrantOrRightOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Outstanding [Roll Forward]",
        "label": "Class Of Warrant Or Right, Outstanding [Roll Forward]",
        "terseLabel": "Shares of Stock under Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstandingRollForward",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Granted In Period Of Warrants Or Rights",
        "label": "Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Granted In Period Of Warrants Or Rights",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Of Warrants Or Rights",
        "label": "Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Of Warrants Or Rights",
        "terseLabel": "Balance"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Weighted-Average Remaining Contractual Term Of Warrants Or Rights [Roll Forward]",
        "label": "Class Of Warrant Or Right, Weighted-Average Remaining Contractual Term Of Warrants Or Rights [Roll Forward]",
        "terseLabel": "Weighted- Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_CommissionFeeMaximumPercentageOfGrossProceeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission Fee, Maximum Percentage Of Gross Proceeds",
        "label": "Commission Fee, Maximum Percentage Of Gross Proceeds",
        "terseLabel": "Commission fee"
       }
      }
     },
     "localname": "CommissionFeeMaximumPercentageOfGrossProceeds",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bngo_CommonWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common warrants.",
        "label": "Common Warrants [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "CommonWarrantsMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_ConsumableRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumable Revenue [Member]",
        "label": "Consumable Revenue [Member]",
        "terseLabel": "Consumables"
       }
      }
     },
     "localname": "ConsumableRevenueMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_CowenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cowen",
        "label": "Cowen [Member]",
        "terseLabel": "Cowen"
       }
      }
     },
     "localname": "CowenMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_DebtInstrumentInterestRateCashRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate, Cash Rate",
        "label": "Debt Instrument, Interest Rate, Cash Rate",
        "terseLabel": "Cash rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateCashRate",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bngo_DebtInstrumentInterestRateDiscountedCashRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate, Discounted Cash Rate",
        "label": "Debt Instrument, Interest Rate, Discounted Cash Rate",
        "terseLabel": "Discounted cash rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDiscountedCashRate",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bngo_DebtInstrumentNumberOfMonthlyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number Of Monthly Payments",
        "label": "Debt Instrument, Number Of Monthly Payments",
        "terseLabel": "Number of monthly payments"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfMonthlyPayments",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bngo_DebtInstrumentPaymentTermsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Payment Terms [Axis]",
        "label": "Debt Instrument, Payment Terms [Axis]",
        "terseLabel": "Debt Instrument, Payment Terms [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTermsAxis",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_DebtInstrumentPaymentTermsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Payment Terms [Domain]",
        "label": "Debt Instrument, Payment Terms [Domain]",
        "terseLabel": "Debt Instrument, Payment Terms [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTermsDomain",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_DebtInstrumentPaymentTermsPeriodFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Payment Terms, Period Four [Member]",
        "label": "Debt Instrument, Payment Terms, Period Four [Member]",
        "terseLabel": "Period Four"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTermsPeriodFourMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_DebtInstrumentPaymentTermsPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Payment Terms, Period One [Member]",
        "label": "Debt Instrument, Payment Terms, Period One [Member]",
        "terseLabel": "Period One"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTermsPeriodOneMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_DebtInstrumentPaymentTermsPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Payment Terms, Period Three [Member]",
        "label": "Debt Instrument, Payment Terms, Period Three [Member]",
        "terseLabel": "Period Three"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTermsPeriodThreeMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_DebtInstrumentPaymentTermsPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Payment Terms, Period Two [Member]",
        "label": "Debt Instrument, Payment Terms, Period Two [Member]",
        "terseLabel": "Period Two"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTermsPeriodTwoMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_DebtInstrumentPrepaymentFeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument prepayment fee percent.",
        "label": "Debt Instrument Prepayment Fee Percent",
        "terseLabel": "Prepayment fee percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercent",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bngo_EscrowedSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Escrowed Shares",
        "label": "Escrowed Shares [Member]",
        "terseLabel": "Escrowed Shares"
       }
      }
     },
     "localname": "EscrowedSharesMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_IlluminaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Illumina",
        "label": "Illumina [Member]",
        "terseLabel": "Illumina"
       }
      }
     },
     "localname": "IlluminaMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_InnovatusLSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovatus LSA",
        "label": "Innovatus LSA [Member]",
        "terseLabel": "Innovatus LSA"
       }
      }
     },
     "localname": "InnovatusLSAMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_InnovatusLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovatus Loan Agreement [Member]",
        "label": "Innovatus Loan Agreement [Member]",
        "terseLabel": "Innovatus LSA"
       }
      }
     },
     "localname": "InnovatusLoanAgreementMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_InnovatusTerm3LoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovatus Term 3 Loan",
        "label": "Innovatus Term 3 Loan [Member]",
        "terseLabel": "Innovatus Term 3 Loan"
       }
      }
     },
     "localname": "InnovatusTerm3LoanMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_InstrumentRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument Revenue [Member]",
        "label": "Instrument Revenue [Member]",
        "terseLabel": "Instruments"
       }
      }
     },
     "localname": "InstrumentRevenueMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_LineagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lineagen",
        "label": "Lineagen [Member]",
        "terseLabel": "Lineagen"
       }
      }
     },
     "localname": "LineagenMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenProFormaInformationDetails",
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity",
        "label": "Liquidity [Policy Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bngo_LoanUnderPaycheckProtectionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Under Paycheck Protection Program [Member]",
        "label": "Loan Under Paycheck Protection Program [Member]",
        "terseLabel": "Loan Under Paycheck Protection Program"
       }
      }
     },
     "localname": "LoanUnderPaycheckProtectionProgramMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_MarkOldakowskiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mark Oldakowski",
        "label": "Mark Oldakowski [Member]",
        "terseLabel": "Mark Oldakowski"
       }
      }
     },
     "localname": "MarkOldakowskiMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_OfferingCostsIncurredNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering Costs Incurred, Not Yet Paid",
        "label": "Offering Costs Incurred, Not Yet Paid",
        "terseLabel": "Offering costs in accounts payable"
       }
      }
     },
     "localname": "OfferingCostsIncurredNotYetPaid",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_PPPLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PPP Loan",
        "label": "PPP Loan [Member]",
        "terseLabel": "PPP Loan"
       }
      }
     },
     "localname": "PPPLoanMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/DebtScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_PerformanceSatisfactionVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Satisfaction Vesting",
        "label": "Performance Satisfaction Vesting [Member]",
        "terseLabel": "Performance Satisfaction Vesting"
       }
      }
     },
     "localname": "PerformanceSatisfactionVestingMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_QuestDiagnositcsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quest Diagnositcs",
        "label": "Quest Diagnositcs [Member]",
        "terseLabel": "Quest Diagnositcs"
       }
      }
     },
     "localname": "QuestDiagnositcsMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_RErikHolmlinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "R. Erik Holmlin",
        "label": "R. Erik Holmlin [Member]",
        "terseLabel": "R. Erik Holmlin"
       }
      }
     },
     "localname": "RErikHolmlinMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_RevolverMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolver [Member]",
        "label": "Revolver [Member]",
        "terseLabel": "Revolver"
       }
      }
     },
     "localname": "RevolverMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_RuhrUniversitayBochumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ruhr-Universitay Bochum",
        "label": "Ruhr-Universitay Bochum [Member]",
        "terseLabel": "Ruhr-Universitay Bochum"
       }
      }
     },
     "localname": "RuhrUniversitayBochumMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_SaleOfStockAuthorizedAmountToBeIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Authorized Amount To Be Issued",
        "label": "Sale Of Stock, Authorized Amount To Be Issued",
        "terseLabel": "Authorized amount of stock to be issued"
       }
      }
     },
     "localname": "SaleOfStockAuthorizedAmountToBeIssued",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_SaleOfStockValueSharesIssuedInTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Value, Shares Issued in Transaction",
        "label": "Sale of Stock, Value, Shares Issued in Transaction",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockValueSharesIssuedInTransaction",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Termination of Employment",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Termination of Employment",
        "terseLabel": "Vesting period, termination of employment"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerminationOfEmployment",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Percentage of Shares Vesting on First and Second Anniversary",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Percentage of Shares Vesting on First and Second Anniversary",
        "terseLabel": "Percentage of shares vesting on the first and second anniversary"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfSharesVestingOnFirstAndSecondAnniversary",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Roll Forward]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Roll Forward]",
        "terseLabel": "Weighted- Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Issue stock for warrant exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "bngo_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Warrants Exercised",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Issue stock for warrant exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_TermA1LoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term A-1 Loan [Member]",
        "label": "Term A-1 Loan [Member]",
        "terseLabel": "Term A-1 Loan"
       }
      }
     },
     "localname": "TermA1LoanMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_TermA2LoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term A-2 Loan [Member]",
        "label": "Term A-2 Loan [Member]",
        "terseLabel": "Term A-2 Loan"
       }
      }
     },
     "localname": "TermA2LoanMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_TermLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loans [Member]",
        "label": "Term Loans [Member]",
        "terseLabel": "Term Loans"
       }
      }
     },
     "localname": "TermLoansMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/DebtScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_TimeBasedVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time-Based Vesting",
        "label": "Time-Based Vesting [Member]",
        "terseLabel": "Time-Based Vesting"
       }
      }
     },
     "localname": "TimeBasedVestingMember",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer Of Instruments And Servers From Property And Equipment Into Inventory",
        "label": "Transfer Of Instruments And Servers From Property And Equipment Into Inventory",
        "terseLabel": "Transfer of instruments and servers from property and equipment into inventory"
       }
      }
     },
     "localname": "TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer of instruments and servers to property and equipment from inventory.",
        "label": "Transfer Of Instruments And Servers To Property And Equipment From Inventory",
        "terseLabel": "Transfer of instruments and servers from inventory to property and equipment"
       }
      }
     },
     "localname": "TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_VestingStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Status",
        "label": "Vesting Status [Axis]",
        "terseLabel": "Vesting Status [Axis]"
       }
      }
     },
     "localname": "VestingStatusAxis",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_VestingStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Status [Domain]",
        "label": "Vesting Status [Domain]",
        "terseLabel": "Vesting Status [Domain]"
       }
      }
     },
     "localname": "VestingStatusDomain",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_WarrantExerciseNonCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Exercise, Non-cash",
        "label": "Warrant Exercise, Non-cash",
        "terseLabel": "Warrant exercise pursuant to cashless exercise"
       }
      }
     },
     "localname": "WarrantExerciseNonCash",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working Capital",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://bionanogenomics.com/20210331",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AsiaPacificMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia Pacific [Member]",
        "terseLabel": "Asia Pacific"
       }
      }
     },
     "localname": "AsiaPacificMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r47",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r135",
      "r199",
      "r205",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r213",
      "r215",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r339",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r213",
      "r215",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r339",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r135",
      "r199",
      "r205",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NorthAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "North America [Member]",
        "terseLabel": "North America"
       }
      }
     },
     "localname": "NorthAmericaMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r132",
      "r199",
      "r203",
      "r313",
      "r338",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r132",
      "r199",
      "r203",
      "r313",
      "r338",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r211",
      "r213",
      "r215",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r339",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r211",
      "r213",
      "r215",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r339",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r133",
      "r134",
      "r199",
      "r204",
      "r341",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r133",
      "r134",
      "r199",
      "r204",
      "r341",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r136",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r137",
      "r138"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, trade"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r16",
      "r137",
      "r138"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $2,091,000 and $2,119,000 as of March\u00a031, 2021 and December\u00a031, 2020, respectively",
        "totalLabel": "Accounts receivable, net",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails",
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Intangible assets useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r216",
      "r218",
      "r248",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r218",
      "r239",
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r22",
      "r139",
      "r143"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedTerseLabel": "Less allowance for doubtful accounts",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails",
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "auth_ref": [
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Recovery",
        "terseLabel": "Recovery of bad debt expense"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r73",
      "r150",
      "r157"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r80",
      "r121",
      "r124",
      "r130",
      "r141",
      "r283",
      "r285",
      "r290",
      "r318",
      "r329"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r46",
      "r80",
      "r141",
      "r283",
      "r285",
      "r290"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r219",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r212",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenProFormaInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r212",
      "r214",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenProFormaInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Shares of common stock issued as consideration (in shares)",
        "verboseLabel": "Number of shares issued or reserved for issuance (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenProFormaInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenProFormaInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenProFormaInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Business Acquisition, Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Stock price per share on closing date (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r265",
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r265",
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r276",
      "r277",
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total estimated purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Value of estimated common stock consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Liabilities assumed of acquiree"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisition of Lineagen"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagen"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred",
        "terseLabel": "Adjustment to original purchase price"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedTerseLabel": "Accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r32",
      "r75"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets",
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r69",
      "r75",
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r69",
      "r291"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r79",
      "r80",
      "r97",
      "r98",
      "r99",
      "r101",
      "r103",
      "r109",
      "r110",
      "r111",
      "r141",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r164",
      "r322",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Litigation"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Litigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit",
      "http://bionanogenomics.com/role/Cover",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value, 400,000,000 shares authorized at March\u00a031, 2021 and December\u00a031, 2020; 278,794,000 and 189,953,000 shares issued and outstanding at March\u00a031, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r114",
      "r115",
      "r135",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r114",
      "r115",
      "r135",
      "r288",
      "r289",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r114",
      "r115",
      "r135",
      "r288",
      "r289",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r114",
      "r115",
      "r135",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r114",
      "r115",
      "r135",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r186",
      "r187",
      "r200"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r186",
      "r187",
      "r200"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r57",
      "r313"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Total cost of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue [Abstract]",
        "terseLabel": "Cost of revenue:"
       }
      }
     },
     "localname": "CostOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r112",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r319",
      "r320",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r12",
      "r167",
      "r320",
      "r328"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/DebtScheduleofDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Total principal"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/DebtScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r301",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Term loan face value"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r39",
      "r169",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails",
      "http://bionanogenomics.com/role/DebtScheduleofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r40",
      "r83",
      "r178",
      "r181",
      "r182",
      "r183",
      "r300",
      "r301",
      "r303",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails",
      "http://bionanogenomics.com/role/DebtScheduleofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r300",
      "r303"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/DebtScheduleofDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Less unamortized debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/DebtScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": {
     "auth_ref": [
      "r300",
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.",
        "label": "Debt Instrument, Unamortized Discount, Current",
        "terseLabel": "End of term fee"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r33",
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Offering costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r73",
      "r119"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r199",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Revenue Recognition"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stockholders\u2019 Equity and Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EMEAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regions of Europe, Middle East and Africa.",
        "label": "EMEA [Member]",
        "terseLabel": "EMEIA"
       }
      }
     },
     "localname": "EMEAMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r89",
      "r94",
      "r96",
      "r108",
      "r142",
      "r177",
      "r184",
      "r242",
      "r243",
      "r244",
      "r256",
      "r257",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination.",
        "label": "Equity Interest Type [Axis]",
        "terseLabel": "Equity Interest Type [Axis]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.",
        "label": "Equity Interest Issued or Issuable, Type [Domain]",
        "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r151",
      "r153",
      "r156",
      "r158",
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r151",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r73",
      "r171",
      "r172"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Gain on forgiveness of PPP Loan",
        "terseLabel": "Gain on forgiveness of Paycheck Protection Program loan"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/DebtNarrativeDetails",
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r147",
      "r148",
      "r317"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r52",
      "r121",
      "r123",
      "r126",
      "r129",
      "r131",
      "r316",
      "r323",
      "r326",
      "r336"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r258",
      "r260",
      "r262",
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r81",
      "r95",
      "r96",
      "r120",
      "r252",
      "r259",
      "r261",
      "r337"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r149",
      "r154"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r51",
      "r118",
      "r299",
      "r302",
      "r325"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r60",
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r68",
      "r70",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r23",
      "r146"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r45"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net",
        "totalLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails",
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r24",
      "r25",
      "r146"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r80",
      "r125",
      "r141",
      "r284",
      "r285",
      "r286",
      "r290"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r80",
      "r141",
      "r290",
      "r321",
      "r332"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r80",
      "r141",
      "r284",
      "r285",
      "r286",
      "r290"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r35",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Term loan facility available"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails",
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r12",
      "r168",
      "r320",
      "r330"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/DebtScheduleofDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total carrying value of debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/DebtScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails",
      "http://bionanogenomics.com/role/DebtScheduleofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r40",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails",
      "http://bionanogenomics.com/role/DebtScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r69",
      "r71",
      "r74"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r49",
      "r50",
      "r53",
      "r74",
      "r80",
      "r88",
      "r90",
      "r91",
      "r92",
      "r93",
      "r95",
      "r96",
      "r100",
      "r121",
      "r123",
      "r126",
      "r129",
      "r131",
      "r141",
      "r290",
      "r324",
      "r335"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued But Not Yet Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r121",
      "r123",
      "r126",
      "r129",
      "r131"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentInKindPIKNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A payment in kind note accrues interest over the term of the note and is repaid at maturity or upon refinancing. A PIK loan is typically unsecured.",
        "label": "Payment in Kind (PIK) Note [Member]",
        "terseLabel": "PIK"
       }
      }
     },
     "localname": "PaymentInKindPIKNoteMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Offering expenses on sale of common stock"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r62",
      "r279"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash",
        "verboseLabel": "Cash consideration transferred in acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March\u00a031, 2021 and December\u00a031, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r30",
      "r31"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from sale of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r65",
      "r84"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from borrowing from line of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r64",
      "r241"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Proceeds from warrant and option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Service and other revenue"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]",
        "terseLabel": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r9",
      "r159",
      "r333"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r55",
      "r144"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for bad debt expense"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r66",
      "r84"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedTerseLabel": "Repayments of borrowing from line of credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Repayment of term-loan debt"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfOtherDebt": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the payment of debt classified as other.",
        "label": "Repayments of Other Debt",
        "terseLabel": "Payment to satisfy outstanding principal and accrued interest amounts",
        "verboseLabel": "Cash transferred for repayment of Lineage PPP Loan"
       }
      }
     },
     "localname": "RepaymentsOfOtherDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r251",
      "r360"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r184",
      "r245",
      "r331",
      "r347",
      "r348"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r89",
      "r94",
      "r96",
      "r142",
      "r242",
      "r243",
      "r244",
      "r256",
      "r257",
      "r344",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r116",
      "r117",
      "r122",
      "r127",
      "r128",
      "r132",
      "r133",
      "r135",
      "r198",
      "r199",
      "r313"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r114",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197",
      "r202",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Timing of satisfaction of remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "terseLabel": "Performance obligation, percentage"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "verboseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r114",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenFairValueofTangibleandIdentifiableIntangibleAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenNarrativeDetails",
      "http://bionanogenomics.com/role/AcquisitionofLineagenProFormaInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r218",
      "r238",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Recognized Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.",
        "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets Acquired as Part of Business Combination"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r151",
      "r155",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock": {
     "auth_ref": [
      "r7",
      "r26",
      "r27",
      "r28",
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.",
        "label": "Schedule of Inventory, Noncurrent [Table Text Block]",
        "terseLabel": "Schedule of Components of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryNoncurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]",
        "terseLabel": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r219",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r221",
      "r227",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Assumptions in Black -Scholes Option Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r42",
      "r79",
      "r109",
      "r110",
      "r174",
      "r175",
      "r176",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r185",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Units granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r223",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares of Stock under Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Vested and exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and exercisable (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r217",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r234",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Average share price (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r79",
      "r80",
      "r97",
      "r98",
      "r99",
      "r101",
      "r103",
      "r109",
      "r110",
      "r111",
      "r141",
      "r177",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r43",
      "r85",
      "r86",
      "r87",
      "r89",
      "r94",
      "r96",
      "r108",
      "r142",
      "r177",
      "r184",
      "r242",
      "r243",
      "r244",
      "r256",
      "r257",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "verboseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r108",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r177",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Issue common stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r177",
      "r184",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "verboseLabel": "Stock option exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r177",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issue common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r43",
      "r177",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r80",
      "r140",
      "r141",
      "r290"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets",
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r298",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r298",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r298",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Account Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade name"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionofLineagenIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Loan"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average common shares outstanding basic and diluted (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=SL65897772-128472"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r361": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r362": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r363": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r364": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r365": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r366": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r367": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001411690-21-000014-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001411690-21-000014-xbrl.zip
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M6N^L5-(D864,<AZRT!Y R-=Z#?O!>GB 7\@91N3RREKYR"B/U%LFF9*22LD
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M3B+E,GC!I21,Z^AXBEKC*'6(R3(AO!?F)Q''@Y_V#ES,?ORK\34&0&9P/QN
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MW<J?I]U&+S2*'=>9)]V8"HK;N@>VW;@L/O]:PM/L"WAK96=E=Z6RV3II=BY
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MJ&>EUM ODM HO6 ("T(19YXB2UU$1"7FG"1,!?'CPWWF-Q1[.PS;.XS-YL@
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M$7Y5!J!)+W-N9@R97MM)NJ^0+"$%@YR.K:YY#Z_8[U6ZT4>P#M>,RY5V[.<
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MIZ ^QG*#0.J><2\](,53XH7+CUPF?XU@SI@BEI&<F5# ZL47C$T,@7O$6 J
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M#50%P,YY+H15<FF52;JLR"1/)9F9LOJO<:;SPEO]RZ^\E%;_?*N_IC*)J,C
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M\*BBL5Y@K47T22AC38%8>(18N$2LF4:LRRO$4D$QD)9#(H1<4#E)Y"(CB+E
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M9ZY/0Z'%E?;?#<_.VC$G#-EVR?M3NWO>"*V^;W?[P]X]^WA6I57G<M;V>5B
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MA&_A-VS ^!O#L3U9?GWRSUO=J!=39EN;8_K3/0.E5?+,F;DISC[4'WU0M1V
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M(%_Y#C__^9-!_ !*O3A7_J<%X@(K_-QU^)<]<7BT<W'PX^#\X,L^/7SS69/
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M70IZW@)&?@IV/>R@J5T1AKV\.S/*E7L5+/A\>8&7=]D>*28524J6),]5E$[
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M'D3.E:J8(-8/@U1NM.!K\:NPJJ@>!_PZ%8$=IA16N&M\U,,;WC:RTUP>>:R
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M%E,L/XQ)6.'#* Q/8"Y\9.6JQP:/W(7[?.OZ"/<3#'3=H1N?%*-TT8U9) 0
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M@BN X%RU/LX)0"!UR&0^(%!A.0),S%'0)&"MN;-9-&8 !.\S^//HI:,-<#;
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M#;'N2E,CL<ZHDH;%*LQ-_=.LE=O!16.MW)=<[%RD\A:M,8TM_*B/;5I@9YK
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MZ2^/:INNZ&5?-E GR]9HVMM UOFLB<HUP9E32 ?)8J&/1-J NK69Q89GGH=
M8@N/#<GT4O_ZWZNZUNL8OG^>N_QG&=%+#NIN;4(W6_N.6WO&B.:22Y<Q1 @8
M(IQ9AY1U.MK47@5%N, \46!=)@FX7=!L'7?VNESCY2',6MD05T3J+Z%-$[J_
M*_Y,0_< (99HG"&<Y6!:4$.0$8$AJ0+.,ROA;1NILS8T6<Y'\7@H]**B\W]$
M-I7>BPO//W$?J%ZUQDZZ!4YU_IAQ@20Q*M-<(Z=LC-(S@JPQ&?Q+T*",I(E,
MB2[/Y+RY^_.\XO/--1XN=G8S5?&01<"KE 0LJ9=<J(V^?7% 5>G(8)_XP3C6
M3=:/][*K!Z22. </#N9*<"TR'=OLB<Q8;&V@*J_(UFZC@YKJ@8?0-[/5 P16
M+S#CD0XY1CPC$ADG,")2>J/ O&"Q>H!O</( &2WWL*.>1G7!0T''L\D.O(\)
M>J*8>G7\\W; VM0G/ :B3B.=TG#*G74(6V<1EQ8L>&\5HEY3KF06',]B>[][
MBW0^&S"]10'#_3STDT".^TO@:"H<UA-#IKD;@CF14_#]E1&QII-3!,@1CTR4
MUY[Z$)LCOJ:; J]1A4-CY#1&SLV/8![0:VQJ)'XZ=$T/6C33PF@!;F3&&.(Y
MX)<)@2*&F:$!R\R&6)ZYH9^90YG";?])U%BS')NST'R;+JG7,&X^)A':S<GY
M$C5:21RT>QI7^;&X^:*3]7OLNAYIV4*_2,R(:6#5N+8J6K;$$/F"2?IP;,\H
M0I;GDB.::X$XL11I@&S$<HE#P%I@[F]*TH>?%$E?R6H_."WYFN^-J:]52_W]
M/C2]T4.70UM UQ_!R95+]M,Y R66M^0,E%(_"%D<N_KCNS#;L6:P3VNP-R,X
M;#@#9S@#EYL!+X_:K2$.;(@#&^+ ACCPJ41P'HLX<+G/MA7#-8>I!<OOY].O
MO#?G\:VM,S/TE8J96?I.U>/G681V#L]WW_T)U_U #^ U_)>U/[=YY]V;[^T]
M1P].WI#]DS8Y./[SZV)H9W=[A^^?_-GK;!^<[&['_[KO^Q>'>'_OS??.Q<')
M_MX_W?V+?T[:)Q_GF08U];D-X&DS%GN'.BF1L2I'AG,N@B8R(^+5:[%!-7Y*
M[!<-#U## _0DB ;O$0H73O+FL@$:@%P-(*='_\&)8%A&$)9&(NXQ0XIS@H)@
M@A E/?7VU6NRJ2_W;7_>V'B+D_UG?G#_$-2$<SAAK\<)NS).7'7B_T2;%/YL
MI)@>\)/8.S,S%,G@.>+:"J24P<CKS+B0"^ED]NJUVI1K=+[?6"[/V')YTH[=
M_&E^8[^LADHS19*&$H$#0Y9;BG@N2>SDSA#Q0=M,<:N(3_P+1*JGY.&]J K*
MAM]P/>HG[POGTGH6=65EZA+=(-PJ"#=+@L@X<R9G#@4J!>(RDTA):I$#'2><
MH@IS!@C'[@7>UKC(\H6!P,-SS-QXMQ<K;?<F3G-_*#"-T^2,$H6-1YA9'=MN
MYV#QY!+E6(9 #,[!"X]VSJ9BSQ@#GOHU&G+ %T#JLX;$&!.HCYDL.T4Q#GX[
MI0:6D%VFO<PFE4[6KD'L51![EAF0.YIAZSUBVJI('P9VFV 9\MABIC-!J4N>
MZ7+NGH86<&WW]W,PV>K]W5AM#X !,X6UV#).L$)&Q\):SA2R+K<H4U1ZIYC"
M>8AM?ZA:(_*N=:3_>\"C@A=P&O \ _Y/*2)V"6_W!B/3:PX![@*S,P5\7%@O
M D<LJ(!X" 99:7.46<T<R2@W&(.IM4$$:X@2&Z+$QA^\+UA[.QCFH3L:#Z?
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M]/)U7(A)%,)@P?9%HQGC6&5(.2AXLP*3&+>FHD@%F=8P2"R87"M*5+$,FX&
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M_'C704K^NL)$*4ZYW$+/^U<9AQ^EE)"%W,,RV7+5@8,+[H-S$38#NYTF@;6
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M%I(1XX)V&#EA"F<;F"??6R5E89_Q$4U(OE%[EFB14B0I$;R?9HG>4#%^F3*
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M7V0+C +X'P_+*U!:^EUP9E$;P\*DY9+7!ZSCHIS](78(Z6PLT ORR('Q8T%
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M^E']EBB#Z]#V?SA'_H=?).SWE8=PQR5ASG=>!)PY!P46A*KKG5G7UJGQK-R
M+IUEZZ85,8@Z4X1"L7U>6[TJOH,YWO4D=S ^V<I.8I:DR2)]L \86N8"B_Z
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MSDW5G?43,FY?)JUY=<A8ILY89#X3A&F(*6[C)&:'$JZ#?Z$^PJ#JIJI'I0)
MW$^=OEY1OHW(WU#(Y$Q#H;-R8Z!80DF'[',*M@]H%=V\!\]1,K6LIHATI;H6
M62*E <,.U2E.2:RUY&6>E2N2$7W/HESC&>+T,9DIBEHK:H9"VR6- HD67"+Z
M.D4MBSJL!-_%[;AMT=8-NV?+.T8J)%-7:!\LQX,<FC96(0< ZQ?>HK@>&Z1W
MB5,^;GE3%E1DK>R)Y]2WP3E+E1N8&:0';5%JA HU'\8O899)(\/VBK< %V+A
M\UE$0J#-&TNERT@$?N%R!4/RT$_#TVP)GZLCSW8L;(5@1W8K3Q@))4UO^7X)
MKE&LO:LL@;.1^',22N+#()!+Q39(IU&\H;I/R5NX:F$5;$BNY5!-.<;KDAL3
M+0^ZF6N>5P:I:$ *?9K+P'I+'/KF9MR[HL)'J)FX1QF95VPZ"&6TRA<![#[F
MH$&[6/E-Q[,3TMHZX!I"0+MB^0V37#NMK3=>5&T@7^CAXZO*9SB[5*PD7[MK
M, *ATF!%0GZ@OL8J&3<74K&E&*TJ5OZ\*3XH<R'@D*HV(*/&U0;DK++P&?-(
M;XO.,OBX3<] 9,+8N8EP'?0Y\/61:]#(\IB6C!7@\R*@((:V$?!@-V^>E1M2
MTWI?4H9DN:I06A4V,X71#8KWB&>MIU$<KQM$@@T[C>NPZ123H[&D0C510,Y:
M0[\DN0=1"$T&I#O73%',;./(41X(QS@[CEHE2R(TLIQXFH)%F_B%9'6)TX.,
M0*UH7+7+%*6.T4OK9TTN?2UVERF<&(WTK:B]G?^Z6\-\E\B5:8M<.8RQM,B5
M(T2N;*G5O,*N@:T)L;4JG$XQ59?*$6M\[@H4I0%E:5P<QD9*<X9*A-%ZK*25
M!3>"G1B(-F"^#8%I:#-JQR'\:E5.<X8!6A0@$4PPZ(1X^P,8;$0#%I!#[3/(
MZZY"'QVXMM\($*U8 .YI"'<(Q8$ 1B5B<!>T:(QSMP]B]( !HTWD\Q(YT:W&
M>2*<N6H VJ)GIKFQ39XF4=$E%=@6:KT+'R(IIYM,E%VFOPW7'*.Y[V'X"(T=
M\ZGS:F;2!GAR:D;#]K2$G=4JYGQP7!!#*LQ8E=W0T1_<Q(52C@*(VJBU]S&5
MAK'8. ",VK7LG%6&_Z(L'C&PDK]9#>JYR73RQ#EFQQ'F#4?JKA=9HLE64>[U
M(QR!Y8X%X#Z3%PJRM]U@V330(&?(C&PKC%6;.I,MW\>-])M]R,9.";[=MPSG
MJE3=\!*KE"LEK+2[S=[QJ;9C1ZR:VK_7R?*ZWD&F[.](S?G,]A):!Y^\)+@F
M ;*$44XI14!AL\C)I%0*2JP'9(!U=P@EF)[OS5$%&M.C""K@8Y $FK*L7(@K
MC=8%SR++0)[\NJ2$4E[2=>ZJ9+EDS-)0.> @..J9!7=-GC!'&-T@>ST-5M,=
MU9WF-&)W6V.8M(PI:_R\05/D;)4KRO2S8H1_&/P%JMIFT:OY_HFZC M)K^B)
M ,$>]/HGF@4$E=LZ7B,"!)7 !8S[62FVT=^S6>&=A6L3#,%?Z;_UPTA_-+7B
M$@ +<;GIN3!%8Y=P()*-9I(2KU*R'I"FDUU\B6V[L"9XBA.89?L.<_!R?CCC
M8_6G$WU"5:U/'2&C%J6G[S!3#U:$(CP,F8TRX;89BS.CH.\JDTVZ/<O!A+F*
M<] "9S&LV0<%RS2G$;S0J<US+KC;5*;VV=F'%^?\ERV<#27,"@T%<X9=.XIB
MH:/6]\7\8IB<:U19<GIJ0[V@Y*QIQ$1!W^H\^M61>=),)E5(,JU%8*[ OL)(
M*JZR.SN.)K4,[WA5SDEACBI78,DI57S.%2' :<')*).>=;BMLEH@45JV!9_,
M,]!H X'$IE IXX5T!$7H5&T<Q?!OV_H@+0]9;OO8T<RX6ZD9HZP-I'0[0];P
M33K29RO*W&T$?DN'^.5A/^67&MS$=QBB\,RRBYA])I]TF.BY>[!D.Q$R/!10
M0&Q0F)M-5+:WHRO6',1D993-YP6R[PI'-L@+>A%\[+" !)^4R6@Y9JF#WSC,
M2;TYE4@:0Y>8_-O_ZT]Z3X=]IY2.A%AO83*#UWJ;;L\UV"1YOH'MP(4=2((\
MF$RZ)X8$&1_P8[\_ZO;TGWRMHLE?XFQ:16-L/U;XF>%!O4%W;)Y-5I=X!B#E
M,>888'GKK;;)C-_Y9+/R&U /B#>'56.\ 66L32V.GB/4IQK[ ,(P[?W%6/%,
ML/3_%35AXD^T?4AN^5B<P_YDU!U4YM N0L,M-&C"4](L\($^.*$;X1_#ZI1C
MR\V$,9KJ"O4^^F#"D4EM.VZ6#^M$N$)B0>P6E!QBI\!UP^>-G44D 1GO)QXW
M/WG7+-STM?CTW4.7>?;D%4Z&^D![>^X?K:OMD9U:=">52N,2W*@L=1X^NT:H
MP")>6=,0-S)C[T,I]B(;**C$P6HE9S&1(("M;&-[9 *'M/6V#:0M@_)9QB"_
M_NET0I47%,>CWAIB@,$%^IC-&=MIT4KFV;PSP9JE0(7QZ]R&E)68X];7RV>M
M B$GDA(NVF<.T8(;7-OU#%VU5X4<(;"&&V76^^(R0,<\SF=^ 0-\E.7,P/J/
M(P?<0]$R7=M>'XQTSFVB9RG%1&DX1[(;6'L:12VN5.2(1B:#][J:!]QJ8:B=
MY)GIL**3;]86<".G-9,Z$$0&+[LB4!V7:&KPB_14C+AJDJ<2;Z'/;]IKVY]6
ME-2+@3>"!2^;SZRXJT[TE]*YH"FX*:JQ"\WI@1#$:U!\AZB\[F@+:@/7Z+ X
ME7@S[9$FH)'LZR#*#&R/O ^VYTV1A&Z*9*3+C>D*=Y_U^B7IN0>HXR&4_O$9
MJ*^K\.A:HAO6:Q5L!$,0)D&\Y,@DG^C&U<-EU6>X=?;0Y0HHS*^= [Q.G$!\
M'_8738R?Z"H^$[H(<JY=1IB0V(#ZMVIG'!OVJ(0\*N S)P)CU;?V T7JQ)OU
MUK"5U[I@6HMAS;/M>N?<!Y8T%%;Q:*5]^^;@G@&,#JD=*UM;C4L?[+T-;NAU
MEB<1PLYM"RSCZ@N0JJJ@[[2E6@*."HSAM(4Q',986AC#8<(8[FA;7-3IGYC4
M3/<=6"5!6"OOV>JW7<T-S!/U2<*,OE0+FHZ3+N^412)PI4@!#ROF&W->F6R/
M<6LLS( 1B[IFISIBYN<P3%7:8G2X'YI! U),HZ1D37]F-4->-4=W4":8I/>.
M7.:6?>Y7:PQLTT@N$FTD3;#$=8=.F7!S47OJO2%/J#_"P$O_E (O=,*0L8!0
M!^\U(372R$D>:%$P'FR%VL5G$7/^%L^5=TY%E##VUXJ]VY?8R?25[[U^3X\Q
MEU>3)@RB,$O/!3R"Y9^!MYQ=DP55KG A?APX 1ZL?BJP0(ID7]MA"@/J\$52
M?%DA/73#0Q*81_=6X[/%/:2EIH!.C="F,#Q>X/$%<)U*&4#.G#:FV1WF^Q(#
M M&B;4L/M!F5)(K!LRLL8<NIZH:V(ZU9)6+6IX5#CXM;V'PBX 2\Z,?^J'O*
MESKMXD"64X2E5OKX.5.SB[3LZ 1\>Y4$350(G,C5B8&7EA2")327UH]/=J'*
M?G+7S.CH"MJ,3/"FVJN?M\DE,>8W QL=%=%3V(,ACX5!W%BH1I%)PY%$):&P
M6$]!R=(7^1@@X=H2;+*;7BDI:WU*"&5="(@*&)M>L?F=!(7$EB@^H_/>0FM)
MMCP\YBEI.'1(T._'D!'>BR !$ '8C6EDWAOHOSLX[BR]V\NH!_*<-I_)<"'*
MPSE$>-.8;Z\Q8.A6WDN57RHF(DK!PHZQY$; >9J\%S$H=&^67P:I"516VWC-
M>3 2=N+3$2-35"FE CR1@FJ_+_5)D/O@0;S;M9U-.:P+12+@!I;>;H,7FY0.
MW2]I"\JKIA$&D 4T9G%^%:88&UAD";6/M U^N;AE&R]8KL17E@BJL-'C1/*U
M7.B[MD "JDQ<!%?\ZET@%'IN8PF&!O?CG,7<%I8U9M:,?,..TOIAS<5%*,+D
MN(JZ=@V1':K//+6V'^7\0UWOU%R8G^W3 GMF4A!OIGG,J,>F@R+4&QO<<NPN
M1VH<V\U=*I)3T50K:T;-E8M5<$+3R&IV5"J[/[;$9%K<FI?#=_Z38M@V-.D<
MK3M-32(+OA7521W)F4JDAF^EQ;+07)(TN[[U[70[]%.'XW4\QBQ\ W59O0$J
M,9+:C]A)R6<M>WTZ[1+U@!1'G0 5C<-:DE(J$+>I4BF2;?KX"JQ9$_IITM6]
M7N W/-W#V$*X4(5-(Q.[AUL.LV(>9HRJB?L!?W1,3*,-_2TT#RDA>H--1 B9
M:U#)63J#K$B ?K]E<U7<MG?0Z_FP>=CR=+<P_=CM&]N3>$C$1*MR=65R6]UR
M'71/&^^V2DL%.1;:XJ]G\'-BIU/6 UTO:5;AYI'J%-<FWQ!P02?!A:2.ME(D
MCZ:/PES3CWW7KL82]FJW8D8N2@C0-#KV99I^[,NLU51>0Y$R10L+1-E&=N_7
M,;/;,/LZ$^;=)6('63!)!//C)%G!YVF=,/S.DPF[ZSZ3*=!^)9Z^0,O<+M?'
MA3&ALT+RH!K?_S5827TL+S!$S5;9U&HVC')#6*%]I)-R]8^:W[2I"J)IGM%R
MEF8"IHJ%K4/90'L<Z+<;H>3%N)/DGL8-MEN%B5YC!RKA(T)N;''3\U?3"<MA
MI8"2HN;IV.JB?_*4JUN,"<<E11K56:@T9I.!N1&H#D:'D=Q^!TZE/,Y7M9D[
M&YD\!((X<A<"G"+32]A^=-9,!O^UXF;^YP;.*N:"R(]K+E!7,MX@^NRO..F&
MCE9X%EPKP.V@H#GH5G!;LM8\0]BE NML@UP55L%765'MW&+*S34LCLK"UJU!
MN#O&#1&(JEIBSY.4BU-;[ 2"N8+%O=]MA.'@6&P! SMP:&+XE>@)7"%*T]YE
M7T1<(AKI7GGA3J+])M5%^Q3?RZ(N<1'\LI!!'.2S.T^_7BCDX^*]'1/$R->T
M7+1[>6_)IH6#-\"):O 6N3".C@9L(1ZD'[$0/*0*=7>#;TM5'/W7#[=G2OJ]
MT?"'FX41>P,]A#0VIT ^4-6/P]6XJPCB$/?9_ND>[=M6V,(P.<.>YR)6FA<"
MQHR;QJ'<WNK_YXM[R_@RP\J^Q=5XA";=.Z)"8$^<J?":2,8$M>7P;=E)-2H&
M"^?@J/M3L\#2]'$_4^QTPWV"%.H$0_N5%>N.@1%TO3?2ZXW4D2FNL\55V_1O
M"7+T; B!Q7AX5&D&<"8M;T6YQK#CN85/1K0\-'#XNP#[RD+H=JC2A5'#_+UR
MSB7P2DEO@#ZC5"%'*_1KM-$+ELR;72TD[;6&>Q#G>T<CT.UU@%.2><OHO&V8
M(^:]*)W^01SX3 DF'[#2=TMX*7RJ:YF<GD-=!C[+T4X PJ8N7KJ75/5U2,C*
M*XR!DT^^S"3:60UCKA#/81TH16M@RNC,<K"2.,-^C=+^?2[V'L._9-)DG@7Y
MV/12)AKDKV,R>RH9TR2D2':'1J0J3-KW*J"8=NT5;!OJO&]MF6U8"^ET6G"+
M<Q ->RVXY3#&TH);#A/<<N/!;9F90#,N\%#61K'%@S2I/:0J+J3 +E>:E3EV
MS'RMNVJ<IN;/7'>%;@.?=0V%B<@:G_-AJ8^C2Y6B'[1:N:^8*8>F"M'MF.32
M0$)M-&A^O8*L,W2E)=L8$:^;K>T '[),B4?:%/QWO?^&KX+S/N3^#4&E]@XY
MY(S&OH%0U#2L8(YCKC&V9['.#X-!"$\E[BAYJ',H4H/#")8AQ^A'8/A98?7@
MRN#2N'7Z1\TK7U#Z=(6?F:XK!'UL*>'280EB!?4CI%"-SIA+Q[_,X'AAP'N@
M$^LTFS("C>RW'T)'<BSQ*O?J>G*'36S,XZ5H[(C(-7R2NR)\U@LYH_[.LM@Z
MU1W#BDF]+?)[R\K"H%#"6(WMTH4*MM58^+O[31RFB7]'O^@,T_A%;/)K?V0Q
M5@LKI&$VJ%]#3.<FY[<ZY1@3F0-0NFNH=BPKG38/<>9NJZET5820;VC>8)L.
M$UA$9"?#V6*[,!-^I6=2I=NGDX$B4)72[T35EW#H%^ZO+IOO:AO;%31WL2FF
MC2(ESC 38<=CRIQJX?TD"Z4$A1 G11ES>]J@(D1-G6L)9"B1??=BYR7&^9-^
M C E<WH^ U0N\V"MD7&NU#'*P\%:B@O+#"[\A1*:UH\1[4"A<2V[FC17+Y%;
M[9WNH.UPJ%<:T/:WD7G<Q.W"P4\*WW:IJDT/&\[?!.GHI6I95\TR;Q'21H%Z
M_+GM=OV0W:ZW*3;9=8.U7<0K"0TX+;#J+84,+_-VC1]69#!&*Z ,4MOA_D%7
MNDPMR6AD>268_RMP.H28 *LY'4(J)(=?VR5\X,V*H=Z2,U+F?, @CUXIT]''
MKQW,:$!:K6W.)>,[Z2.A7>$'7F$\NN7(AS<$EX(4T@&^>1:6FN'<)%HK=JW>
MN%*R%C>>Q^TR/^@R:^?-U+U7U'%NZS_E9[+-+"WEO-I[SX(ZRZ)=V@=>VE56
M%#$NTG4>KU4'27TT\6.<+X7R /F2*HQ11H$[T/1V'0_FK)4THLZGV$";]._;
M[NG4KMZ#KA[EAY@]E)L>(5!((QNK[:)R;&&^HER<3=A174B[A ^YA&'&M)/&
MPM%![?4B1Y@ETFEKGD ,]8C_0N0*:"W]F:5'5M9 J_%2&!0J@2?N_8)AZOA?
MI1("W-BF+Q@UB"E]/&'@#QC2FV57ZL9FI[4(DVM1A 061AVHB#48%2&%6,E=
M#-++,B#*/RGMV3B<O(QCU?UZ3;<\G^A,UI3Y8".'*$:SW-Q;4,]3:A9+(&W&
M.8>V'U$]8[,-3PTT.;@3=K"@/ZZ!(A"?P*LMRM#?AKDAJHN*B,JE,LVHJ$=)
MM<C#]9Y%B:11E7$4S#=IL>P.K-X@I+F5#-E^.DON-S1<V\9.4CS.@BOKL6U-
M!7WD,6YJ04;I*R>N,5.IFL=K'3%U/2$=O=659? N0_<:U!(+45SH*;\A.PEK
MP'.+[?H*K"$.;0JM0<0XK.N6P[&,<=3]$M>D)DS!$NL9I=K0. GP@VM=SKW+
M+(LP9<1D*88NJR9?C4V)?E/8\ ;G985ERR)/7.#JHR8E]8N-&/]4#M%++?."
M0W6FT-1[*RVBPFV\M3F])4&BF6NM3ED@V^#X9+/:W:A"]0>2144>$:DE!'(3
MO%J'_J61CB.V,.>OX06@;U-$E(==FES[IX#8<#HS:O@K9>\YU_9DH!84]XG.
M$L7ZV/9C*VRCLSEE6ZA(M\2&09+A)+8PMR8L5248NY8)C3M4ZQY)A,#6E22U
MJBKZ+PXUX=:LU)Y/_/[DQ!_W>S=AJY\XQ:^V%R_W#P<-29E5+E%G<#RC]LH4
MW*ZH M$U?W3$L.I_5XE:*SO2KL5/OO=CWRFFPM.(QZ&;(>'!89*[M6K[0>U.
M36+0_"Z_0E&P=KE F)-0;C=\"S2(]TE KWZ#U<VPE[F1(!<BG967,(/>P/!H
MSCB-!?J&RDQ][RQ9!W(KG%PS+7IZ2'3U&U R@4J\\Z[W/BA!^[Q?=)]W$;J6
M4.>)U$,2_C!8!:&@&]0GL$8(ZQA<ZG$&8$7GJ=J +=R9._T;1'-N=-U#94)$
MOYCA.)GAP\QTWTH_H \02I[P/JB7$&BP?=-75[H4UT]\"Y%QC_RJ.547L::7
M^-@U(Z)]YI OZI+Y6HA9-R$'T1H.W<:>NSHK1X;HV^2@[:%KGU<H F7XA,S1
M=*]!A+V.&=5RI<Q^[J(<FZHL:7)'Z8^U8&Z;.EJ0D0M:+"&&4)C,^)(.[!W]
M3JLHEMUS1[P]M0=BAML8D]I"H=,0^1+67.BGJ,TIZ YN66M82&_L"W"GUH2_
MF;(8!PD3@0G#^@JD).>\LT.+YLL<57(+B'X1[V1-<1$6@)U2JX$'],DFYK)Q
M(RXU&*U848)(,GZ]>;JTF,.E)S96>$3"D >Q<RZY\Z)2!DC=/#02QDVLA+U.
MSZ'!3CA6)_<B,<V!!3QL'5)SO) ; A-4[]!R;1$,&H#$[R1<#ZQEO7\*!YLV
ML $NA2N/\5U2!(; Z<HLB^DEYC%]163!3OK=0D%N]QH"W8M:4^O @><Y84W'
M#+6<'5*V+GB%W").N#Z] 61AYD+Z]"2N5.KQRKR8:6GQR2X^N=_BDP]C+"T^
M^;CPR;1]=JE8TGQ+[#2;:V^FTA*05;!FWZC!O"(L1/G2I_8AFKEWY#5\(9Q.
M)GC2Q-9@((25P %68@8Q]^>V03MP-O#E>R([33EG+,O@$*C\^R%.[\U1!SK[
M,?:-)CQWD5(BEU3=KVM8:19V32K%&U/FB.!(.U):9<M9G!H;5V);S(N.M(Z&
M]*/K7;#[()U\-%)QOW?C@JJFY=0C(;]06(1E$$S;A=P'E':E\;A!MPVMJ^&$
MU_1AMIT2"8@8<37?&FN?G$IT%\3HU.!:<V>5*PJ8A[I*;VNOTVBDN)\0<VZ0
M@Z6RZSVOS*F\EC, ACQ&7J"'8^DJ;/=FI]/W=D4>D0V9&+L)E3-L3Y- U#87
M1RNYA;=9&HYWQR8.R&0#W+R:2=\JY8@N]2%;BD$S:=M!JK?]HW[P.1)DZ0\=
MJI<J9R9<L]8EEZ^T_W].!1W;W)E;?R?M^!K<M'16YI?>Q2)(\'SR_@V&\-1[
MEG4E9@/+*44BE_IYYBY?ZN%-<I2L= 6S&8L;F#&K7<J.MR;0'-7896Z(W,WK
M:LGL9C,*$'G+5CB/D2B<"ED];CFPU?.&IA+,\<@;G/B]P=@?3D?.$"JOM_7^
MM0FLQ2MK_#@-,3N7>8G.9/PPS8PC_)KFV\S?7>)-&O+$'YQ._?YX\-5'W)_8
M,".8));&IS]P!H5><4EM09B%@ +1!G7.H\%TPQJ9#; *)F29D%CN<.@/)U-_
M.N[?* 197ANO#]J VLT+W3W&'?6K6'L4$M"5>MPE6 D6[Z1'H%UKO^G[>_WN
MU$[ &W@;$D30YC2,1N,O.!53?XC345G:PYB*P=#9L!1\8$)?\^DU,E^J@UYW
M8!HZ4C>OJ9N=;C37&#&Y>".:B/^;>B]QXRG?>_WZ&5U./S52\^H#W3<=8#(\
MQ.&#<R51LQN5B^:+3)U]82;$9$5%:0W'KM;2.Y7+!66( 4]_565RT9<PI:&%
MTXF(*RO-]- LWQ/EEZ.M:*J9K.W C]QQPT?N(&+:&5"K\-!06D&5E!4T-'.Z
M^)OC+VZNFC];CT+.>![&=2T/NE=>V4,N8K<P@*TJ8_'[PJ&"@5"L*7#;%)D7
MF(+!;3ON,.V$.[I!3=6.ZA-82D(:V53CJ:NY#+F$$8=&0)J+!+$Y0+2U@HV4
M/%7??QG$J5NN*+D''H!+I.3<0@'YM7(Y271I(M4Z,6-)9;"V,NH0U_%F5O2F
M[[#J[9:<*[<< 8%/+X/_G[UW;V[D.++%OPIB[V]O2!M->F;\6'EU[T;0'(T]
MEK2:JY&LOQM @6Q/HQON!LB!/OVO\N2CLKH;("G+)FEA(]8:DD _ZI&5CY/G
M7'$)I&V2<M3DG#N%$S6>H[G4;5COV1#B,!-+%Q_X\JNW%V=4,.32@A&+[!&Y
ML5USJ6>;4WCLDS.7NHRKQDT\!9R[K.W@&4ZQKQ[-22?W)J3.<)-4YW'7)MU-
M34FBU$'(?^V"M@V#5GG-F0LR\Z%#7J?=4!B$/O"<*00Q$E^$J3_(AF-W>KM]
M:*<RWXO$MAV[&>XR:<<:[;Q-/4Z]%N4"6FT[[K1$@E_Y1Z(!+KDONE1^G3'7
M#64)1JN4?CO?52BNE$9=I"MU<[WOXSHB<KIXD9+/RO*V)/X^WF-77;EV@#,X
M8Y:?(+8X(,VV797ZL<]G?Q3%RWRPM"%?^_"Y#8KIWPLIB2MY ,OUNMOQ 2M-
MZ)L0NC/">@3JVOYK'(:&X!3QB327AYBAWT8[''Q_N"XE';3"#Y,W&;_2T<T7
MV='O,2L;G$TF5O>CY9Y>Q\&>&[IO"76!UYOQZ]GEF";/?F\$->W6:M?#WG_.
M ?$0)(-1TY=N E("MW$G7.\'CWH^>Y,2J@P8<A>2_GPVI ?F@1T8YMD?ZJX]
M:!9^PA0\.],WD#;.&I5MMX:[MKGF_[B^RT7=L%1:):OS#@7'!BQ3S2Y:20+Z
MCIFF_NO.D3W!M/^Q,.U&8U:SNA"_(^RC[$UK!^8U@7"F%L_#(IH/@6 "9/VW
MGDHD8PY##+#K@[):[6"_$VF+6K!E6 @CI.8SDUA='^IPZD=^_(5S>\U"!=[P
M)D@ (<@;H IOJJNV8^PD-9L3O1DR^A+DGSIM'G<:D< 1'L:,D0@$IJ?)>1)[
M[#H0.?FB[((AA'N+9V BQR>W?'!DU4]3^B2F%!'>('#92V C;M>!B:55D+G=
M/4$A3;;*:H)$.TSW*"EDBGX?'.MX8*,?B!G7E^Y<M3/WM$ >=8$,ZKR"ID6S
M2A__1CJ1Y:TUP5#)][IB<KL/*DZLQ6Q/E$O5J\ %6XKKJ"=*4GGQ+7;DE^\D
MY\YQH;'KPOFSK-#?=F6MT %PQQRQ)[](\-ZK$WCO:3S+";QW-WCO9,G_^98\
M6&9=$U#'*P6G5O9'GTCUV38=<Y:R.XYR28<8EW4KX$;)W[(,MR6?N^49!<9[
M4I@@%QYI,F0Q\X)$,ZP^&%GNU2[Z]/34W*,)V=F#CJ((X%&?K7,[]WI;:P_I
M0K6>[XAR</<TR[%W-E]=?O.7MZ_/7OX^#FQ<Q>LX!JEA7(E669:G_R#='M)T
MM]UKTX]H:2Y#O^BJN7;@"TBR+O>BVVW-D\!"82JRS+;V.-Q2$7%#,@%C78<'
M):PS8;B')JX+29JKO^B5@*9:IY*\)C?Y3W!&'LF%'UP3__U_YMVO_OOAWWL"
MI?U&1+/*#LC2(D=8O"\WUWOE_2W$M29G@J?A*C0MF+_*>M]7KGH\2)#7M*RT
MT,2LTKSNTFKK-Z*G3<C+1<FK'/<PX^-)J4F6IMKN$L/4O&HW-/7E(NRV&G8R
M+6 !@(>05J66K(4KM\3;B73[N#AX%!#OV\N><TOX>!TX;+96E+7RRE7"!ZR3
M;_[X]6!M$+ Y/ND-FL*K."KQE?QU86D>M HR.S)>#0Q-8Y:,C-N<UPC5].HE
M&34L@K1,68=6+ /+1TTO%;_DD8KHG,KPP64_WRVOPM;AN1V9*2]3"E*ICVTA
M( >I,<41W+=2ZC,=9RDGG$AK'[?F!(%M>#7.<S*7"=M)TY?D*9MJP"';=B(X
M?1H3NR;B(64,2KZ$PWD8A]"B!K;U-&%/92>R%392I]#<5%V+G7F:HT=G,M2F
MI*J1 Y&@[XO]HC[E!Y[ #$W&=YKE)EQ4O'4N7*:P!@C9/#M?.&N4JE(KPLO_
M9.SI*BQ![.$.][PSHVJV C%=[+;V\>B3CK1U]/B?@WYF+</V\K-_/Y_]<%W5
M@5&1"<+J(96$R.P=OQYYCWJ]>%\A]/*9 &I Z)8FJ\.$O9S \Z&97H1<W$,*
M;Y-!T3@.0J/QN&68KK BW;_= -Q)#%1*K6(LPY:B@($XZ$IGG7Y,ZN']:=,:
MYG0)H7ST3ZI_;,YXEUV,I7GX"*%U%-?W(KX3X" $Q 3#(,$ZI1VA]:^<7V@Q
MS%;<&6#^<CJN(:'SG33<]&S^+<Q2Y:&X\BEV))IP@F RT*H3$4P.F$A.I2?!
M+.-K$7PP,M-M%Q8D0*^Q;$I@'H[B_\E&" /QK!"9@ZG3(NMP\H01J;9^X3Y!
M)]$PH[W60-RMB=,EVN",^HW^ C:FN,NN8DSTHX*OT6FV!<H?+<=TQ;,8CH-V
M4])3\VF9S+&HF$CFN!R0K;@<7\P&;F1('.62?!"I$GX\Z906$D.0%BIL=)WQ
M(U+D/X[RSZ<[ENP:: T42Y0DBG(]<=6>\Y.C,0P;0?&^4B;7LA+H0:<V661K
M*@*DLQ':4F:%>4[M\]I[!=*[#?->NMM#*YVV] TY?)FB^_GLC]&[:%2<^FI[
M/9783G@N/&^2CA)SO:&M[GJV"N,[8M!XANMU'RSL>/(\]Y+R L=0_&"[C)OP
MC/\UFY=QA0VZYTHG8*J*I38RGI!CQ.'Y$W0%"U'KE=]*LIR [CSU65-\_ 4?
MFG3$WZ5$^!0MT0./%=JE=1L=6\IMVCDJV3IDZ8;Z=6O*T+CQS,R!L8>YLF9.
MMN[QZ,\+76_C92GN2D<*"Z:1YF.N]BYUI)1D*^/SRP9M6%^*'\Z&# "^'X<M
M)XF\PBRW[-9DKV$2;X.;ENS"R.=&?XF\>9E6\@<V5UVY##-1-(&I&SVX)V;S
M!+0H:+ (RB@V8O!;N58:0OD(&FC%6.=)8RFIH9@9388GO266SOBM?;LSF!,W
M.+7>K)E#Z=QDB4/X1M)$DHU*9OJ>X1*]G" YLJ936HC:9CT209 ?9%& K61
M1>.Q#,#S9PUH:6K5GJY:*P1D2YR+C'J7I 1([6D3-#+WNPQ;9J+0,\45VI2@
MA5F5-VVG_:[$DTI+:DM4)D56];HCY)@JF')5Y$'UTJ>Z='X(SA5EV*"OY(#.
M$P2.)F=/6Y>$4:@*T\4[H1+3Q6E;NLP'\KZ<<2PT,LR.A6Q#2FJ?/L_,A4(9
M2<ML&</T7E5FERVVN[8B'5S.H;DF \3L.\RWC'7A'Z_BOGO,)[DQJ/'OV7D9
MM'5R^_2"ZKLMP1-)^!%P#!-[<B7!7*!1U28KPU**PCU0O):U@"4C\"61"M&)
MHT#]0?6XIUY0VAZC[JK!J7UJMGKL9JN.=)PIOF-VV'UR=YFRB]=K8J&2GW&N
MRK$^^<%3COY1)S8:2E&KW76'$W"NEND<G'@T7\?+AVY$$GN"5F?0ZE^?H-5/
MXUE.T.H3M/J1[:V1=RM.<=,R<9*0+\&9:E/"\5A<C<3> 2_P=+ ^MM(F9B+X
MLW143^4,M .B"1^2J*M3AF2.Q* 0=Z(:F,#8V:6$S408[9&F!G.YNWI.T-)S
M:U5W<\*R/.Y2R1@N$C$/Z1Z-%DSE8COFA"Z$;2Y.[-I'8U*"3$URA@BO&'IO
MK7$WT8U:<T4@SZX)F5^\/BUD[:"CT#,^P F^\>@+9U2=HO Z?LKDF-&@,5Q#
MSS"MD\OO(7="U1?&$B]V'7>##,+-.P+4MK-K;"2W?%-Q@BU#O C?'!?<J$OF
MIF*)H8/1$DM@N196R?,0N0@8;1S40[(LY[,OJ"3&KY;9@X/GR)V9(O?H"Z1@
M4IX3ZAI@4FQ19VJ+1"Z497B@AR%YG&>W:@9$0I.#9]DTES^CLJ5+GDYFN%)5
M6@F[)"]O95EJ/\XFFIN@X_9[[15^05P]1, 4^7JRW-U4MC^CB&HS\G]PM4UB
MO(ZXD4(W#I2.U4\U&7@8U3(U2O\*]<4L4SO@HFIBR,Y<B(.4?EWNFF@8!@-=
M#,00->ENA/##@26UFJ<XA'>EX%?$_#<MKLHC,RS>:$(\6F8JP(1NN/[S5O_%
M=5D3<B"H9"9W$X:NH_:))7_(I;RSJPF<P%&(Z701!^78"Q*R46Q2FI#OKI/*
M%U186V! AB^Z:])BF7P.^BK?UY%KXI>+#P?JCUR#S9[N'D4?&(6'8,K^!9OA
MH(HBG,-2BLAJWU- @=6NX_)T: +3@&45<',OZ A1/4'T(-$$)7#B<]K -E9:
MH\]?4E%?WW[_C:NI]:[/BTZ!%B?JZF?J];NKNPN]POI@KU,K\7OK(S5*3T-"
M59WRR?2'RU-32\*E:[CQMJUOV)8Q#WXA&!)!HC))B<,(@-*S&*\A/5>M;CP!
M9BM<D_UA!Z!DA35Q=2@FC+952C;0+@3K+S.7^[9]()KU86ZO6^%DQ@*KRBX5
MXH>=O\G_\0XFB\  Q["M9'N(T90A$I2@!\OAQ/ ,BZ?H\@FQ0(AU*Q2K)LD%
M=8& H/-KU"U+PM3UQ"-/_+VTT0@3"*;QC4-9N9-.]W," IU25(].MF?H (H>
MV4.IFJT2&Y.-[]I;_)NIO)#!6AY?&,S5=\HD/87YA02R=83?/6UC&GY5#G">
MK^,93V[N\_.)?A#P,2,9T0Q4=4NT@E?2T]X39DV$XWCLEB0+7,UWEC P;TKY
M1)T"=Q>N%*M(DX&F=00;U"1.:-\D'PM2E,:T4U@YA1NSNHY 2I+^R7"%\VQ:
MR'ZS/8<L0^@KQI8E1I_LX944U3T0*$K\4XUN9ZOBR$-2YL4AVPCI)@(ADL7(
MD."YRQ)6<1EN>Y&%:?O 8CG[K$1RQPLIR\C1 &J\7)][./0#:WXDP0;5?HAS
M! OUXG-SM0DE2?H0^/W+SWF%DR,LB$KM;.#"DI#[&32L;3#-NUZ$)G:=HY#P
MP+P,]P6$^_.S$M] 4"8NLYWLP*E7A:>?"#$5HR^J7J FK)AB"?T6IJ0'>#;+
M1K/9Q7<\HX7.%'9$C-&TTU [)U;M0N:ADHX\@7S7U2IN_47%B7&[GOIE\8&S
MB(_O 1H,V9Z6:C"8;M4[!\^G8FC4V"H@AF--!9<K!RD&81:6O!S]FSK9D0J6
M,N[IH-'WIA,>4$<Z&T.0BN6@Z[@0I=EO@@(\L^:<XMGU9GRREX<2FJI:.^JJ
M.(\4^?8F5L0E7#6*6L=-?>J+.I#E9%PYZFPW9<T;"L.>03979N/L/EA'9(3U
M%EHUOM=&Q..GRX^77KNCF<>[NR6H!X TZS4MX]CQ&H?LOWNN_LB3<2=?8'VG
M-*QIT6F 8">%PT!K C%7$H+X+<H@/"F4PO4'4UJ=3=N<#66,$M.W]FK%P4B%
MDHPG*&GW\IVD9O+L+!BM_#>O+V9_)(E1K,U&#X37_OR,.^-M,_M+M>U:GW1Y
MI[/U53D/M>S:;]6>?!]G]QM2&HJ_?(M"27552L)#_R:G#)DPSM'&,?_5V[@(
M<44Z(/31XMY>;Z+EC&_7FV7$PV,!2C<? I=V6VHK-#I<JFZQ6_=;%OZ%+Z5M
M??'Z2CB7.JFX/B(9F[1@A=0ZQK9T@,H+ESU;WK=;RQ_&&VT-GQ$W3[UWQUW)
MWV1=K?@Y;0,0M1[&EO?)(DX:_-0YHN%U!7(\DW-<!KCMT3]?;[:BB\F#)97C
M?O;;ER\^^?!ILDK%[-W7%T5JTA&#)@=;-362T1!TK2)%8:KS%>-3[M3YN6!I
M!9FY$V340T9_<X*,/HUG.4%&[X:,/KECS(&>.K&=[& 0T;B:('8N5:J._FJ*
M \X!B3863D\_M'9>DUNE6>,U8APYAPR\AJF+NJS67-FKF@^<*XA^)GJP$VV'
M67LSR/%<B<^T5JTP>[8!7- #O+KT92(AZ]7N4A85W]6\0_:R\>AS>N('[M-"
M(+5:5%O3.C,'".>)?<^$_9B?L:Y3V[L5NE6@*XY[@%0W5S?ME-OU>F#&3Z[J
M2MO/R1O5\Q(NGQWY@1$/RT">(4(,361EWCL^EQVFXG+:XU?>,2E\N-%-:0Y(
M]J%$TV8GU=9J38[T,EVT]5*,NB+P+.MR.5U7*]3?SRN]^>"MJW[>E7@7"B*6
MNWHKFHE)ROF-D-2\:=ME,7O=[:[8A[UL^W6@Q[E8;+.QM#'L#PPBLQ= N VK
M_/CNL6B">;J$JR Z%_3(8Z\CR7MZ7H,%PKRTJ7(JSUZ99:DXL: EEPF$\?I,
M=31R#;/J'/J"XQ48?DM*=_VNYQXU0>>H++-!,VT79$^R:[95[<*][)7+71R'
M3KZ*CE&$;RI/[_7ND"!#VW*#5"N[H=)<R 0X-%6^7^ZV[)"(IR4=GV)+SF@=
MHE7BMKJ_[IJ%;.5%=1,?<AV]6)!QQ?<L 46*?^FJ..\E\ H]I7*-@$.&54<G
M5#]*<LYS^!I'9R8/R9DUT=.+7OCS"XK>KHJ13%Q@^H; /<4>LCN9,3BP-PH?
M+V?KG13 ]TEQV7OJT<Q(BD!B' 2@\9HJF"UT(IG+CJ=X^Y?7/%&RYL3$1Y_E
M'-+9]1XK:>JFM%]E]H=[-K^/7)J+O17UOE/=Z(PS8:A LP('KW:F[LG6"]\D
M!O'6*:$<45RKE[2OTQ)-Y!H$W$,FY;"%&=&[9M!+V;?E$?N$_(?.E1*B^:UM
M,I3S8%DK1&H=GVM.T15)6%L]E'V6I#S3=]- X".=<$\*[L 5508*6.FE')5,
M(=;:F9C[K*E?@23L'LLJ,X$_A0?K82S>3]%^/#S_CHRLIMT=X8,A-E/-#9CN
M;)0%9S*1\CK22Y!?X&ZJZY3(&\,2G^(<W*N -S'B=P\W\W98L<1X!3)N[$.Y
M>*^!O:RHBSJN]U![]0R3%W3$5_V,&W.1K?T?DJ6=7<3)C&8 7_EB1YDG 33Q
M#4J:[WG<2MXU:6\;+XLG7TCU,<O1$'*R:CP&:5W^M54/*>E97A"709S1,GH&
ME]?Q;L7LSR5-*%WY??3SKF=?MM%/?GY+Y+M$%Y4QH!_B :_C>P0I@XR08@$[
MA=MP7!UE1$E13&**!2ZEJ68W@0.$&9 W3%FX&CBT<DX:-0F<35>+=3.=%ZI]
M>79 )?.'Z ;"I?^[[=<0:ZGD?<S!7@B8?M655$U;" 8]^4>Z8[@*P[SM2G/F
M208S6%M%#CJ\@V; P,%ZX"3Z;4U1F *=Q'P&_O5,Y\./+Z2Q031"%&9U2!C-
M+/>B[@')79,#([(2ZY*%WSQ#W3VOM+BN-EZ% #,I53ZCS//?C*;K&CX)NGW:
M#A,NR94XK]NJ9_:1"H73H?8T"<6-J)TT$F_"5>E:[9[)9-]U3J:#[IZ3S""
MK,M0!DZR/Z,*FRN2G\_>AZ UIC_(KH)?^O+S+\-^=G'5!39&"D 0&,%%0^*"
MLV\#&8(!/=_MO1?HO9Y]O.;>5TA9*7=C:8084^M/C QY8ZS_OG9KZV\["G2
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M G%Q"B'4'5+*0J7'R5/!NFR.;L1B:A?>W13Q2SIBR0((\G40$<4):);]HMQ
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MY9W*%!!]SWEK5CZ"'(X@G3*"7Q&VS%R'-&[9>H%N>-!-36-.=6HR&9Q9*U2
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M04F66)N75 ^]X+3NJQ<O7Z -0ID?Q6_\$W/#7:I T!=Q3;#?^"W)4BVJFI6
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MEM#WYRT#!1#(B8O38*L-9C=15_M*_M L>4_7!:*<1H[^%M ^O37T"F]4>E"
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M'J-@A#D0QSPMM:9MSC(N@^/TWUFFD^S6Z61[["4J:TW;P@9K54X>GF*ES:#
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MZP+N.D9[RW717_O%@ J!IPE95,TPXGK<>X#8'EDP!2V6M9[69]5 .Q81$EL
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MIA!<=6N5 ZM :*9*/1'D[E5QG^1!)(#(HH4DV1R;5E_1P2FGB_&#[&+)M48
M,_M,+PZKA,<+2335'F")\OCH&N=DY5OJ@VA-%":9.L'08).DI&3RB3Z7"&4L
M@-:ED:3*JPH'42657*?DSK 98!\RPYD2FU')BUR #ZY"SB )1PL!J=Z,Y)F/
M=:/<7;D5X=10%((IX3@5&2?R:,[E$(0<,Q(ILW@^.)!KJ$;VX\\G30KI0$AM
MFE@*ZFA2,*0&=8*W(,41("6KVEHWJRXH/:\6C"3XE,,<^ZTBK"7$V 0+12(G
M]=]J!HK2FP A4;%)T]"6#\P_R2N\I<0OE9,SS)LC'L3X._@W8-E,N3(]\9#I
M9+/PQAZN;DW3CM<? 4G7M0M'R<H 8_2&%3%9*2X/"\@J=/OB^D4S"BYKK'/U
M"9_&Q:+VQK+PEKKPEA!G0N5!9Q++%J/\+'J!28D):6Q]9]2&.;[!W*P"H:FS
M6"]L'6XJ,99>,J=4K(5N!-SS>H_KUXR$ :XDV+AY9G;W(8_$#D;/VAH%'V[9
M  -O.;*OAHJMPHF_FZ$U_P3 47>^!*RUV7)L- [2@N!UL!_Y]O]]'7)4<W'E
M#Q,4PA$'M/7F_\WJ)9-N"NH0L,-^3Q?WHCBZ2#R[5O;<(HY=21A2^A;[S7MO
MY23>!518ERGO?K454 <:C_XCAI#]XP:%/!K'@V2AGHQ]!Y\@$B4.&:*Z*+(J
ML$524>X5* %JADA2EE% :J@% R0#W6Z_X#I<[^1T)W\4_,:H2F2!22<N$=UW
M 6Q4@E?*G$A"6GVIR &SHABZ*&KQQ7(1)$;05W<.F*/=<-UV6$$UOP,@D\?E
M)?P>#+#C2*;BKCER5+LFCPNLQA?)/#ZAV#B'5UC%[SR9;7NBN?1"+QOX0G>!
MR[OP[^&RZ$+.BQ@1UXRY@3.U3&\IN0=-]PBGI>0&VT>4.L/=Q[H<O?.Q1,(O
MH>>AO$G2:35P7\=\S)J5$=E$C]D8.2NPXBX.>3':-J">(0K)<W;$'.#Q2UU5
M#T=/*X3:&13L-.;HF JP"NU(!*2B'?8U,%8T:'(6VPU(NAAP#&AR.T+7VXXG
M,GVJDZJK/&6C&M:K0S3T$=JJRXP! TLFB\5)FA<YDFB!?>+=V[L\K.(C%X8Z
MXADL\)URZQQT!Q2LJ OW"OV#!+6*>S>:[;CD\K]K%S%FDII\_9195QQ'J1YY
M1]&$^ KKLA&,PS):Z>08I5' B0&VWG2!F0_W5L1&1L>9ALYY&N=B[<S,M #2
MGK QT]5&%<KP /BNH@6M>@98;'-6V- RDV'?-%5"L.8V O$,65=)K 5\611
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M*E6Z-X\:;#7&O)6K7L,2V+V&M"?H;K]A3>S7:U%5)@"F&Y^RZ@KJPHI1KDL
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M![9IWT7,"R0;O6FA<<-S1:3<).Z<IU6%VW81K6QFOOW[T!Z;:I]+JLV?(MQ
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M)G)5-5W!QZQYU-@$P0A634!8K)5S,)%OEOX_VYX8!9CH-/_1XD'W7I8/!/-
M)7@W\N-.R*\A.&1!"<*# M+@07?]8/.'O#!NNO'PWUU=BO@\Y(UM&@+BUAP*
MAW1)$ZG=I).TKJSJ#2\;-]VBTL@/"(= RUTR#VQO?.1FTD(ES)OFL*LR_W"B
MT]%2$H%*7>1QIYB5"XX ,FC,7!..6_(J 04"0[7W:\\+F0-.R-Q3Y>8T*A86
MD!GS[ BM+PRP>7FNPA<0G&)&PK<0#_^]._;D%$3F%UF*K=_._$Z2W 138"D
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M$>V&MY>79I0I<L]B5H/Q35-CSN"7046I$/.LO(S/3L?GP9O2F+-E47X9!5>
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M58-DL<0K449-?)#CLU.GF,TB%;L-#ZYX3C*MQ.4D1(W*A K[I&VPA2H9YUZ
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M7=/_!Y/I?[0^T_]@4L0K\_]NZGGVE_\/4$L#!!0    ( /6 K5+3LW@P8PX
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M@%\P#? #MMDH%%H"C!7,^NQT9JH5D@4@(B%&0LI>^[]TALH4H4]2[5:Z4ZS
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MJ256T_ZX)J@OAPM[C#WTZ</_ 5!+ P04    " #U@*U2HH,3Q9 6  #IY0
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MKQ@&SV!RW&% ?BD> GGQ.8S/RQ'QW_L^?NK&XY$5AFF!$3GDA &ZUYI8(Z#
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MEE1?'8@- IGJ6 )OE8@T-J+#:D2'%#_59T0%*]P@Q=\>WU34:_RYZ86-MU!
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M]"GW'NOP?TW\Q=K@%_.S3[2#?5C6IGU=%E"OU6181XW2A607;8&J+5ZL85X
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M9[)E6B?+ #(P8;W1W)D0;9-"<O=@.M1I4/^:T)>@'\OIT,WE;Q'/)-N,!%"
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M\";)I$^A\70/&K"_T!NTMKL56'C^Y3F.T]DY3/]8&" \V60L<.8<%*8+[36
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MTBILN 6HO@^S[T1S^,/LGMB:M!)USR?:=X-+3F?O#3)3:EMTX4G=G0C,<FV
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MT#?-\NEA#B>H=H=FML&=B@Y3$0-N0^8%# / *K,2&)1B6$0G4BY68)N[C5U
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M40Q*=HQVW Q>>"\.YFM_!=7@!.:JR^EU,FY2\&P3!2]@5MO U#7O$XQJFM%
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M"(9; <5^+[/46EFZ<-#X+% &QU7DEF&J;6A\J&7*B;U"+-(6J[-=#]L\W;/
M+E*_YRRPB\B.>Q;X9CKY93(]AU?C4O]3_['O(\![AFAX\K?MQ-8._)P3SL:
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MQYN?VA0O)/0J$>TO"1S!K7TV7X[&P/-X!PCO]U*^GNX*G%;\TKL"1UH>[:[
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M>I74PR?T/94L^-3C[@?V7^2]V1;^)$W1O:>'E--Y%9R,((\$5Q)P&B& 0BX
MED2!)$*0(:ZPP-3VW/YD+U-C@Z:$CE'>[6BVLT!O& W, 6[P.)WIGU7_TJ/]
MTQV,=L)_5L?F0?_YASOF!C17Y4S+9GMRH_^:S[ O I8$,?!QY)N<S3$@&%&
M(G,0DT"68*?\5H==3&V>;R3T?C<R>H60C@O^$2#MUOK+X!EXBCLBXYZ\[J3R
MO6:O.^QEW/1U)[4\R%]W^LF.\YL_2+&>RUMUO5BE(IVO5^FS;!:^,2<=4I0G
M(8]/Z](G?*O>T\SDR,SK"[1?Y??5&ZW4'S,5^91'O@(8APH@'@6 Q@$$*E8R
M83Y-I'#:&O0OXN3XI=*P**R[7.GA3>E\_N*]JW1MUI5:+$VP:ZFQERZ\MW3.
MU_-R/VZ*R9I7]&],'@U3R'1[(]V[7JVRE&ET3(F3U=)KWF9_6,[U-^.8WF2
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M%8$J-XO%\MGD'O@JL\?PXY+6P4E1X"O)?0Y"&B8 83\!.(@IB' H94(DTEM
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M@'-( <(!!2P06&^Z>!3X,$A("%WK:(XT3*]2''[\$7(Z61H.\[$.GRHA346
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M$8!R3$   QF(0&(!K<J36_<X-?NL%KC,FY%7$X^7B5"*<%K7F-ESD-LQ5Z]
M#DQ7NQC6TAH<FPEE^HRDM<2FWX#:<YV.'%=KB<%A>*WMBYVJ5CP^:C- ,]<'
M*7^FW]/']>,V\^RM^BE;YGDMP2P,L, 0"A"99+%((@8HI#$0"DG)A."AW<T<
M]ZZGQD);X3TE7?R!;H!;^ 0'@W%@#FH@J 6_\BK1&ZFHO5OE%=)[M?B#X>Q4
MCF,@O$<KV-$C[J[U/3I =Z8"B$N+8]8(Z:#I7A61+BVX']]>ZT].F,_NPYS>
MSQ@3IG 1!((@!!!%$- D#(&4IJ:O'U.?6OD"#UJ>&G]OA/.,=/9GM;MPG3^E
M[0S"P.QKJ;_3P>Q172\XDMUM;[3#V*-J-(]ACS_0ZP%LE=F+!:%"2D& 8S\
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M'\0!EC0$8<)]@)BV@7&$?$"3Q%R>H G$5H;PF7ZFME!MQ?0*.3TC:*?<F:>
MM5PS+H=K:&[O@E2'XMJM./1;1_MX5R.7S&[5][ Z=OOC'8_Q%ZM4I/.UN9I:
MV?&IS-]_Y_.UD*(\-GA\6J^J:Q?O:;9(%_>Y)JR2V%Z.-U!\_H$/?5^&(8@4
MC@#"4@(<" 84\SFDG!)E5WAD!%FGQDU-2;VMJ(ZQ!P..K1VU363$!J;'$X/5
M.T&.@&:O(1D#BCMNG,?PN!\$CXS092^'O3,A$QDDIM9X##E  B) E?X8E(!$
M0I%$)([K\/%.1[U6$WTWW'OD@][B!LQ%I[W=3GHG1('[I[R#G>^.<+;[JN>Z
MEF>ZEYSGFJ)SIN1<7AVX!8%",!0<0*040"C&@$#$ 5?4#TB44(9CIU*6C<:G
M9E<5)0H+^1S+-C8!LSB[O0"&H8\^-@ATK6#9A,*Q@&5'2,:L7VD)C7OQRB.Z
MGZU=V7QGW-*51Z0]J%QY[)EN1L4[^91)GI:)+*4)63=NM(5HWOF?A5@*B6)M
M:; H!H@* IC"%"2!9JF8A;Z(G=*MV70Z-?YJREPF6FLFK>@4>&:%O9U]TC>B
M U-A4UP3EE8)7&9<:XC<GS'C E"?%HY5OZ.:/2Y([-M"3N]V,)"^T+F\5<6U
MWNOUZF&9I?^2IO'U8O5U^4:6EVYF<1#(D,H$!(AK.A)8  I]!GQ$!!228C^V
MKP!NU>74R&@KJ:&A=5DYLGG7-2W$=C O[)"WL+]ZQW-H#[N6M[@=6&94:"!;
M"NU]77IO9'6UL'= ':RXWH$=R;;K!V WJ\\)JU9;T*ZE\2Q$)\UV[$:W-R\K
M:OIV^<C21?%A?99\>;\P?=T(_;&E*J6;U%'75;8TO8)\U#].YZ6K3$OR*(5)
M/*Q_8:Y=/FO1%V6NN5@R59QCF-#G( '8+RQ2/Q8<ASZ,<9=*J,.(.[5%HTC@
M;2PL;OXBMX)VJZ<ZT!C;V;O3&;F!EZ?-Q?>&IE?>5E>OJ6R5&\NKU2U&NZ&P
M5VE\Y6V^A?<6GT'GFJ_#CLX0A6('DOA5JLL.B_ZIDK0#]]IA4_'_K&6^>I?2
M^\4R3U=\XT"+_#@*& 90+_@ (1D!)AC7FPK*,=(KB<!6*09;^IC:"E!(Z37$
M=+!G3Z!HL2.X')N!.?8 EB[^V5-?F;V!?SE.(UGT]I^1F]7>#D"KF7[BU?'L
M\G;9=PSQ,X^Z,5R>K69WV5*L^>HV^R*SYY27$7 H1C0,*0(D(-I"]L,(8 4U
MO46"**%HHH@5O9WJ8&K<5LE8&#65F$X1A2>!;&>X/N 9F-XZ(&,];\^IWV*C
MZ5<;]IG^U[YM=K+M46;U.<WJ*7WVN6X[Z891-,,!Q$20P,1XF.MR>L=+21@
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M.,.:U/N=OK)9?0*#\Z;UJ1<[F-<?TX74AM^BSG''F)!1* #GYLZ^CSE@@B)
M@S")HTC32>!;6\N[;4^--FKI',RG/; L;-;N$ Q, ;5@72Y/[L'@8!1VAV,D
M&^_L1^%FG1W7M]78VGME/-OIN*P[IM")1[KFLF.KFT6^RHIQ+1.APS"AD28>
MWX<"("$"@!&,@+9PI$R8@)@IM\QU^UU,C82,A-Y6Q$Y5%8X :6>R7 ;/P 3E
MB$R'%'.GE.\WH=Q!+R.GCSNEY6&RN)-/=DD-9Q(7E1<BWJVS='%?5FXI@DWK
MS5*]AQ(S&"&()(V ]&,($(,48!(D>@O#DS#TDP@)JTQ![EU/C0\*N:O<<&J9
M>=\J5T-UYFY[P[+#&%@8,X,A._0Q=0%G==.JE'Q3,*L0_FKKKMG(/QC0+DGD
MA@)\K&1RO0+OF%2N"W;MR>6<6APQR5P737>3S75JH6,A'2%2\]71^1U-Q<WB
M+7U*5W1>[248443Z$0$R]"E )"  QR(!/F:^@HQ+%%CE6+?J;6KDOQ76,]*"
M=.%5\CK6LVF%V,XV[ VX@;G]-&8]YB9W J77TC"M'8Y;W,5&]X/R+%8O=0Q#
MY0]2K$V6S#J969&E+"\ZS-^\-/[U57Y?O='*_#'#"4H8C02 5)AKKB0$#$<Q
M"(F/88!E'-B=!E\BQ-1HI];!9"7>)#!L".X8V=EE6.PX:6BPAS9#S^"<7YE8
MR<8/O-^_%D&V1AFOT*;/*H(7@-EKZ&$7.<8-$KP J8-PODO:ZBMZQC+BKZBK
M*D5==?7PE',6J5 0E4"@0J:MM<2/@:95"L(X\CEG"87"JM+$\*).C7,K@2\-
MW>AM)"UV_Y,9GX%INB7,XS!>ZG3HN5?I[-W4U;F/AX5,YA.X-+;G-3Z%UX_\
M&?63Z"$TJ.]1<@\<ZDV"5PXKZAO)\T%'O??89RGD3WK^5,F[*.<)#F,)8B6J
M#(@$BQ $(B"((QE"XG0K[UR'4UO<3]2YO?*,R'V4)FY@;>G-Z1'!H1TZ;> -
MD!7-%IKA*_XV^IQ V=Y#!.QJ[QYYKV-\0)K3^_O,W+XI:O=6B1M,#,+-2C[F
MLYA)X5,1@2#4**,($H #K( @,H$Q0KZB3K[B<QU.C69VY35>A3IQR>]&9J\0
MVC66X!SHEI$%/4(Y=)S!92BZQQU80M-K%,*Y/L>-2;!$X"!"P?:]CHE<2I.K
M. O;?N\REC*& @)&4 @0)#%@F$,0) E6!%&I?^R4L.58+U-CEG*_LZRJ@%U
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M&P^#?Y_LW;.$H[+],.CNKPX#]7+1:O)!8W$LY_9F!RP2%$B3G2+R@Q@@P7U
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M&!4M:Q^5Z=I MF.0GJ ;W#CKB%J7%+/G\.@YN>S)[L9.*WM.[R,)9<^^TOE
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MMA^#@'Y$8@2!%*'^&$00ZBTHUN9IJ&3 <(Q4D%0?P_N%^)-_"K4&PWT([\O
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M?J4'/65S679Y709%BNO\CF:K6W7DJ'V[8)'$QP(;KPL5T%S+8X P/P:1)*'
MYC0\0DZY2?J6<&ID4RMHPD^W>E4G*UZMF>8BS^AFGCH6C.)XG;SW8;?CMU<=
MS(&YL3F.I7:@4.^"0?5^_UKDB;2Q*=TOA \U%KU>_>Y=R'$O>0^%\<%U[L$Z
M&CF%S0>:9L5&_MH$Y=<7*LKD?>_2YU3(A?BL=_TS%<;4CR4%RO>-84H#0(2$
M "8T9)R2F"@^2L):6XFGMNYL\H:*2DCO)97STX'UKS3.E@O+E$9OZ(7F\EPD
M1NO*+]K0^VJ;2[96W3.Z3R )B>LP32+]B+70?X[$(ZYCT%O*$>>..WAZWTFV
MNEGH/57A_JIZ_RJSQ[RXPQX',4$)DH K0@'"* 8$)PG 4H:"$2HALZH79-'7
MU-8)(ZVW%?=JPR6%Q$[9 FR0MO +]X??P$P],G0.ON+^(!S)8WP9E&[>9#MP
M6GW*9YH8S[-LI\N.?]GRE:XY%:I@PN+&M-Z'W&9%*+8H"/Y.9L42,$.^'\>0
M(Y $L6_BH@- (40@0HR&)&(:;^EBW=MU.S7JW4A=IWIZHIGW7)AM)L636,[G
M-,L[)Q6T' L["[Q_A <FYRVX51HH+;/^E,O+&:*RCK7<I1W=9\X%%Z#Z3;Q@
MU?/(V1=<T#A,P>#TMAMEY=EJ]ED^Z>_M05NDFU+9;Y=K4_%'3\75RR?]?;U;
M/M)T,5,)%X22"$ 5"8!"B0#C00(X4X@3%L$@L?)'./4Z-<)J2ND9,;W?2T$M
MK1PWR-N):3 @!^:E#AA:<U G3%HH2+?7H!_]KWWJ<>MP%.;IA$%-/-U>=N>=
MZSRE=Y2G*N55X'Z,51@%"0.LX!<6,T#BA *L%(4,<\RXL.67@]:GQB-&0*^2
MT)XY#D$[SQ 703'X:?L6A1XO-K2J?>ED/VQXM$E]4J?FY#W]4,?]3+D]RK\N
MJ].5NVRI[?'5RYT>RI6I/*1_6A0$F6&*] 1&!$2$<( BC@$V^6L#ZB<^XHS@
M.*KO>GYUV-I82V#U:>]>\OPZQBZG8M/<'(,^5<*7M?)JR1WW-?9C8KFWZ1?B
MD?8WE="F+EPEME?+K3<[1O*KLH#<693=]SC.@/6ZS['O?=R]CC,J!_L=]Q;<
M:$W(=/8V7;U<9Y*^70HY\V-A*@U% &.L20M&V@ )"08,1WX8*\P3"6W,COV&
MIV9Q&-D\(YQGI+/CFP.PVMGD$@B&WG/8:6_- Z=4W<[RO)[FN>1_NU\^_ZA?
M*6>X_LO^Q#YH;I1I>TJ)>E*>_'VOQT]WQ46SK]^6E4F;<)G04&,30,H \ED"
M:)0@H&>IXI) ZOMQ#R=1>]U.;;J6XGE:OEZ.3_9!ON@0Z@+H7O4\ZLK;HMHE
M?9@]O+T<5%T \R3.K-S@[NL$ZP1J'0^S]EN;PKG6"0TMC[A.O>UN1KVK/K*[
M^J;P.Q/.!%%"$XQ\H#^>&*"8) "S) 8RD+Z,%%0R\6WMJ:,]3(VI:R'KK_V]
MJ5_:%E1D">1Y6^MB>(9F8U=DG,RO5NTOL,..MSN:0=:J5M,R:W^PF[/GXW)Q
M;UC"T,<V]!W)6(DH2("0, $HX<(DVL9 ,(29_K^,8J<K4D=[F=RTUL*Y>66.
M@V?G@+D8DH&GLI$/:-@?O6+-_WV0@/U6$/KTGQSO:%172:NN^UZ1]H>[%F]_
MEHNU_"S-04ZZN-<THI;9HTG"<<OFZ7UA.FZJRJ>/^I%;]47_-%>4F]]]3!?R
M9B4?\YF((8$$*Q 2)@#BA?<DEB#"/H6!$ER%5CNV_D6;&JE4FEUY&]V\AG+>
M5KM&I'*IH'$=-U7T?C=*>H66CCE(>QQY.W)[G?$<F!'''LH.9>[[1KU/"NY1
MNE%YNW]4]\E^@!XZ^.M^E?E*MVR"C=9E\"U)*.7"9 3QD0*(2 6(X P(DD 1
M^8FBV"I=X?'FI\;4E8!>*:%[)/,A?A8NMXM0&9CO^@?$P4EV$3 C.<-V >K)
MSW52\59_UN%;X_FM3DJ\XY\Z_=2 UJS^H2FD1^_E+ B9PC*4P.1)! @+"2@.
MM=VJ)$5"*NX'5L%&'?N?&MLU+9=EPW)YVD@\@(G9&(X>[<AN($_'6+P[#_DP
MIN A<*/;>PT1IF?4'>+3R7([TDPWRGN7YK1*$:>;O555[T5"A:W[*8DBO36G
M5!,=E,9W!P&)?*39S@\%#7S.@\B%Z*QZG1J]-3-75 +K/_GR?I&ZIQ:QP]V.
MT7I'<VB/_HZ\33B'3.3AA%*?I&77\:A4Y83%/D&YO=P_+<UBYL<T#!2 BN@]
M)&0)P%&, )%8)#2)6"B=S*ZVSJ9&0N?FCJ,7KQ7GR]GG3T0Z(S'-V 0S'5[I
M0B>7^)YNE9*9MI_>+O/5IN;EI^7J_Y6K.YJ*&8&^@@$S]<<8!8AS!@@DQ05:
M2:GB*J'VGJ@SG4V-16IQ/6[D-;5K*.?F<D[N/=$7@[R#3^8<T!8NJQ[A&YA&
M-L@5HF[J[%YY6EI/B^L9>7L$S\&]U2.((SF[+@/3S0=FB4ZK1^Q<&^/YQRRU
MV?&6V;[3/>AC59\NZR:JRZ>,^Q(J 0$.4 "0##3!LHB F"(A) E$$#B5>CS>
MS=3X=3?0X<HSDKJ'@1R!T\XDNQRD@5GT&#X]WM^UPZ'O6) C/8T>#'):VV/1
M("U/]YG/<.:K.$0\9  *%0,410$@B&NC"X;$)S@D06P5S=G>S=1(H$BV4"66
MXPTY^T@=>%&^OPD1P='D>]M49\826'":/]0U%8?.L3<$-YSH:0+9[$YQPYFG
M.]R56YK"9W9)W@^>G]#G6LC5:SKWD]I><@=LI[WQ+H$=4V/G%MC1!SIL[3NG
M2#3W/E<OVRL->5&A\^L#793%^/+MN<JM*IK(JS/FV\6'-,O-W=$O4F,AKA>+
M5&N3T^QEQA@-*2<2P$C_!T4B 3B1"$#,N4*,1E):9>&:H&Y36U.W.A@/7I'-
M*_>>JYB)Y<+3*GO**%-<V<X+=?1?-_HX[,RG-1 V7I1I23PAVNXA%7 )4>.:
M6EZ5=EYIE*JJJGGSW+V(SRR_SU^WW^>'S;=9XN5=_^_P;3HXJ:8E^01]8G_R
M;]7-*3?-KZ'5!S@QD<=S.4Y,\6,>SHF*>/DMNID?^1C%?@+\, H X@D#.)82
M!''@*XIIZ =JMEJNZ-S>C5HW[F3C;;H8C@&_FCX\3K/LQ3!1F<A5,Y2XZ"Y=
MARMT$[)@=AVFPUR6&\HONFG_U:[&M?E #Y[I-EO?KO/5\E%FG^6\()W\(7W*
MJSP.6)&$,L0!EB9ZC@02$)40@/PP"".]7Y2)4[Q*2U]3VZ_5HGI94U:W6=P&
MK=VD[@FPH9U+-58[8O:8\\(!CCXYH*V[42G!0N]]AK!YI2-A&)D7JZQH]G.:
M__'FY8U<\(='FOU17&SQ(1.4^E03AN\#E& "<*A"S1H\"B)&?2*<#DW.=3@Y
MZFC*ZQF!O8V\3A>'K!&W)),><1S<7=T=0G=6L<2E5VHYU^>X_&*)P ')V+[7
ME6GRU:WZ:;D4>;%-R9Y3+O,OR[F8X1#[0<)]$"9!!%" 0\"4("!4$&*?HT P
MISOWI[N:&KM4FPPMK]E:9&7,H2N?G,35EDGZ0&MP#BDA*L2LO$&EH)Z1M$_^
M.(=&O\QQLK>1.>.<UH=L<?:-#D=JOU'C)5F]_RXSGN;RTW+QEN8/LSCR(XH@
M!HS[B38]M"6"(Q0 *1#R8Q+0)%+61UO'^Y@:,U12>K(2TWM:9_G:_&2U]$PL
MPMR4GZU_Z^"T/P&QQ<'.Y< -3!(U9K6$1=P&,&!=CH_#X<+E.(WDY.^ EYMC
MO1V)5@?WB5?'<S2WR[[C\#WS:'=[R5!K%7*4SZ02'#%. 1,^UMLQ&@*L)#+U
M#2E## <1@2[.U_T.INF -1FS:7$6)"LYW<VC'1CMC:*NX(Q@"I4FT/MSB'2R
M?HZIW;?-L]/'Z);.,0V/V3='G^M:26_)I13Y!RW036X6<BYOLR_4% $OCWUF
MH8H8PIR#@$N3O)T00,+ _#,) R3\A 1.GI;S74[-YODI6VJ;YJF2V[4\WEF
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M*6"E/03G7 !*H 9E5BA:9HR8'[P:._?+FQI%V$0CFQJ]Z^/IV?KY#+QNSE%
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MD<AR17F),J= $W_14WOKWWRW?DEE.U:O.I6WV?G+%WF2_WYI1_"3P^%&&W%
MCLPI)[J#;S5/6M63;YWR86MT>B(6MUGX2>E7;AE^#I7SC<///F$8I7U=,ZD^
MVJ]7&YN9YJ7F&$$@TSP'2*:V%#\D  E;F8^D4/EY)*\%3(V>:OT2>X4?^1P
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M6Z_A*J-S4/WA.EI<5BO=>'%\OJR=N+?;)@6[<I:,BU(PG(%,"0[LWA(@:4H
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M_M?=N1M/1YE'%X5+D!/NO$(H!I9H ]0E*6*0@1E1 SOW21D&-#WKN.M5X"U
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MU"LFF),Q$&F1?JX '7H/CHL SO%H'&,A;<N%[0LX=Z@9%C^GJ'<K4DZ1=0.
M>>7FWUY,8_GGS7]>C'^X"3(S?[%XY6:SR_'T[#_<Y"*-O PJ<BM!!N]!>&_1
M?=,&0F#4YBBMDU4LSU[4M0"HDU!PMY%;[RII &<O0BCUM///*21DR4_2A[38
M)&9XPJ350J.!Q@4H-$%[S50"ERT)D2CG7!W[] !1P[9^ZQ]5O2F@ 3"]F_Y
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M,@3.G312TE0G2WDK-8U YW1]W_7]3Q9] Z;H1K^7=>TBX30$GS#VC32"$-R
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MW%H+PE"!GB!#@;BHDXE91%OE(NYP4AM)5CD52UM<K)HZ:\ /N^U$!FN"=32
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MJ.&Q2A;E_B0VF?'6&UCN76E7T=RIX<_7VIOX%GF.HDDV2AN!^URJ+;@&:YT
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M[87UC-_1;#^QA71*TR2H $ERZ>B6/'@J$TC),S,IFJ!K%6$.;2%'B?,@'#7
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MC>4,D?I(: :N3,D?Q@C".8I!*W,IEC*&Q/9K&W3CH<,IOY*^NAZ$UX ?L[Q
MNJJ\M9&;1'#K3=Y:$#0G,(X$\#+@UHDK@M@J9SFWJ!CVGJ]6<'6\H!M R8[[
M]Y*"=;9<4?.7E]OO)J_9GL9/$S>]L=R$S+BF: 2>RCTDM;A2E#>02.!$)Q&,
MKY.V5(&987WL$[!U-U ;6M$-@/USFB]FX[!(JZO5OT_'B_GG+W_?##7WV3N:
M-6@C*-IW7N8&)@94")T],V5<<@W4/DC5P"'>X*#I:FEP8(__ZWA1=J)WTSC^
M,8X7;K)<X%HYYG$? I8C+G!31E=2HB +C&F#CEJE?0SG7M[]5@J&[6Q<(S0\
M7="M(>4?X\6WY2UYR0#Z-O[^M7LS78P7EYL!/48IGI)'_*.'*ZPJU8+"  _1
M*N^U=[P>AAZF;;A0H0<4/(2I'E4R=+CX^<UL_/O_UTW.\:>;<4S292>RA4!I
MZ=K##7@F#9 8D0TMF>?[=>:__^R&$-&G#KO^!#HT'GYSL]\_3J+[O?MC_OMX
MS8 36@BE,R#]I1!.!' Z*0@N"<*EE'K/^7K;GC[,%=R38N)DH0Z-BO] /VP\
M/2N9$1>KD;D>J=/.,$ =XZ[,,T?J@T=;&ECRE%&UY_B.>X\>MM]]WSY)#^)K
M2OF;$S;/LY5E8K(N#7R"]&"#CR!YUL01F64^0OV#SXD^45$[=7Z$U(;6^M?Q
M^2K,6S.RF42<LI<E%86CL2H^% 7TG="'DHQDDZGD5N^E^.W/;T7WQRBLZU=Z
M0P/@4YKE;G9>1N1]00W,\^JJ]S9#RH?2YTV!BA3W14,BAN#.@I%*BDR4-'>S
M+W:UN-OC;0-.;^X5'+U+MH&SMI)NDO[S N7XYD=I\[8YPY21<>%3N9PK0N*:
M@U$T0DQ!*8$A9DY5"MMWT#/L,)2:^5ZG"K]-#&T\[QQD%E*#CY2B<,HNG$MV
M"3K1W%H>Q-W.J=50U,(U02_Z?AQ#1PB_/11MNLCJ9$5R$;2,HG06U6"H#;CS
MNLR5I=&'*KU[ME+3''J.T?3#^#E"[$,GY91+CN4R"B1KSI%*$\JP5N4RN"0C
M,!X2-\Y3)?>Y&=HOZ6;SUF'G+M4XBC].H"V@8 U>6;J,."TA)15!H/L%3F4'
M03!*HQ&6I'YQ,/0AZ9$:NZOS(\0WL-9_&T_+H)PUX>6FW6&H#RIYA#GS! VB
MXI B2]2C-1-ZG^29O?1^Z\T#:_X8O75]"'%H[:_&)&T(5Y(%4EK-6UM*=]#F
MV:QC\:1<0-)9]OL4,^^G_9MO'NX@O!?M'RW$!GS&FQ5<[Z_ZN,I,:6(8@B=/
MRC@N=(QLF:=,4CGU4\XJ6;T@\OU!3=RK3<NK%;F>+O@&T'.S,F(]CW29)3-_
M-Y]?I/AN>J-28I1)(,Y:=*]-X+@RN,(]UBG<7D7(SAN5694VW(<0V4XYY9&8
M>*!JJ5<%'0V^'VGFNSYS.M>L?)J-0QELNOS>R$G+L\L64AFB(1CG8(S /5C)
MI$7V/->9:K63HF'++2L JQ?1-V#"/LVZD%*<OT6A%7;*V?3'V6K=K!K4C)R*
MTC#T!*B0<K6E&RK0J^.,2B%=9+1*[>[CI U;X-0_JGI61@/P>KU^[=OQM#"S
M[/;R(2U&ADFF;$X@ F<@'$K)$ P28F!,VD2D,95&%&^E9]B"A?Z!U(?8A[Z&
MO%F]?+'XULU*:\#5C):OW<NTLKVC&(ARE!0?%$,7093"SX@'C@*B-',?\ITL
MR!WWD'N];MBTV?YP4DG #4&F=-%+NWV]P'6V$GT]RB7Z>MF7@<O(GY08H5I!
MDJ+[%<CM_<IALYOJ0:='00\-G])_93R?(]EO4UH?:Z!?%XJBSI#?O\VZ^7RS
M1X\B8E_R8$&JLA.;4ITN8YELYEC,/G'*]K,\![UVV'OLGF%43^ -N#Z/UM3L
M*JE9>7K7\X7F'Q??TNSK-S===PC]V[)O^KOIJD_N2*$4O/$*N!:XJ6>5P'F/
M'B+3V@?%4]:ZAB_U5 P.>T%6*79L#1A#V]YZ0KEI4%;[U#K?ZN/T[7@V7[R8
MQB\I=-/X8CH=_T!NW.QRQ"(QAO, ,G&T-3XK\"0&8%G3G"BA/C_:;[9!OH8]
M2^[;"6E*M =!YMFNMN6'M3!65J;,K,,H<]7#?=7TO?SV*+,LI74!-9I<N0:4
MX'G2*)T0N!#)1)'KKJ"]:=WOU)O\V9=%'=W^.?J/KX?5; 9Y/$T7\ATO': 7
M^3[LM]&1W&4,-*E)0%C(I;@J@4D(36H$YX1KZEV=@\5!.I*OHJB5_5CK:#U.
MZ>/%8KY ?>):_MQ-)F^[65G=HQ"DLBE:2#S@RB5H4'P)J5),1,M2V.+V*]\Y
MX*7/NO_X(7BZ'=M6TDH#D>UCK(UDR"2GE( I6@Y]+"^9I!%EJ(/G,B<BJEP_
M/D;8@$5&U>"P/:^B']T<C;7_O[UKZVTK.=+O^U\*Z/OE90%[/!,8<&8,Q[O[
M2/2EVF8BBPXI.3/Y]5M-ZF:9HGC(TSQ-31# HT@V59>OJJNZZ_)U'3[\[2HL
MKT:XEMO&TMUS/J;KY?QJCIODMUX_WF2_C&(F401"=J8N#$H*?*9(122?$)5A
M(HK#7=VSOW_"GJ766#N55J;.DO9D\>??*5V<KQXP:2E(+[&04153!^U:!)]4
M *,M<\6@L3Z/";T?*)CF8;P[\!VGF>'P\QOX7>*G&EI\/"D*?ZH/O1</6.5*
M!A-D <D2!X7>05CW!(G$>0X<2U!C@O Q =.\J7>'P:/T,CT$]XXKHG<R"IE!
M!%?;5C4'YTFBP:6 &JW-JDF?U2@QW^A/]GW%?$-T<V3,]_-E;N3R;IWYNMSN
M[H=WZX._$R8),DK.*<A(AH09"D2R+/!*N!@IARM[ONX?2<A9+\<=-_-MI+U>
ML^%GV.4S2]&NUB8""JY A<# &VL@%E4"6I9BTQ:#8=3VEC>W M,^?G54S7:<
M8#_#Y^.\C@ZK%'Q0H$6@\PN1$\-. .<\.2>*+R8V<[F=I]Z-X3J)#KO,S9_A
M=TLZF$*)7B!@D*RF@PE<"0FXQ,1LLM&$_88:C4).;UE[K[@]3H]G&S)(7E*-
MV,&X.H70Y "..4TBC]99GZSRI\NP1@D93IC]=QTR#-%LM_G9_V']$_.K;[@,
MG_ #ULDBE'W^M+A<)Q37X:+6$^R6O7?HBB3+1:R28%H!Y2&&K)DE3)(5^7A:
MRQ"'/ :)T_8<=973G5SC708=!TMAI@J3*A5BG7D$E;F'$+. %$.RSBN.Z8C'
M^(/IZBW;.SW,VB%_D,[/&>Z/<HLMDD E=$["@5[/.>1<@*,3%I*2VI:<&8FI
M.?J?);.W7/)\C6%<1'1I&Z\^?5JN'U[>$N?SR]4\K;NC?F3U[D".2?LDC *F
MZKIHRS4$47MZ<PA!$-OZ\>KU(48PF)YI^V"["F[:ZO*\X3LKT7DL+@ FXE>Y
M&" ZYH&93/]CM1-KO_:(X^CH+5)IC)GQ,#M(@1U?4C_!\ \71%LDP)2)J&3=
ML4:YO1+*@K<Y0]0^B,!95ONNR!R7L-X"CDXQ/;:*S]PAFV!9K WZ)C"*Z'0=
M[! ]Q4\N\,@P,/=X<N%T#OF$-]B=@O=(!8YZ!3AI6\W?KK]\"<L_%IOFITWW
MW6E[;/:A8(*&F\&"Z:/[1E5;B88!D]Y0!D=?A<(,@5K0CS(W(C<I_)^F^^;H
MANZ;=M,G2L)4YLPAJ^-351VJ*#F$^A5JPZP*,A;7;HC;Z.R<=1?0$%R/UNX_
M'CHZ>/(<40J;&MN9$Y)E.C4AB<) %>4AIF0!*>E/T6LO4^_FL>&D\]6_)X!G
M.XLY "N3I[MCB>'[:2#K63JSH!(:P2-H5J=Y<9'!218A,1\36N:Y:;-/97Q>
MIBVN?8%F<RQ>>CAE:K2\&4/VYGIY-\=@,\/C02A]7T(T\Y$2KNPE,(RBKMLB
MB4O+P6"=5\YB9MDWL8C!I$Y;>= CX-MJ^]CFFRX. 9)SP?G5=1W/=ULMEZ,.
M#E.]U*B#KGVP$&5T($MF+GJ2#'9Y"&SA9=H'JQYM8F*\O BC^3& 9!EESMF
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MG6%2MTAX3@J=IJQB9$9?S,O!6=AH2Q2>@Y6.%/D[S8)*WI.W4A$41100DE+
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ML3:<0#DL<P&&I!JG9Q?7-Y<_7IZ]O;G\\'Y;O[Y1""Z;[+K-+HR\93]KE:%
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MMQPKH#@R0%".E;0IB9-8AN1(!$G/0MI8:5OZ+(=<J54 2F%T# )?6[:/N!"
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MP?V9[U+QO^;+MZ6)[GP\EVO_]6#?7[.,:>5SN@6K.=7:BRYR &HK[6J7>[[
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M?8[_ E!+ 0(4 Q0    ( /6 K5(L(68-VT<"  9;$P 1              "
M 0    !B;F=O+3(P,C$P,S,Q+FAT;5!+ 0(4 Q0    ( /6 K5+3LW@P8PX
M $*7   1              "  0I( @!B;F=O+3(P,C$P,S,Q+GAS9%!+ 0(4
M Q0    ( /6 K5*B@Q/%D!8  .GE   5              "  9Q6 @!B;F=O
M+3(P,C$P,S,Q7V-A;"YX;6Q02P$"% ,4    " #U@*U21*@ _OM)  "O( ,
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M,#(Q,#,S,7AE>'@S,3$N:'1M4$L! A0#%     @ ]8"M4K<Z7>X^"   ]"@
M !@              ( !@-T# &)N9V\M,C R,3 S,S%X97AX,S$R+FAT;5!+
M 0(4 Q0    ( /6 K5+,Y9]4G@8  $8D   8              "  ?3E P!B
M;F=O+3(P,C$P,S,Q>&5X>#,R,2YH=&U02P4&      D "0!< @  R.P#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
